[ { "biomarker_id": "AA4686-1", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "10914713", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10914713", "evidence_list": [ { "evidence": "Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning > or = 1, IL-6 > or = 7 pg/ml, PS > or = 1, PSA > 100 ng/ml, and ALP > 620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "10914713", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10914713", "evidence_list": [ { "evidence": "Univariate analysis of all patients demonstrated that an extent of disease (EOD) on bone scanning > or = 1, IL-6 > or = 7 pg/ml, PS > or = 1, PSA > 100 ng/ml, and ALP > 620 IU/liter were associated with a significantly lower survival rate than their respective counterparts. In multivariate analysis, however, the only two significant prognostic factors were EOD and IL-6. These results indicate that the serum IL-6 level is a significant prognostic factor for prostate cancer as well as EOD." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum interleukin 6 as a prognostic factor in patients with prostate cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M", "date": "2000-07-29", "evidence": [], "reference": [ { "id": "10914713", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10914713" } ] }, { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-2", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32259560", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560", "evidence_list": [ { "evidence": "Serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32428990", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32428990", "evidence_list": [ { "evidence": "The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease exacerbation. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Clinical biomarkers for chronic inflammation, in particular Interleukin-6, predict the severity of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32234467", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234467", "evidence_list": [ { "evidence": "Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32442528", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528", "evidence_list": [ { "evidence": "findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines. T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased. lower levels of regulatory T cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32425269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269", "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Since the proportionate rise of IL-6 is correlated with disease severity, this study can prove ground-breaking." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32385523", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32385523", "evidence_list": [ { "evidence": "Up-regulated IL-6 levels may serve as a potential marker for predicting progression of COVID19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32181911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911", "evidence_list": [ { "evidence": "IL-6 and d-D were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "A deep network analysis has suggested clinical biomarkers predicting the higher risk of severe COVID-19 infection: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, and low Lymphocytes count. In particular, patients with diabetes, but also those with prediabetic state, deserve special attention." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32344321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321", "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32259560", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560", "evidence_list": [ { "evidence": "Serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32428990", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32428990", "evidence_list": [ { "evidence": "The decrease of IL-6 was closely related to treatment effectiveness, while the increase of IL-6 indicated disease exacerbation. Collectively, the dynamic change of IL-6 level can be used as a marker for disease monitoring in patients with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Clinical biomarkers for chronic inflammation, in particular Interleukin-6, predict the severity of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32234467", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234467", "evidence_list": [ { "evidence": "Interleukin-6 (IL-6) plays an important role in cytokine release syndrome. If it is possible to block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32442528", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528", "evidence_list": [ { "evidence": "findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines. T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased. lower levels of regulatory T cells." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32425269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269", "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Since the proportionate rise of IL-6 is correlated with disease severity, this study can prove ground-breaking." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32385523", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32385523", "evidence_list": [ { "evidence": "Up-regulated IL-6 levels may serve as a potential marker for predicting progression of COVID19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32181911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911", "evidence_list": [ { "evidence": "IL-6 and d-D were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "A deep network analysis has suggested clinical biomarkers predicting the higher risk of severe COVID-19 infection: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, and low Lymphocytes count. In particular, patients with diabetes, but also those with prediabetic state, deserve special attention." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32344321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321", "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Interleukin-6 as a potential biomarker of COVID-19 progression.", "journal": "Medecine et maladies infectieuses", "authors": "Ulhaq ZS, Soraya GV", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32259560", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560" } ] }, { "title": "The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.", "journal": "EMBO molecular medicine", "authors": "Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, Cheng J, Zhang X, Zhao Y, Xia Z, Zhang L, Wu G, Yi J", "date": "2020-05-20", "evidence": [], "reference": [ { "id": "32428990", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32428990" } ] }, { "title": "The association between biomarkers and clinical outcomes in novel coronavirus\u00a0pneumonia in a US cohort.", "journal": "Biomarkers in medicine", "authors": "Ayanian S, Reyes J, Lynn L, Teufel K", "date": "2020-07-18", "evidence": [], "reference": [ { "id": "32677844", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844" } ] }, { "title": "Diabetes and metabolic syndrome as risk factors for COVID-19.", "journal": "Diabetes & metabolic syndrome", "authors": "Marhl M, Grubelnik V, Magdi\u010d M, Markovi\u010d R", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32438331", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.", "journal": "International journal of antimicrobial agents", "authors": "Zhang C, Wu Z, Li JW, Zhao H, Wang GQ", "date": "2020-04-03", "evidence": [], "reference": [ { "id": "32234467", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234467" } ] }, { "title": "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.", "journal": "Lancet (London, England)", "authors": "Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR", "date": "2020-05-23", "evidence": [], "reference": [ { "id": "32442528", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T", "date": "2020-05-20", "evidence": [], "reference": [ { "id": "32425269", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "IL-6 may be a good biomarker for earlier detection of COVID-19 progression.", "journal": "Intensive care medicine", "authors": "Wang C, Fei D, Li X, Zhao M, Yu K", "date": "2020-05-10", "evidence": [], "reference": [ { "id": "32385523", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32385523" } ] }, { "title": "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.", "journal": "Journal of medical virology", "authors": "Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L", "date": "2020-03-18", "evidence": [], "reference": [ { "id": "32181911", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911" } ] }, { "title": "Diabetes and metabolic syndrome as risk factors for COVID-19.", "journal": "Diabetes & metabolic syndrome", "authors": "Marhl M, Grubelnik V, Magdi\u010d M, Markovi\u010d R", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32438331", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331" } ] }, { "title": "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.", "journal": "Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology", "authors": "Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X", "date": "2020-04-29", "evidence": [], "reference": [ { "id": "32344321", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321" } ] }, { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-3", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-4", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-5", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-6", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-7", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-8", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-9", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-10", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-11", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2531", "recommended_name": { "id": "DOID:2531", "name": "hematologic cancer", "description": "An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, "synonyms": [ { "id": "DOID:2531", "name": "Hematologic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematologic malignancy", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic and lymphoid system tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "blood cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "malignant hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematological tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-12", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "IL-6 plays multifaceted roles in regulation of vascular leakage, complement activation, and coagulation pathways, which ultimately causes poor outcomes for acute respiratory distress syndrome, multiple organ dysfunction syndrome, and SARS." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH, these finds were similar to previous studies. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AA4686-13", "biomarker_component": [ { "biomarker": "increased IL6 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-6", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26881-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26881-3" } ], "evidence_source": [ { "id": "32430456", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456", "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 \u00b1 0.84 mmol/L in the no insulin infusion group and 7.69 \u00b1 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "28848164", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28848164", "evidence_list": [ { "evidence": "Our study is suggestive of S100A8/A9 and IL-6 being related to a persistent diabetes status post-surgically and of different pathophysiological mechanisms being involved in the post-surgical changes in the three groups, despite similar decreases in BMI." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31772933", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31772933", "evidence_list": [ { "evidence": "Significantly higher IL-15 and IL-6 concentrations, HOMAIR, and markedly lower eGDR in newly diagnosed AD patients and first-degree relatives with positive anti-islet antibodies might suggest the role of these pro-inflammatory cytokines and insulin resistance in the pathogenesis of autoimmune diabetes. IL-15 and IL-6 might be used as biomarkers of the risk of autoimmune diabetes development." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "safety" }, { "role": "risk" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "32430456", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456", "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 \u00b1 0.84 mmol/L in the no insulin infusion group and 7.69 \u00b1 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ], "tags": [ { "tag": "condition" } ] }, { "id": "28848164", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28848164", "evidence_list": [ { "evidence": "Our study is suggestive of S100A8/A9 and IL-6 being related to a persistent diabetes status post-surgically and of different pathophysiological mechanisms being involved in the post-surgical changes in the three groups, despite similar decreases in BMI." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31772933", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31772933", "evidence_list": [ { "evidence": "Significantly higher IL-15 and IL-6 concentrations, HOMAIR, and markedly lower eGDR in newly diagnosed AD patients and first-degree relatives with positive anti-islet antibodies might suggest the role of these pro-inflammatory cytokines and insulin resistance in the pathogenesis of autoimmune diabetes. IL-15 and IL-6 might be used as biomarkers of the risk of autoimmune diabetes development." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?", "journal": "Diabetes care", "authors": "Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32430456", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456" } ] }, { "title": "S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery.", "journal": "Obesity facts", "authors": "Lylloff L, Bathum L, Madsbad S, Grundtvig JLG, Nordgaard-Lassen I, Fenger M", "date": "2017-08-30", "evidence": [], "reference": [ { "id": "28848164", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28848164" } ] }, { "title": "Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development.", "journal": "BioMed research international", "authors": "Siewko K, Maciulewski R, Zielinska-Maciulewska A, Poplawska-Kita A, Szumowski P, Wawrusiewicz-Kurylonek N, Lipinska D, Milewski R, Gorska M, Kretowski A, Szelachowska M", "date": "2019-11-28", "evidence": [], "reference": [ { "id": "31772933", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31772933" } ] } ], "biomarker_canonical_id": "AA4686", "collision": 1 }, { "biomarker_id": "AN4071-1", "biomarker_component": [ { "biomarker": "increased PCT level", "assessed_biomarker_entity": { "recommended_name": "Procalcitonin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:56841902", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33959-8" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "We found that pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "We found that pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4071", "collision": 1 }, { "biomarker_id": "AN4071-2", "biomarker_component": [ { "biomarker": "increased PCT level", "assessed_biomarker_entity": { "recommended_name": "Procalcitonin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:56841902", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33959-8" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33959-8" } ], "evidence_source": [ { "id": "32145275", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275", "evidence_list": [ { "evidence": "Procalcitonin values are associated with a nearly 5-fold higher risk of severe SARS-COV-2 infection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Compared with the nonsevere group, most of severe cases demonstrated elevated levels of infection-related biomarkers, including procalcitonin (0.1 vs 0.05 ng/mL; P < .001), serum ferritin (800.4 vs 523.7 ng/mL; P < .001), and C-reactive protein (57.9 vs 33.2 mg/L; P < .001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "The serum levels of CRP, PCT and ferritin are markedly increased in very severe compared with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "This meta-analysis showed that an elevated serum CRP, PCT, D-dimer, and ferritin were associated with a poor outcome in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32145275", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275", "evidence_list": [ { "evidence": "Serial procalcitonin measurement may play a role for predicting evolution towards a more severe form of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "Increased procalcitonin values were associated with a nearly 5-fold higher risk of severe infection (OR = 4.76; 95% CI: 2.74-8.29, I2 = 34%)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32145275", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275", "evidence_list": [ { "evidence": "Procalcitonin values are associated with a nearly 5-fold higher risk of severe SARS-COV-2 infection." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Compared with the nonsevere group, most of severe cases demonstrated elevated levels of infection-related biomarkers, including procalcitonin (0.1 vs 0.05 ng/mL; P < .001), serum ferritin (800.4 vs 523.7 ng/mL; P < .001), and C-reactive protein (57.9 vs 33.2 mg/L; P < .001)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "The serum levels of CRP, PCT and ferritin are markedly increased in very severe compared with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "This meta-analysis showed that an elevated serum CRP, PCT, D-dimer, and ferritin were associated with a poor outcome in COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32145275", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275", "evidence_list": [ { "evidence": "Serial procalcitonin measurement may play a role for predicting evolution towards a more severe form of disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "Increased procalcitonin values were associated with a nearly 5-fold higher risk of severe infection (OR = 4.76; 95% CI: 2.74-8.29, I2 = 34%)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.", "journal": "Clinica chimica acta; international journal of clinical chemistry", "authors": "Lippi G, Plebani M", "date": "2020-03-08", "evidence": [], "reference": [ { "id": "32145275", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.", "journal": "The Lancet. Infectious diseases", "authors": "Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D", "date": "2020-03-30", "evidence": [], "reference": [ { "id": "32220650", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650" } ] }, { "title": "C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.", "journal": "Therapeutic advances in respiratory disease", "authors": "Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32615866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866" } ] }, { "title": "C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.", "journal": "Therapeutic advances in respiratory disease", "authors": "Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32615866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866" } ] }, { "title": "Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.", "journal": "Clinica chimica acta; international journal of clinical chemistry", "authors": "Lippi G, Plebani M", "date": "2020-03-08", "evidence": [], "reference": [ { "id": "32145275", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32145275" } ] }, { "title": "Hematological findings and complications of COVID-19.", "journal": "American journal of hematology", "authors": "Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32282949", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949" } ] } ], "biomarker_canonical_id": "AN4071", "collision": 1 }, { "biomarker_id": "AN4071-3", "biomarker_component": [ { "biomarker": "increased PCT level", "assessed_biomarker_entity": { "recommended_name": "Procalcitonin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:56841902", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33959-8" } ], "evidence_source": [ { "id": "31485450", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31485450", "evidence_list": [ { "evidence": "Procalcitonin is a prognostic marker of hospital outcomes in patients with Critical Limb Ischemia and Diabetic Foot Infection. It could be assumed that PCT may be useful for early diagnosis of systemic inflammatory response including nonseptic patients. It could help to identify high risk patients even without clear clinical signs and may be used to improve clinician's strategies (i.e., need of intensive unit, reinforcement of antibiotic therapy, and close monitoring of vital signs, hemodynamic parameters, and laboratory values)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "31485450", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31485450", "evidence_list": [ { "evidence": "Procalcitonin is a prognostic marker of hospital outcomes in patients with Critical Limb Ischemia and Diabetic Foot Infection. It could be assumed that PCT may be useful for early diagnosis of systemic inflammatory response including nonseptic patients. It could help to identify high risk patients even without clear clinical signs and may be used to improve clinician's strategies (i.e., need of intensive unit, reinforcement of antibiotic therapy, and close monitoring of vital signs, hemodynamic parameters, and laboratory values)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Procalcitonin Is a Prognostic Marker of Hospital Outcomes in Patients with Critical Limb Ischemia and Diabetic Foot Infection.", "journal": "Journal of diabetes research", "authors": "Meloni M, Izzo V, Giurato L, Brocco E, Ferrannini M, Gandini R, Uccioli L", "date": "2019-09-06", "evidence": [], "reference": [ { "id": "31485450", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31485450" } ] } ], "biomarker_canonical_id": "AN4071", "collision": 1 }, { "biomarker_id": "AA4687-1", "biomarker_component": [ { "biomarker": "increased WBC count", "assessed_biomarker_entity": { "recommended_name": "White blood cell", "synonyms": [ { "synonym": "immune cell" }, { "synonym": "leucocyte" }, { "synonym": "white blood cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000738", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26464-8" }, { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252ug/L, WBC>9.5x10^9/L or NC >7.305x10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "A retrospective study including 187 patients with COVID-19 from another hospital in Wuhan showed that patients with high troponin-T levels had leukocytosis (P < .001), increased neutrophils (P < .001) and decreased lymphocytes (P = .01)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "condition" } ] }, { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252ug/L, WBC>9.5x10^9/L or NC >7.305x10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "A retrospective study including 187 patients with COVID-19 from another hospital in Wuhan showed that patients with high troponin-T levels had leukocytosis (P < .001), increased neutrophils (P < .001) and decreased lymphocytes (P = .01)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] }, { "title": "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.", "journal": "BMC infectious diseases", "authors": "Gong J, Dong H, Xia QS, Huang ZY, Wang DK, Zhao Y, Liu WH, Tu SH, Zhang MM, Wang Q, Lu FE", "date": "2020-12-23", "evidence": [], "reference": [ { "id": "33349241", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] }, { "title": "Hematological findings and complications of COVID-19.", "journal": "American journal of hematology", "authors": "Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32282949", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949" } ] } ], "biomarker_canonical_id": "AA4687", "collision": 1 }, { "biomarker_id": "AA4687-2", "biomarker_component": [ { "biomarker": "increased WBC count", "assessed_biomarker_entity": { "recommended_name": "White blood cell", "synonyms": [ { "synonym": "immune cell" }, { "synonym": "leucocyte" }, { "synonym": "white blood cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000738", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30073209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30073209", "evidence_list": [ { "evidence": "The strength of this study is the robust association between leukocytosis and poor prognosis in a homogenous cohort of HNSCC, treated with concurrent cisplatin." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "30073209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30073209", "evidence_list": [ { "evidence": "The strength of this study is the robust association between leukocytosis and poor prognosis in a homogenous cohort of HNSCC, treated with concurrent cisplatin." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Leukocytosis, prognosis biomarker in locally advanced head and neck cancer patients after chemoradiotherapy.", "journal": "Clinical and translational radiation oncology", "authors": "Schernberg A, Blanchard P, Chargari C, Ou D, Levy A, Gorphe P, Breuskin I, Atallah S, Caula A, Escande A, Janot F, Nguyen F, Temam S, Deutsch E, Tao Y", "date": "2018-08-04", "evidence": [], "reference": [ { "id": "30073209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30073209" } ] } ], "biomarker_canonical_id": "AA4687", "collision": 1 }, { "biomarker_id": "AA4687-3", "biomarker_component": [ { "biomarker": "increased WBC count", "assessed_biomarker_entity": { "recommended_name": "White blood cell", "synonyms": [ { "synonym": "immune cell" }, { "synonym": "leucocyte" }, { "synonym": "white blood cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000738", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26464-8" } ], "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4687", "collision": 1 }, { "biomarker_id": "AA4687-4", "biomarker_component": [ { "biomarker": "increased WBC count", "assessed_biomarker_entity": { "recommended_name": "White blood cell", "synonyms": [ { "synonym": "immune cell" }, { "synonym": "leucocyte" }, { "synonym": "white blood cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000738", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26464-8" } ], "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4687", "collision": 1 }, { "biomarker_id": "AA4687-5", "biomarker_component": [ { "biomarker": "increased WBC count", "assessed_biomarker_entity": { "recommended_name": "White blood cell", "synonyms": [ { "synonym": "immune cell" }, { "synonym": "leucocyte" }, { "synonym": "white blood cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000738", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26464-8" } ], "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "The blood count results showed anaemia in 21 (75%) patients, leucopaenia in 9 (32.1%) patients, and lymphopaenia in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4687", "collision": 1 }, { "biomarker_id": "AA4688-1", "biomarker_component": [ { "biomarker": "decreased LYMP count", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26474-7" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4688", "collision": 1 }, { "biomarker_id": "AA4688-2", "biomarker_component": [ { "biomarker": "decreased LYMP count", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "21448592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21448592", "evidence_list": [ { "evidence": "Lymphopenia was found in 49/260 (19%) of patients. Ten of these 49 patients had severe hematological toxicity. Lymphopenia was strongly associated with shorter progression-free survival (median 4 vs. 7 months; P = 0.033) and shorter overall survival (median 16 vs. 24 months, P = 0.024). Multivariate analysis revealed that lymphopenia had an independent effect on survival. Lymphopenia in conclusion is proven to be an independent predictive factor for chemotherapy and hematological toxicity in colorectal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "21448592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21448592", "evidence_list": [ { "evidence": "Lymphopenia was found in 49/260 (19%) of patients. Ten of these 49 patients had severe hematological toxicity. Lymphopenia was strongly associated with shorter progression-free survival (median 4 vs. 7 months; P = 0.033) and shorter overall survival (median 16 vs. 24 months, P = 0.024). Multivariate analysis revealed that lymphopenia had an independent effect on survival. Lymphopenia in conclusion is proven to be an independent predictive factor for chemotherapy and hematological toxicity in colorectal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy.", "journal": "Cancer chemotherapy and pharmacology", "authors": "C\u00e9z\u00e9 N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, Lecomte T", "date": "2011-03-31", "evidence": [], "reference": [ { "id": "21448592", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21448592" } ] } ], "biomarker_canonical_id": "AA4688", "collision": 1 }, { "biomarker_id": "AA4688-3", "biomarker_component": [ { "biomarker": "decreased LYMP count", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26474-7" }, { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Patients with higher initial SAA are more likely to have poor CT imaging. Our study indicated that SAA/L. CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "the combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Clinical biomarkers predicting the higher risk: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, decreased Lymphocytes count." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32352397", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397", "evidence_list": [ { "evidence": "In this study, the most important finding was that the neutrophil count, lymphocyte count and platelet count were independent risk factors for predicting the development of severe illness in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32377400", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32377400", "evidence_list": [ { "evidence": "Lymphopenia is an effective and reliable indicator of the severity and hospitalization in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA and Lymphocytes are sensitive indicators in evaluating the severity and prognosis of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32077115", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115", "evidence_list": [ { "evidence": "Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32376308", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376308", "evidence_list": [ { "evidence": "Lymphopenia is a prominent part of severe COVID-19 and a lymphocyte count of less than 1.5 x 10^9/L may be useful in predicting the severity clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Patients with higher initial SAA are more likely to have poor CT imaging. Our study indicated that SAA/L. CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "the combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Clinical biomarkers predicting the higher risk: Hypertension, elevated serum Alanine aminotransferase, high Interleukin-6, decreased Lymphocytes count." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32352397", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397", "evidence_list": [ { "evidence": "In this study, the most important finding was that the neutrophil count, lymphocyte count and platelet count were independent risk factors for predicting the development of severe illness in COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32377400", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32377400", "evidence_list": [ { "evidence": "Lymphopenia is an effective and reliable indicator of the severity and hospitalization in COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA and Lymphocytes are sensitive indicators in evaluating the severity and prognosis of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32077115", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115", "evidence_list": [ { "evidence": "Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32376308", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376308", "evidence_list": [ { "evidence": "Lymphopenia is a prominent part of severe COVID-19 and a lymphocyte count of less than 1.5 x 10^9/L may be useful in predicting the severity clinical outcomes." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.", "journal": "Science China. Life sciences", "authors": "Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L", "date": "2020-02-13", "evidence": [], "reference": [ { "id": "32048163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163" } ] }, { "title": "Diabetes and metabolic syndrome as risk factors for COVID-19.", "journal": "Diabetes & metabolic syndrome", "authors": "Marhl M, Grubelnik V, Magdi\u010d M, Markovi\u010d R", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32438331", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331" } ] }, { "title": "Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.", "journal": "Archives of medical research", "authors": "Assandri R, Buscarini E, Canetta C, Scartabellati A, Vigan\u00f2 G, Montanelli A", "date": "2020-05-31", "evidence": [], "reference": [ { "id": "32471703", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703" } ] }, { "title": "The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Zheng Y, Zhang Y, Chi H, Chen S, Peng M, Luo L, Chen L, Li J, Shen B, Wang D", "date": "2020-05-01", "evidence": [], "reference": [ { "id": "32352397", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397" } ] }, { "title": "Correction: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.", "journal": "Signal transduction and targeted therapy", "authors": "Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32377400", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32377400" } ] }, { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] }, { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.", "journal": "The Lancet. Infectious diseases", "authors": "Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D", "date": "2020-03-30", "evidence": [], "reference": [ { "id": "32220650", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650" } ] }, { "title": "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.", "journal": "Allergy", "authors": "Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32077115", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115" } ] }, { "title": "Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis.", "journal": "International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases", "authors": "Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32376308", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376308" } ] } ], "biomarker_canonical_id": "AA4688", "collision": 1 }, { "biomarker_id": "AA4688-4", "biomarker_component": [ { "biomarker": "decreased LYMP count", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19549917", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19549917", "evidence_list": [ { "evidence": "In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer (RR: 1.8; 95%CI 1.3-2.4) along with liver metastases and PS; in advanced soft-tissue sarcoma (RR: 1.46; 95%CI 1.0-2.1) along with liver metastases, lung metastases and PS; and in non-Hodgkin's lymphoma (RR: 1.48; 95%CI 1.03-2.1) along with IPI. Our findings demonstrate that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "19549917", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19549917", "evidence_list": [ { "evidence": "In multivariate analysis (Cox model), lymphopenia was an independent prognostic factor for overall survival in metastatic breast cancer (RR: 1.8; 95%CI 1.3-2.4) along with liver metastases and PS; in advanced soft-tissue sarcoma (RR: 1.46; 95%CI 1.0-2.1) along with liver metastases, lung metastases and PS; and in non-Hodgkin's lymphoma (RR: 1.48; 95%CI 1.03-2.1) along with IPI. Our findings demonstrate that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.", "journal": "Cancer research", "authors": "Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY, None None", "date": "2009-06-25", "evidence": [], "reference": [ { "id": "19549917", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19549917" } ] } ], "biomarker_canonical_id": "AA4688", "collision": 1 }, { "biomarker_id": "AA4688-5", "biomarker_component": [ { "biomarker": "decreased LYMP count", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26474-7" } ], "evidence_source": [ { "id": "15225139", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15225139", "evidence_list": [ { "evidence": "In the present study, the number of leukocytes was increased but that of lymphocytes was decreased in diabetic patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "15225139", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15225139", "evidence_list": [ { "evidence": "In the present study, the number of leukocytes was increased but that of lymphocytes was decreased in diabetic patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Diabetes induces apoptosis in lymphocytes.", "journal": "The Journal of endocrinology", "authors": "Otton R, Soriano FG, Verlengia R, Curi R", "date": "2004-07-01", "evidence": [], "reference": [ { "id": "15225139", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15225139" } ] } ], "biomarker_canonical_id": "AA4688", "collision": 1 }, { "biomarker_id": "AA4689-1", "biomarker_component": [ { "biomarker": "decreased PLAT count", "assessed_biomarker_entity": { "recommended_name": "Platelet", "synonyms": [ { "synonym": "anucleate thrombocyte" }, { "synonym": "blood platelet" }, { "synonym": "enucleate thrombocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000233", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "11125-2" } ], "evidence_source": [ { "id": "32178975", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32178975", "evidence_list": [ { "evidence": "Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Meta-analysis of 1799 patients reveal those with severe COVID-19 infections had significantly lower platelet counts. Despite the varying definitions of disease severity and thrombocytopenia having an influence on results analysis, platelet count could possibly be used clinically to indicate infection severity. Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32178975", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32178975", "evidence_list": [ { "evidence": "Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Meta-analysis of 1799 patients reveal those with severe COVID-19 infections had significantly lower platelet counts. Despite the varying definitions of disease severity and thrombocytopenia having an influence on results analysis, platelet count could possibly be used clinically to indicate infection severity. Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.", "journal": "Clinica chimica acta; international journal of clinical chemistry", "authors": "Lippi G, Plebani M, Henry BM", "date": "2020-03-18", "evidence": [], "reference": [ { "id": "32178975", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32178975" } ] }, { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] } ], "biomarker_canonical_id": "AA4689", "collision": 1 }, { "biomarker_id": "AA4690-1", "biomarker_component": [ { "biomarker": "increased SFER level", "assessed_biomarker_entity": { "recommended_name": "Serum ferritin", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050342", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2276-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "2276-4" } ], "evidence_source": [ { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "Higher serum ferritin levels were associated with higher odds of death at the univariate analysis (OR = 9.10, 95%CI: 2.04-40.58; P = .004)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32282949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949", "evidence_list": [ { "evidence": "Higher serum ferritin levels were associated with higher odds of death at the univariate analysis (OR = 9.10, 95%CI: 2.04-40.58; P = .004)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] }, { "title": "Hematological findings and complications of COVID-19.", "journal": "American journal of hematology", "authors": "Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32282949", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32282949" } ] } ], "biomarker_canonical_id": "AA4690", "collision": 1 }, { "biomarker_id": "AA4690-2", "biomarker_component": [ { "biomarker": "increased SFER level", "assessed_biomarker_entity": { "recommended_name": "Serum ferritin", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050342", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2276-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "2276-4" } ], "evidence_source": [ { "id": "29879960", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29879960", "evidence_list": [ { "evidence": "These results indicate that serum ferritin is a valid clinical biochemical marker to predict survival of patients with advanced hepatobiliary cancers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:3119", "recommended_name": { "id": "DOID:3119", "name": "gastrointestinal system cancer", "description": "An organ system cancer located_in gastrointestinal tract that is manifested in organs of the gastrointestinal system.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3119" }, "synonyms": [ { "id": "DOID:3119", "name": "GI tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3119" }, { "id": "DOID:3119", "name": "gastrointestinal tract cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3119" }, { "id": "DOID:3119", "name": "digestive system cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3119" } ] }, "evidence_source": [ { "id": "29879960", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29879960", "evidence_list": [ { "evidence": "These results indicate that serum ferritin is a valid clinical biochemical marker to predict survival of patients with advanced hepatobiliary cancers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study.", "journal": "BMC complementary and alternative medicine", "authors": "Song A, Eo W, Kim S, Shim B, Lee S", "date": "2018-06-09", "evidence": [], "reference": [ { "id": "29879960", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29879960" } ] } ], "biomarker_canonical_id": "AA4690", "collision": 1 }, { "biomarker_id": "AA4691-1", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32379887", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887", "evidence_list": [ { "evidence": "Consequently, the counts of CD8+T and CD4+T cells can be used as diagnostic markers of COVID-19 and predictors of disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32283159", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159", "evidence_list": [ { "evidence": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32379887", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887", "evidence_list": [ { "evidence": "Consequently, the counts of CD8+T and CD4+T cells can be used as diagnostic markers of COVID-19 and predictors of disease severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32283159", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159", "evidence_list": [ { "evidence": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019.", "journal": "The Journal of infectious diseases", "authors": "Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, Le A, Li J, Wan L", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32379887", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887" } ] }, { "title": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.", "journal": "The Journal of infection", "authors": "Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, Chen D, Zhou L, Wang M, Wu M, Huang Q, Xu H, Zeng W, Guo L", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32283159", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-2", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-3", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-4", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-5", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-6", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-7", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-8", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-9", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-10", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-11", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2531", "recommended_name": { "id": "DOID:2531", "name": "hematologic cancer", "description": "An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, "synonyms": [ { "id": "DOID:2531", "name": "Hematologic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematologic malignancy", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic and lymphoid system tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "blood cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "malignant hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematological tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4691-12", "biomarker_component": [ { "biomarker": "decreased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Several risk factors for COVID-19 severity in patients with cancer, including advanced tumour stage, elevated TNF-alpha and NT-proBNP, and decreased CD4+ T cells and albumin-globulin ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4691", "collision": 1 }, { "biomarker_id": "AA4692-1", "biomarker_component": [ { "biomarker": "increased CD4+ T count", "assessed_biomarker_entity": { "recommended_name": "CD4+ T cell", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "oropharynx", "id": "UBERON:0001729", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001729", "loinc_code": "40898-9" } ], "evidence_source": [ { "id": "26879675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675", "evidence_list": [ { "evidence": "Higher CD4 and CD8 TIL levels were associated with improved overall (HR 0.77 [0.65 -0.93] p=.005 and HR 0.77 [0.64-0.94] p=.008 respectively), and relapse free survival (p=.03, and .05 respectively). Higher CD4 levels predicted improved overall and disease specific survival (p=.003 and .004 respectively)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "26879675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675", "evidence_list": [ { "evidence": "Higher CD4 and CD8 TIL levels were associated with improved overall (HR 0.77 [0.65 -0.93] p=.005 and HR 0.77 [0.64-0.94] p=.008 respectively), and relapse free survival (p=.03, and .05 respectively). Higher CD4 levels predicted improved overall and disease specific survival (p=.003 and .004 respectively)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.", "journal": "Head & neck", "authors": "Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT, None None", "date": "2016-02-18", "evidence": [], "reference": [ { "id": "26879675", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675" } ] } ], "biomarker_canonical_id": "AA4692", "collision": 1 }, { "biomarker_id": "AA4693-1", "biomarker_component": [ { "biomarker": "decreased CD8+ T count", "assessed_biomarker_entity": { "recommended_name": "CD8+ T cell", "synonyms": [ { "synonym": "CD8-positive, alpha-beta regulatory T-cell" }, { "synonym": "suppressor T cell" }, { "synonym": "CD8+ Treg" }, { "synonym": "CD8+ regulatory T cell" }, { "synonym": "suppressor T lymphocyte" }, { "synonym": "CD8-positive T(reg)" }, { "synonym": "CD8+ T(reg)" }, { "synonym": "suppressor T-lymphocyte" }, { "synonym": "CD8-positive, alpha-beta regulatory T lymphocyte" }, { "synonym": "CD8-positive Treg" }, { "synonym": "CD8-positive, alpha-beta Treg" }, { "synonym": "CD8-positive, alpha-beta regulatory T-lymphocyte" }, { "synonym": "suppressor T-cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000795", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65759-3" } ], "evidence_source": [ { "id": "32379887", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887", "evidence_list": [ { "evidence": "Consequently, the counts of CD8+T and CD4+T cells can be used as diagnostic markers of COVID-19 and predictors of disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32283159", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159", "evidence_list": [ { "evidence": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32379887", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887", "evidence_list": [ { "evidence": "Consequently, the counts of CD8+T and CD4+T cells can be used as diagnostic markers of COVID-19 and predictors of disease severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32283159", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159", "evidence_list": [ { "evidence": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "T-Cell Subset Counts in Peripheral Blood Can Be Used as Discriminatory Biomarkers for Diagnosis and Severity Prediction of Coronavirus Disease 2019.", "journal": "The Journal of infectious diseases", "authors": "Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, Le A, Li J, Wan L", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32379887", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32379887" } ] }, { "title": "Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.", "journal": "The Journal of infection", "authors": "Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, Chen D, Zhou L, Wang M, Wu M, Huang Q, Xu H, Zeng W, Guo L", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32283159", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283159" } ] } ], "biomarker_canonical_id": "AA4693", "collision": 1 }, { "biomarker_id": "AA4694-1", "biomarker_component": [ { "biomarker": "increased CD8+ T count", "assessed_biomarker_entity": { "recommended_name": "CD8+ T cell", "synonyms": [ { "synonym": "CD8-positive, alpha-beta regulatory T-cell" }, { "synonym": "suppressor T cell" }, { "synonym": "CD8+ Treg" }, { "synonym": "CD8+ regulatory T cell" }, { "synonym": "suppressor T lymphocyte" }, { "synonym": "CD8-positive T(reg)" }, { "synonym": "CD8+ T(reg)" }, { "synonym": "suppressor T-lymphocyte" }, { "synonym": "CD8-positive, alpha-beta regulatory T lymphocyte" }, { "synonym": "CD8-positive Treg" }, { "synonym": "CD8-positive, alpha-beta Treg" }, { "synonym": "CD8-positive, alpha-beta regulatory T-lymphocyte" }, { "synonym": "suppressor T-cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000795", "assessed_entity_type": "cell", "specimen": [ { "name": "oropharynx", "id": "UBERON:0001729", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001729", "loinc_code": "40899-7" } ], "evidence_source": [ { "id": "26879675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675", "evidence_list": [ { "evidence": "Higher CD4 and CD8 TIL levels were associated with improved overall (HR 0.77 [0.65 -0.93] p=.005 and HR 0.77 [0.64-0.94] p=.008 respectively), and relapse free survival (p=.03, and .05 respectively). Higher CD4 levels predicted improved overall and disease specific survival (p=.003 and .004 respectively)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "26879675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675", "evidence_list": [ { "evidence": "Higher CD4 and CD8 TIL levels were associated with improved overall (HR 0.77 [0.65 -0.93] p=.005 and HR 0.77 [0.64-0.94] p=.008 respectively), and relapse free survival (p=.03, and .05 respectively). Higher CD4 levels predicted improved overall and disease specific survival (p=.003 and .004 respectively)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.", "journal": "Head & neck", "authors": "Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT, None None", "date": "2016-02-18", "evidence": [], "reference": [ { "id": "26879675", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26879675" } ] } ], "biomarker_canonical_id": "AA4694", "collision": 1 }, { "biomarker_id": "AA4695-1", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "71426-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA/L, CRP, SAA, and L count are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "The positive correlations between CRP and series cancer biomarkers we showed in this study demonstrate that these cancer biomarkers can present the diffuse and acute lung injuries in COVID-19. CRP increased in 95% of all cases; the increases were significant for all groups (mild: 13.5\u2009\u00b1\u200913.1; severe: 35.0\u2009\u00b1\u200939.2; critical: 66.1\u2009\u00b1\u200967.3; in mg/L; P\u2009=\u2009.002)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252ug/L, WBC>9.5x10^9/L or NC >7.305x10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Surveillance of NLR and lymphocyte subsets is helpful in the early screening of critical illness, diagnosis, and treatment of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32425269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269", "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32566572", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572", "evidence_list": [ { "evidence": "NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32243911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911", "evidence_list": [ { "evidence": "At the early stage of COVID-19, CRP levels were positively correlated with lung lesions. CRP levels could reflect disease severity and should be used as a key indicator for disease monitoring." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "CRP changes before other blood parameters and thus may be an effective evaluation index for patients with COVID-19 infection. [DOI:10.1101/2020.03.10.20033613] CRP in severe COVID-19 patients increased significantly at the initial stage, before CT findings. Importantly, CRP, which was associated with disease development, predicted early severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32368728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728", "evidence_list": [ { "evidence": "The combination of eosinopenia and elevated hs-CRP can effectively triage suspected COVID-19 patients from other patients attending the fever clinic with COVID-19-like initial symptoms." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Patients with higher initial SAA are more likely to have poor CT imaging. Our study indicated that SAA/L. CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "CRP is one of the first biomarkers within blood plasma that changes to reflect physiological complications; if accepted CRP will be the most effective biomarker to predict the progression of COVID-19 infection. CRP values are more reliable for earlier identification of case severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "CRP which was associated with disease development, predicted early severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32511972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511972", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Concentrations of CRP remained high in patients who died of COVID-19 infection, and CRP could be a biomarker for assessing disease lethality." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32344321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321", "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "The serum levels of CRP, PCT and ferritin are markedly increased in very severe compared with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32414383", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32414383", "evidence_list": [ { "evidence": "The plasma CRP level is positively correlated to the severity of COVID-19 on CT performance, and higher level of CRP showed a longer inpatient duration." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA/L, CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32243911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911", "evidence_list": [ { "evidence": "Best baseline predictors of respiratory failure were suPAR with an AUC (95% CI) of 0.88 (0.80-0.95), EWS 0.84 (0.75-0.93), LDH 0.82 (0.71-0.93), and CRP 0.80 (0.70-0.89. [DOI:10.1101/2020.05.27.20114678] At the early stage of COVID-19, CRP levels were positively cor-related with lung lesions. CRP levels could reflect disease severity and should be used as a key indicator for disease monitoring." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA/L, CRP, SAA, and L count are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "The positive correlations between CRP and series cancer biomarkers we showed in this study demonstrate that these cancer biomarkers can present the diffuse and acute lung injuries in COVID-19. CRP increased in 95% of all cases; the increases were significant for all groups (mild: 13.5\u2009\u00b1\u200913.1; severe: 35.0\u2009\u00b1\u200939.2; critical: 66.1\u2009\u00b1\u200967.3; in mg/L; P\u2009=\u2009.002)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >2252ug/L, WBC>9.5x10^9/L or NC >7.305x10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Surveillance of NLR and lymphocyte subsets is helpful in the early screening of critical illness, diagnosis, and treatment of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32425269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269", "evidence_list": [ { "evidence": "The maximal level of IL-6, followed by CRP level, was highly predictive of the need for mechanical ventilation. This suggests the possibility of using IL-6 or CRP level to guide escalation of treatment in patients with COVID-19-related hyperinflammatory syndrome." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32566572", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572", "evidence_list": [ { "evidence": "NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32243911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911", "evidence_list": [ { "evidence": "At the early stage of COVID-19, CRP levels were positively correlated with lung lesions. CRP levels could reflect disease severity and should be used as a key indicator for disease monitoring." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "CRP changes before other blood parameters and thus may be an effective evaluation index for patients with COVID-19 infection. [DOI:10.1101/2020.03.10.20033613] CRP in severe COVID-19 patients increased significantly at the initial stage, before CT findings. Importantly, CRP, which was associated with disease development, predicted early severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32368728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728", "evidence_list": [ { "evidence": "The combination of eosinopenia and elevated hs-CRP can effectively triage suspected COVID-19 patients from other patients attending the fever clinic with COVID-19-like initial symptoms." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Patients with higher initial SAA are more likely to have poor CT imaging. Our study indicated that SAA/L. CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "CRP is one of the first biomarkers within blood plasma that changes to reflect physiological complications; if accepted CRP will be the most effective biomarker to predict the progression of COVID-19 infection. CRP values are more reliable for earlier identification of case severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "CRP which was associated with disease development, predicted early severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32511972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511972", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Concentrations of CRP remained high in patients who died of COVID-19 infection, and CRP could be a biomarker for assessing disease lethality." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32344321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321", "evidence_list": [ { "evidence": "The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32615866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866", "evidence_list": [ { "evidence": "The serum levels of CRP, PCT and ferritin are markedly increased in very severe compared with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32414383", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32414383", "evidence_list": [ { "evidence": "The plasma CRP level is positively correlated to the severity of COVID-19 on CT performance, and higher level of CRP showed a longer inpatient duration." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "SAA/L, CRP, SAA, and l are valuable in predicting the severity and distinguishing critically ill patients from mild ones." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32243911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911", "evidence_list": [ { "evidence": "Best baseline predictors of respiratory failure were suPAR with an AUC (95% CI) of 0.88 (0.80-0.95), EWS 0.84 (0.75-0.93), LDH 0.82 (0.71-0.93), and CRP 0.80 (0.70-0.89. [DOI:10.1101/2020.05.27.20114678] At the early stage of COVID-19, CRP levels were positively cor-related with lung lesions. CRP levels could reflect disease severity and should be used as a key indicator for disease monitoring." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "The association between biomarkers and clinical outcomes in novel coronavirus\u00a0pneumonia in a US cohort.", "journal": "Biomarkers in medicine", "authors": "Ayanian S, Reyes J, Lynn L, Teufel K", "date": "2020-07-18", "evidence": [], "reference": [ { "id": "32677844", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.", "journal": "BMC infectious diseases", "authors": "Gong J, Dong H, Xia QS, Huang ZY, Wang DK, Zhao Y, Liu WH, Tu SH, Zhang MM, Wang Q, Lu FE", "date": "2020-12-23", "evidence": [], "reference": [ { "id": "33349241", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T", "date": "2020-05-20", "evidence": [], "reference": [ { "id": "32425269", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32425269" } ] }, { "title": "Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.", "journal": "Annals of translational medicine", "authors": "Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, Li YL, Wu YZ, Diao B", "date": "2020-06-23", "evidence": [], "reference": [ { "id": "32566572", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572" } ] }, { "title": "C-reactive protein levels in the early stage of COVID-19.", "journal": "Medecine et maladies infectieuses", "authors": "Wang L", "date": "2020-04-04", "evidence": [], "reference": [ { "id": "32243911", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B", "date": "2020-04-17", "evidence": [], "reference": [ { "id": "32296824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824" } ] }, { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] }, { "title": "Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study.", "journal": "EClinicalMedicine", "authors": "Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L, Wang Z", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32368728", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728" } ] }, { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] }, { "title": "C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.", "journal": "Clinica chimica acta; international journal of clinical chemistry", "authors": "Sahu BR, Kampa RK, Padhi A, Panda AK", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511972" } ] }, { "title": "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.", "journal": "Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology", "authors": "Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X", "date": "2020-04-29", "evidence": [], "reference": [ { "id": "32344321", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32344321" } ] }, { "title": "C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis.", "journal": "Therapeutic advances in respiratory disease", "authors": "Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32615866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32615866" } ] }, { "title": "Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.", "journal": "Archives of medical research", "authors": "Assandri R, Buscarini E, Canetta C, Scartabellati A, Vigan\u00f2 G, Montanelli A", "date": "2020-05-31", "evidence": [], "reference": [ { "id": "32471703", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703" } ] }, { "title": "Plasma CRP level is positively associated with the severity of COVID-19.", "journal": "Annals of clinical microbiology and antimicrobials", "authors": "Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z", "date": "2020-05-18", "evidence": [], "reference": [ { "id": "32414383", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32414383" } ] }, { "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.", "journal": "Science China. Life sciences", "authors": "Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L", "date": "2020-02-13", "evidence": [], "reference": [ { "id": "32048163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163" } ] }, { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "C-reactive protein levels in the early stage of COVID-19.", "journal": "Medecine et maladies infectieuses", "authors": "Wang L", "date": "2020-04-04", "evidence": [], "reference": [ { "id": "32243911", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32243911" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-2", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-3", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). Elevated CRP (> 3.9 mg/L) showed a statistically significant association with reduced survival; however, HRs were somewhat lower than for SAA. CRP was associated with disease-free survival across all models in a dose-response fashion (P trend = .04 in model 4). Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] }, { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). Elevated CRP (> 3.9 mg/L) showed a statistically significant association with reduced survival; however, HRs were somewhat lower than for SAA. CRP was associated with disease-free survival across all models in a dose-response fashion (P trend = .04 in model 4). Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] }, { "title": "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM", "date": "2009-05-28", "evidence": [], "reference": [ { "id": "19470939", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-4", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-5", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-6", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-7", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32224151", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151", "evidence_list": [ { "evidence": "Highly sensitive C-reactive protein levels in 23 (82.1%) patients. Patients developed severe clinical events; 6 (21.4%) patients were admitted to ICU, 10 (35.7%) patients had life-threatening complications, and 8 (28.6%) of the patients died" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M", "date": "2020-04-01", "evidence": [], "reference": [ { "id": "32224151", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32224151" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AA4695-8", "biomarker_component": [ { "biomarker": "increased CRP level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "31477553", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31477553", "evidence_list": [ { "evidence": "Increased CRP may represent an extended biomarker of microvascular risk in men with T2DM." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "31477553", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31477553", "evidence_list": [ { "evidence": "Increased CRP may represent an extended biomarker of microvascular risk in men with T2DM." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetes.", "journal": "Journal of diabetes and its complications", "authors": "Hermans MP, Ahn SA, Rousseau MF", "date": "2019-09-04", "evidence": [], "reference": [ { "id": "31477553", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31477553" } ] } ], "biomarker_canonical_id": "AA4695", "collision": 1 }, { "biomarker_id": "AN4452-1", "biomarker_component": [ { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Elevated age and NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32620118", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118", "evidence_list": [ { "evidence": "The rising trend in D-Dimer and NLR, or the test results higher than the critical values may indicate a risk of death for participants with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Age and elevated NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32283162", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283162", "evidence_list": [ { "evidence": "NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32566572", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572", "evidence_list": [ { "evidence": "NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "NLCR could be used as a novel, highly specific and sensitive marker for predicting severity of COVID-19 patients. [DOI:10.21203/rs.3.rs-28850/v1] We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32376581", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376581", "evidence_list": [ { "evidence": "An increased NLR can serve as an early warning signal of severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Elevated age and NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32620118", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118", "evidence_list": [ { "evidence": "The rising trend in D-Dimer and NLR, or the test results higher than the critical values may indicate a risk of death for participants with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Age and elevated NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32283162", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283162", "evidence_list": [ { "evidence": "NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32566572", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572", "evidence_list": [ { "evidence": "NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "NLCR could be used as a novel, highly specific and sensitive marker for predicting severity of COVID-19 patients. [DOI:10.21203/rs.3.rs-28850/v1] We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32376581", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376581", "evidence_list": [ { "evidence": "An increased NLR can serve as an early warning signal of severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Elevated age and NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32620118", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118", "evidence_list": [ { "evidence": "The rising trend in D-Dimer and NLR, or the test results higher than the critical values may indicate a risk of death for participants with COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32304994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994", "evidence_list": [ { "evidence": "Age and elevated NLR can be considered independent biomarkers for indicating poor clinical outcomes." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Lower lymphocyte counts, higher leukocyte counts and neutrophil-lymphocyte ratio (NLR), lower monocytes, eosinophils, and basophils elevated inflammatory cytokines T cells significantly decreased, helper T (Th) cells and suppressor T cells were below normal levels naive Th cells increased and memory Th cells decreased lower levels of regulatory T cells." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32283162", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283162", "evidence_list": [ { "evidence": "NLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32566572", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572", "evidence_list": [ { "evidence": "NLR and CRP are potential and reliable predictors of COVID-19 prognosis and can triage patients at the time of admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "NLCR could be used as a novel, highly specific and sensitive marker for predicting severity of COVID-19 patients. [DOI:10.21203/rs.3.rs-28850/v1] We propose that a few parameters, such Lymphocytes count, L/N ratio, SaO2 and CRP serum level can be used to assess the severity of COVID-19 in emergency room." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32376581", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376581", "evidence_list": [ { "evidence": "An increased NLR can serve as an early warning signal of severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.", "journal": "International immunopharmacology", "authors": "Yang AP, Liu JP, Tao WQ, Li HM", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32304994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994" } ] }, { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] }, { "title": "Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.", "journal": "Respiratory research", "authors": "Ye W, Chen G, Li X, Lan X, Ji C, Hou M, Zhang D, Zeng G, Wang Y, Xu C, Lu W, Cui R, Cai Y, Huang H, Yang L", "date": "2020-07-06", "evidence": [], "reference": [ { "id": "32620118", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118" } ] }, { "title": "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.", "journal": "International immunopharmacology", "authors": "Yang AP, Liu JP, Tao WQ, Li HM", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32304994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.", "journal": "The Journal of infection", "authors": "Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, Luo M, Chen L, Zhao Y", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32283162", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283162" } ] }, { "title": "Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.", "journal": "Annals of translational medicine", "authors": "Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, Li YL, Wu YZ, Diao B", "date": "2020-06-23", "evidence": [], "reference": [ { "id": "32566572", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572" } ] }, { "title": "Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.", "journal": "Archives of medical research", "authors": "Assandri R, Buscarini E, Canetta C, Scartabellati A, Vigan\u00f2 G, Montanelli A", "date": "2020-05-31", "evidence": [], "reference": [ { "id": "32471703", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703" } ] }, { "title": "[An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19].", "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University", "authors": "Xia X, Wen M, Zhan S, He J, Chen W", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32376581", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376581" } ] }, { "title": "Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma.", "journal": "BMC cancer", "authors": "Han S, Liu Y, Li Q, Li Z, Hou H, Wu A", "date": "2015-09-06", "evidence": [], "reference": [ { "id": "26341881", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881" } ] }, { "title": "Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients.", "journal": "BMC endocrine disorders", "authors": "Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L", "date": "2015-04-19", "evidence": [], "reference": [ { "id": "25887236", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236" } ] }, { "title": "Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes.", "journal": "Journal of diabetes and its complications", "authors": "Wang RT, Zhang JR, Li Y, Liu T, Yu KJ", "date": "2014-12-09", "evidence": [], "reference": [ { "id": "25483847", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847" } ] }, { "title": "Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity.", "journal": "Diabetes & metabolic syndrome", "authors": "Yilmaz H, Ucan B, Sayki M, Unsal I, Sahin M, Ozbek M, Delibasi T", "date": "2014-12-04", "evidence": [], "reference": [ { "id": "25470646", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646" } ] }, { "title": "Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study.", "journal": "European journal of endocrinology", "authors": "Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, Shi H, Wang C, Xia Y, Liu X, Li C, Sun S, Wang X, Zhou M, Huang G, Jia Q, Zhao H, Song K, Niu K", "date": "2015-05-09", "evidence": [], "reference": [ { "id": "25953830", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830" } ] }, { "title": "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.", "journal": "International immunopharmacology", "authors": "Yang AP, Liu JP, Tao WQ, Li HM", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32304994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994" } ] }, { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] }, { "title": "Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.", "journal": "Respiratory research", "authors": "Ye W, Chen G, Li X, Lan X, Ji C, Hou M, Zhang D, Zeng G, Wang Y, Xu C, Lu W, Cui R, Cai Y, Huang H, Yang L", "date": "2020-07-06", "evidence": [], "reference": [ { "id": "32620118", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118" } ] }, { "title": "The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.", "journal": "International immunopharmacology", "authors": "Yang AP, Liu JP, Tao WQ, Li HM", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32304994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304994" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] }, { "title": "Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.", "journal": "The Journal of infection", "authors": "Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, Luo M, Chen L, Zhao Y", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32283162", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32283162" } ] }, { "title": "Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.", "journal": "Annals of translational medicine", "authors": "Liu YP, Li GM, He J, Liu Y, Li M, Zhang R, Li YL, Wu YZ, Diao B", "date": "2020-06-23", "evidence": [], "reference": [ { "id": "32566572", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32566572" } ] }, { "title": "Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.", "journal": "Archives of medical research", "authors": "Assandri R, Buscarini E, Canetta C, Scartabellati A, Vigan\u00f2 G, Montanelli A", "date": "2020-05-31", "evidence": [], "reference": [ { "id": "32471703", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703" } ] }, { "title": "[An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19].", "journal": "Nan fang yi ke da xue xue bao = Journal of Southern Medical University", "authors": "Xia X, Wen M, Zhan S, He J, Chen W", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32376581", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376581" } ] }, { "title": "Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma.", "journal": "BMC cancer", "authors": "Han S, Liu Y, Li Q, Li Z, Hou H, Wu A", "date": "2015-09-06", "evidence": [], "reference": [ { "id": "26341881", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881" } ] }, { "title": "Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients.", "journal": "BMC endocrine disorders", "authors": "Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L", "date": "2015-04-19", "evidence": [], "reference": [ { "id": "25887236", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236" } ] }, { "title": "Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes.", "journal": "Journal of diabetes and its complications", "authors": "Wang RT, Zhang JR, Li Y, Liu T, Yu KJ", "date": "2014-12-09", "evidence": [], "reference": [ { "id": "25483847", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847" } ] }, { "title": "Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity.", "journal": "Diabetes & metabolic syndrome", "authors": "Yilmaz H, Ucan B, Sayki M, Unsal I, Sahin M, Ozbek M, Delibasi T", "date": "2014-12-04", "evidence": [], "reference": [ { "id": "25470646", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646" } ] }, { "title": "Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study.", "journal": "European journal of endocrinology", "authors": "Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, Shi H, Wang C, Xia Y, Liu X, Li C, Sun S, Wang X, Zhou M, Huang G, Jia Q, Zhao H, Song K, Niu K", "date": "2015-05-09", "evidence": [], "reference": [ { "id": "25953830", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830" } ] } ], "biomarker_canonical_id": "AN4452", "collision": 0 }, { "biomarker_id": "AN4452-2", "biomarker_component": [ { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1319", "recommended_name": { "id": "DOID:1319", "name": "brain cancer", "description": "A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, "synonyms": [ { "id": "DOID:1319", "name": "malignant brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "BT - Brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult malignant brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary malignant neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of adult brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "tumor of the Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm, adult", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" } ] }, "evidence_source": [ { "id": "26341881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881", "evidence_list": [ { "evidence": "Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients (multivariate hazard ratio =1.050; 95% confidence interval, 1.003-1.100; P = 0.037) High pre-treatment NLR (>/= 4 versus < 4) was significantly associated with high neutrophil infiltration and low CD3(+) T-cell infiltration into tumors, and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma.", "journal": "BMC cancer", "authors": "Han S, Liu Y, Li Q, Li Z, Hou H, Wu A", "date": "2015-09-06", "evidence": [], "reference": [ { "id": "26341881", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881" } ] }, { "title": "Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma.", "journal": "BMC cancer", "authors": "Han S, Liu Y, Li Q, Li Z, Hou H, Wu A", "date": "2015-09-06", "evidence": [], "reference": [ { "id": "26341881", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26341881" } ] } ], "biomarker_canonical_id": "AN4452", "collision": 0 }, { "biomarker_id": "AN4452-3", "biomarker_component": [ { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased NLR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to Lymphocyte ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "25887236", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236", "evidence_list": [ { "evidence": "The NLR values of the diabetic patients were significantly higher than those of the healthy control. Logistic regression analysis showed that the risk predictors of insulin resistance include NLR, TG and HbA1c." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25483847", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847", "evidence_list": [ { "evidence": "NLR and brachial-ankle pulse wave velocity were elevated both in type 2 diabetes melittus and in diabetic retinopathy. Early detection of abnormal NLR levels may be helpful for the search of subclinical atherosclerosis in patients with T2DM and DR." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25470646", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646", "evidence_list": [ { "evidence": "The aim of the present study was to investigate the predictive value of preprocedural (before the OGTT) NLR on development of type 2 diabetes (T2DM) in morbid obesity patients (MOP). MOP have higher NLR than healthy controls. High NLR is a powerful and independent predictor of T2DM in MOP." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25953830", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830", "evidence_list": [ { "evidence": "NLR, but not leukocyte, neutrophil,and lymphocyte counts, was positively related to the incidence of T2D in a reasonably sized sample of urban Chinese adults. Compared to participants in the lowest quintile of NLR, participants in the upper four quintiles tended to be older, to have higher BMI, waist circumference, and levels of tryglycerides. In addition, a higher proportion these participants were current smokers and drinkers and had a family history of CVD, hypertension, and diabetes. Other than these results, no significant differences were observed between the participants in different NLR quintiles." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients.", "journal": "BMC endocrine disorders", "authors": "Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L", "date": "2015-04-19", "evidence": [], "reference": [ { "id": "25887236", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236" } ] }, { "title": "Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes.", "journal": "Journal of diabetes and its complications", "authors": "Wang RT, Zhang JR, Li Y, Liu T, Yu KJ", "date": "2014-12-09", "evidence": [], "reference": [ { "id": "25483847", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847" } ] }, { "title": "Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity.", "journal": "Diabetes & metabolic syndrome", "authors": "Yilmaz H, Ucan B, Sayki M, Unsal I, Sahin M, Ozbek M, Delibasi T", "date": "2014-12-04", "evidence": [], "reference": [ { "id": "25470646", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646" } ] }, { "title": "Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study.", "journal": "European journal of endocrinology", "authors": "Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, Shi H, Wang C, Xia Y, Liu X, Li C, Sun S, Wang X, Zhou M, Huang G, Jia Q, Zhao H, Song K, Niu K", "date": "2015-05-09", "evidence": [], "reference": [ { "id": "25953830", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830" } ] }, { "title": "Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients.", "journal": "BMC endocrine disorders", "authors": "Lou M, Luo P, Tang R, Peng Y, Yu S, Huang W, He L", "date": "2015-04-19", "evidence": [], "reference": [ { "id": "25887236", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25887236" } ] }, { "title": "Neutrophil-Lymphocyte ratio is associated with arterial stiffness in diabetic retinopathy in type 2 diabetes.", "journal": "Journal of diabetes and its complications", "authors": "Wang RT, Zhang JR, Li Y, Liu T, Yu KJ", "date": "2014-12-09", "evidence": [], "reference": [ { "id": "25483847", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25483847" } ] }, { "title": "Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity.", "journal": "Diabetes & metabolic syndrome", "authors": "Yilmaz H, Ucan B, Sayki M, Unsal I, Sahin M, Ozbek M, Delibasi T", "date": "2014-12-04", "evidence": [], "reference": [ { "id": "25470646", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25470646" } ] }, { "title": "Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study.", "journal": "European journal of endocrinology", "authors": "Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, Shi H, Wang C, Xia Y, Liu X, Li C, Sun S, Wang X, Zhou M, Huang G, Jia Q, Zhao H, Song K, Niu K", "date": "2015-05-09", "evidence": [], "reference": [ { "id": "25953830", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25953830" } ] } ], "biomarker_canonical_id": "AN4452", "collision": 0 }, { "biomarker_id": "AA4696-1", "biomarker_component": [ { "biomarker": "increased TG level", "assessed_biomarker_entity": { "recommended_name": "Triglycerides", "synonyms": [ { "synonym": "triacylglycerols" }, { "synonym": "Triglyzerid" }, { "synonym": "Triglyceride" }, { "synonym": "Triglycerid" }, { "synonym": "triglycerides" }, { "synonym": "Triacylglycerol" }, { "synonym": "triglycerides" }, { "synonym": "a triacylglycerol" } ] }, "assessed_biomarker_entity_id": "CHEBI:17855", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3043-7" } ], "evidence_source": [ { "id": "32314799", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32314799", "evidence_list": [ { "evidence": "Clinicians should consider monitoring for hypertriglyceridemia." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32376398", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376398", "evidence_list": [ { "evidence": "We measured an extended panel of circulating biomarkers and used a disease-specific scale (BCRSS) to quickly classify respiratory severity in patients with COVID-19, we found extremely high levels of CRP, ferritin, D-Dimer and triglycerides indicating that a HIS was present at the time when the respiratory condition was rapidly deteriorating." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32430154", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430154", "evidence_list": [ { "evidence": "Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32314799", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32314799", "evidence_list": [ { "evidence": "Clinicians should consider monitoring for hypertriglyceridemia." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32376398", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376398", "evidence_list": [ { "evidence": "We measured an extended panel of circulating biomarkers and used a disease-specific scale (BCRSS) to quickly classify respiratory severity in patients with COVID-19, we found extremely high levels of CRP, ferritin, D-Dimer and triglycerides indicating that a HIS was present at the time when the respiratory condition was rapidly deteriorating." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32430154", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430154", "evidence_list": [ { "evidence": "Development of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.", "journal": "Journal of medical virology", "authors": "Morrison AR, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR", "date": "2020-04-22", "evidence": [], "reference": [ { "id": "32314799", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32314799" } ] }, { "title": "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.", "journal": "Autoimmunity reviews", "authors": "Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Air\u00f2 P, Bazzani C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, De Peri E, Faletti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A, Modina D, Moioli G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccal\u00e0 F, Zunica F, Foc\u00e0 E, Andreoli L, Latronico N", "date": "2020-05-08", "evidence": [], "reference": [ { "id": "32376398", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32376398" } ] }, { "title": "Hypolipidemia is associated with the severity of COVID-19.", "journal": "Journal of clinical lipidology", "authors": "Wei X, Zeng W, Su J, Wan H, Yu X, Cao X, Tan W, Wang H", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32430154", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430154" } ] } ], "biomarker_canonical_id": "AA4696", "collision": 1 }, { "biomarker_id": "AA4696-2", "biomarker_component": [ { "biomarker": "increased TG level", "assessed_biomarker_entity": { "recommended_name": "Triglycerides", "synonyms": [ { "synonym": "triacylglycerols" }, { "synonym": "Triglyzerid" }, { "synonym": "Triglyceride" }, { "synonym": "Triglycerid" }, { "synonym": "triglycerides" }, { "synonym": "Triacylglycerol" }, { "synonym": "triglycerides" }, { "synonym": "a triacylglycerol" } ] }, "assessed_biomarker_entity_id": "CHEBI:17855", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3043-7" } ], "evidence_source": [ { "id": "11196072", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11196072", "evidence_list": [ { "evidence": "The significant difference in low-density lipoprotein-cholesterol and serum triglycerides between patients with metastatic and non-metastatic cancer was lost when lipoprotein cholesterol and serum triglyceride levels were adjusted for nutritional variables. The lipid profile in cancer patients is characterized by low low-density lipoprotein-cholesterol, low high-density lipoprotein-cholesterol and relatively high serum triglycerides. The abnormality is a common feature of both hematological and solid tumors and is not entirely explained by poor nutrition." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "11196072", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11196072", "evidence_list": [ { "evidence": "The significant difference in low-density lipoprotein-cholesterol and serum triglycerides between patients with metastatic and non-metastatic cancer was lost when lipoprotein cholesterol and serum triglyceride levels were adjusted for nutritional variables. The lipid profile in cancer patients is characterized by low low-density lipoprotein-cholesterol, low high-density lipoprotein-cholesterol and relatively high serum triglycerides. The abnormality is a common feature of both hematological and solid tumors and is not entirely explained by poor nutrition." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects.", "journal": "International journal of clinical & laboratory research", "authors": "Fiorenza AM, Branchi A, Sommariva D", "date": "2001-02-24", "evidence": [], "reference": [ { "id": "11196072", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11196072" } ] } ], "biomarker_canonical_id": "AA4696", "collision": 1 }, { "biomarker_id": "AA4696-3", "biomarker_component": [ { "biomarker": "increased TG level", "assessed_biomarker_entity": { "recommended_name": "Triglycerides", "synonyms": [ { "synonym": "triacylglycerols" }, { "synonym": "Triglyzerid" }, { "synonym": "Triglyceride" }, { "synonym": "Triglycerid" }, { "synonym": "triglycerides" }, { "synonym": "Triacylglycerol" }, { "synonym": "triglycerides" }, { "synonym": "a triacylglycerol" } ] }, "assessed_biomarker_entity_id": "CHEBI:17855", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3043-7" } ], "evidence_source": [ { "id": "30325950", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30325950", "evidence_list": [ { "evidence": "The prevalence of dyslipidemia was relatively high among middle-aged and elderly T2DM person. There are different associations between multiple risk factors and dyslipidemia in different diabetic progression stages." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "30325950", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30325950", "evidence_list": [ { "evidence": "The prevalence of dyslipidemia was relatively high among middle-aged and elderly T2DM person. There are different associations between multiple risk factors and dyslipidemia in different diabetic progression stages." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The prevalence and risk factors of dyslipidemia in different diabetic progression stages among middle-aged and elderly populations in China.", "journal": "PloS one", "authors": "Li Y, Zhao L, Yu D, Ding G", "date": "2018-10-17", "evidence": [], "reference": [ { "id": "30325950", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30325950" } ] } ], "biomarker_canonical_id": "AA4696", "collision": 1 }, { "biomarker_id": "AA4697-1", "biomarker_component": [ { "biomarker": "increased CYP3A4 level", "assessed_biomarker_entity": { "recommended_name": "Cytochrome P450 3A4", "synonyms": [ { "synonym": "1,4-cineole 2-exo-monooxygenase" }, { "synonym": "1,8-cineole 2-exo-monooxygenase" }, { "synonym": "Albendazole monooxygenase (sulfoxide-forming)" }, { "synonym": "Albendazole sulfoxidase" }, { "synonym": "CYPIIIA3" }, { "synonym": "CYPIIIA4" }, { "synonym": "Cholesterol 25-hydroxylase" }, { "synonym": "Cytochrome P450 3A3" }, { "synonym": "Cytochrome P450 HLp" }, { "synonym": "Cytochrome P450 NF-25" }, { "synonym": "Cytochrome P450-PCN1" }, { "synonym": "Nifedipine oxidase" }, { "synonym": "Quinine 3-monooxygenase" } ] }, "assessed_biomarker_entity_id": "UPKB:P08684", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32758877", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32758877", "evidence_list": [ { "evidence": "Together with the reported markers of liver injury, such hyperinflammatory state may trigger significant derangements in hepatic cytochrome P450 metabolic machinery, and subsequent modulation of drug clearance that may result in unexpected therapeutic/toxic response. We hypothesize that COVID-19 patients are potentially vulnerable to a significant disease-drug interaction, and therefore, suitable dosing guidelines with therapeutic drug monitoring should be implemented to assure optimal clinical outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "response" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32758877", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32758877", "evidence_list": [ { "evidence": "Together with the reported markers of liver injury, such hyperinflammatory state may trigger significant derangements in hepatic cytochrome P450 metabolic machinery, and subsequent modulation of drug clearance that may result in unexpected therapeutic/toxic response. We hypothesize that COVID-19 patients are potentially vulnerable to a significant disease-drug interaction, and therefore, suitable dosing guidelines with therapeutic drug monitoring should be implemented to assure optimal clinical outcomes." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.", "journal": "Medical hypotheses", "authors": "El-Ghiaty MA, Shoieb SM, El-Kadi AOS", "date": "2020-08-08", "evidence": [], "reference": [ { "id": "32758877", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32758877" } ] } ], "biomarker_canonical_id": "AA4697", "collision": 1 }, { "biomarker_id": "AA4698-1", "biomarker_component": [ { "biomarker": "decreased CYP3A4 level", "assessed_biomarker_entity": { "recommended_name": "Cytochrome P450 3A4", "synonyms": [ { "synonym": "1,4-cineole 2-exo-monooxygenase" }, { "synonym": "1,8-cineole 2-exo-monooxygenase" }, { "synonym": "Albendazole monooxygenase (sulfoxide-forming)" }, { "synonym": "Albendazole sulfoxidase" }, { "synonym": "CYPIIIA3" }, { "synonym": "CYPIIIA4" }, { "synonym": "Cholesterol 25-hydroxylase" }, { "synonym": "Cytochrome P450 3A3" }, { "synonym": "Cytochrome P450 HLp" }, { "synonym": "Cytochrome P450 NF-25" }, { "synonym": "Cytochrome P450-PCN1" }, { "synonym": "Nifedipine oxidase" }, { "synonym": "Quinine 3-monooxygenase" } ] }, "assessed_biomarker_entity_id": "UPKB:P08684", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29109094", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29109094", "evidence_list": [ { "evidence": "CYP3A4 was identified as a novel tumor suppressor gene related to a poor prognosis in HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "29109094", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29109094", "evidence_list": [ { "evidence": "CYP3A4 was identified as a novel tumor suppressor gene related to a poor prognosis in HCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma", "journal": "Cancer genomics & proteomics", "authors": "Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Sugino T, Urakami K, Kusuhara M, Yamaguchi K", "date": "2017-11-08", "evidence": [], "reference": [ { "id": "29109094", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29109094" } ] } ], "biomarker_canonical_id": "AA4698", "collision": 1 }, { "biomarker_id": "AA4699-1", "biomarker_component": [ { "biomarker": "increased SAA1 level", "assessed_biomarker_entity": { "recommended_name": "Serum amyloid A protein", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "48498-0" } ], "evidence_source": [ { "id": "20502455", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20502455", "evidence_list": [ { "evidence": "Study detected increased SAA level in the serum of lung cancer patients and also identified that elevated SAA level may be a non-invasive biomarker useful for the prediction of lung cancer prognosis. A differential protein with m/z 11.6 kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was significantly increased by 1822% in lung cancer patients when compared with the healthy controls, which gave an area under the receiver operator characteristic curve of 0.88. In addition, the protein was also significantly elevated by 77% in lung cancer patients with survival <5 years when compared with patients with survival >/=5 years." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "20502455", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20502455", "evidence_list": [ { "evidence": "Study detected increased SAA level in the serum of lung cancer patients and also identified that elevated SAA level may be a non-invasive biomarker useful for the prediction of lung cancer prognosis. A differential protein with m/z 11.6 kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was significantly increased by 1822% in lung cancer patients when compared with the healthy controls, which gave an area under the receiver operator characteristic curve of 0.88. In addition, the protein was also significantly elevated by 77% in lung cancer patients with survival <5 years when compared with patients with survival >/=5 years." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis.", "journal": "British journal of cancer", "authors": "Cho WC, Yip TT, Cheng WW, Au JS", "date": "2010-05-27", "evidence": [], "reference": [ { "id": "20502455", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20502455" } ] } ], "biomarker_canonical_id": "AA4699", "collision": 1 }, { "biomarker_id": "AA4699-2", "biomarker_component": [ { "biomarker": "increased SAA1 level", "assessed_biomarker_entity": { "recommended_name": "Serum amyloid A protein", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "48498-0" } ], "evidence_source": [ { "id": "16211233", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16211233", "evidence_list": [ { "evidence": "The level of SAA in plasma of pancreatic cancer patients correlated with clinical stage and was significantly higher than in normal volunteers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "16211233", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16211233", "evidence_list": [ { "evidence": "The level of SAA in plasma of pancreatic cancer patients correlated with clinical stage and was significantly higher than in normal volunteers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.", "journal": "International journal of oncology", "authors": "Yokoi K, Shih LC, Kobayashi R, Koomen J, Hawke D, Li D, Hamilton SR, Abbruzzese JL, Coombes KR, Fidler IJ", "date": "2005-10-08", "evidence": [], "reference": [ { "id": "16211233", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16211233" } ] } ], "biomarker_canonical_id": "AA4699", "collision": 1 }, { "biomarker_id": "AA4699-5", "biomarker_component": [ { "biomarker": "increased SAA1 level", "assessed_biomarker_entity": { "recommended_name": "Serum amyloid A protein", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "48498-0" } ], "evidence_source": [ { "id": "19536090", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19536090", "evidence_list": [ { "evidence": "SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by RT-PCR=162 vs 2.21; P=0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "19536090", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19536090", "evidence_list": [ { "evidence": "SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by RT-PCR=162 vs 2.21; P=0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.", "journal": "British journal of cancer", "authors": "Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD", "date": "2009-06-19", "evidence": [], "reference": [ { "id": "19536090", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19536090" } ] } ], "biomarker_canonical_id": "AA4699", "collision": 1 }, { "biomarker_id": "AA4699-3", "biomarker_component": [ { "biomarker": "increased SAA1 level", "assessed_biomarker_entity": { "recommended_name": "Serum amyloid A protein", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Based on the study results, SAA alone or combined with L(SAA/L) could be used as a significant marker to indicate and track inflammation conditions in COVID-19 infected patients. Monitoring dynamic changes of SAA, combined with CT imaging could be a valuable strategy in the diagnosis and treatment of COVID-19. SAA and L are sensitive indicators in evaluating the severity and prognosis of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "The abnormal increase in serum amyloid protein (SAA) may be used as an auxiliary index for diagnosis and treatment. CRP changes before other blood parameters and thus may be an effective evaluation index for patients with COVID-19 infection. [DOI:10.1101/2020.03.10.20033613] C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "33735714", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33735714", "evidence_list": [ { "evidence": "The serum SAA levels were found to be significantly correlated with impending course of the COVID-19, and may serve as a useful biomarker to monitor the complicated clinical course of the disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32277967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967", "evidence_list": [ { "evidence": "Based on the study results, SAA alone or combined with L(SAA/L) could be used as a significant marker to indicate and track inflammation conditions in COVID-19 infected patients. Monitoring dynamic changes of SAA, combined with CT imaging could be a valuable strategy in the diagnosis and treatment of COVID-19. SAA and L are sensitive indicators in evaluating the severity and prognosis of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "The abnormal increase in serum amyloid protein (SAA) may be used as an auxiliary index for diagnosis and treatment. CRP changes before other blood parameters and thus may be an effective evaluation index for patients with COVID-19 infection. [DOI:10.1101/2020.03.10.20033613] C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "condition" } ] }, { "id": "33735714", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33735714", "evidence_list": [ { "evidence": "The serum SAA levels were found to be significantly correlated with impending course of the COVID-19, and may serve as a useful biomarker to monitor the complicated clinical course of the disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis.", "journal": "The Journal of infection", "authors": "Li H, Xiang X, Ren H, Xu L, Zhao L, Chen X, Long H, Wang Q, Wu Q", "date": "2020-04-12", "evidence": [], "reference": [ { "id": "32277967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32277967" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis.", "journal": "International immunopharmacology", "authors": "Pieri M, Ciotti M, Nuccetelli M, Perrone MA, Cali\u00f2 MT, Lia MS, Minieri M, Bernardini S", "date": "2021-03-19", "evidence": [], "reference": [ { "id": "33735714", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33735714" } ] } ], "biomarker_canonical_id": "AA4699", "collision": 1 }, { "biomarker_id": "AA4699-4", "biomarker_component": [ { "biomarker": "increased SAA1 level", "assessed_biomarker_entity": { "recommended_name": "Serum amyloid A protein", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). Higher concentrations of SAA were associated with decreased overall survival (P trend < .0001 in all models; lnSAA, P < .01 in all models). Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Elevated SAA and CRP were associated with reduced overall survival, regardless of adjustment for age, tumor stage, race, and body mass index (SAA P trend < .0001; CRP P trend = .002). Higher concentrations of SAA were associated with decreased overall survival (P trend < .0001 in all models; lnSAA, P < .01 in all models). Systemic C-reactive protein (CRP) and serum amyloid A (SAA) are measures of low-grade chronic inflammation and potential predictors of cancer survival" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM", "date": "2009-05-28", "evidence": [], "reference": [ { "id": "19470939", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939" } ] } ], "biomarker_canonical_id": "AA4699", "collision": 1 }, { "biomarker_id": "AA4701-1", "biomarker_component": [ { "biomarker": "increased CXCL10 level", "assessed_biomarker_entity": { "recommended_name": "IFN-gamma-inducible protein 10", "synonyms": [ { "synonym": "10 kDa interferon gamma-induced protein" }, { "synonym": "Gamma-IP10" }, { "synonym": "IP-10" }, { "synonym": "Small-inducible cytokine B10" } ] }, "assessed_biomarker_entity_id": "UPKB:P02778", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IFN-gamma-induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNF alpha than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IP-10 and MCP-3 were highly associated with disease severity and could be used as excellent predictors of COVID-19 progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IFN-gamma-induced protein 10 and monocyte chemotactic protein-3 were excellent predictors for the progression of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNF alpha than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IP-10 and MCP-3 were highly associated with disease severity and could be used as excellent predictors of COVID-19 progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L, Yang M, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Gao GF, Jiang C, Liu L, Liu Y", "date": "2020-05-04", "evidence": [], "reference": [ { "id": "32360286", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286" } ] }, { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L, Yang M, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Gao GF, Jiang C, Liu L, Liu Y", "date": "2020-05-04", "evidence": [], "reference": [ { "id": "32360286", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286" } ] } ], "biomarker_canonical_id": "AA4701", "collision": 1 }, { "biomarker_id": "AA4702-1", "biomarker_component": [ { "biomarker": "increased CCL7 level", "assessed_biomarker_entity": { "recommended_name": "Monocyte chemotactic protein-3", "synonyms": [ { "synonym": "Monocyte chemoattractant protein 3" }, { "synonym": "Monocyte chemotactic protein 3" }, { "synonym": "MCP-3" }, { "synonym": "NC28" }, { "synonym": "Small-inducible cytokine A7" } ] }, "assessed_biomarker_entity_id": "UPKB:P80098", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNF alpha than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IP-10 and MCP-3 were highly associated with disease severity and could be used as excellent predictors of COVID-19 progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNF alpha than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32360286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286", "evidence_list": [ { "evidence": "IP-10 and MCP-3 were highly associated with disease severity and could be used as excellent predictors of COVID-19 progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.", "journal": "The Journal of allergy and clinical immunology", "authors": "Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L, Peng L, Yang M, Cao M, Zheng H, Wu W, Zou R, Li D, Xu Z, Wang H, Zhang M, Zhang Z, Gao GF, Jiang C, Liu L, Liu Y", "date": "2020-05-04", "evidence": [], "reference": [ { "id": "32360286", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32360286" } ] } ], "biomarker_canonical_id": "AA4702", "collision": 1 }, { "biomarker_id": "AA4702-2", "biomarker_component": [ { "biomarker": "increased CCL7 level", "assessed_biomarker_entity": { "recommended_name": "Monocyte chemotactic protein-3", "synonyms": [ { "synonym": "Monocyte chemoattractant protein 3" }, { "synonym": "Monocyte chemotactic protein 3" }, { "synonym": "MCP-3" }, { "synonym": "NC28" }, { "synonym": "Small-inducible cytokine A7" } ] }, "assessed_biomarker_entity_id": "UPKB:P80098", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "12439927", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12439927", "evidence_list": [ { "evidence": "We detected MCP-3 mRNA expression in MCP-3 gene transfected CMT93 cells. In contrast, the wild type CMT93 cells and the mock transfected CMT93 cells did not express MCP-3. In the tumor tissue derived from CMT93/MCP-3, infiltrating immune cells increased. In addition, no tumor metastasis was found in all mice inoculated with CMT93/ MCP-3 tumor cells. But all mice had tumor metastasis in CMT93 controls. In our study, we found that after the transfecting of CMT93 colorectal cancer cell with MCP-3 gene, tumor growth was retarded and tumor metastasis was inhibited completely by promoting immune cells infiltration in tumor tissue." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "12439927", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12439927", "evidence_list": [ { "evidence": "We detected MCP-3 mRNA expression in MCP-3 gene transfected CMT93 cells. In contrast, the wild type CMT93 cells and the mock transfected CMT93 cells did not express MCP-3. In the tumor tissue derived from CMT93/MCP-3, infiltrating immune cells increased. In addition, no tumor metastasis was found in all mice inoculated with CMT93/ MCP-3 tumor cells. But all mice had tumor metastasis in CMT93 controls. In our study, we found that after the transfecting of CMT93 colorectal cancer cell with MCP-3 gene, tumor growth was retarded and tumor metastasis was inhibited completely by promoting immune cells infiltration in tumor tissue." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis.", "journal": "World journal of gastroenterology", "authors": "Hu JY, Li GC, Wang WM, Zhu JG, Li YF, Zhou GH, Sun QB", "date": "2002-11-20", "evidence": [], "reference": [ { "id": "12439927", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12439927" } ] } ], "biomarker_canonical_id": "AA4702", "collision": 1 }, { "biomarker_id": "AA4704-1", "biomarker_component": [ { "biomarker": "increased GRAN count", "assessed_biomarker_entity": { "recommended_name": "Granulocyte", "synonyms": [ { "synonym": "granular leucocyte" }, { "synonym": "granular leukocyte" }, { "synonym": "polymorphonuclear leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000094", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "30394-1" } ], "evidence_source": [ { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32281668", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668", "evidence_list": [ { "evidence": "Patients with flu had higher WBC, granulocyte and granulocyte/lymphocyte ratio, compared with COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early.", "journal": "Journal of medical virology", "authors": "Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, Jiang X, Li X", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281668", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281668" } ] } ], "biomarker_canonical_id": "AA4704", "collision": 1 }, { "biomarker_id": "AA4704-2", "biomarker_component": [ { "biomarker": "increased GRAN count", "assessed_biomarker_entity": { "recommended_name": "Granulocyte", "synonyms": [ { "synonym": "granular leucocyte" }, { "synonym": "granular leukocyte" }, { "synonym": "polymorphonuclear leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000094", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "30394-1" } ], "evidence_source": [ { "id": "11406548", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11406548", "evidence_list": [ { "evidence": "The chronic presence of the tumor and thus chronic activation of granulocytes with the accompanying production of H2O2 results, ironically, in the suppression of the adaptive immune functions. Here we show specifically that the release of reactive oxygen species during the oxidative burst of granulocytes, i.e., H2O2, is the major contributor to a systemic T-cell dysfunction. This is supported by the observation that cancer patients showed signs of extensive granulocyte activation with massive elevation of plasma levels of 8-isoprostane, a product of lipid oxidation and a marker for oxidative stress, that exceeded measurements found in other diseases with documented oxidative stress." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "11406548", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11406548", "evidence_list": [ { "evidence": "The chronic presence of the tumor and thus chronic activation of granulocytes with the accompanying production of H2O2 results, ironically, in the suppression of the adaptive immune functions. Here we show specifically that the release of reactive oxygen species during the oxidative burst of granulocytes, i.e., H2O2, is the major contributor to a systemic T-cell dysfunction. This is supported by the observation that cancer patients showed signs of extensive granulocyte activation with massive elevation of plasma levels of 8-isoprostane, a product of lipid oxidation and a marker for oxidative stress, that exceeded measurements found in other diseases with documented oxidative stress." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.", "journal": "Cancer research", "authors": "Schmielau J, Finn OJ", "date": "2001-06-19", "evidence": [], "reference": [ { "id": "11406548", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11406548" } ] } ], "biomarker_canonical_id": "AA4704", "collision": 1 }, { "biomarker_id": "AA4705-1", "biomarker_component": [ { "biomarker": "increased D-D level", "assessed_biomarker_entity": { "recommended_name": "D-dimer", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050369", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71427-9" } ], "evidence_source": [ { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32442528", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528", "evidence_list": [ { "evidence": "Findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32306492", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32306492", "evidence_list": [ { "evidence": "Patients with D-dimer levels >/=2.0 \u00b5g/mL had a higher incidence of mortality when comparing with those who with D-dimer levels <2.0 \u00b5g/mL (12/67 vs 1/267, P < .001; hazard ratio, 51.5; 95% confidence interval, 12.9-206.7)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32665858", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32665858", "evidence_list": [ { "evidence": "D-dimer is commonly elevated in patients with COVID-19. D-dimer levels correlate with disease severity and is a reliable prognostic marker for in-hospital mortality in patients admitted for COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32620118", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118", "evidence_list": [ { "evidence": "The rising trend in D-Dimer and NLR, or the test results higher than the critical values may indicate a risk of death for participants with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "This, along with the previous study, suggests that D-dimer levels can be used as a prognostic marker and help clinicians monitor those who are likely to deteriorate earlier." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "D-dimer (10.36 vs. 0.26 ng/L; p<0.001) were higher in patients with SARS-CoV-2 than those in controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "The most important finding was that FAR and PLT count were independent risk factors to predict the development of severe illness in COVID-19. Patients with FAR<0.0883 and PLT count>135*10^9/L were unlikely to develop into severe disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32181911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911", "evidence_list": [ { "evidence": "IL-6 and D-dimer were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32442528", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528", "evidence_list": [ { "evidence": "Findings in this study include determining independent associations between biomarkers for inflammation (interleukin-6) and thrombosis (D-dimer) and mortality." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32306492", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32306492", "evidence_list": [ { "evidence": "Patients with D-dimer levels >/=2.0 \u00b5g/mL had a higher incidence of mortality when comparing with those who with D-dimer levels <2.0 \u00b5g/mL (12/67 vs 1/267, P < .001; hazard ratio, 51.5; 95% confidence interval, 12.9-206.7)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32665858", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32665858", "evidence_list": [ { "evidence": "D-dimer is commonly elevated in patients with COVID-19. D-dimer levels correlate with disease severity and is a reliable prognostic marker for in-hospital mortality in patients admitted for COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32620118", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118", "evidence_list": [ { "evidence": "The rising trend in D-Dimer and NLR, or the test results higher than the critical values may indicate a risk of death for participants with COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "This, along with the previous study, suggests that D-dimer levels can be used as a prognostic marker and help clinicians monitor those who are likely to deteriorate earlier." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "D-dimer (10.36 vs. 0.26 ng/L; p<0.001) were higher in patients with SARS-CoV-2 than those in controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "The most important finding was that FAR and PLT count were independent risk factors to predict the development of severe illness in COVID-19. Patients with FAR<0.0883 and PLT count>135*10^9/L were unlikely to develop into severe disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32181911", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911", "evidence_list": [ { "evidence": "IL-6 and D-dimer were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The association between biomarkers and clinical outcomes in novel coronavirus\u00a0pneumonia in a US cohort.", "journal": "Biomarkers in medicine", "authors": "Ayanian S, Reyes J, Lynn L, Teufel K", "date": "2020-07-18", "evidence": [], "reference": [ { "id": "32677844", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.", "journal": "Lancet (London, England)", "authors": "Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR", "date": "2020-05-23", "evidence": [], "reference": [ { "id": "32442528", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32442528" } ] }, { "title": "Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.", "journal": "The Lancet. Infectious diseases", "authors": "Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D", "date": "2020-03-30", "evidence": [], "reference": [ { "id": "32220650", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650" } ] }, { "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.", "journal": "Lancet (London, England)", "authors": "Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B", "date": "2020-03-15", "evidence": [], "reference": [ { "id": "32171076", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076" } ] }, { "title": "D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.", "journal": "Journal of thrombosis and haemostasis : JTH", "authors": "Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z", "date": "2020-04-20", "evidence": [], "reference": [ { "id": "32306492", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32306492" } ] }, { "title": "D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study.", "journal": "Journal of intensive care", "authors": "Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, Chen X, Chen S, Yu K, Huang Z, Hu B", "date": "2020-07-16", "evidence": [], "reference": [ { "id": "32665858", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32665858" } ] }, { "title": "Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19.", "journal": "Respiratory research", "authors": "Ye W, Chen G, Li X, Lan X, Ji C, Hou M, Zhang D, Zeng G, Wang Y, Xu C, Lu W, Cui R, Cai Y, Huang H, Yang L", "date": "2020-07-06", "evidence": [], "reference": [ { "id": "32620118", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620118" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL", "date": "2020-03-17", "evidence": [], "reference": [ { "id": "32172226", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226" } ] }, { "title": "Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.", "journal": "Platelets", "authors": "Bi X, Su Z, Yan H, Du J, Wang J, Chen L, Peng M, Chen S, Shen B, Li J", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32367765", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765" } ] }, { "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.", "journal": "Journal of thrombosis and haemostasis : JTH", "authors": "Tang N, Li D, Wang X, Sun Z", "date": "2020-02-20", "evidence": [], "reference": [ { "id": "32073213", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213" } ] }, { "title": "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.", "journal": "Journal of medical virology", "authors": "Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L", "date": "2020-03-18", "evidence": [], "reference": [ { "id": "32181911", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32181911" } ] } ], "biomarker_canonical_id": "AA4705", "collision": 1 }, { "biomarker_id": "AA4705-2", "biomarker_component": [ { "biomarker": "increased D-D level", "assessed_biomarker_entity": { "recommended_name": "D-dimer", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050369", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71427-9" } ], "evidence_source": [ { "id": "17454757", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17454757", "evidence_list": [ { "evidence": "We report changes in D-dimer levels that may indicate diabetes disease progression to macrovascular complications. Using D-dimer in conjunction with other biomarkers to identify stages of disease progression, commencing from pre-diabetes and continuing to development of asymptomatic and clinical cardiovascular disease in diabetes mellitus, is worthy of consideration." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32430456", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456", "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 \u00b1 0.84 mmol/L in the no insulin infusion group and 7.69 \u00b1 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32623030", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32623030", "evidence_list": [ { "evidence": "In COVID-19 patients with diabetes, poorly-controlled blood glucose (>11 mmol/L) may be associated with poor outcomes. Admission hyperglycemia, elevated d-dimer and high HRCT score are potential risk factors for adverse outcomes and death." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "17454757", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17454757", "evidence_list": [ { "evidence": "We report changes in D-dimer levels that may indicate diabetes disease progression to macrovascular complications. Using D-dimer in conjunction with other biomarkers to identify stages of disease progression, commencing from pre-diabetes and continuing to development of asymptomatic and clinical cardiovascular disease in diabetes mellitus, is worthy of consideration." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32430456", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456", "evidence_list": [ { "evidence": "The mean of glycemia during hospitalization was 10.65 \u00b1 0.84 mmol/L in the no insulin infusion group and 7.69 \u00b1 1.85 mmol/L in the insulin infusion group. At baseline, IL-6 and D-dimer levels were significantly higher in the hyperglycemic group than in the normoglycemic group (P < 0.001). Even though all patients were on standard treatment for COVID-19 infection, IL-6 and D-dimer levels persisted higher in patients with hyperglycemia during hospitalization." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32623030", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32623030", "evidence_list": [ { "evidence": "In COVID-19 patients with diabetes, poorly-controlled blood glucose (>11 mmol/L) may be associated with poor outcomes. Admission hyperglycemia, elevated d-dimer and high HRCT score are potential risk factors for adverse outcomes and death." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "D-dimer identifies stages in the progression of diabetes mellitus from family history of diabetes to cardiovascular complications.", "journal": "Pathology", "authors": "Nwose EU, Richards RS, Jelinek HF, Kerr PG", "date": "2007-04-25", "evidence": [], "reference": [ { "id": "17454757", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17454757" } ] }, { "title": "Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?", "journal": "Diabetes care", "authors": "Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32430456", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32430456" } ] }, { "title": "Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study.", "journal": "Diabetes research and clinical practice", "authors": "Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J, Gu J, Wang L, Fan Y, Shi H", "date": "2020-07-06", "evidence": [], "reference": [ { "id": "32623030", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32623030" } ] } ], "biomarker_canonical_id": "AA4705", "collision": 1 }, { "biomarker_id": "AA4705-3", "biomarker_component": [ { "biomarker": "increased D-D level", "assessed_biomarker_entity": { "recommended_name": "D-dimer", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050369", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71427-9" } ], "evidence_source": [ { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4705", "collision": 1 }, { "biomarker_id": "AA4706-1", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases. [DOI:10.1101/2020.03.19.20034447] Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Since high levels of LDH continued in the ICU patients number of days post-admission, LDH may be a predictive biomarker of severe disease. There is increasing confidence in using LDH as a biomarker to measure severity of COVID-19 infection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161968", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968", "evidence_list": [ { "evidence": "LDH and alpha-HBDH may be considerable markers for evaluation of NCOVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "As would be anticipated, elevation is LDH is common in COVID-19 patients in the ICU setting and indicates a poor outcome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32738466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32738466", "evidence_list": [ { "evidence": "Elevated LDH levels were associated with a ~6-fold increase in odds of developing severe disease and a ~16-fold increase in odds of mortality in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32677844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844", "evidence_list": [ { "evidence": "Elevated levels of IL-6, D-dimer, CRP, LDH, and ferritin all had an independent increased risk for the clinical outcomes assessed (ICU admission, invasive ventilatory support and death), which were statistically significant." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases. [DOI:10.1101/2020.03.19.20034447] Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] Since high levels of LDH continued in the ICU patients number of days post-admission, LDH may be a predictive biomarker of severe disease. There is increasing confidence in using LDH as a biomarker to measure severity of COVID-19 infection." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161968", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968", "evidence_list": [ { "evidence": "LDH and alpha-HBDH may be considerable markers for evaluation of NCOVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, and renal biomarkers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "As would be anticipated, elevation is LDH is common in COVID-19 patients in the ICU setting and indicates a poor outcome." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "Biomarkers that predict the mortality of individual patients more than 10 days in advance with more than 90% accuracy: lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP). [DOI:10.1038/s42256-020-0180-7] The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32738466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32738466", "evidence_list": [ { "evidence": "Elevated LDH levels were associated with a ~6-fold increase in odds of developing severe disease and a ~16-fold increase in odds of mortality in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The association between biomarkers and clinical outcomes in novel coronavirus\u00a0pneumonia in a US cohort.", "journal": "Biomarkers in medicine", "authors": "Ayanian S, Reyes J, Lynn L, Teufel K", "date": "2020-07-18", "evidence": [], "reference": [ { "id": "32677844", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32677844" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B", "date": "2020-04-17", "evidence": [], "reference": [ { "id": "32296824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824" } ] }, { "title": "A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, Guo F, Zhao H, Gao R", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161968", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "COVID-19 and the clinical hematology laboratory.", "journal": "International journal of laboratory hematology", "authors": "Frater JL, Zini G, d'Onofrio G, Rogers HJ", "date": "2020-04-21", "evidence": [], "reference": [ { "id": "32311826", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826" } ] }, { "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.", "journal": "Science China. Life sciences", "authors": "Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L", "date": "2020-02-13", "evidence": [], "reference": [ { "id": "32048163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163" } ] }, { "title": "Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis.", "journal": "The American journal of emergency medicine", "authors": "Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, Lippi G", "date": "2020-08-02", "evidence": [], "reference": [ { "id": "32738466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32738466" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-2", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-3", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-4", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-5", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-6", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-7", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-8", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-9", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-10", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-11", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2531", "recommended_name": { "id": "DOID:2531", "name": "hematologic cancer", "description": "An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, "synonyms": [ { "id": "DOID:2531", "name": "Hematologic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematologic malignancy", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic and lymphoid system tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "blood cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "malignant hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematological tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4706-12", "biomarker_component": [ { "biomarker": "increased LDH level", "assessed_biomarker_entity": { "recommended_name": "Lactate dehydrogenase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Our results showed that the laboratory tests of cancer patients had the following characteristics: low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH. The increase of these inflammatory indexes indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality. Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32369209", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209", "evidence_list": [ { "evidence": "Low lymphocytes, increased IL-6, CRP, PCT, D dimer, and LDH indicates that the infected patients were in inflammatory state, which may be closely related to the inflammatory storm. The increase of the cancer biomarkers in patients with COVID-19, especially in severe and critical patients, suggests that inflammation is closely related to the development of COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] }, { "title": "Clinical characteristics and outcomes of cancer patients with COVID-19.", "journal": "Journal of medical virology", "authors": "Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32369209", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32369209" } ] } ], "biomarker_canonical_id": "AA4706", "collision": 1 }, { "biomarker_id": "AA4707-1", "biomarker_component": [ { "biomarker": "decreased EOSI count", "assessed_biomarker_entity": { "recommended_name": "Eosinophil", "synonyms": [ { "synonym": "eosinophilic leukocyte" }, { "synonym": "eosinocyte" }, { "synonym": "eosinophilic leucocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "eosinophilic granulocyte" }, { "synonym": "polymorphonuclear leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000771", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26449-9" } ], "evidence_source": [ { "id": "32077115", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115", "evidence_list": [ { "evidence": "Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32368728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728", "evidence_list": [ { "evidence": "The combination of eosinopenia and elevated hs-CRP can effectively triage suspected COVID-19 patients from other patients attending the fever clinic with COVID-19-like initial symptoms." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32077115", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115", "evidence_list": [ { "evidence": "Detailed clinical investigation of 140 hospitalized COVID-19 cases suggests eosinopenia together with lymphopenia may be a potential indicator for diagnosis." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32368728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728", "evidence_list": [ { "evidence": "The combination of eosinopenia and elevated hs-CRP can effectively triage suspected COVID-19 patients from other patients attending the fever clinic with COVID-19-like initial symptoms." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.", "journal": "Allergy", "authors": "Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32077115", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077115" } ] }, { "title": "Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study.", "journal": "EClinicalMedicine", "authors": "Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L, Wang Z", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32368728", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32368728" } ] }, { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4707", "collision": 1 }, { "biomarker_id": "AA4707-2", "biomarker_component": [ { "biomarker": "decreased EOSI count", "assessed_biomarker_entity": { "recommended_name": "Eosinophil", "synonyms": [ { "synonym": "eosinophilic leukocyte" }, { "synonym": "eosinocyte" }, { "synonym": "eosinophilic leucocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "eosinophilic granulocyte" }, { "synonym": "polymorphonuclear leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000771", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26449-9" } ], "evidence_source": [ { "id": "21742945", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21742945", "evidence_list": [ { "evidence": "In age- and multivariate-adjusted models, eosinophil count was inversely associated with CRC incidence." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "21742945", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21742945", "evidence_list": [ { "evidence": "In age- and multivariate-adjusted models, eosinophil count was inversely associated with CRC incidence." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Inverse association of eosinophil count with colorectal cancer incidence: atherosclerosis risk in communities study.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Prizment AE, Anderson KE, Visvanathan K, Folsom AR", "date": "2011-07-12", "evidence": [], "reference": [ { "id": "21742945", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21742945" } ] } ], "biomarker_canonical_id": "AA4707", "collision": 1 }, { "biomarker_id": "AN4453-1", "biomarker_component": [ { "biomarker": "increased IL2R-LR ratio", "assessed_biomarker_entity": { "recommended_name": "Interleukin-2 receptor to Lymphocyte ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:2ERJ", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32365221", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32365221", "evidence_list": [ { "evidence": "The ratio of IL-2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL-2R/lymphocytes were superior compared with other markers for the identification of COVID-19 with critical illness, not only from mild but also from severe illness.Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IL2R-LR ratio", "assessed_biomarker_entity": { "recommended_name": "Interleukin-2 receptor to Lymphocyte ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32365221", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32365221", "evidence_list": [ { "evidence": "The ratio of IL-2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL-2R/lymphocytes were superior compared with other markers for the identification of COVID-19 with critical illness, not only from mild but also from severe illness.Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32365221", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32365221", "evidence_list": [ { "evidence": "The ratio of IL-2R to lymphocytes was found to be remarkably increased in severe and critical patients. IL-2R/lymphocytes were superior compared with other markers for the identification of COVID-19 with critical illness, not only from mild but also from severe illness.Lymphopenia and increased levels of cytokines were closely associated with disease severity. The IL-2R/lymphocyte was a prominent biomarker for early identification of severe COVID-19 and predicting the clinical progression of the disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.", "journal": "Clinical and experimental immunology", "authors": "Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, Liu W, Mao L, Mao L, Wang F, Sun Z", "date": "2020-05-05", "evidence": [], "reference": [ { "id": "32365221", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32365221" } ] }, { "title": "Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.", "journal": "Clinical and experimental immunology", "authors": "Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, Liu W, Mao L, Mao L, Wang F, Sun Z", "date": "2020-05-05", "evidence": [], "reference": [ { "id": "32365221", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32365221" } ] } ], "biomarker_canonical_id": "AN4453", "collision": 0 }, { "biomarker_id": "AA4708-1", "biomarker_component": [ { "biomarker": "increased PLAUR level", "assessed_biomarker_entity": { "recommended_name": "Soluble urokinase plasminogen activator receptor", "synonyms": [ { "synonym": "U-PAR" }, { "synonym": "uPAR" }, { "synonym": "Monocyte activation antigen Mo3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q03405", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17204-9" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "17204-9" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "17204-9" } ], "evidence_source": [ { "id": "32354367", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367", "evidence_list": [ { "evidence": "A low suPAR level (<4.75 ng/ml) at baseline is a useful biomarker for aiding clinical decisions including discharge of patients presenting with symptoms of COVID-19. [DOI:10.1101/2020.05.27.20114678] Findings suggest that suPAR may early trace patients who need intensified management probably in need of anti-inflammatory treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32613288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613288", "evidence_list": [ { "evidence": "In conclusion, suPAR seems extremely promising as a COVID-19 prognostic marker and may assist in the early selection of patients who can stay at home or must be admitted to the hospital and/or intensive care unit. In this difficult outbreak, humanity must use all the available weapons, and suPAR may prove a powerful triage biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32354367", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367", "evidence_list": [ { "evidence": "A low suPAR level (<4.75 ng/ml) at baseline is a useful biomarker for aiding clinical decisions including discharge of patients presenting with symptoms of COVID-19. [DOI:10.1101/2020.05.27.20114678] Admission levels of suPAR were significantly higher among patients who eventually developed severe respiratory failure (SRF)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32354367", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367", "evidence_list": [ { "evidence": "A low suPAR level (<4.75 ng/ml) at baseline is a useful biomarker for aiding clinical decisions including discharge of patients presenting with symptoms of COVID-19. [DOI:10.1101/2020.05.27.20114678] Findings suggest that suPAR may early trace patients who need intensified management probably in need of anti-inflammatory treatment." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32613288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613288", "evidence_list": [ { "evidence": "In conclusion, suPAR seems extremely promising as a COVID-19 prognostic marker and may assist in the early selection of patients who can stay at home or must be admitted to the hospital and/or intensive care unit. In this difficult outbreak, humanity must use all the available weapons, and suPAR may prove a powerful triage biomarker." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32354367", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367", "evidence_list": [ { "evidence": "A low suPAR level (<4.75 ng/ml) at baseline is a useful biomarker for aiding clinical decisions including discharge of patients presenting with symptoms of COVID-19. [DOI:10.1101/2020.05.27.20114678] Admission levels of suPAR were significantly higher among patients who eventually developed severe respiratory failure (SRF)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.", "journal": "Critical care (London, England)", "authors": "Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ", "date": "2020-05-02", "evidence": [], "reference": [ { "id": "32354367", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367" } ] }, { "title": "Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients.", "journal": "Molecular diagnosis & therapy", "authors": "Chalkias A, Mouzarou A, Samara E, Xanthos T, Ischaki E, Pantazopoulos I", "date": "2020-07-03", "evidence": [], "reference": [ { "id": "32613288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613288" } ] }, { "title": "Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.", "journal": "Critical care (London, England)", "authors": "Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ", "date": "2020-05-02", "evidence": [], "reference": [ { "id": "32354367", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32354367" } ] } ], "biomarker_canonical_id": "AA4708", "collision": 1 }, { "biomarker_id": "AA4708-2", "biomarker_component": [ { "biomarker": "increased PLAUR level", "assessed_biomarker_entity": { "recommended_name": "Soluble urokinase plasminogen activator receptor", "synonyms": [ { "synonym": "U-PAR" }, { "synonym": "uPAR" }, { "synonym": "Monocyte activation antigen Mo3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q03405", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17204-9" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "17204-9" } ], "evidence_source": [ { "id": "9581823", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/9581823", "evidence_list": [ { "evidence": "The median suPAR levels found in each patient group were significantly higher than in the control group. Both ovarian and nonovarian malignant carcinoma subgroups showed a 2-fold increase of suPAR compared to controls. This study shows that the level of the soluble receptor for uPA, a proteinase that is considered to play a key role in physiological and malignant invasion, is increased in serum of a subgroup of ovarian carcinoma patients. Moreover, patients with high suPAR levels showed significantly worse prognosis in survival analysis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "9581823", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/9581823", "evidence_list": [ { "evidence": "The median suPAR levels found in each patient group were significantly higher than in the control group. Both ovarian and nonovarian malignant carcinoma subgroups showed a 2-fold increase of suPAR compared to controls. This study shows that the level of the soluble receptor for uPA, a proteinase that is considered to play a key role in physiological and malignant invasion, is increased in serum of a subgroup of ovarian carcinoma patients. Moreover, patients with high suPAR levels showed significantly worse prognosis in survival analysis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.", "journal": "Cancer research", "authors": "Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dan\u00f8 K, Br\u00fcnner N, Blasi F", "date": "1998-05-15", "evidence": [], "reference": [ { "id": "9581823", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/9581823" } ] } ], "biomarker_canonical_id": "AA4708", "collision": 1 }, { "biomarker_id": "AA4709-1", "biomarker_component": [ { "biomarker": "increased P-SEP level", "assessed_biomarker_entity": { "recommended_name": "Presepsin", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050392", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32530491", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530491", "evidence_list": [ { "evidence": "These findings suggest that P-SEP may correlate with lung damage caused by COVID-19 pneumonia and may be useful as a prognostic biomarker for severe COVID-19. Because P-SEP can predict aggravation of ARDS based on laboratory tests on admission, this enables clinicians to identify high-risk COVID-19 patients and determine treatment at an early stage." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32530491", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530491", "evidence_list": [ { "evidence": "These findings suggest that P-SEP may correlate with lung damage caused by COVID-19 pneumonia and may be useful as a prognostic biomarker for severe COVID-19. Because P-SEP can predict aggravation of ARDS based on laboratory tests on admission, this enables clinicians to identify high-risk COVID-19 patients and determine treatment at an early stage." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Presepsin as a predictive biomarker of severity in COVID-19: A\u00a0case series.", "journal": "Journal of medical virology", "authors": "Fukada A, Kitagawa Y, Matsuoka M, Sakai J, Imai K, Tarumoto N, Orihara Y, Kawamura R, Takeuchi S, Maesaki S, Maeda T", "date": "2020-06-13", "evidence": [], "reference": [ { "id": "32530491", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530491" } ] } ], "biomarker_canonical_id": "AA4709", "collision": 1 }, { "biomarker_id": "AA4710-1", "biomarker_component": [ { "biomarker": "increased TNF level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor alpha", "synonyms": [ { "synonym": "Cachectin" }, { "synonym": "TNF-alpha" }, { "synonym": "Tumor necrosis factor ligand superfamily member 2" }, { "synonym": "TNF-a" } ] }, "assessed_biomarker_entity_id": "UPKB:P01375", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3074-2" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "When comparing biochemical indexes of COVID-19 between patients with and without cancer, we found that pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-2R were higher in patients with cancer than in those without cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "Elevated levels of TNF-alpha were found in patients with head and neck squamous cell carcinoma (HNSCC). An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "When comparing biochemical indexes of COVID-19 between patients with and without cancer, we found that pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-2R were higher in patients with cancer than in those without cancer." } ], "tags": [ { "tag": "condition" } ] }, { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "Elevated levels of TNF-alpha were found in patients with head and neck squamous cell carcinoma (HNSCC). An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] } ], "biomarker_canonical_id": "AA4710", "collision": 1 }, { "biomarker_id": "AA4710-2", "biomarker_component": [ { "biomarker": "increased TNF level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor alpha", "synonyms": [ { "synonym": "Cachectin" }, { "synonym": "TNF-alpha" }, { "synonym": "Tumor necrosis factor ligand superfamily member 2" }, { "synonym": "TNF-a" } ] }, "assessed_biomarker_entity_id": "UPKB:P01375", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3074-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "3074-2" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "3074-2" } ], "evidence_source": [ { "id": "32382744", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32382744", "evidence_list": [ { "evidence": "The prevalence of severe and complicated cases of COVID-19 is lower in patients in treatment with anti-TNF-alpha than that reported for patients taking steroids." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32382744", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32382744", "evidence_list": [ { "evidence": "The prevalence of severe and complicated cases of COVID-19 is lower in patients in treatment with anti-TNF-alpha than that reported for patients taking steroids." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Anti-TNF-\u03b1 Agents in Inflammatory Bowel Disease and Course of COVID-19.", "journal": "Inflammatory bowel diseases", "authors": "Tursi A, Vetrone LM, Papa A", "date": "2020-05-10", "evidence": [], "reference": [ { "id": "32382744", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32382744" } ] }, { "title": "An inflammatory cytokine signature helps predict COVID-19 severity and death.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511562", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562" } ] }, { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.", "journal": "Clinical immunology (Orlando, Fla.)", "authors": "Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S", "date": "2020-03-31", "evidence": [], "reference": [ { "id": "32222466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466" } ] } ], "biomarker_canonical_id": "AA4710", "collision": 1 }, { "biomarker_id": "AA4710-3", "biomarker_component": [ { "biomarker": "increased TNF level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor alpha", "synonyms": [ { "synonym": "Cachectin" }, { "synonym": "TNF-alpha" }, { "synonym": "Tumor necrosis factor ligand superfamily member 2" }, { "synonym": "TNF-a" } ] }, "assessed_biomarker_entity_id": "UPKB:P01375", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3074-2" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "When comparing biochemical indexes of COVID-19 between patients with and without cancer, we found that pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-2R were higher in patients with cancer than in those without cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "Elevated levels of TNF-alpha were found in patients with head and neck squamous cell carcinoma (HNSCC). An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "When comparing biochemical indexes of COVID-19 between patients with and without cancer, we found that pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-2R were higher in patients with cancer than in those without cancer." } ], "tags": [ { "tag": "condition" } ] }, { "id": "24481866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866", "evidence_list": [ { "evidence": "Elevated levels of TNF-alpha were found in patients with head and neck squamous cell carcinoma (HNSCC). An upregulated TNF-alpha, in combination with CRP, was significantly related to shorter patient survival, independent of clinical stage. Findings indicate that TNF-alpha might be suitable as biomarkers in combination with tumor TNM staging for predicting survival and individualized treatment." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Plasma tumor necrosis factor-\u03b1 and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Andersson B\u00c5, Lewin F, Lundgren J, Nilsson M, Rutqvist LE, L\u00f6fgren S, Laytragoon-Lewin N", "date": "2014-02-01", "evidence": [], "reference": [ { "id": "24481866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24481866" } ] } ], "biomarker_canonical_id": "AA4710", "collision": 1 }, { "biomarker_id": "AA4711-1", "biomarker_component": [ { "biomarker": "increased TMPRSS2 level", "assessed_biomarker_entity": { "recommended_name": "Transmembrane protease serine 2", "synonyms": [ { "synonym": "Serine protease 10" } ] }, "assessed_biomarker_entity_id": "UPKB:O15393", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32437018", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32437018", "evidence_list": [ { "evidence": "The role of transmembrane protease serine 2 (TMPRSS2) as a contributing factor to the more severe outcomes noted for COVID-19. Validated TMPRSS2 SNPs that are confirmed to be predictive biomarkers can be incorporated in the CDCs current list of clinical biomarkers for disease severity as discussed above." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32437018", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32437018", "evidence_list": [ { "evidence": "The role of transmembrane protease serine 2 (TMPRSS2) as a contributing factor to the more severe outcomes noted for COVID-19. Validated TMPRSS2 SNPs that are confirmed to be predictive biomarkers can be incorporated in the CDCs current list of clinical biomarkers for disease severity as discussed above." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "TMPRSS2: Potential Biomarker for COVID-19 Outcomes.", "journal": "Journal of clinical pharmacology", "authors": "Strope JD, PharmD CHC, Figg WD", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32437018", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32437018" } ] } ], "biomarker_canonical_id": "AA4711", "collision": 1 }, { "biomarker_id": "AA4711-2", "biomarker_component": [ { "biomarker": "increased TMPRSS2 level", "assessed_biomarker_entity": { "recommended_name": "Transmembrane protease serine 2", "synonyms": [ { "synonym": "Serine protease 10" } ] }, "assessed_biomarker_entity_id": "UPKB:O15393", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32660890", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32660890", "evidence_list": [ { "evidence": "TMPRSS2 expression is regulated in part by androgens and is a known biomarker of prostate cancer severity when fused with ERG. It is known that TMPRSS2 expression is upregulated by androgens in prostate cancer cell lines and in vivo. The authors analyzed data from 4,532 men who tested positive for SARS-CoV-2. Of these patients, 430 (9.5%) had cancer and 118 (2.6%) had prostate cancer (28% of all cancers). Consistent with other publications, men with cancer have worse disease presentations than men without cancer, even when stratified for age. In the 5,273 prostate cancer patients on androgen deprivation therapy (ADT); only four of these patients were positive for SARS-CoV-2. The authors stated that men positive for SARS-CoV-2 and on ADT not only had improved outcomes over other men with prostate cancer positive for SARS-CoV-2, but that ADT may have reduced the chance of infection. They concluded that ADT had a protective effect in men positive for SARS-CoV-2 infection. ADT therapy provides the first evidence that reducing androgens or their effect on tissues may have a beneficial impact on outcomes in men infected with SARS-CoV-2." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32660890", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32660890", "evidence_list": [ { "evidence": "TMPRSS2 expression is regulated in part by androgens and is a known biomarker of prostate cancer severity when fused with ERG. It is known that TMPRSS2 expression is upregulated by androgens in prostate cancer cell lines and in vivo. The authors analyzed data from 4,532 men who tested positive for SARS-CoV-2. Of these patients, 430 (9.5%) had cancer and 118 (2.6%) had prostate cancer (28% of all cancers). Consistent with other publications, men with cancer have worse disease presentations than men without cancer, even when stratified for age. In the 5,273 prostate cancer patients on androgen deprivation therapy (ADT); only four of these patients were positive for SARS-CoV-2. The authors stated that men positive for SARS-CoV-2 and on ADT not only had improved outcomes over other men with prostate cancer positive for SARS-CoV-2, but that ADT may have reduced the chance of infection. They concluded that ADT had a protective effect in men positive for SARS-CoV-2 infection. ADT therapy provides the first evidence that reducing androgens or their effect on tissues may have a beneficial impact on outcomes in men infected with SARS-CoV-2." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Are sex discordant outcomes in COVID-19 related to sex hormones?", "journal": "Seminars in oncology", "authors": "Strope JD, Chau CH, Figg WD", "date": "2020-07-15", "evidence": [], "reference": [ { "id": "32660890", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32660890" } ] } ], "biomarker_canonical_id": "AA4711", "collision": 1 }, { "biomarker_id": "AA4712-1", "biomarker_component": [ { "biomarker": "increased ACE2 level", "assessed_biomarker_entity": { "recommended_name": "Angiotensin-converting enzyme 2", "synonyms": [ { "synonym": "Angiotensin-converting enzyme homolog" }, { "synonym": "ACEH" }, { "synonym": "Angiotensin-converting enzyme-related carboxypeptidase" }, { "synonym": "ACE-related carboxypeptidase" }, { "synonym": "Metalloprotease MPROT15" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYF1", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "32916258", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32916258", "evidence_list": [ { "evidence": "Our study showed an increased rate of expression of ACE2 in an elderly male patient in the age group of 60-70 who has LAUD or LUSC. We also conducted a prognostic analysis of ACE2 in lung cancer, we found that ACE2 mRNA is highly expressed. High expression of ACE2 may lead to higher susceptibility of lung cancer patient towards COVID 19 and ACE2 can serve as the best potential biomarker for this disease compared to co-expressed genes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32916258", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32916258", "evidence_list": [ { "evidence": "Our study showed an increased rate of expression of ACE2 in an elderly male patient in the age group of 60-70 who has LAUD or LUSC. We also conducted a prognostic analysis of ACE2 in lung cancer, we found that ACE2 mRNA is highly expressed. High expression of ACE2 may lead to higher susceptibility of lung cancer patient towards COVID 19 and ACE2 can serve as the best potential biomarker for this disease compared to co-expressed genes." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of angiotensin-converting enzyme 2 (ACE2) protein as the potential biomarker in SARS-CoV-2 infection-related lung cancer using computational analyses.", "journal": "Genomics", "authors": "Samad A, Jafar T, Rafi JH", "date": "2020-09-12", "evidence": [], "reference": [ { "id": "32916258", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32916258" } ] } ], "biomarker_canonical_id": "AA4712", "collision": 1 }, { "biomarker_id": "AA4712-2", "biomarker_component": [ { "biomarker": "increased ACE2 level", "assessed_biomarker_entity": { "recommended_name": "Angiotensin-converting enzyme 2", "synonyms": [ { "synonym": "Angiotensin-converting enzyme homolog" }, { "synonym": "ACEH" }, { "synonym": "Angiotensin-converting enzyme-related carboxypeptidase" }, { "synonym": "ACE-related carboxypeptidase" }, { "synonym": "Metalloprotease MPROT15" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYF1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32698840", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32698840", "evidence_list": [ { "evidence": "sACE2 levels showed reliable associations with all individuals components of Metabolic Syndrome. This profile of associations was statistically significantly stronger in men, compared to women, and suggests that preexisting cardiometabolic conditions might confer increased severity of symptoms in some COVID-19 patients through increased expression of ACE2 in the liver." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32698840", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32698840", "evidence_list": [ { "evidence": "sACE2 levels showed reliable associations with all individuals components of Metabolic Syndrome. This profile of associations was statistically significantly stronger in men, compared to women, and suggests that preexisting cardiometabolic conditions might confer increased severity of symptoms in some COVID-19 patients through increased expression of ACE2 in the liver." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19.", "journal": "Critical care (London, England)", "authors": "Kornilov SA, Lucas I, Jade K, Dai CL, Lovejoy JC, Magis AT", "date": "2020-07-24", "evidence": [], "reference": [ { "id": "32698840", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32698840" } ] } ], "biomarker_canonical_id": "AA4712", "collision": 1 }, { "biomarker_id": "AA4713-1", "biomarker_component": [ { "biomarker": "decreased ACE2 level", "assessed_biomarker_entity": { "recommended_name": "Angiotensin-converting enzyme 2", "synonyms": [ { "synonym": "Angiotensin-converting enzyme homolog" }, { "synonym": "ACEH" }, { "synonym": "Angiotensin-converting enzyme-related carboxypeptidase" }, { "synonym": "ACE-related carboxypeptidase" }, { "synonym": "Metalloprotease MPROT15" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYF1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32339157", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32339157", "evidence_list": [ { "evidence": "Expression of ACE2 decreased in vivo and in vitro after SARS-CoV infection. Tumor tissues may be more susceptible to SARS-CoV-2 infection in COVID-19 patients with UCEC (Uterine Corpus Endometrial Carcinoma) and KIRP (Kidney Renal Papillary Cell Carcinoma), which may worsen the prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32339157", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32339157", "evidence_list": [ { "evidence": "Expression of ACE2 decreased in vivo and in vitro after SARS-CoV infection. Tumor tissues may be more susceptible to SARS-CoV-2 infection in COVID-19 patients with UCEC (Uterine Corpus Endometrial Carcinoma) and KIRP (Kidney Renal Papillary Cell Carcinoma), which may worsen the prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.", "journal": "Aging", "authors": "Yang J, Li H, Hu S, Zhou Y", "date": "2020-04-28", "evidence": [], "reference": [ { "id": "32339157", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32339157" } ] } ], "biomarker_canonical_id": "AA4713", "collision": 1 }, { "biomarker_id": "AA4713-2", "biomarker_component": [ { "biomarker": "decreased ACE2 level", "assessed_biomarker_entity": { "recommended_name": "Angiotensin-converting enzyme 2", "synonyms": [ { "synonym": "Angiotensin-converting enzyme homolog" }, { "synonym": "ACEH" }, { "synonym": "Angiotensin-converting enzyme-related carboxypeptidase" }, { "synonym": "ACE-related carboxypeptidase" }, { "synonym": "Metalloprotease MPROT15" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYF1", "assessed_entity_type": "protein", "specimen": [ { "name": "pancreas", "id": "UBERON:0001264", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001264", "loinc_code": "" } ], "evidence_source": [ { "id": "19212105", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19212105", "evidence_list": [ { "evidence": "Expression of ACE2 is decreased in pancreatic ductal adenocarcinoma tissues. The reduction of ACE2 expression by RNA interference promoted the proliferation of cultured pancreatic cancer cells. It was found that ANGII (angiotensin II, a biologically active peptide that works as a regulator of cardiovasular homeostasist) contributes to the down-regulation of ACE2 in cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "19212105", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19212105", "evidence_list": [ { "evidence": "Expression of ACE2 is decreased in pancreatic ductal adenocarcinoma tissues. The reduction of ACE2 expression by RNA interference promoted the proliferation of cultured pancreatic cancer cells. It was found that ANGII (angiotensin II, a biologically active peptide that works as a regulator of cardiovasular homeostasist) contributes to the down-regulation of ACE2 in cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression.", "journal": "The Tohoku journal of experimental medicine", "authors": "Zhou L, Zhang R, Yao W, Wang J, Qian A, Qiao M, Zhang Y, Yuan Y", "date": "2009-02-13", "evidence": [], "reference": [ { "id": "19212105", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19212105" } ] } ], "biomarker_canonical_id": "AA4713", "collision": 1 }, { "biomarker_id": "AA4715-1", "biomarker_component": [ { "biomarker": "increased WFDC2 level", "assessed_biomarker_entity": { "recommended_name": "WAP four-disulfide core domain protein 2", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "55180-4" } ], "evidence_source": [ { "id": "21633297", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21633297", "evidence_list": [ { "evidence": "Early diagnosis is the most important determinant of early survival for ovarian cancer, and increased levels of HE4, in combination with CA125, is used as a diagnostic marker for ovarian cancer. HE4 levels were found to be significantly higher in individuals with ovarian cancer. Combining both HE4 and CA125 yielded specificity for ovarian cancer of 100%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "19732003", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19732003", "evidence_list": [ { "evidence": "Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "21633297", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21633297", "evidence_list": [ { "evidence": "Early diagnosis is the most important determinant of early survival for ovarian cancer, and increased levels of HE4, in combination with CA125, is used as a diagnostic marker for ovarian cancer. HE4 levels were found to be significantly higher in individuals with ovarian cancer. Combining both HE4 and CA125 yielded specificity for ovarian cancer of 100%." } ], "tags": [ { "tag": "condition" } ] }, { "id": "19732003", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19732003", "evidence_list": [ { "evidence": "Preliminary data show that HE4 may have more potential than cancer antigen 125 in discriminating benign from cancerous ovarian masses, and has the strongest correlation with endometrial cancer of all markers tested to date. Utilizing risk stratification, a panel of biomarkers including HE4 may ultimately be useful for detecting ovarian and endometrial cancer at an early stage in patients at high risk." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.", "journal": "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society", "authors": "Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H", "date": "2011-06-03", "evidence": [], "reference": [ { "id": "21633297", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21633297" } ] }, { "title": "HE4 as a biomarker for ovarian and endometrial cancer management.", "journal": "Expert review of molecular diagnostics", "authors": "Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW", "date": "2009-09-08", "evidence": [], "reference": [ { "id": "19732003", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19732003" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4715", "collision": 1 }, { "biomarker_id": "AA4715-2", "biomarker_component": [ { "biomarker": "increased WFDC2 level", "assessed_biomarker_entity": { "recommended_name": "WAP four-disulfide core domain protein 2", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4" } ], "evidence_source": [ { "id": "27446579", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27446579", "evidence_list": [ { "evidence": "There was a significant difference in the median serum levels of HE4 in breast cancer patients, ovarian cancer patients and healthy volunteers (14.63, 16.47 and 11.52 pmol/l, respectively; P=0.013). No significant differences between the breast cancer and ovarian cancer patient groups was observed, the median serum levels of HE4 in these groups were significantly higher than those in the healthy volunteer group (P=0.006 and P=0.017, respectively).The cutoff value for the prediction of breast cancer was determined at >13.24 pmol/l for HE4 with a sensitivity of 61.11%, specificity of 68.75%, positive predictive value of 81.48%, negative predictive value of 44.0% and accuracy of 63.46% [AUC, 0.740 (95% CI, 0.604-0.875), P=0.006] A significant elevation of serum HE4 levels in patients with breast cancer compared with that in healthy controls was identified. HE4 may serve as a novel biomarker for the diagnosis of breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "27446579", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27446579", "evidence_list": [ { "evidence": "There was a significant difference in the median serum levels of HE4 in breast cancer patients, ovarian cancer patients and healthy volunteers (14.63, 16.47 and 11.52 pmol/l, respectively; P=0.013). No significant differences between the breast cancer and ovarian cancer patient groups was observed, the median serum levels of HE4 in these groups were significantly higher than those in the healthy volunteer group (P=0.006 and P=0.017, respectively).The cutoff value for the prediction of breast cancer was determined at >13.24 pmol/l for HE4 with a sensitivity of 61.11%, specificity of 68.75%, positive predictive value of 81.48%, negative predictive value of 44.0% and accuracy of 63.46% [AUC, 0.740 (95% CI, 0.604-0.875), P=0.006] A significant elevation of serum HE4 levels in patients with breast cancer compared with that in healthy controls was identified. HE4 may serve as a novel biomarker for the diagnosis of breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study.", "journal": "Molecular and clinical oncology", "authors": "G\u00fcnd\u00fcz UR, Gunaldi M, Isiksacan N, G\u00fcnd\u00fcz S, Okuturlar Y, Kocoglu H", "date": "2016-07-23", "evidence": [], "reference": [ { "id": "27446579", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27446579" } ] } ], "biomarker_canonical_id": "AA4715", "collision": 1 }, { "biomarker_id": "AA4715-3", "biomarker_component": [ { "biomarker": "increased WFDC2 level", "assessed_biomarker_entity": { "recommended_name": "WAP four-disulfide core domain protein 2", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "55180-4" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated HE4 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated HE4 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4715", "collision": 1 }, { "biomarker_id": "AA4715-4", "biomarker_component": [ { "biomarker": "increased WFDC2 level", "assessed_biomarker_entity": { "recommended_name": "WAP four-disulfide core domain protein 2", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "55180-4" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4715", "collision": 1 }, { "biomarker_id": "AA4715-5", "biomarker_component": [ { "biomarker": "increased WFDC2 level", "assessed_biomarker_entity": { "recommended_name": "WAP four-disulfide core domain protein 2", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "55180-4" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4715", "collision": 1 }, { "biomarker_id": "AA4716-1", "biomarker_component": [ { "biomarker": "increased KRT19 level", "assessed_biomarker_entity": { "recommended_name": "Cytokeratin-19 fragment", "synonyms": [ { "synonym": "Cytokeratin-19" }, { "synonym": "CK-19" }, { "synonym": "Keratin-19" }, { "synonym": "K19" } ] }, "assessed_biomarker_entity_id": "UPKB:P08727", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "7541742", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7541742", "evidence_list": [ { "evidence": "Cyfra 21-1 levels were significantly higher in advanced NSCLC than in early-stage disease. All 29 patients with serum concentrations > 32 ng/mL had stage IIIB-IV and only one of 14 patients with stage I-II disease had Cyfra 21-1 level > 18 ng/mL. In the multivariate analysis of survival, Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC. Cyfra 21-1 is a sensitive and specific tumor marker of NSCLC, especially of squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "7541742", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7541742", "evidence_list": [ { "evidence": "Cyfra 21-1 levels were significantly higher in advanced NSCLC than in early-stage disease. All 29 patients with serum concentrations > 32 ng/mL had stage IIIB-IV and only one of 14 patients with stage I-II disease had Cyfra 21-1 level > 18 ng/mL. In the multivariate analysis of survival, Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC. Cyfra 21-1 is a sensitive and specific tumor marker of NSCLC, especially of squamous cell subtype. It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. Cyfra 21-1 was an independent prognostic factor along with performance status and disease stage in NSCLC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.", "journal": "Anticancer research", "authors": "Molina R, Auge JM, Filella X, Vi\u00f1olas N, Alicarte J, Domingo JM, Ballesta AM", "date": "2005-07-22", "evidence": [], "reference": [ { "id": "16033098", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.", "journal": "Chest", "authors": "Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E", "date": "1995-07-01", "evidence": [], "reference": [ { "id": "7541742", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7541742" } ] } ], "biomarker_canonical_id": "AA4716", "collision": 1 }, { "biomarker_id": "AA4716-2", "biomarker_component": [ { "biomarker": "increased KRT19 level", "assessed_biomarker_entity": { "recommended_name": "Cytokeratin-19 fragment", "synonyms": [ { "synonym": "Cytokeratin-19" }, { "synonym": "CK-19" }, { "synonym": "Keratin-19" }, { "synonym": "K19" } ] }, "assessed_biomarker_entity_id": "UPKB:P08727", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "25966163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25966163", "evidence_list": [ { "evidence": "In all studies considered, patients with bladder cancer had a higher CYFRA21-1 level than healthy subjects. Based on our results, CYFRA21-1 level may be a diagnostic biomarker for diagnosing bladder cancer as well as a possible biomarker for differentiation between local and metastatic bladder cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "25966163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25966163", "evidence_list": [ { "evidence": "In all studies considered, patients with bladder cancer had a higher CYFRA21-1 level than healthy subjects. Based on our results, CYFRA21-1 level may be a diagnostic biomarker for diagnosing bladder cancer as well as a possible biomarker for differentiation between local and metastatic bladder cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis.", "journal": "Genetics and molecular research : GMR", "authors": "Kuang LI, Song WJ, Qing HM, Yan S, Song FL", "date": "2015-05-13", "evidence": [], "reference": [ { "id": "25966163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25966163" } ] } ], "biomarker_canonical_id": "AA4716", "collision": 1 }, { "biomarker_id": "AA4716-3", "biomarker_component": [ { "biomarker": "increased KRT19 level", "assessed_biomarker_entity": { "recommended_name": "Cytokeratin-19 fragment", "synonyms": [ { "synonym": "Cytokeratin-19" }, { "synonym": "CK-19" }, { "synonym": "Keratin-19" }, { "synonym": "K19" } ] }, "assessed_biomarker_entity_id": "UPKB:P08727", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CYFRA21 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Increased levels of CYFRA21-1 were observed in COVID-19 patients, and could predict the clinical outcome of patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CYFRA21 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Increased levels of CYFRA21-1 were observed in COVID-19 patients, and could predict the clinical outcome of patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] } ], "biomarker_canonical_id": "AA4716", "collision": 1 }, { "biomarker_id": "AA4717-1", "biomarker_component": [ { "biomarker": "decreased CEACAM5 level", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19166-8" } ], "evidence_source": [ { "id": "11953875", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11953875", "evidence_list": [ { "evidence": "In those patients where marker levels of carcinoembryonic antigen decreased more than 33%, a significantly higher risk for relapse and death from disease (both P=0.0001) in univariate analyses was observed. In multivariate analysis this decrease of carcinoembryonic antigen proved to be an independent prognostic factor." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "11953875", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11953875", "evidence_list": [ { "evidence": "In those patients where marker levels of carcinoembryonic antigen decreased more than 33%, a significantly higher risk for relapse and death from disease (both P=0.0001) in univariate analyses was observed. In multivariate analysis this decrease of carcinoembryonic antigen proved to be an independent prognostic factor." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum CEA and CA 15-3 as prognostic factors in primary breast cancer.", "journal": "British journal of cancer", "authors": "Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A, Seidel D", "date": "2002-04-16", "evidence": [], "reference": [ { "id": "11953875", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11953875" } ] } ], "biomarker_canonical_id": "AA4717", "collision": 1 }, { "biomarker_id": "AA4718-1", "biomarker_component": [ { "biomarker": "increased CEACAM5 level", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19166-8" } ], "evidence_source": [ { "id": "12174919", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12174919", "evidence_list": [ { "evidence": "In patients with colorectal cancer, CEA was most frequently elevated (54%), followed by CA 242 (46%), CA 19-9 (36%) and CA 72-4 (25%)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "12174919", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12174919", "evidence_list": [ { "evidence": "In patients with colorectal cancer, CEA was most frequently elevated (54%), followed by CA 242 (46%), CA 19-9 (36%) and CA 72-4 (25%)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.", "journal": "Anticancer research", "authors": "Carpelan-Holmstr\u00f6m M, Louhimo J, Stenman UH, Alfthan H, Haglund C", "date": "2002-08-15", "evidence": [], "reference": [ { "id": "12174919", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12174919" } ] } ], "biomarker_canonical_id": "AA4718", "collision": 1 }, { "biomarker_id": "AA4718-2", "biomarker_component": [ { "biomarker": "increased CEACAM5 level", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "96044-3" } ], "evidence_source": [ { "id": "21683503", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21683503", "evidence_list": [ { "evidence": "Our results demonstrated that an elevated serum HE4 level was related to the advanced stage of epithelial ovarian cancer. An elevated serum level of HE4 is a poor prognostic factor for PFS in patients with epithelial ovarian cancer who were treated with debulking surgery and adjuvant taxane and platinum-based chemotherapy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "21683503", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21683503", "evidence_list": [ { "evidence": "Our results demonstrated that an elevated serum HE4 level was related to the advanced stage of epithelial ovarian cancer. An elevated serum level of HE4 is a poor prognostic factor for PFS in patients with epithelial ovarian cancer who were treated with debulking surgery and adjuvant taxane and platinum-based chemotherapy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.", "journal": "European journal of obstetrics, gynecology, and reproductive biology", "authors": "Paek J, Lee SH, Yim GW, Lee M, Kim YJ, Nam EJ, Kim SW, Kim YT", "date": "2011-06-21", "evidence": [], "reference": [ { "id": "21683503", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21683503" } ] } ], "biomarker_canonical_id": "AA4718", "collision": 1 }, { "biomarker_id": "AA4718-3", "biomarker_component": [ { "biomarker": "increased CEACAM5 level", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19166-8" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19166-8" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "19166-8" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32333071", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32333071", "evidence_list": [ { "evidence": "On laboratory work-up, mildly elevated carcinoembryonic antigen (CEA = 9.8 ng/mL, normal range up to 5 ng/mL) was detected." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32540459", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32540459", "evidence_list": [ { "evidence": "In conclusion, the serum CEA levels were found to be increased in patients with severe or critically severe SARS-CoV-2 infection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32333071", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32333071", "evidence_list": [ { "evidence": "On laboratory work-up, mildly elevated carcinoembryonic antigen (CEA = 9.8 ng/mL, normal range up to 5 ng/mL) was detected." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32540459", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32540459", "evidence_list": [ { "evidence": "In conclusion, the serum CEA levels were found to be increased in patients with severe or critically severe SARS-CoV-2 infection." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "A case of COVID-19 lung infection first detected by [18F]FDG PET-CT.", "journal": "European journal of nuclear medicine and molecular imaging", "authors": "Amini H, Divband G, Montahaei Z, Dehghani T, Kaviani H, Adinehpour Z, Akbarian Aghdam R, Rezaee A, Vali R", "date": "2020-04-26", "evidence": [], "reference": [ { "id": "32333071", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32333071" } ] }, { "title": "Prognostic value of carcinoembryonic antigen on outcome in patients with coronavirus disease 2019.", "journal": "The Journal of infection", "authors": "Yu J, Yang Z, Zhou X, Wu D, Chen J, Zhang L, Tong L, Nie L", "date": "2020-06-17", "evidence": [], "reference": [ { "id": "32540459", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32540459" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4718", "collision": 1 }, { "biomarker_id": "AA4718-4", "biomarker_component": [ { "biomarker": "increased CEACAM5 level", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19166-8" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19166-8" } ], "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, CEA in adenocarcinomas. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcino embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, CEA in adenocarcinomas. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcino embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.", "journal": "Anticancer research", "authors": "Molina R, Auge JM, Filella X, Vi\u00f1olas N, Alicarte J, Domingo JM, Ballesta AM", "date": "2005-07-22", "evidence": [], "reference": [ { "id": "16033098", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4718", "collision": 1 }, { "biomarker_id": "AA4719-1", "biomarker_component": [ { "biomarker": "increased MUC16 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-16", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "10334-1" } ], "evidence_source": [ { "id": "29958235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29958235", "evidence_list": [ { "evidence": "The median levels of CA-125 were 9 to 14 times higher for each parameter that demonstrated extrauterine metastasis (all with P < 0.001). Levels of CA-125 were significantly associated with positive cytology (P < 0.0001), omental disease (P < 0.0001), pelvic or para-aortic lymph node metastasis (P < 0.0001), and adnexal involvement (P < 0.0001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "29958235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29958235", "evidence_list": [ { "evidence": "The median levels of CA-125 were 9 to 14 times higher for each parameter that demonstrated extrauterine metastasis (all with P < 0.001). Levels of CA-125 were significantly associated with positive cytology (P < 0.0001), omental disease (P < 0.0001), pelvic or para-aortic lymph node metastasis (P < 0.0001), and adnexal involvement (P < 0.0001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.", "journal": "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society", "authors": "Schmidt M, Segev Y, Sadeh R, Suzan E, Feferkorn I, Kaldawy A, Kligun G, Lavie O", "date": "2018-06-30", "evidence": [], "reference": [ { "id": "29958235", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29958235" } ] } ], "biomarker_canonical_id": "AA4719", "collision": 1 }, { "biomarker_id": "AA4719-2", "biomarker_component": [ { "biomarker": "increased MUC16 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-16", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "10334-1" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199) There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CA125 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199) There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CA125 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4719", "collision": 1 }, { "biomarker_id": "AA4719-3", "biomarker_component": [ { "biomarker": "increased MUC16 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-16", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "10334-1" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4719", "collision": 1 }, { "biomarker_id": "AA4719-4", "biomarker_component": [ { "biomarker": "increased MUC16 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-16", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "10334-1" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4719", "collision": 1 }, { "biomarker_id": "AA4719-5", "biomarker_component": [ { "biomarker": "increased MUC16 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-16", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "10334-1" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4719", "collision": 1 }, { "biomarker_id": "AA4720-1", "biomarker_component": [ { "biomarker": "increased MUC1 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-1", "synonyms": [ { "synonym": "MUC-1" }, { "synonym": "Breast carcinoma-associated antigen DF3" }, { "synonym": "Cancer antigen 15-3" }, { "synonym": "CA 15-3" }, { "synonym": "Carcinoma-associated mucin" }, { "synonym": "Episialin" }, { "synonym": "H23AG" }, { "synonym": "Krebs von den Lungen-6" }, { "synonym": "KL-6" }, { "synonym": "PEMT" }, { "synonym": "Peanut-reactive urinary mucin" }, { "synonym": "PUM" }, { "synonym": "Polymorphic epithelial mucin" }, { "synonym": "PEM" }, { "synonym": "Tumor-associated epithelial membrane antigen" }, { "synonym": "EMA" }, { "synonym": "Tumor-associated mucin" } ] }, "assessed_biomarker_entity_id": "UPKB:P15941", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2007-3" } ], "evidence_source": [ { "id": "24674678", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24674678", "evidence_list": [ { "evidence": "The results indicate an increased level of CA15-3 in breast cancer patients (29.02+/-1.79 IU/ml) as compared to both women with benign tumor and healthy controls (13.78+/-1.24 and 8.92+/-0.48 IU/ml, respectively), and that this increase is associated to advanced stages. Patients with HER2/neu positive malignancies show elevated serum CA15-3 (37.09+/-2.55 IU/ml), as well as patients who developed recurrence (40.75+/-2.11 IU/ml). Study suggests that higher levels of CA 15-3 would be a reliable prognostic marker as they were directly related to advanced stages and recurrence. In addition, persistent elevation of CA 15-3 was associated to HER2/neu positivity in breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "24674678", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24674678", "evidence_list": [ { "evidence": "The results indicate an increased level of CA15-3 in breast cancer patients (29.02+/-1.79 IU/ml) as compared to both women with benign tumor and healthy controls (13.78+/-1.24 and 8.92+/-0.48 IU/ml, respectively), and that this increase is associated to advanced stages. Patients with HER2/neu positive malignancies show elevated serum CA15-3 (37.09+/-2.55 IU/ml), as well as patients who developed recurrence (40.75+/-2.11 IU/ml). Study suggests that higher levels of CA 15-3 would be a reliable prognostic marker as they were directly related to advanced stages and recurrence. In addition, persistent elevation of CA 15-3 was associated to HER2/neu positivity in breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status.", "journal": "International journal of immunopathology and pharmacology", "authors": "Hashim ZM", "date": "2014-03-29", "evidence": [], "reference": [ { "id": "24674678", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24674678" } ] } ], "biomarker_canonical_id": "AA4720", "collision": 1 }, { "biomarker_id": "AA4720-2", "biomarker_component": [ { "biomarker": "increased MUC1 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-1", "synonyms": [ { "synonym": "MUC-1" }, { "synonym": "Breast carcinoma-associated antigen DF3" }, { "synonym": "Cancer antigen 15-3" }, { "synonym": "CA 15-3" }, { "synonym": "Carcinoma-associated mucin" }, { "synonym": "Episialin" }, { "synonym": "H23AG" }, { "synonym": "Krebs von den Lungen-6" }, { "synonym": "KL-6" }, { "synonym": "PEMT" }, { "synonym": "Peanut-reactive urinary mucin" }, { "synonym": "PUM" }, { "synonym": "Polymorphic epithelial mucin" }, { "synonym": "PEM" }, { "synonym": "Tumor-associated epithelial membrane antigen" }, { "synonym": "EMA" }, { "synonym": "Tumor-associated mucin" } ] }, "assessed_biomarker_entity_id": "UPKB:P15941", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "KL-6 was also signicantly higher in severe-cases, but its mean was below the cut-off level for ILDs. [DOI:10.21203/rs.3.rs-29567/v1] Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32470148", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148", "evidence_list": [ { "evidence": "Increased KL-6 serum concentrations were observed in patients with severe pulmonary involvement, suggesting potential usefulness of KL-6 measurement to evaluate COVID-19 patients prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32470148", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148", "evidence_list": [ { "evidence": "Irregular levels of KL-6 present maybe helpful for phenotyping patients according to disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "KL-6 was also signicantly higher in severe-cases, but its mean was below the cut-off level for ILDs. [DOI:10.21203/rs.3.rs-29567/v1] Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32470148", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148", "evidence_list": [ { "evidence": "Increased KL-6 serum concentrations were observed in patients with severe pulmonary involvement, suggesting potential usefulness of KL-6 measurement to evaluate COVID-19 patients prognosis." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32470148", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148", "evidence_list": [ { "evidence": "Irregular levels of KL-6 present maybe helpful for phenotyping patients according to disease severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Serum KL-6 concentrations as a novel biomarker of severe COVID-19.", "journal": "Journal of medical virology", "authors": "d'Alessandro M, Cameli P, Refini RM, Bergantini L, Alonzi V, Lanzarone N, Bennett D, Rana GD, Montagnani F, Scolletta S, Franchi F, Frediani B, Valente S, Mazzei MA, Bonella F, Bargagli E", "date": "2020-05-30", "evidence": [], "reference": [ { "id": "32470148", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148" } ] }, { "title": "Serum KL-6 concentrations as a novel biomarker of severe COVID-19.", "journal": "Journal of medical virology", "authors": "d'Alessandro M, Cameli P, Refini RM, Bergantini L, Alonzi V, Lanzarone N, Bennett D, Rana GD, Montagnani F, Scolletta S, Franchi F, Frediani B, Valente S, Mazzei MA, Bonella F, Bargagli E", "date": "2020-05-30", "evidence": [], "reference": [ { "id": "32470148", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32470148" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4720", "collision": 1 }, { "biomarker_id": "AA4720-3", "biomarker_component": [ { "biomarker": "increased MUC1 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-1", "synonyms": [ { "synonym": "MUC-1" }, { "synonym": "Breast carcinoma-associated antigen DF3" }, { "synonym": "Cancer antigen 15-3" }, { "synonym": "CA 15-3" }, { "synonym": "Carcinoma-associated mucin" }, { "synonym": "Episialin" }, { "synonym": "H23AG" }, { "synonym": "Krebs von den Lungen-6" }, { "synonym": "KL-6" }, { "synonym": "PEMT" }, { "synonym": "Peanut-reactive urinary mucin" }, { "synonym": "PUM" }, { "synonym": "Polymorphic epithelial mucin" }, { "synonym": "PEM" }, { "synonym": "Tumor-associated epithelial membrane antigen" }, { "synonym": "EMA" }, { "synonym": "Tumor-associated mucin" } ] }, "assessed_biomarker_entity_id": "UPKB:P15941", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4720", "collision": 1 }, { "biomarker_id": "AA4720-4", "biomarker_component": [ { "biomarker": "increased MUC1 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-1", "synonyms": [ { "synonym": "MUC-1" }, { "synonym": "Breast carcinoma-associated antigen DF3" }, { "synonym": "Cancer antigen 15-3" }, { "synonym": "CA 15-3" }, { "synonym": "Carcinoma-associated mucin" }, { "synonym": "Episialin" }, { "synonym": "H23AG" }, { "synonym": "Krebs von den Lungen-6" }, { "synonym": "KL-6" }, { "synonym": "PEMT" }, { "synonym": "Peanut-reactive urinary mucin" }, { "synonym": "PUM" }, { "synonym": "Polymorphic epithelial mucin" }, { "synonym": "PEM" }, { "synonym": "Tumor-associated epithelial membrane antigen" }, { "synonym": "EMA" }, { "synonym": "Tumor-associated mucin" } ] }, "assessed_biomarker_entity_id": "UPKB:P15941", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4720", "collision": 1 }, { "biomarker_id": "AA4720-5", "biomarker_component": [ { "biomarker": "increased MUC1 level", "assessed_biomarker_entity": { "recommended_name": "Mucin-1", "synonyms": [ { "synonym": "MUC-1" }, { "synonym": "Breast carcinoma-associated antigen DF3" }, { "synonym": "Cancer antigen 15-3" }, { "synonym": "CA 15-3" }, { "synonym": "Carcinoma-associated mucin" }, { "synonym": "Episialin" }, { "synonym": "H23AG" }, { "synonym": "Krebs von den Lungen-6" }, { "synonym": "KL-6" }, { "synonym": "PEMT" }, { "synonym": "Peanut-reactive urinary mucin" }, { "synonym": "PUM" }, { "synonym": "Polymorphic epithelial mucin" }, { "synonym": "PEM" }, { "synonym": "Tumor-associated epithelial membrane antigen" }, { "synonym": "EMA" }, { "synonym": "Tumor-associated mucin" } ] }, "assessed_biomarker_entity_id": "UPKB:P15941", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4, cytokeratin-19 fragment, carcinoembryonic antigen, carbohydrate antigens 125 and 153 in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4720", "collision": 1 }, { "biomarker_id": "AA4721-1", "biomarker_component": [ { "biomarker": "increased SART3 level", "assessed_biomarker_entity": { "recommended_name": "Squamous cell carcinoma antigen", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19207-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19207-0" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "19207-0" } ], "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CYFRA21 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Increased levels of CYFRA21-1 were observed in COVID-19 patients, and could predict the clinical outcome of patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated SCC levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated CYFRA21 levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Increased levels of CYFRA21-1 were observed in COVID-19 patients, and could predict the clinical outcome of patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated SCC levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4721", "collision": 1 }, { "biomarker_id": "AA4721-2", "biomarker_component": [ { "biomarker": "increased SART3 level", "assessed_biomarker_entity": { "recommended_name": "Squamous cell carcinoma antigen", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19207-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19207-0" } ], "evidence_source": [ { "id": "30479085", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30479085", "evidence_list": [ { "evidence": "Pre-treatment SCC-Ag level higher than 4 ng/mL may be a useful predictor of tumor recurrence in patients with squamous-cell carcinoma of uterine cervix treated with definitive CRT and ICR." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "30479085", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30479085", "evidence_list": [ { "evidence": "Pre-treatment SCC-Ag level higher than 4 ng/mL may be a useful predictor of tumor recurrence in patients with squamous-cell carcinoma of uterine cervix treated with definitive CRT and ICR." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.", "journal": "Journal of gynecologic oncology", "authors": "Choi KH, Lee SW, Yu M, Jeong S, Lee JW, Lee JH", "date": "2018-11-28", "evidence": [], "reference": [ { "id": "30479085", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30479085" } ] } ], "biomarker_canonical_id": "AA4721", "collision": 1 }, { "biomarker_id": "AA4721-3", "biomarker_component": [ { "biomarker": "increased SART3 level", "assessed_biomarker_entity": { "recommended_name": "Squamous cell carcinoma antigen", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19207-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19207-0" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4721", "collision": 1 }, { "biomarker_id": "AA4721-4", "biomarker_component": [ { "biomarker": "increased SART3 level", "assessed_biomarker_entity": { "recommended_name": "Squamous cell carcinoma antigen", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19207-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19207-0" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4721", "collision": 1 }, { "biomarker_id": "AA4721-5", "biomarker_component": [ { "biomarker": "increased SART3 level", "assessed_biomarker_entity": { "recommended_name": "Squamous cell carcinoma antigen", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19207-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19207-0" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4721", "collision": 1 }, { "biomarker_id": "AN4074-1", "biomarker_component": [ { "biomarker": "increased CA199 level", "assessed_biomarker_entity": { "recommended_name": "Carbohydrate antigen 199", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G00053MO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153. Squamous cell carcinoma antigen (SCC) and CA199 increased significantly." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AN4074", "collision": 1 }, { "biomarker_id": "AN4074-2", "biomarker_component": [ { "biomarker": "increased CA199 level", "assessed_biomarker_entity": { "recommended_name": "Carbohydrate antigen 199", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G00053MO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AN4074", "collision": 1 }, { "biomarker_id": "AN4074-3", "biomarker_component": [ { "biomarker": "increased CA199 level", "assessed_biomarker_entity": { "recommended_name": "Carbohydrate antigen 199", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G00053MO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AN4074", "collision": 1 }, { "biomarker_id": "AN4074-4", "biomarker_component": [ { "biomarker": "increased CA199 level", "assessed_biomarker_entity": { "recommended_name": "Carbohydrate antigen 199", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G00053MO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AN4074", "collision": 1 }, { "biomarker_id": "AN4075-1", "biomarker_component": [ { "biomarker": "presence of polymorphism in IL1B", "assessed_biomarker_entity": { "recommended_name": "Interleukin-1 beta gene promoter polymorphism", "synonyms": [ { "synonym": "IL-1 beta" }, { "synonym": "Catabolin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01584", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "25117345", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25117345", "evidence_list": [ { "evidence": "Three genotypes - CT, TT, and CC - of IL-1B-31 were found in the Meizhou Hakka population. This risk was more apparent in male subjects. IL-1B-31 locus polymorphism may be associated with gastric cancer susceptibility in this population, but additional studies with larger sample size are needed to confirm the conclusions." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "25117345", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25117345", "evidence_list": [ { "evidence": "Three genotypes - CT, TT, and CC - of IL-1B-31 were found in the Meizhou Hakka population. This risk was more apparent in male subjects. IL-1B-31 locus polymorphism may be associated with gastric cancer susceptibility in this population, but additional studies with larger sample size are needed to confirm the conclusions." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Interleukin-1B-31 gene polymorphism in Hakka gastric cancer patients in Guangdong, China.", "journal": "Genetics and molecular research : GMR", "authors": "Qiu B, Zou HY, Yang YH, Lai CF", "date": "2014-08-15", "evidence": [], "reference": [ { "id": "25117345", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25117345" } ] } ], "biomarker_canonical_id": "AN4075", "collision": 1 }, { "biomarker_id": "AA4725-1", "biomarker_component": [ { "biomarker": "increased IFNG level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma", "synonyms": [ { "synonym": "IFN-gamma" }, { "synonym": "Immune interferon" } ] }, "assessed_biomarker_entity_id": "UPKB:P01579", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "12729-0" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] } ], "biomarker_canonical_id": "AA4725", "collision": 1 }, { "biomarker_id": "AA4725-2", "biomarker_component": [ { "biomarker": "increased IFNG level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma", "synonyms": [ { "synonym": "IFN-gamma" }, { "synonym": "Immune interferon" } ] }, "assessed_biomarker_entity_id": "UPKB:P01579", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "15296648", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15296648", "evidence_list": [ { "evidence": "IFN gamma level in patients from group 1 (T2DM) was 3.13 \u00b1 0.92 pg/ml, group 2 (CC) 2.73 \u00b1 0.91 pg/ ml, group 3 (T2DM and CC) 2.46 \u00b1 0.98 pg/ml and group 4 (control) 5.02 \u00b1 1.43 pg/ml; p < 0.05. There was no statistically significant difference in the concentration of IFN gamma in patients with T2DM and CC compared to other subjects. However, it has been demonstrated that level of IFN gamma in the control group and the group of patients with T2DM without CC was higher than in the other two groups." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "15296648", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15296648", "evidence_list": [ { "evidence": "IFN gamma level in patients from group 1 (T2DM) was 3.13 \u00b1 0.92 pg/ml, group 2 (CC) 2.73 \u00b1 0.91 pg/ ml, group 3 (T2DM and CC) 2.46 \u00b1 0.98 pg/ml and group 4 (control) 5.02 \u00b1 1.43 pg/ml; p < 0.05. There was no statistically significant difference in the concentration of IFN gamma in patients with T2DM and CC compared to other subjects. However, it has been demonstrated that level of IFN gamma in the control group and the group of patients with T2DM without CC was higher than in the other two groups." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes.", "journal": "Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research", "authors": "Tsiavou A, Degiannis D, Hatziagelaki E, Koniavitou K, Raptis SA", "date": "2004-08-07", "evidence": [], "reference": [ { "id": "15296648", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15296648" } ] } ], "biomarker_canonical_id": "AA4725", "collision": 1 }, { "biomarker_id": "AA4726-1", "biomarker_component": [ { "biomarker": "increased CCL2 level", "assessed_biomarker_entity": { "recommended_name": "Monocyte chemoattractant protein 1", "synonyms": [ { "synonym": "HC11" }, { "synonym": "Monocyte chemoattractant protein 1" }, { "synonym": "Monocyte chemotactic and activating factor" }, { "synonym": "MCAF" }, { "synonym": "Monocyte chemotactic protein 1" }, { "synonym": "MCP-1" }, { "synonym": "Monocyte secretory protein JE" }, { "synonym": "Small-inducible cytokine A2" } ] }, "assessed_biomarker_entity_id": "UPKB:P13500", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "33303843", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33303843", "evidence_list": [ { "evidence": "Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33303843", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33303843", "evidence_list": [ { "evidence": "Elevated levels of pro-inflammatory cytokines were present in patients with severe COVID19. IL-6 and MCP-1 were inversely correlated with P/F with the largest AUC in ROC analyses and should be further explored as biomarkers to identify patients at risk for severe RF and as targets for improved treatment strategies." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19.", "journal": "Scientific reports", "authors": "J\u00f8ntvedt J\u00f8rgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Gr\u00f8ndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM", "date": "2020-12-12", "evidence": [], "reference": [ { "id": "33303843", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33303843" } ] }, { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] } ], "biomarker_canonical_id": "AA4726", "collision": 1 }, { "biomarker_id": "AA4726-2", "biomarker_component": [ { "biomarker": "increased CCL2 level", "assessed_biomarker_entity": { "recommended_name": "Monocyte chemoattractant protein 1", "synonyms": [ { "synonym": "HC11" }, { "synonym": "Monocyte chemoattractant protein 1" }, { "synonym": "Monocyte chemotactic and activating factor" }, { "synonym": "MCAF" }, { "synonym": "Monocyte chemotactic protein 1" }, { "synonym": "MCP-1" }, { "synonym": "Monocyte secretory protein JE" }, { "synonym": "Small-inducible cytokine A2" } ] }, "assessed_biomarker_entity_id": "UPKB:P13500", "assessed_entity_type": "protein", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "19287949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19287949", "evidence_list": [ { "evidence": "Univariate analysis demonstrated that the timing of metastases, tumor size, number of metastases, and MCP-1 expression were significant prognostic factors. Multivariate analysis demonstrated that MCP-1 expression was a significant prognostic factor in hepatic disease-free survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "19287949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19287949", "evidence_list": [ { "evidence": "Univariate analysis demonstrated that the timing of metastases, tumor size, number of metastases, and MCP-1 expression were significant prognostic factors. Multivariate analysis demonstrated that MCP-1 expression was a significant prognostic factor in hepatic disease-free survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Significance of monocyte chemoattractant protein-1 in angiogenesis and survival in colorectal liver metastases.", "journal": "International journal of oncology", "authors": "Yoshidome H, Kohno H, Shida T, Kimura F, Shimizu H, Ohtsuka M, Nakatani Y, Miyazaki M", "date": "2009-03-17", "evidence": [], "reference": [ { "id": "19287949", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19287949" } ] } ], "biomarker_canonical_id": "AA4726", "collision": 1 }, { "biomarker_id": "AA4726-3", "biomarker_component": [ { "biomarker": "increased CCL2 level", "assessed_biomarker_entity": { "recommended_name": "Monocyte chemoattractant protein 1", "synonyms": [ { "synonym": "HC11" }, { "synonym": "Monocyte chemoattractant protein 1" }, { "synonym": "Monocyte chemotactic and activating factor" }, { "synonym": "MCAF" }, { "synonym": "Monocyte chemotactic protein 1" }, { "synonym": "MCP-1" }, { "synonym": "Monocyte secretory protein JE" }, { "synonym": "Small-inducible cytokine A2" } ] }, "assessed_biomarker_entity_id": "UPKB:P13500", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25143907", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25143907", "evidence_list": [ { "evidence": "Glycemic status influences serum MCP-1, and lack of glycemic control contributes to increased serum MCP-1 levels. Serum MCP-1 may thus serve as a biomarker of inflammation and disease progression in diabetes with periodontitis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "25143907", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25143907", "evidence_list": [ { "evidence": "Glycemic status influences serum MCP-1, and lack of glycemic control contributes to increased serum MCP-1 levels. Serum MCP-1 may thus serve as a biomarker of inflammation and disease progression in diabetes with periodontitis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum monocyte chemoattractant protein-1 is a biomarker in patients with diabetes and periodontitis.", "journal": "Indian journal of endocrinology and metabolism", "authors": "Radhakrishnan P, Srikanth P, Seshadri KG, Barani R, Samanta M", "date": "2014-08-22", "evidence": [], "reference": [ { "id": "25143907", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25143907" } ] } ], "biomarker_canonical_id": "AA4726", "collision": 1 }, { "biomarker_id": "AA4727-1", "biomarker_component": [ { "biomarker": "increased CSF3 level", "assessed_biomarker_entity": { "recommended_name": "Granulocyte colony-stimulating factor", "synonyms": [ { "synonym": "G-CSF" }, { "synonym": "Pluripoietin" } ] }, "assessed_biomarker_entity_id": "UPKB:P09919", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "54458-5" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "54458-5" } ], "evidence_source": [ { "id": "21431281", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21431281", "evidence_list": [ { "evidence": "It was found that 12 patients had a white blood cell count increased beyond normal as well as a high G-CSF plasma level and the survival of these patients was shorter as compared to the rest of the patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "21431281", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21431281", "evidence_list": [ { "evidence": "It was found that 12 patients had a white blood cell count increased beyond normal as well as a high G-CSF plasma level and the survival of these patients was shorter as compared to the rest of the patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer.", "journal": "Oncology reports", "authors": "Stathopoulos GP, Armakolas A, Tranga T, Marinou H, Stathopoulos J, Chandrinou H", "date": "2011-03-25", "evidence": [], "reference": [ { "id": "21431281", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21431281" } ] } ], "biomarker_canonical_id": "AA4727", "collision": 1 }, { "biomarker_id": "AA4727-2", "biomarker_component": [ { "biomarker": "increased CSF3 level", "assessed_biomarker_entity": { "recommended_name": "Granulocyte colony-stimulating factor", "synonyms": [ { "synonym": "G-CSF" }, { "synonym": "Pluripoietin" } ] }, "assessed_biomarker_entity_id": "UPKB:P09919", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "54458-5" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "54458-5" } ], "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.", "journal": "Clinical immunology (Orlando, Fla.)", "authors": "Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S", "date": "2020-03-31", "evidence": [], "reference": [ { "id": "32222466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466" } ] } ], "biomarker_canonical_id": "AA4727", "collision": 1 }, { "biomarker_id": "AA4728-1", "biomarker_component": [ { "biomarker": "increased CCL3 level", "assessed_biomarker_entity": { "recommended_name": "Macrophage inflammatory protein 1-alpha", "synonyms": [ { "synonym": "G0/G1 switch regulatory protein 19-1" }, { "synonym": "Macrophage inflammatory protein 1-alpha" }, { "synonym": "MIP-1-alpha" }, { "synonym": "PAT 464.1" }, { "synonym": "SIS-beta" }, { "synonym": "Small-inducible cytokine A3" }, { "synonym": "Tonsillar lymphocyte LD78 alpha protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P10147", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.", "journal": "Clinical immunology (Orlando, Fla.)", "authors": "Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S", "date": "2020-03-31", "evidence": [], "reference": [ { "id": "32222466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466" } ] } ], "biomarker_canonical_id": "AA4728", "collision": 1 }, { "biomarker_id": "AA4729-1", "biomarker_component": [ { "biomarker": "increased IL4 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-4", "synonyms": [ { "synonym": "IL-4" }, { "synonym": "B-cell stimulatory factor 1" }, { "synonym": "BSF-1" }, { "synonym": "Binetrakin" }, { "synonym": "Lymphocyte stimulatory factor 1" }, { "synonym": "Pitrakinra" } ] }, "assessed_biomarker_entity_id": "UPKB:P05112", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "27161-9" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "27161-9" } ], "evidence_source": [ { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "2019-nCoV infection also initiated increased secretion of T-helper-2 (Th2) cytokines (eg, IL4 and IL10) that suppress inflammation, which differs from SARS-CoV infection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "2019-nCoV infection also initiated increased secretion of T-helper-2 (Th2) cytokines (eg, IL4 and IL10) that suppress inflammation, which differs from SARS-CoV infection." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.", "journal": "Clinical immunology (Orlando, Fla.)", "authors": "Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S", "date": "2020-03-31", "evidence": [], "reference": [ { "id": "32222466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466" } ] } ], "biomarker_canonical_id": "AA4729", "collision": 1 }, { "biomarker_id": "AA4729-2", "biomarker_component": [ { "biomarker": "increased IL4 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-4", "synonyms": [ { "synonym": "IL-4" }, { "synonym": "B-cell stimulatory factor 1" }, { "synonym": "BSF-1" }, { "synonym": "Binetrakin" }, { "synonym": "Lymphocyte stimulatory factor 1" }, { "synonym": "Pitrakinra" } ] }, "assessed_biomarker_entity_id": "UPKB:P05112", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "27161-9" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "27161-9" } ], "evidence_source": [ { "id": "24213139", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24213139", "evidence_list": [ { "evidence": "Serum IL-4 increased proportionately with disease progression. Our data are consistent with those reported in two smaller series both of which found that IL-4 levels increases as prostate cancer progresses to castrate resistant status." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "24213139", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24213139", "evidence_list": [ { "evidence": "Serum IL-4 increased proportionately with disease progression. Our data are consistent with those reported in two smaller series both of which found that IL-4 levels increases as prostate cancer progresses to castrate resistant status." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer.", "journal": "Cancers", "authors": "Goldstein R, Hanley C, Morris J, Cahill D, Chandra A, Harper P, Chowdhury S, Maher J, Burbridge S", "date": "2011-01-01", "evidence": [], "reference": [ { "id": "24213139", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24213139" } ] } ], "biomarker_canonical_id": "AA4729", "collision": 1 }, { "biomarker_id": "AA4730-1", "biomarker_component": [ { "biomarker": "increased IL10 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-10", "synonyms": [ { "synonym": "IL-10" }, { "synonym": "Cytokine synthesis inhibitory factor" }, { "synonym": "CSIF" } ] }, "assessed_biomarker_entity_id": "UPKB:P22301", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26848-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26848-2" } ], "evidence_source": [ { "id": "30304975", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30304975", "evidence_list": [ { "evidence": "IL-6, IL-8, and IL-10 showed significant positive correlations with each other. Moreover, high levels of serum IL-6, IL-8, and IL-10 were independently strongly associated with poor survival of patients with pancreatic cancer. Patients with high IL-6, IL-8, or IL-10 expression (greater than median expression levels) exhibited a significantly shorter survival time, compared with patients with low expression (less than median expression levels) (p<0.001 for IL-6, p<0.01 for IL-8, and p<0.05 for IL-10) Univariate Cox analysis revealed that a high expression level of either IL-6, IL-8, or IL-10 was associated with poor survival (IL-6: HR = 0.204, 95% CI: 0.107-0.410, p<0.001; IL-8: HR = 0.303, 95% CI: 0.135-0.683, p<0.01; IL-10: HR = 0.336, 95% CI: 0.125-0.900, p<0.05)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "30304975", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30304975", "evidence_list": [ { "evidence": "IL-6, IL-8, and IL-10 showed significant positive correlations with each other. Moreover, high levels of serum IL-6, IL-8, and IL-10 were independently strongly associated with poor survival of patients with pancreatic cancer. Patients with high IL-6, IL-8, or IL-10 expression (greater than median expression levels) exhibited a significantly shorter survival time, compared with patients with low expression (less than median expression levels) (p<0.001 for IL-6, p<0.01 for IL-8, and p<0.05 for IL-10) Univariate Cox analysis revealed that a high expression level of either IL-6, IL-8, or IL-10 was associated with poor survival (IL-6: HR = 0.204, 95% CI: 0.107-0.410, p<0.001; IL-8: HR = 0.303, 95% CI: 0.135-0.683, p<0.01; IL-10: HR = 0.336, 95% CI: 0.125-0.900, p<0.05)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer.", "journal": "The Journal of international medical research", "authors": "Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, Liu L", "date": "2018-10-12", "evidence": [], "reference": [ { "id": "30304975", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30304975" } ] } ], "biomarker_canonical_id": "AA4730", "collision": 1 }, { "biomarker_id": "AA4730-2", "biomarker_component": [ { "biomarker": "increased IL10 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-10", "synonyms": [ { "synonym": "IL-10" }, { "synonym": "Cytokine synthesis inhibitory factor" }, { "synonym": "CSIF" } ] }, "assessed_biomarker_entity_id": "UPKB:P22301", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26848-2" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "26848-2" } ], "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNF alpha." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNF alpha were higher in ICU patients than non-ICU patients. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNF alpha." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32222466", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466", "evidence_list": [ { "evidence": "IL-2, IL-7, IL-10, G-CSF, IP10, MCP1, MIP1A, TNF alpha were higher in severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] }, { "title": "The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.", "journal": "Clinical immunology (Orlando, Fla.)", "authors": "Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S", "date": "2020-03-31", "evidence": [], "reference": [ { "id": "32222466", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32222466" } ] } ], "biomarker_canonical_id": "AA4730", "collision": 1 }, { "biomarker_id": "AA4731-1", "biomarker_component": [ { "biomarker": "decreased IL10 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-10", "synonyms": [ { "synonym": "IL-10" }, { "synonym": "Cytokine synthesis inhibitory factor" }, { "synonym": "CSIF" } ] }, "assessed_biomarker_entity_id": "UPKB:P22301", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26848-2" } ], "evidence_source": [ { "id": "28420440", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28420440", "evidence_list": [ { "evidence": "A reduction of plasma interleukin-10 levels significantly correlated with an increase in the mean number of metabolic risk factors such as increased waist circumference, BMI, dyslipidaemia, high blood pressure and glucose intolerance." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "28420440", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28420440", "evidence_list": [ { "evidence": "A reduction of plasma interleukin-10 levels significantly correlated with an increase in the mean number of metabolic risk factors such as increased waist circumference, BMI, dyslipidaemia, high blood pressure and glucose intolerance." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus.", "journal": "Stem cell research & therapy", "authors": "Ye L, Li L, Wan B, Yang M, Hong J, Gu W, Wang W, Ning G", "date": "2017-04-20", "evidence": [], "reference": [ { "id": "28420440", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28420440" } ] } ], "biomarker_canonical_id": "AA4731", "collision": 1 }, { "biomarker_id": "AN4076-1", "biomarker_component": [ { "biomarker": "increased CREA level", "assessed_biomarker_entity": { "recommended_name": "Creatinine", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:588", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "38483-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "38483-4" } ], "evidence_source": [ { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "A larger study of 701 patients revealed that elevated serum creatinine levels on admission correlated with severity due to significant abnormalities in the coagulation pathway." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32247631", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631", "evidence_list": [ { "evidence": "We found that patients with elevated baseline serum creatinine were more likely to be admitted to the intensive care unit and to undergo mechanical ventilation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "A larger study of 701 patients revealed that elevated serum creatinine levels on admission correlated with severity due to significant abnormalities in the coagulation pathway." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32247631", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631", "evidence_list": [ { "evidence": "We found that patients with elevated baseline serum creatinine were more likely to be admitted to the intensive care unit and to undergo mechanical ventilation." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Kidney disease is associated with in-hospital death of patients with COVID-19.", "journal": "Kidney international", "authors": "Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G", "date": "2020-04-06", "evidence": [], "reference": [ { "id": "32247631", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631" } ] } ], "biomarker_canonical_id": "AN4076", "collision": 1 }, { "biomarker_id": "AN4077-1", "biomarker_component": [ { "biomarker": "increased UREA level", "assessed_biomarker_entity": { "recommended_name": "Urea", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:1176", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "22664-7" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "22664-7" } ], "evidence_source": [ { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Univariate Cox regression analysis found elevated creatinine levels was also associated with in-hospital mortality (HR 2.99, 95% CI: 2.00, 4.47). Proteinuria, haematuria and elevated urea levels had similar, if not larger, hazard ratios." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32259132", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132", "evidence_list": [ { "evidence": "Urea has very good accuracy in predicting cases with positive RT-PCR for COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "Univariate Cox regression analysis found elevated creatinine levels was also associated with in-hospital mortality (HR 2.99, 95% CI: 2.00, 4.47). Proteinuria, haematuria and elevated urea levels had similar, if not larger, hazard ratios." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32259132", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132", "evidence_list": [ { "evidence": "Urea has very good accuracy in predicting cases with positive RT-PCR for COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "Immunology of COVID-19: Current State of the Science.", "journal": "Immunity", "authors": "Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salom\u00e9 B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, G\u00fcm\u00fc\u015f ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM, None None", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32505227", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227" } ] }, { "title": "A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B", "date": "2020-04-17", "evidence": [], "reference": [ { "id": "32296824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824" } ] }, { "title": "Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study.", "journal": "Archives of academic emergency medicine", "authors": "Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, Kaviani M, Ahmadi N", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32259132", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132" } ] } ], "biomarker_canonical_id": "AN4077", "collision": 1 }, { "biomarker_id": "AN4077-2", "biomarker_component": [ { "biomarker": "increased UREA level", "assessed_biomarker_entity": { "recommended_name": "Urea", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:1176", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "22664-7" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "22664-7" } ], "evidence_source": [ { "id": "18845424", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18845424", "evidence_list": [ { "evidence": "A raised serum urea above the upper limit of normal (ULN) significantly predicted for increased risk of early death. We have identified raised serum urea as a significant contributory factor that is predictive of an increased risk of early death in SCLC patients treated with chemotherapy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "18845424", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18845424", "evidence_list": [ { "evidence": "A raised serum urea above the upper limit of normal (ULN) significantly predicted for increased risk of early death. We have identified raised serum urea as a significant contributory factor that is predictive of an increased risk of early death in SCLC patients treated with chemotherapy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Raised serum urea predicts for early death in small cell lung cancer.", "journal": "Clinical oncology (Royal College of Radiologists (Great Britain))", "authors": "Winter MC, Potter VA, Woll PJ", "date": "2008-10-11", "evidence": [], "reference": [ { "id": "18845424", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18845424" } ] } ], "biomarker_canonical_id": "AN4077", "collision": 1 }, { "biomarker_id": "AA4734-1", "biomarker_component": [ { "biomarker": "increased CST3 level", "assessed_biomarker_entity": { "recommended_name": "Cystatin C", "synonyms": [ { "synonym": "Cystatin-3" }, { "synonym": "Gamma-trace" }, { "synonym": "Neuroendocrine basic polypeptide" }, { "synonym": "Post-gamma-globulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01034", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33863-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33863-2" } ], "evidence_source": [ { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "10.1101/2020.03.19.20034447", "database": "Doi", "url": "https://doi.org/10.1101/2020.03.19.20034447", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "condition" } ] }, { "id": "10.1101/2020.03.19.20034447", "database": "Doi", "url": "https://doi.org/10.1101/2020.03.19.20034447", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immunology of COVID-19: Current State of the Science.", "journal": "Immunity", "authors": "Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salom\u00e9 B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, G\u00fcm\u00fc\u015f ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM, None None", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32505227", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227" } ] } ], "biomarker_canonical_id": "AA4734", "collision": 1 }, { "biomarker_id": "AA4734-2", "biomarker_component": [ { "biomarker": "increased CST3 level", "assessed_biomarker_entity": { "recommended_name": "Cystatin C", "synonyms": [ { "synonym": "Cystatin-3" }, { "synonym": "Gamma-trace" }, { "synonym": "Neuroendocrine basic polypeptide" }, { "synonym": "Post-gamma-globulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01034", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33863-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33863-2" } ], "evidence_source": [ { "id": "23986888", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23986888", "evidence_list": [ { "evidence": "Cystatin C was greatly increased in patients with ovarian cancer compared to patients with benign tumors. Results could be used as to differentiate between malignant and benign gynaecological tumors." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "23986888", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23986888", "evidence_list": [ { "evidence": "Cystatin C was greatly increased in patients with ovarian cancer compared to patients with benign tumors. Results could be used as to differentiate between malignant and benign gynaecological tumors." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer.", "journal": "International journal of circumpolar health", "authors": "Gashenko EA, Lebedeva VA, Brak IV, Tsykalenko EA, Vinokurova GV, Korolenko TA", "date": "2013-08-30", "evidence": [], "reference": [ { "id": "23986888", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23986888" } ] } ], "biomarker_canonical_id": "AA4734", "collision": 1 }, { "biomarker_id": "AN4078-2", "biomarker_component": [ { "biomarker": "increased DBIL level", "assessed_biomarker_entity": { "recommended_name": "Direct bilirubin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5280352", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35672-5" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "35672-5" } ], "evidence_source": [ { "id": "29168585", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29168585", "evidence_list": [ { "evidence": "Elevated TBIL, DBIL, and CEA were significantly associated with poor 5-year OS in stage IV CRC patients. Moreover, DBIL could be considered as an independent prognostic biomarker for OS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "29168585", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29168585", "evidence_list": [ { "evidence": "Elevated TBIL, DBIL, and CEA were significantly associated with poor 5-year OS in stage IV CRC patients. Moreover, DBIL could be considered as an independent prognostic biomarker for OS." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The prognostic impact of serum bilirubin in stage IV colorectal cancer patients.", "journal": "Journal of clinical laboratory analysis", "authors": "Yang L, Ge LY, Yu T, Liang Y, Yin Y, Chen H", "date": "2017-11-24", "evidence": [], "reference": [ { "id": "29168585", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29168585" } ] } ], "biomarker_canonical_id": "AN4078", "collision": 1 }, { "biomarker_id": "AA4736-1", "biomarker_component": [ { "biomarker": "increased BCHE level", "assessed_biomarker_entity": { "recommended_name": "Cholinesterase", "synonyms": [ { "synonym": "Acylcholine acylhydrolase" }, { "synonym": "Butyrylcholine esterase" }, { "synonym": "Choline esterase II" }, { "synonym": "Pseudocholinesterase" } ] }, "assessed_biomarker_entity_id": "UPKB:P06276", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "11154-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "11154-2" } ], "evidence_source": [ { "id": "10.1101/2020.03.19.20034447", "database": "Doi", "url": "https://doi.org/10.1101/2020.03.19.20034447", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.03.19.20034447", "database": "Doi", "url": "https://doi.org/10.1101/2020.03.19.20034447", "evidence_list": [ { "evidence": "Serum urea, CREA, CysC, DBIL, CHE and LDH could be used to distinguish severe COVID-19 cases from mild COVID-19 cases." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immunology of COVID-19: Current State of the Science.", "journal": "Immunity", "authors": "Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salom\u00e9 B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, G\u00fcm\u00fc\u015f ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM, None None", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32505227", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227" } ] } ], "biomarker_canonical_id": "AA4736", "collision": 1 }, { "biomarker_id": "AA4736-2", "biomarker_component": [ { "biomarker": "increased BCHE level", "assessed_biomarker_entity": { "recommended_name": "Cholinesterase", "synonyms": [ { "synonym": "Acylcholine acylhydrolase" }, { "synonym": "Butyrylcholine esterase" }, { "synonym": "Choline esterase II" }, { "synonym": "Pseudocholinesterase" } ] }, "assessed_biomarker_entity_id": "UPKB:P06276", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "11154-2" } ], "evidence_source": [ { "id": "30711999", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30711999", "evidence_list": [ { "evidence": "Serum concentrations of albumin, cholinesterase and total cholesterol, and total peripheral lymphocyte count (TLC) were used as nutrition related markers. Results: In multivariate analysis of nutrition related markers, serum albumin and cholinesterase levels were found to be independent prognostic indicators." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "30711999", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30711999", "evidence_list": [ { "evidence": "Serum concentrations of albumin, cholinesterase and total cholesterol, and total peripheral lymphocyte count (TLC) were used as nutrition related markers. Results: In multivariate analysis of nutrition related markers, serum albumin and cholinesterase levels were found to be independent prognostic indicators." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients ith Colorectal Cancer.", "journal": "Anticancer research", "authors": "Yamamoto M, Saito H, Uejima C, Tanio A, Tada Y, Matsunaga T, Sakamoto T, Honjo S, Ashida K, Fujiwara Y", "date": "2019-02-04", "evidence": [], "reference": [ { "id": "30711999", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30711999" } ] } ], "biomarker_canonical_id": "AA4736", "collision": 1 }, { "biomarker_id": "AA4736-3", "biomarker_component": [ { "biomarker": "increased BCHE level", "assessed_biomarker_entity": { "recommended_name": "Cholinesterase", "synonyms": [ { "synonym": "Acylcholine acylhydrolase" }, { "synonym": "Butyrylcholine esterase" }, { "synonym": "Choline esterase II" }, { "synonym": "Pseudocholinesterase" } ] }, "assessed_biomarker_entity_id": "UPKB:P06276", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "11154-2" } ], "evidence_source": [ { "id": "16233931", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16233931", "evidence_list": [ { "evidence": "Serum cholinesterase activity was measured in diabetes, hypertensive and diabetic/hypertensive patients. The sample consisted of volunteer patients and was divided in a control group (n = 26), type 2 diabetic group (n = 16), hypertensive group (n = 12) and type 2 diabetic/hypertensive group (n = 26). In addition, blood glucose, cholesterol and triglyceride levels were determined. Serum cholinesterase activity in the control group was significantly lower in relation to the other groups (p < 0.001). Blood glucose levels were elevated in type 2 diabetic and type 2 diabetic/hypertensive groups. In vitro studies showed increased cholinesterase activity in the presence of glucose 5100 mM or insulin 0.525 UI (p < 0.001). Cholesterol and triglycerides were at normal levels only in the control group. Possibly, a relationship exists between the increase in serum cholinesterase and the vascular complications in the diabetic patients, potentially stimulated by the levels of glycemia and dyslipidemia. Although patients were receiving different medicines, the increase in enzyme activity was similar in all groups. This enzymatic profile suggests a possible interference of the diseases in the catalytic mechanism of the serum cholinesterase enzyme." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "16233931", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16233931", "evidence_list": [ { "evidence": "Serum cholinesterase activity was measured in diabetes, hypertensive and diabetic/hypertensive patients. The sample consisted of volunteer patients and was divided in a control group (n = 26), type 2 diabetic group (n = 16), hypertensive group (n = 12) and type 2 diabetic/hypertensive group (n = 26). In addition, blood glucose, cholesterol and triglyceride levels were determined. Serum cholinesterase activity in the control group was significantly lower in relation to the other groups (p < 0.001). Blood glucose levels were elevated in type 2 diabetic and type 2 diabetic/hypertensive groups. In vitro studies showed increased cholinesterase activity in the presence of glucose 5100 mM or insulin 0.525 UI (p < 0.001). Cholesterol and triglycerides were at normal levels only in the control group. Possibly, a relationship exists between the increase in serum cholinesterase and the vascular complications in the diabetic patients, potentially stimulated by the levels of glycemia and dyslipidemia. Although patients were receiving different medicines, the increase in enzyme activity was similar in all groups. This enzymatic profile suggests a possible interference of the diseases in the catalytic mechanism of the serum cholinesterase enzyme." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum cholinesterase activity in diabetes and associated pathologies.", "journal": "Diabetes research and clinical practice", "authors": "In\u00e1cio Lunkes G, Stefanello F, Sausen Lunkes D, Maria Morsch V, Schetinger MR, Gon\u00e7alves JF", "date": "2005-10-20", "evidence": [], "reference": [ { "id": "16233931", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16233931" } ] } ], "biomarker_canonical_id": "AA4736", "collision": 1 }, { "biomarker_id": "AA4737-1", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32304745", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304745", "evidence_list": [ { "evidence": "Decreased albumin (p <0.001), and increased lactate dehydrogenase (LDH) (p <0.001) at admission were significantly associated with severe and critical disease conditions (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32490680", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32490680", "evidence_list": [ { "evidence": "Albumin levels could be used as an independent predictor of the risk of nonsurvivors in critically ill patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32048163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163", "evidence_list": [ { "evidence": "The combinations of the hypoalbuminemia, lymphopenia, and high concentrations of CRP and LDH in 2019-nCoV infected patients upon hospital admission may predict more severe acute lung injury." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32304745", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304745", "evidence_list": [ { "evidence": "Decreased albumin (p <0.001), and increased lactate dehydrogenase (LDH) (p <0.001) at admission were significantly associated with severe and critical disease conditions (Table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32490680", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32490680", "evidence_list": [ { "evidence": "Albumin levels could be used as an independent predictor of the risk of nonsurvivors in critically ill patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.", "journal": "Science China. Life sciences", "authors": "Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, Wang L, Peng L, Chen L, Qin Y, Zhao D, Tan S, Yin L, Xu J, Zhou C, Jiang C, Liu L", "date": "2020-02-13", "evidence": [], "reference": [ { "id": "32048163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32048163" } ] }, { "title": "Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.", "journal": "Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases", "authors": "Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, Wei J, Gong Z, Zhou C, Yu H, Yu M, Lei H, Cheng F, Zhang B, Xu Y, Wang G, Dong W", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32304745", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32304745" } ] }, { "title": "A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B", "date": "2020-04-17", "evidence": [], "reference": [ { "id": "32296824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824" } ] }, { "title": "Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19.", "journal": "Biomarkers in medicine", "authors": "Li J, Li M, Zheng S, Li M, Zhang M, Sun M, Li X, Deng A, Cai Y, Zhang H", "date": "2020-06-04", "evidence": [], "reference": [ { "id": "32490680", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32490680" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-2", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-3", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-4", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-5", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-6", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-7", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-8", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-9", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-10", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-11", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:8584", "recommended_name": { "id": "DOID:8584", "name": "lymphoma", "description": "A mature B-cell neoplasm of B-cells found in the germinal center.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, "synonyms": [ { "id": "DOID:8584", "name": "Burkitt's tumor or lymphoma", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "small Non-Cleaved cell Lymphoma, Burkitt's type", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt lymphoma/leukaemia", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt's Lymphoma", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt's tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "malignant lymphoma, Burkitt's type", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AA4737-12", "biomarker_component": [ { "biomarker": "decreased ALB level", "assessed_biomarker_entity": { "recommended_name": "Albumin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AA4737", "collision": 1 }, { "biomarker_id": "AN4073-1", "biomarker_component": [ { "biomarker": "increased IL-2R level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-2 receptor", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:2ERJ", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "76039-7" } ], "evidence_source": [ { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >ug/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >ug/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.", "journal": "BMC infectious diseases", "authors": "Gong J, Dong H, Xia QS, Huang ZY, Wang DK, Zhao Y, Liu WH, Tu SH, Zhang MM, Wang Q, Lu FE", "date": "2020-12-23", "evidence": [], "reference": [ { "id": "33349241", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241" } ] } ], "biomarker_canonical_id": "AN4073", "collision": 1 }, { "biomarker_id": "AN4073-2", "biomarker_component": [ { "biomarker": "increased IL-2R level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-2 receptor", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:2ERJ", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "76039-7" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "76039-7" } ], "evidence_source": [ { "id": "11961349", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11961349", "evidence_list": [ { "evidence": "In 6 cases with lymph node metastasis, serum soluble IL-2R levels were significantly higher than in those without lymph node metastasis. Five of these 6 cases demonstrated statistically significantly increased levels of serum soluble IL-2R suggesting serum soluble IL-2R as a predictor of lymph node metastasis in early gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "11961349", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11961349", "evidence_list": [ { "evidence": "In 6 cases with lymph node metastasis, serum soluble IL-2R levels were significantly higher than in those without lymph node metastasis. Five of these 6 cases demonstrated statistically significantly increased levels of serum soluble IL-2R suggesting serum soluble IL-2R as a predictor of lymph node metastasis in early gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum soluble interleukin-2 receptor as a predictor of lymph node metastasis in early gastric cancer.", "journal": "Digestive surgery", "authors": "Murakami S, Sakata H, Tsuji Y, Okubo K, Hamada S, Hirayama R", "date": "2002-04-19", "evidence": [], "reference": [ { "id": "11961349", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11961349" } ] } ], "biomarker_canonical_id": "AN4073", "collision": 1 }, { "biomarker_id": "AA4739-1", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >ug/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32352397", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397", "evidence_list": [ { "evidence": "In this study, the most important finding was that the neutrophil count, lymphocyte count and platelet count were independent risk factors for predicting the development of severe illness in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33349241", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241", "evidence_list": [ { "evidence": "With following parameters such as age >67.5 years, IL2R >793.5U/mL, CRP >30.7ng/mL, ferroprotein >ug/L, WBC>9.5*10^9/L or NC >7.305*10^9/L, the progress of COVID-19 to critical stage should be closely observed and possibly prevented." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32352397", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397", "evidence_list": [ { "evidence": "In this study, the most important finding was that the neutrophil count, lymphocyte count and platelet count were independent risk factors for predicting the development of severe illness in COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study.", "journal": "BMC infectious diseases", "authors": "Gong J, Dong H, Xia QS, Huang ZY, Wang DK, Zhao Y, Liu WH, Tu SH, Zhang MM, Wang Q, Lu FE", "date": "2020-12-23", "evidence": [], "reference": [ { "id": "33349241", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33349241" } ] }, { "title": "The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Zheng Y, Zhang Y, Chi H, Chen S, Peng M, Luo L, Chen L, Li J, Shen B, Wang D", "date": "2020-05-01", "evidence": [], "reference": [ { "id": "32352397", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32352397" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-2", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-3", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-4", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-5", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-6", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-7", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-8", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-9", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-10", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-11", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2531", "recommended_name": { "id": "DOID:2531", "name": "hematologic cancer", "description": "An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, "synonyms": [ { "id": "DOID:2531", "name": "Hematologic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematologic malignancy", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic and lymphoid system tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "blood cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "malignant hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematological tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4739-12", "biomarker_component": [ { "biomarker": "increased NEUT count", "assessed_biomarker_entity": { "recommended_name": "Neutrophil", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21418-9" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Pro-inflammatory and infection-related biomarkers, including TNF-alpha, IL-6, procalcitonin, and C-reactive protein, as well as organ damage indices (leucocytes, neutrophils, and lactate dehydrogenase), coagulation-related indicators (D-dimer, prothrombin time, and activated partial thromboplastin time), and NT-proBNP were significantly associated with worse severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32357994", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994", "evidence_list": [ { "evidence": "Post-COVID-19 infection, lower hemoglobin levels, higher total white blood cell (WBC) counts, and higher absolute neutrophil counts were associated with increased mortality (Table 3). Analysis of other serologic biomarkers demonstrated that elevated D-dimer, lactate, and lactate dehydrogenase (LDH) in patients were significantly correlated with dying (Table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] }, { "title": "Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.", "journal": "Cancer discovery", "authors": "Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B, Verma A", "date": "2020-05-03", "evidence": [], "reference": [ { "id": "32357994", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32357994" } ] } ], "biomarker_canonical_id": "AA4739", "collision": 1 }, { "biomarker_id": "AA4740-1", "biomarker_component": [ { "biomarker": "increased MONO count", "assessed_biomarker_entity": { "recommended_name": "Monocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000576", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27823973", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27823973", "evidence_list": [ { "evidence": "Serum monocyte fraction were significantly associated with high Gleason score prostate cancer. The number of white blood cell count was a lot higher in patients with a Gleason score higher than 7 prostate cancer than in patients without it. Suggesting an interaction of monocytes with the progression of prostate cancer. Serum monocyte fraction was also significantly higher in men with Gleason score prostate cancer than in men with negative biopsy and Gleason score prostate cancer in the cohort of men." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "27823973", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27823973", "evidence_list": [ { "evidence": "Serum monocyte fraction were significantly associated with high Gleason score prostate cancer. The number of white blood cell count was a lot higher in patients with a Gleason score higher than 7 prostate cancer than in patients without it. Suggesting an interaction of monocytes with the progression of prostate cancer. Serum monocyte fraction was also significantly higher in men with Gleason score prostate cancer than in men with negative biopsy and Gleason score prostate cancer in the cohort of men." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer.", "journal": "Oncotarget", "authors": "Hayashi T, Fujita K, Tanigawa G, Kawashima A, Nagahara A, Ujike T, Uemura M, Takao T, Yamaguchi S, Nonomura N", "date": "2016-11-09", "evidence": [], "reference": [ { "id": "27823973", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27823973" } ] } ], "biomarker_canonical_id": "AA4740", "collision": 1 }, { "biomarker_id": "AA4741-1", "biomarker_component": [ { "biomarker": "decreased MONO count", "assessed_biomarker_entity": { "recommended_name": "Monocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000576", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26484-6" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4741", "collision": 1 }, { "biomarker_id": "AA4740-2", "biomarker_component": [ { "biomarker": "increased MONO count", "assessed_biomarker_entity": { "recommended_name": "Monocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000576", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26484-6" } ], "evidence_source": [ { "id": "25814648", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25814648", "evidence_list": [ { "evidence": "This monocyte signature was expressed at early disease onset, remained robust over the course of disease progression, and was specific for the monocytic fraction of mononuclear cells. The identified distinct signature in tumour-educated monocytes might be used as a candidate biomarker in CRC diagnosis and harbours the potential for disease follow-up and therapeutic monitoring." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "25814648", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25814648", "evidence_list": [ { "evidence": "This monocyte signature was expressed at early disease onset, remained robust over the course of disease progression, and was specific for the monocytic fraction of mononuclear cells. The identified distinct signature in tumour-educated monocytes might be used as a candidate biomarker in CRC diagnosis and harbours the potential for disease follow-up and therapeutic monitoring." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.", "journal": "Gut", "authors": "Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Roth\u00e9 F, Schmitz R, D'Hoore A, Iserentant H, Hendlisz A, Mazzone M", "date": "2015-03-31", "evidence": [], "reference": [ { "id": "25814648", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25814648" } ] } ], "biomarker_canonical_id": "AA4740", "collision": 1 }, { "biomarker_id": "AA4741-2", "biomarker_component": [ { "biomarker": "decreased MONO count", "assessed_biomarker_entity": { "recommended_name": "Monocyte", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000576", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26484-6" } ], "evidence_source": [ { "id": "32810439", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439", "evidence_list": [ { "evidence": "We performed high dimensional flow cytometry and single cell RNA sequencing of COVID-19 patient peripheral blood cells and detected the disappearance of non-classical CD14LowCD16High monocytes, the accumulation of HLA-DRLow classical monocytes, and the release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101-CXCR4+/- neutrophils with an immuno-suppressive profile accumulated as well in blood and lungs, suggesting emergency myelopoiesis. We finally showed that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe COVID-19 form, suggesting a predictive value that deserves prospective evaluation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "32810439", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439", "evidence_list": [ { "evidence": "We performed high dimensional flow cytometry and single cell RNA sequencing of COVID-19 patient peripheral blood cells and detected the disappearance of non-classical CD14LowCD16High monocytes, the accumulation of HLA-DRLow classical monocytes, and the release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101-CXCR4+/- neutrophils with an immuno-suppressive profile accumulated as well in blood and lungs, suggesting emergency myelopoiesis. We finally showed that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe COVID-19 form, suggesting a predictive value that deserves prospective evaluation." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.", "journal": "Cell", "authors": "Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, H\u00e9non C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V, Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, P\u00e8ne F, Gachot B, Andr\u00e9 F, Zitvogel L, Ginhoux F, Fontenay M, Solary E", "date": "2020-08-19", "evidence": [], "reference": [ { "id": "32810439", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439" } ] } ], "biomarker_canonical_id": "AA4741", "collision": 1 }, { "biomarker_id": "AA4742-1", "biomarker_component": [ { "biomarker": "decreased BASO count", "assessed_biomarker_entity": { "recommended_name": "Basophil", "synonyms": [ { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "basophilic leucocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "basophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000767", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26444-0" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4742", "collision": 1 }, { "biomarker_id": "AA4742-2", "biomarker_component": [ { "biomarker": "decreased BASO count", "assessed_biomarker_entity": { "recommended_name": "Basophil", "synonyms": [ { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "basophilic leucocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "basophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000767", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "26444-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "26444-0" } ], "evidence_source": [ { "id": "32037496", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32037496", "evidence_list": [ { "evidence": "As a common immune/inflammation-related biomarker available from the blood routine examination, low level of preoperative serum basophil count was associated with aggressive biology and indicated evidently poor survival. Preoperative serum basophil count would be a useful and simple marker for the management of CRC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32037496", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32037496", "evidence_list": [ { "evidence": "As a common immune/inflammation-related biomarker available from the blood routine examination, low level of preoperative serum basophil count was associated with aggressive biology and indicated evidently poor survival. Preoperative serum basophil count would be a useful and simple marker for the management of CRC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.", "journal": "Clinical and translational medicine", "authors": "Liu Q, Luo D, Cai S, Li Q, Li X", "date": "2020-02-11", "evidence": [], "reference": [ { "id": "32037496", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32037496" } ] } ], "biomarker_canonical_id": "AA4742", "collision": 1 }, { "biomarker_id": "AA4743-1", "biomarker_component": [ { "biomarker": "decreased TH count", "assessed_biomarker_entity": { "recommended_name": "Helper T cell", "synonyms": [ { "synonym": "helper T-lymphocyte" }, { "synonym": "helper T lymphocyte" }, { "synonym": "helper T-cell" }, { "synonym": "T-helper cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000912", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65758-5" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4743", "collision": 1 }, { "biomarker_id": "AA4744-1", "biomarker_component": [ { "biomarker": "increased TH count", "assessed_biomarker_entity": { "recommended_name": "Helper T cell", "synonyms": [ { "synonym": "helper T-lymphocyte" }, { "synonym": "helper T lymphocyte" }, { "synonym": "helper T-cell" }, { "synonym": "T-helper cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000912", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "65758-5" } ], "evidence_source": [ { "id": "31270583", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31270583", "evidence_list": [ { "evidence": "Our results demonstrate that circulating CXCR5-PD-1hi Tph cells are associated with progression to clinical type 1 diabetes. Consequently, Tph cells could have potential both as a biomarker of disease progression and as a target for immunotherapy in type 1 diabetes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "31270583", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31270583", "evidence_list": [ { "evidence": "Our results demonstrate that circulating CXCR5-PD-1hi Tph cells are associated with progression to clinical type 1 diabetes. Consequently, Tph cells could have potential both as a biomarker of disease progression and as a target for immunotherapy in type 1 diabetes." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating CXCR5", "journal": "Diabetologia", "authors": "Ekman I, Ihantola EL, Viisanen T, Rao DA, N\u00e4nt\u00f6-Salonen K, Knip M, Veijola R, Toppari J, Ilonen J, Kinnunen T", "date": "2019-07-05", "evidence": [], "reference": [ { "id": "31270583", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31270583" } ] } ], "biomarker_canonical_id": "AA4744", "collision": 1 }, { "biomarker_id": "AA4745-1", "biomarker_component": [ { "biomarker": "increased NTH count", "assessed_biomarker_entity": { "recommended_name": "Naive Th cell", "synonyms": [ { "synonym": "naive T-cell" }, { "synonym": "naive T lymphocyte" }, { "synonym": "naive T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000898", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "80720-6" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4745", "collision": 1 }, { "biomarker_id": "AA4746-1", "biomarker_component": [ { "biomarker": "decreased NTH count", "assessed_biomarker_entity": { "recommended_name": "Naive Th cell", "synonyms": [ { "synonym": "naive T-cell" }, { "synonym": "naive T lymphocyte" }, { "synonym": "naive T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000898", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "80720-6" } ], "evidence_source": [ { "id": "30246868", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30246868", "evidence_list": [ { "evidence": "The frequency of Treg, HLA-DRlow monocytes and naive CD4+ and CD8+ T cells as well as the ratios of CD4/HLA-DRlow monocytes and HLA-DRlow monocytes/pDC correlated with patient's overall survival. Next to Treg, HLA-DRlow monocytes and naive T cells represent prognostic markers for NSCLC patients and might be useful for monitoring of patients' responses to immunotherapies in future studies." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30246868", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30246868", "evidence_list": [ { "evidence": "The frequency of Treg, HLA-DRlow monocytes and naive CD4+ and CD8+ T cells as well as the ratios of CD4/HLA-DRlow monocytes and HLA-DRlow monocytes/pDC correlated with patient's overall survival. Next to Treg, HLA-DRlow monocytes and naive T cells represent prognostic markers for NSCLC patients and might be useful for monitoring of patients' responses to immunotherapies in future studies." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Blood immune cell biomarkers in lung cancer.", "journal": "Clinical and experimental immunology", "authors": "Riemann D, Cwikowski M, Turzer S, Giese T, Grallert M, Sch\u00fctte W, Seliger B", "date": "2018-09-25", "evidence": [], "reference": [ { "id": "30246868", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30246868" } ] } ], "biomarker_canonical_id": "AA4746", "collision": 1 }, { "biomarker_id": "AA4747-1", "biomarker_component": [ { "biomarker": "decreased MTH count", "assessed_biomarker_entity": { "recommended_name": "Memory Th cell", "synonyms": [ { "synonym": "memory T-cell" }, { "synonym": "memory T lymphocyte" }, { "synonym": "memory T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000813", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4747", "collision": 1 }, { "biomarker_id": "AA4748-1", "biomarker_component": [ { "biomarker": "increased MTH count", "assessed_biomarker_entity": { "recommended_name": "Memory Th cell", "synonyms": [ { "synonym": "memory T-cell" }, { "synonym": "memory T lymphocyte" }, { "synonym": "memory T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000813", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30574794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30574794", "evidence_list": [ { "evidence": "Subjects with type 2 diabetes mellitus had elevated percentages of effector memory T cells ((CD4+CD45RO+CD62L-; 21.8% \u00b1 11.2% vs 17.0% \u00b1 9.2% in non-type 2 diabetes mellitus, p < 0.01) and central memory T cells (CD4+CD45RO+CD62L+; 38.0% \u00b1 10.7% vs 36.0% \u00b1 9.5% in non-type 2 diabetes mellitus, p < 0.01). The proportion of effector memory T cells was increased in type 2 diabetes mellitus subjects with cardiovascular disease as compared to those without (26.4% \u00b1 11.5% vs 18.4% \u00b1 10.2%, p < 0.05), while no difference in regulatory T cells was observed between these two patient groups. This study identifies effector memory T cells as a potential cellular biomarker for cardiovascular disease among subjects with type 2 diabetes mellitus, suggesting a state of exacerbated immune activation in type 2 diabetes mellitus patients with cardiovascular disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "30574794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30574794", "evidence_list": [ { "evidence": "Subjects with type 2 diabetes mellitus had elevated percentages of effector memory T cells ((CD4+CD45RO+CD62L-; 21.8% \u00b1 11.2% vs 17.0% \u00b1 9.2% in non-type 2 diabetes mellitus, p < 0.01) and central memory T cells (CD4+CD45RO+CD62L+; 38.0% \u00b1 10.7% vs 36.0% \u00b1 9.5% in non-type 2 diabetes mellitus, p < 0.01). The proportion of effector memory T cells was increased in type 2 diabetes mellitus subjects with cardiovascular disease as compared to those without (26.4% \u00b1 11.5% vs 18.4% \u00b1 10.2%, p < 0.05), while no difference in regulatory T cells was observed between these two patient groups. This study identifies effector memory T cells as a potential cellular biomarker for cardiovascular disease among subjects with type 2 diabetes mellitus, suggesting a state of exacerbated immune activation in type 2 diabetes mellitus patients with cardiovascular disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated circulating effector memory T cells but similar levels of regulatory T cells in patients with type 2 diabetes mellitus and cardiovascular disease.", "journal": "Diabetes & vascular disease research", "authors": "Rattik S, Engelbertsen D, Wigren M, Ljungcrantz I, \u00d6stling G, Persson M, Nordin Fredrikson G, Bengtsson E, Nilsson J, Bj\u00f6rkbacka H", "date": "2018-12-24", "evidence": [], "reference": [ { "id": "30574794", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30574794" } ] } ], "biomarker_canonical_id": "AA4748", "collision": 1 }, { "biomarker_id": "AA4749-1", "biomarker_component": [ { "biomarker": "decreased TREG count", "assessed_biomarker_entity": { "recommended_name": "Regulatory T cell", "synonyms": [ { "synonym": "regulatory T-cell" }, { "synonym": "regulatory T lymphocyte" }, { "synonym": "suppressor T cell" }, { "synonym": "regulatory T-lymphocyte" }, { "synonym": "suppressor T lymphocyte" }, { "synonym": "suppressor T-lymphocyte" }, { "synonym": "Treg" }, { "synonym": "suppressor T-cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000815", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" }, { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14135-8" } ], "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161940", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940", "evidence_list": [ { "evidence": "Severe cases tend to have lower lymphocytes counts, higher leukocyte counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory cytokines. The number of T cells significantly decreased, and more hampered in severe cases. Both helper T cells and suppressor T cells in patients with COVID-19 were below normal levels, and lower level of helper T cells in severe group. The percentage of naive helper T cells increased and memory helper T cells decreased in severe cases. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161940", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161940" } ] } ], "biomarker_canonical_id": "AA4749", "collision": 1 }, { "biomarker_id": "AA4750-1", "biomarker_component": [ { "biomarker": "increased TREG count", "assessed_biomarker_entity": { "recommended_name": "Regulatory T cell", "synonyms": [ { "synonym": "regulatory T-cell" }, { "synonym": "regulatory T lymphocyte" }, { "synonym": "suppressor T cell" }, { "synonym": "regulatory T-lymphocyte" }, { "synonym": "suppressor T lymphocyte" }, { "synonym": "suppressor T-lymphocyte" }, { "synonym": "Treg" }, { "synonym": "suppressor T-cell" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000815", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "27976733", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27976733", "evidence_list": [ { "evidence": "The percentages of naive Treg were found elevated in NSCLC patients compared to HD and were associated with poor clinical outcome, whereas the percentage of terminal effector Treg was lower compared to HD and higher levels were correlated with improved clinical response. At baseline, normal levels of naive and effector Treg were associated with longer overall survival (OS) compared to high levels, while the high frequency of the terminal effector Treg was correlated with longer Progression-Free Survival and OS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "27976733", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27976733", "evidence_list": [ { "evidence": "The percentages of naive Treg were found elevated in NSCLC patients compared to HD and were associated with poor clinical outcome, whereas the percentage of terminal effector Treg was lower compared to HD and higher levels were correlated with improved clinical response. At baseline, normal levels of naive and effector Treg were associated with longer overall survival (OS) compared to high levels, while the high frequency of the terminal effector Treg was correlated with longer Progression-Free Survival and OS." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.", "journal": "Scientific reports", "authors": "Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK", "date": "2016-12-16", "evidence": [], "reference": [ { "id": "27976733", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27976733" } ] } ], "biomarker_canonical_id": "AA4750", "collision": 1 }, { "biomarker_id": "AA4751-1", "biomarker_component": [ { "biomarker": "increased ESR", "assessed_biomarker_entity": { "recommended_name": "Erythrocyte sedimentation rate", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74611", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "30341-2" } ], "evidence_source": [ { "id": "29285390", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29285390", "evidence_list": [ { "evidence": "Elevated ESR was found to be associated with metastatic disease and was also found to be a prognostic factor adversely affecting survival in patients with cutaneous melanoma." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "29285390", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29285390", "evidence_list": [ { "evidence": "Elevated ESR was found to be associated with metastatic disease and was also found to be a prognostic factor adversely affecting survival in patients with cutaneous melanoma." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma.", "journal": "Molecular and clinical oncology", "authors": "Tas F, Erturk K", "date": "2017-12-30", "evidence": [], "reference": [ { "id": "29285390", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29285390" } ] } ], "biomarker_canonical_id": "AA4751", "collision": 1 }, { "biomarker_id": "AA4751-2", "biomarker_component": [ { "biomarker": "increased ESR", "assessed_biomarker_entity": { "recommended_name": "Erythrocyte sedimentation rate", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74611", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "30341-2" } ], "evidence_source": [ { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "Erythrocyte sedimentation rate (ESR) (R=0.55, p < .01) was positively associated with CT severity scores. To sum up, we can conclude from the analysis of published studies that hematological (lymphocyte count, neutrophil count, and NLR), inflammatory (CRP, ESR, IL-6), and especially biochemical (D-dimer, Troponins, CK) parameters correlate with severe prognosis or exitus in COVID-19 patients and can therefore be used as predictive biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32324595", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32324595", "evidence_list": [ { "evidence": "Inflammatory biomarkers such as CRP and erythrocyte sedimentation rate were increased." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "Erythrocyte sedimentation rate (ESR) (R=0.55, p < .01) was positively associated with CT severity scores. To sum up, we can conclude from the analysis of published studies that hematological (lymphocyte count, neutrophil count, and NLR), inflammatory (CRP, ESR, IL-6), and especially biochemical (D-dimer, Troponins, CK) parameters correlate with severe prognosis or exitus in COVID-19 patients and can therefore be used as predictive biomarkers." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32324595", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32324595", "evidence_list": [ { "evidence": "Inflammatory biomarkers such as CRP and erythrocyte sedimentation rate were increased." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Biomarkers associated with COVID-19 disease progression.", "journal": "Critical reviews in clinical laboratory sciences", "authors": "Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32503382", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382" } ] }, { "title": "The laboratory tests and host immunity of COVID-19 patients with different severity of illness.", "journal": "JCI insight", "authors": "Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, Liu W, Zhu Y, Lin Q, Mao L, Fang M, Zhang H, Sun Z", "date": "2020-04-24", "evidence": [], "reference": [ { "id": "32324595", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32324595" } ] } ], "biomarker_canonical_id": "AA4751", "collision": 1 }, { "biomarker_id": "AA4752-1", "biomarker_component": [ { "biomarker": "increased IL8 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-8", "synonyms": [ { "synonym": "IL-8" }, { "synonym": "C-X-C motif chemokine 8" }, { "synonym": "Chemokine (C-X-C motif) ligand 8" }, { "synonym": "Emoctakin" }, { "synonym": "Granulocyte chemotactic protein 1" }, { "synonym": "GCP-1" }, { "synonym": "Monocyte-derived neutrophil chemotactic factor" }, { "synonym": "MDNCF" }, { "synonym": "Monocyte-derived neutrophil-activating peptide" }, { "synonym": "MONAP" }, { "synonym": "Neutrophil-activating protein 1" }, { "synonym": "NAP-1" }, { "synonym": "Protein 3-10C" }, { "synonym": "T-cell chemotactic factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P10145", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33211-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33211-4" } ], "evidence_source": [ { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of [IL-6, TNF-a, IL-1b, and CXCL8/IL-8]. We found that high serum IL-6, IL-8, and TNF alpha levels at the time of hospitalization were strong and independent predictors of patient survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of [IL-6, TNF-a, IL-1b, and CXCL8/IL-8]. We found that high serum IL-6, IL-8, and TNF alpha levels at the time of hospitalization were strong and independent predictors of patient survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "An inflammatory cytokine signature helps predict COVID-19 severity and death.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511562", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562" } ] } ], "biomarker_canonical_id": "AA4752", "collision": 1 }, { "biomarker_id": "AA4752-2", "biomarker_component": [ { "biomarker": "increased IL8 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-8", "synonyms": [ { "synonym": "IL-8" }, { "synonym": "C-X-C motif chemokine 8" }, { "synonym": "Chemokine (C-X-C motif) ligand 8" }, { "synonym": "Emoctakin" }, { "synonym": "Granulocyte chemotactic protein 1" }, { "synonym": "GCP-1" }, { "synonym": "Monocyte-derived neutrophil chemotactic factor" }, { "synonym": "MDNCF" }, { "synonym": "Monocyte-derived neutrophil-activating peptide" }, { "synonym": "MONAP" }, { "synonym": "Neutrophil-activating protein 1" }, { "synonym": "NAP-1" }, { "synonym": "Protein 3-10C" }, { "synonym": "T-cell chemotactic factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P10145", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33211-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33211-4" } ], "evidence_source": [ { "id": "28791816", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28791816", "evidence_list": [ { "evidence": "The study showed that IL-6, IL-8 and TNF-alpha levels correlated with clinical disease stage and lymph node metastasis as well as with ER and HER2 antigen expression. Specifically, IL-6 and IL-8 seem to have significant potential as prognostic cancer biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "28791816", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28791816", "evidence_list": [ { "evidence": "The study showed that IL-6, IL-8 and TNF-alpha levels correlated with clinical disease stage and lymph node metastasis as well as with ER and HER2 antigen expression. Specifically, IL-6 and IL-8 seem to have significant potential as prognostic cancer biomarkers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "IL-6, IL-8 and TNF-\u03b1 levels correlate with disease stage in breast cancer patients.", "journal": "Advances in clinical and experimental medicine : official organ Wroclaw Medical University", "authors": "Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J", "date": "2017-08-10", "evidence": [], "reference": [ { "id": "28791816", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28791816" } ] } ], "biomarker_canonical_id": "AA4752", "collision": 1 }, { "biomarker_id": "AA4752-3", "biomarker_component": [ { "biomarker": "increased IL8 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-8", "synonyms": [ { "synonym": "IL-8" }, { "synonym": "C-X-C motif chemokine 8" }, { "synonym": "Chemokine (C-X-C motif) ligand 8" }, { "synonym": "Emoctakin" }, { "synonym": "Granulocyte chemotactic protein 1" }, { "synonym": "GCP-1" }, { "synonym": "Monocyte-derived neutrophil chemotactic factor" }, { "synonym": "MDNCF" }, { "synonym": "Monocyte-derived neutrophil-activating peptide" }, { "synonym": "MONAP" }, { "synonym": "Neutrophil-activating protein 1" }, { "synonym": "NAP-1" }, { "synonym": "Protein 3-10C" }, { "synonym": "T-cell chemotactic factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P10145", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33211-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33211-4" } ], "evidence_source": [ { "id": "28836077", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28836077", "evidence_list": [ { "evidence": "Patients with T2D exhibited significantly higher serum IL-8 levels than non-diabetic subjects (69.27 \u00b1 112.83 vs. 16.03 \u00b1 24.27 pg/mL, p < 0.001). Patients with T2D display a marked elevation of circulating IL-8 levels which identify subjects with worse inflammatory, glycometabolic and lipid profile and lower vitamin D levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "28836077", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28836077", "evidence_list": [ { "evidence": "Patients with T2D exhibited significantly higher serum IL-8 levels than non-diabetic subjects (69.27 \u00b1 112.83 vs. 16.03 \u00b1 24.27 pg/mL, p < 0.001). Patients with T2D display a marked elevation of circulating IL-8 levels which identify subjects with worse inflammatory, glycometabolic and lipid profile and lower vitamin D levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile.", "journal": "Acta diabetologica", "authors": "Cimini FA, Barchetta I, Porzia A, Mainiero F, Costantino C, Bertoccini L, Ceccarelli V, Morini S, Baroni MG, Lenzi A, Cavallo MG", "date": "2017-08-25", "evidence": [], "reference": [ { "id": "28836077", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28836077" } ] } ], "biomarker_canonical_id": "AA4752", "collision": 1 }, { "biomarker_id": "AA4753-1", "biomarker_component": [ { "biomarker": "increased TNNI3 level", "assessed_biomarker_entity": { "recommended_name": "Cardiac troponin I", "synonyms": [ { "synonym": "Cardiac troponin I" } ] }, "assessed_biomarker_entity_id": "UPKB:P19429", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10839-9" } ], "evidence_source": [ { "id": "32169400", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32169400", "evidence_list": [ { "evidence": "cTnI values are significantly increased in patients with severe SARS-CoV-2 infection compared to those with milder forms of disease. It is hence reasonable to hypothesize that initial measurement of cardiac damage biomarkers immediately after hospitalization for SARS-CoV-2 infection, as well as longitudinal monitoring during hospital stay, may help identifying a subset of patients with possible cardiac injury and thereby predict the progression of COVID-19 towards a worse clinical picture." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32530509", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509", "evidence_list": [ { "evidence": "High troponin I levels with either advanced age more than 60 years or elevated AST levels was the best model to predict poor outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "A retrospective study performed in China of patients with confirmed COVID-19 based on SARS-CoV-2 RNA detection, revealed a univariable odds ratio for death at 80.1 (95% CI 10.3-620.4, p<0.0001) for hs-TnI. Another study of 416 hospitalised patients with COVID-19 reported that hs-TnI was elevated in 1 in 5 patients on presentation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32251612", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32251612", "evidence_list": [ { "evidence": "In a cohort of 191 patients with confirmed COVID-19 based on SARS-CoV-2 RNA detection, the univariable odds ratio for death when high-sensitivity cardiac troponin I concentrations were above the 99th percentile upper reference limit was 80.1 (95% CI, 10.3-620.4; P<0.0001). This was higher than the odds ratios observed for all other biomarkers tested, including D-dimer and lymphocyte count." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32169400", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32169400", "evidence_list": [ { "evidence": "cTnI values are significantly increased in patients with severe SARS-CoV-2 infection compared to those with milder forms of disease. It is hence reasonable to hypothesize that initial measurement of cardiac damage biomarkers immediately after hospitalization for SARS-CoV-2 infection, as well as longitudinal monitoring during hospital stay, may help identifying a subset of patients with possible cardiac injury and thereby predict the progression of COVID-19 towards a worse clinical picture." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32530509", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509", "evidence_list": [ { "evidence": "High troponin I levels with either advanced age more than 60 years or elevated AST levels was the best model to predict poor outcomes." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32475810", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810", "evidence_list": [ { "evidence": "A retrospective study performed in China of patients with confirmed COVID-19 based on SARS-CoV-2 RNA detection, revealed a univariable odds ratio for death at 80.1 (95% CI 10.3-620.4, p<0.0001) for hs-TnI. Another study of 416 hospitalised patients with COVID-19 reported that hs-TnI was elevated in 1 in 5 patients on presentation." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32251612", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32251612", "evidence_list": [ { "evidence": "In a cohort of 191 patients with confirmed COVID-19 based on SARS-CoV-2 RNA detection, the univariable odds ratio for death when high-sensitivity cardiac troponin I concentrations were above the 99th percentile upper reference limit was 80.1 (95% CI, 10.3-620.4; P<0.0001). This was higher than the odds ratios observed for all other biomarkers tested, including D-dimer and lymphocyte count." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis.", "journal": "Progress in cardiovascular diseases", "authors": "Lippi G, Lavie CJ, Sanchis-Gomar F", "date": "2020-03-15", "evidence": [], "reference": [ { "id": "32169400", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32169400" } ] }, { "title": "Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.", "journal": "Journal of medical virology", "authors": "Toraih EA, Elshazli RM, Hussein MH, Elgaml A, Amin M, El-Mowafy M, El-Mesery M, Ellythy A, Duchesne J, Killackey MT, Ferdinand KC, Kandil E, Fawzy MS", "date": "2020-06-13", "evidence": [], "reference": [ { "id": "32530509", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509" } ] }, { "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.", "journal": "Lancet (London, England)", "authors": "Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B", "date": "2020-03-15", "evidence": [], "reference": [ { "id": "32171076", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076" } ] }, { "title": "The role of biomarkers in diagnosis of COVID-19 - A systematic review.", "journal": "Life sciences", "authors": "Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32475810", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32475810" } ] }, { "title": "High-Sensitivity Cardiac Troponin Can Be an Ally in the Fight Against COVID-19.", "journal": "Circulation", "authors": "Chapman AR, Bularga A, Mills NL", "date": "2020-04-07", "evidence": [], "reference": [ { "id": "32251612", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32251612" } ] } ], "biomarker_canonical_id": "AA4753", "collision": 1 }, { "biomarker_id": "AA4754-2", "biomarker_component": [ { "biomarker": "decreased K+ level", "assessed_biomarker_entity": { "recommended_name": "Potassium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5462222", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "51720-1" }, { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "51720-1" } ], "evidence_source": [ { "id": "10.1101/2020.02.27.20028530", "database": "Doi", "url": "https://doi.org/10.1101/2020.02.27.20028530", "evidence_list": [ { "evidence": "Hypokalemia is prevailing in patients with COVID-19. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "10.1101/2020.02.27.20028530", "database": "Doi", "url": "https://doi.org/10.1101/2020.02.27.20028530", "evidence_list": [ { "evidence": "Hypokalemia is prevailing in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal K+ loss resulting from the degradation of ACE2." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.02.27.20028530", "database": "Doi", "url": "https://doi.org/10.1101/2020.02.27.20028530", "evidence_list": [ { "evidence": "Hypokalemia is prevailing in patients with COVID-19. The end of urine K+ loss indicates a good prognosis and may be a reliable, in-time, and sensitive biomarker directly reflecting the end of adverse effect on RAS system." } ], "tags": [ { "tag": "condition" } ] }, { "id": "10.1101/2020.02.27.20028530", "database": "Doi", "url": "https://doi.org/10.1101/2020.02.27.20028530", "evidence_list": [ { "evidence": "Hypokalemia is prevailing in patients with COVID-19. The correction of hypokalemia is challenging because of continuous renal K+ loss resulting from the degradation of ACE2." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AA4754", "collision": 1 }, { "biomarker_id": "AA4754-1", "biomarker_component": [ { "biomarker": "decreased K+ level", "assessed_biomarker_entity": { "recommended_name": "Potassium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5462222", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "51720-1" } ], "evidence_source": [ { "id": "25325058", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25325058", "evidence_list": [ { "evidence": "Diabetic patients frequently develop a constellation of electrolyte disorders. These disturbances are particularly common in decompensated diabetics, especially in the context of diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome. These patients are markedly potassium, magnesium and phosphate-depleted." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "25325058", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25325058", "evidence_list": [ { "evidence": "Diabetic patients frequently develop a constellation of electrolyte disorders. These disturbances are particularly common in decompensated diabetics, especially in the context of diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome. These patients are markedly potassium, magnesium and phosphate-depleted." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Diabetes mellitus and electrolyte disorders.", "journal": "World journal of clinical cases", "authors": "Liamis G, Liberopoulos E, Barkas F, Elisaf M", "date": "2014-10-18", "evidence": [], "reference": [ { "id": "25325058", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25325058" } ] } ], "biomarker_canonical_id": "AA4754", "collision": 1 }, { "biomarker_id": "AN4454-1", "biomarker_component": [ { "biomarker": "increased NCD4LR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to CD4+ Lymphocyte ratio", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32531713", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32531713", "evidence_list": [ { "evidence": "The NCDLR value can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased NCD4LR ratio", "assessed_biomarker_entity": { "recommended_name": "Neutrophil to CD4+ Lymphocyte ratio", "synonyms": [ { "synonym": "CD4-positive, alpha-beta T-cell" }, { "synonym": "CD4-positive, alpha-beta T lymphocyte" }, { "synonym": "CD4-positive, alpha-beta T-lymphocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000624", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32531713", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32531713", "evidence_list": [ { "evidence": "The NCDLR value can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32531713", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32531713", "evidence_list": [ { "evidence": "The NCDLR value can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.", "journal": "International immunopharmacology", "authors": "Wang H, Zhang Y, Mo P, Liu J, Wang H, Wang F, Zhao Q", "date": "2020-06-13", "evidence": [], "reference": [ { "id": "32531713", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32531713" } ] }, { "title": "Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.", "journal": "International immunopharmacology", "authors": "Wang H, Zhang Y, Mo P, Liu J, Wang H, Wang F, Zhao Q", "date": "2020-06-13", "evidence": [], "reference": [ { "id": "32531713", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32531713" } ] } ], "biomarker_canonical_id": "AN4454", "collision": 0 }, { "biomarker_id": "AA4755-1", "biomarker_component": [ { "biomarker": "decreased SERPINC1 level", "assessed_biomarker_entity": { "recommended_name": "Antithrombin", "synonyms": [ { "synonym": "ATIII" }, { "synonym": "Serpin C1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01008", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "20991-6" } ], "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "Compared with healthy controls, the AT values were found to be lower in COVID-19 patients (85% vs. 99%; p<0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32829961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32829961", "evidence_list": [ { "evidence": "The correlation between AT reduction to clinical outcomes can be extrapolated from studies in sepsis where this association has already been well established." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "Compared with healthy controls, the AT values were found to be lower in COVID-19 patients (85% vs. 99%; p<0.001)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32829961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32829961", "evidence_list": [ { "evidence": "The correlation between AT reduction to clinical outcomes can be extrapolated from studies in sepsis where this association has already been well established." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL", "date": "2020-03-17", "evidence": [], "reference": [ { "id": "32172226", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226" } ] }, { "title": "Understanding the andromeda strain - The role of cytokine release, coagulopathy and antithrombin III in SARS-CoV2 critical illness.", "journal": "Blood reviews", "authors": "Mir N, D'Amico A, Dasher J, Tolwani A, Valentine V", "date": "2020-08-25", "evidence": [], "reference": [ { "id": "32829961", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32829961" } ] } ], "biomarker_canonical_id": "AA4755", "collision": 1 }, { "biomarker_id": "AA4756-1", "biomarker_component": [ { "biomarker": "increased SERPINC1 level", "assessed_biomarker_entity": { "recommended_name": "Antithrombin", "synonyms": [ { "synonym": "ATIII" }, { "synonym": "Serpin C1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01008", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "20991-6" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "20991-6" } ], "evidence_source": [ { "id": "19227008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19227008", "evidence_list": [ { "evidence": "Our results pointed antithrombin (down) and fibrinogen (up) regulated after a four months treatment deserving to be further verified as prognostic markers for this treatment. Possible links between tumor progression and anti-thrombin expression level are also discussed." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1319", "recommended_name": { "id": "DOID:1319", "name": "brain cancer", "description": "A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, "synonyms": [ { "id": "DOID:1319", "name": "malignant brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "BT - Brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult malignant brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary malignant neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of adult brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "tumor of the Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm, adult", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" } ] }, "evidence_source": [ { "id": "19227008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19227008", "evidence_list": [ { "evidence": "Our results pointed antithrombin (down) and fibrinogen (up) regulated after a four months treatment deserving to be further verified as prognostic markers for this treatment. Possible links between tumor progression and anti-thrombin expression level are also discussed." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol.", "journal": "Journal of experimental therapeutics & oncology", "authors": "Fischer Jde S, Carvalho PC, Neves-Ferreira AG, da Fonseca CO, Perales J, Carvalho Mda G, Domont GB", "date": "2009-02-21", "evidence": [], "reference": [ { "id": "19227008", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19227008" } ] } ], "biomarker_canonical_id": "AA4756", "collision": 1 }, { "biomarker_id": "AN4079-1", "biomarker_component": [ { "biomarker": "increased FDP level", "assessed_biomarker_entity": { "recommended_name": "Fibrin degradation product", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:439199", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "29263-1" } ], "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "FDP (33.83 vs. 1.55 mg/L; p<0.001) were higher in patients with SARS-CoV-2 than those in controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "FDP (33.83 vs. 1.55 mg/L; p<0.001) were higher in patients with SARS-CoV-2 than those in controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL", "date": "2020-03-17", "evidence": [], "reference": [ { "id": "32172226", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226" } ] }, { "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.", "journal": "Journal of thrombosis and haemostasis : JTH", "authors": "Tang N, Li D, Wang X, Sun Z", "date": "2020-02-20", "evidence": [], "reference": [ { "id": "32073213", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213" } ] } ], "biomarker_canonical_id": "AN4079", "collision": 1 }, { "biomarker_id": "AN4080-1", "biomarker_component": [ { "biomarker": "increased FIB level", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3GHG", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "30009-5" } ], "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "FIB values in SARS-CoV-2 patients were also higher than those in the control group (5.02 vs. 2.90 g/L; p<0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "Fibrinogen levels were shown to be much higher in patients with severe COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32172226", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226", "evidence_list": [ { "evidence": "FIB values in SARS-CoV-2 patients were also higher than those in the control group (5.02 vs. 2.90 g/L; p<0.001)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "Fibrinogen levels were shown to be much higher in patients with severe COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL", "date": "2020-03-17", "evidence": [], "reference": [ { "id": "32172226", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32172226" } ] }, { "title": "Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.", "journal": "Platelets", "authors": "Bi X, Su Z, Yan H, Du J, Wang J, Chen L, Peng M, Chen S, Shen B, Li J", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32367765", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765" } ] } ], "biomarker_canonical_id": "AN4080", "collision": 1 }, { "biomarker_id": "AA4758-1", "biomarker_component": [ { "biomarker": "increased NET level", "assessed_biomarker_entity": { "recommended_name": "Neutrophil extracellular trap", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C180931", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "We now report that sera from patients with COVID-19 (n=50 patients, n=84 samples) have elevated levels of cell-free DNA, myeloperoxidase (MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32302401", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32302401", "evidence_list": [ { "evidence": "Indeed, we posit here that excess NETs may elicit the severe multi-organ consequences of COVID-19 via their known effects on tissues and the immune, vascular, and coagulation systems. There are multiple individual or combinatorial - and likely safe - therapeutic strategies available to antagonize NETs in COVID-19 patients today, and NETs themselves may be an appropriate biomarker to follow studies to test their efficacy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "We now report that sera from patients with COVID-19 (n=50 patients, n=84 samples) have elevated levels of cell-free DNA, myeloperoxidase (MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32302401", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32302401", "evidence_list": [ { "evidence": "Indeed, we posit here that excess NETs may elicit the severe multi-organ consequences of COVID-19 via their known effects on tissues and the immune, vascular, and coagulation systems. There are multiple individual or combinatorial - and likely safe - therapeutic strategies available to antagonize NETs in COVID-19 patients today, and NETs themselves may be an appropriate biomarker to follow studies to test their efficacy." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633" } ] }, { "title": "Targeting potential drivers of COVID-19: Neutrophil extracellular traps.", "journal": "The Journal of experimental medicine", "authors": "Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Da\u00dfler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M", "date": "2020-04-18", "evidence": [], "reference": [ { "id": "32302401", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32302401" } ] }, { "title": "Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633" } ] } ], "biomarker_canonical_id": "AA4758", "collision": 1 }, { "biomarker_id": "AA4758-2", "biomarker_component": [ { "biomarker": "increased NET level", "assessed_biomarker_entity": { "recommended_name": "Neutrophil extracellular trap", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C180931", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30671057", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30671057", "evidence_list": [ { "evidence": "The results showed that NETs formation was obviously elevated in T2DM patients. An increased NETs formation was observed in DWR, NPDR, and PDR groups when compared with healthy controls. NE expression was also elevated in T2DM patients when compared with healthy controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "30671057", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30671057", "evidence_list": [ { "evidence": "The results showed that NETs formation was obviously elevated in T2DM patients. An increased NETs formation was observed in DWR, NPDR, and PDR groups when compared with healthy controls. NE expression was also elevated in T2DM patients when compared with healthy controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Hyperglycemia Induces Neutrophil Extracellular Traps Formation Through an NADPH Oxidase-Dependent Pathway in Diabetic Retinopathy.", "journal": "Frontiers in immunology", "authors": "Wang L, Zhou X, Yin Y, Mai Y, Wang D, Zhang X", "date": "2019-01-24", "evidence": [], "reference": [ { "id": "30671057", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30671057" } ] } ], "biomarker_canonical_id": "AA4758", "collision": 1 }, { "biomarker_id": "AN4081-1", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "We now report that sera from patients with COVID-19 (n=50 patients, n=84 samples) have elevated levels of cell-free DNA, myeloperoxidase (MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "Cit-H3 associated strongly with platelet levels. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "We now report that sera from patients with COVID-19 (n=50 patients, n=84 samples) have elevated levels of cell-free DNA, myeloperoxidase (MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "Cit-H3 associated strongly with platelet levels. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633" } ] }, { "title": "Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-2", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-3", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-4", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-5", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-6", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-7", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "29324871", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871", "evidence_list": [ { "evidence": "Our results are the first to unveil H3Cit as a potential diagnostic and prognostic blood marker associated with an exacerbated inflammatory response in patients with advanced cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Citrullinated histone H3 as a novel prognostic blood marker in patients with advanced cancer.", "journal": "PloS one", "authors": "Th\u00e5lin C, Lundstr\u00f6m S, Seignez C, Daleskog M, Lundstr\u00f6m A, Henriksson P, Helleday T, Phillipson M, Wall\u00e9n H, Demers M", "date": "2018-01-13", "evidence": [], "reference": [ { "id": "29324871", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29324871" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4081-8", "biomarker_component": [ { "biomarker": "increased CIT-H3 level", "assessed_biomarker_entity": { "recommended_name": "Citrullinated histone H3", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050386", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30992036", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30992036", "evidence_list": [ { "evidence": "In T2DM, NETosis markers in circulating plasma, such as H3Cit and cfDNA, are related to glycemia control, systemic low-grade inflammation markers and previous MI. Enhanced NETosis detectable in circulating blood is associated with a prothrombotic state, especially hypofibrinolysis in T2DM patients. The present study shows that NETosis might contribute to thrombotic and cardiovascular risk in that disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "30992036", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30992036", "evidence_list": [ { "evidence": "In T2DM, NETosis markers in circulating plasma, such as H3Cit and cfDNA, are related to glycemia control, systemic low-grade inflammation markers and previous MI. Enhanced NETosis detectable in circulating blood is associated with a prothrombotic state, especially hypofibrinolysis in T2DM patients. The present study shows that NETosis might contribute to thrombotic and cardiovascular risk in that disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis.", "journal": "Cardiovascular diabetology", "authors": "Bryk AH, Prior SM, Plens K, Konieczynska M, Hohendorff J, Malecki MT, Butenas S, Undas A", "date": "2019-04-18", "evidence": [], "reference": [ { "id": "30992036", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30992036" } ] } ], "biomarker_canonical_id": "AN4081", "collision": 1 }, { "biomarker_id": "AN4082-1", "biomarker_component": [ { "biomarker": "increased ALT level", "assessed_biomarker_entity": { "recommended_name": "Alanine aminotransferase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050341", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "76625-3" } ], "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "Alanine aminotransferase is present at increased level in COVID-19 patients with severe disease and as such may be useful to monitor in patients admitted to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32669866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32669866", "evidence_list": [ { "evidence": "Liver enzymes including ALT and AST are useful biomarkers of hepatic dysfunction in COVID-19 patients. Most liver diseases initially cause mild symptoms, but they must be detected early." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Liver dysfunction with chronically increased serum Alanine aminotransferase indicates adverse outcome of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32234718", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234718", "evidence_list": [ { "evidence": "Increase in alanine aminotransferase can be used to predict COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32259132", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132", "evidence_list": [ { "evidence": "Our findings suggest that level of LDH, CRP, ALT and NEU can be used to predict the result of COVID-19 test." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "Alanine aminotransferase is present at increased level in COVID-19 patients with severe disease and as such may be useful to monitor in patients admitted to the ICU." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32669866", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32669866", "evidence_list": [ { "evidence": "Liver enzymes including ALT and AST are useful biomarkers of hepatic dysfunction in COVID-19 patients. Most liver diseases initially cause mild symptoms, but they must be detected early." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32438331", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331", "evidence_list": [ { "evidence": "Liver dysfunction with chronically increased serum Alanine aminotransferase indicates adverse outcome of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32234718", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234718", "evidence_list": [ { "evidence": "Increase in alanine aminotransferase can be used to predict COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32259132", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132", "evidence_list": [ { "evidence": "Our findings suggest that level of LDH, CRP, ALT and NEU can be used to predict the result of COVID-19 test." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "COVID-19 and the clinical hematology laboratory.", "journal": "International journal of laboratory hematology", "authors": "Frater JL, Zini G, d'Onofrio G, Rogers HJ", "date": "2020-04-21", "evidence": [], "reference": [ { "id": "32311826", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826" } ] }, { "title": "Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19).", "journal": "Journal of inflammation research", "authors": "Gholizadeh P, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H", "date": "2020-07-17", "evidence": [], "reference": [ { "id": "32669866", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32669866" } ] }, { "title": "Diabetes and metabolic syndrome as risk factors for COVID-19.", "journal": "Diabetes & metabolic syndrome", "authors": "Marhl M, Grubelnik V, Magdi\u010d M, Markovi\u010d R", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32438331", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32438331" } ] }, { "title": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.", "journal": "BMJ (Clinical research ed.)", "authors": "", "date": "2020-04-03", "evidence": [], "reference": [ { "id": "32234718", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32234718" } ] }, { "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.", "journal": "Lancet (London, England)", "authors": "Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B", "date": "2020-03-15", "evidence": [], "reference": [ { "id": "32171076", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076" } ] }, { "title": "Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study.", "journal": "Archives of academic emergency medicine", "authors": "Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, Kaviani M, Ahmadi N", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32259132", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259132" } ] } ], "biomarker_canonical_id": "AN4082", "collision": 1 }, { "biomarker_id": "AN4082-2", "biomarker_component": [ { "biomarker": "increased ALT level", "assessed_biomarker_entity": { "recommended_name": "Alanine aminotransferase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050341", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "76625-3" } ], "evidence_source": [ { "id": "25043373", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25043373", "evidence_list": [ { "evidence": "Several prospective studies have demonstrated associations between GGT or ALT and risk of type 2 diabetes mellitus, cardiovascular disease, vascular and nonvascular mortality, and all cause mortality outcomes. Emerging evidence indicates that increasing levels of GGT and ALT may each be linked to cancer risk. A number of prospective studies have been published reporting on the associations between baseline levels of these enzymes and risk of cancer, but their results have been inconsistent, particularly for ALT. Whereas some studies have observed positive associations of circulating levels of these enzymes with risk of cancer, others have shown inverse associations, with some studies showing no associations at all." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "25043373", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25043373", "evidence_list": [ { "evidence": "Several prospective studies have demonstrated associations between GGT or ALT and risk of type 2 diabetes mellitus, cardiovascular disease, vascular and nonvascular mortality, and all cause mortality outcomes. Emerging evidence indicates that increasing levels of GGT and ALT may each be linked to cancer risk. A number of prospective studies have been published reporting on the associations between baseline levels of these enzymes and risk of cancer, but their results have been inconsistent, particularly for ALT. Whereas some studies have observed positive associations of circulating levels of these enzymes with risk of cancer, others have shown inverse associations, with some studies showing no associations at all." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis.", "journal": "International journal of cancer", "authors": "Kunutsor SK, Apekey TA, Van Hemelrijck M, Calori G, Perseghin G", "date": "2014-07-22", "evidence": [], "reference": [ { "id": "25043373", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25043373" } ] } ], "biomarker_canonical_id": "AN4082", "collision": 1 }, { "biomarker_id": "AA4761-2", "biomarker_component": [ { "biomarker": "increased HGF level", "assessed_biomarker_entity": { "recommended_name": "Hepatocyte growth factor", "synonyms": [ { "synonym": "Hepatopoietin-A" }, { "synonym": "Scatter factor" }, { "synonym": "SF" } ] }, "assessed_biomarker_entity_id": "UPKB:P14210", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "79394-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "79394-3" } ], "evidence_source": [ { "id": "10.1101/2020.05.31.20118315", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.31.20118315", "evidence_list": [ { "evidence": "The accuracy of classification of severe case was also the highest when using HGF. Thus, HGF was ultimately used as the biomarker to discriminate severe from nonsevere COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.05.31.20118315", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.31.20118315", "evidence_list": [ { "evidence": "The accuracy of classification of severe case was also the highest when using HGF. Thus, HGF was ultimately used as the biomarker to discriminate severe from nonsevere COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AA4761", "collision": 1 }, { "biomarker_id": "AA4761-1", "biomarker_component": [ { "biomarker": "increased HGF level", "assessed_biomarker_entity": { "recommended_name": "Hepatocyte growth factor", "synonyms": [ { "synonym": "Hepatopoietin-A" }, { "synonym": "Scatter factor" }, { "synonym": "SF" } ] }, "assessed_biomarker_entity_id": "UPKB:P14210", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "79394-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "79394-3" } ], "evidence_source": [ { "id": "16759302", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16759302", "evidence_list": [ { "evidence": "Serum HGF concentration may be a new marker of atherosclerotic complications in patients with Type 2 DM." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "16759302", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16759302", "evidence_list": [ { "evidence": "Serum HGF concentration may be a new marker of atherosclerotic complications in patients with Type 2 DM." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical significance of circulating hepatocyte growth factor, a new risk marker of carotid atherosclerosis in patients with Type 2 diabetes.", "journal": "Diabetic medicine : a journal of the British Diabetic Association", "authors": "Satani K, Konya H, Hamaguchi T, Umehara A, Katsuno T, Ishikawa T, Kohri K, Hasegawa Y, Suehiro A, Kakishita E, Namba M", "date": "2006-06-09", "evidence": [], "reference": [ { "id": "16759302", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16759302" } ] } ], "biomarker_canonical_id": "AA4761", "collision": 1 }, { "biomarker_id": "AA4762-1", "biomarker_component": [ { "biomarker": "increased GOT1 level", "assessed_biomarker_entity": { "recommended_name": "Aspartate aminotransferase", "synonyms": [ { "synonym": "cAspAT" }, { "synonym": "Cysteine aminotransferase, cytoplasmic" }, { "synonym": "Cysteine transaminase, cytoplasmic" }, { "synonym": "cCAT" }, { "synonym": "Glutamate oxaloacetate transaminase 1" }, { "synonym": "Transaminase A" } ] }, "assessed_biomarker_entity_id": "UPKB:P17174", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "AST is strongly associated with mortality risk compared to other parameters. Significant elevation in liver enzymes (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) is associated with critical changes in renal function parameters (blood urea nitrogen, creatinine) and coagulation markers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32530509", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509", "evidence_list": [ { "evidence": "High troponin I levels with either advanced age more than 60 years or elevated AST levels was the best model to predict poor outcomes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32492406", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406", "evidence_list": [ { "evidence": "Compared to non-severe patients, severe patients showed significant suppression of lymphocyte count and monocyte count, as well as increase of CRP and AST." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "Combined with significant elevations in liver enzymes (alanine aminotransferase and aspartate aminotransferase), renal biomarkers (blood urea nitrogen, creatinine), and coagulation measures, a picture of MOF becomes very apparent in patients who develop the severe form of the disease, even with laboratory parameters measured primarily at admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32293098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32293098", "evidence_list": [ { "evidence": "Impending hyperinflammation can manifest as cytopenias (thrombocytopenia and lymphopenia), coagulopathy (low platelet and fibrinogen levels, and elevated d -dimer levels), tissue damage/hepatitis (elevated LDH, aspartate aminotransferase, and alanine aminotransferase levels), and macrophage/hepatocyte activation (elevated ferritin levels)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "AST is strongly associated with mortality risk compared to other parameters. Significant elevation in liver enzymes (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) is associated with critical changes in renal function parameters (blood urea nitrogen, creatinine) and coagulation markers." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32530509", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509", "evidence_list": [ { "evidence": "High troponin I levels with either advanced age more than 60 years or elevated AST levels was the best model to predict poor outcomes." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32492406", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406", "evidence_list": [ { "evidence": "Compared to non-severe patients, severe patients showed significant suppression of lymphocyte count and monocyte count, as well as increase of CRP and AST." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32286245", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245", "evidence_list": [ { "evidence": "Combined with significant elevations in liver enzymes (alanine aminotransferase and aspartate aminotransferase), renal biomarkers (blood urea nitrogen, creatinine), and coagulation measures, a picture of MOF becomes very apparent in patients who develop the severe form of the disease, even with laboratory parameters measured primarily at admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32293098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32293098", "evidence_list": [ { "evidence": "Impending hyperinflammation can manifest as cytopenias (thrombocytopenia and lymphopenia), coagulopathy (low platelet and fibrinogen levels, and elevated d -dimer levels), tissue damage/hepatitis (elevated LDH, aspartate aminotransferase, and alanine aminotransferase levels), and macrophage/hepatocyte activation (elevated ferritin levels)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Biomarkers associated with COVID-19 disease progression.", "journal": "Critical reviews in clinical laboratory sciences", "authors": "Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32503382", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382" } ] }, { "title": "Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.", "journal": "Journal of medical virology", "authors": "Toraih EA, Elshazli RM, Hussein MH, Elgaml A, Amin M, El-Mowafy M, El-Mesery M, Ellythy A, Duchesne J, Killackey MT, Ferdinand KC, Kandil E, Fawzy MS", "date": "2020-06-13", "evidence": [], "reference": [ { "id": "32530509", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32530509" } ] }, { "title": "Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.", "journal": "Cell", "authors": "Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S, Xiao Q, Lu T, Zhu Y, Liu H, Chen H, Guo T", "date": "2020-06-04", "evidence": [], "reference": [ { "id": "32492406", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406" } ] }, { "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.", "journal": "Clinical chemistry and laboratory medicine", "authors": "Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G", "date": "2020-04-15", "evidence": [], "reference": [ { "id": "32286245", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32286245" } ] }, { "title": "On the Alert for Cytokine Storm: Immunopathology in COVID-19.", "journal": "Arthritis & rheumatology (Hoboken, N.J.)", "authors": "Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, Caricchio R, Mahmud S, Hazen MM, Halyabar O, Hoyt KJ, Han J, Grom AA, Gattorno M, Ravelli A, De Benedetti F, Behrens EM, Cron RQ, Nigrovic PA", "date": "2020-04-16", "evidence": [], "reference": [ { "id": "32293098", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32293098" } ] } ], "biomarker_canonical_id": "AA4762", "collision": 1 }, { "biomarker_id": "AA4762-2", "biomarker_component": [ { "biomarker": "increased GOT1 level", "assessed_biomarker_entity": { "recommended_name": "Aspartate aminotransferase", "synonyms": [ { "synonym": "cAspAT" }, { "synonym": "Cysteine aminotransferase, cytoplasmic" }, { "synonym": "Cysteine transaminase, cytoplasmic" }, { "synonym": "cCAT" }, { "synonym": "Glutamate oxaloacetate transaminase 1" }, { "synonym": "Transaminase A" } ] }, "assessed_biomarker_entity_id": "UPKB:P17174", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "20376881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20376881", "evidence_list": [ { "evidence": "Increased levels of AST had a higher risk for esophageal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "20376881", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20376881", "evidence_list": [ { "evidence": "Increased levels of AST had a higher risk for esophageal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The independent effects of cigarette smoking, alcohol consumption, and serum aspartate aminotransferase on the alanine aminotransferase ratio in korean men for the risk for esophageal cancer.", "journal": "Yonsei medical journal", "authors": "Kimm H, Kim S, Jee SH", "date": "2010-04-09", "evidence": [], "reference": [ { "id": "20376881", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20376881" } ] } ], "biomarker_canonical_id": "AA4762", "collision": 1 }, { "biomarker_id": "AA4763-1", "biomarker_component": [ { "biomarker": "increased CK level", "assessed_biomarker_entity": { "recommended_name": "Creatine kinase", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050361", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2157-6" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "2157-6" } ], "evidence_source": [ { "id": "32589600", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32589600", "evidence_list": [ { "evidence": "COVID-19 patients typically present increased levels of biomarkers of muscle injury, namely creatine-kinase (CK) and myoglobin. However, the alterations of such biomarkers could be the result of several clinical conditions, including kidney dysfunction and cardiac injury, or a direct effect of the SARS-CoV-2, which can also infect cells of the muscle tissue due to the expression of the ACE2 receptor." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "To sum up, we can conclude from the analysis of published studies that hematological (lymphocyte count, neutrophil count, and NLR), inflammatory (CRP, ESR, IL-6), and especially biochemical (D-dimer, Troponins, CK) parameters correlate with severe prognosis or exitus in COVID-19 patients and can therefore be used as predictive biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32247631", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631", "evidence_list": [ { "evidence": "In keeping with this observation, 138 patients with COVID-19, who were admitted to an intensive care unit, showed a tendency toward increased creatine kinase levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32589600", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32589600", "evidence_list": [ { "evidence": "COVID-19 patients typically present increased levels of biomarkers of muscle injury, namely creatine-kinase (CK) and myoglobin. However, the alterations of such biomarkers could be the result of several clinical conditions, including kidney dysfunction and cardiac injury, or a direct effect of the SARS-CoV-2, which can also infect cells of the muscle tissue due to the expression of the ACE2 receptor." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32503382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382", "evidence_list": [ { "evidence": "To sum up, we can conclude from the analysis of published studies that hematological (lymphocyte count, neutrophil count, and NLR), inflammatory (CRP, ESR, IL-6), and especially biochemical (D-dimer, Troponins, CK) parameters correlate with severe prognosis or exitus in COVID-19 patients and can therefore be used as predictive biomarkers." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32247631", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631", "evidence_list": [ { "evidence": "In keeping with this observation, 138 patients with COVID-19, who were admitted to an intensive care unit, showed a tendency toward increased creatine kinase levels." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32171076", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076", "evidence_list": [ { "evidence": "Age, comorbidities, lymphocytopenia and elevated alanine aminotransferase, d-dimer, creatine kinase, high-sensitivity cardiac troponin I, prothrombin time, and disease severity were reported to be associated with intensive care unit admission." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19).", "journal": "Diagnosis (Berlin, Germany)", "authors": "Ciaccio M, Agnello L", "date": "2020-06-27", "evidence": [], "reference": [ { "id": "32589600", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32589600" } ] }, { "title": "Biomarkers associated with COVID-19 disease progression.", "journal": "Critical reviews in clinical laboratory sciences", "authors": "Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32503382", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503382" } ] }, { "title": "Kidney disease is associated with in-hospital death of patients with COVID-19.", "journal": "Kidney international", "authors": "Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G", "date": "2020-04-06", "evidence": [], "reference": [ { "id": "32247631", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32247631" } ] }, { "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.", "journal": "Lancet (London, England)", "authors": "Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B", "date": "2020-03-15", "evidence": [], "reference": [ { "id": "32171076", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32171076" } ] } ], "biomarker_canonical_id": "AA4763", "collision": 1 }, { "biomarker_id": "AA4764-1", "biomarker_component": [ { "biomarker": "decreased Na+ level", "assessed_biomarker_entity": { "recommended_name": "Sodium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5360545", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33552948", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33552948", "evidence_list": [ { "evidence": "Lower levels of sodium can indicate poorer results of esophageal carcinoma, but higher survival benefits of adjuvant therapy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "33552948", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33552948", "evidence_list": [ { "evidence": "Lower levels of sodium can indicate poorer results of esophageal carcinoma, but higher survival benefits of adjuvant therapy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Preoperative Serum Sodium Level as a Prognostic and Predictive Biomarker for Adjuvant Therapy in Esophageal Cancer.", "journal": "Frontiers in oncology", "authors": "Wang Q, Peng L, Han Y, Li T, Dai W, Wang Y, Wu L, Wei Y, Xie T, Fang Q, Li Q, Lang J, Cao B", "date": "2021-02-09", "evidence": [], "reference": [ { "id": "33552948", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33552948" } ] } ], "biomarker_canonical_id": "AA4764", "collision": 1 }, { "biomarker_id": "AA4764-2", "biomarker_component": [ { "biomarker": "decreased Na+ level", "assessed_biomarker_entity": { "recommended_name": "Sodium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5360545", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2947-0" } ], "evidence_source": [ { "id": "32766546", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32766546", "evidence_list": [ { "evidence": "Interestingly, a large proportion of patients had sodium and calcium levels below the reference range on admission (28.7% and 20.6%, respectively). Hong et al. [15] recently reported similar findings, where 50% of COVID-19 patients they examined had hyponatremia and hypokalemia and they suggested there was a correlation with the degree of renal injury in those patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32766546", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32766546", "evidence_list": [ { "evidence": "Interestingly, a large proportion of patients had sodium and calcium levels below the reference range on admission (28.7% and 20.6%, respectively). Hong et al. [15] recently reported similar findings, where 50% of COVID-19 patients they examined had hyponatremia and hypokalemia and they suggested there was a correlation with the degree of renal injury in those patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait.", "journal": "EClinicalMedicine", "authors": "Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, Al-Sabah S", "date": "2020-08-09", "evidence": [], "reference": [ { "id": "32766546", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32766546" } ] } ], "biomarker_canonical_id": "AA4764", "collision": 1 }, { "biomarker_id": "AA4766-1", "biomarker_component": [ { "biomarker": "increased Na+ level", "assessed_biomarker_entity": { "recommended_name": "Sodium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5360545", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2947-0" } ], "evidence_source": [ { "id": "32219933", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32219933", "evidence_list": [ { "evidence": "The influx of sodium (Na+ ) ions into a resting cell is regulated by Na+ channels and by Na+/H+ and Na+/Ca2+ exchangers, whereas Na+ ion efflux is mediated by the activity of Na+ /K+ -ATPase to maintain a high transmembrane Na+ ion gradient. Dysfunction of this system leads to changes in the intracellular sodium concentration that promotes cancer metastasis by mediating invasion and migration. Alterations in the Na+ ion concentration may potentially be used as a biomarker for malignant tumor diagnosis and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32219933", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32219933", "evidence_list": [ { "evidence": "The influx of sodium (Na+ ) ions into a resting cell is regulated by Na+ channels and by Na+/H+ and Na+/Ca2+ exchangers, whereas Na+ ion efflux is mediated by the activity of Na+ /K+ -ATPase to maintain a high transmembrane Na+ ion gradient. Dysfunction of this system leads to changes in the intracellular sodium concentration that promotes cancer metastasis by mediating invasion and migration. Alterations in the Na+ ion concentration may potentially be used as a biomarker for malignant tumor diagnosis and prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "", "journal": "Journal of magnetic resonance imaging : JMRI", "authors": "Poku LO, Phil M, Cheng Y, Wang K, Sun X", "date": "2020-03-29", "evidence": [], "reference": [ { "id": "32219933", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32219933" } ] } ], "biomarker_canonical_id": "AA4766", "collision": 1 }, { "biomarker_id": "AA4766-2", "biomarker_component": [ { "biomarker": "increased Na+ level", "assessed_biomarker_entity": { "recommended_name": "Sodium", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5360545", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2947-0" } ], "evidence_source": [ { "id": "18488152", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18488152", "evidence_list": [ { "evidence": "The results of this study showed that Na level were higher in blood and scalp hair samples of hypertensive diabetic (HD) patients and nonhypertensive diabetic (NHD) patients as compared to control subjects of both genders (p < 0.05)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "18488152", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18488152", "evidence_list": [ { "evidence": "The results of this study showed that Na level were higher in blood and scalp hair samples of hypertensive diabetic (HD) patients and nonhypertensive diabetic (NHD) patients as compared to control subjects of both genders (p < 0.05)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Potassium, calcium, magnesium, and sodium levels in biological samples of hypertensive and nonhypertensive diabetes mellitus patients.", "journal": "Biological trace element research", "authors": "Afridi HI, Kazi TG, Kazi N, Jamali MK, Arain MB, Jalbani N, Sarfaraz RA, Shah A, Kandhro GA, Shah AQ, Baig JA", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18488152", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18488152" } ] } ], "biomarker_canonical_id": "AA4766", "collision": 1 }, { "biomarker_id": "AN4083-1", "biomarker_component": [ { "biomarker": "decreased CIT level", "assessed_biomarker_entity": { "recommended_name": "Plasma citrulline", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:9750", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2129-5" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "2129-5" } ], "evidence_source": [ { "id": "32646736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32646736", "evidence_list": [ { "evidence": "In our cohort study, we showed that a majority of patients with moderate to severe COVID-19 had decreased levels of plasma citrulline, which correlated with digestive symptoms and systemic inflammation. Low citrulline is likely involved in SARS-CoV-2-associated diarrhea by causing alteration of intestinal permeability and enterocyte malabsorption. It could also participate in the significant weight loss that is observed in patients with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32646736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32646736", "evidence_list": [ { "evidence": "In our cohort study, we showed that a majority of patients with moderate to severe COVID-19 had decreased levels of plasma citrulline, which correlated with digestive symptoms and systemic inflammation. Low citrulline is likely involved in SARS-CoV-2-associated diarrhea by causing alteration of intestinal permeability and enterocyte malabsorption. It could also participate in the significant weight loss that is observed in patients with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms.", "journal": "Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver", "authors": "Uzzan M, Soudan D, Peoc'h K, Weiss E, Corcos O, Treton X", "date": "2020-07-11", "evidence": [], "reference": [ { "id": "32646736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32646736" } ] } ], "biomarker_canonical_id": "AN4083", "collision": 1 }, { "biomarker_id": "AN4083-2", "biomarker_component": [ { "biomarker": "decreased CIT level", "assessed_biomarker_entity": { "recommended_name": "Plasma citrulline", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:9750", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2129-5" } ], "evidence_source": [ { "id": "25473654", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25473654", "evidence_list": [ { "evidence": "Plasma citrulline (Cit) is an amino acid that is produced by small bowel enterocytes. The plasma citrulline level is a reliable and objective biochemical marker of enterocyte mass and function in humans, and therefore can be used to monitor enterocyte toxicity resulting from chemotherapy and radiotherapy during anticancer therapy in patients with severely disturbed gut integrity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "25473654", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25473654", "evidence_list": [ { "evidence": "Plasma citrulline (Cit) is an amino acid that is produced by small bowel enterocytes. The plasma citrulline level is a reliable and objective biochemical marker of enterocyte mass and function in humans, and therefore can be used to monitor enterocyte toxicity resulting from chemotherapy and radiotherapy during anticancer therapy in patients with severely disturbed gut integrity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage.", "journal": "Acta biochimica Polonica", "authors": "Barza\u0142 JA, Szczylik C, Rzepecki P, Jaworska M, Anuszewska E", "date": "2014-12-05", "evidence": [], "reference": [ { "id": "25473654", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25473654" } ] } ], "biomarker_canonical_id": "AN4083", "collision": 1 }, { "biomarker_id": "AA4768-1", "biomarker_component": [ { "biomarker": "increased CK-MB level", "assessed_biomarker_entity": { "recommended_name": "Creatine kinase MB", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050356", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "20569-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "20569-0" } ], "evidence_source": [ { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32596365", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32596365", "evidence_list": [ { "evidence": "A meta-analysis which included 4189 confirmed patients of COVID-19 from 28 studies pointed out that cardiac injury biomarkers rose above normal by the midpoint of hospitalization and spiked immediately before death, which seemed to be the most seen in severe cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32220650", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650", "evidence_list": [ { "evidence": "Besides radiographic presentations, variables that were associated significantly with severity of COVID-19 were decreased lymphocytes, elevated body temperature, and high levels of procalcitonin, D-dimer, and creatine kinase MB." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32596365", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32596365", "evidence_list": [ { "evidence": "A meta-analysis which included 4189 confirmed patients of COVID-19 from 28 studies pointed out that cardiac injury biomarkers rose above normal by the midpoint of hospitalization and spiked immediately before death, which seemed to be the most seen in severe cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.", "journal": "The Lancet. Infectious diseases", "authors": "Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D", "date": "2020-03-30", "evidence": [], "reference": [ { "id": "32220650", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32220650" } ] }, { "title": "Changes of Laboratory Cardiac Markers and Mechanisms of Cardiac Injury in Coronavirus Disease 2019.", "journal": "BioMed research international", "authors": "Li L, Zhou Q, Xu J", "date": "2020-07-01", "evidence": [], "reference": [ { "id": "32596365", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32596365" } ] } ], "biomarker_canonical_id": "AA4768", "collision": 1 }, { "biomarker_id": "AA4769-1", "biomarker_component": [ { "biomarker": "increased ALDH5A1 level", "assessed_biomarker_entity": { "recommended_name": "Alpha-hydroxybutyric dehydrogenase", "synonyms": [ { "synonym": "Aldehyde dehydrogenase family 5 member A1" }, { "synonym": "NAD(+)-dependent succinic semialdehyde dehydrogenase" } ] }, "assessed_biomarker_entity_id": "UPKB:P51649", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "1677-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "1677-4" } ], "evidence_source": [ { "id": "32161968", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968", "evidence_list": [ { "evidence": "LDH and alpha-HBDH may be considerable markers for evaluation of NCOVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32209382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32209382", "evidence_list": [ { "evidence": "This study reveals that the heart is also a major target of COVID-19 infection, and myocardial enzyme spectrum assays could help the diagnosis, prognosis and guide the treatments to prevent heart failure in COVID-19 patients. [DOI:https://doi.org/10.21203/rs.3.rs-23849/v1] We noted significantly increased cTnI, CK, HBDB and LDH levels in very severe group as compare to severe." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32161968", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968", "evidence_list": [ { "evidence": "LDH and alpha-HBDH may be considerable markers for evaluation of NCOVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32209382", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32209382", "evidence_list": [ { "evidence": "This study reveals that the heart is also a major target of COVID-19 infection, and myocardial enzyme spectrum assays could help the diagnosis, prognosis and guide the treatments to prevent heart failure in COVID-19 patients. [DOI:https://doi.org/10.21203/rs.3.rs-23849/v1] We noted significantly increased cTnI, CK, HBDB and LDH levels in very severe group as compare to severe." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, Guo F, Zhao H, Gao R", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32161968", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32161968" } ] }, { "title": "The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease.", "journal": "The Journal of infection", "authors": "Zhou B, She J, Wang Y, Ma X", "date": "2020-03-27", "evidence": [], "reference": [ { "id": "32209382", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32209382" } ] } ], "biomarker_canonical_id": "AA4769", "collision": 1 }, { "biomarker_id": "AA4770-1", "biomarker_component": [ { "biomarker": "increased CSF1 level", "assessed_biomarker_entity": { "recommended_name": "Macrophage colony-stimulating factor 1", "synonyms": [ { "synonym": "CSF-1" }, { "synonym": "M-CSF" }, { "synonym": "MCSF" }, { "synonym": "Lanimostim" }, { "synonym": "Proteoglycan macrophage colony-stimulating factor" }, { "synonym": "PG-M-CSF" } ] }, "assessed_biomarker_entity_id": "UPKB:P09603", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "23688065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065", "evidence_list": [ { "evidence": "Macrophage-colony stimulating factor (M-CSF) regulates growth and differentiation of hematopoietic progenitor cells and functionally activates the maturation of macrophages. The M-CSF in breast cancer patients were investigated and compared with control groups. The medians of M-CSF, which was 464.28 pg/ml in its levels similarly to the level of the commonly accepted tumor marker, which is CA 15-3 at 25.00 U/ml in the total group of breast cancer patients were significantly higher when compared to the healthy subjects, which is 298.55 pg/ml (p < 0.001). In other words, the median levels of M-CSF in breast cancer total group were statistically higher than in benign breast tumor patients group (p = 0.0004)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "23688065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065", "evidence_list": [ { "evidence": "Macrophage-colony stimulating factor (M-CSF) regulates growth and differentiation of hematopoietic progenitor cells and functionally activates the maturation of macrophages. The M-CSF in breast cancer patients were investigated and compared with control groups. The medians of M-CSF, which was 464.28 pg/ml in its levels similarly to the level of the commonly accepted tumor marker, which is CA 15-3 at 25.00 U/ml in the total group of breast cancer patients were significantly higher when compared to the healthy subjects, which is 298.55 pg/ml (p < 0.001). In other words, the median levels of M-CSF in breast cancer total group were statistically higher than in benign breast tumor patients group (p = 0.0004)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.", "journal": "Growth factors (Chur, Switzerland)", "authors": "\u0141awicki S, B\u0119dkowska GE, Szmitkowski M", "date": "2013-05-22", "evidence": [], "reference": [ { "id": "23688065", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065" } ] } ], "biomarker_canonical_id": "AA4770", "collision": 1 }, { "biomarker_id": "AA4770-2", "biomarker_component": [ { "biomarker": "increased CSF1 level", "assessed_biomarker_entity": { "recommended_name": "Macrophage colony-stimulating factor 1", "synonyms": [ { "synonym": "CSF-1" }, { "synonym": "M-CSF" }, { "synonym": "MCSF" }, { "synonym": "Lanimostim" }, { "synonym": "Proteoglycan macrophage colony-stimulating factor" }, { "synonym": "PG-M-CSF" } ] }, "assessed_biomarker_entity_id": "UPKB:P09603", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17106-6" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "17106-6" } ], "evidence_source": [ { "id": "10.1101/2020.05.31.20118315", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.31.20118315", "evidence_list": [ { "evidence": "Three cytokines, M-CSF, IL-8 and SCF, which were clustered into 3 different correlation groups and had relatively small fluctuations during SARS-CoV-2 infection, were selected for the construction of a multiclass classification model. This model discriminated healthy individuals and asymptomatic and nonsevere patients with accuracy of 77.4% but was not successful in classifying severe patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.05.31.20118315", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.31.20118315", "evidence_list": [ { "evidence": "Three cytokines, M-CSF, IL-8 and SCF, which were clustered into 3 different correlation groups and had relatively small fluctuations during SARS-CoV-2 infection, were selected for the construction of a multiclass classification model. This model discriminated healthy individuals and asymptomatic and nonsevere patients with accuracy of 77.4% but was not successful in classifying severe patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AA4770", "collision": 1 }, { "biomarker_id": "AA4771-1", "biomarker_component": [ { "biomarker": "increased KITLG level", "assessed_biomarker_entity": { "recommended_name": "Stem cell factor", "synonyms": [ { "synonym": "Mast cell growth factor" }, { "synonym": "MGF" }, { "synonym": "Stem cell factor" }, { "synonym": "SCF" }, { "synonym": "c-Kit ligand" } ] }, "assessed_biomarker_entity_id": "UPKB:P21583", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32561706", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32561706", "evidence_list": [ { "evidence": "SCF were significantly higher in fatal than severe and/or mild COVID-19 patients. The temporal changes of the identified CCGFs may serve as biomarkers for prognosis of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32292113", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32292113", "evidence_list": [ { "evidence": "Regulatory DCs (regDCs) play an important role in controlling immune homeostasis and can possess an immunosuppressive ability to induce specific immune tolerance and dampen Th2 type inflammation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32257537", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32257537", "evidence_list": [ { "evidence": "Therefore, the fact that the transplantation of MSCs improved the outcome of COVID-2019 patients may be due to regulating inflammatory response and promoting tissue repair and regeneration." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32561706", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32561706", "evidence_list": [ { "evidence": "SCF were significantly higher in fatal than severe and/or mild COVID-19 patients. The temporal changes of the identified CCGFs may serve as biomarkers for prognosis of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32292113", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32292113", "evidence_list": [ { "evidence": "Regulatory DCs (regDCs) play an important role in controlling immune homeostasis and can possess an immunosuppressive ability to induce specific immune tolerance and dampen Th2 type inflammation." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32257537", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32257537", "evidence_list": [ { "evidence": "Therefore, the fact that the transplantation of MSCs improved the outcome of COVID-2019 patients may be due to regulating inflammatory response and promoting tissue repair and regeneration." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients.", "journal": "Signal transduction and targeted therapy", "authors": "Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, Sun XL, Zhou X, Wang YY", "date": "2020-06-21", "evidence": [], "reference": [ { "id": "32561706", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32561706" } ] }, { "title": "Stem Cell-Based Therapy for Coronavirus Disease 2019.", "journal": "Stem cells and development", "authors": "Zhao RC", "date": "2020-04-16", "evidence": [], "reference": [ { "id": "32292113", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32292113" } ] }, { "title": "Transplantation of ACE2", "journal": "Aging and disease", "authors": "Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32257537", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32257537" } ] } ], "biomarker_canonical_id": "AA4771", "collision": 1 }, { "biomarker_id": "AA4772-1", "biomarker_component": [ { "biomarker": "increase KITLG level", "assessed_biomarker_entity": { "recommended_name": "Stem cell factor", "synonyms": [ { "synonym": "Mast cell growth factor" }, { "synonym": "MGF" }, { "synonym": "Stem cell factor" }, { "synonym": "SCF" }, { "synonym": "c-Kit ligand" } ] }, "assessed_biomarker_entity_id": "UPKB:P21583", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31254605", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254605", "evidence_list": [ { "evidence": "Increase in SCF causes a downregulation of certain proteins which induces and activates metastasis in breast cancer patients after surgery. SCF triggers the activation of transcription factors involved in cell proliferation, apoptosis and differentiation, which are frequently associated with tumor progression or metastasis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "31254605", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254605", "evidence_list": [ { "evidence": "Increase in SCF causes a downregulation of certain proteins which induces and activates metastasis in breast cancer patients after surgery. SCF triggers the activation of transcription factors involved in cell proliferation, apoptosis and differentiation, which are frequently associated with tumor progression or metastasis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Adipose derived stem cells promote tumor metastasis in breast Cancer cells by stem cell factor inhibition of miR20b.", "journal": "Cellular signalling", "authors": "Xu H, Li W, Luo S, Yuan J, Hao L", "date": "2019-06-30", "evidence": [], "reference": [ { "id": "31254605", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254605" } ] } ], "biomarker_canonical_id": "AA4772", "collision": 1 }, { "biomarker_id": "AN4078-3", "biomarker_component": [ { "biomarker": "increased BIL level", "assessed_biomarker_entity": { "recommended_name": "Bilirubin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5280352", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33898-8" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33898-8" } ], "evidence_source": [ { "id": "32509218", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32509218", "evidence_list": [ { "evidence": "This study found that the increased level of serum bilirubin correlates with better prognosis in patients with EOC. In this study, patients with higher preoperative serum TBIL and IBL levels showed prolonged OS and PFS compared with those with lower preoperative TBIL and IBL levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32509218", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32509218", "evidence_list": [ { "evidence": "This study found that the increased level of serum bilirubin correlates with better prognosis in patients with EOC. In this study, patients with higher preoperative serum TBIL and IBL levels showed prolonged OS and PFS compared with those with lower preoperative TBIL and IBL levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic value of preoperative serum bilirubin levels in ovarian cancer.", "journal": "American journal of translational research", "authors": "Xi XX, Wang HL, Chen T, Dai JR, Hou SY, Chen YG", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32509218", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32509218" } ] } ], "biomarker_canonical_id": "AN4078", "collision": 1 }, { "biomarker_id": "AN4078-1", "biomarker_component": [ { "biomarker": "increased BIL level", "assessed_biomarker_entity": { "recommended_name": "Bilirubin", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:5280352", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33898-8" } ], "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "Increased levels of total bilirubin have been shown to distinguish between COVID-19 patients admitted to the ICU vs those with less severe disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "Increased levels of total bilirubin have been shown to distinguish between COVID-19 patients admitted to the ICU vs those with less severe disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32505227", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227", "evidence_list": [ { "evidence": "Other consistently reported markers in non-survivors are increased procalcitonin (PCT) and IL-6 levels, as well as increased serum urea, creatinine, cystatin C, direct bilirubin, and cholinesterase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "COVID-19 and the clinical hematology laboratory.", "journal": "International journal of laboratory hematology", "authors": "Frater JL, Zini G, d'Onofrio G, Rogers HJ", "date": "2020-04-21", "evidence": [], "reference": [ { "id": "32311826", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826" } ] }, { "title": "Immunology of COVID-19: Current State of the Science.", "journal": "Immunity", "authors": "Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD, Pia L, Risson E, Saffern M, Salom\u00e9 B, Esai Selvan M, Spindler MP, Tan J, van der Heide V, Gregory JK, Alexandropoulos K, Bhardwaj N, Brown BD, Greenbaum B, G\u00fcm\u00fc\u015f ZH, Homann D, Horowitz A, Kamphorst AO, Curotto de Lafaille MA, Mehandru S, Merad M, Samstein RM, None None", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32505227", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32505227" } ] } ], "biomarker_canonical_id": "AN4078", "collision": 1 }, { "biomarker_id": "AN4084-1", "biomarker_component": [ { "biomarker": "increased APTT", "assessed_biomarker_entity": { "recommended_name": "Activated partial thromboplastin time", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C38462", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3173-2" } ], "evidence_source": [ { "id": "32753955", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955", "evidence_list": [ { "evidence": "This study also showed that APTT increased gradually in patients with CRC, which could cause decreases in blood coagulation function and render patients prone to colorectal bleeding." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32753955", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955", "evidence_list": [ { "evidence": "This study also showed that APTT increased gradually in patients with CRC, which could cause decreases in blood coagulation function and render patients prone to colorectal bleeding." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).", "journal": "Cancer management and research", "authors": "Zhang L, Ye J, Luo Q, Kuang M, Mao M, Dai S, Wang X", "date": "2020-08-06", "evidence": [], "reference": [ { "id": "32753955", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955" } ] } ], "biomarker_canonical_id": "AN4084", "collision": 1 }, { "biomarker_id": "AN4085-1", "biomarker_component": [ { "biomarker": "prolonged APTT", "assessed_biomarker_entity": { "recommended_name": "Activated partial thromboplastin time", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C38462", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3173-2" } ], "evidence_source": [ { "id": "32267008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32267008", "evidence_list": [ { "evidence": "Activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA) is a form of global haemostatic assay. In conclusion, the rise of CWA (clot waveform analysis) parameters precedes and coincides with ICU admission. COVID-19 patients requiring intensive care unit (ICU) support exhibit haemostatic disturbances and interrogated their aPTT-based CWA parameters as surrogates of their haemostatic functions." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "The nonsurvivors demonstrated significantly higher D-dimer and FDP levels, and longer PT and APTT compared to survivors on admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32267008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32267008", "evidence_list": [ { "evidence": "Activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA) is a form of global haemostatic assay. In conclusion, the rise of CWA (clot waveform analysis) parameters precedes and coincides with ICU admission. COVID-19 patients requiring intensive care unit (ICU) support exhibit haemostatic disturbances and interrogated their aPTT-based CWA parameters as surrogates of their haemostatic functions." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "The nonsurvivors demonstrated significantly higher D-dimer and FDP levels, and longer PT and APTT compared to survivors on admission." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability.", "journal": "American journal of hematology", "authors": "Tan CW, Low JGH, Wong WH, Chua YY, Goh SL, Ng HJ", "date": "2020-04-09", "evidence": [], "reference": [ { "id": "32267008", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32267008" } ] }, { "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.", "journal": "Journal of thrombosis and haemostasis : JTH", "authors": "Tang N, Li D, Wang X, Sun Z", "date": "2020-02-20", "evidence": [], "reference": [ { "id": "32073213", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213" } ] }, { "title": "COVID-19 and the clinical hematology laboratory.", "journal": "International journal of laboratory hematology", "authors": "Frater JL, Zini G, d'Onofrio G, Rogers HJ", "date": "2020-04-21", "evidence": [], "reference": [ { "id": "32311826", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826" } ] } ], "biomarker_canonical_id": "AN4085", "collision": 1 }, { "biomarker_id": "AN4086-1", "biomarker_component": [ { "biomarker": "increased PT", "assessed_biomarker_entity": { "recommended_name": "Prothrombin time", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C62656", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "5894-1" } ], "evidence_source": [ { "id": "32753955", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955", "evidence_list": [ { "evidence": "The PT level in patients with advanced stage colorectal cancer was increased significantly compared with those in an early stage, which indicated that PT could be used as a marker for evaluating prognosis in patients with CRC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32753955", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955", "evidence_list": [ { "evidence": "The PT level in patients with advanced stage colorectal cancer was increased significantly compared with those in an early stage, which indicated that PT could be used as a marker for evaluating prognosis in patients with CRC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).", "journal": "Cancer management and research", "authors": "Zhang L, Ye J, Luo Q, Kuang M, Mao M, Dai S, Wang X", "date": "2020-08-06", "evidence": [], "reference": [ { "id": "32753955", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753955" } ] } ], "biomarker_canonical_id": "AN4086", "collision": 1 }, { "biomarker_id": "AN4087-1", "biomarker_component": [ { "biomarker": "prolonged PT", "assessed_biomarker_entity": { "recommended_name": "Prothrombin time", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C62656", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "5894-1" } ], "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "The nonsurvivors demonstrated significantly higher D-dimer and FDP levels, and longer PT and APTT compared to survivors on admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32311826", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826", "evidence_list": [ { "evidence": "The nonsurvivors demonstrated significantly higher D-dimer and FDP levels, and longer PT and APTT compared to survivors on admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32073213", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213", "evidence_list": [ { "evidence": "Non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) levels, longer prothrombin time and activated partial thromboplastin time." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "COVID-19 and the clinical hematology laboratory.", "journal": "International journal of laboratory hematology", "authors": "Frater JL, Zini G, d'Onofrio G, Rogers HJ", "date": "2020-04-21", "evidence": [], "reference": [ { "id": "32311826", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32311826" } ] }, { "title": "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.", "journal": "Journal of thrombosis and haemostasis : JTH", "authors": "Tang N, Li D, Wang X, Sun Z", "date": "2020-02-20", "evidence": [], "reference": [ { "id": "32073213", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32073213" } ] } ], "biomarker_canonical_id": "AN4087", "collision": 1 }, { "biomarker_id": "AA4773-1", "biomarker_component": [ { "biomarker": "decreased PF4 level", "assessed_biomarker_entity": { "recommended_name": "Platelet factor 4", "synonyms": [ { "synonym": "PF-4" }, { "synonym": "C-X-C motif chemokine 4" }, { "synonym": "Iroplact" }, { "synonym": "Oncostatin-A" } ] }, "assessed_biomarker_entity_id": "UPKB:P02776", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "6002-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "6002-0" } ], "evidence_source": [ { "id": "32492406", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406", "evidence_list": [ { "evidence": "In a proteomic investigation of sera in SARS patients, decreasing PF4 was found to be associated with poor prognosis which is in consistent with our findings in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32492406", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406", "evidence_list": [ { "evidence": "In a proteomic investigation of sera in SARS patients, decreasing PF4 was found to be associated with poor prognosis which is in consistent with our findings in COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.", "journal": "Cell", "authors": "Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, Ge W, Liu W, Liang S, Chen H, Zhang Y, Li J, Xu J, He Z, Chen B, Wang J, Yan H, Zheng Y, Wang D, Zhu J, Kong Z, Kang Z, Liang X, Ding X, Ruan G, Xiang N, Cai X, Gao H, Li L, Li S, Xiao Q, Lu T, Zhu Y, Liu H, Chen H, Guo T", "date": "2020-06-04", "evidence": [], "reference": [ { "id": "32492406", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32492406" } ] } ], "biomarker_canonical_id": "AA4773", "collision": 1 }, { "biomarker_id": "AN4088-1", "biomarker_component": [ { "biomarker": "increased EWSR1 level", "assessed_biomarker_entity": { "recommended_name": "RNA-binding protein EWS", "synonyms": [ { "synonym": "EWS oncogene" }, { "synonym": "Ewing sarcoma breakpoint region 1 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q01844", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "10.1101/2020.05.27.20114678", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.27.20114678", "evidence_list": [ { "evidence": "Best baseline predictors of respiratory failure were suPAR with an AUC (95% CI) of 0.88 (0.80-0.95), EWS 0.84 (0.75-0.93), LDH 0.82 (0.71-0.93), and CRP 0.80 (0.70-0.89)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.05.27.20114678", "database": "Doi", "url": "https://doi.org/10.1101/2020.05.27.20114678", "evidence_list": [ { "evidence": "Best baseline predictors of respiratory failure were suPAR with an AUC (95% CI) of 0.88 (0.80-0.95), EWS 0.84 (0.75-0.93), LDH 0.82 (0.71-0.93), and CRP 0.80 (0.70-0.89)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4088", "collision": 1 }, { "biomarker_id": "AN4089-1", "biomarker_component": [ { "biomarker": "presence of rs12674822 in angiopoietin-2 gene", "assessed_biomarker_entity": { "recommended_name": "Angiopoietin-2 gene", "synonyms": [ { "synonym": "ANG-2" } ] }, "assessed_biomarker_entity_id": "UPKB:O15123", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "31929743", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31929743", "evidence_list": [ { "evidence": "Genetic variants of the Angpt2 rs12674822 polymorphism appears to be correlated with the risk of CRC and PFS in CRC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "31929743", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31929743", "evidence_list": [ { "evidence": "Genetic variants of the Angpt2 rs12674822 polymorphism appears to be correlated with the risk of CRC and PFS in CRC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Angiopoietin-2 gene polymorphisms are biomarkers for the development and progression of colorectal cancer in Han Chinese.", "journal": "International journal of medical sciences", "authors": "Du Z, Tang CH, Li LJ, Kang L, Zhao J, Jin L, Wang CQ, Su CM", "date": "2020-01-14", "evidence": [], "reference": [ { "id": "31929743", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31929743" } ] } ], "biomarker_canonical_id": "AN4089", "collision": 1 }, { "biomarker_id": "AN4090-1", "biomarker_component": [ { "biomarker": "increased SFTPA1 level", "assessed_biomarker_entity": { "recommended_name": "Surfactant protein A", "synonyms": [ { "synonym": "PSP-A" }, { "synonym": "PSPA" }, { "synonym": "SP-A" }, { "synonym": "SP-A1" }, { "synonym": "35 kDa pulmonary surfactant-associated protein" }, { "synonym": "Alveolar proteinosis protein" }, { "synonym": "Collectin-4" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8IWL2", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "10.21203/rs.3.rs-29567/v1", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-29567/v1", "evidence_list": [ { "evidence": "Serum SP-A and SP-D levels were significantly higher in severe cases than in non severe cases. Additionally, SP-A was higher in non-severe cases than in healthy subjects. We propose that serum SP-A and SP-D level might be useful as biomarkers of COVID-19 pneumonia severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.21203/rs.3.rs-29567/v1", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-29567/v1", "evidence_list": [ { "evidence": "Serum SP-A and SP-D levels were significantly higher in severe cases than in non severe cases. Additionally, SP-A was higher in non-severe cases than in healthy subjects. We propose that serum SP-A and SP-D level might be useful as biomarkers of COVID-19 pneumonia severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4090", "collision": 1 }, { "biomarker_id": "AN4091-1", "biomarker_component": [ { "biomarker": "increased SFTPD level", "assessed_biomarker_entity": { "recommended_name": "Surfactant protein D", "synonyms": [ { "synonym": "PSP-D" }, { "synonym": "SP-D" }, { "synonym": "Collectin-7" }, { "synonym": "Lung surfactant protein D" } ] }, "assessed_biomarker_entity_id": "UPKB:P35247", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "74541-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "74541-4" } ], "evidence_source": [ { "id": "10.21203/rs.3.rs-29567/v1", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-29567/v1", "evidence_list": [ { "evidence": "Serum SP-A and SP-D levels were significantly higher in severe cases than in non severe cases. Additionally, SP-A was higher in non-severe cases than in healthy subjects. We propose that serum SP-A and SP-D level might be useful as biomarkers of COVID-19 pneumonia severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.21203/rs.3.rs-29567/v1", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-29567/v1", "evidence_list": [ { "evidence": "Serum SP-A and SP-D levels were significantly higher in severe cases than in non severe cases. Additionally, SP-A was higher in non-severe cases than in healthy subjects. We propose that serum SP-A and SP-D level might be useful as biomarkers of COVID-19 pneumonia severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4091", "collision": 1 }, { "biomarker_id": "AA4775-1", "biomarker_component": [ { "biomarker": "increased ENO2 level", "assessed_biomarker_entity": { "recommended_name": "Neuron-specific enolase", "synonyms": [ { "synonym": "2-phospho-D-glycerate hydro-lyase" }, { "synonym": "Enolase 2" }, { "synonym": "Neural enolase" }, { "synonym": "Neuron-specific enolase" }, { "synonym": "NSE" } ] }, "assessed_biomarker_entity_id": "UPKB:P09104", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19193-2" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "19193-2" } ], "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16062024", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16062024", "evidence_list": [ { "evidence": "Alteration of serum tumor markers cytokeratin 19 fragment, carcinoembryonic antigen and neuron-specific enolase is associated with particular tumor histology, smoking habit, more advanced disease and poor prognosis. The number of patients with elevated levels of cytokeratin 19 fragment and neuron-specific enolase was higher in more advanced disease than in early lung cancer (p=0.036 and p=0.036, respectively). Preoperative levels of cytokeratin 19 fragment (p=0.017 and p=0.016, respectively) and neuron-specific enolase (p=0.03 and p=0.006, respectively) were significantly associated with more advanced disease and tumor size, as well as tumor histology in non-small cell lung cancer (p=0.03 and p=0.016, respectively)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "30994045", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30994045", "evidence_list": [ { "evidence": "Our results confirm that patients with lung cancer have increased serum levels of CEA, CYFRA 21-1, ProGRP, and NSE compared to patients with benign disease. Moreover, we found a strong association among the SCLC patients and high levels of ProGRP and NSE." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC, CEA in adenocarcinomas and CYFRA 21-1 in squamous tumors. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ], "tags": [ { "tag": "condition" } ] }, { "id": "16062024", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16062024", "evidence_list": [ { "evidence": "Alteration of serum tumor markers cytokeratin 19 fragment, carcinoembryonic antigen and neuron-specific enolase is associated with particular tumor histology, smoking habit, more advanced disease and poor prognosis. The number of patients with elevated levels of cytokeratin 19 fragment and neuron-specific enolase was higher in more advanced disease than in early lung cancer (p=0.036 and p=0.036, respectively). Preoperative levels of cytokeratin 19 fragment (p=0.017 and p=0.016, respectively) and neuron-specific enolase (p=0.03 and p=0.006, respectively) were significantly associated with more advanced disease and tumor size, as well as tumor histology in non-small cell lung cancer (p=0.03 and p=0.016, respectively)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "30994045", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30994045", "evidence_list": [ { "evidence": "Our results confirm that patients with lung cancer have increased serum levels of CEA, CYFRA 21-1, ProGRP, and NSE compared to patients with benign disease. Moreover, we found a strong association among the SCLC patients and high levels of ProGRP and NSE." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] }, { "title": "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.", "journal": "Anticancer research", "authors": "Molina R, Auge JM, Filella X, Vi\u00f1olas N, Alicarte J, Domingo JM, Ballesta AM", "date": "2005-07-22", "evidence": [], "reference": [ { "id": "16033098", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "[Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].", "journal": "Medicina (Kaunas, Lithuania)", "authors": "Zemaitis M, Sakalauskas R, Malakauskas K, Muley T, Fischer JR, Lahm H", "date": "2005-08-03", "evidence": [], "reference": [ { "id": "16062024", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16062024" } ] }, { "title": "New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.", "journal": "The International journal of biological markers", "authors": "Mauro C, Passerini R, Spaggiari L, Galetta D, Radice D, Lentati P, Sandri MT", "date": "2019-04-18", "evidence": [], "reference": [ { "id": "30994045", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30994045" } ] } ], "biomarker_canonical_id": "AA4775", "collision": 1 }, { "biomarker_id": "AA4775-2", "biomarker_component": [ { "biomarker": "increased ENO2 level", "assessed_biomarker_entity": { "recommended_name": "Neuron-specific enolase", "synonyms": [ { "synonym": "2-phospho-D-glycerate hydro-lyase" }, { "synonym": "Enolase 2" }, { "synonym": "Neural enolase" }, { "synonym": "Neuron-specific enolase" }, { "synonym": "NSE" } ] }, "assessed_biomarker_entity_id": "UPKB:P09104", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "19193-2" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "19193-2" } ], "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predicte the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated NSE levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predicte the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32347972", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972", "evidence_list": [ { "evidence": "Presence of elevated NSE levels shown as predictor of COVID-19 severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020-04-30", "evidence": [], "reference": [ { "id": "32347972", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32347972" } ] } ], "biomarker_canonical_id": "AA4775", "collision": 1 }, { "biomarker_id": "AA4776-1", "biomarker_component": [ { "biomarker": "increased PROGRP level", "assessed_biomarker_entity": { "recommended_name": "Progastrin releasing peptide", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050383", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated in cases than those in controls (pall<0.01." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "27747005", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27747005", "evidence_list": [ { "evidence": "Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging. At cutoff level of 63 pg/mL, proGRP shows 85.7% sensitivity, 90.2% specificity, 72.5% positive predictive value and 95.4% negative predictive value in patients with SCLC. Median proGRP level was higher in extensive disease (1,055.2 pg/mL) than limited disease (253.8 pg/mL, P=0.005). Median OS was significantly shorter in patients with extensive disease (6.0\u00b10.7 months) than limited disease (12.7\u00b14.5 months, P<0.01)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" }, { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "16033098", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098", "evidence_list": [ { "evidence": "Tumor marker serum levels were related to histological type and tumor extension, with ProGRP being the most sensitive marker in SCLC. The most sensitive combinations of tumor markers were ProGRP and NSE in SCLC (88%), and CEA plus CYFRA in NSCLC (82%). In summary, ProGRP is the tumor marker of choice in SCLC and NSE is a complementary tumor marker in this histological type." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "Tumor biomarkers, such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated in cases than those in controls (pall<0.01." } ], "tags": [ { "tag": "condition" } ] }, { "id": "27747005", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27747005", "evidence_list": [ { "evidence": "Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging. At cutoff level of 63 pg/mL, proGRP shows 85.7% sensitivity, 90.2% specificity, 72.5% positive predictive value and 95.4% negative predictive value in patients with SCLC. Median proGRP level was higher in extensive disease (1,055.2 pg/mL) than limited disease (253.8 pg/mL, P=0.005). Median OS was significantly shorter in patients with extensive disease (6.0\u00b10.7 months) than limited disease (12.7\u00b14.5 months, P<0.01)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.", "journal": "Anticancer research", "authors": "Molina R, Auge JM, Filella X, Vi\u00f1olas N, Alicarte J, Domingo JM, Ballesta AM", "date": "2005-07-22", "evidence": [], "reference": [ { "id": "16033098", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16033098" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] }, { "title": "Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.", "journal": "Journal of thoracic disease", "authors": "Oh HJ, Park HY, Kim KH, Park CK, Shin HJ, Lim JH, Kwon YS, Oh IJ, Kim YI, Lim SC, Kim YC, Kim SH, Shin MG", "date": "2016-10-18", "evidence": [], "reference": [ { "id": "27747005", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27747005" } ] } ], "biomarker_canonical_id": "AA4776", "collision": 1 }, { "biomarker_id": "AA4776-2", "biomarker_component": [ { "biomarker": "increased PROGRP level", "assessed_biomarker_entity": { "recommended_name": "Progastrin releasing peptide", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050383", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predicte the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32504736", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736", "evidence_list": [ { "evidence": "In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predicte the clinical outcome of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32504736", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32504736" } ] } ], "biomarker_canonical_id": "AA4776", "collision": 1 }, { "biomarker_id": "AA4777-1", "biomarker_component": [ { "biomarker": "decreased SaO2 level", "assessed_biomarker_entity": { "recommended_name": "Oxygen saturation", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C60832", "assessed_entity_type": "chemical element", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2713-6" } ], "evidence_source": [ { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "Oxygen saturation (SaO2) was found as another candidate marker of progressive severity. The fact that it was so tightly associated to hospitalization or even death in our model is unsurprising, because a low SaO2 is one of the main criteria for the definition of a severe case." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32471703", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703", "evidence_list": [ { "evidence": "Oxygen saturation (SaO2) was found as another candidate marker of progressive severity. The fact that it was so tightly associated to hospitalization or even death in our model is unsurprising, because a low SaO2 is one of the main criteria for the definition of a severe case." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.", "journal": "Archives of medical research", "authors": "Assandri R, Buscarini E, Canetta C, Scartabellati A, Vigan\u00f2 G, Montanelli A", "date": "2020-05-31", "evidence": [], "reference": [ { "id": "32471703", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32471703" } ] } ], "biomarker_canonical_id": "AA4777", "collision": 1 }, { "biomarker_id": "AN4455-1", "biomarker_component": [ { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3GHG", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio.", "journal": "Journal of Cancer", "authors": "Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, Zhang L, Yang H, Fu J", "date": "2017-05-23", "evidence": [], "reference": [ { "id": "28529615", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615" } ] }, { "title": "A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio.", "journal": "Journal of Cancer", "authors": "Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, Zhang L, Yang H, Fu J", "date": "2017-05-23", "evidence": [], "reference": [ { "id": "28529615", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615" } ] } ], "biomarker_canonical_id": "AN4455", "collision": 0 }, { "biomarker_id": "AN4455-2", "biomarker_component": [ { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3GHG", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.", "journal": "International journal of clinical oncology", "authors": "Matsuoka H, Ando K, Hu Q, Zaitsu Y, Tsuda Y, Hisamatsu Y, Nakashima Y, Kimura Y, Oki E, Mori M", "date": "2020-04-13", "evidence": [], "reference": [ { "id": "32279124", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124" } ] }, { "title": "Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.", "journal": "International journal of clinical oncology", "authors": "Matsuoka H, Ando K, Hu Q, Zaitsu Y, Tsuda Y, Hisamatsu Y, Nakashima Y, Kimura Y, Oki E, Mori M", "date": "2020-04-13", "evidence": [], "reference": [ { "id": "32279124", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124" } ] } ], "biomarker_canonical_id": "AN4455", "collision": 0 }, { "biomarker_id": "AN4455-3", "biomarker_component": [ { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3GHG", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "The most important finding was that FAR and PLT count were independent risk factors to predict the development of severe illness in COVID-19. Patients with FAR<0.0883 and PLT count>135*109/L were unlikely to develop into severe disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased FAR ratio", "assessed_biomarker_entity": { "recommended_name": "Fibrinogen to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "The most important finding was that FAR and PLT count were independent risk factors to predict the development of severe illness in COVID-19. Patients with FAR<0.0883 and PLT count>135*109/L were unlikely to develop into severe disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32367765", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765", "evidence_list": [ { "evidence": "The most important finding was that FAR and PLT count were independent risk factors to predict the development of severe illness in COVID-19. Patients with FAR<0.0883 and PLT count>135*109/L were unlikely to develop into severe disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "28529615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615", "evidence_list": [ { "evidence": "In our study, higher FAR was thought to be associated with a number of important clinicopathological parameters shown to be predictive of worse outcomes. Moreover, higher FAR was also associated with poor survival in ESCC patients, which indicated that elevated FAR might be associated with aggressive burden and systemic progression of ESCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.", "journal": "Platelets", "authors": "Bi X, Su Z, Yan H, Du J, Wang J, Chen L, Peng M, Chen S, Shen B, Li J", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32367765", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765" } ] }, { "title": "A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio.", "journal": "Journal of Cancer", "authors": "Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, Zhang L, Yang H, Fu J", "date": "2017-05-23", "evidence": [], "reference": [ { "id": "28529615", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615" } ] }, { "title": "Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count.", "journal": "Platelets", "authors": "Bi X, Su Z, Yan H, Du J, Wang J, Chen L, Peng M, Chen S, Shen B, Li J", "date": "2020-05-06", "evidence": [], "reference": [ { "id": "32367765", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32367765" } ] }, { "title": "A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio.", "journal": "Journal of Cancer", "authors": "Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, Zhang L, Yang H, Fu J", "date": "2017-05-23", "evidence": [], "reference": [ { "id": "28529615", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28529615" } ] } ], "biomarker_canonical_id": "AN4455", "collision": 0 }, { "biomarker_id": "AA4778-1", "biomarker_component": [ { "biomarker": "increased VEGF-D level", "assessed_biomarker_entity": { "recommended_name": "Vascular endothelial growth factor D", "synonyms": [ { "synonym": "VEGF-D" }, { "synonym": "c-Fos-induced growth factor" }, { "synonym": "FIGF" } ] }, "assessed_biomarker_entity_id": "UPKB:O43915", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "82911-9" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "82911-9" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "82911-9" } ], "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "VEGF-D was identified as the most important indicator related to the severity of COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Initial plasma VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "VEGF-D was identified as the most important indicator related to the severity of COVID-19." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "Initial plasma VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "VEGF-D: a novel biomarker for detection of COVID-19 progression.", "journal": "Critical care (London, England)", "authors": "Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H", "date": "2020-06-25", "evidence": [], "reference": [ { "id": "32576222", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222" } ] }, { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] } ], "biomarker_canonical_id": "AA4778", "collision": 1 }, { "biomarker_id": "AA4778-2", "biomarker_component": [ { "biomarker": "increased VEGF-D level", "assessed_biomarker_entity": { "recommended_name": "Vascular endothelial growth factor D", "synonyms": [ { "synonym": "VEGF-D" }, { "synonym": "c-Fos-induced growth factor" }, { "synonym": "FIGF" } ] }, "assessed_biomarker_entity_id": "UPKB:O43915", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "82911-9" } ], "evidence_source": [ { "id": "12576440", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12576440", "evidence_list": [ { "evidence": "VEGF-D expression may play a crucial role for lymph node metastasis of breast cancers. Our data identifying VEGF-D expression in tumors of patients with a poor survival prognosis provides, to our knowledge, a first analysis of this VEGF as prognostic factor in patients with breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "12576440", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12576440", "evidence_list": [ { "evidence": "VEGF-D expression may play a crucial role for lymph node metastasis of breast cancers. Our data identifying VEGF-D expression in tumors of patients with a poor survival prognosis provides, to our knowledge, a first analysis of this VEGF as prognostic factor in patients with breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K", "date": "2003-02-11", "evidence": [], "reference": [ { "id": "12576440", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12576440" } ] } ], "biomarker_canonical_id": "AA4778", "collision": 1 }, { "biomarker_id": "AA4779-1", "biomarker_component": [ { "biomarker": "increased BTK level", "assessed_biomarker_entity": { "recommended_name": "Bruton tyrosine kinase", "synonyms": [ { "synonym": "Agammaglobulinemia tyrosine kinase" }, { "synonym": "ATK" }, { "synonym": "B-cell progenitor kinase" }, { "synonym": "BPK" }, { "synonym": "Bruton tyrosine kinase" } ] }, "assessed_biomarker_entity_id": "UPKB:Q06187", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "75708-8" } ], "evidence_source": [ { "id": "32503877", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503877", "evidence_list": [ { "evidence": "Analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32388230", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32388230", "evidence_list": [ { "evidence": "In contrast, Bruton tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, may actually have some protective effect." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32503877", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503877", "evidence_list": [ { "evidence": "Analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32388230", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32388230", "evidence_list": [ { "evidence": "In contrast, Bruton tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, may actually have some protective effect." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.", "journal": "Science immunology", "authors": "Roschewski M, Lionakis MS, Sharman JP, Roswarski J, Goy A, Monticelli MA, Roshon M, Wrzesinski SH, Desai JV, Zarakas MA, Collen J, Rose K, Hamdy A, Izumi R, Wright GW, Chung KK, Baselga J, Staudt LM, Wilson WH", "date": "2020-06-07", "evidence": [], "reference": [ { "id": "32503877", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32503877" } ] }, { "title": "Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.", "journal": "Leukemia research", "authors": "Paneesha S, Pratt G, Parry H, Moss P", "date": "2020-05-11", "evidence": [], "reference": [ { "id": "32388230", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32388230" } ] } ], "biomarker_canonical_id": "AA4779", "collision": 1 }, { "biomarker_id": "AA4780-1", "biomarker_component": [ { "biomarker": "increased MB level", "assessed_biomarker_entity": { "recommended_name": "Myoglobin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02144", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2639-3" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "2639-3" } ], "evidence_source": [ { "id": "32450473", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32450473", "evidence_list": [ { "evidence": "An increased concentration of myoglobin was associated with an increased risk of hospitalization mortality in non-survivors with NCIP. In conclusion, our study provides important documentation that in this single-center, an elevated serum concentration of myoglobin (>/=306.5 ug/L) is associated with an increased risk of hospitalization mortality in non-survivor with NCIP, independent of elevation in CK-MB and Troponin I levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32305557", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305557", "evidence_list": [ { "evidence": "The severity of COVID-19 is associated with acute cardiac injury, and acute cardiac injury is associated with death. Cardiac injury biomarkers mainly increase in non-survivors. This highlights the need to effectively monitor heart health to prevent myocarditis in patients infected with COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32450473", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32450473", "evidence_list": [ { "evidence": "An increased concentration of myoglobin was associated with an increased risk of hospitalization mortality in non-survivors with NCIP. In conclusion, our study provides important documentation that in this single-center, an elevated serum concentration of myoglobin (>/=306.5 ug/L) is associated with an increased risk of hospitalization mortality in non-survivor with NCIP, independent of elevation in CK-MB and Troponin I levels." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32305557", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305557", "evidence_list": [ { "evidence": "The severity of COVID-19 is associated with acute cardiac injury, and acute cardiac injury is associated with death. Cardiac injury biomarkers mainly increase in non-survivors. This highlights the need to effectively monitor heart health to prevent myocarditis in patients infected with COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated cardiac biomarkers are associated with increased mortality for inpatients with COVID-19: A retrospective case-control study.", "journal": "Journal of clinical anesthesia", "authors": "Su M, Wang Y, Peng J, Wu MJ, Deng W, Yang YS", "date": "2020-05-26", "evidence": [], "reference": [ { "id": "32450473", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32450473" } ] }, { "title": "The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.", "journal": "Progress in cardiovascular diseases", "authors": "Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, Neal B", "date": "2020-04-20", "evidence": [], "reference": [ { "id": "32305557", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305557" } ] } ], "biomarker_canonical_id": "AA4780", "collision": 1 }, { "biomarker_id": "AA4781-1", "biomarker_component": [ { "biomarker": "increased HBA1C level", "assessed_biomarker_entity": { "recommended_name": "Glycosylated hemoglobin", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3B75", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4548-4" } ], "evidence_source": [ { "id": "32416121", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32416121", "evidence_list": [ { "evidence": "High HbA1c level is associated with inflammation, hypercoagulability, and low SaO2 in COVID-19 patients, and the mortality rate (27.7%) is higher in patients with diabetes. Determining HbA1c level after hospital admission is thus helpful assessing inflammation, hypercoagulability, and prognosis of COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32416121", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32416121", "evidence_list": [ { "evidence": "High HbA1c level is associated with inflammation, hypercoagulability, and low SaO2 in COVID-19 patients, and the mortality rate (27.7%) is higher in patients with diabetes. Determining HbA1c level after hospital admission is thus helpful assessing inflammation, hypercoagulability, and prognosis of COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients.", "journal": "Diabetes research and clinical practice", "authors": "Wang Z, Du Z, Zhu F", "date": "2020-05-18", "evidence": [], "reference": [ { "id": "32416121", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32416121" } ] } ], "biomarker_canonical_id": "AA4781", "collision": 1 }, { "biomarker_id": "AA4781-2", "biomarker_component": [ { "biomarker": "increased HBA1C level", "assessed_biomarker_entity": { "recommended_name": "Glycosylated hemoglobin", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3B75", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4548-4" } ], "evidence_source": [ { "id": "32189971", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32189971", "evidence_list": [ { "evidence": "Glycosylated Hemoglobin A1c Is associated with Anthropometric Measurements and Tumor Characteristics in Breast Cancer Patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32189971", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32189971", "evidence_list": [ { "evidence": "Glycosylated Hemoglobin A1c Is associated with Anthropometric Measurements and Tumor Characteristics in Breast Cancer Patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Glycosylated Hemoglobin A1c Is Associated with Anthropometric Measurements and Tumor Characteristics in Breast Cancer Patients.", "journal": "International journal of women's health", "authors": "Ayoub NM, Jaradat SK, Alhusban A, Tahaineh L", "date": "2020-03-20", "evidence": [], "reference": [ { "id": "32189971", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32189971" } ] } ], "biomarker_canonical_id": "AA4781", "collision": 1 }, { "biomarker_id": "AA4781-3", "biomarker_component": [ { "biomarker": "increased HBA1C level", "assessed_biomarker_entity": { "recommended_name": "Glycosylated hemoglobin", "synonyms": [] }, "assessed_biomarker_entity_id": "PDB:3B75", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4548-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "4548-4" } ], "evidence_source": [ { "id": "32403389", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32403389", "evidence_list": [ { "evidence": "HbA1c measurements may be useful not only in optimizing glycemic control but also as a tool for managing overall vascular risk in patients with diabetes. The degree of glycemic control (HbA1c levels) provide valuable information on the vascular status of patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "32403389", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32403389", "evidence_list": [ { "evidence": "HbA1c measurements may be useful not only in optimizing glycemic control but also as a tool for managing overall vascular risk in patients with diabetes. The degree of glycemic control (HbA1c levels) provide valuable information on the vascular status of patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Use of Glycated Hemoglobin (A1c) as a Biomarker for Vascular Risk in Type 2 Diabetes: Its Relationship with Matrix Metalloproteinases-2, -9 and the Metabolism of Collagen IV and Elastin.", "journal": "Medicina (Kaunas, Lithuania)", "authors": "Kostov K, Blazhev A", "date": "2020-05-15", "evidence": [], "reference": [ { "id": "32403389", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32403389" } ] } ], "biomarker_canonical_id": "AA4781", "collision": 1 }, { "biomarker_id": "AA4782-1", "biomarker_component": [ { "biomarker": "increased LILRB4 level", "assessed_biomarker_entity": { "recommended_name": "Leukocyte immunoglobulin like receptor B4", "synonyms": [ { "synonym": "B4" }, { "synonym": "CD85 antigen-like family member K" }, { "synonym": "Immunoglobulin-like transcript 3" }, { "synonym": "ILT-3" }, { "synonym": "Leukocyte immunoglobulin-like receptor 5" }, { "synonym": "LIR-5" }, { "synonym": "Monocyte inhibitory receptor HM18" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8NHJ6", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33737684", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33737684", "evidence_list": [ { "evidence": "Increased expression of LILRB4 was associated with increased disease severity in this study, suggesting a possible decrease in monocyte activation leading to an immune suppressive microenvironment. LILRB4 represents a compelling target to investigate COVID343 19 treatment." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33737684", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33737684", "evidence_list": [ { "evidence": "Increased expression of LILRB4 was associated with increased disease severity in this study, suggesting a possible decrease in monocyte activation leading to an immune suppressive microenvironment. LILRB4 represents a compelling target to investigate COVID343 19 treatment." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Proteomic blood profiling in mild, severe and critical COVID-19 patients.", "journal": "Scientific reports", "authors": "Patel H, Ashton NJ, Dobson RJB, Andersson LM, Yilmaz A, Blennow K, Gisslen M, Zetterberg H", "date": "2021-03-20", "evidence": [], "reference": [ { "id": "33737684", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33737684" } ] } ], "biomarker_canonical_id": "AA4782", "collision": 1 }, { "biomarker_id": "AA4783-1", "biomarker_component": [ { "biomarker": "increased IGG level", "assessed_biomarker_entity": { "recommended_name": "Immunoglobulin G", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050252", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2465-3" } ], "evidence_source": [ { "id": "33372199", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199", "evidence_list": [ { "evidence": "IgM and IgG immunogenic epitopes of SARS-CoV-2 proteins were profiled in the serum of ten COVID-19 patients. Such epitope biomarkers provide insight into the immune response to COVID-19 and are potential targets for COVID-19 diagnosis and vaccine development." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33372199", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199", "evidence_list": [ { "evidence": "IgM and IgG immunogenic epitopes of SARS-CoV-2 proteins were profiled in the serum of ten COVID-19 patients. Such epitope biomarkers provide insight into the immune response to COVID-19 and are potential targets for COVID-19 diagnosis and vaccine development." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.", "journal": "ACS central science", "authors": "Wang H, Wu X, Zhang X, Hou X, Liang T, Wang D, Teng F, Dai J, Duan H, Guo S, Li Y, Yu X", "date": "2020-12-30", "evidence": [], "reference": [ { "id": "33372199", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199" } ] } ], "biomarker_canonical_id": "AA4783", "collision": 1 }, { "biomarker_id": "AA4783-2", "biomarker_component": [ { "biomarker": "increased IGG level", "assessed_biomarker_entity": { "recommended_name": "Immunoglobulin G", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050252", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2465-3" } ], "evidence_source": [ { "id": "10.1371/journal.pone.0097359", "database": "Doi", "url": "https://doi.org/10.1371/journal.pone.0097359", "evidence_list": [ { "evidence": "In this study, we found that the extents of IgG expression in 86 lung cancers were positively related to clinical stage, pathological grade and lymph node metastasis. We also found that IgG of cancerous origin has the ability of promoting growth and survival of tumor cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "10.1371/journal.pone.0097359", "database": "Doi", "url": "https://doi.org/10.1371/journal.pone.0097359", "evidence_list": [ { "evidence": "In this study, we found that the extents of IgG expression in 86 lung cancers were positively related to clinical stage, pathological grade and lymph node metastasis. We also found that IgG of cancerous origin has the ability of promoting growth and survival of tumor cells." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AA4783", "collision": 1 }, { "biomarker_id": "AA4784-1", "biomarker_component": [ { "biomarker": "increased IGM level", "assessed_biomarker_entity": { "recommended_name": "Immunoglobulin M", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050257", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2472-9" } ], "evidence_source": [ { "id": "33372199", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199", "evidence_list": [ { "evidence": "IgM and IgG immunogenic epitopes of SARS-CoV-2 proteins were profiled in the serum of ten COVID-19 patients. Such epitope biomarkers provide insight into the immune response to COVID-19 and are potential targets for COVID-19 diagnosis and vaccine development." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33372199", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199", "evidence_list": [ { "evidence": "IgM and IgG immunogenic epitopes of SARS-CoV-2 proteins were profiled in the serum of ten COVID-19 patients. Such epitope biomarkers provide insight into the immune response to COVID-19 and are potential targets for COVID-19 diagnosis and vaccine development." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.", "journal": "ACS central science", "authors": "Wang H, Wu X, Zhang X, Hou X, Liang T, Wang D, Teng F, Dai J, Duan H, Guo S, Li Y, Yu X", "date": "2020-12-30", "evidence": [], "reference": [ { "id": "33372199", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33372199" } ] } ], "biomarker_canonical_id": "AA4784", "collision": 1 }, { "biomarker_id": "AN4093-1", "biomarker_component": [ { "biomarker": "increased EB level", "assessed_biomarker_entity": { "recommended_name": "Ethyl butanoate", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:7762", "assessed_entity_type": "metabolite", "specimen": [ { "name": "gas in respiratory system", "id": "UBERON:0034947", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0034947", "loinc_code": "" } ], "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4093", "collision": 1 }, { "biomarker_id": "AN4093-2", "biomarker_component": [ { "biomarker": "increased EB level", "assessed_biomarker_entity": { "recommended_name": "Ethyl butanoate", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:7762", "assessed_entity_type": "metabolite", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "" } ], "evidence_source": [ { "id": "30828825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825", "evidence_list": [ { "evidence": "Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "30828825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825", "evidence_list": [ { "evidence": "Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer.", "journal": "Alimentary pharmacology & therapeutics", "authors": "Bond A, Greenwood R, Lewis S, Corfe B, Sarkar S, O'Toole P, Rooney P, Burkitt M, Hold G, Probert C", "date": "2019-03-05", "evidence": [], "reference": [ { "id": "30828825", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825" } ] } ], "biomarker_canonical_id": "AN4093", "collision": 1 }, { "biomarker_id": "AN4093-3", "biomarker_component": [ { "biomarker": "increased EB level", "assessed_biomarker_entity": { "recommended_name": "Ethyl butanoate", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:7762", "assessed_entity_type": "metabolite", "specimen": [ { "name": "pus", "id": "UBERON:0000177", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000177", "loinc_code": "" } ], "evidence_source": [ { "id": "10.1016/B978-0-12-816413-6.00023-X", "database": "Doi", "url": "https://doi.org/10.1016/B978-0-12-816413-6.00023-X", "evidence_list": [ { "evidence": "While the use of VOCs to diagnose wounds is in its infancy, limited results show promise, including early results on the detection of bacterial infections in diabetic foot ulcers using an eNose." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "10.1016/B978-0-12-816413-6.00023-X", "database": "Doi", "url": "https://doi.org/10.1016/B978-0-12-816413-6.00023-X", "evidence_list": [ { "evidence": "While the use of VOCs to diagnose wounds is in its infancy, limited results show promise, including early results on the detection of bacterial infections in diabetic foot ulcers using an eNose." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4093", "collision": 1 }, { "biomarker_id": "AN4094-1", "biomarker_component": [ { "biomarker": "decreased BA level", "assessed_biomarker_entity": { "recommended_name": "Butyraldehyde", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:261", "assessed_entity_type": "metabolite", "specimen": [ { "name": "gas in respiratory system", "id": "UBERON:0034947", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0034947", "loinc_code": "" } ], "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4094", "collision": 1 }, { "biomarker_id": "AN4095-1", "biomarker_component": [ { "biomarker": "decreased IP level", "assessed_biomarker_entity": { "recommended_name": "Isopropanol", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:3776", "assessed_entity_type": "metabolite", "specimen": [ { "name": "gas in respiratory system", "id": "UBERON:0034947", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0034947", "loinc_code": "32084-6" } ], "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.1101/2020.06.21.20136523", "database": "Doi", "url": "https://doi.org/10.1101/2020.06.21.20136523", "evidence_list": [ { "evidence": "Higher levels of ethyl butanoate were detected in exhaled breath of COVID-19 patients. breath-borne butyraldehyde and isopropanol were significantly higher for non-COVID-19 respiratory infections." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4095", "collision": 1 }, { "biomarker_id": "AN4095-2", "biomarker_component": [ { "biomarker": "decreased IP level", "assessed_biomarker_entity": { "recommended_name": "Isopropanol", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:3776", "assessed_entity_type": "metabolite", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "32084-6" } ], "evidence_source": [ { "id": "30828825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825", "evidence_list": [ { "evidence": "Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "30828825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825", "evidence_list": [ { "evidence": "Volatile organic compound analysis may have a superior diagnostic ability for the identification of colorectal adenocarcinoma, when compared to other faecal biomarkers, including those currently employed in UK." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer.", "journal": "Alimentary pharmacology & therapeutics", "authors": "Bond A, Greenwood R, Lewis S, Corfe B, Sarkar S, O'Toole P, Rooney P, Burkitt M, Hold G, Probert C", "date": "2019-03-05", "evidence": [], "reference": [ { "id": "30828825", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30828825" } ] } ], "biomarker_canonical_id": "AN4095", "collision": 1 }, { "biomarker_id": "AN4095-3", "biomarker_component": [ { "biomarker": "decreased IP level", "assessed_biomarker_entity": { "recommended_name": "Isopropanol", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:3776", "assessed_entity_type": "metabolite", "specimen": [ { "name": "pus", "id": "UBERON:0000177", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000177", "loinc_code": "32084-6" } ], "evidence_source": [ { "id": "10.1016/B978-0-12-816413-6.00023-X", "database": "Doi", "url": "https://doi.org/10.1016/B978-0-12-816413-6.00023-X", "evidence_list": [ { "evidence": "While the use of VOCs to diagnose wounds is in its infancy, limited results show promise, including early results on the detection of bacterial infections in diabetic foot ulcers using an eNose." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "10.1016/B978-0-12-816413-6.00023-X", "database": "Doi", "url": "https://doi.org/10.1016/B978-0-12-816413-6.00023-X", "evidence_list": [ { "evidence": "While the use of VOCs to diagnose wounds is in its infancy, limited results show promise, including early results on the detection of bacterial infections in diabetic foot ulcers using an eNose." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4095", "collision": 1 }, { "biomarker_id": "AN4456-1", "biomarker_component": [ { "biomarker": "decreased LCR ratio", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte to C-reactive protein ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased LCR ratio", "assessed_biomarker_entity": { "recommended_name": "Lymphocyte to C-reactive protein ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.", "journal": "Journal of clinical medicine research", "authors": "Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, Haq S, Madara J, Boigon M, Haas DC, Fischman DL", "date": "2020-07-14", "evidence": [], "reference": [ { "id": "32655735", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735" } ] }, { "title": "Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.", "journal": "Journal of clinical medicine research", "authors": "Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, Haq S, Madara J, Boigon M, Haas DC, Fischman DL", "date": "2020-07-14", "evidence": [], "reference": [ { "id": "32655735", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735" } ] } ], "biomarker_canonical_id": "AN4456", "collision": 0 }, { "biomarker_id": "AA4787-1", "biomarker_component": [ { "biomarker": "increased SIGLEC1 level", "assessed_biomarker_entity": { "recommended_name": "Sialoadhesin", "synonyms": [ { "synonym": "Sialic acid-binding Ig-like lectin 1" }, { "synonym": "Siglec-1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZZ2", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "33206973", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33206973", "evidence_list": [ { "evidence": "mCD169 could predict SARS-CoV-2 infection at hospital admission during the outbreak. This biomarker could be relevant for triage and rapid therapeutic decision in patients suspected of acute viral infections since mCD169 can be overexpressed in other infections responsible of outbreaks such as influenza or dengue fever." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33206973", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33206973", "evidence_list": [ { "evidence": "mCD169 could predict SARS-CoV-2 infection at hospital admission during the outbreak. This biomarker could be relevant for triage and rapid therapeutic decision in patients suspected of acute viral infections since mCD169 can be overexpressed in other infections responsible of outbreaks such as influenza or dengue fever." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Monocyte CD169 Expression as a Biomarker in the Early Diagnosis of Coronavirus Disease 2019.", "journal": "The Journal of infectious diseases", "authors": "Bedin AS, Makinson A, Picot MC, Mennechet F, Malergue F, Pisoni A, Nyiramigisha E, Montagnier L, Bollore K, Debiesse S, Morquin D, Veyrenche N, Renault C, Foulongne V, Bret C, Bourdin A, Le Moing V, Van de Perre P, Tuaillon E", "date": "2020-11-19", "evidence": [], "reference": [ { "id": "33206973", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33206973" } ] } ], "biomarker_canonical_id": "AA4787", "collision": 1 }, { "biomarker_id": "AA4787-2", "biomarker_component": [ { "biomarker": "increased SIGLEC1 level", "assessed_biomarker_entity": { "recommended_name": "Sialoadhesin", "synonyms": [ { "synonym": "Sialic acid-binding Ig-like lectin 1" }, { "synonym": "Siglec-1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZZ2", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26509874", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26509874", "evidence_list": [ { "evidence": "Quantitative analysis revealed that the percentages of circulating CD14+CD169+ monocytes from the patients were significantly higher than from HC (18.21% vs. 1.42%, P<0.0001; Fig 1C). Hence, significantly increased percentages of circulating CD14+CD169+ monocytes existed in CRC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "26509874", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26509874", "evidence_list": [ { "evidence": "Quantitative analysis revealed that the percentages of circulating CD14+CD169+ monocytes from the patients were significantly higher than from HC (18.21% vs. 1.42%, P<0.0001; Fig 1C). Hence, significantly increased percentages of circulating CD14+CD169+ monocytes existed in CRC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.", "journal": "PloS one", "authors": "Li C, Luo X, Lin Y, Tang X, Ling L, Wang L, Jiang Y", "date": "2015-10-29", "evidence": [], "reference": [ { "id": "26509874", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26509874" } ] } ], "biomarker_canonical_id": "AA4787", "collision": 1 }, { "biomarker_id": "AA4788-1", "biomarker_component": [ { "biomarker": "increased VWF level", "assessed_biomarker_entity": { "recommended_name": "von Willebrand factor", "synonyms": [ { "synonym": "vWF" } ] }, "assessed_biomarker_entity_id": "UPKB:P04275", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "41867-3" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "41867-3" } ], "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.", "journal": "The Lancet. Haematology", "authors": "Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32619411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411" } ] } ], "biomarker_canonical_id": "AA4788", "collision": 1 }, { "biomarker_id": "AA4788-2", "biomarker_component": [ { "biomarker": "increased VWF level", "assessed_biomarker_entity": { "recommended_name": "von Willebrand factor", "synonyms": [ { "synonym": "vWF" } ] }, "assessed_biomarker_entity_id": "UPKB:P04275", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "41867-3" } ], "evidence_source": [ { "id": "30386613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30386613", "evidence_list": [ { "evidence": "The VWF: Ag levels were higher in patients with severe liver fibrosis stage and/or HCC development than in those without. The area under the curve of VWF: Ag for diagnosis of severe liver fibrosis stage was 0.721. Multivariable analysis showed that only VWF: Ag was a predictive biomarker for HCC development." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "30386613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30386613", "evidence_list": [ { "evidence": "The VWF: Ag levels were higher in patients with severe liver fibrosis stage and/or HCC development than in those without. The area under the curve of VWF: Ag for diagnosis of severe liver fibrosis stage was 0.721. Multivariable analysis showed that only VWF: Ag was a predictive biomarker for HCC development." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.", "journal": "United European gastroenterology journal", "authors": "Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H", "date": "2018-11-06", "evidence": [], "reference": [ { "id": "30386613", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30386613" } ] } ], "biomarker_canonical_id": "AA4788", "collision": 1 }, { "biomarker_id": "AA4789-1", "biomarker_component": [ { "biomarker": "increased SELP level", "assessed_biomarker_entity": { "recommended_name": "P-selectin", "synonyms": [ { "synonym": "CD62 antigen-like family member P" }, { "synonym": "Granule membrane protein 140" }, { "synonym": "GMP-140" }, { "synonym": "Leukocyte-endothelial cell adhesion molecule 3" }, { "synonym": "LECAM3" }, { "synonym": "Platelet activation dependent granule-external membrane protein" }, { "synonym": "PADGEM" } ] }, "assessed_biomarker_entity_id": "UPKB:P16109", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17181-9" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "17181-9" } ], "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. P-selectin and sCD40L contribute to thrombosis by supporting platelet-myeloid heteroaggregate formation and thrombi stability by interaction with PSGL-1 and alpha IIb beta3, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. P-selectin and sCD40L contribute to thrombosis by supporting platelet-myeloid heteroaggregate formation and thrombi stability by interaction with PSGL-1 and alpha IIb beta3, respectively." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease.", "journal": "Circulation research", "authors": "Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, Hochman J, Berger JS", "date": "2020-08-08", "evidence": [], "reference": [ { "id": "32757722", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722" } ] }, { "title": "Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.", "journal": "The Lancet. Haematology", "authors": "Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32619411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411" } ] } ], "biomarker_canonical_id": "AA4789", "collision": 1 }, { "biomarker_id": "AA4790-1", "biomarker_component": [ { "biomarker": "increased CD40LG level", "assessed_biomarker_entity": { "recommended_name": "CD40 ligand", "synonyms": [ { "synonym": "CD40-L" }, { "synonym": "T-cell antigen Gp39" }, { "synonym": "TNF-related activation protein" }, { "synonym": "TRAP" }, { "synonym": "Tumor necrosis factor ligand superfamily member 5" } ] }, "assessed_biomarker_entity_id": "UPKB:P29965", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "14760083", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/14760083", "evidence_list": [ { "evidence": "Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P < 0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P < 0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/ml; P < 0.05). sCD40L levels significantly correlated with sP-selectin (P < 0.001), prothrombin fragment 1 + 2 (P < 0.001), or thrombin-antithrombin III complex (P < 0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "14760083", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/14760083", "evidence_list": [ { "evidence": "Patients with lung cancer had median sCD40L levels higher than in control subjects (0.46 versus 0.13 ng/ml; P < 0.0001), although correlation with the stage of disease was not evident. Nonetheless, sCD40L levels were significantly higher in squamous cancer compared with adenocarcinoma (0.75 versus 0.27 ng/ml; P < 0.05). Moreover, median sCD40L levels were higher in stage IV compared with nonmetastatic squamous lung cancer (1.02 versus 0.61 ng/ml; P < 0.05). sCD40L levels significantly correlated with sP-selectin (P < 0.001), prothrombin fragment 1 + 2 (P < 0.001), or thrombin-antithrombin III complex (P < 0.05) in squamous lung cancer, but only sP-selectin (P = 0.011) was independently related to sCD40L." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Soluble CD40 ligand plasma levels in lung cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Roselli M, Mineo TC, Basili S, Martini F, Mariotti S, Aloe S, Del Monte G, Ambrogi V, Spila A, Palmirotta R, D'Alessandro R, Dav\u00ec G, Guadagni F, Ferroni P", "date": "2004-02-05", "evidence": [], "reference": [ { "id": "14760083", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/14760083" } ] } ], "biomarker_canonical_id": "AA4790", "collision": 1 }, { "biomarker_id": "AA4790-2", "biomarker_component": [ { "biomarker": "increased CD40LG level", "assessed_biomarker_entity": { "recommended_name": "CD40 ligand", "synonyms": [ { "synonym": "CD40-L" }, { "synonym": "T-cell antigen Gp39" }, { "synonym": "TNF-related activation protein" }, { "synonym": "TRAP" }, { "synonym": "Tumor necrosis factor ligand superfamily member 5" } ] }, "assessed_biomarker_entity_id": "UPKB:P29965", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "24745825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24745825", "evidence_list": [ { "evidence": "Serum sCD40L levels were significantly higher in PDAC group compared with non-cancer groups in both training (p < 0.05) and validation (p < 0.05 datasets. Kaplan-Meier survival analysis demonstrated patients with high-serum sCD40L (> 35,000 ng/ml) had a poorer prognosis than those with low serum sCD40L (log-rank, p = 0.015). Serum sCD40L is correlated with immunosuppression and angiogenesis in PDAC carcinogenesis/progression, and is a promising diagnostic and prognostic biomarker for PDAC superior to CA19-9 and CEA." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "24745825", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24745825", "evidence_list": [ { "evidence": "Serum sCD40L levels were significantly higher in PDAC group compared with non-cancer groups in both training (p < 0.05) and validation (p < 0.05 datasets. Kaplan-Meier survival analysis demonstrated patients with high-serum sCD40L (> 35,000 ng/ml) had a poorer prognosis than those with low serum sCD40L (log-rank, p = 0.015). Serum sCD40L is correlated with immunosuppression and angiogenesis in PDAC carcinogenesis/progression, and is a promising diagnostic and prognostic biomarker for PDAC superior to CA19-9 and CEA." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.", "journal": "Journal of translational medicine", "authors": "Chung HW, Lim JB", "date": "2014-04-22", "evidence": [], "reference": [ { "id": "24745825", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24745825" } ] } ], "biomarker_canonical_id": "AA4790", "collision": 1 }, { "biomarker_id": "AA4790-3", "biomarker_component": [ { "biomarker": "increased CD40LG level", "assessed_biomarker_entity": { "recommended_name": "CD40 ligand", "synonyms": [ { "synonym": "CD40-L" }, { "synonym": "T-cell antigen Gp39" }, { "synonym": "TNF-related activation protein" }, { "synonym": "TRAP" }, { "synonym": "Tumor necrosis factor ligand superfamily member 5" } ] }, "assessed_biomarker_entity_id": "UPKB:P29965", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. P-selectin and sCD40L contribute to thrombosis by supporting platelet-myeloid heteroaggregate formation and thrombi stability by interaction with PSGL-1 and alpha IIb beta3, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "We also show that critical illness is associated with further elevations in VWF, as well as increases in soluble P-selectin and sCD40L when compared with controls. Together, these results provide biochemical evidence that endotheliopathy and platelet activation are ubiquitous in COVID-19-associated coagulopathy and might play key roles in the progression of disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. P-selectin and sCD40L contribute to thrombosis by supporting platelet-myeloid heteroaggregate formation and thrombi stability by interaction with PSGL-1 and alpha IIb beta3, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.", "journal": "The Lancet. Haematology", "authors": "Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32619411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411" } ] }, { "title": "Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease.", "journal": "Circulation research", "authors": "Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, Hochman J, Berger JS", "date": "2020-08-08", "evidence": [], "reference": [ { "id": "32757722", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722" } ] } ], "biomarker_canonical_id": "AA4790", "collision": 1 }, { "biomarker_id": "AA4791-1", "biomarker_component": [ { "biomarker": "increased THBD level", "assessed_biomarker_entity": { "recommended_name": "Thrombomodulin", "synonyms": [ { "synonym": "TM" }, { "synonym": "Fetomodulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P07204", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "11570577", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11570577", "evidence_list": [ { "evidence": "The preoperative plasma TM level of patients with HCC (10.2+/-5.7 ng/ml) was significantly higher than that of those patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml) and that of normal controls (5.7+/-1.0 ng/ml), respectively (P<0.05). Plasma TM increases in patients with HCC and can be a biomarker of the formation of PVTT." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "11570577", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11570577", "evidence_list": [ { "evidence": "The preoperative plasma TM level of patients with HCC (10.2+/-5.7 ng/ml) was significantly higher than that of those patients with benign liver-occupying lesion (6.1+/-2.2 ng/ml) and that of normal controls (5.7+/-1.0 ng/ml), respectively (P<0.05). Plasma TM increases in patients with HCC and can be a biomarker of the formation of PVTT." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The potential of plasma thrombomodulin as a biomarker of portal vein tumor thrombus in hepatocellular carcinoma.", "journal": "Journal of cancer research and clinical oncology", "authors": "Zhou J, Tang ZY, Fan J, Wu ZQ, Ji Y, Ye SL", "date": "2001-09-26", "evidence": [], "reference": [ { "id": "11570577", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11570577" } ] } ], "biomarker_canonical_id": "AA4791", "collision": 1 }, { "biomarker_id": "AN4097-1", "biomarker_component": [ { "biomarker": "decreased THBD level", "assessed_biomarker_entity": { "recommended_name": "Thrombomodulin", "synonyms": [ { "synonym": "TM" }, { "synonym": "Fetomodulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P07204", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "23918310", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23918310", "evidence_list": [ { "evidence": "The migratory ability of ovarian cancer cells was enhanced dramatically after TM silencing. TM overexpression in ovarian cells suppressed the proliferation and migration capability. Furthermore, we found that skov-3 cells treated with TM shRNA expressed high levels of fibronectin and vimentin and that the expression of these markers correlated positively with their migratory ability. Our results demonstrate that TM expression may regulate cell growth and migration in ovarian cancer cells. This finding suggests that TM may be a novel prognostic and therapeutic target for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "23918310", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23918310", "evidence_list": [ { "evidence": "The migratory ability of ovarian cancer cells was enhanced dramatically after TM silencing. TM overexpression in ovarian cells suppressed the proliferation and migration capability. Furthermore, we found that skov-3 cells treated with TM shRNA expressed high levels of fibronectin and vimentin and that the expression of these markers correlated positively with their migratory ability. Our results demonstrate that TM expression may regulate cell growth and migration in ovarian cancer cells. This finding suggests that TM may be a novel prognostic and therapeutic target for ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Thrombomodulin mediates the progression of epithelial ovarian cancer cells.", "journal": "Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine", "authors": "Chen LM, Wang W, Lee JC, Chiu FH, Wu CT, Tai CJ, Wang CK, Tai CJ, Huang MT, Chang YJ", "date": "2013-08-07", "evidence": [], "reference": [ { "id": "23918310", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23918310" } ] } ], "biomarker_canonical_id": "AN4097", "collision": 1 }, { "biomarker_id": "AA4791-2", "biomarker_component": [ { "biomarker": "increased THBD level", "assessed_biomarker_entity": { "recommended_name": "Thrombomodulin", "synonyms": [ { "synonym": "TM" }, { "synonym": "Fetomodulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P07204", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "In all patients, soluble thrombomodulin concentrations greater than 3.26 ng/mL were associated with lower rates of hospital discharge (22 [88%] of 25 patients with low concentrations vs 13 [52%] of 25 patients with high concentrations; p=0.0050) and lower likelihood of survival on Kaplan-Meier analysis (hazard ratio 5.9, 95% CI 1.9-18.4; p=0.0087)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32619411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411", "evidence_list": [ { "evidence": "In all patients, soluble thrombomodulin concentrations greater than 3.26 ng/mL were associated with lower rates of hospital discharge (22 [88%] of 25 patients with low concentrations vs 13 [52%] of 25 patients with high concentrations; p=0.0050) and lower likelihood of survival on Kaplan-Meier analysis (hazard ratio 5.9, 95% CI 1.9-18.4; p=0.0087)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.", "journal": "The Lancet. Haematology", "authors": "Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI", "date": "2020-07-04", "evidence": [], "reference": [ { "id": "32619411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32619411" } ] } ], "biomarker_canonical_id": "AA4791", "collision": 1 }, { "biomarker_id": "AA4793-1", "biomarker_component": [ { "biomarker": "increased EDN1 level", "assessed_biomarker_entity": { "recommended_name": "Endothelin-1", "synonyms": [ { "synonym": "Preproendothelin-1" }, { "synonym": "PPET1" } ] }, "assessed_biomarker_entity_id": "UPKB:P05305", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26537720", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26537720", "evidence_list": [ { "evidence": "Serum big ET-1 levels may be useful as a diagnostic tool in OSCC and as an adjunct to OSCC staging. By comparing the mean of the big ET-1 concentrations of cases and controls, the independent t-test revealed significant higher big ET-1 concentration of OSCC cases when compared to controls (p<0.0001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "26537720", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26537720", "evidence_list": [ { "evidence": "Serum big ET-1 levels may be useful as a diagnostic tool in OSCC and as an adjunct to OSCC staging. By comparing the mean of the big ET-1 concentrations of cases and controls, the independent t-test revealed significant higher big ET-1 concentration of OSCC cases when compared to controls (p<0.0001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum big endothelin-1 as a biomarker in oral squamous cell carcinoma patients: an analytical study.", "journal": "Journal of applied oral science : revista FOB", "authors": "Mankapure PK, Barpande SR, Bhavthankar JD, Mandale M", "date": "2015-11-06", "evidence": [], "reference": [ { "id": "26537720", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26537720" } ] } ], "biomarker_canonical_id": "AA4793", "collision": 1 }, { "biomarker_id": "AA4793-2", "biomarker_component": [ { "biomarker": "increased EDN1 level", "assessed_biomarker_entity": { "recommended_name": "Endothelin-1", "synonyms": [ { "synonym": "Preproendothelin-1" }, { "synonym": "PPET1" } ] }, "assessed_biomarker_entity_id": "UPKB:P05305", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "10.33218/001c.13525", "database": "Doi", "url": "https://doi.org/10.33218/001c.13525", "evidence_list": [ { "evidence": "We propose that elevated circulating ET-1 levels might also serve as a prominent biomarker and prognostic tool to identify individuals with the greatest risks of severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.33218/001c.13525", "database": "Doi", "url": "https://doi.org/10.33218/001c.13525", "evidence_list": [ { "evidence": "We propose that elevated circulating ET-1 levels might also serve as a prominent biomarker and prognostic tool to identify individuals with the greatest risks of severe COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AA4793", "collision": 1 }, { "biomarker_id": "AN4098-1", "biomarker_component": [ { "biomarker": "increased CFDNA level", "assessed_biomarker_entity": { "recommended_name": "Cell-free DNA", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C156117", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "75605-6" } ], "evidence_source": [ { "id": "29175734", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29175734", "evidence_list": [ { "evidence": "Baseline cfDNA concentration correlated with pre-treatment tumour burden (p = 0.52, P < 0.001). Baseline cfDNA levels correlated significantly with hazard of death and overall survival, and a cut off value of 89 pg/ul identified two distinct prognostic groups (HR = 2.22 for high cfDNA, P = 0.004). Patients with cfDNA 89 pg/ul had shorter OS (10.0 versus 22.7 months, P = 0.009; HR = 2.22 for high cfDNA, P = 0.004) In addition, the ratio between baseline cfDNA and tumour burden was prognostic (HR = 2.7 for cfDNA/tumour volume 8 pg/(l*cm3), P = 0.024). Plasma cfDNA level correlates to tumour volume and is a surrogate biomarker for tumour burden and a prognostic marker for survival in metastatic melanoma patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "29175734", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29175734", "evidence_list": [ { "evidence": "Baseline cfDNA concentration correlated with pre-treatment tumour burden (p = 0.52, P < 0.001). Baseline cfDNA levels correlated significantly with hazard of death and overall survival, and a cut off value of 89 pg/ul identified two distinct prognostic groups (HR = 2.22 for high cfDNA, P = 0.004). Patients with cfDNA 89 pg/ul had shorter OS (10.0 versus 22.7 months, P = 0.009; HR = 2.22 for high cfDNA, P = 0.004) In addition, the ratio between baseline cfDNA and tumour burden was prognostic (HR = 2.7 for cfDNA/tumour volume 8 pg/(l*cm3), P = 0.024). Plasma cfDNA level correlates to tumour volume and is a surrogate biomarker for tumour burden and a prognostic marker for survival in metastatic melanoma patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.", "journal": "European journal of cancer (Oxford, England : 1990)", "authors": "Valpione S, Gremel G, Mundra P, Middlehurst P, Galvani E, Girotti MR, Lee RJ, Garner G, Dhomen N, Lorigan PC, Marais R", "date": "2017-11-28", "evidence": [], "reference": [ { "id": "29175734", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29175734" } ] } ], "biomarker_canonical_id": "AN4098", "collision": 1 }, { "biomarker_id": "AN4098-2", "biomarker_component": [ { "biomarker": "increased CFDNA level", "assessed_biomarker_entity": { "recommended_name": "Cell-free DNA", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C156117", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "Cell-free DNA strongly correlated with absolute neutrophil count. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32511633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633", "evidence_list": [ { "evidence": "Cell-free DNA strongly correlated with absolute neutrophil count. In summary, these data reveal high levels of NETs in many patients with COVID-19, where they may contribute to cytokine release and respiratory failure." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, Blair C, Weber A, Barnes BJ, Egeblad M, Woods RJ, Kanthi Y, Knight JS", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511633" } ] } ], "biomarker_canonical_id": "AN4098", "collision": 1 }, { "biomarker_id": "AA4795-1", "biomarker_component": [ { "biomarker": "increased OXLDL level", "assessed_biomarker_entity": { "recommended_name": "Oxidized low-density lipoprotein", "synonyms": [] }, "assessed_biomarker_entity_id": "CHEBI:39026", "assessed_entity_type": "lipoprotein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "54238-1" } ], "evidence_source": [ { "id": "15533907", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15533907", "evidence_list": [ { "evidence": "Higher levels of serum oxLDL may increase risk of colorectal cancer. Cases included both colon and rectal cancers. Risk for colon cancer only was increased with high serum oxLDL levels after adjusting for gender, age, study area, and potential confounders." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "15533907", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15533907", "evidence_list": [ { "evidence": "Higher levels of serum oxLDL may increase risk of colorectal cancer. Cases included both colon and rectal cancers. Risk for colon cancer only was increased with high serum oxLDL levels after adjusting for gender, age, study area, and potential confounders." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum oxidized low-density lipoprotein levels and risk of colorectal cancer: a case-control study nested in the Japan Collaborative Cohort Study.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Toyoshima H, Kojima M, Tokudome S, Hayakawa N, Watanabe Y, Tamakoshi K, Suzuki S, Ozasa K, Tamakoshi A, None None", "date": "2004-11-10", "evidence": [], "reference": [ { "id": "15533907", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15533907" } ] } ], "biomarker_canonical_id": "AA4795", "collision": 1 }, { "biomarker_id": "AN4099-1", "biomarker_component": [ { "biomarker": "decreased OXLDL level", "assessed_biomarker_entity": { "recommended_name": "Oxidized low-density lipoprotein", "synonyms": [] }, "assessed_biomarker_entity_id": "CHEBI:39026", "assessed_entity_type": "lipoprotein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "10.2139/ssrn.3552854", "database": "Doi", "url": "https://doi.org/10.2139/ssrn.3552854", "evidence_list": [ { "evidence": "SARS-COV-2 infection caused an LDL decrease to occur in the majority of the mild cases; this could be used, in combination with viral RNA detection, as a potential biomarker to facilitate early diagnosis. Serum cancer biomarkers, including CYFRA21-1 and HE4, can be used to monitor the pathological progression of the disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.2139/ssrn.3552854", "database": "Doi", "url": "https://doi.org/10.2139/ssrn.3552854", "evidence_list": [ { "evidence": "SARS-COV-2 infection caused an LDL decrease to occur in the majority of the mild cases; this could be used, in combination with viral RNA detection, as a potential biomarker to facilitate early diagnosis. Serum cancer biomarkers, including CYFRA21-1 and HE4, can be used to monitor the pathological progression of the disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4099", "collision": 1 }, { "biomarker_id": "AN4100-1", "biomarker_component": [ { "biomarker": "increased SC2 level", "assessed_biomarker_entity": { "recommended_name": "Severe acute respiratory syndrome coronavirus 2 RNA", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:2697049", "assessed_entity_type": "RNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "94660-8" } ], "evidence_source": [ { "id": "10.2139/ssrn.3552854", "database": "Doi", "url": "https://doi.org/10.2139/ssrn.3552854", "evidence_list": [ { "evidence": "SARS-COV-2 infection caused an LDL decrease to occur in the majority of the mild cases; this could be used, in combination with viral RNA detection, as a potential biomarker to facilitate early diagnosis. Serum cancer biomarkers, including CYFRA21-1 and HE4, can be used to monitor the pathological progression of the disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.2139/ssrn.3552854", "database": "Doi", "url": "https://doi.org/10.2139/ssrn.3552854", "evidence_list": [ { "evidence": "SARS-COV-2 infection caused an LDL decrease to occur in the majority of the mild cases; this could be used, in combination with viral RNA detection, as a potential biomarker to facilitate early diagnosis. Serum cancer biomarkers, including CYFRA21-1 and HE4, can be used to monitor the pathological progression of the disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4100", "collision": 1 }, { "biomarker_id": "AA4796-1", "biomarker_component": [ { "biomarker": "increased NPPB level", "assessed_biomarker_entity": { "recommended_name": "N-terminal pro-brain natriuretic peptide", "synonyms": [ { "synonym": "Brain natriuretic factor prohormone" }, { "synonym": "preproBNP" }, { "synonym": "proBNP" }, { "synonym": "Gamma-brain natriuretic peptide" }, { "synonym": "Iso-ANP" } ] }, "assessed_biomarker_entity_id": "UPKB:P16860", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71425-3" } ], "evidence_source": [ { "id": "20837460", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20837460", "evidence_list": [ { "evidence": "Among 35 patients with lung cancer, 26 (74%) had elevated NT-proBNP (>/= 125 pg/mL), versus 9 (26%) with NT-proBNP < 125 pg/mL (P < .0001). By multivariate analysis, the presence of lung cancer was an independent risk factor for a level of NT-proBNP >/= 125 pg/mL (odds ratio, 7; 95% CI, 2.9-17; P < .0001). In our study, patients with lung cancer were 7 times more likely to have elevated NT-proBNP (>/= 125 pg/mL)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "20837460", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20837460", "evidence_list": [ { "evidence": "Among 35 patients with lung cancer, 26 (74%) had elevated NT-proBNP (>/= 125 pg/mL), versus 9 (26%) with NT-proBNP < 125 pg/mL (P < .0001). By multivariate analysis, the presence of lung cancer was an independent risk factor for a level of NT-proBNP >/= 125 pg/mL (odds ratio, 7; 95% CI, 2.9-17; P < .0001). In our study, patients with lung cancer were 7 times more likely to have elevated NT-proBNP (>/= 125 pg/mL)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer?", "journal": "Clinical lung cancer", "authors": "Aujollet N, Meyer M, Cailliod R, Combier F, Coignet Y, Campard S, Facy O, Bernard A, Girard C", "date": "2010-09-15", "evidence": [], "reference": [ { "id": "20837460", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20837460" } ] } ], "biomarker_canonical_id": "AA4796", "collision": 1 }, { "biomarker_id": "AA4796-2", "biomarker_component": [ { "biomarker": "increased NPPB level", "assessed_biomarker_entity": { "recommended_name": "N-terminal pro-brain natriuretic peptide", "synonyms": [ { "synonym": "Brain natriuretic factor prohormone" }, { "synonym": "preproBNP" }, { "synonym": "proBNP" }, { "synonym": "Gamma-brain natriuretic peptide" }, { "synonym": "Iso-ANP" } ] }, "assessed_biomarker_entity_id": "UPKB:P16860", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71425-3" } ], "evidence_source": [ { "id": "32434874", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32434874", "evidence_list": [ { "evidence": "This meta-analysis showed elevated NT-proBNP level was associated with increased mortality in COVID-19 pneumonia." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32434874", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32434874", "evidence_list": [ { "evidence": "This meta-analysis showed elevated NT-proBNP level was associated with increased mortality in COVID-19 pneumonia." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated N-terminal pro-brain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis.", "journal": "Postgraduate medical journal", "authors": "Pranata R, Huang I, Lukito AA, Raharjo SB", "date": "2020-05-22", "evidence": [], "reference": [ { "id": "32434874", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32434874" } ] } ], "biomarker_canonical_id": "AA4796", "collision": 1 }, { "biomarker_id": "AA4797-1", "biomarker_component": [ { "biomarker": "increased RDW", "assessed_biomarker_entity": { "recommended_name": "Coefficient of RBC distribution width", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C64800", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32296824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824", "evidence_list": [ { "evidence": "We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China.", "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America", "authors": "Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L, Cao J, Tan M, Xu W, Zheng F, Shi Y, Hu B", "date": "2020-04-17", "evidence": [], "reference": [ { "id": "32296824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32296824" } ] } ], "biomarker_canonical_id": "AA4797", "collision": 1 }, { "biomarker_id": "AN4101-1", "biomarker_component": [ { "biomarker": "increased S100A8/S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Calprotectin", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C105971", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "93771-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "93771-4" } ], "evidence_source": [ { "id": "32869342", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32869342", "evidence_list": [ { "evidence": "As compared with serum samples from 47 healthy controls, the COVID-19 samples showed markedly higher levels of calprotectin. Calprotectin levels were significantly higher in those individuals who required mechanical ventilation at any point during their hospitalization (n = 32), as compared with those who did not (P < 0.0001, Fig. 2F). We found that high levels of serum calprotectin on day 1 or 2 of hospitalization tracked with a requirement for mechanical ventilation at any point during the admission." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32810439", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439", "evidence_list": [ { "evidence": "Calprotectin level positively correlates with neutrophil count and disease severity. Expression of the S100A8 and S100A9 genes in peripheral blood nucleated cells of patients with severe COVID-19. This study presents evidence that patients who develop severe COVID-19 exhibit high levels of calprotectin and inflammatory cytokines and chemokines, correlating with emergency myelopoiesis generating ROS- and NOS-expressing immunosuppressive myeloid cells (HLA-DRLow monocytes and immature subsets of neutrophils)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32869342", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32869342", "evidence_list": [ { "evidence": "As compared with serum samples from 47 healthy controls, the COVID-19 samples showed markedly higher levels of calprotectin. Calprotectin levels were significantly higher in those individuals who required mechanical ventilation at any point during their hospitalization (n = 32), as compared with those who did not (P < 0.0001, Fig. 2F). We found that high levels of serum calprotectin on day 1 or 2 of hospitalization tracked with a requirement for mechanical ventilation at any point during the admission." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32810439", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439", "evidence_list": [ { "evidence": "Calprotectin level positively correlates with neutrophil count and disease severity. Expression of the S100A8 and S100A9 genes in peripheral blood nucleated cells of patients with severe COVID-19. This study presents evidence that patients who develop severe COVID-19 exhibit high levels of calprotectin and inflammatory cytokines and chemokines, correlating with emergency myelopoiesis generating ROS- and NOS-expressing immunosuppressive myeloid cells (HLA-DRLow monocytes and immature subsets of neutrophils)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neutrophil calprotectin identifies severe pulmonary disease in COVID-19.", "journal": "Journal of leukocyte biology", "authors": "Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, Blair C, Woodward W, Lezak SP, Lugogo NL, Woods RJ, Lood C, Knight JS, Kanthi Y", "date": "2020-09-02", "evidence": [], "reference": [ { "id": "32869342", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32869342" } ] }, { "title": "Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.", "journal": "Cell", "authors": "Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, H\u00e9non C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V, Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, P\u00e8ne F, Gachot B, Andr\u00e9 F, Zitvogel L, Ginhoux F, Fontenay M, Solary E", "date": "2020-08-19", "evidence": [], "reference": [ { "id": "32810439", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32810439" } ] } ], "biomarker_canonical_id": "AN4101", "collision": 1 }, { "biomarker_id": "AN4101-2", "biomarker_component": [ { "biomarker": "increased S100A8/S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Calprotectin", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C105971", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "93771-4" } ], "evidence_source": [ { "id": "24378824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24378824", "evidence_list": [ { "evidence": "Urothelial malignancies are associated with highly increased concentrations of calprotecin in the urine. In absence of renal failure and pyuria, calprotectin constitutes a promising biomarker for the detection of bladder cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "24378824", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24378824", "evidence_list": [ { "evidence": "Urothelial malignancies are associated with highly increased concentrations of calprotecin in the urine. In absence of renal failure and pyuria, calprotectin constitutes a promising biomarker for the detection of bladder cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder.", "journal": "World journal of urology", "authors": "Ebbing J, Mathia S, Seibert FS, Pagonas N, Bauer F, Erber B, G\u00fcnzel K, Kilic E, Kempkensteffen C, Miller K, Bachmann A, Rosenberger C, Zidek W, Westhoff TH", "date": "2014-01-01", "evidence": [], "reference": [ { "id": "24378824", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24378824" } ] } ], "biomarker_canonical_id": "AN4101", "collision": 1 }, { "biomarker_id": "AN4101-3", "biomarker_component": [ { "biomarker": "increased S100A8/S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Calprotectin", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C105971", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "93771-4" } ], "evidence_source": [ { "id": "33138021", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33138021", "evidence_list": [ { "evidence": "These first results in T2DM patients appear to be a good starting point to investigate the potential role of serum calprotectin as a biomarker in prospective studies." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "33138021", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33138021", "evidence_list": [ { "evidence": "These first results in T2DM patients appear to be a good starting point to investigate the potential role of serum calprotectin as a biomarker in prospective studies." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Determinants of Increased Serum Calprotectin in Patients with Type 2 Diabetes Mellitus.", "journal": "International journal of molecular sciences", "authors": "Oosterwijk MM, Bakker SJL, Nilsen T, Navis G, Laverman GD", "date": "2020-11-04", "evidence": [], "reference": [ { "id": "33138021", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33138021" } ] } ], "biomarker_canonical_id": "AN4101", "collision": 1 }, { "biomarker_id": "AA4798-1", "biomarker_component": [ { "biomarker": "increased MMP8 level", "assessed_biomarker_entity": { "recommended_name": "Matrix metalloproteinase-8", "synonyms": [ { "synonym": "Matrix metalloproteinase-8" }, { "synonym": "MMP-8" }, { "synonym": "PMNL collagenase" }, { "synonym": "PMNL-CL" } ] }, "assessed_biomarker_entity_id": "UPKB:P22894", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "33254580", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33254580", "evidence_list": [ { "evidence": "Periodontitis could be associated with severe COVID-19 infections. According to several studies, the excessive elevation and activation of MMP-8 (aMMP-8) is linked to the progression of periodontitis, which is also reflected in oral fluids." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33254580", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33254580", "evidence_list": [ { "evidence": "Periodontitis could be associated with severe COVID-19 infections. According to several studies, the excessive elevation and activation of MMP-8 (aMMP-8) is linked to the progression of periodontitis, which is also reflected in oral fluids." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Periodontal disease and targeted prevention using aMMP-8 point-of-care oral fluid analytics in the COVID-19 era.", "journal": "Medical hypotheses", "authors": "R\u00e4is\u00e4nen IT, Umeizudike KA, P\u00e4rn\u00e4nen P, Heikkil\u00e4 P, Tervahartiala T, Nwhator SO, Grigoriadis A, Sakellari D, Sorsa T", "date": "2020-12-02", "evidence": [], "reference": [ { "id": "33254580", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33254580" } ] } ], "biomarker_canonical_id": "AA4798", "collision": 1 }, { "biomarker_id": "AA4798-2", "biomarker_component": [ { "biomarker": "increased MMP8 level", "assessed_biomarker_entity": { "recommended_name": "Matrix metalloproteinase-8", "synonyms": [ { "synonym": "Matrix metalloproteinase-8" }, { "synonym": "MMP-8" }, { "synonym": "PMNL collagenase" }, { "synonym": "PMNL-CL" } ] }, "assessed_biomarker_entity_id": "UPKB:P22894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "29808017", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29808017", "evidence_list": [ { "evidence": "The patients with high-serum MMP-8 levels (>100 ng/mL) had poor cancer-specific survival, independent of tumour stage, grade, lymphatic invasion, patient age, BRAF VE1 immunohistochemistry, mismatch repair deficiency, Immunoscore and mGPS. High-serum MMP-8 levels are associated with systemic inflammation and adverse outcome in CRC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "29808017", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29808017", "evidence_list": [ { "evidence": "The patients with high-serum MMP-8 levels (>100 ng/mL) had poor cancer-specific survival, independent of tumour stage, grade, lymphatic invasion, patient age, BRAF VE1 immunohistochemistry, mismatch repair deficiency, Immunoscore and mGPS. High-serum MMP-8 levels are associated with systemic inflammation and adverse outcome in CRC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer.", "journal": "British journal of cancer", "authors": "Sirni\u00f6 P, Tuomisto A, Tervahartiala T, Sorsa T, Klintrup K, Karhu T, Herzig KH, M\u00e4kel\u00e4 J, Karttunen TJ, Salo T, M\u00e4kinen MJ, V\u00e4yrynen JP", "date": "2018-05-29", "evidence": [], "reference": [ { "id": "29808017", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29808017" } ] } ], "biomarker_canonical_id": "AA4798", "collision": 1 }, { "biomarker_id": "AN4102-1", "biomarker_component": [ { "biomarker": "decreased PTGDR2 level", "assessed_biomarker_entity": { "recommended_name": "Prostaglandin D2 receptor 2", "synonyms": [ { "synonym": "Chemoattractant receptor-homologous molecule expressed on Th2 cells" }, { "synonym": "G-protein coupled receptor 44" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y5Y4", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "3294161", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/3294161", "evidence_list": [ { "evidence": "COVID-19 alters the frequency and functional phenotypes of granulocyte subsets with the emergence of CRTH2 as a disease biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "3294161", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/3294161", "evidence_list": [ { "evidence": "COVID-19 alters the frequency and functional phenotypes of granulocyte subsets with the emergence of CRTH2 as a disease biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21.", "journal": "Genomics", "authors": "Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB, Ruddle FH", "date": "1988-04-01", "evidence": [], "reference": [ { "id": "3294161", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/3294161" } ] } ], "biomarker_canonical_id": "AN4102", "collision": 1 }, { "biomarker_id": "AA4799-1", "biomarker_component": [ { "biomarker": "increased TGFBI level", "assessed_biomarker_entity": { "recommended_name": "Transforming growth factor-beta-induced protein", "synonyms": [ { "synonym": "Beta ig-h3" }, { "synonym": "Kerato-epithelin" }, { "synonym": "RGD-containing collagen-associated protein" }, { "synonym": "RGD-CAP" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15582", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32937590", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32937590", "evidence_list": [ { "evidence": "We report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor-beta-induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia (n = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32937590", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32937590", "evidence_list": [ { "evidence": "We report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor-beta-induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia (n = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia.", "journal": "Science advances", "authors": "Park HH, Kim HN, Kim H, Yoo Y, Shin H, Choi EY, Bae JS, Lee W", "date": "2020-09-17", "evidence": [], "reference": [ { "id": "32937590", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32937590" } ] } ], "biomarker_canonical_id": "AA4799", "collision": 1 }, { "biomarker_id": "AN4457-1", "biomarker_component": [ { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02461", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:B8V7R6", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P08572", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [ { "synonym": "CPI-B" }, { "synonym": "Liver thiol proteinase inhibitor" }, { "synonym": "Stefin-B" } ] }, "assessed_biomarker_entity_id": "UPKB:P04080", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [ { "synonym": "Alpha-2 type I collagen" } ] }, "assessed_biomarker_entity_id": "UPKB:O46392", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:O35206", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [ { "synonym": "Alpha-2 type I collagen" } ] }, "assessed_biomarker_entity_id": "UPKB:C0HJN6", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [ { "synonym": "Alpha-1 type II collagen" } ] }, "assessed_biomarker_entity_id": "UPKB:P02458", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q14055", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [ { "synonym": "Alpha-1 type I collagen" } ] }, "assessed_biomarker_entity_id": "UPKB:P02452", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P13942", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q14050", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level of 20 urinary peptides", "assessed_biomarker_entity": { "recommended_name": "COVID20 endogenous peptides panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P20908", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32960510", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510", "evidence_list": [ { "evidence": "COVID20 is composed of 20 endogenous peptides mainly derived from various collagen chains that enable differentiating moderate or severe disease from critical state or death with 83% sensitivity at 100% specificity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] }, { "title": "Urinary Proteomics Associates with COVID-19 Severity: Pilot Proof-of-Principle Data and Design of a Multicentric Diagnostic Study.", "journal": "Proteomics", "authors": "Wendt R, Kalbitz S, L\u00fcbbert C, Kellner N, Macholz M, Schroth S, Ermisch J, Latosisnka A, Arnold B, Mischak H, Beige J, Metzger J", "date": "2020-09-23", "evidence": [], "reference": [ { "id": "32960510", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32960510" } ] } ], "biomarker_canonical_id": "AN4457", "collision": 0 }, { "biomarker_id": "AA4800-1", "biomarker_component": [ { "biomarker": "increased TNNT2 level", "assessed_biomarker_entity": { "recommended_name": "High-sensitivity troponin-T", "synonyms": [ { "synonym": "TnTc" }, { "synonym": "Cardiac muscle troponin T" }, { "synonym": "cTnT" } ] }, "assessed_biomarker_entity_id": "UPKB:P45379", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "89575-5" } ], "evidence_source": [ { "id": "33003961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33003961", "evidence_list": [ { "evidence": "In patients hospitalized with COVID-19, hs-TnT identifies patients at high risk for adverse in-hospital events, and trends of hs-TnT over time, particularly during the first day, provide additional prognostic information." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33003961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33003961", "evidence_list": [ { "evidence": "In patients hospitalized with COVID-19, hs-TnT identifies patients at high risk for adverse in-hospital events, and trends of hs-TnT over time, particularly during the first day, provide additional prognostic information." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Association between cardiac troponin I and mortality in patients with COVID-19.", "journal": "Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals", "authors": "Salvatici M, Barbieri B, Cioffi SMG, Morenghi E, Leone FP, Maura F, Moriello G, Sandri MT", "date": "2020-10-03", "evidence": [], "reference": [ { "id": "33003961", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33003961" } ] } ], "biomarker_canonical_id": "AA4800", "collision": 1 }, { "biomarker_id": "AA4801-1", "biomarker_component": [ { "biomarker": "increased LGALS3 level", "assessed_biomarker_entity": { "recommended_name": "Galectin-3", "synonyms": [ { "synonym": "Gal-3" }, { "synonym": "35 kDa lectin" }, { "synonym": "Carbohydrate-binding protein 35" }, { "synonym": "CBP 35" }, { "synonym": "Galactose-specific lectin 3" }, { "synonym": "Galactoside-binding protein" }, { "synonym": "GALBP" }, { "synonym": "IgE-binding protein" }, { "synonym": "L-31" }, { "synonym": "Laminin-binding protein" }, { "synonym": "Lectin L-29" }, { "synonym": "Mac-2 antigen" } ] }, "assessed_biomarker_entity_id": "UPKB:P17931", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32973815", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32973815", "evidence_list": [ { "evidence": "GAL3 could be a good prognostic marker for severe COVID-19 and that elevated plasma levels of GAL3 can participate in triggering the cytokine storm observed in severe COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32973815", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32973815", "evidence_list": [ { "evidence": "GAL3 could be a good prognostic marker for severe COVID-19 and that elevated plasma levels of GAL3 can participate in triggering the cytokine storm observed in severe COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider.", "journal": "Frontiers in immunology", "authors": "Garcia-Revilla J, Deierborg T, Venero JL, Boza-Serrano A", "date": "2020-09-26", "evidence": [], "reference": [ { "id": "32973815", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32973815" } ] } ], "biomarker_canonical_id": "AA4801", "collision": 1 }, { "biomarker_id": "AA4801-2", "biomarker_component": [ { "biomarker": "increased LGALS3 level", "assessed_biomarker_entity": { "recommended_name": "Galectin-3", "synonyms": [ { "synonym": "Gal-3" }, { "synonym": "35 kDa lectin" }, { "synonym": "Carbohydrate-binding protein 35" }, { "synonym": "CBP 35" }, { "synonym": "Galactose-specific lectin 3" }, { "synonym": "Galactoside-binding protein" }, { "synonym": "GALBP" }, { "synonym": "IgE-binding protein" }, { "synonym": "L-31" }, { "synonym": "Laminin-binding protein" }, { "synonym": "Lectin L-29" }, { "synonym": "Mac-2 antigen" } ] }, "assessed_biomarker_entity_id": "UPKB:P17931", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "" } ], "evidence_source": [ { "id": "28085015", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28085015", "evidence_list": [ { "evidence": "High expression of tumoral gal-3 was associated with tumor size, poor differentiation and negatively related to low E-cadherin expression. Multivariate analysis revealed that tumoral gal-3 expression was the only independent predictor of both tumor recurrence and overall survival after resection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "28085015", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28085015", "evidence_list": [ { "evidence": "High expression of tumoral gal-3 was associated with tumor size, poor differentiation and negatively related to low E-cadherin expression. Multivariate analysis revealed that tumoral gal-3 expression was the only independent predictor of both tumor recurrence and overall survival after resection." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Huang Z, Ai Z, Li N, Xi H, Gao X, Wang F, Tan X, Liu H", "date": "2017-01-14", "evidence": [], "reference": [ { "id": "28085015", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28085015" } ] } ], "biomarker_canonical_id": "AA4801", "collision": 1 }, { "biomarker_id": "AA4801-3", "biomarker_component": [ { "biomarker": "increased LGALS3 level", "assessed_biomarker_entity": { "recommended_name": "Galectin-3", "synonyms": [ { "synonym": "Gal-3" }, { "synonym": "35 kDa lectin" }, { "synonym": "Carbohydrate-binding protein 35" }, { "synonym": "CBP 35" }, { "synonym": "Galactose-specific lectin 3" }, { "synonym": "Galactoside-binding protein" }, { "synonym": "GALBP" }, { "synonym": "IgE-binding protein" }, { "synonym": "L-31" }, { "synonym": "Laminin-binding protein" }, { "synonym": "Lectin L-29" }, { "synonym": "Mac-2 antigen" } ] }, "assessed_biomarker_entity_id": "UPKB:P17931", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "25501605", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25501605", "evidence_list": [ { "evidence": "Gal-3 is a promising biomarker for detecting prediabetes and diabetes. Sixty-one patients had prediabetes (Group 1), 57 had diabetes (Group 2), and 56 had neither diabetes nor prediabetes (Group 3) Gal-3 levels were higher in Group 2 than in Groups 1 and 3. [1,053.9 (358.1) and 744.1 (119.3) vs. 481.7 (175.4) pg/mL; P < 0.001." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "25501605", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25501605", "evidence_list": [ { "evidence": "Gal-3 is a promising biomarker for detecting prediabetes and diabetes. Sixty-one patients had prediabetes (Group 1), 57 had diabetes (Group 2), and 56 had neither diabetes nor prediabetes (Group 3) Gal-3 levels were higher in Group 2 than in Groups 1 and 3. [1,053.9 (358.1) and 744.1 (119.3) vs. 481.7 (175.4) pg/mL; P < 0.001." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?", "journal": "Journal of endocrinological investigation", "authors": "Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A", "date": "2014-12-17", "evidence": [], "reference": [ { "id": "25501605", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25501605" } ] } ], "biomarker_canonical_id": "AA4801", "collision": 1 }, { "biomarker_id": "AA4802-1", "biomarker_component": [ { "biomarker": "increased S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Protein S100A9", "synonyms": [ { "synonym": "Calgranulin-B" }, { "synonym": "Calprotectin L1H subunit" }, { "synonym": "Leukocyte L1 complex heavy chain" }, { "synonym": "Migration inhibitory factor-related protein 14" }, { "synonym": "MRP-14" }, { "synonym": "p14" }, { "synonym": "S100 calcium-binding protein A9" } ] }, "assessed_biomarker_entity_id": "UPKB:P06702", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32989935", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32989935", "evidence_list": [ { "evidence": "Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32989935", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32989935", "evidence_list": [ { "evidence": "Among the most highly increased inflammatory mediators in severe/critically ill patients, S100A9, an alarmin and TLR4 ligand, was found as a noteworthy biomarker, because it inversely correlated with the serum albumin levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis.", "journal": "Journal of Korean medical science", "authors": "Sohn KM, Lee SG, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S, Chung C, Park C, Kim YS, Jo EK", "date": "2020-09-30", "evidence": [], "reference": [ { "id": "32989935", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32989935" } ] } ], "biomarker_canonical_id": "AA4802", "collision": 1 }, { "biomarker_id": "AA4802-2", "biomarker_component": [ { "biomarker": "increased S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Protein S100A9", "synonyms": [ { "synonym": "Calgranulin-B" }, { "synonym": "Calprotectin L1H subunit" }, { "synonym": "Leukocyte L1 complex heavy chain" }, { "synonym": "Migration inhibitory factor-related protein 14" }, { "synonym": "MRP-14" }, { "synonym": "p14" }, { "synonym": "S100 calcium-binding protein A9" } ] }, "assessed_biomarker_entity_id": "UPKB:P06702", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "25673070", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25673070", "evidence_list": [ { "evidence": "Serum and mRNA expression levels of S100A8 and S100A9 were found to be upregulated in patients with RCC. The overexpression of S100A8 and S100A9 in cancer cells was also confirmed by immunohistochemistry." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "25673070", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25673070", "evidence_list": [ { "evidence": "Serum and mRNA expression levels of S100A8 and S100A9 were found to be upregulated in patients with RCC. The overexpression of S100A8 and S100A9 in cancer cells was also confirmed by immunohistochemistry." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Proteins S100A8 and S100A9 are potential biomarkers for renal cell carcinoma in the early stages: results from a proteomic study integrated with bioinformatics analysis.", "journal": "Molecular medicine reports", "authors": "Zhang L, Jiang H, Xu G, Wen H, Gu B, Liu J, Mao S, Na R, Jing Y, Ding Q, Zhang Y", "date": "2015-02-13", "evidence": [], "reference": [ { "id": "25673070", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25673070" } ] } ], "biomarker_canonical_id": "AA4802", "collision": 1 }, { "biomarker_id": "AA4802-3", "biomarker_component": [ { "biomarker": "Increased S100A9 level", "assessed_biomarker_entity": { "recommended_name": "Protein S100A9", "synonyms": [ { "synonym": "Calgranulin-B" }, { "synonym": "Calprotectin L1H subunit" }, { "synonym": "Leukocyte L1 complex heavy chain" }, { "synonym": "Migration inhibitory factor-related protein 14" }, { "synonym": "MRP-14" }, { "synonym": "p14" }, { "synonym": "S100 calcium-binding protein A9" } ] }, "assessed_biomarker_entity_id": "UPKB:P06702", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31262951", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31262951", "evidence_list": [ { "evidence": "S100A9 and Galectin-3 are overexpressed in PCDM tumors and mediate insulin resistance. Galectin-3 and S100A9 distinguish PCDM from type 2 diabetes in subjects with new-onset diabetes." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "31262951", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31262951", "evidence_list": [ { "evidence": "S100A9 and Galectin-3 are overexpressed in PCDM tumors and mediate insulin resistance. Galectin-3 and S100A9 distinguish PCDM from type 2 diabetes in subjects with new-onset diabetes." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer-Associated Diabetes.", "journal": "Diabetes care", "authors": "Liao WC, Huang BS, Yu YH, Yang HH, Chen PR, Huang CC, Huang HY, Wu MS, Chow LP", "date": "2019-07-03", "evidence": [], "reference": [ { "id": "31262951", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31262951" } ] } ], "biomarker_canonical_id": "AA4802", "collision": 1 }, { "biomarker_id": "AA4803-1", "biomarker_component": [ { "biomarker": "increased NEFL level", "assessed_biomarker_entity": { "recommended_name": "Neurofilament light chain", "synonyms": [ { "synonym": "NF-L" }, { "synonym": "68 kDa neurofilament protein" }, { "synonym": "Neurofilament triplet L protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P07196", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "33875374", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33875374", "evidence_list": [ { "evidence": "COVID-19 patients who later developed intensive care unit acquired weakness had significantly higher NfL and GFAp in the early phase of ICU care." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33875374", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33875374", "evidence_list": [ { "evidence": "COVID-19 patients who later developed intensive care unit acquired weakness had significantly higher NfL and GFAp in the early phase of ICU care." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study.", "journal": "Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology", "authors": "Frithiof R, Rostami E, Kumlien E, Virhammar J, F\u00e4llmar D, Hultstr\u00f6m M, Lipcsey M, Ashton N, Blennow K, Zetterberg H, Punga AR", "date": "2021-04-21", "evidence": [], "reference": [ { "id": "33875374", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33875374" } ] } ], "biomarker_canonical_id": "AA4803", "collision": 1 }, { "biomarker_id": "AA4803-2", "biomarker_component": [ { "biomarker": "increased NEFL level", "assessed_biomarker_entity": { "recommended_name": "Neurofilament light chain", "synonyms": [ { "synonym": "NF-L" }, { "synonym": "68 kDa neurofilament protein" }, { "synonym": "Neurofilament triplet L protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P07196", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "33023150", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33023150", "evidence_list": [ { "evidence": "The median NfL level was significantly higher in patients with brain metastases than in patients without (35 versus 16 pg/mL, p = 0.001) and separated patients with an area under the curve of 0.77 (0.66-0.89). An increase in NfL could be measured median 3 months (range: 1-5) before the brain metastasis diagnosis. Further, a high level of NfL at time of brain metastasis diagnosis correlated with an inferior survival (hazard ratio: 2.10 (95% confidence interval: 1.11-3.98))." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1319", "recommended_name": { "id": "DOID:1319", "name": "brain cancer", "description": "A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, "synonyms": [ { "id": "DOID:1319", "name": "malignant brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "BT - Brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult malignant brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary malignant neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of adult brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "tumor of the Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm, adult", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" } ] }, "evidence_source": [ { "id": "33023150", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33023150", "evidence_list": [ { "evidence": "The median NfL level was significantly higher in patients with brain metastases than in patients without (35 versus 16 pg/mL, p = 0.001) and separated patients with an area under the curve of 0.77 (0.66-0.89). An increase in NfL could be measured median 3 months (range: 1-5) before the brain metastasis diagnosis. Further, a high level of NfL at time of brain metastasis diagnosis correlated with an inferior survival (hazard ratio: 2.10 (95% confidence interval: 1.11-3.98))." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neurofilament Light Chain as A Biomarker for Brain Metastases.", "journal": "Cancers", "authors": "Winther-Larsen A, Hviid CVB, Meldgaard P, Sorensen BS, Sandfeld-Paulsen B", "date": "2020-10-08", "evidence": [], "reference": [ { "id": "33023150", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33023150" } ] } ], "biomarker_canonical_id": "AA4803", "collision": 1 }, { "biomarker_id": "AN4116-1", "biomarker_component": [ { "biomarker": "increased GFAP level", "assessed_biomarker_entity": { "recommended_name": "Glial fibrillary acidic protein", "synonyms": [ { "synonym": "GFAP" } ] }, "assessed_biomarker_entity_id": "UPKB:P14136", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "93424-0" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "93424-0" } ], "evidence_source": [ { "id": "10.21203/rs.3.rs-78038/v2", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-78038/v2", "evidence_list": [ { "evidence": "COVID-19 patients who later developed intensive care unit acquired weakness had significantly higher NfL and GFAp in the early phase of ICU care." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "10.21203/rs.3.rs-78038/v2", "database": "Doi", "url": "https://doi.org/10.21203/rs.3.rs-78038/v2", "evidence_list": [ { "evidence": "COVID-19 patients who later developed intensive care unit acquired weakness had significantly higher NfL and GFAp in the early phase of ICU care." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4116", "collision": 1 }, { "biomarker_id": "AA4804-1", "biomarker_component": [ { "biomarker": "increased TXB2 level", "assessed_biomarker_entity": { "recommended_name": "Thromboxane B2", "synonyms": [ { "synonym": "Thromboxane B2" }, { "synonym": "(5Z,13E,15S)-9alpha,11,15-trihydroxythromboxa-5,13-dien-1-oic acid" }, { "synonym": "TXB2" } ] }, "assessed_biomarker_entity_id": "CHEBI:28728", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "3012-2" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "3012-2" } ], "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. Increased plasma TxB2 levels indicate the activation of platelets via COX-1." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. Increased plasma TxB2 levels indicate the activation of platelets via COX-1." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease.", "journal": "Circulation research", "authors": "Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, Hochman J, Berger JS", "date": "2020-08-08", "evidence": [], "reference": [ { "id": "32757722", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722" } ] } ], "biomarker_canonical_id": "AA4804", "collision": 1 }, { "biomarker_id": "AA4804-2", "biomarker_component": [ { "biomarker": "increased TXB2 level", "assessed_biomarker_entity": { "recommended_name": "Thromboxane B2", "synonyms": [ { "synonym": "Thromboxane B2" }, { "synonym": "(5Z,13E,15S)-9alpha,11,15-trihydroxythromboxa-5,13-dien-1-oic acid" }, { "synonym": "TXB2" } ] }, "assessed_biomarker_entity_id": "CHEBI:28728", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "3012-2" } ], "evidence_source": [ { "id": "21983220", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21983220", "evidence_list": [ { "evidence": "We found increased levels of thromboxane B(2) (TXB(2)) the major metabolite of TXAS and increased levels of the TP beta receptor. These results raised the possibility that patients with bladder cancer may be followed for progression or remission of their disease by quantitation of these substances in their urine." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "21983220", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21983220", "evidence_list": [ { "evidence": "We found increased levels of thromboxane B(2) (TXB(2)) the major metabolite of TXAS and increased levels of the TP beta receptor. These results raised the possibility that patients with bladder cancer may be followed for progression or remission of their disease by quantitation of these substances in their urine." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring.", "journal": "Prostaglandins & other lipid mediators", "authors": "Moussa O, Ciupek A, Watson DK, Halushka PV", "date": "2011-10-11", "evidence": [], "reference": [ { "id": "21983220", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21983220" } ] } ], "biomarker_canonical_id": "AA4804", "collision": 1 }, { "biomarker_id": "AA4805-1", "biomarker_component": [ { "biomarker": "increased MPV level", "assessed_biomarker_entity": { "recommended_name": "Mean platelet volume", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74730", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "28542-9" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "28542-9" } ], "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. MPV is a biomarker of platelet hyperactivity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32757722", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722", "evidence_list": [ { "evidence": "Biomarkers of platelet activity and vascular health are significantly associated with the composite outcome of thrombosis or death in hospitalized patients with COVID-19. MPV is a biomarker of platelet hyperactivity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease.", "journal": "Circulation research", "authors": "Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, Hochman J, Berger JS", "date": "2020-08-08", "evidence": [], "reference": [ { "id": "32757722", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32757722" } ] } ], "biomarker_canonical_id": "AA4805", "collision": 1 }, { "biomarker_id": "AA4806-1", "biomarker_component": [ { "biomarker": "decreased MPV", "assessed_biomarker_entity": { "recommended_name": "Mean platelet volume", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74730", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "28542-9" } ], "evidence_source": [ { "id": "30800188", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30800188", "evidence_list": [ { "evidence": "NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "30800188", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30800188", "evidence_list": [ { "evidence": "NRL, PLR, and MPV may be useful markers in diagnostic and early recognition of different stages of CRC; additionally combined all together have stronger diagnostic efficacy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer.", "journal": "Disease markers", "authors": "Stojkovic Lalosevic M, Pavlovic Markovic A, Stankovic S, Stojkovic M, Dimitrijevic I, Radoman Vujacic I, Lalic D, Milovanovic T, Dumic I, Krivokapic Z", "date": "2019-02-26", "evidence": [], "reference": [ { "id": "30800188", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30800188" } ] } ], "biomarker_canonical_id": "AA4806", "collision": 1 }, { "biomarker_id": "AA4807-1", "biomarker_component": [ { "biomarker": "increased C5 level", "assessed_biomarker_entity": { "recommended_name": "Complement C5A", "synonyms": [ { "synonym": "C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P01031", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4505-4" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "4505-4" } ], "evidence_source": [ { "id": "33123364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364", "evidence_list": [ { "evidence": "We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33123364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364", "evidence_list": [ { "evidence": "We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.", "journal": "Clinical kidney journal", "authors": "Prendecki M, Clarke C, Medjeral-Thomas N, McAdoo SP, Sandhu E, Peters JE, Thomas DC, Willicombe M, Botto M, Pickering MC", "date": "2020-10-31", "evidence": [], "reference": [ { "id": "33123364", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364" } ] } ], "biomarker_canonical_id": "AA4807", "collision": 1 }, { "biomarker_id": "AA4807-2", "biomarker_component": [ { "biomarker": "increased C5 level", "assessed_biomarker_entity": { "recommended_name": "Complement C5A", "synonyms": [ { "synonym": "C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P01031", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4505-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "4505-4" } ], "evidence_source": [ { "id": "29423024", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29423024", "evidence_list": [ { "evidence": "Higher C5a concentrations correlated with tumor differentiation and OSCC extension state." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "29423024", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29423024", "evidence_list": [ { "evidence": "Higher C5a concentrations correlated with tumor differentiation and OSCC extension state." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma.", "journal": "Oncotarget", "authors": "Gallenkamp J, Spanier G, W\u00f6rle E, Englbrecht M, Kirschfink M, Greslechner R, Braun R, Sch\u00e4fer N, Bauer RJ, Pauly D", "date": "2018-02-10", "evidence": [], "reference": [ { "id": "29423024", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29423024" } ] } ], "biomarker_canonical_id": "AA4807", "collision": 1 }, { "biomarker_id": "AA4808-1", "biomarker_component": [ { "biomarker": "increased C3 level", "assessed_biomarker_entity": { "recommended_name": "Complement 3A", "synonyms": [ { "synonym": "C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01024", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "33123364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364", "evidence_list": [ { "evidence": "We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33123364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364", "evidence_list": [ { "evidence": "We identified elevated levels of plasma C3a and C5a in HD patients with severe COVID-19 compared with controls. Serial sampling identified that C5a levels were elevated prior to clinical deterioration in patients who developed severe disease. C3a more closely mirrored both clinical and biochemical disease severity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Temporal changes in complement activation in haemodialysis patients with COVID-19 as a predictor of disease progression.", "journal": "Clinical kidney journal", "authors": "Prendecki M, Clarke C, Medjeral-Thomas N, McAdoo SP, Sandhu E, Peters JE, Thomas DC, Willicombe M, Botto M, Pickering MC", "date": "2020-10-31", "evidence": [], "reference": [ { "id": "33123364", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33123364" } ] } ], "biomarker_canonical_id": "AA4808", "collision": 1 }, { "biomarker_id": "AA4808-2", "biomarker_component": [ { "biomarker": "increased C3 level", "assessed_biomarker_entity": { "recommended_name": "Complement 3A", "synonyms": [ { "synonym": "C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01024", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "20012107", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20012107", "evidence_list": [ { "evidence": "C3a fragment is a potential marker for the early detection of HCV-related HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "20012107", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20012107", "evidence_list": [ { "evidence": "C3a fragment is a potential marker for the early detection of HCV-related HCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.", "journal": "Journal of gastroenterology", "authors": "Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO, Tsubouchi H", "date": "2009-12-17", "evidence": [], "reference": [ { "id": "20012107", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20012107" } ] } ], "biomarker_canonical_id": "AA4808", "collision": 1 }, { "biomarker_id": "AA4809-1", "biomarker_component": [ { "biomarker": "increased CX3CL1 level", "assessed_biomarker_entity": { "recommended_name": "Fractalkine", "synonyms": [ { "synonym": "C-X3-C motif chemokine 1" }, { "synonym": "CX3C membrane-anchored chemokine" }, { "synonym": "Neurotactin" }, { "synonym": "Small-inducible cytokine D1" } ] }, "assessed_biomarker_entity_id": "UPKB:P78423", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients.", "journal": "The Journal of infectious diseases", "authors": "Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, Zou L, Xiao W, Zhu Y", "date": "2020-06-26", "evidence": [], "reference": [ { "id": "32582936", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936" } ] } ], "biomarker_canonical_id": "AA4809", "collision": 1 }, { "biomarker_id": "AA4809-2", "biomarker_component": [ { "biomarker": "increased CX3CL1 level", "assessed_biomarker_entity": { "recommended_name": "Fractalkine", "synonyms": [ { "synonym": "C-X3-C motif chemokine 1" }, { "synonym": "CX3C membrane-anchored chemokine" }, { "synonym": "Neurotactin" }, { "synonym": "Small-inducible cytokine D1" } ] }, "assessed_biomarker_entity_id": "UPKB:P78423", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "28845524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28845524", "evidence_list": [ { "evidence": "Fractalkine/CX3CR1 could serve as a diagnostic marker and as a potential target for chemotherapy in early stage pancreatic cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "28845524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28845524", "evidence_list": [ { "evidence": "Fractalkine/CX3CR1 could serve as a diagnostic marker and as a potential target for chemotherapy in early stage pancreatic cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-\u03baB cascade in pancreatic cancer cells.", "journal": "Cell biochemistry and function", "authors": "Wang H, Cai J, Du S, Guo Z, Xin B, Wang J, Wei W, Shen X", "date": "2017-08-29", "evidence": [], "reference": [ { "id": "28845524", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28845524" } ] } ], "biomarker_canonical_id": "AA4809", "collision": 1 }, { "biomarker_id": "AA4810-1", "biomarker_component": [ { "biomarker": "increased VCAM-1 level", "assessed_biomarker_entity": { "recommended_name": "Vascular cell adhesion molecule-1", "synonyms": [ { "synonym": "V-CAM 1" }, { "synonym": "VCAM-1" }, { "synonym": "INCAM-100" } ] }, "assessed_biomarker_entity_id": "UPKB:P19320", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "75627-0" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "75627-0" } ], "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients.", "journal": "The Journal of infectious diseases", "authors": "Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, Zou L, Xiao W, Zhu Y", "date": "2020-06-26", "evidence": [], "reference": [ { "id": "32582936", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936" } ] } ], "biomarker_canonical_id": "AA4810", "collision": 1 }, { "biomarker_id": "AA4810-2", "biomarker_component": [ { "biomarker": "increased VCAM-1 level", "assessed_biomarker_entity": { "recommended_name": "Vascular cell adhesion molecule-1", "synonyms": [ { "synonym": "V-CAM 1" }, { "synonym": "VCAM-1" }, { "synonym": "INCAM-100" } ] }, "assessed_biomarker_entity_id": "UPKB:P19320", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "75627-0" } ], "evidence_source": [ { "id": "24771582", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24771582", "evidence_list": [ { "evidence": "The current findings demonstrate that VCAM1 promotes tumor progression in CRC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "24771582", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24771582", "evidence_list": [ { "evidence": "The current findings demonstrate that VCAM1 promotes tumor progression in CRC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis.", "journal": "International journal of cancer", "authors": "Schlesinger M, Bendas G", "date": "2014-04-29", "evidence": [], "reference": [ { "id": "24771582", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24771582" } ] } ], "biomarker_canonical_id": "AA4810", "collision": 1 }, { "biomarker_id": "AA4811-1", "biomarker_component": [ { "biomarker": "increased ICAM-1 level", "assessed_biomarker_entity": { "recommended_name": "Intercellular adhesion molecule 1", "synonyms": [ { "synonym": "ICAM-1" }, { "synonym": "Major group rhinovirus receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:P05362", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17174-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "17174-4" } ], "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients.", "journal": "The Journal of infectious diseases", "authors": "Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, Zou L, Xiao W, Zhu Y", "date": "2020-06-26", "evidence": [], "reference": [ { "id": "32582936", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936" } ] } ], "biomarker_canonical_id": "AA4811", "collision": 1 }, { "biomarker_id": "AA4812-1", "biomarker_component": [ { "biomarker": "decreased ICAM-1 level", "assessed_biomarker_entity": { "recommended_name": "Intercellular adhesion molecule 1", "synonyms": [ { "synonym": "ICAM-1" }, { "synonym": "Major group rhinovirus receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:P05362", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "17174-4" } ], "evidence_source": [ { "id": "32195055", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32195055", "evidence_list": [ { "evidence": "Improved prognosis was associated with \u2026 decreased Intercellular adhesion molecule 1 (ICAM1) mRNA expression in lung cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32195055", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32195055", "evidence_list": [ { "evidence": "Improved prognosis was associated with \u2026 decreased Intercellular adhesion molecule 1 (ICAM1) mRNA expression in lung cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification and validation of HELLS (Helicase, Lymphoid-Specific) and ICAM1 (Intercellular adhesion molecule 1) as potential diagnostic biomarkers of lung cancer.", "journal": "PeerJ", "authors": "Zhu W, Li LL, Songyang Y, Shi Z, Li D", "date": "2020-03-21", "evidence": [], "reference": [ { "id": "32195055", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32195055" } ] } ], "biomarker_canonical_id": "AA4812", "collision": 1 }, { "biomarker_id": "AA4813-1", "biomarker_component": [ { "biomarker": "increased AOC3 level", "assessed_biomarker_entity": { "recommended_name": "Vascular adhesion protein-1", "synonyms": [ { "synonym": "Copper amine oxidase" }, { "synonym": "HPAO" }, { "synonym": "Semicarbazide-sensitive amine oxidase" }, { "synonym": "SSAO" }, { "synonym": "Vascular adhesion protein 1" }, { "synonym": "VAP-1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16853", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32582936", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936", "evidence_list": [ { "evidence": "Serum levels of fractalkine, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and vascular adhesion protein-1 (VAP-1) were elevated in patients with mild disease, dramatically elevated in severe cases, and decreased in the convalescence phase." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients.", "journal": "The Journal of infectious diseases", "authors": "Tong M, Jiang Y, Xia D, Xiong Y, Zheng Q, Chen F, Zou L, Xiao W, Zhu Y", "date": "2020-06-26", "evidence": [], "reference": [ { "id": "32582936", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32582936" } ] } ], "biomarker_canonical_id": "AA4813", "collision": 1 }, { "biomarker_id": "AA4813-2", "biomarker_component": [ { "biomarker": "increased AOC3 level", "assessed_biomarker_entity": { "recommended_name": "Vascular adhesion protein-1", "synonyms": [ { "synonym": "Copper amine oxidase" }, { "synonym": "HPAO" }, { "synonym": "Semicarbazide-sensitive amine oxidase" }, { "synonym": "SSAO" }, { "synonym": "Vascular adhesion protein 1" }, { "synonym": "VAP-1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16853", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30160019", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30160019", "evidence_list": [ { "evidence": "VAP-1 is shown to be a biomarker that can predict invasive potential and clinical outcome in breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30160019", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30160019", "evidence_list": [ { "evidence": "VAP-1 is shown to be a biomarker that can predict invasive potential and clinical outcome in breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Vascular adhesion protein-1 as indicator of breast cancer tumor aggressiveness and invasiveness.", "journal": "APMIS : acta pathologica, microbiologica, et immunologica Scandinavica", "authors": "Lai YC, Chang SJ, Kostoro J, Kwan AL, Chai CY", "date": "2018-08-31", "evidence": [], "reference": [ { "id": "30160019", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30160019" } ] } ], "biomarker_canonical_id": "AA4813", "collision": 1 }, { "biomarker_id": "AN4458-1", "biomarker_component": [ { "biomarker": "increased GOT1 to GPT ratio", "assessed_biomarker_entity": { "recommended_name": "De Ritis ratio", "synonyms": [ { "synonym": "cAspAT" }, { "synonym": "Cysteine aminotransferase, cytoplasmic" }, { "synonym": "Cysteine transaminase, cytoplasmic" }, { "synonym": "cCAT" }, { "synonym": "Glutamate oxaloacetate transaminase 1" }, { "synonym": "Transaminase A" } ] }, "assessed_biomarker_entity_id": "UPKB:P17174", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33043447", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33043447", "evidence_list": [ { "evidence": "De Ritis ratio on admission was significantly associated with in-hospital mortality in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased GOT1 to GPT ratio", "assessed_biomarker_entity": { "recommended_name": "De Ritis ratio", "synonyms": [ { "synonym": "ALT1" }, { "synonym": "Glutamate pyruvate transaminase 1" }, { "synonym": "GPT 1" }, { "synonym": "Glutamic--alanine transaminase 1" }, { "synonym": "Glutamic--pyruvic transaminase 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P24298", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33043447", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33043447", "evidence_list": [ { "evidence": "De Ritis ratio on admission was significantly associated with in-hospital mortality in COVID-19 patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33043447", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33043447", "evidence_list": [ { "evidence": "De Ritis ratio on admission was significantly associated with in-hospital mortality in COVID-19 patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients.", "journal": "European journal of clinical investigation", "authors": "Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, Zinellu E, Perra R, Madeddu G, Carru C, Pirina P, Mangoni AA, Babudieri S, Fois AG", "date": "2020-10-13", "evidence": [], "reference": [ { "id": "33043447", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33043447" } ] }, { "title": "The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients.", "journal": "European journal of clinical investigation", "authors": "Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, Zinellu E, Perra R, Madeddu G, Carru C, Pirina P, Mangoni AA, Babudieri S, Fois AG", "date": "2020-10-13", "evidence": [], "reference": [ { "id": "33043447", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33043447" } ] } ], "biomarker_canonical_id": "AN4458", "collision": 0 }, { "biomarker_id": "AN4459-1", "biomarker_component": [ { "biomarker": "increased IL-6 to IL-10 score", "assessed_biomarker_entity": { "recommended_name": "Dublin-Boston score", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33039714", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33039714", "evidence_list": [ { "evidence": "The Dublin-Boston score uses the change between two IL-6:IL-10 ratio measurements taken 4 days apart to guide clinical decision-making by identifying hospitalized patients at risk of impending poor outcome, and is applicable to patients both in the ICU and on the ward. The score, and the change in IL-6:IL-10 from which it is derived, significantly outperform the predictive capabilities of IL-6 alone." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IL-6 to IL-10 score", "assessed_biomarker_entity": { "recommended_name": "Dublin-Boston score", "synonyms": [ { "synonym": "IL-10" }, { "synonym": "Cytokine synthesis inhibitory factor" }, { "synonym": "CSIF" } ] }, "assessed_biomarker_entity_id": "UPKB:P22301", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33039714", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33039714", "evidence_list": [ { "evidence": "The Dublin-Boston score uses the change between two IL-6:IL-10 ratio measurements taken 4 days apart to guide clinical decision-making by identifying hospitalized patients at risk of impending poor outcome, and is applicable to patients both in the ICU and on the ward. The score, and the change in IL-6:IL-10 from which it is derived, significantly outperform the predictive capabilities of IL-6 alone." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "33039714", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33039714", "evidence_list": [ { "evidence": "The Dublin-Boston score uses the change between two IL-6:IL-10 ratio measurements taken 4 days apart to guide clinical decision-making by identifying hospitalized patients at risk of impending poor outcome, and is applicable to patients both in the ICU and on the ward. The score, and the change in IL-6:IL-10 from which it is derived, significantly outperform the predictive capabilities of IL-6 alone." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19.", "journal": "EBioMedicine", "authors": "McElvaney OJ, Hobbs BD, Qiao D, McElvaney OF, Moll M, McEvoy NL, Clarke J, O'Connor E, Walsh S, Cho MH, Curley GF, McElvaney NG", "date": "2020-10-12", "evidence": [], "reference": [ { "id": "33039714", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33039714" } ] }, { "title": "A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19.", "journal": "EBioMedicine", "authors": "McElvaney OJ, Hobbs BD, Qiao D, McElvaney OF, Moll M, McEvoy NL, Clarke J, O'Connor E, Walsh S, Cho MH, Curley GF, McElvaney NG", "date": "2020-10-12", "evidence": [], "reference": [ { "id": "33039714", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33039714" } ] } ], "biomarker_canonical_id": "AN4459", "collision": 0 }, { "biomarker_id": "AA4814-1", "biomarker_component": [ { "biomarker": "decreased SELENOP level", "assessed_biomarker_entity": { "recommended_name": "Selenoprotein P", "synonyms": [ { "synonym": "SeP" } ] }, "assessed_biomarker_entity_id": "UPKB:P49908", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32708526", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32708526", "evidence_list": [ { "evidence": "The Se status was significantly higher in samples from surviving COVID patients as compared with non-survivors (Se; 53.3 \u00b1 16.2 vs. 40.8 \u00b1 8.1 \u00b5g/L, SELENOP; 3.3 \u00b1 1.3 vs. 2.1 \u00b1 0.9 mg/L), recovering with time in survivors while remaining low or even declining in non-survivors. We conclude that Se status analysis in COVID patients provides diagnostic information patients suffering from COVID-19 display a deficiency in the essential trace element Se in blood, along with low concentrations of the Se transporter SELENOP and low enzymatic activity of the secreted GPx3." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32708526", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32708526", "evidence_list": [ { "evidence": "The Se status was significantly higher in samples from surviving COVID patients as compared with non-survivors (Se; 53.3 \u00b1 16.2 vs. 40.8 \u00b1 8.1 \u00b5g/L, SELENOP; 3.3 \u00b1 1.3 vs. 2.1 \u00b1 0.9 mg/L), recovering with time in survivors while remaining low or even declining in non-survivors. We conclude that Se status analysis in COVID patients provides diagnostic information patients suffering from COVID-19 display a deficiency in the essential trace element Se in blood, along with low concentrations of the Se transporter SELENOP and low enzymatic activity of the secreted GPx3." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Selenium Deficiency Is Associated with Mortality Risk from COVID-19.", "journal": "Nutrients", "authors": "Moghaddam A, Heller RA, Sun Q, Seelig J, Cherkezov A, Seibert L, Hackler J, Seemann P, Diegmann J, Pilz M, Bachmann M, Minich WB, Schomburg L", "date": "2020-07-28", "evidence": [], "reference": [ { "id": "32708526", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32708526" } ] } ], "biomarker_canonical_id": "AA4814", "collision": 1 }, { "biomarker_id": "AA4815-1", "biomarker_component": [ { "biomarker": "increased IL17A level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-17A", "synonyms": [ { "synonym": "IL-17" }, { "synonym": "IL-17A" }, { "synonym": "Cytotoxic T-lymphocyte-associated antigen 8" }, { "synonym": "CTLA-8" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16552", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "82334-4" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "82334-4" } ], "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "VEGF-D: a novel biomarker for detection of COVID-19 progression.", "journal": "Critical care (London, England)", "authors": "Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H", "date": "2020-06-25", "evidence": [], "reference": [ { "id": "32576222", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222" } ] } ], "biomarker_canonical_id": "AA4815", "collision": 1 }, { "biomarker_id": "AA4816-1", "biomarker_component": [ { "biomarker": "increased IL18 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-18", "synonyms": [ { "synonym": "IL-18" }, { "synonym": "Iboctadekin" }, { "synonym": "Interferon gamma-inducing factor" }, { "synonym": "IFN-gamma-inducing factor" }, { "synonym": "Interleukin-1 gamma" }, { "synonym": "IL-1 gamma" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14116", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "33823-6" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "33823-6" } ], "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "VEGF-D: a novel biomarker for detection of COVID-19 progression.", "journal": "Critical care (London, England)", "authors": "Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H", "date": "2020-06-25", "evidence": [], "reference": [ { "id": "32576222", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222" } ] } ], "biomarker_canonical_id": "AA4816", "collision": 1 }, { "biomarker_id": "AA4817-1", "biomarker_component": [ { "biomarker": "increased IL15 level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-15", "synonyms": [ { "synonym": "IL-15" } ] }, "assessed_biomarker_entity_id": "UPKB:P40933", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "" } ], "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32576222", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222", "evidence_list": [ { "evidence": "Levels of VEGF-D, TNF-alpha, SCF, LIF, IL-2, IL-4, IL-6, IL-8, IL-10, IL-15, IL-17A, IL-18, IL-1 beta, and IFN-gamma were significantly higher in the critical group than in the severe group (Table 1)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "VEGF-D: a novel biomarker for detection of COVID-19 progression.", "journal": "Critical care (London, England)", "authors": "Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H", "date": "2020-06-25", "evidence": [], "reference": [ { "id": "32576222", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32576222" } ] } ], "biomarker_canonical_id": "AA4817", "collision": 1 }, { "biomarker_id": "AN4117-1", "biomarker_component": [ { "biomarker": "presence of mutation L858R in EGFR", "assessed_biomarker_entity": { "recommended_name": "Epidermal growth factor receptor gene", "synonyms": [ { "synonym": "Proto-oncogene c-ErbB-1" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P00533", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "13659-8" } ], "evidence_source": [ { "id": "23599147", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23599147", "evidence_list": [ { "evidence": "EGFR mutation-specific (E746-A750del and L858R) antibodies could be an additional tool distinguishing primary versus metastatic carcinomas in the lung. EGFR mutation-specific antibodies are negative in other tumors that overexpress wild-type EGFR protein." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "23599147", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23599147", "evidence_list": [ { "evidence": "EGFR mutation-specific (E746-A750del and L858R) antibodies could be an additional tool distinguishing primary versus metastatic carcinomas in the lung. EGFR mutation-specific antibodies are negative in other tumors that overexpress wild-type EGFR protein." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma.", "journal": "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc", "authors": "Wen YH, Brogi E, Hasanovic A, Ladanyi M, Soslow RA, Chitale D, Shia J, Moreira AL", "date": "2013-04-20", "evidence": [], "reference": [ { "id": "23599147", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23599147" } ] } ], "biomarker_canonical_id": "AN4117", "collision": 1 }, { "biomarker_id": "AA4819-1", "biomarker_component": [ { "biomarker": "increased HP level", "assessed_biomarker_entity": { "recommended_name": "Haptoglobin", "synonyms": [ { "synonym": "Zonulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P00738", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "4542-7" } ], "evidence_source": [ { "id": "27648369", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27648369", "evidence_list": [ { "evidence": "HP may be a potential serological biomarker for lung adenocarcinoma diagnostics, especially in male subjects. We found that HP levels were significantly higher and APOA1 levels were significantly lower in lung cancer patients. However, after the participants were stratified by gender, the expression trends of HP and APOA1 in lung cancer patients existed only in men, which is gender specific phenomenon. HP, APOA1 and carcinoembryonic antigen (CEA), used for distinguishing lung adenocarcinoma, had a sensitivity of 64%, 64% and 79%, respectively. Area under the ROC curve (AUC) of HP, APOA1 and CEA were 0.768, 0.761 and 0.884, respectively. When restricted to male subjects, HP, APOA1 and CEA showed sensitivity of 89%, 73% and 100%, respectively. AUC of HP, APOA1 and CEA were 0.929, 0.840 and 0.877, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "27648369", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27648369", "evidence_list": [ { "evidence": "HP may be a potential serological biomarker for lung adenocarcinoma diagnostics, especially in male subjects. We found that HP levels were significantly higher and APOA1 levels were significantly lower in lung cancer patients. However, after the participants were stratified by gender, the expression trends of HP and APOA1 in lung cancer patients existed only in men, which is gender specific phenomenon. HP, APOA1 and carcinoembryonic antigen (CEA), used for distinguishing lung adenocarcinoma, had a sensitivity of 64%, 64% and 79%, respectively. Area under the ROC curve (AUC) of HP, APOA1 and CEA were 0.768, 0.761 and 0.884, respectively. When restricted to male subjects, HP, APOA1 and CEA showed sensitivity of 89%, 73% and 100%, respectively. AUC of HP, APOA1 and CEA were 0.929, 0.840 and 0.877, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Haptoglobin is a serological biomarker for adenocarcinoma lung cancer by using the ProteomeLab PF2D combined with mass spectrometry.", "journal": "American journal of cancer research", "authors": "Chang YK, Lai YH, Chu Y, Lee MC, Huang CY, Wu S", "date": "2016-09-21", "evidence": [], "reference": [ { "id": "27648369", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27648369" } ] } ], "biomarker_canonical_id": "AA4819", "collision": 1 }, { "biomarker_id": "AA4820-1", "biomarker_component": [ { "biomarker": "increased ALCAM level", "assessed_biomarker_entity": { "recommended_name": "Activated leukocyte cell adhesion molecule", "synonyms": [ { "synonym": "Activated leukocyte cell adhesion molecule" } ] }, "assessed_biomarker_entity_id": "UPKB:Q13740", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" }, { "name": "lymph node", "id": "UBERON:0000029", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000029", "loinc_code": "" } ], "evidence_source": [ { "id": "26134500", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26134500", "evidence_list": [ { "evidence": "High ALCAM expression in primary melanoma cells (IRS >/=8) is strongly correlated with unfavorable prognosis as compared with patients with lower ALCAM immunoreactivity in tumor compartment as regards cancer specific overall survival (CSOS) (P = 0.001) and disease free survival (DFS) (P < 0.001). High ALCAM expression in melanoma cells of the primary tumor can be used as a marker of negative outcome and may indicate a more invasive phenotype of cancer cells, which would require a more intensive therapeutic strategy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "26134500", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26134500", "evidence_list": [ { "evidence": "High ALCAM expression in primary melanoma cells (IRS >/=8) is strongly correlated with unfavorable prognosis as compared with patients with lower ALCAM immunoreactivity in tumor compartment as regards cancer specific overall survival (CSOS) (P = 0.001) and disease free survival (DFS) (P < 0.001). High ALCAM expression in melanoma cells of the primary tumor can be used as a marker of negative outcome and may indicate a more invasive phenotype of cancer cells, which would require a more intensive therapeutic strategy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.", "journal": "Diagnostic pathology", "authors": "Donizy P, Zietek M, Halon A, Leskiewicz M, Kozyra C, Matkowski R", "date": "2015-07-03", "evidence": [], "reference": [ { "id": "26134500", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26134500" } ] } ], "biomarker_canonical_id": "AA4820", "collision": 1 }, { "biomarker_id": "AA4821-1", "biomarker_component": [ { "biomarker": "decreased BRMS1 level", "assessed_biomarker_entity": { "recommended_name": "Breast cancer metastasis suppressor 1", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9HCU9", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" }, { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" }, { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "20935672", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20935672", "evidence_list": [ { "evidence": "BRMS1 expression was significantly correlated with disease-specific 5-year survival of melanoma patients (P=0.007, log-rank test). Multivariate Cox regression analysis revealed that BRMS1 staining was an independent prognostic factor for melanoma patients (relative risk=0.51; confidence interval=0.29-0.91; P=0.022). BRMS1 expression was significantly decreased in metastatic melanoma compared with primary melanoma or dysplastic nevi (P=0.021 and 0.001, respectively, chi(2) test). BRMS1 may serve an important prognostic marker and therapeutic target for melanoma patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "20935672", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20935672", "evidence_list": [ { "evidence": "BRMS1 expression was significantly correlated with disease-specific 5-year survival of melanoma patients (P=0.007, log-rank test). Multivariate Cox regression analysis revealed that BRMS1 staining was an independent prognostic factor for melanoma patients (relative risk=0.51; confidence interval=0.29-0.91; P=0.022). BRMS1 expression was significantly decreased in metastatic melanoma compared with primary melanoma or dysplastic nevi (P=0.021 and 0.001, respectively, chi(2) test). BRMS1 may serve an important prognostic marker and therapeutic target for melanoma patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.", "journal": "Oncogene", "authors": "Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G", "date": "2010-10-12", "evidence": [], "reference": [ { "id": "20935672", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20935672" } ] } ], "biomarker_canonical_id": "AA4821", "collision": 1 }, { "biomarker_id": "AN4118-1", "biomarker_component": [ { "biomarker": "presence of promoter methylation in Netrin", "assessed_biomarker_entity": { "recommended_name": "Netrin receptor gene", "synonyms": [ { "synonym": "Colorectal cancer suppressor" }, { "synonym": "Immunoglobulin superfamily DCC subclass member 1" }, { "synonym": "Tumor suppressor protein DCC" } ] }, "assessed_biomarker_entity_id": "UPKB:P43146", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4118", "collision": 1 }, { "biomarker_id": "AA4823-1", "biomarker_component": [ { "biomarker": "decreased EDNRB level", "assessed_biomarker_entity": { "recommended_name": "Endothelin receptor type B", "synonyms": [ { "synonym": "ET-B" }, { "synonym": "ET-BR" }, { "synonym": "Endothelin receptor non-selective type" } ] }, "assessed_biomarker_entity_id": "UPKB:P24530", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "32934717", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32934717", "evidence_list": [ { "evidence": "EDNRB expression was low in TNBC samples (P<0.01). In conclusion, EDNRB was associated with a favorable prognosis in patients with TNBC, and may be used as a novel prognostic biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32934717", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32934717", "evidence_list": [ { "evidence": "EDNRB expression was low in TNBC samples (P<0.01). In conclusion, EDNRB was associated with a favorable prognosis in patients with TNBC, and may be used as a novel prognostic biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic values of EDNRB in triple-negative breast cancer.", "journal": "Oncology letters", "authors": "Liu S, Zhang J, Zhu J, Jiao D, Liu Z", "date": "2020-09-17", "evidence": [], "reference": [ { "id": "32934717", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32934717" } ] } ], "biomarker_canonical_id": "AA4823", "collision": 1 }, { "biomarker_id": "AN4119-1", "biomarker_component": [ { "biomarker": "presence of promoter methylation", "assessed_biomarker_entity": { "recommended_name": "Endothelin receptor type B gene", "synonyms": [ { "synonym": "ET-B" }, { "synonym": "ET-BR" }, { "synonym": "Endothelin receptor non-selective type" } ] }, "assessed_biomarker_entity_id": "UPKB:P24530", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4119", "collision": 1 }, { "biomarker_id": "AA4825-1", "biomarker_component": [ { "biomarker": "decreased GATA-4 level", "assessed_biomarker_entity": { "recommended_name": "Transcription factor GATA-4", "synonyms": [ { "synonym": "GATA-binding factor 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P43694", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "30187949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30187949", "evidence_list": [ { "evidence": "GATA4 overexpression decreased viability, invasion, migration, and epithelial-to-mesenchymal transition of MB-231 and BT549 cells, and markedly induced cell cycle arrest and apoptosis. Our findings suggest that GATA4 is a potential prognostic biomarker and gene therapeutic target for human BrCa." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30187949", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30187949", "evidence_list": [ { "evidence": "GATA4 overexpression decreased viability, invasion, migration, and epithelial-to-mesenchymal transition of MB-231 and BT549 cells, and markedly induced cell cycle arrest and apoptosis. Our findings suggest that GATA4 is a potential prognostic biomarker and gene therapeutic target for human BrCa." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Restoration of GATA4 expression impedes breast cancer progression by transcriptional repression of ReLA and inhibition of NF-\u03baB signaling.", "journal": "Journal of cellular biochemistry", "authors": "Han X, Tang J, Chen T, Ren G", "date": "2018-09-07", "evidence": [], "reference": [ { "id": "30187949", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30187949" } ] } ], "biomarker_canonical_id": "AA4825", "collision": 1 }, { "biomarker_id": "AA4826-1", "biomarker_component": [ { "biomarker": "increased GATA-4 level", "assessed_biomarker_entity": { "recommended_name": "Transcription factor GATA-4", "synonyms": [ { "synonym": "GATA-binding factor 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P43694", "assessed_entity_type": "protein", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "27788486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27788486", "evidence_list": [ { "evidence": "This GATA4/miR125b/DKK3 axis may be a major regulator of growth, migration, invasion, and survival in hepatoma cells, and is therefore a potential therapeutic target or biomarker for progression in HB patients. GATA4 expression and activity were high in liver tumors in children, but not in adults." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "27788486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27788486", "evidence_list": [ { "evidence": "This GATA4/miR125b/DKK3 axis may be a major regulator of growth, migration, invasion, and survival in hepatoma cells, and is therefore a potential therapeutic target or biomarker for progression in HB patients. GATA4 expression and activity were high in liver tumors in children, but not in adults." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.", "journal": "Oncotarget", "authors": "Pei Y, Yao Q, Yuan S, Xie B, Liu Y, Ye C, Zhuo H", "date": "2016-10-28", "evidence": [], "reference": [ { "id": "27788486", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27788486" } ] } ], "biomarker_canonical_id": "AA4826", "collision": 1 }, { "biomarker_id": "AN4120-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Transcription factor GATA-4 gene promoter methylation", "synonyms": [ { "synonym": "GATA-binding factor 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P43694", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] }, { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4120", "collision": 1 }, { "biomarker_id": "AN4121-1", "biomarker_component": [ { "biomarker": "increased HOXA9 meth-ctDNA level", "assessed_biomarker_entity": { "recommended_name": "Homeobox protein Hox-A9 gene", "synonyms": [ { "synonym": "Homeobox protein Hox-1G" } ] }, "assessed_biomarker_entity_id": "UPKB:P31269", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31865042", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31865042", "evidence_list": [ { "evidence": "Detection of HOXA9 meth-ctDNA during treatment with a PARP inhibitor was associated with worse clinical outcomes. Longitudinal monitoring of HOXA9 meth-ctDNA is clinically feasible and is strongly correlated to clinical outcomes (PFS, OS), suggesting that it may serve as a valuable predictive biomarker to inform clinical decision-making in the setting of platinum-resistant BRCA-mutated OC treated with a PARP inhibitor." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "31865042", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31865042", "evidence_list": [ { "evidence": "Detection of HOXA9 meth-ctDNA during treatment with a PARP inhibitor was associated with worse clinical outcomes. Longitudinal monitoring of HOXA9 meth-ctDNA is clinically feasible and is strongly correlated to clinical outcomes (PFS, OS), suggesting that it may serve as a valuable predictive biomarker to inform clinical decision-making in the setting of platinum-resistant BRCA-mutated OC treated with a PARP inhibitor." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.", "journal": "European journal of cancer (Oxford, England : 1990)", "authors": "Rusan M, Andersen RF, Jakobsen A, Steffensen KD", "date": "2019-12-23", "evidence": [], "reference": [ { "id": "31865042", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31865042" } ] } ], "biomarker_canonical_id": "AN4121", "collision": 1 }, { "biomarker_id": "AN4122-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Homeobox HoxA9 gene promoter methylation", "synonyms": [ { "synonym": "Homeobox protein Hox-1G" } ] }, "assessed_biomarker_entity_id": "UPKB:P31269", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4122", "collision": 1 }, { "biomarker_id": "AN4123-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Kinesin-like protein KIF1A gene promoter methylation", "synonyms": [ { "synonym": "Axonal transporter of synaptic vesicles" }, { "synonym": "Microtubule-based motor KIF1A" }, { "synonym": "Unc-104- and KIF1A-related protein" }, { "synonym": "hUnc-104" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12756", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4123", "collision": 1 }, { "biomarker_id": "AA4831-1", "biomarker_component": [ { "biomarker": "increased NID2 level", "assessed_biomarker_entity": { "recommended_name": "Nidogen-2", "synonyms": [ { "synonym": "NID-2" }, { "synonym": "Osteonidogen" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14112", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29278876", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29278876", "evidence_list": [ { "evidence": "The serum NID2 levels in ESCC patients (median 24.4 ug/L) are significantly higher (p= 4.3e-09) than that of the healthy controls (median 15.85 ug/L). In conclusion, we show that detecting the elevation of serum NID2 levels has potential diagnostic and prognostic value for ESCC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "29278876", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29278876", "evidence_list": [ { "evidence": "The serum NID2 levels in ESCC patients (median 24.4 ug/L) are significantly higher (p= 4.3e-09) than that of the healthy controls (median 15.85 ug/L). In conclusion, we show that detecting the elevation of serum NID2 levels has potential diagnostic and prognostic value for ESCC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Chai AWY, Cheung AKL, Dai W, Ko JMY, Lee NPY, Chan KT, Law SY, Lung ML", "date": "2017-12-28", "evidence": [], "reference": [ { "id": "29278876", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29278876" } ] } ], "biomarker_canonical_id": "AA4831", "collision": 1 }, { "biomarker_id": "AN4124-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Nidogen-2 gene promoter methylation", "synonyms": [ { "synonym": "NID-2" }, { "synonym": "Osteonidogen" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14112", "assessed_entity_type": "protein", "specimen": [ { "name": "oral cavity", "id": "UBERON:0000167", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000167", "loinc_code": "" } ], "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21558411", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411", "evidence_list": [ { "evidence": "EDNRB, HOXA9, GATA4, NID2, KIF1A, DCC show differential methylation between cases and controls. Promoter methylation of KIF1A, NID2, and EDNRB had a moderate to substantial agreement with clinical diagnosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.", "journal": "Cancer prevention research (Philadelphia, Pa.)", "authors": "Guerrero-Preston R, Soudry E, Acero J, Orera M, Moreno-L\u00f3pez L, Mac\u00eda-Col\u00f3n G, Jaffe A, Berdasco M, Ili-Gangas C, Brebi-Mieville P, Fu Y, Engstrom C, Irizarry RA, Esteller M, Westra W, Koch W, Califano J, Sidransky D", "date": "2011-05-12", "evidence": [], "reference": [ { "id": "21558411", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21558411" } ] } ], "biomarker_canonical_id": "AN4124", "collision": 1 }, { "biomarker_id": "AA4833-1", "biomarker_component": [ { "biomarker": "decreased MIR-498-5P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-498-5p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003142", "assessed_entity_type": "miRNA", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "30592286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30592286", "evidence_list": [ { "evidence": "The miR-498 expression level was significantly lower in liver cancer patient tissues than that in healthy control tissues. Furthermore, ZEB2 knockdown recapitulated the inhibitory effects of miR-498 overexpression in liver cancer cells. Thus, we demonstrated that miR-498 suppresses the growth and metastasis of liver cancer cells, partly at least, by directly targeting ZEB2, suggesting that miR-498 may serve as a potential biomarker for the diagnosis and therapy of liver cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "30592286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30592286", "evidence_list": [ { "evidence": "The miR-498 expression level was significantly lower in liver cancer patient tissues than that in healthy control tissues. Furthermore, ZEB2 knockdown recapitulated the inhibitory effects of miR-498 overexpression in liver cancer cells. Thus, we demonstrated that miR-498 suppresses the growth and metastasis of liver cancer cells, partly at least, by directly targeting ZEB2, suggesting that miR-498 may serve as a potential biomarker for the diagnosis and therapy of liver cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "miR\u2011498 inhibits the growth and metastasis of liver cancer by targeting ZEB2.", "journal": "Oncology reports", "authors": "Zhang X, Xu X, Ge G, Zang X, Shao M, Zou S, Zhang Y, Mao Z, Zhang J, Mao F, Qian H, Xu W", "date": "2018-12-29", "evidence": [], "reference": [ { "id": "30592286", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30592286" } ] } ], "biomarker_canonical_id": "AA4833", "collision": 1 }, { "biomarker_id": "AN4125-1", "biomarker_component": [ { "biomarker": "decreased OGDHL level", "assessed_biomarker_entity": { "recommended_name": "Oxoglutarate dehydrogenase-like", "synonyms": [ { "synonym": "2-oxoglutarate dehydrogenase complex component E1-like" }, { "synonym": "OGDC-E1-like" }, { "synonym": "Alpha-ketoglutarate dehydrogenase-like" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9ULD0", "assessed_entity_type": "protein", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "31781311", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31781311", "evidence_list": [ { "evidence": "OGDHL had lower expression in cancerous liver tissues than noncancerous adjacent tissues, and low expression correlated with more advanced patient age, histologic grade, stage, T classification, and poor survival. Survival analysis showed that patients with lower OGDHL levels had shorter overall survival (OS), and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage I/II, T3, N0, and M0 cancers. In addition, patients with lower OGDHL levels had shorter relapse-free survival, and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage III/IV, T1, T3, N0, and M1 cancers. Patients with lower OGDHL expression had shorter OS and relapse-free survival. Multivariate Cox regression indicated that low OGDHL expression was an independent risk factor for poor prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "31781311", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31781311", "evidence_list": [ { "evidence": "OGDHL had lower expression in cancerous liver tissues than noncancerous adjacent tissues, and low expression correlated with more advanced patient age, histologic grade, stage, T classification, and poor survival. Survival analysis showed that patients with lower OGDHL levels had shorter overall survival (OS), and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage I/II, T3, N0, and M0 cancers. In addition, patients with lower OGDHL levels had shorter relapse-free survival, and subgroup analysis indicated this relationship also held for patients with grade G1/G2, stage III/IV, T1, T3, N0, and M1 cancers. Patients with lower OGDHL expression had shorter OS and relapse-free survival. Multivariate Cox regression indicated that low OGDHL expression was an independent risk factor for poor prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "", "journal": "Disease markers", "authors": "Jiao Y, Li Y, Fu Z, Hou L, Chen Q, Cai Y, Jiang P, He M, Yang Z", "date": "2019-11-30", "evidence": [], "reference": [ { "id": "31781311", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31781311" } ] } ], "biomarker_canonical_id": "AN4125", "collision": 1 }, { "biomarker_id": "AA4835-1", "biomarker_component": [ { "biomarker": "increased HSP90AA1 level", "assessed_biomarker_entity": { "recommended_name": "Heat shock protein 90 alpha", "synonyms": [ { "synonym": "Heat shock 86 kDa" }, { "synonym": "HSP 86" }, { "synonym": "HSP86" }, { "synonym": "Lipopolysaccharide-associated protein 2" }, { "synonym": "LAP-2" }, { "synonym": "LPS-associated protein 2" }, { "synonym": "Renal carcinoma antigen NY-REN-38" } ] }, "assessed_biomarker_entity_id": "UPKB:P07900", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "28939487", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28939487", "evidence_list": [ { "evidence": "Diagnostic performance of plasma Hsp90a was evaluated by the calculated sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). ROC curve showed plasma Hsp90a can discriminating liver cancer with a sensitivity of 92.7% and specificity of 91.3% from non-liver cancer control." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "28939487", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28939487", "evidence_list": [ { "evidence": "Diagnostic performance of plasma Hsp90a was evaluated by the calculated sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). ROC curve showed plasma Hsp90a can discriminating liver cancer with a sensitivity of 92.7% and specificity of 91.3% from non-liver cancer control." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial.", "journal": "EBioMedicine", "authors": "Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Liu J, Zheng S, Luo Y", "date": "2017-09-25", "evidence": [], "reference": [ { "id": "28939487", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28939487" } ] } ], "biomarker_canonical_id": "AA4835", "collision": 1 }, { "biomarker_id": "AN4126-1", "biomarker_component": [ { "biomarker": "decreased SLC25A11 level", "assessed_biomarker_entity": { "recommended_name": "Mitochondrial 2-oxoglutarate/malate carrier protein", "synonyms": [ { "synonym": "OGCP" }, { "synonym": "alpha-oxoglutarate carrier" }, { "synonym": "Solute carrier family 25 member 11" }, { "synonym": "SLC25A11" } ] }, "assessed_biomarker_entity_id": "UPKB:Q02978", "assessed_entity_type": "protein", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "32555317", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32555317", "evidence_list": [ { "evidence": "Liver cancer patients with low SLC25A11 expression had shorter OS and RFS than patients with high SLC25A11 expression. Multivariate analysis showed that the expression of SLC25A11 was an independent predictor of RFS and OS. In conclusion, this study identified that SLC25A11 serves as a new prognostic marker for liver cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32555317", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32555317", "evidence_list": [ { "evidence": "Liver cancer patients with low SLC25A11 expression had shorter OS and RFS than patients with high SLC25A11 expression. Multivariate analysis showed that the expression of SLC25A11 was an independent predictor of RFS and OS. In conclusion, this study identified that SLC25A11 serves as a new prognostic marker for liver cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "SLC25A11 serves as a novel prognostic biomarker in liver cancer.", "journal": "Scientific reports", "authors": "Pan G, Wang R, Jia S, Li Y, Jiao Y, Liu N", "date": "2020-06-20", "evidence": [], "reference": [ { "id": "32555317", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32555317" } ] } ], "biomarker_canonical_id": "AN4126", "collision": 1 }, { "biomarker_id": "AN4127-1", "biomarker_component": [ { "biomarker": "increased DCK level", "assessed_biomarker_entity": { "recommended_name": "Deoxycytidine kinase", "synonyms": [ { "synonym": "dCK" }, { "synonym": "Deoxyadenosine kinase" }, { "synonym": "Deoxyguanosine kinase" } ] }, "assessed_biomarker_entity_id": "UPKB:P27707", "assessed_entity_type": "protein", "specimen": [ { "name": "liver", "id": "UBERON:0002107", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002107", "loinc_code": "" } ], "evidence_source": [ { "id": "32588770", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32588770", "evidence_list": [ { "evidence": "The deoxycytidine kinase messenger RNA level significantly upregulated in patients with liver cancer compared to normal liver samples. All the above findings suggested that increased expression of deoxycytidine kinase was significantly related to unfavorable prognosis in patients with liver cancer. Deoxycytidine kinase is correlated with immune infiltrating levels, including those of B cells, macrophages, neutrophils, and dendritic cells in patients with liver cancer. The survival curves revealed that in patients with liver cancer, the high expression level of DCK (RNA-SeqID:1633) indicated worse prognosis. high expression of DCK resulted in shorter OS (HR = 1.90, 95% CI = 1.32-2.72, P value = .00043) and RFS (HR = 1.53, 95% CI = 1.10-2.13, P value = .011)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32588770", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32588770", "evidence_list": [ { "evidence": "The deoxycytidine kinase messenger RNA level significantly upregulated in patients with liver cancer compared to normal liver samples. All the above findings suggested that increased expression of deoxycytidine kinase was significantly related to unfavorable prognosis in patients with liver cancer. Deoxycytidine kinase is correlated with immune infiltrating levels, including those of B cells, macrophages, neutrophils, and dendritic cells in patients with liver cancer. The survival curves revealed that in patients with liver cancer, the high expression level of DCK (RNA-SeqID:1633) indicated worse prognosis. high expression of DCK resulted in shorter OS (HR = 1.90, 95% CI = 1.32-2.72, P value = .00043) and RFS (HR = 1.53, 95% CI = 1.10-2.13, P value = .011)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer.", "journal": "Technology in cancer research & treatment", "authors": "Hu SF, Lin X, Xu LP, Chen HG, Guo JF, Jin L", "date": "2020-06-27", "evidence": [], "reference": [ { "id": "32588770", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32588770" } ] } ], "biomarker_canonical_id": "AN4127", "collision": 1 }, { "biomarker_id": "AA4838-1", "biomarker_component": [ { "biomarker": "increased H2AX level", "assessed_biomarker_entity": { "recommended_name": "Histone H2AX", "synonyms": [ { "synonym": "H2a/x" }, { "synonym": "Histone H2A.X" } ] }, "assessed_biomarker_entity_id": "UPKB:P16104", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "31552812", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31552812", "evidence_list": [ { "evidence": "Greater tumor size, higher grade, and the number of affected lymph nodes are significantly associated with greater values of gamma-H2AX. Higher values of estrogen receptor and progesterone receptor are significantly associated with lower gamma-H2AX values. In conclusion, a positive association between gamma-H2AX expression and infaust histopathological parameters was observed." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "31552812", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31552812", "evidence_list": [ { "evidence": "Greater tumor size, higher grade, and the number of affected lymph nodes are significantly associated with greater values of gamma-H2AX. Higher values of estrogen receptor and progesterone receptor are significantly associated with lower gamma-H2AX values. In conclusion, a positive association between gamma-H2AX expression and infaust histopathological parameters was observed." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "gamma-H2AX: A potential biomarker in breast cancer.", "journal": "Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine", "authors": "Varvara PV, Karaolanis G, Valavanis C, Stanc G, Tzaida O, Trihia H, Patapis P, Dimitroulis D, Perrea D", "date": "2019-09-26", "evidence": [], "reference": [ { "id": "31552812", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31552812" } ] } ], "biomarker_canonical_id": "AA4838", "collision": 1 }, { "biomarker_id": "AA4839-1", "biomarker_component": [ { "biomarker": "increased CTDNA level", "assessed_biomarker_entity": { "recommended_name": "Circulating tumor-derived DNA", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C113243", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31070691", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31070691", "evidence_list": [ { "evidence": "During surveillance after definitive therapy, ctDNA-positive patients were more than 40 times more likely to experience disease recurrence than ctDNA negative patients (HR, 43.5; 95% CI, 9.8-193.5 P < .001). In all multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathologic risk factors. Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "31070691", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31070691", "evidence_list": [ { "evidence": "During surveillance after definitive therapy, ctDNA-positive patients were more than 40 times more likely to experience disease recurrence than ctDNA negative patients (HR, 43.5; 95% CI, 9.8-193.5 P < .001). In all multivariate analyses, ctDNA status was independently associated with relapse after adjusting for known clinicopathologic risk factors. Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.", "journal": "JAMA oncology", "authors": "Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskj\u00f8t L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C", "date": "2019-05-10", "evidence": [], "reference": [ { "id": "31070691", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31070691" } ] } ], "biomarker_canonical_id": "AA4839", "collision": 1 }, { "biomarker_id": "AA4840-1", "biomarker_component": [ { "biomarker": "increased of TRAF2 level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor receptor-associated factor 2", "synonyms": [ { "synonym": "E3 ubiquitin-protein ligase TRAF2" }, { "synonym": "RING-type E3 ubiquitin transferase TRAF2" }, { "synonym": "Tumor necrosis factor type 2 receptor-associated protein 3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12933", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "28855498", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28855498", "evidence_list": [ { "evidence": "We found that TRAF2 was significantly upregulated in prostate cancer compared with normal prostate samples (P<0.001). TRAF2 high expression was associated with poorer recurrence-free survival in prostate cancer patients (P=0.013). TRAF2 was found to be a valuable independent prognostic factor for predicting recurrence-free survival (P=0.026). TRAF2 could be a novel prognostic biomarker for predicting recurrence-free survival in patients with prostate cancer, which might be associated with the effects of TRAF2 in regulating TRAIL-induced apoptosis in prostate cancer cells via c-Flip/Caspase-8 signaling." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "28855498", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28855498", "evidence_list": [ { "evidence": "We found that TRAF2 was significantly upregulated in prostate cancer compared with normal prostate samples (P<0.001). TRAF2 high expression was associated with poorer recurrence-free survival in prostate cancer patients (P=0.013). TRAF2 was found to be a valuable independent prognostic factor for predicting recurrence-free survival (P=0.026). TRAF2 could be a novel prognostic biomarker for predicting recurrence-free survival in patients with prostate cancer, which might be associated with the effects of TRAF2 in regulating TRAIL-induced apoptosis in prostate cancer cells via c-Flip/Caspase-8 signaling." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.", "journal": "Medical science monitor : international medical journal of experimental and clinical research", "authors": "Wei B, Liang J, Hu J, Mi Y, Ruan J, Zhang J, Wang Z, Hu Q, Jiang H, Ding Q", "date": "2017-09-01", "evidence": [], "reference": [ { "id": "28855498", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28855498" } ] } ], "biomarker_canonical_id": "AA4840", "collision": 1 }, { "biomarker_id": "AA4841-1", "biomarker_component": [ { "biomarker": "decreased MIR-214 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-214", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000290", "assessed_entity_type": "miRNA", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "25975233", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25975233", "evidence_list": [ { "evidence": "Underexpressed extracellular miR-214 in urine was significantly associated with higher tumor stage, higher lymph node status, higher grade, age and history of non-muscle-invasive bladder cancer (NMIBC). Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "25975233", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25975233", "evidence_list": [ { "evidence": "Underexpressed extracellular miR-214 in urine was significantly associated with higher tumor stage, higher lymph node status, higher grade, age and history of non-muscle-invasive bladder cancer (NMIBC). Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Downregulation of urinary cell-free microRNA-214 as a diagnostic and prognostic biomarker in bladder cancer.", "journal": "Journal of surgical oncology", "authors": "Wang J, Zhang X, Wang L, Dong Z, Du L, Yang Y, Guo Y, Wang C", "date": "2015-05-16", "evidence": [], "reference": [ { "id": "25975233", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25975233" } ] } ], "biomarker_canonical_id": "AA4841", "collision": 1 }, { "biomarker_id": "AA4842-1", "biomarker_component": [ { "biomarker": "decreased NDRG2 level", "assessed_biomarker_entity": { "recommended_name": "N-myc downstream-regulated gene 2", "synonyms": [ { "synonym": "N-myc downstream-regulated gene 2 protein" }, { "synonym": "Protein Syld709613" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UN36", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "28953854", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28953854", "evidence_list": [ { "evidence": "The relative NDRG2 expression were significantly downregulated both at mRNA and protein levels in urine of patients with bladder cancer and in cell lines, and its low expression was distinctively correlated with tumor grade and stage. NDRG2 was decreased in patients with bladder cancer and might be involved in the progression of this malignancy. Moreover, NDRG2 could be a potential independent diagnostic biomarker for bladder cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "28953854", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28953854", "evidence_list": [ { "evidence": "The relative NDRG2 expression were significantly downregulated both at mRNA and protein levels in urine of patients with bladder cancer and in cell lines, and its low expression was distinctively correlated with tumor grade and stage. NDRG2 was decreased in patients with bladder cancer and might be involved in the progression of this malignancy. Moreover, NDRG2 could be a potential independent diagnostic biomarker for bladder cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker.", "journal": "Medical science monitor : international medical journal of experimental and clinical research", "authors": "Zhang M, Ren B, Li Z, Niu W, Wang Y", "date": "2017-09-28", "evidence": [], "reference": [ { "id": "28953854", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28953854" } ] } ], "biomarker_canonical_id": "AA4842", "collision": 1 }, { "biomarker_id": "AA4843-1", "biomarker_component": [ { "biomarker": "increased FCN3 level", "assessed_biomarker_entity": { "recommended_name": "Ficolin-3", "synonyms": [ { "synonym": "Collagen/fibrinogen domain-containing lectin 3 p35" }, { "synonym": "Collagen/fibrinogen domain-containing protein 3" }, { "synonym": "Hakata antigen" } ] }, "assessed_biomarker_entity_id": "UPKB:O75636", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31373851", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31373851", "evidence_list": [ { "evidence": "The serum ficolin-3 level in the esophageal squamous cell carcinoma (ESCC) group was significantly higher than in the esophageal adenocarcinoma (EAC) group (19.59 \u00b1 4.35 ng/mL vs. 18.39 \u00b1 5.42 ng/mL, p < 0.01). Serum ficolin-3 levels were identified as an independent prognostic biomarker for DSS and OS in Chinese patients with EC, especially EAC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "31373851", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31373851", "evidence_list": [ { "evidence": "The serum ficolin-3 level in the esophageal squamous cell carcinoma (ESCC) group was significantly higher than in the esophageal adenocarcinoma (EAC) group (19.59 \u00b1 4.35 ng/mL vs. 18.39 \u00b1 5.42 ng/mL, p < 0.01). Serum ficolin-3 levels were identified as an independent prognostic biomarker for DSS and OS in Chinese patients with EC, especially EAC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of Ficolin-3 as a Potential Prognostic Serum Biomarker in Chinese Patients with Esophageal Cancer.", "journal": "Genetic testing and molecular biomarkers", "authors": "Li Q, Lin Y", "date": "2019-08-03", "evidence": [], "reference": [ { "id": "31373851", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31373851" } ] } ], "biomarker_canonical_id": "AA4843", "collision": 1 }, { "biomarker_id": "AA4844-1", "biomarker_component": [ { "biomarker": "increased CHI3L1 level", "assessed_biomarker_entity": { "recommended_name": "Chitinase-3-like protein 1", "synonyms": [ { "synonym": "39 kDa synovial protein" }, { "synonym": "Cartilage glycoprotein 39" }, { "synonym": "CGP-39" }, { "synonym": "GP-39" }, { "synonym": "hCGP-39" }, { "synonym": "YKL-40" } ] }, "assessed_biomarker_entity_id": "UPKB:P36222", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32162865", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32162865", "evidence_list": [ { "evidence": "Plasma YKL-40 levels were significantly higher in patients with lymph node metastasis than those that were non-metastatic (p = 0.005). This study indicated that YKL-40 may be a biomarker for esophageal cancer and potential biomarker for identification of invasive esophageal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32162865", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32162865", "evidence_list": [ { "evidence": "Plasma YKL-40 levels were significantly higher in patients with lymph node metastasis than those that were non-metastatic (p = 0.005). This study indicated that YKL-40 may be a biomarker for esophageal cancer and potential biomarker for identification of invasive esophageal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma YKL-40: a Potential Biomarker for Tumor Invasion in Esophageal Cancer.", "journal": "Clinical laboratory", "authors": "Huang R, Yao J, Ding X, Liu J, Fan C, Duan H, Ye H", "date": "2020-03-13", "evidence": [], "reference": [ { "id": "32162865", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32162865" } ] } ], "biomarker_canonical_id": "AA4844", "collision": 1 }, { "biomarker_id": "AA4844-2", "biomarker_component": [ { "biomarker": "increased CHI3L1 level", "assessed_biomarker_entity": { "recommended_name": "Chitinase-3-like protein 1", "synonyms": [ { "synonym": "39 kDa synovial protein" }, { "synonym": "Cartilage glycoprotein 39" }, { "synonym": "CGP-39" }, { "synonym": "GP-39" }, { "synonym": "hCGP-39" }, { "synonym": "YKL-40" } ] }, "assessed_biomarker_entity_id": "UPKB:P36222", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "32613636", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613636", "evidence_list": [ { "evidence": "Here, we investigated the prognostic significance of CHI3L1 expression in thyroid neoplasms and examined the potential oncogenic roles. Compared with normal thyroid tissue and benign thyroid lesions that had low or no detectable CHI3L1 expression, CHI3L1 was overexpressed in both differentiated and undifferentiated thyroid cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32613636", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613636", "evidence_list": [ { "evidence": "Here, we investigated the prognostic significance of CHI3L1 expression in thyroid neoplasms and examined the potential oncogenic roles. Compared with normal thyroid tissue and benign thyroid lesions that had low or no detectable CHI3L1 expression, CHI3L1 was overexpressed in both differentiated and undifferentiated thyroid cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Overexpression of chitinase-3-like protein 1 is associated with structural recurrence in patients with differentiated thyroid cancer.", "journal": "The Journal of pathology", "authors": "Cheng SP, Lee JJ, Chang YC, Lin CH, Li YS, Liu CL", "date": "2020-07-03", "evidence": [], "reference": [ { "id": "32613636", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32613636" } ] } ], "biomarker_canonical_id": "AA4844", "collision": 1 }, { "biomarker_id": "AN4128-1", "biomarker_component": [ { "biomarker": "decreased P4HA1 level", "assessed_biomarker_entity": { "recommended_name": "Prolyl 4-hydroxylase subunit alpha 1", "synonyms": [ { "synonym": "4-PH alpha-1" }, { "synonym": "Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P13674", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "32053263", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32053263", "evidence_list": [ { "evidence": "We studied further the significance of one of the genes, prolyl 4-hydroxylase subunit alpha 1 (P4HA1), in melanoma progression. P4HA1 depletion in melanoma cells reduced cell adhesion, invasion, and viability in vitro. Taken together, P4HA1 is an interesting potential prognostic marker and therapeutic target in primary melanomas, influencing many aspects of melanoma tumor progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "32053263", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32053263", "evidence_list": [ { "evidence": "We studied further the significance of one of the genes, prolyl 4-hydroxylase subunit alpha 1 (P4HA1), in melanoma progression. P4HA1 depletion in melanoma cells reduced cell adhesion, invasion, and viability in vitro. Taken together, P4HA1 is an interesting potential prognostic marker and therapeutic target in primary melanomas, influencing many aspects of melanoma tumor progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls.", "journal": "Molecular oncology", "authors": "Eriksson J, Le Joncour V, Jahkola T, Juteau S, Laakkonen P, Saksela O, H\u00f6ltt\u00e4 E", "date": "2020-02-14", "evidence": [], "reference": [ { "id": "32053263", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32053263" } ] } ], "biomarker_canonical_id": "AN4128", "collision": 1 }, { "biomarker_id": "AA4846-1", "biomarker_component": [ { "biomarker": "increased GDF15 level", "assessed_biomarker_entity": { "recommended_name": "Macrophage inhibitory cytokine 1", "synonyms": [ { "synonym": "GDF-15" }, { "synonym": "Macrophage inhibitory cytokine 1" }, { "synonym": "MIC-1" }, { "synonym": "NSAID-activated gene 1 protein" }, { "synonym": "NAG-1" }, { "synonym": "NSAID-regulated gene 1 protein" }, { "synonym": "NRG-1" }, { "synonym": "Placental TGF-beta" }, { "synonym": "Placental bone morphogenetic protein" }, { "synonym": "Prostate differentiation factor" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99988", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "16428484", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16428484", "evidence_list": [ { "evidence": "Ninety percent of patients with pancreatic cancer had MIC-1 levels >2 SD above age-matched controls. By logistic regression analysis, MIC-1 and CA19-9 were significant independent predictors of diagnosis. Receiver operating characteristic curve analysis showed that MIC-1 was significantly better than CA19-9 in differentiating patients with pancreatic cancer from healthy controls (area under the curve is 0.99 and 0.78, respectively; P = 0.003), but not in distinguishing pancreatic cancer from chronic pancreatitis (area under the curve of 0.81 and 0.74, respectively; P = 0.63). In the differentiation of patients with resectable pancreatic cancer from controls, serum MIC-1 outperforms other markers including CA19-9." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "16428484", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16428484", "evidence_list": [ { "evidence": "Ninety percent of patients with pancreatic cancer had MIC-1 levels >2 SD above age-matched controls. By logistic regression analysis, MIC-1 and CA19-9 were significant independent predictors of diagnosis. Receiver operating characteristic curve analysis showed that MIC-1 was significantly better than CA19-9 in differentiating patients with pancreatic cancer from healthy controls (area under the curve is 0.99 and 0.78, respectively; P = 0.003), but not in distinguishing pancreatic cancer from chronic pancreatitis (area under the curve of 0.81 and 0.74, respectively; P = 0.63). In the differentiation of patients with resectable pancreatic cancer from controls, serum MIC-1 outperforms other markers including CA19-9." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M", "date": "2006-01-24", "evidence": [], "reference": [ { "id": "16428484", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16428484" } ] } ], "biomarker_canonical_id": "AA4846", "collision": 1 }, { "biomarker_id": "AA4847-1", "biomarker_component": [ { "biomarker": "increased BNIP3L level", "assessed_biomarker_entity": { "recommended_name": "BCL2/Adenovirus E1B 19 kDa protein-interacting protein 3-like", "synonyms": [ { "synonym": "Adenovirus E1B19K-binding protein B5" }, { "synonym": "BCL2/adenovirus E1B 19 kDa protein-interacting protein 3A" }, { "synonym": "NIP3-like protein X" }, { "synonym": "NIP3L" } ] }, "assessed_biomarker_entity_id": "UPKB:O60238", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32620611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620611", "evidence_list": [ { "evidence": "A specific antibody response was raised against an antigen identified as BNIP3L, which correlated with a good prognosis. Medium and high expression of BNIP3L was also linked with longer overall survival. BNIP3L is a candidate prognostic marker of clinical outcome of melanoma patients treated with AGI-101H, and may be considered as a prediction marker for patient survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "32620611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620611", "evidence_list": [ { "evidence": "A specific antibody response was raised against an antigen identified as BNIP3L, which correlated with a good prognosis. Medium and high expression of BNIP3L was also linked with longer overall survival. BNIP3L is a candidate prognostic marker of clinical outcome of melanoma patients treated with AGI-101H, and may be considered as a prediction marker for patient survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H.", "journal": "Anticancer research", "authors": "Kazimierczak U, Kolenda T, Kowalczyk D, Mackiewicz J, Mackiewicz A", "date": "2020-07-06", "evidence": [], "reference": [ { "id": "32620611", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32620611" } ] } ], "biomarker_canonical_id": "AA4847", "collision": 1 }, { "biomarker_id": "AN4129-1", "biomarker_component": [ { "biomarker": "increased GPC6 level", "assessed_biomarker_entity": { "recommended_name": "Glypican 6", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9Y625", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "31199813", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31199813", "evidence_list": [ { "evidence": "GPC6 expression was up-regulated in a melanoma cell line compared to normal melanocytes and in metastatic melanoma compared to primary melanoma. Together, our findings identified GPC6 as an early biomarker for melanoma metastatic progression, one that can be regulated by miR-509-3p." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "31199813", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31199813", "evidence_list": [ { "evidence": "GPC6 expression was up-regulated in a melanoma cell line compared to normal melanocytes and in metastatic melanoma compared to primary melanoma. Together, our findings identified GPC6 as an early biomarker for melanoma metastatic progression, one that can be regulated by miR-509-3p." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma.", "journal": "PloS one", "authors": "Li Y, Li M, Shats I, Krahn JM, Flake GP, Umbach DM, Li X, Li L", "date": "2019-06-15", "evidence": [], "reference": [ { "id": "31199813", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31199813" } ] } ], "biomarker_canonical_id": "AN4129", "collision": 1 }, { "biomarker_id": "AA4849-1", "biomarker_component": [ { "biomarker": "decreased MIR-125A-5P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-125a-5p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000443", "assessed_entity_type": "miRNA", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "31325708", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31325708", "evidence_list": [ { "evidence": "miR-125a-5p downregulation was associated with recurrent disease in a panel of high-risk HNSCC and then confirmed poor survival associated with low expression in HNSCC via the Cancer Genome Atlas, suggesting that miR-125a-5p acts as a tumor suppressor miRNA. results reveal that in patients who developed a local recurrence, there was an associated decreased in miR-125a-5p expression, compared to patients who did not have evidence of disease (P = .0036), out of a total of 77 evaluable patient samples analyzed. patients with low levels of miR-125a-5p is associated with a worse overall survival than patients with high levels of miR-125a-5p (P = .006)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "31325708", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31325708", "evidence_list": [ { "evidence": "miR-125a-5p downregulation was associated with recurrent disease in a panel of high-risk HNSCC and then confirmed poor survival associated with low expression in HNSCC via the Cancer Genome Atlas, suggesting that miR-125a-5p acts as a tumor suppressor miRNA. results reveal that in patients who developed a local recurrence, there was an associated decreased in miR-125a-5p expression, compared to patients who did not have evidence of disease (P = .0036), out of a total of 77 evaluable patient samples analyzed. patients with low levels of miR-125a-5p is associated with a worse overall survival than patients with high levels of miR-125a-5p (P = .006)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.", "journal": "Neoplasia (New York, N.Y.)", "authors": "Vo DT, Karanam NK, Ding L, Saha D, Yordy JS, Giri U, Heymach JV, Story MD", "date": "2019-07-22", "evidence": [], "reference": [ { "id": "31325708", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31325708" } ] } ], "biomarker_canonical_id": "AA4849", "collision": 1 }, { "biomarker_id": "AN4130-1", "biomarker_component": [ { "biomarker": "increased GLT8D1 level", "assessed_biomarker_entity": { "recommended_name": "Glycosyltransferase 8 domain containing 1", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q68CQ7", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "31305325", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31305325", "evidence_list": [ { "evidence": "The GEO data analysis exhibited that the GLT8D1 mRNA expression was upregulated in the melanoma samples compared with the benign nevus samples. Furthermore, the GLT8D1 protein expression in cutaneous melanoma was higher than that in mucosal melanoma (P = 0.001). The high GLT8D1 protein expression was remarkably correlated with Clark level (P = 0.027), AJCC stage (P = 0.003), ulceration status (P = 0.041) Ki-67 expression (P = 0.030) and especially with histopathological type (P = 0.001). The results of the Kaplan-Meier survival and Cox regression analyses revealed that cutaneous melanoma patients with high GLT8D1 expression (P = 0.036), Clark level (P = 0.018) and advanced AJCC stage (P = 0.003) encountered poor overall survival. Overall survival (P = 0.040) and progression free survival (P = 0.019) were worse for the patients with high GLT8D1 expression than for the patients with low expression. These data implied that GLT8D1 could be an independent prognostic factor for an unfavorable prognosis in cutaneous malignant melanoma patients and that GLT8D1 overexpression might serve as a novel prognostic biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "31305325", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31305325", "evidence_list": [ { "evidence": "The GEO data analysis exhibited that the GLT8D1 mRNA expression was upregulated in the melanoma samples compared with the benign nevus samples. Furthermore, the GLT8D1 protein expression in cutaneous melanoma was higher than that in mucosal melanoma (P = 0.001). The high GLT8D1 protein expression was remarkably correlated with Clark level (P = 0.027), AJCC stage (P = 0.003), ulceration status (P = 0.041) Ki-67 expression (P = 0.030) and especially with histopathological type (P = 0.001). The results of the Kaplan-Meier survival and Cox regression analyses revealed that cutaneous melanoma patients with high GLT8D1 expression (P = 0.036), Clark level (P = 0.018) and advanced AJCC stage (P = 0.003) encountered poor overall survival. Overall survival (P = 0.040) and progression free survival (P = 0.019) were worse for the patients with high GLT8D1 expression than for the patients with low expression. These data implied that GLT8D1 could be an independent prognostic factor for an unfavorable prognosis in cutaneous malignant melanoma patients and that GLT8D1 overexpression might serve as a novel prognostic biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.", "journal": "Melanoma research", "authors": "Hu H, Li Z, Zhou Y, Zhang Y, Zhao L, Zhao W, Huang Y, Song X", "date": "2019-07-16", "evidence": [], "reference": [ { "id": "31305325", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31305325" } ] } ], "biomarker_canonical_id": "AN4130", "collision": 1 }, { "biomarker_id": "AA4851-1", "biomarker_component": [ { "biomarker": "decreased MIR-1231 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-1231", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0006321", "assessed_entity_type": "miRNA", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "31822000", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31822000", "evidence_list": [ { "evidence": "miR-1231 expression was downregulated in both prostate cancer tissues and cell lines. Downregulation of miR-1231 was significantly associated with lymph node metastasis, higher TNM stage, higher clinical stage, and shorter overall survival. The expression of miR-1231 was predicted as a prognostic factor for prostate cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "31822000", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31822000", "evidence_list": [ { "evidence": "miR-1231 expression was downregulated in both prostate cancer tissues and cell lines. Downregulation of miR-1231 was significantly associated with lymph node metastasis, higher TNM stage, higher clinical stage, and shorter overall survival. The expression of miR-1231 was predicted as a prognostic factor for prostate cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "miR-1231 Is Downregulated in Prostate Cancer with Prognostic and Functional Implications.", "journal": "Oncology research and treatment", "authors": "Wang Y, Zhang Q, Guo B, Feng J, Zhao D", "date": "2019-12-11", "evidence": [], "reference": [ { "id": "31822000", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31822000" } ] } ], "biomarker_canonical_id": "AA4851", "collision": 1 }, { "biomarker_id": "AA4852-1", "biomarker_component": [ { "biomarker": "increased YAP1 level", "assessed_biomarker_entity": { "recommended_name": "Yes-associated protein 1", "synonyms": [ { "synonym": "Yes-associated protein 1" }, { "synonym": "Protein yorkie homolog" }, { "synonym": "Yes-associated protein YAP65 homolog" } ] }, "assessed_biomarker_entity_id": "UPKB:P46937", "assessed_entity_type": "protein", "specimen": [ { "name": "pancreas", "id": "UBERON:0001264", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001264", "loinc_code": "" } ], "evidence_source": [ { "id": "32054505", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32054505", "evidence_list": [ { "evidence": "Mass spectrometry based proteomics showed that YAP1 is the top upregulated protein in pancreatic cancer tissue when compared to normal controls (log2 fold change 6.4; p = 5E-06). Prognostic analysis of YAP1 demonstrated a significant correlation between mRNA expression level data and reduced overall survival (p = 0.001). In addition, TMA and immunohistochemistry analysis suggested that YAP1 protein expression is an independent predictor of poor overall survival [hazard ratio (HR) 1.870, 95% confidence interval (CI) 1.224-2.855, p = 0.004], as well as reduced disease-free survival (HR 1.950, 95% CI 1.299-2.927, p = 0.001). Bioinformatic analyses coupled with in vitro assays indicated that YAP1 is involved in the transcriptional control of target genes, associated with extracellular matrix remodeling, which could be modified by selected substances disrupting the YAP1-TEAD interaction. We demonstrate that YAP1 is an independent prognostic marker associated with recurrence and unfavorable survival in pancreatic cancer. We also show that inhibition of YAP1/TEAD interaction interferes with the expression of AREG, CTGF, CYR61, and MSLN suggesting that YAP1 transcriptional activity may affect the development and persistence of a fibrotic tumor microenvironment. YAP1 is thus considered as a clinically and biologically relevant biomarker derived from pancreatic cancer tissue." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32054505", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32054505", "evidence_list": [ { "evidence": "Mass spectrometry based proteomics showed that YAP1 is the top upregulated protein in pancreatic cancer tissue when compared to normal controls (log2 fold change 6.4; p = 5E-06). Prognostic analysis of YAP1 demonstrated a significant correlation between mRNA expression level data and reduced overall survival (p = 0.001). In addition, TMA and immunohistochemistry analysis suggested that YAP1 protein expression is an independent predictor of poor overall survival [hazard ratio (HR) 1.870, 95% confidence interval (CI) 1.224-2.855, p = 0.004], as well as reduced disease-free survival (HR 1.950, 95% CI 1.299-2.927, p = 0.001). Bioinformatic analyses coupled with in vitro assays indicated that YAP1 is involved in the transcriptional control of target genes, associated with extracellular matrix remodeling, which could be modified by selected substances disrupting the YAP1-TEAD interaction. We demonstrate that YAP1 is an independent prognostic marker associated with recurrence and unfavorable survival in pancreatic cancer. We also show that inhibition of YAP1/TEAD interaction interferes with the expression of AREG, CTGF, CYR61, and MSLN suggesting that YAP1 transcriptional activity may affect the development and persistence of a fibrotic tumor microenvironment. YAP1 is thus considered as a clinically and biologically relevant biomarker derived from pancreatic cancer tissue." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "YAP1 is an independent prognostic marker in pancreatic cancer and associated with extracellular matrix remodeling.", "journal": "Journal of translational medicine", "authors": "Zhou Q, Bauden M, Andersson R, Hu D, Marko-Varga G, Xu J, Sasor A, Dai H, Paw\u0142owski K, Said Hilmersson K, Chen X, Ansari D", "date": "2020-02-15", "evidence": [], "reference": [ { "id": "32054505", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32054505" } ] } ], "biomarker_canonical_id": "AA4852", "collision": 1 }, { "biomarker_id": "AN4131-1", "biomarker_component": [ { "biomarker": "increased ASPM level", "assessed_biomarker_entity": { "recommended_name": "Abnormal spindle-like microcephaly-associated protein", "synonyms": [ { "synonym": "Abnormal spindle protein homolog" }, { "synonym": "Asp homolog" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8IZT6", "assessed_entity_type": "protein", "specimen": [ { "name": "urinary bladder", "id": "UBERON:0001255", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001255", "loinc_code": "" } ], "evidence_source": [ { "id": "32274607", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607", "evidence_list": [ { "evidence": "The upregulation of ASPM expression and the downregulation of TEF expression were observed in bladder cancer tissues compared to adjacent normal tissues, and these levels were correlated with high-grade tumors, advanced stage disease and the presence of metastasis. Both genes had the ability to predict metastatic association with sensitivity (84.62%) and specificity (68.42%; *P < 0.001) for the ASPM gene and for the TEF gene with sensitivity (80.77%) and specificity (78.95%; *P < 0.001). Additionally, Kaplan-Meier survival analysis indicated that elevated ASPM expression levels and reduced TEF expression levels significantly correlated with decreased overall survival and progression-free survival. The current analysis concludes that ASPM and TEF expressions might be used as potential biomarkers in bladder cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32274607", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607", "evidence_list": [ { "evidence": "The upregulation of ASPM expression and the downregulation of TEF expression were observed in bladder cancer tissues compared to adjacent normal tissues, and these levels were correlated with high-grade tumors, advanced stage disease and the presence of metastasis. Both genes had the ability to predict metastatic association with sensitivity (84.62%) and specificity (68.42%; *P < 0.001) for the ASPM gene and for the TEF gene with sensitivity (80.77%) and specificity (78.95%; *P < 0.001). Additionally, Kaplan-Meier survival analysis indicated that elevated ASPM expression levels and reduced TEF expression levels significantly correlated with decreased overall survival and progression-free survival. The current analysis concludes that ASPM and TEF expressions might be used as potential biomarkers in bladder cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer.", "journal": "Biochemical genetics", "authors": "Saleh AA, Gohar SF, Hemida AS, Elgharbawy M, Soliman SE", "date": "2020-04-11", "evidence": [], "reference": [ { "id": "32274607", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607" } ] } ], "biomarker_canonical_id": "AN4131", "collision": 1 }, { "biomarker_id": "AN4132-1", "biomarker_component": [ { "biomarker": "decreased TEF level", "assessed_biomarker_entity": { "recommended_name": "Thyrotroph embryonic factor", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q10587", "assessed_entity_type": "protein", "specimen": [ { "name": "urinary bladder", "id": "UBERON:0001255", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001255", "loinc_code": "" } ], "evidence_source": [ { "id": "32274607", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607", "evidence_list": [ { "evidence": "The upregulation of ASPM expression and the downregulation of TEF expression were observed in bladder cancer tissues compared to adjacent normal tissues, and these levels were correlated with high-grade tumors, advanced stage disease and the presence of metastasis. Both genes had the ability to predict metastatic association with sensitivity (84.62%) and specificity (68.42%; *P < 0.001) for the ASPM gene and for the TEF gene with sensitivity (80.77%) and specificity (78.95%; *P < 0.001). Additionally, Kaplan-Meier survival analysis indicated that elevated ASPM expression levels and reduced TEF expression levels significantly correlated with decreased overall survival and progression-free survival. The current analysis concludes that ASPM and TEF expressions might be used as potential biomarkers in bladder cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32274607", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607", "evidence_list": [ { "evidence": "The upregulation of ASPM expression and the downregulation of TEF expression were observed in bladder cancer tissues compared to adjacent normal tissues, and these levels were correlated with high-grade tumors, advanced stage disease and the presence of metastasis. Both genes had the ability to predict metastatic association with sensitivity (84.62%) and specificity (68.42%; *P < 0.001) for the ASPM gene and for the TEF gene with sensitivity (80.77%) and specificity (78.95%; *P < 0.001). Additionally, Kaplan-Meier survival analysis indicated that elevated ASPM expression levels and reduced TEF expression levels significantly correlated with decreased overall survival and progression-free survival. The current analysis concludes that ASPM and TEF expressions might be used as potential biomarkers in bladder cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer.", "journal": "Biochemical genetics", "authors": "Saleh AA, Gohar SF, Hemida AS, Elgharbawy M, Soliman SE", "date": "2020-04-11", "evidence": [], "reference": [ { "id": "32274607", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32274607" } ] } ], "biomarker_canonical_id": "AN4132", "collision": 1 }, { "biomarker_id": "AN4133-1", "biomarker_component": [ { "biomarker": "increased SVV level", "assessed_biomarker_entity": { "recommended_name": "Survivin", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C37449", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "11176843", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11176843", "evidence_list": [ { "evidence": "The sensitivity of the urine survivin test for new or recurrent bladder cancer was 100%, and its specificity for other neoplastic and nonneoplastic genitourinary tract diseases was 95%. Undetectable in most normal adult tissues, survivin becomes the top fourth transcript expressed in common human cancers, in which it correlates with unfavorable disease and abbreviated overall survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "11176843", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11176843", "evidence_list": [ { "evidence": "The sensitivity of the urine survivin test for new or recurrent bladder cancer was 100%, and its specificity for other neoplastic and nonneoplastic genitourinary tract diseases was 95%. Undetectable in most normal adult tissues, survivin becomes the top fourth transcript expressed in common human cancers, in which it correlates with unfavorable disease and abbreviated overall survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urine detection of survivin and diagnosis of bladder cancer.", "journal": "JAMA", "authors": "Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC", "date": "2001-02-15", "evidence": [], "reference": [ { "id": "11176843", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11176843" } ] } ], "biomarker_canonical_id": "AN4133", "collision": 1 }, { "biomarker_id": "AA4855-1", "biomarker_component": [ { "biomarker": "increased A1AT level", "assessed_biomarker_entity": { "recommended_name": "Alpha-1-antitrypsin", "synonyms": [ { "synonym": "Alpha-1 protease inhibitor" }, { "synonym": "Alpha-1-antiproteinase" }, { "synonym": "Serpin A1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01009", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "21459797", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21459797", "evidence_list": [ { "evidence": "Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "21459797", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21459797", "evidence_list": [ { "evidence": "Increased levels of urinary A1AT glycoprotein were indicative of the presence of bladder cancer (P < 0.0001) and augmented voided urine cytology results. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the noninvasive detection of bladder cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S", "date": "2011-04-05", "evidence": [], "reference": [ { "id": "21459797", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21459797" } ] } ], "biomarker_canonical_id": "AA4855", "collision": 1 }, { "biomarker_id": "AA4856-1", "biomarker_component": [ { "biomarker": "increased OPN level", "assessed_biomarker_entity": { "recommended_name": "Osteopontin", "synonyms": [ { "synonym": "Bone sialoprotein 1" }, { "synonym": "Nephropontin" }, { "synonym": "Secreted phosphoprotein 1" }, { "synonym": "SPP-1" }, { "synonym": "Urinary stone protein" }, { "synonym": "Uropontin" } ] }, "assessed_biomarker_entity_id": "UPKB:P10451", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "15006928", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15006928", "evidence_list": [ { "evidence": "Serum OPN levels, as measured by ELISA, were elevated in the sera of 50 patients with resectable pancreatic adenocarcinoma compared to 22 healthy control individuals (mean +/- SD for OPN was 482 +/- 170 ng/ml and 204 +/- 65 ng/ml, respectively; P < 0.001). Serum OPN may have utility as a diagnostic marker in patients with pancreatic cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "15006928", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15006928", "evidence_list": [ { "evidence": "Serum OPN levels, as measured by ELISA, were elevated in the sera of 50 patients with resectable pancreatic adenocarcinoma compared to 22 healthy control individuals (mean +/- SD for OPN was 482 +/- 170 ng/ml and 204 +/- 65 ng/ml, respectively; P < 0.001). Serum OPN may have utility as a diagnostic marker in patients with pancreatic cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M", "date": "2004-03-10", "evidence": [], "reference": [ { "id": "15006928", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15006928" } ] } ], "biomarker_canonical_id": "AA4856", "collision": 1 }, { "biomarker_id": "AA4856-2", "biomarker_component": [ { "biomarker": "increased OPN level", "assessed_biomarker_entity": { "recommended_name": "Osteopontin", "synonyms": [ { "synonym": "Bone sialoprotein 1" }, { "synonym": "Nephropontin" }, { "synonym": "Secreted phosphoprotein 1" }, { "synonym": "SPP-1" }, { "synonym": "Urinary stone protein" }, { "synonym": "Uropontin" } ] }, "assessed_biomarker_entity_id": "UPKB:P10451", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "11926891", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891", "evidence_list": [ { "evidence": "Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "11926891", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891", "evidence_list": [ { "evidence": "Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Osteopontin as a potential diagnostic biomarker for ovarian cancer.", "journal": "JAMA", "authors": "Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC", "date": "2002-04-03", "evidence": [], "reference": [ { "id": "11926891", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891" } ] } ], "biomarker_canonical_id": "AA4856", "collision": 1 }, { "biomarker_id": "AN4134-1", "biomarker_component": [ { "biomarker": "increased TNFSF9 level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor ligand superfamily member 9", "synonyms": [ { "synonym": "4-1BB ligand" }, { "synonym": "4-1BBL" } ] }, "assessed_biomarker_entity_id": "UPKB:P41273", "assessed_entity_type": "protein", "specimen": [ { "name": "pancreas", "id": "UBERON:0001264", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001264", "loinc_code": "" } ], "evidence_source": [ { "id": "32077004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077004", "evidence_list": [ { "evidence": "TNFSF9 mRNA expression level was remarkably increased in pancreatic cancer than that in normal tissues (both P < 0.05). In addition, high TNFSF9 expression was significantly related to poor overall survival (OS) and relapse-free survival (RFS) in pancreatic cancer (OS HR = 2.02, P = 0.0012; RFS HR = 2.63, P = 0.022). These findings indicate that TNFSF9 can be serves as a prognostic biomarker in determining the prognosis of pancreatic cancer and is associated with different types of phenotypes of immune cell infiltration." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32077004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077004", "evidence_list": [ { "evidence": "TNFSF9 mRNA expression level was remarkably increased in pancreatic cancer than that in normal tissues (both P < 0.05). In addition, high TNFSF9 expression was significantly related to poor overall survival (OS) and relapse-free survival (RFS) in pancreatic cancer (OS HR = 2.02, P = 0.0012; RFS HR = 2.63, P = 0.022). These findings indicate that TNFSF9 can be serves as a prognostic biomarker in determining the prognosis of pancreatic cancer and is associated with different types of phenotypes of immune cell infiltration." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.", "journal": "Journal of gastrointestinal cancer", "authors": "Wu J, Wang Y, Jiang Z", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32077004", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32077004" } ] } ], "biomarker_canonical_id": "AN4134", "collision": 1 }, { "biomarker_id": "AN4135-1", "biomarker_component": [ { "biomarker": "increased NCEH1 level", "assessed_biomarker_entity": { "recommended_name": "Neutral cholesterol ester hydrolase 1", "synonyms": [ { "synonym": "NCEH" }, { "synonym": "Acetylalkylglycerol acetylhydrolase" }, { "synonym": "2-acetyl MAGE hydrolase" }, { "synonym": "Arylacetamide deacetylase-like 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q6PIU2", "assessed_entity_type": "protein", "specimen": [ { "name": "pancreas", "id": "UBERON:0001264", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001264", "loinc_code": "" } ], "evidence_source": [ { "id": "33284889", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33284889", "evidence_list": [ { "evidence": "Elevated ether lipid metabolism is one of the characteristics of cancer cells. NCEH1 is involved in ether lipid metabolism and is robustly expressed in macrophages. We also found that the expression level of NCEH1 in patients with pancreatic cancer is related to the N classification (P = 0.039), indicating that patients with local lymph node involvement express higher levels of NCEH1. From the differential analysis, the expression level of NCEH1 in cancer tissues was significantly higher than that in healthy tissues (P = 1.732 e-50) Wilcoxon test indicated that the expression level of NCEH1 is related to the N classification in patients with pancreatic cancer (P = 0.039). Further, NCEH1 expression was higher in patients with regional lymph node involvement than in the control group." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "33284889", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33284889", "evidence_list": [ { "evidence": "Elevated ether lipid metabolism is one of the characteristics of cancer cells. NCEH1 is involved in ether lipid metabolism and is robustly expressed in macrophages. We also found that the expression level of NCEH1 in patients with pancreatic cancer is related to the N classification (P = 0.039), indicating that patients with local lymph node involvement express higher levels of NCEH1. From the differential analysis, the expression level of NCEH1 in cancer tissues was significantly higher than that in healthy tissues (P = 1.732 e-50) Wilcoxon test indicated that the expression level of NCEH1 is related to the N classification in patients with pancreatic cancer (P = 0.039). Further, NCEH1 expression was higher in patients with regional lymph node involvement than in the control group." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NCEH1 may be a prognostic biomarker for pancreatic cancer.", "journal": "International journal of clinical and experimental pathology", "authors": "Lu Y, Zhang L, Chen X, Zhang Q", "date": "2020-12-08", "evidence": [], "reference": [ { "id": "33284889", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33284889" } ] } ], "biomarker_canonical_id": "AN4135", "collision": 1 }, { "biomarker_id": "AA4859-1", "biomarker_component": [ { "biomarker": "increased PSMD11 level", "assessed_biomarker_entity": { "recommended_name": "26S proteasome non-ATPase regulatory subunit 11", "synonyms": [ { "synonym": "26S proteasome regulatory subunit RPN6" }, { "synonym": "26S proteasome regulatory subunit S9" }, { "synonym": "26S proteasome regulatory subunit p44.5" } ] }, "assessed_biomarker_entity_id": "UPKB:O00231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.", "journal": "Biochimica et biophysica acta. General subjects", "authors": "Sahni S, Krisp C, Molloy MP, Nahm C, Maloney S, Gillson J, Gill AJ, Samra J, Mittal A", "date": "2020-07-15", "evidence": [], "reference": [ { "id": "32663515", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515" } ] } ], "biomarker_canonical_id": "AA4859", "collision": 1 }, { "biomarker_id": "AA4860-1", "biomarker_component": [ { "biomarker": "decreased PTPRM level", "assessed_biomarker_entity": { "recommended_name": "Receptor-type tyrosine-protein phosphatase mu", "synonyms": [ { "synonym": "Protein-tyrosine phosphatase mu" }, { "synonym": "R-PTP-mu" } ] }, "assessed_biomarker_entity_id": "UPKB:P28827", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.", "journal": "Biochimica et biophysica acta. General subjects", "authors": "Sahni S, Krisp C, Molloy MP, Nahm C, Maloney S, Gillson J, Gill AJ, Samra J, Mittal A", "date": "2020-07-15", "evidence": [], "reference": [ { "id": "32663515", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515" } ] } ], "biomarker_canonical_id": "AA4860", "collision": 1 }, { "biomarker_id": "AA4861-1", "biomarker_component": [ { "biomarker": "decreased PTPRB level", "assessed_biomarker_entity": { "recommended_name": "Receptor-type tyrosine-protein phosphatase beta", "synonyms": [ { "synonym": "Protein-tyrosine phosphatase beta" }, { "synonym": "R-PTP-beta" }, { "synonym": "Vascular endothelial protein tyrosine phosphatase" }, { "synonym": "VE-PTP" } ] }, "assessed_biomarker_entity_id": "UPKB:P23467", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "32663515", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515", "evidence_list": [ { "evidence": "This exploratory study, using SWATH-MS analysis, identified potential prognostic biomarkers for PDAC in plasma (PTPRM and PTPRB) and plasma derived microparticles (PSMD11). Protein tyrosine phosphatases, PTPRM and PTPRB, were decreased in plasma of patients with poor PDAC prognosis, while proteasomal subunit PSMD11 was increased in microparticles of patients with poor prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.", "journal": "Biochimica et biophysica acta. General subjects", "authors": "Sahni S, Krisp C, Molloy MP, Nahm C, Maloney S, Gillson J, Gill AJ, Samra J, Mittal A", "date": "2020-07-15", "evidence": [], "reference": [ { "id": "32663515", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32663515" } ] } ], "biomarker_canonical_id": "AA4861", "collision": 1 }, { "biomarker_id": "AN4136-1", "biomarker_component": [ { "biomarker": "increased TYMS level", "assessed_biomarker_entity": { "recommended_name": "Thymidylate synthase", "synonyms": [ { "synonym": "TS" }, { "synonym": "TSase" } ] }, "assessed_biomarker_entity_id": "UPKB:P04818", "assessed_entity_type": "protein", "specimen": [ { "name": "pancreas", "id": "UBERON:0001264", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001264", "loinc_code": "" } ], "evidence_source": [ { "id": "31861032", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31861032", "evidence_list": [ { "evidence": "Upregulation of TYMS was associated with poor RFS in patients with pancreatic cancer (P = .021). Subgroup analysis revealed that TYMS upregulation was associated with poor RFS in clinical stage I/II (P = .0038). Higher TYMS expression was associated with worse OS (P = .014) (Fig. 3). Subgroup analysis further indicated that high TYMS expression significantly affected the OS of patients in histologic grades G1/G2 (P = .025) and clinical stages I/II (P = .023). patients with pancreatic cancer, higher TYMS expression is associated with advanced clinical stages and undesirable prognosis, and that TYMS could be used as a biomarker for diagnostic and prognostic evaluation in patients with pancreatic cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "31861032", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31861032", "evidence_list": [ { "evidence": "Upregulation of TYMS was associated with poor RFS in patients with pancreatic cancer (P = .021). Subgroup analysis revealed that TYMS upregulation was associated with poor RFS in clinical stage I/II (P = .0038). Higher TYMS expression was associated with worse OS (P = .014) (Fig. 3). Subgroup analysis further indicated that high TYMS expression significantly affected the OS of patients in histologic grades G1/G2 (P = .025) and clinical stages I/II (P = .023). patients with pancreatic cancer, higher TYMS expression is associated with advanced clinical stages and undesirable prognosis, and that TYMS could be used as a biomarker for diagnostic and prognostic evaluation in patients with pancreatic cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer.", "journal": "Medicine", "authors": "Fu Z, Jiao Y, Li Y, Ji B, Jia B, Liu B", "date": "2019-12-22", "evidence": [], "reference": [ { "id": "31861032", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31861032" } ] } ], "biomarker_canonical_id": "AN4136", "collision": 1 }, { "biomarker_id": "AN4137-1", "biomarker_component": [ { "biomarker": "increased ST6GALNAC6 level", "assessed_biomarker_entity": { "recommended_name": "Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6", "synonyms": [ { "synonym": "GalNAc alpha-2,6-sialyltransferase VI" }, { "synonym": "ST6GalNAc VI" }, { "synonym": "ST6GalNAcVI" }, { "synonym": "hST6GalNAc VI" }, { "synonym": "Sialyltransferase 7F" }, { "synonym": "SIAT7-F" } ] }, "assessed_biomarker_entity_id": "UPKB:Q969X2", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30131287", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30131287", "evidence_list": [ { "evidence": "In patients with pancreatic cancer, 8.4% of subjects were Lewis (-), but only 41.9% of Lewis (-) subjects had CA19-9 values 37 U/mL) in 27.4% of Lewis (-) patients. CA19-9 can retain its utility as a biomarker in these patients in spite of Lewis (-) genotype. The area under the receiver operating characteristic (ROC) curve for CA19-9 as a diagnostic biomarker was 0.842 in Lewis (-) patients with pancreatic cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "30131287", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30131287", "evidence_list": [ { "evidence": "In patients with pancreatic cancer, 8.4% of subjects were Lewis (-), but only 41.9% of Lewis (-) subjects had CA19-9 values 37 U/mL) in 27.4% of Lewis (-) patients. CA19-9 can retain its utility as a biomarker in these patients in spite of Lewis (-) genotype. The area under the receiver operating characteristic (ROC) curve for CA19-9 as a diagnostic biomarker was 0.842 in Lewis (-) patients with pancreatic cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.", "journal": "Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]", "authors": "Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X", "date": "2018-08-23", "evidence": [], "reference": [ { "id": "30131287", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30131287" } ] } ], "biomarker_canonical_id": "AN4137", "collision": 1 }, { "biomarker_id": "AA4864-1", "biomarker_component": [ { "biomarker": "increased ARHGDIB level", "assessed_biomarker_entity": { "recommended_name": "Rho GDP dissociation inhibitor protein", "synonyms": [ { "synonym": "Rho GDI 2" }, { "synonym": "Ly-GDI" }, { "synonym": "Rho-GDI beta" } ] }, "assessed_biomarker_entity_id": "UPKB:P52566", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "32176626", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32176626", "evidence_list": [ { "evidence": "We observed the expression of ARHGDIB is significantly higher in human breast cancer tissues compared with the benign tissues. ARHGDIB expression was positively correlated with tumor size, lymph node metastasis and TNM stage in breast cancer patients. Hence, our results suggested the significance and predictive role of ARHGDIB in breast cancer. High expression of ARHGDIB indicated the poor prognosis for breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32176626", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32176626", "evidence_list": [ { "evidence": "We observed the expression of ARHGDIB is significantly higher in human breast cancer tissues compared with the benign tissues. ARHGDIB expression was positively correlated with tumor size, lymph node metastasis and TNM stage in breast cancer patients. Hence, our results suggested the significance and predictive role of ARHGDIB in breast cancer. High expression of ARHGDIB indicated the poor prognosis for breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Systematic investigation of biomarker-like role of ARHGDIB in breast cancer.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Wang X, Bi X, Huang X, Wang B, Guo Q, Wu Z", "date": "2020-03-17", "evidence": [], "reference": [ { "id": "32176626", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32176626" } ] } ], "biomarker_canonical_id": "AA4864", "collision": 1 }, { "biomarker_id": "AA4865-1", "biomarker_component": [ { "biomarker": "decreased SMPD1 level", "assessed_biomarker_entity": { "recommended_name": "Acid sphingomyelinase", "synonyms": [ { "synonym": "Acid sphingomyelinase" }, { "synonym": "aSMase" } ] }, "assessed_biomarker_entity_id": "UPKB:P17405", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "26125272", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26125272", "evidence_list": [ { "evidence": "The levels of ASM were reducing with the development of ovarian cancer. ASM is higher expressed in normal cell than that in ovarian cancer, and can be a negative biomarker for the diagnosis of ovarian cancer. ASM can be developed a new drug for the ovarian cancer therapy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "26125272", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26125272", "evidence_list": [ { "evidence": "The levels of ASM were reducing with the development of ovarian cancer. ASM is higher expressed in normal cell than that in ovarian cancer, and can be a negative biomarker for the diagnosis of ovarian cancer. ASM can be developed a new drug for the ovarian cancer therapy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Acid sphingomyelinase, a novel negative biomarker of ovarian cancer.", "journal": "European review for medical and pharmacological sciences", "authors": "Dai SY, Liu JJ, Sun XF, Wang N", "date": "2015-07-01", "evidence": [], "reference": [ { "id": "26125272", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26125272" } ] } ], "biomarker_canonical_id": "AA4865", "collision": 1 }, { "biomarker_id": "AN4138-1", "biomarker_component": [ { "biomarker": "increased NFE2L2 level", "assessed_biomarker_entity": { "recommended_name": "Nuclear factor erythroid 2-related factor 2", "synonyms": [ { "synonym": "NF-E2-related factor 2" }, { "synonym": "NFE2-related factor 2" }, { "synonym": "Nrf-2" }, { "synonym": "HEBP1" }, { "synonym": "Nuclear factor, erythroid derived 2, like 2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16236", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "" } ], "evidence_source": [ { "id": "32871287", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32871287", "evidence_list": [ { "evidence": "High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets. NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32871287", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32871287", "evidence_list": [ { "evidence": "High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets. NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.", "journal": "Cancer genetics", "authors": "O'Cathail SM, Wu CH, Lewis A, Holmes C, Hawkins MA, Maughan T", "date": "2020-09-02", "evidence": [], "reference": [ { "id": "32871287", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32871287" } ] } ], "biomarker_canonical_id": "AN4138", "collision": 1 }, { "biomarker_id": "AN4139-1", "biomarker_component": [ { "biomarker": "increased KRT15 level", "assessed_biomarker_entity": { "recommended_name": "Keratin-15", "synonyms": [ { "synonym": "Cytokeratin-15" }, { "synonym": "CK-15" }, { "synonym": "Keratin-15" }, { "synonym": "K15" } ] }, "assessed_biomarker_entity_id": "UPKB:P19012", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "" } ], "evidence_source": [ { "id": "31884802", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31884802", "evidence_list": [ { "evidence": "QRT-PCR results revealed that the mRNA levels of KRT15 in colorectal cancer tissues were significantly higher compared with those in normal tissues (p<0.0001). The rates of KRT15 high-expression in colorectal cancer and normal tissues were 57.1% and 8.9%, respectively, and the difference was statistically significant (p<0.0001). KRT15 high-expression correlated with differentiation, T stage, lymph node metastasis and clinical stage in colorectal cancer (p<0.05). KRT15 overexpression predicted poor prognosis and could be used as an independent prognostic factor. These data indicate KRT15 is highly expressed in colorectal cancer and may serve as a prognostic biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "31884802", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31884802", "evidence_list": [ { "evidence": "QRT-PCR results revealed that the mRNA levels of KRT15 in colorectal cancer tissues were significantly higher compared with those in normal tissues (p<0.0001). The rates of KRT15 high-expression in colorectal cancer and normal tissues were 57.1% and 8.9%, respectively, and the difference was statistically significant (p<0.0001). KRT15 high-expression correlated with differentiation, T stage, lymph node metastasis and clinical stage in colorectal cancer (p<0.05). KRT15 overexpression predicted poor prognosis and could be used as an independent prognostic factor. These data indicate KRT15 is highly expressed in colorectal cancer and may serve as a prognostic biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "KRT15 overexpression predicts poor prognosis in\u00a0colorectal cancer.", "journal": "Neoplasma", "authors": "Rao X, Wang J, Song HM, Deng B, Li JG", "date": "2019-12-31", "evidence": [], "reference": [ { "id": "31884802", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31884802" } ] } ], "biomarker_canonical_id": "AN4139", "collision": 1 }, { "biomarker_id": "AA4868-1", "biomarker_component": [ { "biomarker": "increased MIR-135A-5P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-135a-5p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000428", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27126269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27126269", "evidence_list": [ { "evidence": "Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls, suggesting that serum miR-135a-5p may prove to be an important biomarker for auxiliary diagnosis of colorectal cancer. The relative expression level of serum miR-135a-5p in colorectal cancer patients, colorectal polyps patients and healthy controls was 2.451 (1.107, 4.413), 0.946 (0.401, 1.942) and 0.949 (0.194, 1.415), respectively, indicating that it was significantly higher in colorectal cancer patients than that in the other two groups (U = 351.0, 313.0, both P < 0.001). Additionally, it was significantly correlated with different degrees of tumour differentiation (U = 215.0, P = 0.029) and different tumour stages (U = 202.0, P = 0.013)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "27126269", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27126269", "evidence_list": [ { "evidence": "Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls, suggesting that serum miR-135a-5p may prove to be an important biomarker for auxiliary diagnosis of colorectal cancer. The relative expression level of serum miR-135a-5p in colorectal cancer patients, colorectal polyps patients and healthy controls was 2.451 (1.107, 4.413), 0.946 (0.401, 1.942) and 0.949 (0.194, 1.415), respectively, indicating that it was significantly higher in colorectal cancer patients than that in the other two groups (U = 351.0, 313.0, both P < 0.001). Additionally, it was significantly correlated with different degrees of tumour differentiation (U = 215.0, P = 0.029) and different tumour stages (U = 202.0, P = 0.013)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer.", "journal": "Annals of clinical biochemistry", "authors": "Wang Q, Zhang H, Shen X, Ju S", "date": "2016-04-30", "evidence": [], "reference": [ { "id": "27126269", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27126269" } ] } ], "biomarker_canonical_id": "AA4868", "collision": 1 }, { "biomarker_id": "AA4869-1", "biomarker_component": [ { "biomarker": "decreased B3GALT5-AS1 level", "assessed_biomarker_entity": { "recommended_name": "Putative uncharacterized protein B3GALT5-AS1", "synonyms": [ { "synonym": "B3GALT5 antisense RNA 1" }, { "synonym": "B3GALT5 antisense gene protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P59052", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32207329", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32207329", "evidence_list": [ { "evidence": "The level of B3GALT5-AS1 in CRC patients was significantly lower than that of healthy patients (p < 0.0001). B3GALT5-AS1 may be served as a diagnostic marker for distinguishing CRC patients from healthy people. Further exploration validated that high serum B3GALT5-AS1 level was related to tumor node metastasis (TNM) stage (p = 0.008) and histological differentiation (p = 0.027). Compared with the healthy control group, AUCROC of serum B3GALT5-AS1 in the CRC group was 0.762 with 95% CI: 0.698-0.826 (p < 0.0001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32207329", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32207329", "evidence_list": [ { "evidence": "The level of B3GALT5-AS1 in CRC patients was significantly lower than that of healthy patients (p < 0.0001). B3GALT5-AS1 may be served as a diagnostic marker for distinguishing CRC patients from healthy people. Further exploration validated that high serum B3GALT5-AS1 level was related to tumor node metastasis (TNM) stage (p = 0.008) and histological differentiation (p = 0.027). Compared with the healthy control group, AUCROC of serum B3GALT5-AS1 in the CRC group was 0.762 with 95% CI: 0.698-0.826 (p < 0.0001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer.", "journal": "Future oncology (London, England)", "authors": "Ding Y, Feng W, Ge JK, Dai L, Liu TT, Hua XY, Lu X, Ju SQ, Yu J", "date": "2020-03-25", "evidence": [], "reference": [ { "id": "32207329", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32207329" } ] } ], "biomarker_canonical_id": "AA4869", "collision": 1 }, { "biomarker_id": "AN4460-1", "biomarker_component": [ { "biomarker": "measured CRP, ALB level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured CRP, ALB level", "assessed_biomarker_entity": { "recommended_name": "C-reactive protein to Albumin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02768", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32279124", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124", "evidence_list": [ { "evidence": "Patients with CAR (C-reactive protein/albumin ratios) were predictors for overall survival (OS). Different analysis showed that patients with postoperative complications, preoperative NLR, and postoperative CAR, were more subject to recurrence-free survival (RFS). It showed that patients who did not receive chemotherapy with CAR >/= 0.035 had a shorter RFS and OS than those who did receive chemo. The postoperative CAR is strongly associated with a poor prognosis in patients with stage III colorectal cancer. It is more readily available than other proposed prognostic scores based on inflammation markers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.", "journal": "International journal of clinical oncology", "authors": "Matsuoka H, Ando K, Hu Q, Zaitsu Y, Tsuda Y, Hisamatsu Y, Nakashima Y, Kimura Y, Oki E, Mori M", "date": "2020-04-13", "evidence": [], "reference": [ { "id": "32279124", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124" } ] }, { "title": "Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.", "journal": "International journal of clinical oncology", "authors": "Matsuoka H, Ando K, Hu Q, Zaitsu Y, Tsuda Y, Hisamatsu Y, Nakashima Y, Kimura Y, Oki E, Mori M", "date": "2020-04-13", "evidence": [], "reference": [ { "id": "32279124", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32279124" } ] } ], "biomarker_canonical_id": "AN4460", "collision": 0 }, { "biomarker_id": "AA4870-1", "biomarker_component": [ { "biomarker": "increased MIR-10B level", "assessed_biomarker_entity": { "recommended_name": "miRNA-10b", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000267", "assessed_entity_type": "miRNA", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Salivary microRNAs as promising biomarkers for detection of esophageal cancer.", "journal": "PloS one", "authors": "Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z", "date": "2013-04-06", "evidence": [], "reference": [ { "id": "23560033", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033" } ] } ], "biomarker_canonical_id": "AA4870", "collision": 1 }, { "biomarker_id": "AA4871-1", "biomarker_component": [ { "biomarker": "increased MIR-144 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-144", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000460", "assessed_entity_type": "miRNA", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Salivary microRNAs as promising biomarkers for detection of esophageal cancer.", "journal": "PloS one", "authors": "Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z", "date": "2013-04-06", "evidence": [], "reference": [ { "id": "23560033", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033" } ] } ], "biomarker_canonical_id": "AA4871", "collision": 1 }, { "biomarker_id": "AA4872-1", "biomarker_component": [ { "biomarker": "increased MIR-451 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-451", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0001729", "assessed_entity_type": "miRNA", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Salivary microRNAs as promising biomarkers for detection of esophageal cancer.", "journal": "PloS one", "authors": "Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z", "date": "2013-04-06", "evidence": [], "reference": [ { "id": "23560033", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033" } ] } ], "biomarker_canonical_id": "AA4872", "collision": 1 }, { "biomarker_id": "AA4873-1", "biomarker_component": [ { "biomarker": "increased MIR-21 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-21", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000077", "assessed_entity_type": "miRNA", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "23560033", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033", "evidence_list": [ { "evidence": "miR-10b*, miR-144, miR-21, and miR-451 in saliva supernatant were significantly upregulated in patients, with sensitivities of 89.7, 92.3, 84.6, 79.5, 43.6, 89.7, and 51.3% and specificities of 57.9, 47.4, 57.9%, 57.9, 89.5, 47.4, and 84.2%, respectively. We found distinctive miRNAs for esophageal cancer in both whole saliva and saliva supernatant. These miRNAs possess discriminatory power for detection of esophageal cancer. Because saliva collection is noninvasive and convenient, salivary miRNAs show great promise as biomarkers for detection of esophageal cancer in areas at high risk." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Salivary microRNAs as promising biomarkers for detection of esophageal cancer.", "journal": "PloS one", "authors": "Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z", "date": "2013-04-06", "evidence": [], "reference": [ { "id": "23560033", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23560033" } ] } ], "biomarker_canonical_id": "AA4873", "collision": 1 }, { "biomarker_id": "AA4873-2", "biomarker_component": [ { "biomarker": "increased MIR-21 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-21", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000077", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31030498", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31030498", "evidence_list": [ { "evidence": "Expression of circulating miR-21 was significantly elevated in breast cancer patients compared to healthy women (median miR-21 expression levels were 7.67\u00b12.2 and 1.28\u00b10.16, respectively; p<0.0001) Patients with upregulation of circulating miR-21 were associated with poor progression-free survival (median survival 72 vs 86 weeks, respectively; log-rank (Mantel-Cox) test, p=0.049). MiR-21 expression was upregulated in breast cancer patients and might serve as a therapeutic monitoring marker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "31030498", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31030498", "evidence_list": [ { "evidence": "Expression of circulating miR-21 was significantly elevated in breast cancer patients compared to healthy women (median miR-21 expression levels were 7.67\u00b12.2 and 1.28\u00b10.16, respectively; p<0.0001) Patients with upregulation of circulating miR-21 were associated with poor progression-free survival (median survival 72 vs 86 weeks, respectively; log-rank (Mantel-Cox) test, p=0.049). MiR-21 expression was upregulated in breast cancer patients and might serve as a therapeutic monitoring marker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer.", "journal": "Asian Pacific journal of cancer prevention : APJCP", "authors": "Anwar SL, Sari DNI, Kartika AI, Fitria MS, Tanjung DS, Rakhmina D, Wardana T, Astuti I, Haryana SM, Aryandono T", "date": "2019-04-30", "evidence": [], "reference": [ { "id": "31030498", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31030498" } ] } ], "biomarker_canonical_id": "AA4873", "collision": 1 }, { "biomarker_id": "AA4873-3", "biomarker_component": [ { "biomarker": "increased MIR-21 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-21", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000077", "assessed_entity_type": "miRNA", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "25316501", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25316501", "evidence_list": [ { "evidence": "At enrollment, high miR-21 levels were associated with high calcitonin levels (P = .0003), lymph node metastases (P = .001), and advanced stages (P = .0003). At the end of follow-up, high miR-21 levels were associated with biochemically persistent disease (P = .0076). This study showed, in MTCs, that miR-21 regulates PDCD4 expression and also that the miR-21/PDCD4 pathway correlates with clinicopathological variables and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "25316501", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25316501", "evidence_list": [ { "evidence": "At enrollment, high miR-21 levels were associated with high calcitonin levels (P = .0003), lymph node metastases (P = .001), and advanced stages (P = .0003). At the end of follow-up, high miR-21 levels were associated with biochemically persistent disease (P = .0076). This study showed, in MTCs, that miR-21 regulates PDCD4 expression and also that the miR-21/PDCD4 pathway correlates with clinicopathological variables and prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The PDCD4/miR-21 pathway in medullary thyroid carcinoma.", "journal": "Human pathology", "authors": "Pennelli G, Galuppini F, Barollo S, Cavedon E, Bertazza L, Fassan M, Guzzardo V, Pelizzo MR, Rugge M, Mian C", "date": "2014-10-16", "evidence": [], "reference": [ { "id": "25316501", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25316501" } ] } ], "biomarker_canonical_id": "AA4873", "collision": 1 }, { "biomarker_id": "AA4874-1", "biomarker_component": [ { "biomarker": "increased NAS level", "assessed_biomarker_entity": { "recommended_name": "N1-acetylspermidine", "synonyms": [ { "synonym": "N1-Acetylspermidine" }, { "synonym": "1-N-acetylspermidine" }, { "synonym": "N-{3-[(4-aminobutyl)amino]propyl}acetamide" } ] }, "assessed_biomarker_entity_id": "CHEBI:17927", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of polyamines as carbamoyl derivatives in urine and serum by liquid chromatography-tandem mass spectrometry.", "journal": "Biomedical chromatography : BMC", "authors": "Byun JA, Lee SH, Jung BH, Choi MH, Moon MH, Chung BC", "date": "2007-08-02", "evidence": [], "reference": [ { "id": "17668437", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437" } ] } ], "biomarker_canonical_id": "AA4874", "collision": 1 }, { "biomarker_id": "AA4875-1", "biomarker_component": [ { "biomarker": "increased DAP level", "assessed_biomarker_entity": { "recommended_name": "1,3-Diaminopropane", "synonyms": [ { "synonym": "alpha,omega-propanediamine" }, { "synonym": "trimethylenediamine" }, { "synonym": "1,3-diamino-n-propane" }, { "synonym": "1,3-trimethylenediamine" }, { "synonym": "Propane-1,3-diamine" }, { "synonym": "propane-1,3-diamine" }, { "synonym": "1,3-propylenediamine" }, { "synonym": "3-aminopropylamine" }, { "synonym": "1,3-propanediamine" }, { "synonym": "tn" }, { "synonym": "1,3-diaminopropane" } ] }, "assessed_biomarker_entity_id": "CHEBI:15725", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of polyamines as carbamoyl derivatives in urine and serum by liquid chromatography-tandem mass spectrometry.", "journal": "Biomedical chromatography : BMC", "authors": "Byun JA, Lee SH, Jung BH, Choi MH, Moon MH, Chung BC", "date": "2007-08-02", "evidence": [], "reference": [ { "id": "17668437", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437" } ] } ], "biomarker_canonical_id": "AA4875", "collision": 1 }, { "biomarker_id": "AA4876-1", "biomarker_component": [ { "biomarker": "increased PUT level", "assessed_biomarker_entity": { "recommended_name": "Putrescine", "synonyms": [ { "synonym": "butylenediamine" }, { "synonym": "Putreszin" }, { "synonym": "1,4-DIAMINOBUTANE" }, { "synonym": "butane-1,4-diamine" }, { "synonym": "Tetramethylendiamin" }, { "synonym": "1,4-Butanediamine" }, { "synonym": "1,4-tetramethylenediamine" }, { "synonym": "Tetramethylenediamine" }, { "synonym": "Putrescin" }, { "synonym": "Putrescine" }, { "synonym": "H2N(CH2)4NH2" }, { "synonym": "Butane-1,4-diamine" }, { "synonym": "1,4-butylenediamine" }, { "synonym": "putrescina" } ] }, "assessed_biomarker_entity_id": "CHEBI:17148", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of polyamines as carbamoyl derivatives in urine and serum by liquid chromatography-tandem mass spectrometry.", "journal": "Biomedical chromatography : BMC", "authors": "Byun JA, Lee SH, Jung BH, Choi MH, Moon MH, Chung BC", "date": "2007-08-02", "evidence": [], "reference": [ { "id": "17668437", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437" } ] } ], "biomarker_canonical_id": "AA4876", "collision": 1 }, { "biomarker_id": "AA4877-1", "biomarker_component": [ { "biomarker": "increased SPE level", "assessed_biomarker_entity": { "recommended_name": "Spermine", "synonyms": [ { "synonym": "Spermine" }, { "synonym": "4,9-diazadodecane-1,12-diamine" }, { "synonym": "4,9-diaza-1,12-dodecanediamine" }, { "synonym": "SPERMINE" }, { "synonym": "N,N'-bis(3-aminopropyl)butane-1,4-diamine" }, { "synonym": "N,N'-Bis(3-aminopropyl)-1,4-butanediamine" } ] }, "assessed_biomarker_entity_id": "CHEBI:15746", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "17668437", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437", "evidence_list": [ { "evidence": "Serum samples from 30 breast cancer patients and 30 healthy female controls were tested using the procedure described in the notes section. Breast cancer patients have higher levels of N-acetylspermidine in their blood. The serum polyamines can be a helpful method in assessing the polyamine status of breast cancer patients, as well as a strong index for studying both polyamine synthesis and metabolism. The method was used for monitoring the polyamine concentration range in urine and serum samples obtained in 30 breast cancer patients and 30 age- and gender-matched normal controls. There was no significant difference between the urine of breast cancer patients and the controls in urinary polyamine levels. In contrast, the concentrations of 1,3-Dap, Put, Sp, and N-actSpd levels in serum were significantly increased in breast cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of polyamines as carbamoyl derivatives in urine and serum by liquid chromatography-tandem mass spectrometry.", "journal": "Biomedical chromatography : BMC", "authors": "Byun JA, Lee SH, Jung BH, Choi MH, Moon MH, Chung BC", "date": "2007-08-02", "evidence": [], "reference": [ { "id": "17668437", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17668437" } ] } ], "biomarker_canonical_id": "AA4877", "collision": 1 }, { "biomarker_id": "AA4878-1", "biomarker_component": [ { "biomarker": "increased GOLM1 level", "assessed_biomarker_entity": { "recommended_name": "Golgi membrane protein 1", "synonyms": [ { "synonym": "Golgi membrane protein GP73" }, { "synonym": "Golgi phosphoprotein 2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8NBJ4", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "18953438", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18953438", "evidence_list": [ { "evidence": "Our data indicating the up-regulation of GOLM1 expression and its appearance in patients' urine suggest GOLM1 as a potential novel biomarker for clinically localized prostate cancer. our group has shown that increased GOLM1 transcript in urine, along with SPINK1 and PCA3 transcript expression, and TMPRSS2:ERG fusion status were able to predict prostate cancer outcome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "18953438", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18953438", "evidence_list": [ { "evidence": "Our data indicating the up-regulation of GOLM1 expression and its appearance in patients' urine suggest GOLM1 as a potential novel biomarker for clinically localized prostate cancer. our group has shown that increased GOLM1 transcript in urine, along with SPINK1 and PCA3 transcript expression, and TMPRSS2:ERG fusion status were able to predict prostate cancer outcome." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.", "journal": "Neoplasia (New York, N.Y.)", "authors": "Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, Gu W, Shen R, Ghosh D, Wright LM, Kladney RD, Kuefer R, Rubin MA, Fimmel CJ, Chinnaiyan AM", "date": "2008-10-28", "evidence": [], "reference": [ { "id": "18953438", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18953438" } ] } ], "biomarker_canonical_id": "AA4878", "collision": 1 }, { "biomarker_id": "AA4879-1", "biomarker_component": [ { "biomarker": "increased AFP level", "assessed_biomarker_entity": { "recommended_name": "Alpha-fetoprotein", "synonyms": [ { "synonym": "Alpha-1-fetoprotein" }, { "synonym": "Alpha-fetoglobulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P02771", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC. High levels of AFP correlated with diffuse type of HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease. Four groups were studied: G1, normal healthy subjects; G2, patients with noncirrhotic chronic hepatitis; G3, patients with compensated cirrhosis; and G4, patients with histologically proven HCC. AFP levels increased progressively from G1 to G4." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25382443", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443", "evidence_list": [ { "evidence": "This study aimed to investigate the clinical utility of simultaneous measurement of alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) diagnosis caused by hepatitis B virus infection. Subjects were 1,153 individuals had serum levels of AFP that were measured and clinicopathological features were determined for all subjects. Results showed that the levels of AFP were significantly higher in hepatocellular carcinoma group (550 patients, 74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating curves (ROC) indicated the optimal cut-off value was 21 ng/mL for AFP with a sensitivity of 68.00% and specificity of 93.20%. The area under ROC curve was 0.832 for AFP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC. High levels of AFP correlated with diffuse type of HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease. Four groups were studied: G1, normal healthy subjects; G2, patients with noncirrhotic chronic hepatitis; G3, patients with compensated cirrhosis; and G4, patients with histologically proven HCC. AFP levels increased progressively from G1 to G4." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25382443", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443", "evidence_list": [ { "evidence": "This study aimed to investigate the clinical utility of simultaneous measurement of alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) diagnosis caused by hepatitis B virus infection. Subjects were 1,153 individuals had serum levels of AFP that were measured and clinicopathological features were determined for all subjects. Results showed that the levels of AFP were significantly higher in hepatocellular carcinoma group (550 patients, 74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating curves (ROC) indicated the optimal cut-off value was 21 ng/mL for AFP with a sensitivity of 68.00% and specificity of 93.20%. The area under ROC curve was 0.832 for AFP." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.", "journal": "Journal of gastroenterology and hepatology", "authors": "Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ", "date": "2008-04-22", "evidence": [], "reference": [ { "id": "18422961", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961" } ] }, { "title": "Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA", "date": "2007-05-25", "evidence": [], "reference": [ { "id": "17522429", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429" } ] }, { "title": "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.", "journal": "Gastroenterology", "authors": "Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M", "date": "2009-04-14", "evidence": [], "reference": [ { "id": "19362088", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088" } ] }, { "title": "Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.", "journal": "Hepatology (Baltimore, Md.)", "authors": "Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS", "date": "2003-04-30", "evidence": [], "reference": [ { "id": "12717392", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392" } ] }, { "title": "Clinical utility of simultaneous measurement of alpha-fetoprotein and des-\u03b3-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.", "journal": "Bioscience trends", "authors": "Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W, None None", "date": "2014-11-11", "evidence": [], "reference": [ { "id": "25382443", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443" } ] } ], "biomarker_canonical_id": "AA4879", "collision": 1 }, { "biomarker_id": "AA4880-1", "biomarker_component": [ { "biomarker": "increased C1GALT1 level", "assessed_biomarker_entity": { "recommended_name": "Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1", "synonyms": [ { "synonym": "B3Gal-T8" }, { "synonym": "Core 1 O-glycan T-synthase" }, { "synonym": "Core 1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase 1" }, { "synonym": "Beta-1,3-galactosyltransferase" }, { "synonym": "Core 1 beta1,3-galactosyltransferase 1" }, { "synonym": "C1GalT1" }, { "synonym": "Core 1 beta3-Gal-T1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NS00", "assessed_entity_type": "protein", "specimen": [ { "name": "squamous epithelium", "id": "UBERON:0006914", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0006914", "loinc_code": "" } ], "evidence_source": [ { "id": "29930379", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29930379", "evidence_list": [ { "evidence": "C1GALT1 expression is upregulated in HNSCC tumors and is associated with adverse clinicopathologic features. Moreover, high C1GALT1 expression predicts poor disease-free and overall survivals. For Kaplan-Meier analysis, we further classified C1GALT1 scores 0-1 and scores 2-3 as low and high expression, respectively. Results showed that high C1GALT1 expression was significantly associated with poor disease-free survival and overall survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "29930379", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29930379", "evidence_list": [ { "evidence": "C1GALT1 expression is upregulated in HNSCC tumors and is associated with adverse clinicopathologic features. Moreover, high C1GALT1 expression predicts poor disease-free and overall survivals. For Kaplan-Meier analysis, we further classified C1GALT1 scores 0-1 and scores 2-3 as low and high expression, respectively. Results showed that high C1GALT1 expression was significantly associated with poor disease-free survival and overall survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer.", "journal": "Oncogene", "authors": "Lin MC, Chien PH, Wu HY, Chen ST, Juan HF, Lou PJ, Huang MC", "date": "2018-06-23", "evidence": [], "reference": [ { "id": "29930379", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29930379" } ] } ], "biomarker_canonical_id": "AA4880", "collision": 1 }, { "biomarker_id": "AA4881-1", "biomarker_component": [ { "biomarker": "increased LRAG1 level", "assessed_biomarker_entity": { "recommended_name": "Leucine-rich alpha-2-glycoprotein 1", "synonyms": [ { "synonym": "LRG" } ] }, "assessed_biomarker_entity_id": "UPKB:P02750", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31582665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31582665", "evidence_list": [ { "evidence": "Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p < 0.01) and well discriminated (area under the curve (AUC) of the receiver operating characteristic (ROC) curve >0.8) between responder and non-responder groups. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "31582665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31582665", "evidence_list": [ { "evidence": "Among them, the serum levels of leucine-rich alpha-2-glycoprotein 1 (LRG1) were significantly different (p < 0.01) and well discriminated (area under the curve (AUC) of the receiver operating characteristic (ROC) curve >0.8) between responder and non-responder groups. The present results suggest that LRG1 and its combination with CRP and sIL-6R are promising biomarker candidates to predict response to PCRT in esophageal cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer.", "journal": "Biological & pharmaceutical bulletin", "authors": "Nambu M, Masuda T, Ito S, Kato K, Kojima T, Daiko H, Ito Y, Honda K, Ohtsuki S", "date": "2019-10-05", "evidence": [], "reference": [ { "id": "31582665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31582665" } ] } ], "biomarker_canonical_id": "AA4881", "collision": 1 }, { "biomarker_id": "AA4882-1", "biomarker_component": [ { "biomarker": "increased KIF20A level", "assessed_biomarker_entity": { "recommended_name": "Kinesin family member 20A", "synonyms": [ { "synonym": "GG10_2" }, { "synonym": "Mitotic kinesin-like protein 2" }, { "synonym": "MKlp2" }, { "synonym": "Rab6-interacting kinesin-like protein" }, { "synonym": "Rabkinesin-6" } ] }, "assessed_biomarker_entity_id": "UPKB:O95235", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "32467984", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32467984", "evidence_list": [ { "evidence": "Moreover, KIF20A expression was significantly associated with the poor prognosis of patients with breast cancer. A multivariate analysis indicated that KIF20A expression was an independent prognostic factor for patients with breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32467984", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32467984", "evidence_list": [ { "evidence": "Moreover, KIF20A expression was significantly associated with the poor prognosis of patients with breast cancer. A multivariate analysis indicated that KIF20A expression was an independent prognostic factor for patients with breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer.", "journal": "International journal of oncology", "authors": "Nakamura M, Takano A, Thang PM, Tsevegjav B, Zhu M, Yokose T, Yamashita T, Miyagi Y, Daigo Y", "date": "2020-05-30", "evidence": [], "reference": [ { "id": "32467984", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32467984" } ] } ], "biomarker_canonical_id": "AA4882", "collision": 1 }, { "biomarker_id": "AA4883-1", "biomarker_component": [ { "biomarker": "increased KLK4 level", "assessed_biomarker_entity": { "recommended_name": "Kallikrein-related peptidase 4", "synonyms": [ { "synonym": "Enamel matrix serine proteinase 1" }, { "synonym": "Kallikrein-like protein 1" }, { "synonym": "KLK-L1" }, { "synonym": "Prostase" }, { "synonym": "Serine protease 17" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y5K2", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "20180634", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20180634", "evidence_list": [ { "evidence": "Distinct KLK4 immunostaining was observed with both antibodies in cancerous glandular epithelial cells, but not in surrounding stromal cells. KLK4 expression was lower in stage pT3q4 than in pT1q2 tumors, which was highly significant when employing pAb 617A. Thus, the results indicate that KLK4, which is expressed in the healthy prostate, is upregulated in early-stage but not late-stage prostate cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "20180634", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20180634", "evidence_list": [ { "evidence": "Distinct KLK4 immunostaining was observed with both antibodies in cancerous glandular epithelial cells, but not in surrounding stromal cells. KLK4 expression was lower in stage pT3q4 than in pT1q2 tumors, which was highly significant when employing pAb 617A. Thus, the results indicate that KLK4, which is expressed in the healthy prostate, is upregulated in early-stage but not late-stage prostate cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer.", "journal": "Biological chemistry", "authors": "Seiz L, Kotzsch M, Grebenchtchikov NI, Geurts-Moespot AJ, Fuessel S, Goettig P, Gkazepis A, Wirth MP, Schmitt M, Lossnitzer A, Sweep FC, Magdolen V", "date": "2010-02-26", "evidence": [], "reference": [ { "id": "20180634", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20180634" } ] } ], "biomarker_canonical_id": "AA4883", "collision": 1 }, { "biomarker_id": "AA4884-1", "biomarker_component": [ { "biomarker": "increased CDH1 level", "assessed_biomarker_entity": { "recommended_name": "E-cadherin", "synonyms": [ { "synonym": "CAM 120/80" }, { "synonym": "Epithelial cadherin" }, { "synonym": "E-cadherin" }, { "synonym": "Uvomorulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P12830", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "29540-2" } ], "evidence_source": [ { "id": "15870707", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15870707", "evidence_list": [ { "evidence": "There is a significant difference in the expression level of the 80 kDa fragment in the serum of healthy individuals vs patients with BPH and between BPH vs Loc PCA and Met PCA (P<0.001). Highest expression levels are observed in advanced metastatic disease. High expression at the time of diagnosis is associated with a significantly increased risk of biochemical failure." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "15870707", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15870707", "evidence_list": [ { "evidence": "There is a significant difference in the expression level of the 80 kDa fragment in the serum of healthy individuals vs patients with BPH and between BPH vs Loc PCA and Met PCA (P<0.001). Highest expression levels are observed in advanced metastatic disease. High expression at the time of diagnosis is associated with a significantly increased risk of biochemical failure." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.", "journal": "British journal of cancer", "authors": "Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juarez-Brito MA, Eggel M, Gschwend JE, Rubin MA, Day ML", "date": "2005-05-05", "evidence": [], "reference": [ { "id": "15870707", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15870707" } ] } ], "biomarker_canonical_id": "AA4884", "collision": 1 }, { "biomarker_id": "AA4884-2", "biomarker_component": [ { "biomarker": "increased CDH1 level", "assessed_biomarker_entity": { "recommended_name": "E-cadherin", "synonyms": [ { "synonym": "CAM 120/80" }, { "synonym": "Epithelial cadherin" }, { "synonym": "E-cadherin" }, { "synonym": "Uvomorulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P12830", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "21652-3" } ], "evidence_source": [ { "id": "23341533", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23341533", "evidence_list": [ { "evidence": "CDH1 somatic alterations were found in approximately 30% of all patients with GC. CDH1 somatic alterations exist in all clinical settings and histotypes of GC and associate with different survival rates. Their screening at GC diagnosis may predict patient prognosis and is likely to improve management of patients with this disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "23341533", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23341533", "evidence_list": [ { "evidence": "CDH1 somatic alterations were found in approximately 30% of all patients with GC. CDH1 somatic alterations exist in all clinical settings and histotypes of GC and associate with different survival rates. Their screening at GC diagnosis may predict patient prognosis and is likely to improve management of patients with this disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Corso G, Carvalho J, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, Oliveira C", "date": "2013-01-24", "evidence": [], "reference": [ { "id": "23341533", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23341533" } ] } ], "biomarker_canonical_id": "AA4884", "collision": 1 }, { "biomarker_id": "AA4886-1", "biomarker_component": [ { "biomarker": "decreased 5HMC level", "assessed_biomarker_entity": { "recommended_name": "5-Hydroxymethylcytosine", "synonyms": [ { "synonym": "4-Amino-5-(hydroxymethyl)-2(1H)-pyrimidinone" }, { "synonym": "4-amino-5-(hydroxymethyl)pyrimidin-2(1H)-one" }, { "synonym": "5-hydroxymethylcytosine" } ] }, "assessed_biomarker_entity_id": "CHEBI:76792", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29156615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29156615", "evidence_list": [ { "evidence": "When the measured levels of 5hmC2 in white blood cells were lower the patients showed significantly different distributions of prostate cancer conditions. Patients with low and elevated 5hmC content showed significantly different distributions across different prostate conditions. The distribution of these patients in prostate cancer was similar to that observed in healthy subjects, while for atypical small acinar proliferation, most patients had increased 5hmC levels. This 5hmC-based biomarker had a lower performance in the detection of prostate cancer in comparison with blood levels of prostate-specific antigen when using a cut-off point of 2.5 nanograms per milliliter. Above this threshold value, however, this biomarker allowed us to distinguish almost three-quarters of patients with prostate cancer from controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "29156615", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29156615", "evidence_list": [ { "evidence": "When the measured levels of 5hmC2 in white blood cells were lower the patients showed significantly different distributions of prostate cancer conditions. Patients with low and elevated 5hmC content showed significantly different distributions across different prostate conditions. The distribution of these patients in prostate cancer was similar to that observed in healthy subjects, while for atypical small acinar proliferation, most patients had increased 5hmC levels. This 5hmC-based biomarker had a lower performance in the detection of prostate cancer in comparison with blood levels of prostate-specific antigen when using a cut-off point of 2.5 nanograms per milliliter. Above this threshold value, however, this biomarker allowed us to distinguish almost three-quarters of patients with prostate cancer from controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.", "journal": "International journal of molecular sciences", "authors": "Grelus A, Nica DV, Miklos I, Belengeanu V, Ioiart I, Popescu C", "date": "2017-11-22", "evidence": [], "reference": [ { "id": "29156615", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29156615" } ] } ], "biomarker_canonical_id": "AA4886", "collision": 1 }, { "biomarker_id": "AN4142-1", "biomarker_component": [ { "biomarker": "increased ATOX1 level", "assessed_biomarker_entity": { "recommended_name": "Copper chaperone ATOX1", "synonyms": [ { "synonym": "Metal transport protein ATX1" } ] }, "assessed_biomarker_entity_id": "UPKB:O00244", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "31898157", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31898157", "evidence_list": [ { "evidence": "Since most cancer-related deaths are due to metastasis, we hypothesized that ATOX1 mRNA expression may be associated with breast cancer disease progression and thus, a prognostic biomarker in breast cancer. Our results indicate ATOX1 expression levels as a potential prognostic biomarker for ER-positive subtypes and early stages of breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "31898157", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31898157", "evidence_list": [ { "evidence": "Since most cancer-related deaths are due to metastasis, we hypothesized that ATOX1 mRNA expression may be associated with breast cancer disease progression and thus, a prognostic biomarker in breast cancer. Our results indicate ATOX1 expression levels as a potential prognostic biomarker for ER-positive subtypes and early stages of breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of copper chaperone ATOX1 as prognostic biomarker in breast cancer.", "journal": "Breast cancer (Tokyo, Japan)", "authors": "Blockhuys S, Brady DC, Wittung-Stafshede P", "date": "2020-01-04", "evidence": [], "reference": [ { "id": "31898157", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31898157" } ] } ], "biomarker_canonical_id": "AN4142", "collision": 1 }, { "biomarker_id": "AA4888-1", "biomarker_component": [ { "biomarker": "decreased MIR-193B level", "assessed_biomarker_entity": { "recommended_name": "miRNA-193b", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003137", "assessed_entity_type": "miRNA", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "26675282", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26675282", "evidence_list": [ { "evidence": "Reduction of miR-193b was found in ovarian cancer and its lower expression was associated with poorer prognosis. Tissue miR-193b showed potential as novel biomarker for ovarian cancer. The results showed that the miR-193b expression was significantly down-regulated in ovarian cancer cell lines and tumor tissues compared with normal controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "26675282", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26675282", "evidence_list": [ { "evidence": "Reduction of miR-193b was found in ovarian cancer and its lower expression was associated with poorer prognosis. Tissue miR-193b showed potential as novel biomarker for ovarian cancer. The results showed that the miR-193b expression was significantly down-regulated in ovarian cancer cell lines and tumor tissues compared with normal controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Tissue miR-193b as a Novel Biomarker for Patients with Ovarian Cancer.", "journal": "Medical science monitor : international medical journal of experimental and clinical research", "authors": "Li H, Xu Y, Qiu W, Zhao D, Zhang Y", "date": "2015-12-18", "evidence": [], "reference": [ { "id": "26675282", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26675282" } ] } ], "biomarker_canonical_id": "AA4888", "collision": 1 }, { "biomarker_id": "AA4889-1", "biomarker_component": [ { "biomarker": "increased AFP-L3 level", "assessed_biomarker_entity": { "recommended_name": "Lectin-bound alpha-fetoprotein", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C96564", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. Each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16534867", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867", "evidence_list": [ { "evidence": "AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. Each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "16534867", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867", "evidence_list": [ { "evidence": "AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis." } ], "tags": [ { "tag": "condition" } ] }, { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA", "date": "2007-05-25", "evidence": [], "reference": [ { "id": "17522429", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429" } ] }, { "title": "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.", "journal": "Gastroenterology", "authors": "Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M", "date": "2009-04-14", "evidence": [], "reference": [ { "id": "19362088", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088" } ] }, { "title": "Serum tumor markers for detection of hepatocellular carcinoma.", "journal": "World journal of gastroenterology", "authors": "Zhou L, Liu J, Luo F", "date": "2006-03-15", "evidence": [], "reference": [ { "id": "16534867", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867" } ] }, { "title": "Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.", "journal": "Journal of gastroenterology and hepatology", "authors": "Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ", "date": "2008-04-22", "evidence": [], "reference": [ { "id": "18422961", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961" } ] }, { "title": "Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.", "journal": "Hepatology (Baltimore, Md.)", "authors": "Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS", "date": "2003-04-30", "evidence": [], "reference": [ { "id": "12717392", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392" } ] } ], "biomarker_canonical_id": "AA4889", "collision": 1 }, { "biomarker_id": "AA4890-1", "biomarker_component": [ { "biomarker": "increased DCP1A level", "assessed_biomarker_entity": { "recommended_name": "Des-gamma carboxy-prothrombin", "synonyms": [ { "synonym": "Smad4-interacting transcriptional co-activator" }, { "synonym": "Transcription factor SMIF" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NPI6", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. Each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16534867", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867", "evidence_list": [ { "evidence": "AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25382443", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443", "evidence_list": [ { "evidence": "This study aimed to investigate the clinical utility of simultaneous measurement of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma (HCC) diagnosis caused by hepatitis B virus infection. Subjects were 1,153 individuals had serum levels of DCP that were measured and clinicopathological features were determined for all subjects. Results showed that the levels of DCP and AFP were significantly higher in hepatocellular carcinoma group (550 patients, 74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating curves (ROC) indicated the optimal cut-off value was 86 mAU/mL for DCP with a sensitivity of 71.50% and specificity of 86.30%. The area under ROC curve was 0.846 for AFP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "17522429", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429", "evidence_list": [ { "evidence": "DCP was significantly better than total AFP and AFP-L3 in differentiating HCC from cirrhosis, with a sensitivity of 86% and specificity of 93%. All 3 markers had a lower area under the ROC curve and lower sensitivity in the group with high versus that with low risk for HCC. DCP has the best performance characteristics of all 3 serum markers for the diagnosis of HCC. Performance of all 3 biomarkers is lower in patients with high risk for HCC. Each marker had higher levels in patients with HCC compared to cirrhotic controls." } ], "tags": [ { "tag": "condition" } ] }, { "id": "19362088", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088", "evidence_list": [ { "evidence": "AFP was more sensitive than DCP and AFP-L3 for the diagnosis of early and very early stage HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "16534867", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867", "evidence_list": [ { "evidence": "AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis." } ], "tags": [ { "tag": "condition" } ] }, { "id": "18422961", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961", "evidence_list": [ { "evidence": "Levels of DCP, AFP and AFP L-3 were significantly higher in patients with HCC than in those without HCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "12717392", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392", "evidence_list": [ { "evidence": "DCP was more sensitive and specific than AFP for differentiating HCC from nonmalignant chronic liver disease." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25382443", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443", "evidence_list": [ { "evidence": "This study aimed to investigate the clinical utility of simultaneous measurement of des-gamma-carboxy prothrombin (DCP) for hepatocellular carcinoma (HCC) diagnosis caused by hepatitis B virus infection. Subjects were 1,153 individuals had serum levels of DCP that were measured and clinicopathological features were determined for all subjects. Results showed that the levels of DCP and AFP were significantly higher in hepatocellular carcinoma group (550 patients, 74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating curves (ROC) indicated the optimal cut-off value was 86 mAU/mL for DCP with a sensitivity of 71.50% and specificity of 86.30%. The area under ROC curve was 0.846 for AFP." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA", "date": "2007-05-25", "evidence": [], "reference": [ { "id": "17522429", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17522429" } ] }, { "title": "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.", "journal": "Gastroenterology", "authors": "Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M", "date": "2009-04-14", "evidence": [], "reference": [ { "id": "19362088", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19362088" } ] }, { "title": "Serum tumor markers for detection of hepatocellular carcinoma.", "journal": "World journal of gastroenterology", "authors": "Zhou L, Liu J, Luo F", "date": "2006-03-15", "evidence": [], "reference": [ { "id": "16534867", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16534867" } ] }, { "title": "Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.", "journal": "Journal of gastroenterology and hepatology", "authors": "Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ", "date": "2008-04-22", "evidence": [], "reference": [ { "id": "18422961", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18422961" } ] }, { "title": "Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.", "journal": "Hepatology (Baltimore, Md.)", "authors": "Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS", "date": "2003-04-30", "evidence": [], "reference": [ { "id": "12717392", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12717392" } ] }, { "title": "Clinical utility of simultaneous measurement of alpha-fetoprotein and des-\u03b3-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.", "journal": "Bioscience trends", "authors": "Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W, None None", "date": "2014-11-11", "evidence": [], "reference": [ { "id": "25382443", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25382443" } ] } ], "biomarker_canonical_id": "AA4890", "collision": 1 }, { "biomarker_id": "AN4143-1", "biomarker_component": [ { "biomarker": "increased mutation", "assessed_biomarker_entity": { "recommended_name": "Tumor protein gene mutation", "synonyms": [ { "synonym": "Antigen NY-CO-13" }, { "synonym": "Phosphoprotein p53" }, { "synonym": "Tumor suppressor p53" } ] }, "assessed_biomarker_entity_id": "UPKB:P04637", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "21720365", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21720365", "evidence_list": [ { "evidence": "Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%). Mutations in TP53 predominated, occurring in at least 96% of HGS-OvCa samples." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "21720365", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21720365", "evidence_list": [ { "evidence": "Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%). Mutations in TP53 predominated, occurring in at least 96% of HGS-OvCa samples." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Integrated genomic analyses of ovarian carcinoma.", "journal": "Nature", "authors": "None None", "date": "2011-07-02", "evidence": [], "reference": [ { "id": "21720365", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21720365" } ] } ], "biomarker_canonical_id": "AN4143", "collision": 1 }, { "biomarker_id": "AA4892-1", "biomarker_component": [ { "biomarker": "increased VEGF level", "assessed_biomarker_entity": { "recommended_name": "Vascular endothelial growth factor", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C92514", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19623180", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19623180", "evidence_list": [ { "evidence": "The most potent stimulator of angiogenesis, an important mechanism in tumor development, proliferation, and metastasis, is vascular endothelial growth factor (VEGF)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "23688065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065", "evidence_list": [ { "evidence": "The plasma levels of Vascular endothelial growth factor (VEGF) in breast cancer patients were investigated and compared with control groups. The medians of VEGF, which was 134.96 pg/ml, levels similarly to the level of the commonly accepted tumor marker (CA 15-3 - 25.00 U/ml) in the total group of breast cancer patients were significantly higher when compared to the healthy subjects, which is 43.40 pg/ml (p < 0.001). In other words, the median levels of VEGF in breast cancer total group were statistically higher than in benign breast tumor patients group (p = 0.054)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "19623180", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19623180", "evidence_list": [ { "evidence": "The most potent stimulator of angiogenesis, an important mechanism in tumor development, proliferation, and metastasis, is vascular endothelial growth factor (VEGF)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "23688065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065", "evidence_list": [ { "evidence": "The plasma levels of Vascular endothelial growth factor (VEGF) in breast cancer patients were investigated and compared with control groups. The medians of VEGF, which was 134.96 pg/ml, levels similarly to the level of the commonly accepted tumor marker (CA 15-3 - 25.00 U/ml) in the total group of breast cancer patients were significantly higher when compared to the healthy subjects, which is 43.40 pg/ml (p < 0.001). In other words, the median levels of VEGF in breast cancer total group were statistically higher than in benign breast tumor patients group (p = 0.054)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.", "journal": "British journal of cancer", "authors": "Bluff JE, Menakuru SR, Cross SS, Higham SE, Balasubramanian SP, Brown NJ, Reed MW, Staton CA", "date": "2009-07-23", "evidence": [], "reference": [ { "id": "19623180", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19623180" } ] }, { "title": "VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.", "journal": "Growth factors (Chur, Switzerland)", "authors": "\u0141awicki S, B\u0119dkowska GE, Szmitkowski M", "date": "2013-05-22", "evidence": [], "reference": [ { "id": "23688065", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23688065" } ] } ], "biomarker_canonical_id": "AA4892", "collision": 1 }, { "biomarker_id": "AN4461-1", "biomarker_component": [ { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Alpha-1 protease inhibitor" }, { "synonym": "Alpha-1-antiproteinase" }, { "synonym": "Serpin A1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01009", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Zonulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P00738", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Transferrin" }, { "synonym": "Beta-1 metal-binding globulin" }, { "synonym": "Siderophilin" } ] }, "assessed_biomarker_entity_id": "UPKB:P02787", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Alpha-2-thiol proteinase inhibitor" }, { "synonym": "Fitzgerald factor" }, { "synonym": "High molecular weight kininogen" }, { "synonym": "HMWK" }, { "synonym": "Williams-Fitzgerald-Flaujeac factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P01042", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "AGP 1" }, { "synonym": "Orosomucoid-1" }, { "synonym": "OMD 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P02763", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Beta-1B-glycoprotein" } ] }, "assessed_biomarker_entity_id": "UPKB:P02790", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [ { "synonym": "Immunoglobulin gamma-1 heavy chain NIE" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DOX5", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G06110VR", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G23453IV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G39188ZX", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G33609NS", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G81295CK", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G31936TA", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G82119TF", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G49347SB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G50045TK", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G10256JP", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G23432EQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G64527OM", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G12313PD", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G23863VK", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G70101JE", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G06356OH", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G44215PV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G24835MQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G20425TQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G39619TI", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G84452RH", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G72797UR", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G48414YA", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G75983OB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G22625SJ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G95977AE", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G66163OV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G02030ZB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G59536GA", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G70375MX", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G47012YE", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G96747WW", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G22310AV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G81263BG", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G90093AU", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G86795LJ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G31596VW", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G49874UX", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G46687AB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G03382KH", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G79568CQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G91636VS", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "MALDI-MS measured N-glycans", "assessed_biomarker_entity": { "recommended_name": "Glyco-typer 50 N-glycan liver disease panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G40099BA", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "31721442", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442", "evidence_list": [ { "evidence": "Quantities (measured by MALDI-MS Glyco-typer technology) of 44 N-glycans covalently attached to serum glycoproteins Alpha-1-antitrypsin, Haptoglobin, Serotransferrin, Alpha-1-acid glycoprotein 1, Low molecular weight kininogen, Immunoglobulin G, and Hemopexin in cirrhosis, HCC, and transplant cohorts. Quantities (measured by MALDI-MS Glyco-typer technology) of an additional 6 N-glycans covalently attached to serum glycoproteins Low molecular weight kininogen and Immunoglobulin G in the cirrhosis, HCC, and transplant cohorts." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] }, { "title": "Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.", "journal": "Current protocols in protein science", "authors": "Black AP, Angel PM, Drake RR, Mehta AS", "date": "2019-11-14", "evidence": [], "reference": [ { "id": "31721442", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31721442" } ] } ], "biomarker_canonical_id": "AN4461", "collision": 0 }, { "biomarker_id": "AA4893-1", "biomarker_component": [ { "biomarker": "increased VSIG4 level", "assessed_biomarker_entity": { "recommended_name": "Protein V-set and Ig domain-containing 4", "synonyms": [ { "synonym": "Protein Z39Ig" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y279", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "28498255", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28498255", "evidence_list": [ { "evidence": "VSIG4 messenger RNA and protein expression levels in ovarian cancer tissues were higher than those in benign ovarian tumors (P = 0.0013 and 0.0001, respectively). Furthermore, soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "28498255", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28498255", "evidence_list": [ { "evidence": "VSIG4 messenger RNA and protein expression levels in ovarian cancer tissues were higher than those in benign ovarian tumors (P = 0.0013 and 0.0001, respectively). Furthermore, soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The Significance of VSIG4 Expression in Ovarian Cancer.", "journal": "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society", "authors": "Byun JM, Jeong DH, Choi IH, Lee DS, Kang MS, Jung KO, Jeon YK, Kim YN, Jung EJ, Lee KB, Sung MS, Kim KT", "date": "2017-05-13", "evidence": [], "reference": [ { "id": "28498255", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28498255" } ] } ], "biomarker_canonical_id": "AA4893", "collision": 1 }, { "biomarker_id": "AA4894-1", "biomarker_component": [ { "biomarker": "decreased MIR-613 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-613", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003626", "assessed_entity_type": "miRNA", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "27010138", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27010138", "evidence_list": [ { "evidence": "miR-613 expression in ovarian cancer tissue specimens was significantly (p < 0.001) lower than that in matched normal adjacent tissue specimens. miR-613 expression levels are low in ovarian cancer tissue and correlate with progression-free and overall survival. Thus, miR-613 may be useful as a prognostic marker in ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "27010138", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27010138", "evidence_list": [ { "evidence": "miR-613 expression in ovarian cancer tissue specimens was significantly (p < 0.001) lower than that in matched normal adjacent tissue specimens. miR-613 expression levels are low in ovarian cancer tissue and correlate with progression-free and overall survival. Thus, miR-613 may be useful as a prognostic marker in ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Diminished miR-613 expression as a novel prognostic biomarker for human ovarian cancer.", "journal": "European review for medical and pharmacological sciences", "authors": "Zhang X, Zhang H", "date": "2016-03-25", "evidence": [], "reference": [ { "id": "27010138", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27010138" } ] } ], "biomarker_canonical_id": "AA4894", "collision": 1 }, { "biomarker_id": "AA4895-1", "biomarker_component": [ { "biomarker": "increased MIR-375-3P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-375-3p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000783", "assessed_entity_type": "miRNA", "specimen": [ { "name": "esophagus", "id": "UBERON:0001043", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001043", "loinc_code": "" } ], "evidence_source": [ { "id": "30638952", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30638952", "evidence_list": [ { "evidence": "We performed Gene Set Enrichment Analysis (GSEA) to identify the top three gene sets that significantly altered between the patients with miR-375 low expression and high expression. In conclusion, our findings suggest that miR-375 serves as a promising independent prognostic factor for ESCC and function as a tumor suppressor. patients with high miR-375 expression in ESCC had a well prognosis due to down-regulated activity of RNA polymerase I and III." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "30638952", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30638952", "evidence_list": [ { "evidence": "We performed Gene Set Enrichment Analysis (GSEA) to identify the top three gene sets that significantly altered between the patients with miR-375 low expression and high expression. In conclusion, our findings suggest that miR-375 serves as a promising independent prognostic factor for ESCC and function as a tumor suppressor. patients with high miR-375 expression in ESCC had a well prognosis due to down-regulated activity of RNA polymerase I and III." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of miR-375 as a potential prognostic biomarker for esophageal squamous cell cancer: A bioinformatics analysis based on TCGA and meta-analysis.", "journal": "Pathology, research and practice", "authors": "Luo HS, Wu DH", "date": "2019-01-15", "evidence": [], "reference": [ { "id": "30638952", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30638952" } ] } ], "biomarker_canonical_id": "AA4895", "collision": 1 }, { "biomarker_id": "AN4194-1", "biomarker_component": [ { "biomarker": "increased AZGP1 level", "assessed_biomarker_entity": { "recommended_name": "Zinc alpha-2-glycoprotein", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C113815", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "23020913", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23020913", "evidence_list": [ { "evidence": "Receiver operating characteristic curve analysis showed a significant predictive ability of ZAG for prostate cancer. The area under the curve (AUC) for the prediction of prostate cancer was 0.68 (95% CI 0.59-0.78) ... The optimal cut-off was 1.13 for ZAG, which corresponded to 6.88 times greater odds for prostate cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "23020913", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23020913", "evidence_list": [ { "evidence": "Receiver operating characteristic curve analysis showed a significant predictive ability of ZAG for prostate cancer. The area under the curve (AUC) for the prediction of prostate cancer was 0.68 (95% CI 0.59-0.78) ... The optimal cut-off was 1.13 for ZAG, which corresponded to 6.88 times greater odds for prostate cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Zinc \u03b12-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.", "journal": "BJU international", "authors": "Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA", "date": "2012-10-02", "evidence": [], "reference": [ { "id": "23020913", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23020913" } ] } ], "biomarker_canonical_id": "AN4194", "collision": 1 }, { "biomarker_id": "AN4195-1", "biomarker_component": [ { "biomarker": "decreased AZGP1 level", "assessed_biomarker_entity": { "recommended_name": "Zinc alpha-2-glycoprotein", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C113815", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "28486686", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28486686", "evidence_list": [ { "evidence": "In the phase II cohort, with a median follow-up of 15.8 years, low/absent AZGP1 expression was an independent predictor of poor BRFS (HR, 1.4; 95% CI, 1.1-1.9; P = 0.03), MFS (HR, 2.8; 95% CI, 1.2-6.6; P = 0.02) and PCSS (HR, 3.8; 95% CI, 1.5-9.5; P = 0.005). These results were validated in our prospective phase III cohort. Low/absent AZGP1 expression independently predicted for BRFS (HR, 1.9; 95% CI, 1.1-3.3; P = 0.02), with shorter MFS (HR, 2.0; 95% CI, 1.1-3.4; P = 0.02). AZGP1 improved the discriminatory value when incorporated into existing prognostic risk models." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "28486686", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28486686", "evidence_list": [ { "evidence": "In the phase II cohort, with a median follow-up of 15.8 years, low/absent AZGP1 expression was an independent predictor of poor BRFS (HR, 1.4; 95% CI, 1.1-1.9; P = 0.03), MFS (HR, 2.8; 95% CI, 1.2-6.6; P = 0.02) and PCSS (HR, 3.8; 95% CI, 1.5-9.5; P = 0.005). These results were validated in our prospective phase III cohort. Low/absent AZGP1 expression independently predicted for BRFS (HR, 1.9; 95% CI, 1.1-3.3; P = 0.02), with shorter MFS (HR, 2.0; 95% CI, 1.1-3.4; P = 0.02). AZGP1 improved the discriminatory value when incorporated into existing prognostic risk models." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.", "journal": "Annals of oncology : official journal of the European Society for Medical Oncology", "authors": "Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG", "date": "2017-05-10", "evidence": [], "reference": [ { "id": "28486686", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28486686" } ] } ], "biomarker_canonical_id": "AN4195", "collision": 1 }, { "biomarker_id": "AA4896-2", "biomarker_component": [ { "biomarker": "increased Th17 level", "assessed_biomarker_entity": { "recommended_name": "T Helper cytokine 17", "synonyms": [ { "synonym": "Zn-alpha-2-GP" }, { "synonym": "Zn-alpha-2-glycoprotein" } ] }, "assessed_biomarker_entity_id": "UPKB:P25311", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "31428522", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31428522", "evidence_list": [ { "evidence": "Greater varieties of helper t cell can infiltrate a breast cancer microenvironment. We found that Th17, was the most favorable prognostic signature in a subset of TN breast cancer with low T cell infiltrate. We provide evidence that a Th17 signature is associated with good prognosis in TN breast cancer specifically in T-low tumors." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "31428522", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31428522", "evidence_list": [ { "evidence": "Greater varieties of helper t cell can infiltrate a breast cancer microenvironment. We found that Th17, was the most favorable prognostic signature in a subset of TN breast cancer with low T cell infiltrate. We provide evidence that a Th17 signature is associated with good prognosis in TN breast cancer specifically in T-low tumors." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer.", "journal": "Oncoimmunology", "authors": "Faucheux L, Grandclaudon M, Perrot-Dock\u00e8s M, Sirven P, Berger F, Hamy AS, Fourchotte V, Vincent-Salomon A, Mechta-Grigoriou F, Reyal F, Scholer-Dahirel A, Guillot-Delost M, Soumelis V", "date": "2019-08-21", "evidence": [], "reference": [ { "id": "31428522", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31428522" } ] } ], "biomarker_canonical_id": "AA4896", "collision": 1 }, { "biomarker_id": "AN4196-1", "biomarker_component": [ { "biomarker": "increased LMNB1 level", "assessed_biomarker_entity": { "recommended_name": "Lamin B1", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P20700", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19522540", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19522540", "evidence_list": [ { "evidence": "Lamin B1 (LMNB1) mRNA was detected in 16 of 21 (76%) plasma from patients with early stage HCC and 12 of 14 (86%) from patients with late stage HCC, whereas only 19% and 17% in cirrhosis and normal subjects demonstrated LMNB1, respectively. The positivity rate of circulating LMNB1 mRNA gradually increased with tumor stages progression and it was significantly higher in HCC than in cirrhosis and normal individuals (p < 0.05 and p < 0.01, respectively). The overall detection sensitivity of LMNB1 mRNA for Hepatocellular carcinoma HCC was 80 and the specificity was 82%, where in particular for the detection of early stage and late stage HCCs the sensitivity is 76% and 86%, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "19522540", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19522540", "evidence_list": [ { "evidence": "Lamin B1 (LMNB1) mRNA was detected in 16 of 21 (76%) plasma from patients with early stage HCC and 12 of 14 (86%) from patients with late stage HCC, whereas only 19% and 17% in cirrhosis and normal subjects demonstrated LMNB1, respectively. The positivity rate of circulating LMNB1 mRNA gradually increased with tumor stages progression and it was significantly higher in HCC than in cirrhosis and normal individuals (p < 0.05 and p < 0.01, respectively). The overall detection sensitivity of LMNB1 mRNA for Hepatocellular carcinoma HCC was 80 and the specificity was 82%, where in particular for the detection of early stage and late stage HCCs the sensitivity is 76% and 86%, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients.", "journal": "Journal of proteome research", "authors": "Sun S, Xu MZ, Poon RT, Day PJ, Luk JM", "date": "2009-06-16", "evidence": [], "reference": [ { "id": "19522540", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19522540" } ] } ], "biomarker_canonical_id": "AN4196", "collision": 1 }, { "biomarker_id": "AA4899-1", "biomarker_component": [ { "biomarker": "increased MKI67 level", "assessed_biomarker_entity": { "recommended_name": "KI67 antigen", "synonyms": [ { "synonym": "Antigen identified by monoclonal antibody Ki-67" }, { "synonym": "Antigen KI-67" }, { "synonym": "Antigen Ki67" } ] }, "assessed_biomarker_entity_id": "UPKB:P46013", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "" } ], "evidence_source": [ { "id": "23645542", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23645542", "evidence_list": [ { "evidence": "The data indicated that patients whose tumors contained high levels of Ki67 effectively responded to anthracycline and taxane-containing neoadjuvant chemotherapy. Ki67 LI was a predictive marker for pCR, and all patients whose tumors achieved pathologic Complete Response (pCR) are currently disease-free." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "23645542", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23645542", "evidence_list": [ { "evidence": "The data indicated that patients whose tumors contained high levels of Ki67 effectively responded to anthracycline and taxane-containing neoadjuvant chemotherapy. Ki67 LI was a predictive marker for pCR, and all patients whose tumors achieved pathologic Complete Response (pCR) are currently disease-free." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.", "journal": "Breast cancer (Tokyo, Japan)", "authors": "Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H", "date": "2013-05-07", "evidence": [], "reference": [ { "id": "23645542", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23645542" } ] } ], "biomarker_canonical_id": "AA4899", "collision": 1 }, { "biomarker_id": "AA4900-1", "biomarker_component": [ { "biomarker": "increased AQP1 level", "assessed_biomarker_entity": { "recommended_name": "Aquaporin-1", "synonyms": [ { "synonym": "AQP-1" }, { "synonym": "Aquaporin-CHIP" }, { "synonym": "Urine water channel" }, { "synonym": "Water channel protein for red blood cells and kidney proximal tubule" } ] }, "assessed_biomarker_entity_id": "UPKB:P29972", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "20375178", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178", "evidence_list": [ { "evidence": "The AQP1 concentrations in patients with either clear cell or papillary carcinoma were significantly greater and clearly separated from those in the nonnephrectomy surgical control patients and the healthy individuals. High concentration of AQP1 in urine demonstrated 100% sensitivity and 100% specificity in detecting renal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "20375178", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178", "evidence_list": [ { "evidence": "The AQP1 concentrations in patients with either clear cell or papillary carcinoma were significantly greater and clearly separated from those in the nonnephrectomy surgical control patients and the healthy individuals. High concentration of AQP1 in urine demonstrated 100% sensitivity and 100% specificity in detecting renal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary biomarkers for the early diagnosis of kidney cancer.", "journal": "Mayo Clinic proceedings", "authors": "Morrissey JJ, London AN, Luo J, Kharasch ED", "date": "2010-04-09", "evidence": [], "reference": [ { "id": "20375178", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178" } ] } ], "biomarker_canonical_id": "AA4900", "collision": 1 }, { "biomarker_id": "AA4901-1", "biomarker_component": [ { "biomarker": "increased ADFP level", "assessed_biomarker_entity": { "recommended_name": "Adipophilin", "synonyms": [ { "synonym": "Adipophilin" }, { "synonym": "Adipose differentiation-related protein" }, { "synonym": "ADRP" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99541", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "20375178", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178", "evidence_list": [ { "evidence": "The ADFP concentrations in patients with either clear cell or papillary carcinoma were significantly greater and clearly separated from those in the nonnephrectomy surgical control patients and the healthy individuals. High ADFP concentration in the urine demonstrated 100% sensitivity and 100% specificity in detecting renal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "20375178", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178", "evidence_list": [ { "evidence": "The ADFP concentrations in patients with either clear cell or papillary carcinoma were significantly greater and clearly separated from those in the nonnephrectomy surgical control patients and the healthy individuals. High ADFP concentration in the urine demonstrated 100% sensitivity and 100% specificity in detecting renal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urinary biomarkers for the early diagnosis of kidney cancer.", "journal": "Mayo Clinic proceedings", "authors": "Morrissey JJ, London AN, Luo J, Kharasch ED", "date": "2010-04-09", "evidence": [], "reference": [ { "id": "20375178", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20375178" } ] } ], "biomarker_canonical_id": "AA4901", "collision": 1 }, { "biomarker_id": "AA4902-1", "biomarker_component": [ { "biomarker": "increased LACCER level", "assessed_biomarker_entity": { "recommended_name": "Lactosylceramide", "synonyms": [ { "synonym": "N-[(2S,3R,4E)-1-{[(2R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxyoctadec-4-en-2-yl]dodecanamide" }, { "synonym": "Lactosylceramide" }, { "synonym": "1-O-(4-O-beta-delta-Galactopyranosyl-beta-glucopyranosyl)ceramide" }, { "synonym": "LacCer(d18:1/12:0)" }, { "synonym": "1-O-(4-O-beta-delta-Galactopyranosyl-beta-delta-glucopyranosyl)-Ceramide" }, { "synonym": "beta-delta-Galactosyl-1,4-beta-delta-Glucosylceramide" }, { "synonym": "CDH" }, { "synonym": "1-O-(4-O-b-D-Galactopyranosyl-b-D-glucopyranosyl)-Ceramide" }, { "synonym": "N-Lignoceryl sphingosyl lactoside" }, { "synonym": "Gal-beta1->4Glc-beta1->1'Cer" }, { "synonym": "delta-Galactosyl-1,4-beta-delta-glucosylceramide" }, { "synonym": "D-Galactosyl-1,4-beta-D-glucosylceramide" }, { "synonym": "1ylce-O-(4-O-beta-delta-Galactopyranosyl-beta-glucopyranosyl)ceramide" }, { "synonym": "LacCer" }, { "synonym": "Lactosyl-N-acylsphingosine" }, { "synonym": "N-(Dodecanoyl)-1-b-lactosyl-sphing-4-enine" }, { "synonym": "Cytolipin H" }, { "synonym": "CDw17 antigen" }, { "synonym": "beta-D-Galactosyl-1,4-beta-D-Glucosylceramide" }, { "synonym": "N-(Dodecanoyl)-1-beta-lactosyl-sphing-4-enine" }, { "synonym": "1-O-(4-O-beta-D-Galactopyranosyl-beta-glucopyranosyl)ceramide" }, { "synonym": "Lactosyl ceramide (d18:1/12:0)" }, { "synonym": "beta-delta-Galactosyl-1,4-beta-delta-glucosramide" } ] }, "assessed_biomarker_entity_id": "CHEBI:89446", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "In terms of lipid classes, it was noted that HexCer species were in general more abundant in urinary exosomes from prostate cancer patients than from healthy controls, and that LacCer species were increased or unchanged. This is an interesting result since antibodies against LacCer and GlcCer are available, opening the alternative of analyzing these lipids by antibody-based methods, which are widely used in clinical laboratories. LacCer also showed the highest patient-to-control ratio." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "In terms of lipid classes, it was noted that HexCer species were in general more abundant in urinary exosomes from prostate cancer patients than from healthy controls, and that LacCer species were increased or unchanged. This is an interesting result since antibodies against LacCer and GlcCer are available, opening the alternative of analyzing these lipids by antibody-based methods, which are widely used in clinical laboratories. LacCer also showed the highest patient-to-control ratio." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers.", "journal": "European journal of cancer (Oxford, England : 1990)", "authors": "Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A", "date": "2016-12-04", "evidence": [], "reference": [ { "id": "27914242", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242" } ] } ], "biomarker_canonical_id": "AA4902", "collision": 1 }, { "biomarker_id": "AA4903-1", "biomarker_component": [ { "biomarker": "increased HEXCER level", "assessed_biomarker_entity": { "recommended_name": "Hexosylceramide", "synonyms": [ { "synonym": "N-hexadecanoyl hexosylceramide" }, { "synonym": "HexCer d18:1/16:0" }, { "synonym": "N-hexadecanoyl-(1<->1)-hexosyl-sphing-4-enine" } ] }, "assessed_biomarker_entity_id": "CHEBI:77462", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "It was noted that HexCer species were in general more abundant in urinary exosomes from prostate cancer patients than from healthy controls, and that LacCer species were increased or unchanged." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "It was noted that HexCer species were in general more abundant in urinary exosomes from prostate cancer patients than from healthy controls, and that LacCer species were increased or unchanged." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers.", "journal": "European journal of cancer (Oxford, England : 1990)", "authors": "Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A", "date": "2016-12-04", "evidence": [], "reference": [ { "id": "27914242", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242" } ] } ], "biomarker_canonical_id": "AA4903", "collision": 1 }, { "biomarker_id": "AA4904-1", "biomarker_component": [ { "biomarker": "decreased PS level", "assessed_biomarker_entity": { "recommended_name": "Phosphatidylserine", "synonyms": [ { "synonym": "PS(18:1/18:1)" } ] }, "assessed_biomarker_entity_id": "CHEBI:90437", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "PS 18:1/18:1 alone demonstrated lower expression in urine in patients as compared to the controls. Also, the author calculated that in urinary exosomes, PS 18:0e18:1 in the inner leaflet could occupy 72 18% (mean SD; n Z 13) and 66 22% (mean SD; n Z 15) of the area occupied by long-chain sphingolipids (N amidated C22 and C24) in urinary exosomes from controls and prostate cancer patients, respectively. The highest significance was shown for phosphatidylserine (PS) 18:1/18:1 and lactosylceramide (d18:1/16:0), the latter also showed the highest patient-to-control ratio. Furthermore, combinations of these lipid species and PS 18:0-18:2 distinguished the two groups with 93% sensitivity and 100% specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "27914242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242", "evidence_list": [ { "evidence": "PS 18:1/18:1 alone demonstrated lower expression in urine in patients as compared to the controls. Also, the author calculated that in urinary exosomes, PS 18:0e18:1 in the inner leaflet could occupy 72 18% (mean SD; n Z 13) and 66 22% (mean SD; n Z 15) of the area occupied by long-chain sphingolipids (N amidated C22 and C24) in urinary exosomes from controls and prostate cancer patients, respectively. The highest significance was shown for phosphatidylserine (PS) 18:1/18:1 and lactosylceramide (d18:1/16:0), the latter also showed the highest patient-to-control ratio. Furthermore, combinations of these lipid species and PS 18:0-18:2 distinguished the two groups with 93% sensitivity and 100% specificity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers.", "journal": "European journal of cancer (Oxford, England : 1990)", "authors": "Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A", "date": "2016-12-04", "evidence": [], "reference": [ { "id": "27914242", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27914242" } ] } ], "biomarker_canonical_id": "AA4904", "collision": 1 }, { "biomarker_id": "AA4905-1", "biomarker_component": [ { "biomarker": "increased TM256 level", "assessed_biomarker_entity": { "recommended_name": "Transmembrane protein 256", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q8N2U0", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "26196085", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26196085", "evidence_list": [ { "evidence": "The most interesting potential prostate cancer biomarker identified in our study (both at 100% specificity and combined specificity and sensitivity) is TM256/C17orf61, a protein that has been predicted to be located at the plasma membrane and in exosomes. TM256 showed the highest sensitivity (94%) and level of enrichment (140-fold) of all the detected proteins. The fact that TM256 is also relatively abundant in patient exosomes further increases the interest for this protein as a promising biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "26196085", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26196085", "evidence_list": [ { "evidence": "The most interesting potential prostate cancer biomarker identified in our study (both at 100% specificity and combined specificity and sensitivity) is TM256/C17orf61, a protein that has been predicted to be located at the plasma membrane and in exosomes. TM256 showed the highest sensitivity (94%) and level of enrichment (140-fold) of all the detected proteins. The fact that TM256 is also relatively abundant in patient exosomes further increases the interest for this protein as a promising biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of prostate cancer biomarkers in urinary exosomes.", "journal": "Oncotarget", "authors": "\u00d8verbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K, Llorente A", "date": "2015-07-22", "evidence": [], "reference": [ { "id": "26196085", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26196085" } ] } ], "biomarker_canonical_id": "AA4905", "collision": 1 }, { "biomarker_id": "AA4906-1", "biomarker_component": [ { "biomarker": "increased FKBP4 level", "assessed_biomarker_entity": { "recommended_name": "Peptidyl-prolyl cis-trans isomerase", "synonyms": [ { "synonym": "PPIase FKBP4" }, { "synonym": "51 kDa FK506-binding protein" }, { "synonym": "FKBP51" }, { "synonym": "52 kDa FK506-binding protein" }, { "synonym": "52 kDa FKBP" }, { "synonym": "FKBP-52" }, { "synonym": "59 kDa immunophilin" }, { "synonym": "p59" }, { "synonym": "FK506-binding protein 4" }, { "synonym": "FKBP-4" }, { "synonym": "FKBP59" }, { "synonym": "HSP-binding immunophilin" }, { "synonym": "HBI" }, { "synonym": "Immunophilin FKBP52" }, { "synonym": "Rotamase" } ] }, "assessed_biomarker_entity_id": "UPKB:Q02790", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "17722004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004", "evidence_list": [ { "evidence": "FKBP4 was increased in PCa specimen. It was also interesting that FKBP4 (also known as FKBP52) was up-regulated in Pca." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "17722004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004", "evidence_list": [ { "evidence": "FKBP4 was increased in PCa specimen. It was also interesting that FKBP4 (also known as FKBP52) was up-regulated in Pca." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.", "journal": "International journal of cancer", "authors": "Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK", "date": "2007-08-28", "evidence": [], "reference": [ { "id": "17722004", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004" } ] } ], "biomarker_canonical_id": "AA4906", "collision": 1 }, { "biomarker_id": "AA4907-1", "biomarker_component": [ { "biomarker": "decreased FLNA level", "assessed_biomarker_entity": { "recommended_name": "Filamin-A", "synonyms": [ { "synonym": "FLN-A" }, { "synonym": "Actin-binding protein 280" }, { "synonym": "ABP-280" }, { "synonym": "Alpha-filamin" }, { "synonym": "Endothelial actin-binding protein" }, { "synonym": "Filamin-1" }, { "synonym": "Non-muscle filamin" } ] }, "assessed_biomarker_entity_id": "UPKB:P21333", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "17722004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004", "evidence_list": [ { "evidence": "2-DE protein profile of FLNA(7-15) clearly reveals a decrease in this protein in PNBX specimens from PCa patients. FLNA(7-15) levels were notably reduced in AMACR-positive PCa specimens as measured by immunoblot analysis (Fig. 3e). These results, taken with proteomics observations, suggest that FLNA(7-15) is down-regulated in prostate cancer. Among the proteins identified, the most notable was the endogenous 100-kDa fragment of FLNA and FKBP4, FLNA(7-15), which was found to be markedly down-regulated in PCa specimens." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "17722004", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004", "evidence_list": [ { "evidence": "2-DE protein profile of FLNA(7-15) clearly reveals a decrease in this protein in PNBX specimens from PCa patients. FLNA(7-15) levels were notably reduced in AMACR-positive PCa specimens as measured by immunoblot analysis (Fig. 3e). These results, taken with proteomics observations, suggest that FLNA(7-15) is down-regulated in prostate cancer. Among the proteins identified, the most notable was the endogenous 100-kDa fragment of FLNA and FKBP4, FLNA(7-15), which was found to be markedly down-regulated in PCa specimens." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.", "journal": "International journal of cancer", "authors": "Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK", "date": "2007-08-28", "evidence": [], "reference": [ { "id": "17722004", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17722004" } ] } ], "biomarker_canonical_id": "AA4907", "collision": 1 }, { "biomarker_id": "AA4908-1", "biomarker_component": [ { "biomarker": "increased MYO5A level", "assessed_biomarker_entity": { "recommended_name": "Unconventional myosin-Va", "synonyms": [ { "synonym": "Dilute myosin heavy chain, non-muscle" }, { "synonym": "Myosin heavy chain 12" }, { "synonym": "Myosin-12" }, { "synonym": "Myoxin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y4I1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "On the bottom left is the WASF1 module which included MYO5A and WASF1. These two genes both interacted with NCKAP1, CYFIP2, and CYFIP1. In this WASF1 module, four genes (CYFIP1, CYFIP2, NCKAP1, and WASF1) were involved in hsa04810: regulation of actin cytoskeleton. It has been reported that actin cytoskeleton was associated with lung cancer migration and invasion" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "On the bottom left is the WASF1 module which included MYO5A and WASF1. These two genes both interacted with NCKAP1, CYFIP2, and CYFIP1. In this WASF1 module, four genes (CYFIP1, CYFIP2, NCKAP1, and WASF1) were involved in hsa04810: regulation of actin cytoskeleton. It has been reported that actin cytoskeleton was associated with lung cancer migration and invasion" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] } ], "biomarker_canonical_id": "AA4908", "collision": 1 }, { "biomarker_id": "AA4909-1", "biomarker_component": [ { "biomarker": "increased WASF1 level", "assessed_biomarker_entity": { "recommended_name": "Wiskott-Aldrich syndrome protein family member 1", "synonyms": [ { "synonym": "Protein WAVE-1" }, { "synonym": "Verprolin homology domain-containing protein 1" }, { "synonym": "Wiskott-Aldrich syndrome protein family member 1" }, { "synonym": "WASP family protein member 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q92558", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "On the bottom left is the WASF1 module which included MYO5A and WASF1. These two genes both interacted with NCKAP1, CYFIP2, and CYFIP1. In this WASF1 module, four genes (CYFIP1, CYFIP2, NCKAP1, and WASF1) were involved in hsa04810: regulation of actin cytoskeleton. It has been reported that actin cytoskeleton was associated with lung cancer migration and invasion" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "On the bottom left is the WASF1 module which included MYO5A and WASF1. These two genes both interacted with NCKAP1, CYFIP2, and CYFIP1. In this WASF1 module, four genes (CYFIP1, CYFIP2, NCKAP1, and WASF1) were involved in hsa04810: regulation of actin cytoskeleton. It has been reported that actin cytoskeleton was associated with lung cancer migration and invasion" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] } ], "biomarker_canonical_id": "AA4909", "collision": 1 }, { "biomarker_id": "AA4910-1", "biomarker_component": [ { "biomarker": "increased PDHB level", "assessed_biomarker_entity": { "recommended_name": "Pyruvate dehydrogenase E1 component subunit beta, mitochondrial", "synonyms": [ { "synonym": "PDHE1-B" } ] }, "assessed_biomarker_entity_id": "UPKB:P11177", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "The PDHB module, which was involved in carbohydrate metabolism. The PDHB module interacted with the RSRC1 module, which was associated with protein biosynthesis, growth, and migration. These biomarkers can accurately predict NSCLC. In-depth biological network analysis suggested that there were four modules and three intermodule hubs that may trigger NSCLC" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "The PDHB module, which was involved in carbohydrate metabolism. The PDHB module interacted with the RSRC1 module, which was associated with protein biosynthesis, growth, and migration. These biomarkers can accurately predict NSCLC. In-depth biological network analysis suggested that there were four modules and three intermodule hubs that may trigger NSCLC" } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] } ], "biomarker_canonical_id": "AA4910", "collision": 1 }, { "biomarker_id": "AN4197-1", "biomarker_component": [ { "biomarker": "increased RSRC1 level", "assessed_biomarker_entity": { "recommended_name": "Serine/arginine-related protein 53", "synonyms": [ { "synonym": "SRrp53" }, { "synonym": "Arginine/serine-rich coiled-coil protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96IZ7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "At the top middle was the RSRC1 module, which included RSRC1 and FLOT1. Within this module, eight genes (RPS11, RPS14, RPS15, RPS26, RPS28, RPS3, RPS3A, and RPS9) that RSRC1 interacted with were ribosomal protein genes. Ribosome is important for protein biosynthesis, and there have been several reports that downregulation of ribosomal protein can inhibit or attenuate NSCLC growth and migration." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "At the top middle was the RSRC1 module, which included RSRC1 and FLOT1. Within this module, eight genes (RPS11, RPS14, RPS15, RPS26, RPS28, RPS3, RPS3A, and RPS9) that RSRC1 interacted with were ribosomal protein genes. Ribosome is important for protein biosynthesis, and there have been several reports that downregulation of ribosomal protein can inhibit or attenuate NSCLC growth and migration." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] } ], "biomarker_canonical_id": "AN4197", "collision": 1 }, { "biomarker_id": "AN4198-1", "biomarker_component": [ { "biomarker": "increased methylation", "assessed_biomarker_entity": { "recommended_name": "Pituitary homeobox 2 gene methylation", "synonyms": [ { "synonym": "ALL1-responsive protein ARP1" }, { "synonym": "Homeobox protein PITX2" }, { "synonym": "Paired-like homeodomain transcription factor 2" }, { "synonym": "RIEG bicoid-related homeobox transcription factor" }, { "synonym": "Solurshin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99697", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "25402584", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25402584", "evidence_list": [ { "evidence": "However, after FDR adjustment at 5% was applied, only methylation of PITX2 remained significant (p = 0.005) for predicting PCa related death and is interpreted as the following: for each 10% increase in methylation of PITX2, the risk of PCa-related death increased by a factor of 1.56." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "25402584", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25402584", "evidence_list": [ { "evidence": "However, after FDR adjustment at 5% was applied, only methylation of PITX2 remained significant (p = 0.005) for predicting PCa related death and is interpreted as the following: for each 10% increase in methylation of PITX2, the risk of PCa-related death increased by a factor of 1.56." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "DNA methylation of PITX2 predicts poor survival in men with prostate cancer.", "journal": "Biomarkers in medicine", "authors": "Vasiljevi\u0107 N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT", "date": "2014-11-18", "evidence": [], "reference": [ { "id": "25402584", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25402584" } ] } ], "biomarker_canonical_id": "AN4198", "collision": 1 }, { "biomarker_id": "AA4913-1", "biomarker_component": [ { "biomarker": "increased CXCR4 level", "assessed_biomarker_entity": { "recommended_name": "C-X-C chemokine receptor type 4", "synonyms": [ { "synonym": "CXC-R4" }, { "synonym": "CXCR-4" }, { "synonym": "FB22" }, { "synonym": "Fusin" }, { "synonym": "HM89" }, { "synonym": "LCR1" }, { "synonym": "Leukocyte-derived seven transmembrane domain receptor" }, { "synonym": "LESTR" }, { "synonym": "Lipopolysaccharide-associated protein 3" }, { "synonym": "LAP-3" }, { "synonym": "LPS-associated protein 3" }, { "synonym": "NPYRL" }, { "synonym": "Stromal cell-derived factor 1 receptor" }, { "synonym": "SDF-1 receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:P61073", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "15756007", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15756007", "evidence_list": [ { "evidence": "The CXCR4 expression on tumor cells was correlated with an unfavorable prognosis with a median disease-free and overall survival of 22 and 35 months, respectively. The hazard ratios of relapse and death, compared with patients with CXCR4-negative tumors, were 2.5 (95% confidence interval, 1.2-6.1) and 3.1 (95% confidence interval, 1.1-7.2), respectively. This article provides the first evidence that CXCR4 expression could be an independent and powerful prognostic marker in primary cutaneous malignant melanomas." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "15756007", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15756007", "evidence_list": [ { "evidence": "The CXCR4 expression on tumor cells was correlated with an unfavorable prognosis with a median disease-free and overall survival of 22 and 35 months, respectively. The hazard ratios of relapse and death, compared with patients with CXCR4-negative tumors, were 2.5 (95% confidence interval, 1.2-6.1) and 3.1 (95% confidence interval, 1.1-7.2), respectively. This article provides the first evidence that CXCR4 expression could be an independent and powerful prognostic marker in primary cutaneous malignant melanomas." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G", "date": "2005-03-10", "evidence": [], "reference": [ { "id": "15756007", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15756007" } ] } ], "biomarker_canonical_id": "AA4913", "collision": 1 }, { "biomarker_id": "AA4914-1", "biomarker_component": [ { "biomarker": "increased CTSB level", "assessed_biomarker_entity": { "recommended_name": "Cathepsin B", "synonyms": [ { "synonym": "APP secretase" }, { "synonym": "APPS" }, { "synonym": "Cathepsin B1" } ] }, "assessed_biomarker_entity_id": "UPKB:P07858", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "21673904", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21673904", "evidence_list": [ { "evidence": "Indeed, significantly elevated levels of Cathepsin B (as determined by unpaired t test) were observed in melanoma patients. However, Cathepsin B levels were also elevated in breast cancer patients, indicating that cathepsin B is not unique to melanoma but may be associated with general tumor progression. Cathepsin B levels were also independent of age and stages of melanoma. In our study, serum cathepsin B levels were elevated in both melanoma and breast cancer patients. Based on these data, it is suggested that cathepsin B might be relevant to the development of a broad range of tumor, possibly contributing to the tumor cell migration and metastasis due to its protease function." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "21673904", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21673904", "evidence_list": [ { "evidence": "Indeed, significantly elevated levels of Cathepsin B (as determined by unpaired t test) were observed in melanoma patients. However, Cathepsin B levels were also elevated in breast cancer patients, indicating that cathepsin B is not unique to melanoma but may be associated with general tumor progression. Cathepsin B levels were also independent of age and stages of melanoma. In our study, serum cathepsin B levels were elevated in both melanoma and breast cancer patients. Based on these data, it is suggested that cathepsin B might be relevant to the development of a broad range of tumor, possibly contributing to the tumor cell migration and metastasis due to its protease function." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "IL-8 and cathepsin B as melanoma serum biomarkers.", "journal": "International journal of molecular sciences", "authors": "Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X", "date": "2011-06-16", "evidence": [], "reference": [ { "id": "21673904", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21673904" } ] } ], "biomarker_canonical_id": "AA4914", "collision": 1 }, { "biomarker_id": "AN4199-1", "biomarker_component": [ { "biomarker": "increased C1QTNF3 level", "assessed_biomarker_entity": { "recommended_name": "Complement C1q tumor necrosis factor-related protein 3", "synonyms": [ { "synonym": "Collagenous repeat-containing sequence 26 kDa protein" }, { "synonym": "CORS26" }, { "synonym": "Secretory protein CORS26" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BXJ4", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "29861410", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29861410", "evidence_list": [ { "evidence": "We were able to draw the conclusion that C1QTNF3 was significantly overexpressed in prostate tumor tissues." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "29861410", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29861410", "evidence_list": [ { "evidence": "We were able to draw the conclusion that C1QTNF3 was significantly overexpressed in prostate tumor tissues." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.", "journal": "EBioMedicine", "authors": "Hou Q, Bing ZT, Hu C, Li MY, Yang KH, Mo Z, Xie XW, Liao JL, Lu Y, Horie S, Lou MW", "date": "2018-06-05", "evidence": [], "reference": [ { "id": "29861410", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29861410" } ] } ], "biomarker_canonical_id": "AN4199", "collision": 1 }, { "biomarker_id": "AN4200-1", "biomarker_component": [ { "biomarker": "decreased EIF2B5 level", "assessed_biomarker_entity": { "recommended_name": "Translation initiation factor eIF-2B subunit epsilon", "synonyms": [ { "synonym": "eIF-2B GDP-GTP exchange factor subunit epsilon" } ] }, "assessed_biomarker_entity_id": "UPKB:Q13144", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "32000373", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32000373", "evidence_list": [ { "evidence": "Low EIF2B5 expression was found in ovarian cancer tissues and correlated with survival status. Survival analysis showed that ovarian cancer patients with low EIF2B5 expression had a short OS. Low EIF2B5 expression predicts poor prognosis in ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32000373", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32000373", "evidence_list": [ { "evidence": "Low EIF2B5 expression was found in ovarian cancer tissues and correlated with survival status. Survival analysis showed that ovarian cancer patients with low EIF2B5 expression had a short OS. Low EIF2B5 expression predicts poor prognosis in ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Low EIF2B5 expression predicts poor prognosis in ovarian cancer.", "journal": "Medicine", "authors": "Hou L, Jiao Y, Li Y, Luo Z, Zhang X, Pan G, Zhao Y, Yang Z, He M", "date": "2020-02-01", "evidence": [], "reference": [ { "id": "32000373", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32000373" } ] } ], "biomarker_canonical_id": "AN4200", "collision": 1 }, { "biomarker_id": "AA4917-1", "biomarker_component": [ { "biomarker": "decreased MLH1 level", "assessed_biomarker_entity": { "recommended_name": "DNA mismatch repair protein Mlh1", "synonyms": [ { "synonym": "MutL protein homolog 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P40692", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "31570444", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31570444", "evidence_list": [ { "evidence": "Low MLH1 expression was associated with improved prognosis and is a possible predictor of the chemosensitivity of ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "31570444", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31570444", "evidence_list": [ { "evidence": "Low MLH1 expression was associated with improved prognosis and is a possible predictor of the chemosensitivity of ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "MLH1 Is a Prognostic Biomarker for Serous Ovarian Cancer Treated With Platinum- and Taxane-based Chemotherapy.", "journal": "Anticancer research", "authors": "Kawashima N, Yoshida H, Miwa M, Fujiwara K", "date": "2019-10-02", "evidence": [], "reference": [ { "id": "31570444", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31570444" } ] } ], "biomarker_canonical_id": "AA4917", "collision": 1 }, { "biomarker_id": "AN4201-1", "biomarker_component": [ { "biomarker": "decreased ZNF660 level", "assessed_biomarker_entity": { "recommended_name": "Zinc finger protein 660", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q6AZW8", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "29465788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788", "evidence_list": [ { "evidence": "We furthermore identify ZNF660 hypermethylation as associated with increased risk of BCR, as well as with reduced OS and reduced CSS, thus showing promising prognostic potential. ZNF660 hypermethylation was also significantly associated with poor overall and PC-specific survival in the RP." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "29465788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788", "evidence_list": [ { "evidence": "We furthermore identify ZNF660 hypermethylation as associated with increased risk of BCR, as well as with reduced OS and reduced CSS, thus showing promising prognostic potential. ZNF660 hypermethylation was also significantly associated with poor overall and PC-specific survival in the RP." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.", "journal": "Molecular oncology", "authors": "Haldrup C, Pedersen AL, \u00d8gaard N, Strand SH, H\u00f8yer S, Borre M, \u00d8rntoft TF, S\u00f8rensen KD", "date": "2018-02-22", "evidence": [], "reference": [ { "id": "29465788", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788" } ] } ], "biomarker_canonical_id": "AN4201", "collision": 1 }, { "biomarker_id": "AN4202-1", "biomarker_component": [ { "biomarker": "decreased ST6GALNAC3 level", "assessed_biomarker_entity": { "recommended_name": "Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3", "synonyms": [ { "synonym": "GalNAc alpha-2,6-sialyltransferase III" }, { "synonym": "ST6GalNAc III" }, { "synonym": "ST6GalNAcIII" }, { "synonym": "STY" }, { "synonym": "Sialyltransferase 7C" }, { "synonym": "SIAT7-C" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8NDV1", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "29465788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788", "evidence_list": [ { "evidence": "ST6GALNAC3 and ZNF660 mRNA levels were significantly downregulated in PC compared to AN tissue samples (P < 0.0001; Fig. 1K,L). Furthermore, the mRNA expression level of each gene was moderately, but significantly, inversely correlated with the promoter methylation level (P < 0.001; Fig. 1M,N), collectively suggesting that aberrant promoter hypermethylation may contribute to downregulation of ST6GALNAC3 and ZNF660 in PC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "29465788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788", "evidence_list": [ { "evidence": "ST6GALNAC3 and ZNF660 mRNA levels were significantly downregulated in PC compared to AN tissue samples (P < 0.0001; Fig. 1K,L). Furthermore, the mRNA expression level of each gene was moderately, but significantly, inversely correlated with the promoter methylation level (P < 0.001; Fig. 1M,N), collectively suggesting that aberrant promoter hypermethylation may contribute to downregulation of ST6GALNAC3 and ZNF660 in PC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.", "journal": "Molecular oncology", "authors": "Haldrup C, Pedersen AL, \u00d8gaard N, Strand SH, H\u00f8yer S, Borre M, \u00d8rntoft TF, S\u00f8rensen KD", "date": "2018-02-22", "evidence": [], "reference": [ { "id": "29465788", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29465788" } ] } ], "biomarker_canonical_id": "AN4202", "collision": 1 }, { "biomarker_id": "AN4203-1", "biomarker_component": [ { "biomarker": "increased XPO6 level", "assessed_biomarker_entity": { "recommended_name": "Exportin-6", "synonyms": [ { "synonym": "Exp6" }, { "synonym": "Ran-binding protein 20" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96QU8", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "26709895", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26709895", "evidence_list": [ { "evidence": "XPO6 expression was significantly higher in patients with elevated PSA levels (>20 ng/ml) prior to radical prostatectomy (P=0.02). Elevated XPO6 expression was also found in patients with higher combined Gleason score (>/=8) in both biopsy and radical prostatectomy specimens (P=1.34E-3, P=3.09E-3, respectively). Furthermore, a positive association was found for the elevated expression of XPO6 and lymph node metastasis occurrence (P=0.01), biochemical recurrence (P=1.57E-3), and distant metastasis occurrence (P=3.27E-4)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "26709895", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26709895", "evidence_list": [ { "evidence": "XPO6 expression was significantly higher in patients with elevated PSA levels (>20 ng/ml) prior to radical prostatectomy (P=0.02). Elevated XPO6 expression was also found in patients with higher combined Gleason score (>/=8) in both biopsy and radical prostatectomy specimens (P=1.34E-3, P=3.09E-3, respectively). Furthermore, a positive association was found for the elevated expression of XPO6 and lymph node metastasis occurrence (P=0.01), biochemical recurrence (P=1.57E-3), and distant metastasis occurrence (P=3.27E-4)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence.", "journal": "Frontiers in bioscience (Scholar edition)", "authors": "Hao J, Chiang YT, Gout PW, Wang Y", "date": "2015-12-29", "evidence": [], "reference": [ { "id": "26709895", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26709895" } ] } ], "biomarker_canonical_id": "AN4203", "collision": 1 }, { "biomarker_id": "AN4204-1", "biomarker_component": [ { "biomarker": "decreased ZFP36 level", "assessed_biomarker_entity": { "recommended_name": "Tristetraprolin", "synonyms": [ { "synonym": "G0/G1 switch regulatory protein 24" }, { "synonym": "Growth factor-inducible nuclear protein NUP475" }, { "synonym": "Tristetraprolin" }, { "synonym": "Zinc finger protein 36" }, { "synonym": "Zfp-36" } ] }, "assessed_biomarker_entity_id": "UPKB:P26651", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "30420441", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30420441", "evidence_list": [ { "evidence": "Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "30420441", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30420441", "evidence_list": [ { "evidence": "Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, B\u00f6rnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ", "date": "2018-11-14", "evidence": [], "reference": [ { "id": "30420441", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30420441" } ] } ], "biomarker_canonical_id": "AN4204", "collision": 1 }, { "biomarker_id": "AA4922-1", "biomarker_component": [ { "biomarker": "increased EZH2 level", "assessed_biomarker_entity": { "recommended_name": "Zeste homolog 2", "synonyms": [ { "synonym": "ENX-1" }, { "synonym": "Enhancer of zeste homolog 2" }, { "synonym": "Lysine N-methyltransferase 6" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15910", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "96964-2" } ], "evidence_source": [ { "id": "12374981", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12374981", "evidence_list": [ { "evidence": "EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis. Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal Progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "12374981", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12374981", "evidence_list": [ { "evidence": "EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis. Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal Progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The polycomb group protein EZH2 is involved in progression of prostate cancer.", "journal": "Nature", "authors": "Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM", "date": "2002-10-11", "evidence": [], "reference": [ { "id": "12374981", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12374981" } ] } ], "biomarker_canonical_id": "AA4922", "collision": 1 }, { "biomarker_id": "AA4923-1", "biomarker_component": [ { "biomarker": "increased FABP4 level", "assessed_biomarker_entity": { "recommended_name": "Fatty acid-binding protein, adipocyte", "synonyms": [ { "synonym": "Adipocyte lipid-binding protein" }, { "synonym": "ALBP" }, { "synonym": "Adipocyte-type fatty acid-binding protein" }, { "synonym": "A-FABP" }, { "synonym": "AFABP" }, { "synonym": "Fatty acid-binding protein 4" } ] }, "assessed_biomarker_entity_id": "UPKB:P15090", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30100196", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30100196", "evidence_list": [ { "evidence": "Using clinical samples, we demonstrated that circulating A-FABP levels were significantly increased in obese patients with breast cancer in comparison with those without breast cancer. Collectively, these data suggest circulating A-FABP as a new link between obesity and breast cancer risk, thereby revealing A-FABP as a potential new therapeutic target for treatment of obesity-associated cancers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30100196", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30100196", "evidence_list": [ { "evidence": "Using clinical samples, we demonstrated that circulating A-FABP levels were significantly increased in obese patients with breast cancer in comparison with those without breast cancer. Collectively, these data suggest circulating A-FABP as a new link between obesity and breast cancer risk, thereby revealing A-FABP as a potential new therapeutic target for treatment of obesity-associated cancers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated Breast/Mammary Tumor Development.", "journal": "Cell metabolism", "authors": "Hao J, Zhang Y, Yan X, Yan F, Sun Y, Zeng J, Waigel S, Yin Y, Fraig MM, Egilmez NK, Suttles J, Kong M, Liu S, Cleary MP, Sauter E, Li B", "date": "2018-08-14", "evidence": [], "reference": [ { "id": "30100196", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30100196" } ] } ], "biomarker_canonical_id": "AA4923", "collision": 1 }, { "biomarker_id": "AA4924-1", "biomarker_component": [ { "biomarker": "increased ENG level", "assessed_biomarker_entity": { "recommended_name": "Endoglin", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P17813", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "19004009", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19004009", "evidence_list": [ { "evidence": "Elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication. In the present study, we show that endoglin is increased in urine collected after DRE from men with prostate cancer on biopsy compared to men without prostate cancer, and that post-DRE urinary endoglin levels are predictive of prostate cancer in a cohort of men at increased risk by PSA and DRE criteria." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "19004009", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19004009", "evidence_list": [ { "evidence": "Elevations in post-DRE urinary endoglin suggest there may be value in further studying endoglin as a urinary biomarker of prostate cancer. Endoglin levels in both urine and serum may aid in prostate cancer detection and prognostication. In the present study, we show that endoglin is increased in urine collected after DRE from men with prostate cancer on biopsy compared to men without prostate cancer, and that post-DRE urinary endoglin levels are predictive of prostate cancer in a cohort of men at increased risk by PSA and DRE criteria." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Endoglin (CD105) as a urinary and serum marker of prostate cancer.", "journal": "International journal of cancer", "authors": "Fujita K, Ewing CM, Chan DY, Mangold LA, Partin AW, Isaacs WB, Pavlovich CP", "date": "2008-11-13", "evidence": [], "reference": [ { "id": "19004009", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19004009" } ] } ], "biomarker_canonical_id": "AA4924", "collision": 1 }, { "biomarker_id": "AA4925-1", "biomarker_component": [ { "biomarker": "increased AMACR level", "assessed_biomarker_entity": { "recommended_name": "Alpha-methylacyl-CoA racemase", "synonyms": [ { "synonym": "2-methylacyl-CoA racemase" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UHK6", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "15371879", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15371879", "evidence_list": [ { "evidence": "AMACR was detected in the urine in 18 of 26 patients (69%). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100 sensitivity, 95% CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58% specificity, 95% CI 29 to 78) and in 1 of 2 (50%, 95% CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86%). A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "15371879", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15371879", "evidence_list": [ { "evidence": "AMACR was detected in the urine in 18 of 26 patients (69%). AMACR was detected in all 12 patients with biopsy confirmed adenocarcinoma of the prostate (100 sensitivity, 95% CI 75 to 100), in 5 of 12 with no evidence of cancer on biopsy (58% specificity, 95% CI 29 to 78) and in 1 of 2 (50%, 95% CI 3 to 80) with atypia on biopsy. Overall AMACR detection was associated with cancer status by prostate biopsy in 21 of 26 patients (86%). A screening test based on urinary AMACR may develop into a useful adjunct to serum prostate specific antigen and digital rectal examination for identifying men at increased risk for harboring prostate cancer despite negative biopsy. Such a test has potential application for stratifying patients into low and high risk groups for surveillance vs repeat biopsy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.", "journal": "The Journal of urology", "authors": "Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, De Marzo AM, Nelson WG, Pavlovich CP", "date": "2004-09-17", "evidence": [], "reference": [ { "id": "15371879", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15371879" } ] } ], "biomarker_canonical_id": "AA4925", "collision": 1 }, { "biomarker_id": "AA4926-1", "biomarker_component": [ { "biomarker": "increased IMPDH2 level", "assessed_biomarker_entity": { "recommended_name": "Inosine 5'-monophosphate dehydrogenase type II", "synonyms": [ { "synonym": "IMP dehydrogenase 2" }, { "synonym": "IMPD 2" }, { "synonym": "IMPDH 2" }, { "synonym": "Inosine-5'-monophosphate dehydrogenase type II" }, { "synonym": "IMP dehydrogenase II" }, { "synonym": "IMPDH-II" } ] }, "assessed_biomarker_entity_id": "UPKB:P12268", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "32305001", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305001", "evidence_list": [ { "evidence": "IMPDH2 is highly expressed in ovarian cancer and correlates with prognosis, which may serve as a potential prognostic biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32305001", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305001", "evidence_list": [ { "evidence": "IMPDH2 is highly expressed in ovarian cancer and correlates with prognosis, which may serve as a potential prognostic biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The expression and prognostic role of IMPDH2 in ovarian cancer.", "journal": "Annals of diagnostic pathology", "authors": "Tian Y, Zhang J, Chen L, Zhang X", "date": "2020-04-19", "evidence": [], "reference": [ { "id": "32305001", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32305001" } ] } ], "biomarker_canonical_id": "AA4926", "collision": 1 }, { "biomarker_id": "AA4927-1", "biomarker_component": [ { "biomarker": "increased MIR-106A-5P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-106a-5p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000103", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "miR-106a-5p was found to be significantly (p < 0.05) upregulated in BC tissue samples compared to paired adjacent healthy tissue samples." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "miR-106a-5p was found to be significantly (p < 0.05) upregulated in BC tissue samples compared to paired adjacent healthy tissue samples." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer.", "journal": "Cancer letters", "authors": "Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y", "date": "2015-08-16", "evidence": [], "reference": [ { "id": "26276721", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721" } ] } ], "biomarker_canonical_id": "AA4927", "collision": 1 }, { "biomarker_id": "AA4928-1", "biomarker_component": [ { "biomarker": "decreased MIR-495 level", "assessed_biomarker_entity": { "recommended_name": "miRNA-495", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003135", "assessed_entity_type": "RNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways. The present study delineated the importance of miR-195-5p and miR-495 miRNAs as prospective circulating surrogate molecular signatures for early detection of breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways. The present study delineated the importance of miR-195-5p and miR-495 miRNAs as prospective circulating surrogate molecular signatures for early detection of breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer.", "journal": "Cancer letters", "authors": "Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y", "date": "2015-08-16", "evidence": [], "reference": [ { "id": "26276721", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721" } ] } ], "biomarker_canonical_id": "AA4928", "collision": 1 }, { "biomarker_id": "AA4929-1", "biomarker_component": [ { "biomarker": "increased MIR-454-3P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-454-3p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0003885", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "26276721", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721", "evidence_list": [ { "evidence": "Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer.", "journal": "Cancer letters", "authors": "Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y", "date": "2015-08-16", "evidence": [], "reference": [ { "id": "26276721", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26276721" } ] } ], "biomarker_canonical_id": "AA4929", "collision": 1 }, { "biomarker_id": "AA4930-1", "biomarker_component": [ { "biomarker": "decreased MIR-195-5P level", "assessed_biomarker_entity": { "recommended_name": "miRNA-195-5p", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000461", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32259560", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560", "evidence_list": [ { "evidence": "In early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32259560", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560", "evidence_list": [ { "evidence": "In early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. Results showed differential pattern of expressions of these miRNAs in multiple cohorts, however in early stage breast cancer, miR-106a-5p and miR-454-3p were upregulated (p < 0.05), miR-195-5p and miR-495 were downregulated (p < 0.05) in PBMCs. In addition, these miRNAs were also significantly associated with cancer and ErbB signaling pathways." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Interleukin-6 as a potential biomarker of COVID-19 progression.", "journal": "Medecine et maladies infectieuses", "authors": "Ulhaq ZS, Soraya GV", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32259560", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32259560" } ] } ], "biomarker_canonical_id": "AA4930", "collision": 1 }, { "biomarker_id": "AN4205-1", "biomarker_component": [ { "biomarker": "decreased PLA2R1 level", "assessed_biomarker_entity": { "recommended_name": "Secretory phospholipase A2 receptor", "synonyms": [ { "synonym": "PLA2-R" }, { "synonym": "PLA2R" }, { "synonym": "180 kDa secretory phospholipase A2 receptor" }, { "synonym": "C-type lectin domain family 13 member C" }, { "synonym": "M-type receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:Q13018", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "31965517", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31965517", "evidence_list": [ { "evidence": "The main objective of this study was to characterize the stage-specific deregulation in genes and miRNA expression in PTC to identify potential prognostic biomarkers. LTF and PLA2R1 were identified as two promising biomarkers down-regulated in a subgroup of stage I (both in TCGA and in the validation data set) and in the majority of stage IV of PTC (in TCGA data set)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "31965517", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31965517", "evidence_list": [ { "evidence": "The main objective of this study was to characterize the stage-specific deregulation in genes and miRNA expression in PTC to identify potential prognostic biomarkers. LTF and PLA2R1 were identified as two promising biomarkers down-regulated in a subgroup of stage I (both in TCGA and in the validation data set) and in the majority of stage IV of PTC (in TCGA data set)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.", "journal": "Journal of endocrinological investigation", "authors": "Hosseinkhan N, Honardoost M, Blighe K, Moore CBT, Khamseh ME", "date": "2020-01-23", "evidence": [], "reference": [ { "id": "31965517", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31965517" } ] } ], "biomarker_canonical_id": "AN4205", "collision": 1 }, { "biomarker_id": "AN4206-1", "biomarker_component": [ { "biomarker": "increased KCNN4 level", "assessed_biomarker_entity": { "recommended_name": "Intermediate conductance calcium-activated potassium channel protein 4", "synonyms": [ { "synonym": "SK4" }, { "synonym": "SKCa 4" }, { "synonym": "SKCa4" }, { "synonym": "IKCa1" }, { "synonym": "IK1" }, { "synonym": "KCa3.1" }, { "synonym": "KCa4" }, { "synonym": "Putative Gardos channel" } ] }, "assessed_biomarker_entity_id": "UPKB:O15554", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "32857728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32857728", "evidence_list": [ { "evidence": "We examined expression of KCNN4 in public databases and discovered that it is upregulated in PTC. These results suggest that KCNN4 promotes PTC progression by inducing epithelial-mesenchymal transition and suppressing apoptosis, which suggests KCNN4 may be a useful diagnostic and prognostic biomarker of PTC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32857728", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32857728", "evidence_list": [ { "evidence": "We examined expression of KCNN4 in public databases and discovered that it is upregulated in PTC. These results suggest that KCNN4 promotes PTC progression by inducing epithelial-mesenchymal transition and suppressing apoptosis, which suggests KCNN4 may be a useful diagnostic and prognostic biomarker of PTC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "", "journal": "Aging", "authors": "Wen J, Lin B, Lin L, Chen Y, Wang O", "date": "2020-08-29", "evidence": [], "reference": [ { "id": "32857728", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32857728" } ] } ], "biomarker_canonical_id": "AN4206", "collision": 1 }, { "biomarker_id": "AN4207-1", "biomarker_component": [ { "biomarker": "increased 8-OHDG level", "assessed_biomarker_entity": { "recommended_name": "8-Hydroxy-2-deoxyguanosine", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C1297", "assessed_entity_type": "metabolite", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30683611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30683611", "evidence_list": [ { "evidence": "The concentrations of 8-OHdG were significantly increased in the BC group (55.2 ng/dL) compared with the benign tumor group (30.2 ng/dL) and with the healthy control group (9.08 ng/dL)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30683611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30683611", "evidence_list": [ { "evidence": "The concentrations of 8-OHdG were significantly increased in the BC group (55.2 ng/dL) compared with the benign tumor group (30.2 ng/dL) and with the healthy control group (9.08 ng/dL)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "8-Hydroxy-2'-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer.", "journal": "Clinical breast cancer", "authors": "Nour Eldin EEM, El-Readi MZ, Nour Eldein MM, Alfalki AA, Althubiti MA, Mohamed Kamel HF, Eid SY, Al-Amodi HS, Mirza AA", "date": "2019-01-27", "evidence": [], "reference": [ { "id": "30683611", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30683611" } ] } ], "biomarker_canonical_id": "AN4207", "collision": 1 }, { "biomarker_id": "AA4934-1", "biomarker_component": [ { "biomarker": "increased TNFRSF11B level", "assessed_biomarker_entity": { "recommended_name": "Tumor necrosis factor receptor superfamily member 11B", "synonyms": [ { "synonym": "Osteoclastogenesis inhibitory factor" }, { "synonym": "Osteoprotegerin" } ] }, "assessed_biomarker_entity_id": "UPKB:O00300", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30348163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30348163", "evidence_list": [ { "evidence": "Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific. High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30348163", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30348163", "evidence_list": [ { "evidence": "Especially in women with ER+ disease, higher circulating OPG concentrations were associated with higher risk of breast cancer-specific. High pre-diagnosis endogenous concentrations of OPG, the decoy receptor for RANKL, were associated with increased risk of death after a breast cancer diagnosis, especially in those with ER+ disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.", "journal": "BMC cancer", "authors": "Sarink D, Schock H, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tj\u00f8nneland A, Arveux P, Fournier A, Kvaskoff M, Boeing H, Karakatsani A, Trichopoulou A, La Vecchia C, Masala G, Agnoli C, Panico S, Tumino R, Sacerdote C, van Gils CH, Peeters PHM, Weiderpass E, Agudo A, Rodr\u00edguez-Barranco M, Huerta JM, Ardanaz E, Gil L, Kaw KT, Schmidt JA, Dossus L, His M, Aune D, Riboli E, Kaaks R, Fortner RT", "date": "2018-10-24", "evidence": [], "reference": [ { "id": "30348163", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30348163" } ] } ], "biomarker_canonical_id": "AA4934", "collision": 1 }, { "biomarker_id": "AA4935-1", "biomarker_component": [ { "biomarker": "increased PTDNA level", "assessed_biomarker_entity": { "recommended_name": "Plasma tumor DNA", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C179394", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "24504125", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24504125", "evidence_list": [ { "evidence": "This prospective study demonstrates accurate mutation detection in tumor tissues using ddPCR, and that ptDNA can be detected in blood before and after surgery in patients with early-stage breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "24504125", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24504125", "evidence_list": [ { "evidence": "This prospective study demonstrates accurate mutation detection in tumor tissues using ddPCR, and that ptDNA can be detected in blood before and after surgery in patients with early-stage breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Detection of cancer DNA in plasma of patients with early-stage breast cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH", "date": "2014-02-08", "evidence": [], "reference": [ { "id": "24504125", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24504125" } ] } ], "biomarker_canonical_id": "AA4935", "collision": 1 }, { "biomarker_id": "AN4208-1", "biomarker_component": [ { "biomarker": "increased SPAG5 level", "assessed_biomarker_entity": { "recommended_name": "Sperm-associated antigen 5", "synonyms": [ { "synonym": "Astrin" }, { "synonym": "Deepest" }, { "synonym": "Mitotic spindle-associated protein p126" }, { "synonym": "MAP126" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96R06", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "31985007", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985007", "evidence_list": [ { "evidence": "These results suggest that high SPAG5 expression was correlated with multiple clinicopathological features of ovarian cancer and can be used as an evaluation indicator for a poor ovarian cancer prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "31985007", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985007", "evidence_list": [ { "evidence": "These results suggest that high SPAG5 expression was correlated with multiple clinicopathological features of ovarian cancer and can be used as an evaluation indicator for a poor ovarian cancer prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer.", "journal": "Bioscience reports", "authors": "Zhang M, Sha L, Hou N, Shi C, Tan L", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31985007", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985007" } ] } ], "biomarker_canonical_id": "AN4208", "collision": 1 }, { "biomarker_id": "AA4937-1", "biomarker_component": [ { "biomarker": "increased PRDX-1 level", "assessed_biomarker_entity": { "recommended_name": "Peroxiredoxin-1", "synonyms": [ { "synonym": "Natural killer cell-enhancing factor A" }, { "synonym": "NKEF-A" }, { "synonym": "Proliferation-associated gene protein" }, { "synonym": "PAG" }, { "synonym": "Thioredoxin peroxidase 2" }, { "synonym": "Thioredoxin-dependent peroxide reductase 2" }, { "synonym": "Thioredoxin-dependent peroxiredoxin 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q06830", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "31559796", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31559796", "evidence_list": [ { "evidence": "Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "31559796", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31559796", "evidence_list": [ { "evidence": "Multivariate analysis showed that a high expression of PRDX-1 is an independent prognostic factor of poor, overall survival (P<0.002) and a disease-free survival (P<0.01)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.", "journal": "Annals of agricultural and environmental medicine : AAEM", "authors": "Sie\u0144ko J, Teliga-Czajkowska J, Przytula E, Czajkowski K, Smolarczyk R, Nowis D", "date": "2019-09-29", "evidence": [], "reference": [ { "id": "31559796", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31559796" } ] } ], "biomarker_canonical_id": "AA4937", "collision": 1 }, { "biomarker_id": "AA4938-1", "biomarker_component": [ { "biomarker": "increased HSPB1 level", "assessed_biomarker_entity": { "recommended_name": "Heat shock protein beta-1", "synonyms": [ { "synonym": "HspB1" }, { "synonym": "28 kDa heat shock protein" }, { "synonym": "Estrogen-regulated 24 kDa protein" }, { "synonym": "Heat shock 27 kDa protein" }, { "synonym": "HSP 27" }, { "synonym": "Stress-responsive protein 27" }, { "synonym": "SRP27" } ] }, "assessed_biomarker_entity_id": "UPKB:P04792", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33130378", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33130378", "evidence_list": [ { "evidence": "Taken together, our findings demonstrate that high levels of circulating HSP27 in serum are associated with improved overall survival of OC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "33130378", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33130378", "evidence_list": [ { "evidence": "Taken together, our findings demonstrate that high levels of circulating HSP27 in serum are associated with improved overall survival of OC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer.", "journal": "European journal of obstetrics, gynecology, and reproductive biology", "authors": "K\u00f6nsgen D, Klinkmann G, Kaul A, Diesing K, Sehouli J, Braicu I, S\u00fcmnig A, Erb HHH, Stope MB, Mustea A", "date": "2020-11-02", "evidence": [], "reference": [ { "id": "33130378", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33130378" } ] } ], "biomarker_canonical_id": "AA4938", "collision": 1 }, { "biomarker_id": "AA4939-1", "biomarker_component": [ { "biomarker": "increased REG4 level", "assessed_biomarker_entity": { "recommended_name": "Regenerating islet-derived protein 4", "synonyms": [ { "synonym": "REG-4" }, { "synonym": "Gastrointestinal secretory protein" }, { "synonym": "REG-like protein" }, { "synonym": "Regenerating islet-derived protein IV" }, { "synonym": "Reg IV" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYZ8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26981633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26981633", "evidence_list": [ { "evidence": "Finally, an ELISA based serum biomarker assay demonstrated increased expression only in patients with mucinous ovarian cancer. This study identifies REG4 as a potential serum biomarker for histotype-specific detection of mucinous ovarian cancer and suggests serum REG4 measurement as a non-invasive diagnostic tool for postoperative follow-up of patients with mucinous ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "26981633", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26981633", "evidence_list": [ { "evidence": "Finally, an ELISA based serum biomarker assay demonstrated increased expression only in patients with mucinous ovarian cancer. This study identifies REG4 as a potential serum biomarker for histotype-specific detection of mucinous ovarian cancer and suggests serum REG4 measurement as a non-invasive diagnostic tool for postoperative follow-up of patients with mucinous ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.", "journal": "PloS one", "authors": "Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O", "date": "2016-03-18", "evidence": [], "reference": [ { "id": "26981633", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26981633" } ] } ], "biomarker_canonical_id": "AA4939", "collision": 1 }, { "biomarker_id": "AA4939-2", "biomarker_component": [ { "biomarker": "increased REG4 level", "assessed_biomarker_entity": { "recommended_name": "Regenerating islet-derived protein 4", "synonyms": [ { "synonym": "REG-4" }, { "synonym": "Gastrointestinal secretory protein" }, { "synonym": "REG-like protein" }, { "synonym": "Regenerating islet-derived protein IV" }, { "synonym": "Reg IV" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYZ8", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "27036049", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036049", "evidence_list": [ { "evidence": "In the present study, we show that high expression of REG4 correlates with advanced stage and poor survival prognosis for gastric cancer patients. REG4 overexpression significantly enhances peritoneal metastasis by increasing adhesion ability. Moreover, SP1 is proved to be a transcription factor of REG4 and induce REG4 expression upon TGF-alpha stimulation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "27036049", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036049", "evidence_list": [ { "evidence": "In the present study, we show that high expression of REG4 correlates with advanced stage and poor survival prognosis for gastric cancer patients. REG4 overexpression significantly enhances peritoneal metastasis by increasing adhesion ability. Moreover, SP1 is proved to be a transcription factor of REG4 and induce REG4 expression upon TGF-alpha stimulation." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "REG4 promotes peritoneal metastasis of gastric cancer through GPR37.", "journal": "Oncotarget", "authors": "Wang H, Hu L, Zang M, Zhang B, Duan Y, Fan Z, Li J, Su L, Yan M, Zhu Z, Liu B, Yang Q", "date": "2016-04-02", "evidence": [], "reference": [ { "id": "27036049", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036049" } ] } ], "biomarker_canonical_id": "AA4939", "collision": 1 }, { "biomarker_id": "AA4940-1", "biomarker_component": [ { "biomarker": "increased HOTAIR level", "assessed_biomarker_entity": { "recommended_name": "HOX transcript antisense RNA", "synonyms": [] }, "assessed_biomarker_entity_id": "RNAC:URS0000759B00", "assessed_entity_type": "RNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "26033707", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033707", "evidence_list": [ { "evidence": "We measured the HOTAIR and GAPDH DNA in 24 randomly selected patients and 24 age-matched healthy individuals using the direct serum qPCR assay, and found that the relative concentration of HOTAIR DNA was significantly higher in the breast cancer patients than in healthy individuals, corresponding to an average fold change of 2.01 (P = 0.0008)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "26033707", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033707", "evidence_list": [ { "evidence": "We measured the HOTAIR and GAPDH DNA in 24 randomly selected patients and 24 age-matched healthy individuals using the direct serum qPCR assay, and found that the relative concentration of HOTAIR DNA was significantly higher in the breast cancer patients than in healthy individuals, corresponding to an average fold change of 2.01 (P = 0.0008)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating DNA of HOTAIR in serum is a novel biomarker for breast cancer.", "journal": "Breast cancer research and treatment", "authors": "Zhang L, Song X, Wang X, Xie Y, Wang Z, Xu Y, You X, Liang Z, Cao H", "date": "2015-06-03", "evidence": [], "reference": [ { "id": "26033707", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033707" } ] } ], "biomarker_canonical_id": "AA4940", "collision": 1 }, { "biomarker_id": "AA4941-1", "biomarker_component": [ { "biomarker": "increased LNCRNA H19 level", "assessed_biomarker_entity": { "recommended_name": "Long non-coding RNA H19", "synonyms": [] }, "assessed_biomarker_entity_id": "RNAC:URS00008B9C5E", "assessed_entity_type": "RNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27540977", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27540977", "evidence_list": [ { "evidence": "The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "27540977", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27540977", "evidence_list": [ { "evidence": "The results revealed that the expression of H19 was significantly increased in BC tissues and plasma compared with healthy controls (P< 0.05)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Zhang K, Luo Z, Zhang Y, Zhang L, Wu L, Liu L, Yang J, Song X, Liu J", "date": "2016-08-20", "evidence": [], "reference": [ { "id": "27540977", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27540977" } ] } ], "biomarker_canonical_id": "AA4941", "collision": 1 }, { "biomarker_id": "AA4942-1", "biomarker_component": [ { "biomarker": "increased SREBP1 level", "assessed_biomarker_entity": { "recommended_name": "Sterol regulatory element-binding protein 1", "synonyms": [ { "synonym": "SREBP-1" }, { "synonym": "Class D basic helix-loop-helix protein 1" }, { "synonym": "bHLHd1" }, { "synonym": "Sterol regulatory element-binding transcription factor 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P36956", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "31887541", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31887541", "evidence_list": [ { "evidence": "The expression of SREBP1 was significantly different among DTCs, thyroid nodules and the adjacent normal tissues. SREBP1 was upregulated follow with the malignancy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "31887541", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31887541", "evidence_list": [ { "evidence": "The expression of SREBP1 was significantly different among DTCs, thyroid nodules and the adjacent normal tissues. SREBP1 was upregulated follow with the malignancy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer.", "journal": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie", "authors": "Li C, Peng X, Lv J, Zou H, Liu J, Zhang K, Li Z", "date": "2019-12-31", "evidence": [], "reference": [ { "id": "31887541", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31887541" } ] } ], "biomarker_canonical_id": "AA4942", "collision": 1 }, { "biomarker_id": "AA4943-1", "biomarker_component": [ { "biomarker": "decreased ANXA3 level", "assessed_biomarker_entity": { "recommended_name": "Annexin A3", "synonyms": [ { "synonym": "35-alpha calcimedin" }, { "synonym": "Annexin III" }, { "synonym": "Annexin-3" }, { "synonym": "Inositol 1,2-cyclic phosphate 2-phosphohydrolase" }, { "synonym": "Lipocortin III" }, { "synonym": "Placental anticoagulant protein III" }, { "synonym": "PAP-III" } ] }, "assessed_biomarker_entity_id": "UPKB:P12429", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "18222597", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18222597", "evidence_list": [ { "evidence": "ANXA3 represents a promising candidate tissue marker, and when combined with the standard prognostic parameters, is suggested to provide a more precise prediction of prognosis in the individual patient, therefore harboring the potential to contribute to future patient management." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "18222597", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18222597", "evidence_list": [ { "evidence": "ANXA3 represents a promising candidate tissue marker, and when combined with the standard prognostic parameters, is suggested to provide a more precise prediction of prognosis in the individual patient, therefore harboring the potential to contribute to future patient management." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression and prognostic relevance of annexin A3 in prostate cancer.", "journal": "European urology", "authors": "K\u00f6llermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A", "date": "2008-01-29", "evidence": [], "reference": [ { "id": "18222597", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18222597" } ] } ], "biomarker_canonical_id": "AA4943", "collision": 1 }, { "biomarker_id": "AN4209-1", "biomarker_component": [ { "biomarker": "increased SAMD5 level", "assessed_biomarker_entity": { "recommended_name": "Sterile alpha motif domain-containing protein 5", "synonyms": [ { "synonym": "SAM domain-containing protein 5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q5TGI4", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "30739268", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30739268", "evidence_list": [ { "evidence": "SAMD5 mRNA was shown to be up-regulated in multiple microarray datasets of prostate cancer with the strict statistic criteria: p<0.01 and fold change >/=2. In TCGA_PCa cohort study, high expression of SAMD5 was a risk factor for patients on post-operative BCR (HR 2.181, 95%CI 1.199-3.966, p=0.011) and this predictive ability was independent of Gleason score and pathologic T stage (HR 2.018, 95%CI 1.102-3.698, p=0.023). In another validating cohort study, the statistic trend was similar, and the pooled analysis by combining the two cohort study further confirmed its prognostic effect." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "30739268", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30739268", "evidence_list": [ { "evidence": "SAMD5 mRNA was shown to be up-regulated in multiple microarray datasets of prostate cancer with the strict statistic criteria: p<0.01 and fold change >/=2. In TCGA_PCa cohort study, high expression of SAMD5 was a risk factor for patients on post-operative BCR (HR 2.181, 95%CI 1.199-3.966, p=0.011) and this predictive ability was independent of Gleason score and pathologic T stage (HR 2.018, 95%CI 1.102-3.698, p=0.023). In another validating cohort study, the statistic trend was similar, and the pooled analysis by combining the two cohort study further confirmed its prognostic effect." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy.", "journal": "International urology and nephrology", "authors": "Li F, Xu Y, Liu RL", "date": "2019-02-11", "evidence": [], "reference": [ { "id": "30739268", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30739268" } ] } ], "biomarker_canonical_id": "AN4209", "collision": 1 }, { "biomarker_id": "AA4945-1", "biomarker_component": [ { "biomarker": "increased HOXC6 level", "assessed_biomarker_entity": { "recommended_name": "Homeobox C6", "synonyms": [ { "synonym": "Homeobox protein CP25" }, { "synonym": "Homeobox protein HHO.C8" }, { "synonym": "Homeobox protein Hox-3C" } ] }, "assessed_biomarker_entity_id": "UPKB:P09630", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "31271305", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31271305", "evidence_list": [ { "evidence": "Relative expressions of HOXC6 at mRNA and protein levels were obviously higher in both PCa tissues and cells than in adjacent non-cancerous tissues and normal human prostate epithelial cells (p < .05). Chi-square test demonstrated that high expression of HOXC6 was significantly associated with PSA concentration, Gleason score and TNM stage (p < .05)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "31271305", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31271305", "evidence_list": [ { "evidence": "Relative expressions of HOXC6 at mRNA and protein levels were obviously higher in both PCa tissues and cells than in adjacent non-cancerous tissues and normal human prostate epithelial cells (p < .05). Chi-square test demonstrated that high expression of HOXC6 was significantly associated with PSA concentration, Gleason score and TNM stage (p < .05)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "", "journal": "Artificial cells, nanomedicine, and biotechnology", "authors": "Zhou J, Yang X, Song P, Wang H, Wang X", "date": "2019-07-05", "evidence": [], "reference": [ { "id": "31271305", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31271305" } ] } ], "biomarker_canonical_id": "AA4945", "collision": 1 }, { "biomarker_id": "AN4210-1", "biomarker_component": [ { "biomarker": "increased PNKD level", "assessed_biomarker_entity": { "recommended_name": "Myofibrillogenesis regulator 1", "synonyms": [ { "synonym": "Myofibrillogenesis regulator 1" }, { "synonym": "MR-1" }, { "synonym": "Paroxysmal nonkinesiogenic dyskinesia protein" }, { "synonym": "Trans-activated by hepatitis C virus core protein 2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8N490", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "21702971", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21702971", "evidence_list": [ { "evidence": "MR-1 was overexpressed in ovarian cancer tissues and SKOV3 cells. Knockdown of MR-1 expression inhibited cell adhesion and invasion, and treatment with anti-cancer drugs decreased its expression in cancer cells. Taken together, these results provide the first evidence of the cellular and molecular mechanisms by which MR-1 might serve as a novel biological marker and potential therapeutic target for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "21702971", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21702971", "evidence_list": [ { "evidence": "MR-1 was overexpressed in ovarian cancer tissues and SKOV3 cells. Knockdown of MR-1 expression inhibited cell adhesion and invasion, and treatment with anti-cancer drugs decreased its expression in cancer cells. Taken together, these results provide the first evidence of the cellular and molecular mechanisms by which MR-1 might serve as a novel biological marker and potential therapeutic target for ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.", "journal": "BMC cancer", "authors": "Lu R, Sun M, Feng J, Gao X, Guo L", "date": "2011-06-28", "evidence": [], "reference": [ { "id": "21702971", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21702971" } ] } ], "biomarker_canonical_id": "AN4210", "collision": 1 }, { "biomarker_id": "AA4947-1", "biomarker_component": [ { "biomarker": "increased AGR2 level", "assessed_biomarker_entity": { "recommended_name": "Anterior gradient protein 2 homolog", "synonyms": [ { "synonym": "AG-2" }, { "synonym": "hAG-2" }, { "synonym": "HPC8" }, { "synonym": "Secreted cement gland protein XAG-2 homolog" } ] }, "assessed_biomarker_entity_id": "UPKB:O95994", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "21200134", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21200134", "evidence_list": [ { "evidence": "We noted a marked overexpression of AGR2 mRNA and protein in early stage mucinous ovarian tumors compared to normal ovarian tissues and serous type ovarian tumors by Western blot analysis and immunohistochemistry. To further elucidate the role of AGR2 in ovarian tumorigenesis, stable 2774 human ovarian cancer cell lines overexpressing AGR2 were established. Forced expression of AGR2 in 2774 cells enhanced the growth and migration of ovarian cancer cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "21200134", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21200134", "evidence_list": [ { "evidence": "We noted a marked overexpression of AGR2 mRNA and protein in early stage mucinous ovarian tumors compared to normal ovarian tissues and serous type ovarian tumors by Western blot analysis and immunohistochemistry. To further elucidate the role of AGR2 in ovarian tumorigenesis, stable 2774 human ovarian cancer cell lines overexpressing AGR2 were established. Forced expression of AGR2 in 2774 cells enhanced the growth and migration of ovarian cancer cells." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration.", "journal": "Experimental & molecular medicine", "authors": "Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, Song SY, Bae DS, Kim BG, Lee JH", "date": "2011-01-05", "evidence": [], "reference": [ { "id": "21200134", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21200134" } ] } ], "biomarker_canonical_id": "AA4947", "collision": 1 }, { "biomarker_id": "AA4947-2", "biomarker_component": [ { "biomarker": "increased AGR2 level", "assessed_biomarker_entity": { "recommended_name": "Anterior gradient protein 2 homolog", "synonyms": [ { "synonym": "AG-2" }, { "synonym": "hAG-2" }, { "synonym": "HPC8" }, { "synonym": "Secreted cement gland protein XAG-2 homolog" } ] }, "assessed_biomarker_entity_id": "UPKB:O95994", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "26998125", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26998125", "evidence_list": [ { "evidence": "AGR2 and CTSD expression were both elevated in GC lesions compared with noncancerous tissues. In 204/436 (46.8%) GC patients, high expression of AGR2 was positively correlated with the expression of CTSD (r=0.577, P<0.01). Furthermore, several clinicopathological parameters were significantly associated with AGR2 expression level, including tumor size, depth of invasion and TNM stage (P<0.05). The findings of the present study indicate that AGR2 expression is significantly associated with location and size of GC, depth of invasion, TNM stage, lymphatic metastasis, vessel invasion, distant metastasis, Lauren's classification, high CTSD expression and poor prognosis. Thus, AGR2 may be a novel GC marker and may present a potential therapeutic target for GC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "26998125", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26998125", "evidence_list": [ { "evidence": "AGR2 and CTSD expression were both elevated in GC lesions compared with noncancerous tissues. In 204/436 (46.8%) GC patients, high expression of AGR2 was positively correlated with the expression of CTSD (r=0.577, P<0.01). Furthermore, several clinicopathological parameters were significantly associated with AGR2 expression level, including tumor size, depth of invasion and TNM stage (P<0.05). The findings of the present study indicate that AGR2 expression is significantly associated with location and size of GC, depth of invasion, TNM stage, lymphatic metastasis, vessel invasion, distant metastasis, Lauren's classification, high CTSD expression and poor prognosis. Thus, AGR2 may be a novel GC marker and may present a potential therapeutic target for GC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "AGR2 is associated with gastric cancer progression and poor survival.", "journal": "Oncology letters", "authors": "Zhang J, Jin Y, Xu S, Zheng J, Zhang QI, Wang Y, Chen J, Huang Y, He X, Zhao Z", "date": "2016-03-22", "evidence": [], "reference": [ { "id": "26998125", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26998125" } ] } ], "biomarker_canonical_id": "AA4947", "collision": 1 }, { "biomarker_id": "AA4948-1", "biomarker_component": [ { "biomarker": "increased PLG level", "assessed_biomarker_entity": { "recommended_name": "Plasminogen", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P00747", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "27935848", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27935848", "evidence_list": [ { "evidence": "PLG staining was positively associated with prolonged overall survival (OS) [hazard ratio (HR)=0.59, p=0.026] of the patients. In summary, these data indicate that elevated PLG expression represents a favorable prognostic biomarker in advanced (FIGO III/IV) high-grade serous ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "27935848", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27935848", "evidence_list": [ { "evidence": "PLG staining was positively associated with prolonged overall survival (OS) [hazard ratio (HR)=0.59, p=0.026] of the patients. In summary, these data indicate that elevated PLG expression represents a favorable prognostic biomarker in advanced (FIGO III/IV) high-grade serous ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.", "journal": "Biological chemistry", "authors": "Zhao S, Dorn J, Napieralski R, Walch A, Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M, Magdolen V", "date": "2016-12-10", "evidence": [], "reference": [ { "id": "27935848", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27935848" } ] } ], "biomarker_canonical_id": "AA4948", "collision": 1 }, { "biomarker_id": "AN4211-1", "biomarker_component": [ { "biomarker": "increased PRSS8 level", "assessed_biomarker_entity": { "recommended_name": "Serine protease prostasin", "synonyms": [ { "synonym": "Channel-activating protease 1" }, { "synonym": "CAP1" }, { "synonym": "Serine protease 8" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16651", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "27036110", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036110", "evidence_list": [ { "evidence": "Overexpression of PRSS8 mRNA and high levels of prostasin in multiple subtypes of early stage ovarian tumors may provide clinical biomarkers for early detection of OVC, which can potentially be used with CA125 and HE4." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "27036110", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036110", "evidence_list": [ { "evidence": "Overexpression of PRSS8 mRNA and high levels of prostasin in multiple subtypes of early stage ovarian tumors may provide clinical biomarkers for early detection of OVC, which can potentially be used with CA125 and HE4." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.", "journal": "Journal of ovarian research", "authors": "Tamir A, Gangadharan A, Balwani S, Tanaka T, Patel U, Hassan A, Benke S, Agas A, D'Agostino J, Shin D, Yoon S, Goy A, Pecora A, Suh KS", "date": "2016-04-03", "evidence": [], "reference": [ { "id": "27036110", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27036110" } ] } ], "biomarker_canonical_id": "AN4211", "collision": 1 }, { "biomarker_id": "AA4950-1", "biomarker_component": [ { "biomarker": "increased HMGA1 level", "assessed_biomarker_entity": { "recommended_name": "High mobility group protein A1", "synonyms": [ { "synonym": "HMG-I(Y)" }, { "synonym": "High mobility group AT-hook protein 1" }, { "synonym": "High mobility group protein A1" }, { "synonym": "High mobility group protein R" } ] }, "assessed_biomarker_entity_id": "UPKB:P17096", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "25586095", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25586095", "evidence_list": [ { "evidence": "Urine HMGA1 was significantly elevated in serous epithelial ovarian cancer specimen relative to healthy control specimens with G3 specimens exhibiting higher levels than G1-G2 specimens. Furthermore, urine HMGA1 and serum CA-125 combined AUC indicated that urine HMGA1 is an excellent diagnostic biomarker for serous epithelial ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "25586095", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25586095", "evidence_list": [ { "evidence": "Urine HMGA1 was significantly elevated in serous epithelial ovarian cancer specimen relative to healthy control specimens with G3 specimens exhibiting higher levels than G1-G2 specimens. Furthermore, urine HMGA1 and serum CA-125 combined AUC indicated that urine HMGA1 is an excellent diagnostic biomarker for serous epithelial ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Increases urinary HMGA1 in serous epithelial ovarian cancer patients.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Zhou J, Xie M, He H, Shi Y, Luo B, Gong G, Li J, Wang J, Wu X, Wen J", "date": "2015-01-15", "evidence": [], "reference": [ { "id": "25586095", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25586095" } ] } ], "biomarker_canonical_id": "AA4950", "collision": 1 }, { "biomarker_id": "AN4212-1", "biomarker_component": [ { "biomarker": "increased IL1RN level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-1 receptor antagonist", "synonyms": [ { "synonym": "IL-1RN" }, { "synonym": "IL-1ra" }, { "synonym": "IRAP" }, { "synonym": "ICIL-1RA" }, { "synonym": "IL1 inhibitor" } ] }, "assessed_biomarker_entity_id": "UPKB:P18510", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "33238942", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33238942", "evidence_list": [ { "evidence": "IL1RN showed higher expression levels and lower methylation levels in PTC tissues than in normal tissues. IL1RN is a good prognostic and diagnostic biomarker for PTC. IL1RN may promote thyroid cancer progression through immune-related pathways." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "33238942", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33238942", "evidence_list": [ { "evidence": "IL1RN showed higher expression levels and lower methylation levels in PTC tissues than in normal tissues. IL1RN is a good prognostic and diagnostic biomarker for PTC. IL1RN may promote thyroid cancer progression through immune-related pathways." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.", "journal": "BMC cancer", "authors": "Xie Z, Li X, He Y, Wu S, Wang S, Sun J, He Y, Lun Y, Xin S, Zhang J", "date": "2020-11-27", "evidence": [], "reference": [ { "id": "33238942", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33238942" } ] } ], "biomarker_canonical_id": "AN4212", "collision": 1 }, { "biomarker_id": "AA4952-1", "biomarker_component": [ { "biomarker": "decreased BTG1 level", "assessed_biomarker_entity": { "recommended_name": "B cell translocation gene 1 protein", "synonyms": [ { "synonym": "B-cell translocation gene 1 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P62324", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "25017022", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25017022", "evidence_list": [ { "evidence": "We determined the expression and function of B cell translocation gene 1 (BTG1) in thyroid carcinoma. Thyroid samples were obtained from cancer lesions (n=83) and adjacent normal tissue (n=35) in thyroid cancer patients immediately after endoscopic biopsy. TG1 protein expression was significantly lower in thyroid cancer tissue biopsies compared to normal tissue. Reduced BTG1 expression is associated with increased disease severity, suggesting it is a negative regulator of thyroid cancer and can serve as a prognostic indicator." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "25017022", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25017022", "evidence_list": [ { "evidence": "We determined the expression and function of B cell translocation gene 1 (BTG1) in thyroid carcinoma. Thyroid samples were obtained from cancer lesions (n=83) and adjacent normal tissue (n=35) in thyroid cancer patients immediately after endoscopic biopsy. TG1 protein expression was significantly lower in thyroid cancer tissue biopsies compared to normal tissue. Reduced BTG1 expression is associated with increased disease severity, suggesting it is a negative regulator of thyroid cancer and can serve as a prognostic indicator." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "BTG1 expression in thyroid carcinoma: diagnostic indicator and prognostic marker.", "journal": "International journal of oncology", "authors": "Lu YF, Sun GG, Liu Q, Yang CR, Cheng YJ", "date": "2014-07-16", "evidence": [], "reference": [ { "id": "25017022", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25017022" } ] } ], "biomarker_canonical_id": "AA4952", "collision": 1 }, { "biomarker_id": "AA4953-1", "biomarker_component": [ { "biomarker": "increased CAP2 level", "assessed_biomarker_entity": { "recommended_name": "Cyclase-associated actin cytoskeleton regulatory protein 2", "synonyms": [ { "synonym": "CAP 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P40123", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "32211793", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32211793", "evidence_list": [ { "evidence": "Multivariate analyses showed that CAP2 expression in ovarian cancer is an independent prognostic factor for recurrence-free survival (P = 0.019). CAP2 expression is upregulated in aggressive histologic types of epithelial ovarian cancer and serves as a novel prognostic biomarker for patient survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32211793", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32211793", "evidence_list": [ { "evidence": "Multivariate analyses showed that CAP2 expression in ovarian cancer is an independent prognostic factor for recurrence-free survival (P = 0.019). CAP2 expression is upregulated in aggressive histologic types of epithelial ovarian cancer and serves as a novel prognostic biomarker for patient survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Upregulation of cyclase-associated actin cytoskeleton regulatory protein 2 in epithelial ovarian cancer correlates with aggressive histologic types and worse outcomes.", "journal": "Japanese journal of clinical oncology", "authors": "Adachi M, Masugi Y, Yamazaki K, Emoto K, Kobayashi Y, Tominaga E, Banno K, Aoki D, Sakamoto M", "date": "2020-03-27", "evidence": [], "reference": [ { "id": "32211793", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32211793" } ] } ], "biomarker_canonical_id": "AA4953", "collision": 1 }, { "biomarker_id": "AA4954-1", "biomarker_component": [ { "biomarker": "increased RNF126 level", "assessed_biomarker_entity": { "recommended_name": "RING finger protein 126", "synonyms": [ { "synonym": "RING finger protein 126" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BV68", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "32254065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32254065", "evidence_list": [ { "evidence": "Upregulated protein level of RNF126 in EOC tissues is a biomarker predicting poor outcomes of EOC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32254065", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32254065", "evidence_list": [ { "evidence": "Upregulated protein level of RNF126 in EOC tissues is a biomarker predicting poor outcomes of EOC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "High Expression of RING Finger Protein 126 Predicts Unfavorable Prognosis of Epithelial Ovarian Cancer.", "journal": "Medical science monitor : international medical journal of experimental and clinical research", "authors": "Wang C, Wen A, Qiao J, Liu Y, Guo Y, Wang W", "date": "2020-04-08", "evidence": [], "reference": [ { "id": "32254065", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32254065" } ] } ], "biomarker_canonical_id": "AA4954", "collision": 1 }, { "biomarker_id": "AA4955-1", "biomarker_component": [ { "biomarker": "increased KLK10 level", "assessed_biomarker_entity": { "recommended_name": "Kallikrein-10", "synonyms": [ { "synonym": "Normal epithelial cell-specific 1" }, { "synonym": "Protease serine-like 1" } ] }, "assessed_biomarker_entity_id": "UPKB:O43240", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "12591730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12591730", "evidence_list": [ { "evidence": "HK10 concentration is significantly elevated in serum of presurgical ovarian cancer patients (range: 106-11,746 ng/liter; mean = 1067 ng/liter) but not in serum of patients with benign gynecologic diseases (range: 120-1200 ng/liter; mean = 447 ng/liter). Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "12591730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12591730", "evidence_list": [ { "evidence": "HK10 concentration is significantly elevated in serum of presurgical ovarian cancer patients (range: 106-11,746 ng/liter; mean = 1067 ng/liter) but not in serum of patients with benign gynecologic diseases (range: 120-1200 ng/liter; mean = 447 ng/liter). Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.", "journal": "Cancer research", "authors": "Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP", "date": "2003-02-20", "evidence": [], "reference": [ { "id": "12591730", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/12591730" } ] } ], "biomarker_canonical_id": "AA4955", "collision": 1 }, { "biomarker_id": "AA4956-1", "biomarker_component": [ { "biomarker": "increased STAT3 level", "assessed_biomarker_entity": { "recommended_name": "Signal transducer and activator of transcription 3", "synonyms": [ { "synonym": "Acute-phase response factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P40763", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "21577321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21577321", "evidence_list": [ { "evidence": "Expression of STAT3 in all PTC primary tumors was 98% (40/41) and thus significantly higher than corresponding benign thyroid tissue." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "21577321", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21577321", "evidence_list": [ { "evidence": "Expression of STAT3 in all PTC primary tumors was 98% (40/41) and thus significantly higher than corresponding benign thyroid tissue." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer.", "journal": "International journal of clinical and experimental pathology", "authors": "Zhang J, Gill A, Atmore B, Johns A, Delbridge L, Lai R, McMullen T", "date": "2011-05-18", "evidence": [], "reference": [ { "id": "21577321", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21577321" } ] } ], "biomarker_canonical_id": "AA4956", "collision": 1 }, { "biomarker_id": "AA4956-2", "biomarker_component": [ { "biomarker": "increased STAT3 level", "assessed_biomarker_entity": { "recommended_name": "Signal transducer and activator of transcription 3", "synonyms": [ { "synonym": "Acute-phase response factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P40763", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "26622669", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669", "evidence_list": [ { "evidence": "The data demonstrated that eight genes associated with ApoE were differentially expressed, with six of these upregulated and two downregulated. Functionally, these genes were involved in the JAK-STAT cascade, acute-phase response, acute inflammatory response, and the steroid hormone response. Among these ApoE-associated genes, expression of the signal transducer and activator of transcription 2 (STAT2) and STAT3 transcription factors was upregulated. To the best of our knowledge, this is the first study to demonstrate the network of ApoE-related genes and transcription factors in gastric cancer. Additional studies are required in order to confirm these data and to translate the results into the identification of clinical biomarkers and novel treatment strategies for gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "26622669", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669", "evidence_list": [ { "evidence": "The data demonstrated that eight genes associated with ApoE were differentially expressed, with six of these upregulated and two downregulated. Functionally, these genes were involved in the JAK-STAT cascade, acute-phase response, acute inflammatory response, and the steroid hormone response. Among these ApoE-associated genes, expression of the signal transducer and activator of transcription 2 (STAT2) and STAT3 transcription factors was upregulated. To the best of our knowledge, this is the first study to demonstrate the network of ApoE-related genes and transcription factors in gastric cancer. Additional studies are required in order to confirm these data and to translate the results into the identification of clinical biomarkers and novel treatment strategies for gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression analysis of apolipoprotein E and its associated genes in gastric cancer.", "journal": "Oncology letters", "authors": "Shi X, Xu J, Wang J, Cui M, Gao Y, Niu H, Jin H", "date": "2015-12-02", "evidence": [], "reference": [ { "id": "26622669", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669" } ] } ], "biomarker_canonical_id": "AA4956", "collision": 1 }, { "biomarker_id": "AA4957-1", "biomarker_component": [ { "biomarker": "increased SPHK1 level", "assessed_biomarker_entity": { "recommended_name": "Sphingosine kinase 1", "synonyms": [ { "synonym": "SK 1" }, { "synonym": "SPK 1" }, { "synonym": "Acetyltransferase SPHK1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NYA1", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "28982849", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28982849", "evidence_list": [ { "evidence": "Sphingosine kinase 1 is up-regulated in many different types of human malignancies and plays a crucial role in cancer development and progression. Sphingosine kinase 1 expression in papillary thyroid carcinoma tissue was significantly higher than in nodular goiter (p<0.001) or normal thyroid (p<0.001) tissue." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "28982849", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28982849", "evidence_list": [ { "evidence": "Sphingosine kinase 1 is up-regulated in many different types of human malignancies and plays a crucial role in cancer development and progression. Sphingosine kinase 1 expression in papillary thyroid carcinoma tissue was significantly higher than in nodular goiter (p<0.001) or normal thyroid (p<0.001) tissue." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Predictive Value of Sphingosine Kinase 1 Expression in Papillary Thyroid Carcinoma.", "journal": "Anticancer research", "authors": "Do SI, Kim HS, Kim K, Lee H, Do IG, Kim DH, Chae SW, Sohn JH", "date": "2017-10-07", "evidence": [], "reference": [ { "id": "28982849", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28982849" } ] } ], "biomarker_canonical_id": "AA4957", "collision": 1 }, { "biomarker_id": "AA4958-1", "biomarker_component": [ { "biomarker": "increased PINX1 level", "assessed_biomarker_entity": { "recommended_name": "PIN2/TERF1 interacting telomerase inhibitor 1", "synonyms": [ { "synonym": "Liver-related putative tumor suppressor" }, { "synonym": "Pin2-interacting protein X1" }, { "synonym": "Protein 67-11-3" }, { "synonym": "TRF1-interacting protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96BK5", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "30026037", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30026037", "evidence_list": [ { "evidence": "Immunohistochemistry for PINX1 was performed using a tissue microarray of samples taken from the 160 patients with PTC. PINX1 expression was significantly associated with tumor size, lymph node metastasis, telomerase reverse transcriptase, promoter mutation and recurrence. PINX1 mRNA expression was more pronounced in the recurrent group than in the nonrecurrent group. In addition, results of the binary logistic regression model showed that PINX1 protein expression had a significant influence on recurrence." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "30026037", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30026037", "evidence_list": [ { "evidence": "Immunohistochemistry for PINX1 was performed using a tissue microarray of samples taken from the 160 patients with PTC. PINX1 expression was significantly associated with tumor size, lymph node metastasis, telomerase reverse transcriptase, promoter mutation and recurrence. PINX1 mRNA expression was more pronounced in the recurrent group than in the nonrecurrent group. In addition, results of the binary logistic regression model showed that PINX1 protein expression had a significant influence on recurrence." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The clinical significance of PINX1 expression in papillary thyroid carcinoma.", "journal": "Human pathology", "authors": "Kang J, Han K, Kim HJ, Park JH, Kong JS, Park S, Myung JK", "date": "2018-07-22", "evidence": [], "reference": [ { "id": "30026037", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30026037" } ] } ], "biomarker_canonical_id": "AA4958", "collision": 1 }, { "biomarker_id": "AA4959-1", "biomarker_component": [ { "biomarker": "decreased PINX1 level", "assessed_biomarker_entity": { "recommended_name": "PIN2/TERF1 interacting telomerase inhibitor 1", "synonyms": [ { "synonym": "Liver-related putative tumor suppressor" }, { "synonym": "Pin2-interacting protein X1" }, { "synonym": "Protein 67-11-3" }, { "synonym": "TRF1-interacting protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96BK5", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "26033551", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033551", "evidence_list": [ { "evidence": "PinX1 low expression staining was observed in 7 of 35 (20%) normal renal tissues, and 168 of 278 (60%) ccRCC tissues (P < 0.001) low PinX1 staining correlated with both worse overall and disease-specific survival in ccRCC (P = 0.002 and P = 0.002)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31254127", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254127", "evidence_list": [ { "evidence": "To further understand the molecular mechanism of PinX1 in renal cancer angiogenesis, we obtained the gene microarray to determine the downstream molecules of PinX1 in renal cancer. Surprisingly, PinX1 promoted the expression level of miR-125a-3p, which is a tumor suppressor of multiple oncogenes, including VEGF, CDK3, FUT5/6, and ERBB2/3." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "26033551", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033551", "evidence_list": [ { "evidence": "PinX1 low expression staining was observed in 7 of 35 (20%) normal renal tissues, and 168 of 278 (60%) ccRCC tissues (P < 0.001) low PinX1 staining correlated with both worse overall and disease-specific survival in ccRCC (P = 0.002 and P = 0.002)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31254127", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254127", "evidence_list": [ { "evidence": "To further understand the molecular mechanism of PinX1 in renal cancer angiogenesis, we obtained the gene microarray to determine the downstream molecules of PinX1 in renal cancer. Surprisingly, PinX1 promoted the expression level of miR-125a-3p, which is a tumor suppressor of multiple oncogenes, including VEGF, CDK3, FUT5/6, and ERBB2/3." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "PinX1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis by suppressing MMP-2 via NF-\u03baB-dependent transcription.", "journal": "Oncotarget", "authors": "Li HL, Han L, Chen HR, Meng F, Liu QH, Pan ZQ, Bai J, Zheng JN", "date": "2015-06-03", "evidence": [], "reference": [ { "id": "26033551", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26033551" } ] }, { "title": "PinX1 represses renal cancer angiogenesis via the mir-125a-3p/VEGF signaling pathway.", "journal": "Angiogenesis", "authors": "Hou P, Li H, Yong H, Chen F, Chu S, Zheng J, Bai J", "date": "2019-06-30", "evidence": [], "reference": [ { "id": "31254127", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31254127" } ] } ], "biomarker_canonical_id": "AA4959", "collision": 1 }, { "biomarker_id": "AA4960-1", "biomarker_component": [ { "biomarker": "decreased 5-MC GDNA level", "assessed_biomarker_entity": { "recommended_name": "Genomic DNA cytosine methylation", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C17961", "assessed_entity_type": "DNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18339581", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18339581", "evidence_list": [ { "evidence": "We have shown in a large case-control study that leucocyte DNA hypomethylation is associated with increased risk of developing bladder cancer, and this association is independent of smoking and the other assessed risk factors." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "18339581", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18339581", "evidence_list": [ { "evidence": "We have shown in a large case-control study that leucocyte DNA hypomethylation is associated with increased risk of developing bladder cancer, and this association is independent of smoking and the other assessed risk factors." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study.", "journal": "The Lancet. Oncology", "authors": "Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, Garc\u00eda-Closas R, Chanock S, Tard\u00f3n A, Serra C, Carrato A, Dosemeci M, Garc\u00eda-Closas M, Esteller M, Fraga M, Rothman N, Malats N", "date": "2008-03-15", "evidence": [], "reference": [ { "id": "18339581", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18339581" } ] } ], "biomarker_canonical_id": "AA4960", "collision": 1 }, { "biomarker_id": "AA4961-1", "biomarker_component": [ { "biomarker": "increased DKK-1 level", "assessed_biomarker_entity": { "recommended_name": "Dickkopf-1", "synonyms": [ { "synonym": "Dickkopf-1" }, { "synonym": "Dkk-1" }, { "synonym": "hDkk-1" }, { "synonym": "SK" } ] }, "assessed_biomarker_entity_id": "UPKB:O94907", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "18561248", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18561248", "evidence_list": [ { "evidence": "DKK-1 expression index (EI) was found to increase in PIN and primary lesions compared to non-neoplastic tissue (106\u00b110 vs. 19\u00b16, respectively, where the EI is the product of the percent expression and staining intensity). DKK-1 expression was also found to be higher in all PCa metastatic lesions (56\u00b121 EI) compared to non-neoplastic tissues but was significantly decreased vs. primary PCa lesions (p<0.008). The decline in DKK-1 correlated with a shift of beta-catenin staining from the nucleus to the cytoplasm suggesting possible mechanism for the observed decrease in DKK-1 levels during PCa progression. Within metastatic lesions, DKK-1 expression was least abundant in PCa bone metastases relative to all soft tissue PCa metastatic lesions except lymph node metastases. High DKK-1 expression within PCa metastases was further associated with shorter over-all patient survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "18561248", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18561248", "evidence_list": [ { "evidence": "DKK-1 expression index (EI) was found to increase in PIN and primary lesions compared to non-neoplastic tissue (106\u00b110 vs. 19\u00b16, respectively, where the EI is the product of the percent expression and staining intensity). DKK-1 expression was also found to be higher in all PCa metastatic lesions (56\u00b121 EI) compared to non-neoplastic tissues but was significantly decreased vs. primary PCa lesions (p<0.008). The decline in DKK-1 correlated with a shift of beta-catenin staining from the nucleus to the cytoplasm suggesting possible mechanism for the observed decrease in DKK-1 levels during PCa progression. Within metastatic lesions, DKK-1 expression was least abundant in PCa bone metastases relative to all soft tissue PCa metastatic lesions except lymph node metastases. High DKK-1 expression within PCa metastases was further associated with shorter over-all patient survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.", "journal": "The Prostate", "authors": "Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET", "date": "2008-06-19", "evidence": [], "reference": [ { "id": "18561248", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18561248" } ] } ], "biomarker_canonical_id": "AA4961", "collision": 1 }, { "biomarker_id": "AA4962-1", "biomarker_component": [ { "biomarker": "increased DPP-4 level", "assessed_biomarker_entity": { "recommended_name": "Dipeptidyl peptidase-IV", "synonyms": [ { "synonym": "ADABP" }, { "synonym": "Adenosine deaminase complexing protein 2" }, { "synonym": "ADCP-2" }, { "synonym": "Dipeptidyl peptidase IV" }, { "synonym": "DPP IV" }, { "synonym": "T-cell activation antigen CD26" }, { "synonym": "TP103" } ] }, "assessed_biomarker_entity_id": "UPKB:P27487", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30594915", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30594915", "evidence_list": [ { "evidence": "The serum DPP-IV concentration was measured in 171 male patients with PTC, 81 male patients with a benign thyroid nodule (BTN), and 52 male healthy controls (HCs). he ROC curve indicated a good performance of DPP-IV for discriminating PTC from BTN, with an area under the curve (AUC) of 0.881 (95% CI, 0.840-0.922). Serum DPP-IV demonstrated a modest performance in predicting nonstructurally persistent disease/recurrent disease (NSPRD) survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "30594915", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30594915", "evidence_list": [ { "evidence": "The serum DPP-IV concentration was measured in 171 male patients with PTC, 81 male patients with a benign thyroid nodule (BTN), and 52 male healthy controls (HCs). he ROC curve indicated a good performance of DPP-IV for discriminating PTC from BTN, with an area under the curve (AUC) of 0.881 (95% CI, 0.840-0.922). Serum DPP-IV demonstrated a modest performance in predicting nonstructurally persistent disease/recurrent disease (NSPRD) survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Zhang N, Cong X, Zhou D, Guo L, Yuan C, Xu D, Su C", "date": "2018-12-31", "evidence": [], "reference": [ { "id": "30594915", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30594915" } ] } ], "biomarker_canonical_id": "AA4962", "collision": 1 }, { "biomarker_id": "AA4963-1", "biomarker_component": [ { "biomarker": "increased CHL1 level", "assessed_biomarker_entity": { "recommended_name": "Close homolog of L1", "synonyms": [ { "synonym": "Close homolog of L1" } ] }, "assessed_biomarker_entity_id": "UPKB:O00533", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "30311656", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30311656", "evidence_list": [ { "evidence": "CHL1 was found to have greater than 15-fold higher expression in fragments per kilobase million in HCC compared with benign Hurthle cell tumors. This was confirmed by qRT-PCR. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign H\u00fcrthle cell nodules. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign H\u00fcrthle cell nodules. CHL1 expression may represent a novel and useful prognostic biomarker to distinguish HCC from benign H\u00fcrthle cell disease." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "30311656", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30311656", "evidence_list": [ { "evidence": "CHL1 was found to have greater than 15-fold higher expression in fragments per kilobase million in HCC compared with benign Hurthle cell tumors. This was confirmed by qRT-PCR. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign H\u00fcrthle cell nodules. Moreover, the immunoreactivity score of the CHL1 protein was significantly higher in HCC compared with benign H\u00fcrthle cell nodules. CHL1 expression may represent a novel and useful prognostic biomarker to distinguish HCC from benign H\u00fcrthle cell disease." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CHL1 expression differentiates H\u00fcrthle cell carcinoma from benign H\u00fcrthle cell nodules.", "journal": "Journal of surgical oncology", "authors": "Li W, Xia S, Aronova A, Min IM, Verma A, Scognamiglio T, Gray KD, Ullmann TM, Liang H, Moore MD, Elemento O, Zarnegar R, Fahey TJ", "date": "2018-10-13", "evidence": [], "reference": [ { "id": "30311656", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30311656" } ] } ], "biomarker_canonical_id": "AA4963", "collision": 1 }, { "biomarker_id": "AA4964-1", "biomarker_component": [ { "biomarker": "increased NPM level", "assessed_biomarker_entity": { "recommended_name": "Nucleophosmin", "synonyms": [ { "synonym": "NPM" }, { "synonym": "Nucleolar phosphoprotein B23" }, { "synonym": "Nucleolar protein NO38" }, { "synonym": "Numatrin" } ] }, "assessed_biomarker_entity_id": "UPKB:P06748", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "20515654", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20515654", "evidence_list": [ { "evidence": "In these cells, a positive correlation between NPM protein levels, but not mRNA, and proliferation state was detected. By using thyroid tumor cell lines, we demonstrated that such a post-mRNA regulation may depend on NPM binding to p-Akt, whose levels were found to be increased in the tumor cells, in parallel with reduction of PTEN. In conclusion, our present data demonstrate for the first time that nucleophosmin is overexpressed in thyroid tumors, as an early event of thyroid tumorigenesis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "20515654", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20515654", "evidence_list": [ { "evidence": "In these cells, a positive correlation between NPM protein levels, but not mRNA, and proliferation state was detected. By using thyroid tumor cell lines, we demonstrated that such a post-mRNA regulation may depend on NPM binding to p-Akt, whose levels were found to be increased in the tumor cells, in parallel with reduction of PTEN. In conclusion, our present data demonstrate for the first time that nucleophosmin is overexpressed in thyroid tumors, as an early event of thyroid tumorigenesis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Nucleophosmin is overexpressed in thyroid tumors.", "journal": "Biochemical and biophysical research communications", "authors": "Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, Filetti S, Russo D, Damante G", "date": "2010-06-03", "evidence": [], "reference": [ { "id": "20515654", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20515654" } ] } ], "biomarker_canonical_id": "AA4964", "collision": 1 }, { "biomarker_id": "AN4213-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Actin gamma 1 gene amplification", "synonyms": [ { "synonym": "Gamma-actin" } ] }, "assessed_biomarker_entity_id": "UPKB:P63261", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" } ], "evidence_source": [ { "id": "33217970", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33217970", "evidence_list": [ { "evidence": "Given that ACTG1 and MYLK2 amplifications or overexpression were consistently observed in uterine cancers, we sought to analyze their potential as uterine cancer biomarkers. We found that patients with ACTG1 gains in the UCEC cohort, relative to those without, had a worse prognosis, while patients with MYLK2 gains did not. Based on Kaplan-Meier curves, ACTG1 gains predicted significantly shorter overall survival (p-value = 6.198 \u00d7 10-4)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "33217970", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33217970", "evidence_list": [ { "evidence": "Given that ACTG1 and MYLK2 amplifications or overexpression were consistently observed in uterine cancers, we sought to analyze their potential as uterine cancer biomarkers. We found that patients with ACTG1 gains in the UCEC cohort, relative to those without, had a worse prognosis, while patients with MYLK2 gains did not. Based on Kaplan-Meier curves, ACTG1 gains predicted significantly shorter overall survival (p-value = 6.198 \u00d7 10-4)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Genomic Amplification and Functional Dependency of the Gamma Actin Gene ", "journal": "International journal of molecular sciences", "authors": "Richter C, Mayhew D, Rennhack JP, So J, Stover EH, Hwang JH, Szczesna-Cordary D", "date": "2020-11-22", "evidence": [], "reference": [ { "id": "33217970", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33217970" } ] } ], "biomarker_canonical_id": "AN4213", "collision": 1 }, { "biomarker_id": "AA4966-1", "biomarker_component": [ { "biomarker": "Increased NDRG1 level", "assessed_biomarker_entity": { "recommended_name": "Differentiation-related gene 1 protein", "synonyms": [ { "synonym": "Differentiation-related gene 1 protein" }, { "synonym": "DRG-1" }, { "synonym": "N-myc downstream-regulated gene 1 protein" }, { "synonym": "Nickel-specific induction protein Cap43" }, { "synonym": "Reducing agents and tunicamycin-responsive protein" }, { "synonym": "RTP" }, { "synonym": "Rit42" } ] }, "assessed_biomarker_entity_id": "UPKB:Q92597", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "24386364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24386364", "evidence_list": [ { "evidence": "Increase in the expression of BTF3, HINT1, NDRG1 and ODC1 in malignant cores, diagnosed by histopathology, compared to non-malignant cores (p<0.0001, Mann Whitney U test). These results identify BTF3, HINT1, NDRG1 and ODC1 as proteins that are overexpressed in prostate cancer. NDRG1 could be a useful protein biomarker for prostate cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "24386364", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24386364", "evidence_list": [ { "evidence": "Increase in the expression of BTF3, HINT1, NDRG1 and ODC1 in malignant cores, diagnosed by histopathology, compared to non-malignant cores (p<0.0001, Mann Whitney U test). These results identify BTF3, HINT1, NDRG1 and ODC1 as proteins that are overexpressed in prostate cancer. NDRG1 could be a useful protein biomarker for prostate cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Quantitative analysis of BTF3, HINT1, NDRG1 and ODC1 protein over-expression in human prostate cancer tissue.", "journal": "PloS one", "authors": "Symes AJ, Eilertsen M, Millar M, Nariculam J, Freeman A, Notara M, Feneley MR, Patel HR, Masters JR, Ahmed A", "date": "2014-01-05", "evidence": [], "reference": [ { "id": "24386364", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24386364" } ] } ], "biomarker_canonical_id": "AA4966", "collision": 1 }, { "biomarker_id": "AA4967-1", "biomarker_component": [ { "biomarker": "increased ERBB2 level", "assessed_biomarker_entity": { "recommended_name": "Receptor tyrosine-protein kinase erbB-2", "synonyms": [ { "synonym": "Metastatic lymph node gene 19 protein" }, { "synonym": "MLN 19" }, { "synonym": "Proto-oncogene Neu" }, { "synonym": "Proto-oncogene c-ErbB-2" }, { "synonym": "Tyrosine kinase-type cell surface receptor HER2" }, { "synonym": "p185erbB2" } ] }, "assessed_biomarker_entity_id": "UPKB:P04626", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "10829039", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10829039", "evidence_list": [ { "evidence": "Kaplan-Meier analysis (log-rank statistics) revealed a significant association of increasing expression of c-erbB-2 with shorter disease-free (P =. 0023) and overall survival (P =.0160). High amounts of p185 were significantly associated with a high expression of urokinase-type plasminogen activator (uPA) (P <.010), uPA-receptor (P =.030), type-1 plasminogen activator inhibitor (PAI) (P <.010), type-2 PAI (P =.021), cathepsin D (P =.036), matrix metalloproteinase-2 (P =. 024), alpha-1-antichymotrypsin (P =.025), and alpha-2-macroglobulin (P =.017). Multivariate analysis considering these proteases/protease inhibitors, in addition to alpha-1-antitrypsin, tissue plasminogen activator, plasminogen, alpha-2-antiplasmin, and antithrombin III, and established prognostic parameters revealed that, in addition to surgical curability, pT stage, pN stage, and PAI-1, c-erbB-2 is an independent prognostic factor for overall survival of curatively resected patients (n = 139; P =.049; relative risk, 1.54; 95% confidence interval, 1.08 to 1.67) and all patients (P =.028; relative risk 1.33; 95% CI, 1.28 to 1.38)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "10829039", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10829039", "evidence_list": [ { "evidence": "Kaplan-Meier analysis (log-rank statistics) revealed a significant association of increasing expression of c-erbB-2 with shorter disease-free (P =. 0023) and overall survival (P =.0160). High amounts of p185 were significantly associated with a high expression of urokinase-type plasminogen activator (uPA) (P <.010), uPA-receptor (P =.030), type-1 plasminogen activator inhibitor (PAI) (P <.010), type-2 PAI (P =.021), cathepsin D (P =.036), matrix metalloproteinase-2 (P =. 024), alpha-1-antichymotrypsin (P =.025), and alpha-2-macroglobulin (P =.017). Multivariate analysis considering these proteases/protease inhibitors, in addition to alpha-1-antitrypsin, tissue plasminogen activator, plasminogen, alpha-2-antiplasmin, and antithrombin III, and established prognostic parameters revealed that, in addition to surgical curability, pT stage, pN stage, and PAI-1, c-erbB-2 is an independent prognostic factor for overall survival of curatively resected patients (n = 139; P =.049; relative risk, 1.54; 95% confidence interval, 1.08 to 1.67) and all patients (P =.028; relative risk 1.33; 95% CI, 1.28 to 1.38)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM", "date": "2000-06-01", "evidence": [], "reference": [ { "id": "10829039", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/10829039" } ] } ], "biomarker_canonical_id": "AA4967", "collision": 1 }, { "biomarker_id": "AA4968-1", "biomarker_component": [ { "biomarker": "increased RCAS1 level", "assessed_biomarker_entity": { "recommended_name": "Receptor-binding cancer antigen expressed on SiSo cells", "synonyms": [ { "synonym": "Cancer-associated surface antigen RCAS1" }, { "synonym": "Estrogen receptor-binding fragment-associated gene 9 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:O00559", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "16842844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16842844", "evidence_list": [ { "evidence": "Uterine cancer patients had significantly higher serum RCAS1 concentrations than did healthy women. The RCAS1 level was dramatically reduced in patients who had a positive response to treatment; however, the RCAS1 value increased in patients whose tumors clearly grew (P= 0.0007 and P= 0.0008, respectively) (Fig. 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "16842844", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16842844", "evidence_list": [ { "evidence": "Uterine cancer patients had significantly higher serum RCAS1 concentrations than did healthy women. The RCAS1 level was dramatically reduced in patients who had a positive response to treatment; however, the RCAS1 value increased in patients whose tumors clearly grew (P= 0.0007 and P= 0.0008, respectively) (Fig. 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical significance of RCAS1 as a biomarker of uterine cancer.", "journal": "Gynecologic oncology", "authors": "Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T, Nakano H", "date": "2006-07-18", "evidence": [], "reference": [ { "id": "16842844", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16842844" } ] } ], "biomarker_canonical_id": "AA4968", "collision": 1 }, { "biomarker_id": "AN4214-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Fibroblast growth factor receptor 2 gene amplification", "synonyms": [ { "synonym": "FGFR-2" }, { "synonym": "K-sam" }, { "synonym": "KGFR" }, { "synonym": "Keratinocyte growth factor receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:P21802", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "48972-4" } ], "evidence_source": [ { "id": "23493349", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23493349", "evidence_list": [ { "evidence": "Amplification of the FGFR2 gene was identified in a subset of Chinese and Caucasian patients with gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "23493349", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23493349", "evidence_list": [ { "evidence": "Amplification of the FGFR2 gene was identified in a subset of Chinese and Caucasian patients with gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q", "date": "2013-03-16", "evidence": [], "reference": [ { "id": "23493349", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23493349" } ] } ], "biomarker_canonical_id": "AN4214", "collision": 1 }, { "biomarker_id": "AN4215-1", "biomarker_component": [ { "biomarker": "increased copy number", "assessed_biomarker_entity": { "recommended_name": "Hepatocyte growth factor receptor gene copy number", "synonyms": [ { "synonym": "HGF receptor" }, { "synonym": "HGF/SF receptor" }, { "synonym": "Proto-oncogene c-Met" }, { "synonym": "Scatter factor receptor" }, { "synonym": "SF receptor" }, { "synonym": "Tyrosine-protein kinase Met" } ] }, "assessed_biomarker_entity_id": "UPKB:P08581", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "22042954", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22042954", "evidence_list": [ { "evidence": "In 216 assessable patients, MET CNG five or more copies and homozygous HGF-truncated DATE occurred in 21 patients (10%) and 30 patients (13%), respectively. Patients with MET CNG five or more copies (MET-positive) showed significantly worse prognosis with multivariate hazard ratio (HR) of 3.02 (95% CI, 1.71 to 5.33; P < .001) for DFS and multivariate HR of 2.91 (95% CI, 1.65 to 5.11; P < .001) for OS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "22042954", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22042954", "evidence_list": [ { "evidence": "In 216 assessable patients, MET CNG five or more copies and homozygous HGF-truncated DATE occurred in 21 patients (10%) and 30 patients (13%), respectively. Patients with MET CNG five or more copies (MET-positive) showed significantly worse prognosis with multivariate hazard ratio (HR) of 3.02 (95% CI, 1.71 to 5.33; P < .001) for DFS and multivariate HR of 2.91 (95% CI, 1.65 to 5.11; P < .001) for OS." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M", "date": "2011-11-02", "evidence": [], "reference": [ { "id": "22042954", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22042954" } ] } ], "biomarker_canonical_id": "AN4215", "collision": 1 }, { "biomarker_id": "AN4216-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform gene amplification", "synonyms": [ { "synonym": "PI3-kinase subunit alpha" }, { "synonym": "PI3K-alpha" }, { "synonym": "PI3Kalpha" }, { "synonym": "PtdIns-3-kinase subunit alpha" }, { "synonym": "Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha" }, { "synonym": "PtdIns-3-kinase subunit p110-alpha" }, { "synonym": "p110alpha" }, { "synonym": "Phosphoinositide 3-kinase alpha" }, { "synonym": "Phosphoinositide-3-kinase catalytic alpha polypeptide" }, { "synonym": "Serine/threonine protein kinase PIK3CA" } ] }, "assessed_biomarker_entity_id": "UPKB:P42336", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "63419-6" } ], "evidence_source": [ { "id": "22292935", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22292935", "evidence_list": [ { "evidence": "PIK3CA mutations and amplification were found in 8/113 (7.1%) and 88/131 (67%) gastric cancer patients, respectively. Our data showed that PIK3CA mutations were not common, but its amplification was very common in gastric cancer and may be a major mechanism in activating the PI3K/Akt pathway in gastric cancer. Importantly, Kaplan-Meier survival curves revealed that PIK3CA amplification was significantly positively associated with poor survival of gastric cancer patients. In the present study, a high prevalence of PIK3CA amplification was found in gastric cancer, which was significantly associated with poor prognosis of gastric cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "22292935", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22292935", "evidence_list": [ { "evidence": "PIK3CA mutations and amplification were found in 8/113 (7.1%) and 88/131 (67%) gastric cancer patients, respectively. Our data showed that PIK3CA mutations were not common, but its amplification was very common in gastric cancer and may be a major mechanism in activating the PI3K/Akt pathway in gastric cancer. Importantly, Kaplan-Meier survival curves revealed that PIK3CA amplification was significantly positively associated with poor survival of gastric cancer patients. In the present study, a high prevalence of PIK3CA amplification was found in gastric cancer, which was significantly associated with poor prognosis of gastric cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.", "journal": "BMC cancer", "authors": "Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P", "date": "2012-02-02", "evidence": [], "reference": [ { "id": "22292935", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22292935" } ] } ], "biomarker_canonical_id": "AN4216", "collision": 1 }, { "biomarker_id": "AA4972-1", "biomarker_component": [ { "biomarker": "decreased P2RX7 level", "assessed_biomarker_entity": { "recommended_name": "P2X purinoceptor 7", "synonyms": [ { "synonym": "P2X7" }, { "synonym": "ATP receptor" }, { "synonym": "P2Z receptor" }, { "synonym": "Purinergic receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99572", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" } ], "evidence_source": [ { "id": "17035398", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17035398", "evidence_list": [ { "evidence": "The P2X7 is expressed predominantly in the epithelial components of the uterus, (a) Levels of the P2X(7) are lower in uterine epithelial cancer tissues than in the corresponding normal tissues. (b) The data suggest that tissue P2X(7) mRNA and protein levels could be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. Uterine epithelial cancerous lesions lack expression of the P2X7." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "17035398", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17035398", "evidence_list": [ { "evidence": "The P2X7 is expressed predominantly in the epithelial components of the uterus, (a) Levels of the P2X(7) are lower in uterine epithelial cancer tissues than in the corresponding normal tissues. (b) The data suggest that tissue P2X(7) mRNA and protein levels could be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. Uterine epithelial cancerous lesions lack expression of the P2X7." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The P2X7 receptor: a novel biomarker of uterine epithelial cancers.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI", "date": "2006-10-13", "evidence": [], "reference": [ { "id": "17035398", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17035398" } ] } ], "biomarker_canonical_id": "AA4972", "collision": 1 }, { "biomarker_id": "AA4973-1", "biomarker_component": [ { "biomarker": "increased KLK6 level", "assessed_biomarker_entity": { "recommended_name": "Kallikrein-6", "synonyms": [ { "synonym": "Neurosin" }, { "synonym": "Protease M" }, { "synonym": "SP59" }, { "synonym": "Serine protease 18" }, { "synonym": "Serine protease 9" }, { "synonym": "Zyme" } ] }, "assessed_biomarker_entity_id": "UPKB:Q92876", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "15867230", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15867230", "evidence_list": [ { "evidence": "In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "15867230", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15867230", "evidence_list": [ { "evidence": "In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S", "date": "2005-05-04", "evidence": [], "reference": [ { "id": "15867230", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15867230" } ] } ], "biomarker_canonical_id": "AA4973", "collision": 1 }, { "biomarker_id": "AN4217-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "miRNA-9-1 gene hypermethylation", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000466", "assessed_entity_type": "miRNA", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "29313235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235", "evidence_list": [ { "evidence": "These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "29313235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235", "evidence_list": [ { "evidence": "These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer.", "journal": "Bulletin of experimental biology and medicine", "authors": "Braga EA, Loginov VI, Burdennyi AM, Filippova EA, Pronina IV, Kurevlev SV, Kazubskaya TP, Kushlinskii DN, Utkin DO, Ermilova VD, Kushlinskii NE", "date": "2018-01-10", "evidence": [], "reference": [ { "id": "29313235", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235" } ] } ], "biomarker_canonical_id": "AN4217", "collision": 1 }, { "biomarker_id": "AN4218-1", "biomarker_component": [ { "biomarker": "increased EMC1 level", "assessed_biomarker_entity": { "recommended_name": "Extracellular matrix protein 1", "synonyms": [ { "synonym": "Secretory component p85" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16610", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "16135921", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921", "evidence_list": [ { "evidence": "By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "16135921", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921", "evidence_list": [ { "evidence": "By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.", "journal": "Annals of surgery", "authors": "Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A", "date": "2005-09-02", "evidence": [], "reference": [ { "id": "16135921", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921" } ] } ], "biomarker_canonical_id": "AN4218", "collision": 1 }, { "biomarker_id": "AN4219-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "CYP17 A2 allele polymorphism", "synonyms": [ { "synonym": "17-alpha-hydroxyprogesterone aldolase" }, { "synonym": "CYPXVII" }, { "synonym": "Cytochrome P450 17A1" }, { "synonym": "Cytochrome P450-C17" }, { "synonym": "Cytochrome P450c17" }, { "synonym": "Steroid 17-alpha-monooxygenase" } ] }, "assessed_biomarker_entity_id": "UPKB:P05093", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "77057-8" } ], "evidence_source": [ { "id": "16783967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16783967", "evidence_list": [ { "evidence": "Our data indicate that the CYP17 A2 allele polymorphism may confer an increased risk and can provide a biomarker for ovarian cancer patients in whom no mutations in the BRCA genes are observed." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "16783967", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16783967", "evidence_list": [ { "evidence": "Our data indicate that the CYP17 A2 allele polymorphism may confer an increased risk and can provide a biomarker for ovarian cancer patients in whom no mutations in the BRCA genes are observed." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Are CYP17 genotypes a biomarker for ovarian cancer in patients with cancer history in their family?", "journal": "Oncology research", "authors": "Yazici H, Tigli H, Kadehci Z, Kucucuk S, Saip P, Issever H, Ozcelik H, Dalay N", "date": "2006-06-21", "evidence": [], "reference": [ { "id": "16783967", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16783967" } ] } ], "biomarker_canonical_id": "AN4219", "collision": 1 }, { "biomarker_id": "AA4977-1", "biomarker_component": [ { "biomarker": "increased GGT level", "assessed_biomarker_entity": { "recommended_name": "Gamma-glutamyltransferase", "synonyms": [ { "synonym": "Gamma-glutamyltransferase 1" }, { "synonym": "Gamma-glutamyltranspeptidase 1" }, { "synonym": "GGT 1" }, { "synonym": "Leukotriene-C4 hydrolase" } ] }, "assessed_biomarker_entity_id": "UPKB:P19440", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "2324-2" } ], "evidence_source": [ { "id": "27646551", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27646551", "evidence_list": [ { "evidence": "Women with higher pre-treatment GGT serum levels showed impaired Overall Survival (OS) compared to women with normal low levels. Higher pre-treatment GGT serum levels were independently associated with unfavorable prognosis in women with ULMS. Thus, GGT seems to be a useful novel biomarker in ULMS." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "27646551", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27646551", "evidence_list": [ { "evidence": "Women with higher pre-treatment GGT serum levels showed impaired Overall Survival (OS) compared to women with normal low levels. Higher pre-treatment GGT serum levels were independently associated with unfavorable prognosis in women with ULMS. Thus, GGT seems to be a useful novel biomarker in ULMS." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma.", "journal": "Scientific reports", "authors": "Schwameis R, Grimm C, Brodowicz T, Petru E, Hefler-Frischmuth K, Staudigl C, Reinthaller A, Heinze G, Polterauer S, Polterauer M", "date": "2016-09-21", "evidence": [], "reference": [ { "id": "27646551", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27646551" } ] } ], "biomarker_canonical_id": "AA4977", "collision": 1 }, { "biomarker_id": "AA4978-1", "biomarker_component": [ { "biomarker": "decreased PSMB9 level", "assessed_biomarker_entity": { "recommended_name": "Proteasome subunit beta type 9", "synonyms": [ { "synonym": "Low molecular mass protein 2" }, { "synonym": "Macropain chain 7" }, { "synonym": "Multicatalytic endopeptidase complex chain 7" }, { "synonym": "Proteasome chain 7" }, { "synonym": "Proteasome subunit beta-1i" }, { "synonym": "Really interesting new gene 12 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P28065", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" }, { "name": "uterine wall", "id": "UBERON:0000459", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000459", "loinc_code": "" } ], "evidence_source": [ { "id": "28482675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28482675", "evidence_list": [ { "evidence": "The immunohistochemistry (IHC) experiments, performed separately at several medical facilities, revealed a serious loss in the ability to induce PSMB9/beta1i expression in human uterine LMS tissues in comparison with normal human myometrium tissues located in same tissue sections." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "28482675", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28482675", "evidence_list": [ { "evidence": "The immunohistochemistry (IHC) experiments, performed separately at several medical facilities, revealed a serious loss in the ability to induce PSMB9/beta1i expression in human uterine LMS tissues in comparison with normal human myometrium tissues located in same tissue sections." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/\u03b21i.", "journal": "Chinese clinical oncology", "authors": "Hayashi T, Kawano M, Sano K, Ichimura T, Gur G, Yaish P, Zharhary D, Kanai Y, Tonegawa S, Shiozawa T, Yaegashi N, Konishi I", "date": "2017-05-10", "evidence": [], "reference": [ { "id": "28482675", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28482675" } ] } ], "biomarker_canonical_id": "AA4978", "collision": 1 }, { "biomarker_id": "AA4979-1", "biomarker_component": [ { "biomarker": "increased ACKR3 level", "assessed_biomarker_entity": { "recommended_name": "Atypical chemokine receptor 3", "synonyms": [ { "synonym": "C-X-C chemokine receptor type 7" }, { "synonym": "CXC-R7" }, { "synonym": "CXCR-7" }, { "synonym": "Chemokine orphan receptor 1" }, { "synonym": "G-protein coupled receptor 159" }, { "synonym": "G-protein coupled receptor RDC1 homolog" }, { "synonym": "RDC-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P25106", "assessed_entity_type": "protein", "specimen": [ { "name": "esophagus", "id": "UBERON:0001043", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001043", "loinc_code": "" } ], "evidence_source": [ { "id": "33709176", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33709176", "evidence_list": [ { "evidence": "High CXCR7 expression was associated with poor prognosis in patients with EAC, and high expression of CXCR7 with its ligand CXCL12 had a stronger association with prognosis. High CXCR7 expression was significantly associated with lymphatic invasion (present vs absent, P = 0.005) and higher number of lymph node metastases (pN0-1 vs pN2-3, P = 0.0014)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "33709176", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33709176", "evidence_list": [ { "evidence": "High CXCR7 expression was associated with poor prognosis in patients with EAC, and high expression of CXCR7 with its ligand CXCL12 had a stronger association with prognosis. High CXCR7 expression was significantly associated with lymphatic invasion (present vs absent, P = 0.005) and higher number of lymph node metastases (pN0-1 vs pN2-3, P = 0.0014)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma.", "journal": "Annals of surgical oncology", "authors": "Goto M, Shibahara Y, Baciu C, Allison F, Yeung JC, Darling GE, Liu M", "date": "2021-03-13", "evidence": [], "reference": [ { "id": "33709176", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33709176" } ] } ], "biomarker_canonical_id": "AA4979", "collision": 1 }, { "biomarker_id": "AA4980-1", "biomarker_component": [ { "biomarker": "increased CXCR12 level", "assessed_biomarker_entity": { "recommended_name": "Stromal cell-derived factor 1", "synonyms": [ { "synonym": "SDF-1" }, { "synonym": "hSDF-1" }, { "synonym": "C-X-C motif chemokine 12" }, { "synonym": "Intercrine reduced in hepatomas" }, { "synonym": "IRH" }, { "synonym": "hIRH" }, { "synonym": "Pre-B cell growth-stimulating factor" }, { "synonym": "PBSF" } ] }, "assessed_biomarker_entity_id": "UPKB:P48061", "assessed_entity_type": "protein", "specimen": [ { "name": "esophagus", "id": "UBERON:0001043", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001043", "loinc_code": "" } ], "evidence_source": [ { "id": "27439769", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27439769", "evidence_list": [ { "evidence": "Immunohistochemistry revealed positive CXCR4 and CXCL12 expression in 48 (61 %) and 62 (78 %) patients, respectively. The MIB-1 proliferation index was markedly higher in ESCC with a positive expression of CXCR4 or CXCL12." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "27439769", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27439769", "evidence_list": [ { "evidence": "Immunohistochemistry revealed positive CXCR4 and CXCL12 expression in 48 (61 %) and 62 (78 %) patients, respectively. The MIB-1 proliferation index was markedly higher in ESCC with a positive expression of CXCR4 or CXCL12." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CXCL12 expression promotes esophageal squamous cell carcinoma proliferation and worsens the prognosis.", "journal": "BMC cancer", "authors": "Uchi Y, Takeuchi H, Matsuda S, Saikawa Y, Kawakubo H, Wada N, Takahashi T, Nakamura R, Fukuda K, Omori T, Kitagawa Y", "date": "2016-07-22", "evidence": [], "reference": [ { "id": "27439769", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27439769" } ] } ], "biomarker_canonical_id": "AA4980", "collision": 1 }, { "biomarker_id": "AN4220-1", "biomarker_component": [ { "biomarker": "decreased GNK1 level", "assessed_biomarker_entity": { "recommended_name": "Gastrokine 1", "synonyms": [ { "synonym": "18 kDa antrum mucosa protein" }, { "synonym": "AMP-18" }, { "synonym": "Protein CA11" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NS71", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "25469040", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25469040", "evidence_list": [ { "evidence": "The present study investigated GNK1 expression in different mucosa biopsy specimens from gastric cancer, cancer-adjacent lesions, atrophic gastritis and normal control subjects (superficial gastritis patients). We found that GKN1 mRNA expression was progressively downregulated from corresponding distant non-tumour tissues to tumour tissues, and was lower than in the control tissues of both groups. This suggested that low or absent expression of GKN1 may contribute to gastric carcinogenesis. This is consistent with a previous study that demonstrated decreased GKN1 expression in gastric cancer tissues. In addition, we analysed GKN1 expression in two types of gastric cancer and found that the mRNA level of GKN1 was lower in patients with diffuse type gastric cancer. This indicates that GKN1 may be related to tumour classification." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "25469040", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25469040", "evidence_list": [ { "evidence": "The present study investigated GNK1 expression in different mucosa biopsy specimens from gastric cancer, cancer-adjacent lesions, atrophic gastritis and normal control subjects (superficial gastritis patients). We found that GKN1 mRNA expression was progressively downregulated from corresponding distant non-tumour tissues to tumour tissues, and was lower than in the control tissues of both groups. This suggested that low or absent expression of GKN1 may contribute to gastric carcinogenesis. This is consistent with a previous study that demonstrated decreased GKN1 expression in gastric cancer tissues. In addition, we analysed GKN1 expression in two types of gastric cancer and found that the mRNA level of GKN1 was lower in patients with diffuse type gastric cancer. This indicates that GKN1 may be related to tumour classification." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Decreased expression of gastrokine 1 in gastric mucosa of gastric cancer patients.", "journal": "World journal of gastroenterology", "authors": "Guo XY, Dong L, Qin B, Jiang J, Shi AM", "date": "2014-12-04", "evidence": [], "reference": [ { "id": "25469040", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25469040" } ] } ], "biomarker_canonical_id": "AN4220", "collision": 1 }, { "biomarker_id": "AN4221-1", "biomarker_component": [ { "biomarker": "increased methylation", "assessed_biomarker_entity": { "recommended_name": "Nuclear receptor ROR-alpha gene promoter methylation", "synonyms": [ { "synonym": "Nuclear receptor RZR-alpha" }, { "synonym": "Nuclear receptor subfamily 1 group F member 1" }, { "synonym": "RAR-related orphan receptor A" }, { "synonym": "Retinoid-related orphan receptor-alpha" } ] }, "assessed_biomarker_entity_id": "UPKB:P35398", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "19375421", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19375421", "evidence_list": [ { "evidence": "When considering progressive stages, 2 patterns were evident: (1) type 1 markers, showing consistently high levels of methylation in both gastric dysplasia and cancer (MINT25 and GDNF); (2) type 2 markers, showing high levels of methylation in early gastric cancer and gastric dysplasia but decreased levels in advanced gastric cancer (RORA, ADAM23, PRDM5, and MLF1). Of interest, use of the type 2 markers showed higher methylation levels in gastric dysplasia than in advanced gastric cancer (P < .001), which is consistent with our studies in ulcerative colitis and colon cancer. RORA and MINT25 were more hypermethylated in intestinal type GCs than those of diffuse type GCs, whereas CDH1 showed opposite patterns of methylation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "19375421", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19375421", "evidence_list": [ { "evidence": "When considering progressive stages, 2 patterns were evident: (1) type 1 markers, showing consistently high levels of methylation in both gastric dysplasia and cancer (MINT25 and GDNF); (2) type 2 markers, showing high levels of methylation in early gastric cancer and gastric dysplasia but decreased levels in advanced gastric cancer (RORA, ADAM23, PRDM5, and MLF1). Of interest, use of the type 2 markers showed higher methylation levels in gastric dysplasia than in advanced gastric cancer (P < .001), which is consistent with our studies in ulcerative colitis and colon cancer. RORA and MINT25 were more hypermethylated in intestinal type GCs than those of diffuse type GCs, whereas CDH1 showed opposite patterns of methylation." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes.", "journal": "Gastroenterology", "authors": "Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP", "date": "2009-04-21", "evidence": [], "reference": [ { "id": "19375421", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19375421" } ] } ], "biomarker_canonical_id": "AN4221", "collision": 1 }, { "biomarker_id": "AA4983-1", "biomarker_component": [ { "biomarker": "increased COX-2 level", "assessed_biomarker_entity": { "recommended_name": "Cyclooxygenase-2", "synonyms": [ { "synonym": "Cyclooxygenase-2" }, { "synonym": "COX-2" }, { "synonym": "PHS II" }, { "synonym": "Prostaglandin H2 synthase 2" }, { "synonym": "PGH synthase 2" }, { "synonym": "PGHS-2" }, { "synonym": "Prostaglandin-endoperoxide synthase 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P35354", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "49476-5" } ], "evidence_source": [ { "id": "15589595", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15589595", "evidence_list": [ { "evidence": "COX-2 overexpression was noted in one third of the cases in both early and advanced stage disease. These patients fared significantly worse than those without COX-2 overexpression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "15589595", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15589595", "evidence_list": [ { "evidence": "COX-2 overexpression was noted in one third of the cases in both early and advanced stage disease. These patients fared significantly worse than those without COX-2 overexpression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?", "journal": "Gynecologic oncology", "authors": "Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, Scarselli G, Taddei GL", "date": "2004-12-14", "evidence": [], "reference": [ { "id": "15589595", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15589595" } ] } ], "biomarker_canonical_id": "AA4983", "collision": 1 }, { "biomarker_id": "AA4984-1", "biomarker_component": [ { "biomarker": "increased NAV2 level", "assessed_biomarker_entity": { "recommended_name": "Neuron navigator-2", "synonyms": [ { "synonym": "Helicase APC down-regulated 1" }, { "synonym": "Pore membrane and/or filament-interacting-like protein 2" }, { "synonym": "Retinoic acid inducible in neuroblastoma 1" }, { "synonym": "Steerin-2" }, { "synonym": "Unc-53 homolog 2" }, { "synonym": "unc53H2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8IVL1", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" } ], "evidence_source": [ { "id": "28643014", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014", "evidence_list": [ { "evidence": "The presence of any degree of NAV2, assessed in 159 of these patients who had informative cores, was significantly related to shorter Overall Survival (OS) (p = 0.037; Fig. 2a). Expression was analyzed for association with clinicopathologic parameters and survival. TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG-ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "28643014", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014", "evidence_list": [ { "evidence": "The presence of any degree of NAV2, assessed in 159 of these patients who had informative cores, was significantly related to shorter Overall Survival (OS) (p = 0.037; Fig. 2a). Expression was analyzed for association with clinicopathologic parameters and survival. TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG-ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.", "journal": "Virchows Archiv : an international journal of pathology", "authors": "Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B", "date": "2017-06-24", "evidence": [], "reference": [ { "id": "28643014", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014" } ] } ], "biomarker_canonical_id": "AA4984", "collision": 1 }, { "biomarker_id": "AA4985-1", "biomarker_component": [ { "biomarker": "increased CCND2 level", "assessed_biomarker_entity": { "recommended_name": "Cyclin D2", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P30279", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" } ], "evidence_source": [ { "id": "28643014", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014", "evidence_list": [ { "evidence": "The presence of nuclear CCND2 expression in >10% tumor cells, assessed in 62 of these patients who had informative cores, was significantly related to longer Overall Survival (OS) (p = 0.012; Fig. 2b). TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 expression was associated with shorter overall survival in patients with LMS (p = 0.037), whereas nuclear CCND2 expression in LG-ESS was significantly related to longer survival (p = 0.012) in univariate analysis. Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis (p = 0.023). In conclusion, TGLN, FABP3, NAV2, and nuclear CCND2 aid in differentiating LG-ESS from LMS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "28643014", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014", "evidence_list": [ { "evidence": "The presence of nuclear CCND2 expression in >10% tumor cells, assessed in 62 of these patients who had informative cores, was significantly related to longer Overall Survival (OS) (p = 0.012; Fig. 2b). TGLN (p < 0.001), NAV2 (p < 0.001), and FABP3 (p = 0.005) were overexpressed in LMS compared to LG ESS, whereas nuclear CCND2 (p < 0.001) was overexpressed in LG-ESS. NAV2 expression was associated with shorter overall survival in patients with LMS (p = 0.037), whereas nuclear CCND2 expression in LG-ESS was significantly related to longer survival (p = 0.012) in univariate analysis. Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis (p = 0.023). In conclusion, TGLN, FABP3, NAV2, and nuclear CCND2 aid in differentiating LG-ESS from LMS. NAV2 and CCND2 are novel candidate prognostic markers in LMS and LG-ESS, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.", "journal": "Virchows Archiv : an international journal of pathology", "authors": "Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B", "date": "2017-06-24", "evidence": [], "reference": [ { "id": "28643014", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28643014" } ] } ], "biomarker_canonical_id": "AA4985", "collision": 1 }, { "biomarker_id": "AA4986-1", "biomarker_component": [ { "biomarker": "increased TAGLN level", "assessed_biomarker_entity": { "recommended_name": "Transgelin", "synonyms": [ { "synonym": "22 kDa actin-binding protein" }, { "synonym": "Protein WS3-10" }, { "synonym": "Smooth muscle protein 22-alpha" }, { "synonym": "SM22-alpha" } ] }, "assessed_biomarker_entity_id": "UPKB:Q01995", "assessed_entity_type": "protein", "specimen": [ { "name": "smooth muscle tissue", "id": "UBERON:0001135", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001135", "loinc_code": "" } ], "evidence_source": [ { "id": "23174934", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23174934", "evidence_list": [ { "evidence": "For the diagnosis of leiomyosarcomas versus all other sarcomas including GIST, transgelin emerged as the best diagnostic marker with 83% Se, 82% Sp, a PPV of 67%, a NPV of 92% and an accuracy rate of 83%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "23174934", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23174934", "evidence_list": [ { "evidence": "For the diagnosis of leiomyosarcomas versus all other sarcomas including GIST, transgelin emerged as the best diagnostic marker with 83% Se, 82% Sp, a PPV of 67%, a NPV of 92% and an accuracy rate of 83%." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors.", "journal": "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc", "authors": "Robin YM, Penel N, P\u00e9rot G, Neuville A, V\u00e9lasco V, Ranch\u00e8re-Vince D, Terrier P, Coindre JM", "date": "2012-11-24", "evidence": [], "reference": [ { "id": "23174934", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23174934" } ] } ], "biomarker_canonical_id": "AA4986", "collision": 1 }, { "biomarker_id": "AA4987-1", "biomarker_component": [ { "biomarker": "increased IMP3 level", "assessed_biomarker_entity": { "recommended_name": "Insulin-like growth factor II messenger RNA-binding protein-3", "synonyms": [ { "synonym": "U3 snoRNP protein IMP3" }, { "synonym": "BRMS2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NV31", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "" } ], "evidence_source": [ { "id": "18223334", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18223334", "evidence_list": [ { "evidence": "IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001). We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer. It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions. Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions. Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "18223334", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18223334", "evidence_list": [ { "evidence": "IMP3 expression was predominantly found in endometrial serous carcinoma and its putative precursor lesions, with 3 (14%) of 21 endometrial glandular dysplasia, 16 (89%) of 18 serous endometrial intraepithelial carcinoma, and 48 (94%) of 51 serous carcinomas (P<0.001). We conclude that expression of IMP3, a newly identified cytoplasmic marker, is closely associated with type II endometrial cancer. It seems that IMP3 expression is associated with an aggressive histologic phenotype among endometrial neoplastic lesions. Strong and diffuse IMP3 expression is highly sensitive for endometrial serous and clear cell carcinomas including their putative precursor lesions. Therefore, IMP3 may be a useful diagnostic marker in the assessment of endometrial cancers and their precursor lesions, particularly when the amount of available tissue material is limited and a concern of type II cancer arises." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.", "journal": "The American journal of surgical pathology", "authors": "Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z", "date": "2008-01-29", "evidence": [], "reference": [ { "id": "18223334", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18223334" } ] } ], "biomarker_canonical_id": "AA4987", "collision": 1 }, { "biomarker_id": "AA4988-1", "biomarker_component": [ { "biomarker": "increased CD10 level", "assessed_biomarker_entity": { "recommended_name": "Cluster of differentiation 10", "synonyms": [ { "synonym": "Atriopeptidase" }, { "synonym": "Common acute lymphocytic leukemia antigen" }, { "synonym": "CALLA" }, { "synonym": "Enkephalinase" }, { "synonym": "Neutral endopeptidase 24.11" }, { "synonym": "NEP" }, { "synonym": "Neutral endopeptidase" }, { "synonym": "Skin fibroblast elastase" }, { "synonym": "SFE" } ] }, "assessed_biomarker_entity_id": "UPKB:P08473", "assessed_entity_type": "protein", "specimen": [ { "name": "uterus", "id": "UBERON:0000995", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000995", "loinc_code": "51214-5" } ], "evidence_source": [ { "id": "15571618", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15571618", "evidence_list": [ { "evidence": "Uterine Adenosarcoma (UAS) with sarcomatous overgrowth stained strongly positive in five of eight (63%) cases. Pattern of strong positivity was focal in four of five (80%). These findings suggest that CD10 can be used to differentiate UAS from cellular leiomyoma, or in case endometrial stromal cells exhibit muscle differentiation. Furthermore, CD10 positivity in recurrent UAS might guide the pathologist toward an endometrial stromal origin." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "11532038", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11532038", "evidence_list": [ { "evidence": "CD10 is a reliable and sensitive immunohistochemical marker of normal endometrial stroma. Positivity, which is often strong and/or diffuse is found in endometrial stromal nodules and low-grade ESS. Positive staining with CD10, when strong and diffuse, may be useful in distinguishing these tumours from histological mimics, especially cellular leiomyoma and AGCT which are generally negative. There was positive staining of all low-grade Endometrial stromal sarcoma (ESS)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "15571618", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15571618", "evidence_list": [ { "evidence": "Uterine Adenosarcoma (UAS) with sarcomatous overgrowth stained strongly positive in five of eight (63%) cases. Pattern of strong positivity was focal in four of five (80%). These findings suggest that CD10 can be used to differentiate UAS from cellular leiomyoma, or in case endometrial stromal cells exhibit muscle differentiation. Furthermore, CD10 positivity in recurrent UAS might guide the pathologist toward an endometrial stromal origin." } ], "tags": [ { "tag": "condition" } ] }, { "id": "11532038", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11532038", "evidence_list": [ { "evidence": "CD10 is a reliable and sensitive immunohistochemical marker of normal endometrial stroma. Positivity, which is often strong and/or diffuse is found in endometrial stromal nodules and low-grade ESS. Positive staining with CD10, when strong and diffuse, may be useful in distinguishing these tumours from histological mimics, especially cellular leiomyoma and AGCT which are generally negative. There was positive staining of all low-grade Endometrial stromal sarcoma (ESS)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immunohistochemical expression of CD10 antigen in uterine adenosarcoma.", "journal": "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society", "authors": "Amant F, Steenkiste E, Schurmans K, Verbist L, Abeler VM, Tulunay G, de Jonge E, Massuger L, Moerman P, Vergote I", "date": "2004-12-02", "evidence": [], "reference": [ { "id": "15571618", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/15571618" } ] }, { "title": "CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms.", "journal": "Histopathology", "authors": "McCluggage WG, Sumathi VP, Maxwell P", "date": "2001-09-05", "evidence": [], "reference": [ { "id": "11532038", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11532038" } ] } ], "biomarker_canonical_id": "AA4988", "collision": 1 }, { "biomarker_id": "AA4989-1", "biomarker_component": [ { "biomarker": "increased CD274 level", "assessed_biomarker_entity": { "recommended_name": "Programmed cell death 1 ligand 1", "synonyms": [ { "synonym": "PD-L1" }, { "synonym": "PDCD1 ligand 1" }, { "synonym": "Programmed death ligand 1" }, { "synonym": "hPD-L1" }, { "synonym": "B7 homolog 1" }, { "synonym": "B7-H1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZQ7", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "31981446", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31981446", "evidence_list": [ { "evidence": "Based on our established CTC detection platform, CTCs were isolated from peripheral blood samples collected from 70 patients (38 resectable and 32 unresectable) with GC using magnetic positive selection and a CSV-specific monoclonal antibody, 84-1. CSV+ PD-L1+ CTCs were observed in 50 of 70 (71%) GC patient samples, ranging from 0 to 261 mL-1. A higher number of CSV+ PD-L1+ CTCs were significantly associated with a short survival duration and poor therapeutic response. This study demonstrated that detection of PD-L1+ CTCs using a CSV-enrichment method has promising value as a clinically relevant prognostic marker for GC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "30925913", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30925913", "evidence_list": [ { "evidence": "We found that inhibition of autophagy by pharmacological inhibitors or small interfering RNAs increased the levels of PD-L1 in cultured gastric cancer cells and in xenografts. Mechanistically, autophagy inhibition led to the accumulation of p62/SQSTM1 and activation of nuclear factor (NF)-kB, in which NF-kB inhibition or p62/SQSTM1 knockdown attenuated PD-L1 induction by autophagy inhibition. Immunohistochemical staining of primary tumor tissues of 137 patients with gastric cancer showed that LC3 and p62/SQSTM1 protein levels were positively correlated with PD-L1 (LC3, p < 0.001; p62/SQSTM1, p < 0.05). The expression of PD-L1 was also positively correlated with tumor lymphocyte infiltration (p < 0.001). We discovered that autophagy regulates PD-L1 expression in gastric cancer through the p62/SQSTM1-NF-kB pathway. Pharmacological modulation of autophagy may thus influence the therapeutic efficacy of PD-L1 blockade in gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "31981446", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31981446", "evidence_list": [ { "evidence": "Based on our established CTC detection platform, CTCs were isolated from peripheral blood samples collected from 70 patients (38 resectable and 32 unresectable) with GC using magnetic positive selection and a CSV-specific monoclonal antibody, 84-1. CSV+ PD-L1+ CTCs were observed in 50 of 70 (71%) GC patient samples, ranging from 0 to 261 mL-1. A higher number of CSV+ PD-L1+ CTCs were significantly associated with a short survival duration and poor therapeutic response. This study demonstrated that detection of PD-L1+ CTCs using a CSV-enrichment method has promising value as a clinically relevant prognostic marker for GC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "30925913", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30925913", "evidence_list": [ { "evidence": "We found that inhibition of autophagy by pharmacological inhibitors or small interfering RNAs increased the levels of PD-L1 in cultured gastric cancer cells and in xenografts. Mechanistically, autophagy inhibition led to the accumulation of p62/SQSTM1 and activation of nuclear factor (NF)-kB, in which NF-kB inhibition or p62/SQSTM1 knockdown attenuated PD-L1 induction by autophagy inhibition. Immunohistochemical staining of primary tumor tissues of 137 patients with gastric cancer showed that LC3 and p62/SQSTM1 protein levels were positively correlated with PD-L1 (LC3, p < 0.001; p62/SQSTM1, p < 0.05). The expression of PD-L1 was also positively correlated with tumor lymphocyte infiltration (p < 0.001). We discovered that autophagy regulates PD-L1 expression in gastric cancer through the p62/SQSTM1-NF-kB pathway. Pharmacological modulation of autophagy may thus influence the therapeutic efficacy of PD-L1 blockade in gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.", "journal": "Molecular oncology", "authors": "Liu M, Wang R, Sun X, Liu Y, Wang Z, Yan J, Kong X, Liang S, Liu Q, Zhao T, Ji X, Wang G, Wang F, Wang G, Chen L, Zhang Q, Lv W, Li H, Sun M", "date": "2020-01-26", "evidence": [], "reference": [ { "id": "31981446", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31981446" } ] }, { "title": "Autophagy inhibition enhances PD-L1 expression in gastric cancer.", "journal": "Journal of experimental & clinical cancer research : CR", "authors": "Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin X, Li Y, Li Y, Gong J, Qi C, Peng Z, Yu J, Shen L", "date": "2019-03-31", "evidence": [], "reference": [ { "id": "30925913", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30925913" } ] } ], "biomarker_canonical_id": "AA4989", "collision": 1 }, { "biomarker_id": "AA4989-2", "biomarker_component": [ { "biomarker": "increased CD274 level", "assessed_biomarker_entity": { "recommended_name": "Programmed cell death 1 ligand 1", "synonyms": [ { "synonym": "PD-L1" }, { "synonym": "PDCD1 ligand 1" }, { "synonym": "Programmed death ligand 1" }, { "synonym": "hPD-L1" }, { "synonym": "B7 homolog 1" }, { "synonym": "B7-H1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZQ7", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31653140", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31653140", "evidence_list": [ { "evidence": "Among the 150 samples, 66 (44%) expressed PDL1 expression in the tumor cell surface, and a significant association was between the PDL1 expression and the high graded tumors" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "33797012", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33797012", "evidence_list": [ { "evidence": "PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31653140", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31653140", "evidence_list": [ { "evidence": "Among the 150 samples, 66 (44%) expressed PDL1 expression in the tumor cell surface, and a significant association was between the PDL1 expression and the high graded tumors" } ], "tags": [ { "tag": "condition" } ] }, { "id": "33797012", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33797012", "evidence_list": [ { "evidence": "PD-L1 expression predicts response to immune checkpoint inhibitors in renal cell carcinomas (RCC), but has also been suggested to be linked to poor patient outcome." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.", "journal": "Asian Pacific journal of cancer prevention : APJCP", "authors": "Chandrasekaran D, Sundaram S, N K, R P", "date": "2019-10-28", "evidence": [], "reference": [ { "id": "31653140", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31653140" } ] }, { "title": "Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.", "journal": "International urology and nephrology", "authors": "M\u00f6ller K, Fraune C, Blessin NC, Lennartz M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer T, Riechardt S, Simon R, Sauter G, B\u00fcscheck F, H\u00f6ppner W, Matthies C, Doh O, Krech T, Marx AH, Zecha H, Rink M, Steurer S, Clauditz TS", "date": "2021-04-03", "evidence": [], "reference": [ { "id": "33797012", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33797012" } ] } ], "biomarker_canonical_id": "AA4989", "collision": 1 }, { "biomarker_id": "AN4222-1", "biomarker_component": [ { "biomarker": "increased ARPP-19 level", "assessed_biomarker_entity": { "recommended_name": "cAMP-regulated phosphoprotein 19", "synonyms": [ { "synonym": "ARPP-19" } ] }, "assessed_biomarker_entity_id": "UPKB:P56211", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "32753897", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753897", "evidence_list": [ { "evidence": "We observed ARPP-19 was up-regulated in Herceptin resistance gastric cancer cells NCI-N87-HR and MKN45-HR. The forced expression of ARPP-19 promoted, whereas the silencing of ARPP-19 impaired Herceptin resistance of HER2-positive gastric cancer cells both in vitro and in vivo. Moreover, ARPP-19 significantly enhanced the sphere formation capacity and CD44 expression, CD44 was also a positive factor of Herceptin resistance in HER2-positive gastric cancer cells. In addition, high level of ARPP-19 was positively associated with Herceptin resistance and poor survival rate of gastric cancer patients. We have demonstrated that ARPP-19 promoted Herceptin resistance of gastric cancer via up-regulation of CD44, our study suggested that ARPP-19 could be a potential diagnostic and therapeutic candidate for HER2-positive gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "32753897", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753897", "evidence_list": [ { "evidence": "We observed ARPP-19 was up-regulated in Herceptin resistance gastric cancer cells NCI-N87-HR and MKN45-HR. The forced expression of ARPP-19 promoted, whereas the silencing of ARPP-19 impaired Herceptin resistance of HER2-positive gastric cancer cells both in vitro and in vivo. Moreover, ARPP-19 significantly enhanced the sphere formation capacity and CD44 expression, CD44 was also a positive factor of Herceptin resistance in HER2-positive gastric cancer cells. In addition, high level of ARPP-19 was positively associated with Herceptin resistance and poor survival rate of gastric cancer patients. We have demonstrated that ARPP-19 promoted Herceptin resistance of gastric cancer via up-regulation of CD44, our study suggested that ARPP-19 could be a potential diagnostic and therapeutic candidate for HER2-positive gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer.", "journal": "OncoTargets and therapy", "authors": "Gao X, Lu C, Chen C, Sun K, Liang Q, Shuai J, Wang X, Xu Y", "date": "2020-08-06", "evidence": [], "reference": [ { "id": "32753897", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32753897" } ] } ], "biomarker_canonical_id": "AN4222", "collision": 1 }, { "biomarker_id": "AN4223-1", "biomarker_component": [ { "biomarker": "increased STAT2 level", "assessed_biomarker_entity": { "recommended_name": "Signal transducer and activator of transcription 2", "synonyms": [ { "synonym": "p113" } ] }, "assessed_biomarker_entity_id": "UPKB:P52630", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "26622669", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669", "evidence_list": [ { "evidence": "The data demonstrated that eight genes associated with ApoE were differentially expressed, with six of these upregulated and two downregulated. Functionally, these genes were involved in the JAK-STAT cascade, acute-phase response, acute inflammatory response, and the steroid hormone response. Among these ApoE-associated genes, expression of the signal transducer and activator of transcription 2 (STAT2) and STAT3 transcription factors was upregulated. To the best of our knowledge, this is the first study to demonstrate the network of ApoE-related genes and transcription factors in gastric cancer. Additional studies are required in order to confirm these data and to translate the results into the identification of clinical biomarkers and novel treatment strategies for gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "26622669", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669", "evidence_list": [ { "evidence": "The data demonstrated that eight genes associated with ApoE were differentially expressed, with six of these upregulated and two downregulated. Functionally, these genes were involved in the JAK-STAT cascade, acute-phase response, acute inflammatory response, and the steroid hormone response. Among these ApoE-associated genes, expression of the signal transducer and activator of transcription 2 (STAT2) and STAT3 transcription factors was upregulated. To the best of our knowledge, this is the first study to demonstrate the network of ApoE-related genes and transcription factors in gastric cancer. Additional studies are required in order to confirm these data and to translate the results into the identification of clinical biomarkers and novel treatment strategies for gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression analysis of apolipoprotein E and its associated genes in gastric cancer.", "journal": "Oncology letters", "authors": "Shi X, Xu J, Wang J, Cui M, Gao Y, Niu H, Jin H", "date": "2015-12-02", "evidence": [], "reference": [ { "id": "26622669", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26622669" } ] } ], "biomarker_canonical_id": "AN4223", "collision": 1 }, { "biomarker_id": "AN4224-1", "biomarker_component": [ { "biomarker": "increased DSC2 level", "assessed_biomarker_entity": { "recommended_name": "Desmocollin-2", "synonyms": [ { "synonym": "Cadherin family member 2" }, { "synonym": "Desmocollin-3" }, { "synonym": "Desmosomal glycoprotein II" }, { "synonym": "Desmosomal glycoprotein III" } ] }, "assessed_biomarker_entity_id": "UPKB:Q02487", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "20527021", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20527021", "evidence_list": [ { "evidence": "Gastric cancer (GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue, and especially on the cell membrane, will be useful molecular markers for diagnosis and may also be good therapeutic targets. To identify genes that encode transmembrane proteins present in GC, we generated Escherichia coli ampicillin secretion trap (CAST) libraries from two GC cell lines and normal stomach. By sequencing 4320 colonies from CAST libraries, we identified 30 candidate genes that encode transmembrane proteins present in GC. Quantitative reverse transcription-polymerase chain reaction analysis of these candidates revealed that ZDHHC14, BST2, DRAM2, and DSC2 were expressed much more highly in GC than in 14 kinds of normal tissues. Among these, DSC2 encodes desmocollin 2, which is one of three known desmocollins. Immunohistochemical analysis demonstrated that 22 (28%) of 80 GC cases were positive for desmocollin 2, and desmocollin 2 expression was observed frequently in GC with the intestinal mucin phenotype. Furthermore, desmocollin 2 expression was correlated with CDX2 expression. These results suggest that expression of desmocollin 2, induced by CDX2, may be a key regulator for GC with the intestinal mucin phenotype. Our results provide a list of genes that have high potential as a diagnostic and therapeutic target for GC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "20527021", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20527021", "evidence_list": [ { "evidence": "Gastric cancer (GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue, and especially on the cell membrane, will be useful molecular markers for diagnosis and may also be good therapeutic targets. To identify genes that encode transmembrane proteins present in GC, we generated Escherichia coli ampicillin secretion trap (CAST) libraries from two GC cell lines and normal stomach. By sequencing 4320 colonies from CAST libraries, we identified 30 candidate genes that encode transmembrane proteins present in GC. Quantitative reverse transcription-polymerase chain reaction analysis of these candidates revealed that ZDHHC14, BST2, DRAM2, and DSC2 were expressed much more highly in GC than in 14 kinds of normal tissues. Among these, DSC2 encodes desmocollin 2, which is one of three known desmocollins. Immunohistochemical analysis demonstrated that 22 (28%) of 80 GC cases were positive for desmocollin 2, and desmocollin 2 expression was observed frequently in GC with the intestinal mucin phenotype. Furthermore, desmocollin 2 expression was correlated with CDX2 expression. These results suggest that expression of desmocollin 2, induced by CDX2, may be a key regulator for GC with the intestinal mucin phenotype. Our results provide a list of genes that have high potential as a diagnostic and therapeutic target for GC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Search for transmembrane protein in gastric cancer by the Escherichia coli ampicillin secretion trap: expression of DSC2 in gastric cancer with intestinal phenotype.", "journal": "The Journal of pathology", "authors": "Anami K, Oue N, Noguchi T, Sakamoto N, Sentani K, Hayashi T, Hinoi T, Okajima M, Graff JM, Yasui W", "date": "2010-06-09", "evidence": [], "reference": [ { "id": "20527021", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20527021" } ] } ], "biomarker_canonical_id": "AN4224", "collision": 1 }, { "biomarker_id": "AA4992-1", "biomarker_component": [ { "biomarker": "increased HOXA10 level", "assessed_biomarker_entity": { "recommended_name": "Homeobox protein HOXA10", "synonyms": [ { "synonym": "Homeobox protein Hox-1.8" }, { "synonym": "Homeobox protein Hox-1H" }, { "synonym": "PL" } ] }, "assessed_biomarker_entity_id": "UPKB:P31260", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "31406476", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31406476", "evidence_list": [ { "evidence": "HOXA10 expression was obviously increased in gastric cancer tissues and cells when compared with the normal gastric tissue samples and cells. Upregulation of HOXA10 significantly enhanced cell proliferation, cloning formation and tumorigenesis abilities and reduced cell apoptosis in gastric cancer, and promoted the activation of JAK1/STAT3 signaling." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "31406476", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31406476", "evidence_list": [ { "evidence": "HOXA10 expression was obviously increased in gastric cancer tissues and cells when compared with the normal gastric tissue samples and cells. Upregulation of HOXA10 significantly enhanced cell proliferation, cloning formation and tumorigenesis abilities and reduced cell apoptosis in gastric cancer, and promoted the activation of JAK1/STAT3 signaling." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway.", "journal": "Cancer management and research", "authors": "Chen W, Wu G, Zhu Y, Zhang W, Zhang H, Zhou Y, Sun P", "date": "2019-08-14", "evidence": [], "reference": [ { "id": "31406476", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31406476" } ] } ], "biomarker_canonical_id": "AA4992", "collision": 1 }, { "biomarker_id": "AN4225-1", "biomarker_component": [ { "biomarker": "decreased OLFM4 level", "assessed_biomarker_entity": { "recommended_name": "Olfactomedin-4", "synonyms": [ { "synonym": "OLM4" }, { "synonym": "Antiapoptotic protein GW112" }, { "synonym": "G-CSF-stimulated clone 1 protein" }, { "synonym": "hGC-1" }, { "synonym": "hOLfD" } ] }, "assessed_biomarker_entity_id": "UPKB:Q6UX06", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "22471589", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22471589", "evidence_list": [ { "evidence": "Our study suggests that depletion of OLFM4 significantly inhibits tumorigenicity of the gastric cancer SGC-7901 and MKN45 cells. Blocking OLFM4 expression can sensitize gastric cancer cells to H2O2 or TNF alpha treatment by increasing caspase-3 dependent apoptosis. The elimination of OLFM4 protein by RNA interference in SGC-7901 and MKN45 cells significantly inhibits tumorigenicity both in vitro and in vivo by induction of cell G1 arrest (all P < 0.01). OLFM4 knockdown did not trigger obvious cell apoptosis but increased H2O2 or TNF alpha-induced apoptosis and caspase-3 activity (all P < 0.01)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "22471589", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22471589", "evidence_list": [ { "evidence": "Our study suggests that depletion of OLFM4 significantly inhibits tumorigenicity of the gastric cancer SGC-7901 and MKN45 cells. Blocking OLFM4 expression can sensitize gastric cancer cells to H2O2 or TNF alpha treatment by increasing caspase-3 dependent apoptosis. The elimination of OLFM4 protein by RNA interference in SGC-7901 and MKN45 cells significantly inhibits tumorigenicity both in vitro and in vivo by induction of cell G1 arrest (all P < 0.01). OLFM4 knockdown did not trigger obvious cell apoptosis but increased H2O2 or TNF alpha-induced apoptosis and caspase-3 activity (all P < 0.01)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells.", "journal": "Journal of biomedical science", "authors": "Liu RH, Yang MH, Xiang H, Bao LM, Yang HA, Yue LW, Jiang X, Ang N, Wu LY, Huang Y", "date": "2012-04-05", "evidence": [], "reference": [ { "id": "22471589", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22471589" } ] } ], "biomarker_canonical_id": "AN4225", "collision": 1 }, { "biomarker_id": "AA4994-1", "biomarker_component": [ { "biomarker": "increased CDH17 level", "assessed_biomarker_entity": { "recommended_name": "Cadherin-17", "synonyms": [ { "synonym": "Intestinal peptide-associated transporter HPT-1" }, { "synonym": "Liver-intestine cadherin" }, { "synonym": "LI-cadherin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12864", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "20398667", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20398667", "evidence_list": [ { "evidence": "Expression of CDH17 or MUC13 correlated with patient survival in the test and validation sets. Multivariate analysis showed that CDH17 was an independent prognostic factor in patients with stage I or node-negative disease. Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "20398667", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20398667", "evidence_list": [ { "evidence": "Expression of CDH17 or MUC13 correlated with patient survival in the test and validation sets. Multivariate analysis showed that CDH17 was an independent prognostic factor in patients with stage I or node-negative disease. Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer.", "journal": "Gastroenterology", "authors": "Lee HJ, Nam KT, Park HS, Kim MA, Lafleur BJ, Aburatani H, Yang HK, Kim WH, Goldenring JR", "date": "2010-04-20", "evidence": [], "reference": [ { "id": "20398667", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20398667" } ] } ], "biomarker_canonical_id": "AA4994", "collision": 1 }, { "biomarker_id": "AA4995-1", "biomarker_component": [ { "biomarker": "increased PVT1 level", "assessed_biomarker_entity": { "recommended_name": "Plasmacytoma variant translocation 1", "synonyms": [] }, "assessed_biomarker_entity_id": "RNAC:URS0000D3E92F", "assessed_entity_type": "RNA", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "31966056", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31966056", "evidence_list": [ { "evidence": "Compared with paracancerous tissues, the expression of PVT1 and miR-125 was significantly increased in gastric cancer tissues. There were no significant differences in the expression level of PVT1 between gastric cancer patients of different genders and ages. The higher the gastric cancer staging was, the more obvious the expression level of PVT1 in the tissues of patients with gastric cancer was, and the more obvious the expression of PVT1 in the tissues of patients with gastric lymph node metastasis was." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "31966056", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31966056", "evidence_list": [ { "evidence": "Compared with paracancerous tissues, the expression of PVT1 and miR-125 was significantly increased in gastric cancer tissues. There were no significant differences in the expression level of PVT1 between gastric cancer patients of different genders and ages. The higher the gastric cancer staging was, the more obvious the expression level of PVT1 in the tissues of patients with gastric cancer was, and the more obvious the expression of PVT1 in the tissues of patients with gastric lymph node metastasis was." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells.", "journal": "Oncology letters", "authors": "Niu J, Song X, Zhang X", "date": "2020-01-23", "evidence": [], "reference": [ { "id": "31966056", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31966056" } ] } ], "biomarker_canonical_id": "AA4995", "collision": 1 }, { "biomarker_id": "AA4996-1", "biomarker_component": [ { "biomarker": "decreased PRMT1 level", "assessed_biomarker_entity": { "recommended_name": "Protein arginine methyltransferase-1", "synonyms": [ { "synonym": "Histone-arginine N-methyltransferase PRMT1" }, { "synonym": "Interferon receptor 1-bound protein 4" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99873", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31655611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31655611", "evidence_list": [ { "evidence": "Nuclear PRMT1 IHC expression was seen in all samples of the renal parenchyma used as a positive control. PRMT1 expression together with low-nuclear tumor grade and stage were significantly associated with better cancer-specific survival (p = 0.029). Patients who died of clear cell Renal Cell Carcinoma (ccRCC) showed homogenous loss of PRMT1 in 44.7%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "33859753", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33859753", "evidence_list": [ { "evidence": "Taken together, our study revealed a PRMT1-dependent epigenetic mechanism in the control of clear cell renal cell carcinoma (ccRCC) tumor growth and drug resistance, indicating PRMT1 may serve as a promising target for therapeutic intervention in ccRCC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31655611", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31655611", "evidence_list": [ { "evidence": "Nuclear PRMT1 IHC expression was seen in all samples of the renal parenchyma used as a positive control. PRMT1 expression together with low-nuclear tumor grade and stage were significantly associated with better cancer-specific survival (p = 0.029). Patients who died of clear cell Renal Cell Carcinoma (ccRCC) showed homogenous loss of PRMT1 in 44.7%." } ], "tags": [ { "tag": "condition" } ] }, { "id": "33859753", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33859753", "evidence_list": [ { "evidence": "Taken together, our study revealed a PRMT1-dependent epigenetic mechanism in the control of clear cell renal cell carcinoma (ccRCC) tumor growth and drug resistance, indicating PRMT1 may serve as a promising target for therapeutic intervention in ccRCC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.", "journal": "Diagnostic pathology", "authors": "Filipovi\u0107 J, Bosi\u0107 M, \u0106irovi\u0107 S, \u017divoti\u0107 M, Dun\u0111erovi\u0107 D, \u0110or\u0111evi\u0107 D, \u017divkovi\u0107-Peri\u0161i\u0107 S, Lipkovski A, Markovi\u0107-Lipkovski J", "date": "2019-10-28", "evidence": [], "reference": [ { "id": "31655611", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31655611" } ] }, { "title": "PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.", "journal": "Theranostics", "authors": "Wang J, Wang C, Xu P, Li X, Lu Y, Jin D, Yin X, Jiang H, Huang J, Xiong H, Ye F, Jin J, Chen Y, Xie Y, Chen Z, Ding H, Zhang H, Liu R, Jiang H, Chen K, Yao Z, Luo C, Huang Y, Zhang Y, Zhang J", "date": "2021-04-17", "evidence": [], "reference": [ { "id": "33859753", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33859753" } ] } ], "biomarker_canonical_id": "AA4996", "collision": 1 }, { "biomarker_id": "AA4997-1", "biomarker_component": [ { "biomarker": "increased NUPR1 level", "assessed_biomarker_entity": { "recommended_name": "Nuclear protein 1", "synonyms": [ { "synonym": "Candidate of metastasis 1" }, { "synonym": "Protein p8" } ] }, "assessed_biomarker_entity_id": "UPKB:O60356", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "34030133", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34030133", "evidence_list": [ { "evidence": "NUPR1 mRNA levels were significantly increased in ccRCC cells and cancer tissues compared with HK-2 cells (human renal cortex/proximal tubular epithelial cells) and adjacent normal kidney tissues. High NUPR1 mRNA level in primary tumors was correlated with poor overall survival (OS) and disease-free survival (DFS)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "27451286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27451286", "evidence_list": [ { "evidence": "Finally, immunohistochemical analysis revealed strong expression of NUPR1 in the nuclei of renal proximal tubules of injured human kidney allografts, but not in those of stable allografts. Taken together, these results suggest that epithelial expression of NUPR1 has a protective role in response to injury after renal transplant and, presumably, in other forms of acute tubular damage." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "34030133", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34030133", "evidence_list": [ { "evidence": "NUPR1 mRNA levels were significantly increased in ccRCC cells and cancer tissues compared with HK-2 cells (human renal cortex/proximal tubular epithelial cells) and adjacent normal kidney tissues. High NUPR1 mRNA level in primary tumors was correlated with poor overall survival (OS) and disease-free survival (DFS)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "27451286", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27451286", "evidence_list": [ { "evidence": "Finally, immunohistochemical analysis revealed strong expression of NUPR1 in the nuclei of renal proximal tubules of injured human kidney allografts, but not in those of stable allografts. Taken together, these results suggest that epithelial expression of NUPR1 has a protective role in response to injury after renal transplant and, presumably, in other forms of acute tubular damage." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.", "journal": "Aging", "authors": "He W, Cheng F, Zheng B, Wang J, Zhao G, Yao Z, Zhang T", "date": "2021-05-25", "evidence": [], "reference": [ { "id": "34030133", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34030133" } ] }, { "title": "Stress Response Gene Nupr1 Alleviates Cyclosporin A Nephrotoxicity In Vivo.", "journal": "Journal of the American Society of Nephrology : JASN", "authors": "Galichon P, Bataille A, Vandermeersch S, Wetzstein M, Xu-Dubois YC, Legouis D, Hertig A, Buob D, Placier S, Big\u00e9 N, Lefevre G, Jouanneau C, Martin C, Iovanna JL, Rondeau E", "date": "2016-07-28", "evidence": [], "reference": [ { "id": "27451286", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27451286" } ] } ], "biomarker_canonical_id": "AA4997", "collision": 1 }, { "biomarker_id": "AA4998-1", "biomarker_component": [ { "biomarker": "increased DKC1 level", "assessed_biomarker_entity": { "recommended_name": "H/ACA ribonucleoprotein complex subunit", "synonyms": [ { "synonym": "CBF5 homolog" }, { "synonym": "Dyskerin" }, { "synonym": "Nopp140-associated protein of 57 kDa" }, { "synonym": "Nucleolar protein NAP57" }, { "synonym": "Nucleolar protein family A member 4" }, { "synonym": "snoRNP protein DKC1" } ] }, "assessed_biomarker_entity_id": "UPKB:O60832", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "29901172", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29901172", "evidence_list": [ { "evidence": "High DKC1 expression was detected in 61.3% ccRCC tissues and 34.7% paracancerous tissues. ccRCC patients with high DKC1 expression were correlated with greater unfavorable 5-year overall and disease-specific survival than the rest of the patients with low DKC1 expression (P<0.001 and P<0.001, respectively)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "29901172", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29901172", "evidence_list": [ { "evidence": "High DKC1 expression was detected in 61.3% ccRCC tissues and 34.7% paracancerous tissues. ccRCC patients with high DKC1 expression were correlated with greater unfavorable 5-year overall and disease-specific survival than the rest of the patients with low DKC1 expression (P<0.001 and P<0.001, respectively)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF\u2011\u03baB pathway.", "journal": "Oncology reports", "authors": "Zhang M, Pan Y, Jiang R, Hou P, Shan H, Chen F, Jiang T, Bai J, Zheng J", "date": "2018-06-15", "evidence": [], "reference": [ { "id": "29901172", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29901172" } ] } ], "biomarker_canonical_id": "AA4998", "collision": 1 }, { "biomarker_id": "AA4999-1", "biomarker_component": [ { "biomarker": "increased SCARB1 level", "assessed_biomarker_entity": { "recommended_name": "Scavenger receptor class B member 1", "synonyms": [ { "synonym": "SRB1" }, { "synonym": "CD36 and LIMPII analogous 1" }, { "synonym": "CLA-1" }, { "synonym": "CD36 antigen-like 1" }, { "synonym": "Collagen type I receptor, thrombospondin receptor-like 1" }, { "synonym": "SR-BI" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WTV0", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "29357836", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29357836", "evidence_list": [ { "evidence": "The expression of SR-BI was significantly increased in ccRCC tissues compared with normal matched tissues. Patients with tumors that expressed high levels of SR-BI had a shorter PFS survival (P = 0.0062)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "26936883", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26936883", "evidence_list": [ { "evidence": "Our findings demonstrate that hSR-BII, and to a lesser extent hSR-BI, significantly increase LPS-induced inflammation and contribute to LPS-induced tissue injury in the liver and kidney, two major organs susceptible to LPS toxicity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "29357836", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29357836", "evidence_list": [ { "evidence": "The expression of SR-BI was significantly increased in ccRCC tissues compared with normal matched tissues. Patients with tumors that expressed high levels of SR-BI had a shorter PFS survival (P = 0.0062)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "26936883", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26936883", "evidence_list": [ { "evidence": "Our findings demonstrate that hSR-BII, and to a lesser extent hSR-BI, significantly increase LPS-induced inflammation and contribute to LPS-induced tissue injury in the liver and kidney, two major organs susceptible to LPS toxicity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma.", "journal": "BMC cancer", "authors": "Xu GH, Lou N, Shi HC, Xu YC, Ruan HL, Xiao W, Liu L, Li X, Xiao HB, Qiu B, Bao L, Yuan CF, Zhou YL, Hu WJ, Chen K, Yang HM, Zhang XP", "date": "2018-01-24", "evidence": [], "reference": [ { "id": "29357836", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29357836" } ] }, { "title": "Human SR-BI and SR-BII Potentiate Lipopolysaccharide-Induced Inflammation and Acute Liver and Kidney Injury in Mice.", "journal": "Journal of immunology (Baltimore, Md. : 1950)", "authors": "Baranova IN, Souza AC, Bocharov AV, Vishnyakova TG, Hu X, Vaisman BL, Amar MJ, Chen Z, Kost Y, Remaley AT, Patterson AP, Yuen PS, Star RA, Eggerman TL", "date": "2016-03-05", "evidence": [], "reference": [ { "id": "26936883", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26936883" } ] } ], "biomarker_canonical_id": "AA4999", "collision": 1 }, { "biomarker_id": "AA5000-1", "biomarker_component": [ { "biomarker": "decreased QKI level", "assessed_biomarker_entity": { "recommended_name": "Protein quaking", "synonyms": [ { "synonym": "Protein quaking" }, { "synonym": "Hqk" }, { "synonym": "HqkI" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96PU8", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "27767378", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27767378", "evidence_list": [ { "evidence": "The relative expression level of QKI-5 was significantly lower in the tumor tissues than it was in their noncancerous counterparts (P < 0.01). Decreased QKI-5 expression significantly correlated with poorer overall survival in ccRCC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "34804823", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34804823", "evidence_list": [ { "evidence": "Our results revealed that downregulation of QKI-5 by miR-200c attenuated KIRC migration and invasion via the EMT process, indicating that QKI-5 may be a potential therapeutic target and a key indicator of kidney renal clear cell carcinoma (KIRC) progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "27767378", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27767378", "evidence_list": [ { "evidence": "The relative expression level of QKI-5 was significantly lower in the tumor tissues than it was in their noncancerous counterparts (P < 0.01). Decreased QKI-5 expression significantly correlated with poorer overall survival in ccRCC patients." } ], "tags": [ { "tag": "condition" } ] }, { "id": "34804823", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34804823", "evidence_list": [ { "evidence": "Our results revealed that downregulation of QKI-5 by miR-200c attenuated KIRC migration and invasion via the EMT process, indicating that QKI-5 may be a potential therapeutic target and a key indicator of kidney renal clear cell carcinoma (KIRC) progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA.", "journal": "Cell cycle (Georgetown, Tex.)", "authors": "Zhang RL, Yang JP, Peng LX, Zheng LS, Xie P, Wang MY, Cao Y, Zhang ZL, Zhou FJ, Qian CN, Bao YX", "date": "2016-10-22", "evidence": [], "reference": [ { "id": "27767378", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27767378" } ] }, { "title": "Quaking I-5 protein inhibits invasion and migration of kidney renal clear cell carcinoma via inhibiting epithelial-mesenchymal transition suppression through the regulation of microRNA 200c.", "journal": "Translational andrology and urology", "authors": "Zhang R, Wang W, Aimudula A, Lu S, Lu P, Aihaiti R, Bao Y", "date": "2021-11-23", "evidence": [], "reference": [ { "id": "34804823", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34804823" } ] } ], "biomarker_canonical_id": "AA5000", "collision": 1 }, { "biomarker_id": "AA5001-1", "biomarker_component": [ { "biomarker": "decreased SORBS2 level", "assessed_biomarker_entity": { "recommended_name": "Sorbin and SH3 domain-containing protein 2", "synonyms": [ { "synonym": "Arg-binding protein 2" }, { "synonym": "ArgBP2" }, { "synonym": "Arg/Abl-interacting protein 2" }, { "synonym": "Sorbin" } ] }, "assessed_biomarker_entity_id": "UPKB:O94875", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "33311452", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33311452", "evidence_list": [ { "evidence": "There was significantly lower expression of SORBS2 protein in metastatic tissues than that in primary tissues and normal tissues. Kaplan-Meier survival analysis indicated that patients with low SORBS2 had a poorer overall survival than those belonging to high SORBS2 levels in ccRCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32905431", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32905431", "evidence_list": [ { "evidence": "KCNQ1OT1 and SORBS2 were elevated in DN. Both knockdown of KCNQ1OT1 and silencing of SORBS2 restrained proliferation and fibrosis and induced apoptosis in diabetic nephropathy (DN) cells." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "33311452", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33311452", "evidence_list": [ { "evidence": "There was significantly lower expression of SORBS2 protein in metastatic tissues than that in primary tissues and normal tissues. Kaplan-Meier survival analysis indicated that patients with low SORBS2 had a poorer overall survival than those belonging to high SORBS2 levels in ccRCC." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32905431", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32905431", "evidence_list": [ { "evidence": "KCNQ1OT1 and SORBS2 were elevated in DN. Both knockdown of KCNQ1OT1 and silencing of SORBS2 restrained proliferation and fibrosis and induced apoptosis in diabetic nephropathy (DN) cells." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "RNA-binding protein SORBS2 suppresses clear cell renal cell carcinoma metastasis by enhancing MTUS1 mRNA stability.", "journal": "Cell death & disease", "authors": "Lv Q, Dong F, Zhou Y, Cai Z, Wang G", "date": "2020-12-15", "evidence": [], "reference": [ { "id": "33311452", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33311452" } ] }, { "title": "LncRNA KCNQ1OT1 affects cell proliferation, apoptosis and fibrosis through regulating miR-18b-5p/SORBS2 axis and NF-\u0138B pathway in diabetic nephropathy.", "journal": "Diabetology & metabolic syndrome", "authors": "Jie R, Zhu P, Zhong J, Zhang Y, Wu H", "date": "2020-09-10", "evidence": [], "reference": [ { "id": "32905431", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32905431" } ] } ], "biomarker_canonical_id": "AA5001", "collision": 1 }, { "biomarker_id": "AA5002-1", "biomarker_component": [ { "biomarker": "increased IGF2BP3 level", "assessed_biomarker_entity": { "recommended_name": "Insulin-like growth factor 2 mRNA-binding protein 3", "synonyms": [ { "synonym": "IGF2 mRNA-binding protein 3" }, { "synonym": "IMP-3" }, { "synonym": "IGF-II mRNA-binding protein 3" }, { "synonym": "KH domain-containing protein overexpressed in cancer" }, { "synonym": "hKOC" }, { "synonym": "VICKZ family member 3" } ] }, "assessed_biomarker_entity_id": "UPKB:O00425", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "30650187", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30650187", "evidence_list": [ { "evidence": "IMP3 concentration was significantly elevated in plasma samples of tumor patients compared to healthy controls (p=0.015). IMP3 mRNA expression was significantly higher in Renal Cell Carcinoma (RCC) tissues compared to tumor neighboring normal tissues (p=0.001). high IMP3 plasma concentration was an independent risk factor of Overall Survival, OS, (p=0.002) and DSS (p=0.039) and elevated IMP3 mRNA expression levels were independently associated with poor DSS (p=0.047)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "25919292", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25919292", "evidence_list": [ { "evidence": "IMP3 promotes RCC cell migration and invasion by activation of NF-kB pathway. IMP3 is validated to be an independent prognostic marker for localized CCRCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "30650187", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30650187", "evidence_list": [ { "evidence": "IMP3 concentration was significantly elevated in plasma samples of tumor patients compared to healthy controls (p=0.015). IMP3 mRNA expression was significantly higher in Renal Cell Carcinoma (RCC) tissues compared to tumor neighboring normal tissues (p=0.001). high IMP3 plasma concentration was an independent risk factor of Overall Survival, OS, (p=0.002) and DSS (p=0.039) and elevated IMP3 mRNA expression levels were independently associated with poor DSS (p=0.047)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "25919292", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25919292", "evidence_list": [ { "evidence": "IMP3 promotes RCC cell migration and invasion by activation of NF-kB pathway. IMP3 is validated to be an independent prognostic marker for localized CCRCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.", "journal": "International journal of cancer", "authors": "Tschirdewahn S, Panic A, P\u00fcllen L, Harke NN, Hadaschik B, Riesz P, Horv\u00e1th A, Szalontai J, Nyir\u00e1dy P, Baba HA, Reis H, Szarvas T", "date": "2019-01-17", "evidence": [], "reference": [ { "id": "30650187", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30650187" } ] }, { "title": "Enhanced IMP3 Expression Activates NF-\u043aB Pathway and Promotes Renal Cell Carcinoma Progression.", "journal": "PloS one", "authors": "Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L, Aydin H, Elson P, Zhou M, He H, Zhang H", "date": "2015-04-29", "evidence": [], "reference": [ { "id": "25919292", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25919292" } ] } ], "biomarker_canonical_id": "AA5002", "collision": 1 }, { "biomarker_id": "AA5003-1", "biomarker_component": [ { "biomarker": "increased APOC1 level", "assessed_biomarker_entity": { "recommended_name": "Apolipoprotein C-I", "synonyms": [ { "synonym": "Apo-CI" }, { "synonym": "ApoC-I" }, { "synonym": "Apolipoprotein C1" } ] }, "assessed_biomarker_entity_id": "UPKB:P02654", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "31555694", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31555694", "evidence_list": [ { "evidence": "It was firstly found that concentration of APOC1 in serum was significantly higher in GC than that in control. Expression of APOC1 protein was also higher in GC than that in adjacent issues of GC and normal tissues using tissues array by immunohistochemistry." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "31555694", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31555694", "evidence_list": [ { "evidence": "It was firstly found that concentration of APOC1 in serum was significantly higher in GC than that in control. Expression of APOC1 protein was also higher in GC than that in adjacent issues of GC and normal tissues using tissues array by immunohistochemistry." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer.", "journal": "Annals of translational medicine", "authors": "Yi J, Ren L, Wu J, Li W, Zheng X, Du G, Wang J", "date": "2019-09-27", "evidence": [], "reference": [ { "id": "31555694", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31555694" } ] } ], "biomarker_canonical_id": "AA5003", "collision": 1 }, { "biomarker_id": "AN4226-1", "biomarker_component": [ { "biomarker": "decreased ATP4B level", "assessed_biomarker_entity": { "recommended_name": "Potassium-transporting ATPase subunit beta", "synonyms": [ { "synonym": "Gastric H(+)/K(+) ATPase subunit beta" }, { "synonym": "Proton pump beta chain" } ] }, "assessed_biomarker_entity_id": "UPKB:P51164", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "28281974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28281974", "evidence_list": [ { "evidence": "ATP4B expression was decreased in human GC tissues and cell lines associated with DNA hypermethylation and histone hypoacetylation of histone H3 lysine 9 at its intragenic region close to the transcriptional start site." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "28281974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28281974", "evidence_list": [ { "evidence": "ATP4B expression was decreased in human GC tissues and cell lines associated with DNA hypermethylation and histone hypoacetylation of histone H3 lysine 9 at its intragenic region close to the transcriptional start site." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Silencing of ATP4B of ATPase H", "journal": "Oncology research", "authors": "Lin S, Lin B, Wang X, Pan Y, Xu Q, He JS, Gong W, Xing R, He Y, Guo L, Lu Y, Wang JM, Huang J", "date": "2017-03-11", "evidence": [], "reference": [ { "id": "28281974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28281974" } ] } ], "biomarker_canonical_id": "AN4226", "collision": 1 }, { "biomarker_id": "AA5005-1", "biomarker_component": [ { "biomarker": "increased DDX5 level", "assessed_biomarker_entity": { "recommended_name": "Probable ATP-dependent RNA helicase", "synonyms": [ { "synonym": "DEAD box protein 5" }, { "synonym": "RNA helicase p68" } ] }, "assessed_biomarker_entity_id": "UPKB:P17844", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "28216662", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28216662", "evidence_list": [ { "evidence": "In this study, we observed that DDX5 was significantly up-regulated in gastric cancer tissues compared with the paired adjacent normal tissues. The expression of DDX5 correlated strongly with Ki67 index and pathological stage of gastric cancer. In vitro and in vivo studies suggested that knockdown of DDX5 inhibited gastric cancer cell proliferation, colony formation and xenografts growth, whereas ectopic expression of DDX5 promoted these cellular functions." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "28216662", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28216662", "evidence_list": [ { "evidence": "In this study, we observed that DDX5 was significantly up-regulated in gastric cancer tissues compared with the paired adjacent normal tissues. The expression of DDX5 correlated strongly with Ki67 index and pathological stage of gastric cancer. In vitro and in vivo studies suggested that knockdown of DDX5 inhibited gastric cancer cell proliferation, colony formation and xenografts growth, whereas ectopic expression of DDX5 promoted these cellular functions." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway.", "journal": "Scientific reports", "authors": "Du C, Li DQ, Li N, Chen L, Li SS, Yang Y, Hou MX, Xie MJ, Zheng ZD", "date": "2017-02-22", "evidence": [], "reference": [ { "id": "28216662", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28216662" } ] } ], "biomarker_canonical_id": "AA5005", "collision": 1 }, { "biomarker_id": "AN4227-1", "biomarker_component": [ { "biomarker": "increased mutation", "assessed_biomarker_entity": { "recommended_name": "Low-density lipoprotein receptor-related protein 1B gene mutation", "synonyms": [ { "synonym": "LRP-1B" }, { "synonym": "Low-density lipoprotein receptor-related protein-deleted in tumor" }, { "synonym": "LRP-DIT" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZR2", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "34603481", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34603481", "evidence_list": [ { "evidence": "LRP1B is one of the top 10 genes with high gene mutation frequency in gastric cancer. The mutation status of LRP1B in gastric cancer patients was significantly correlated with age and TP53 and MUC16 mutation status. The result of ROC curve analysis revealed that the mutation status of LRP1B could be considered as an indicator of the degree of TMB in patients with gastric cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "34603481", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34603481", "evidence_list": [ { "evidence": "LRP1B is one of the top 10 genes with high gene mutation frequency in gastric cancer. The mutation status of LRP1B in gastric cancer patients was significantly correlated with age and TP53 and MUC16 mutation status. The result of ROC curve analysis revealed that the mutation status of LRP1B could be considered as an indicator of the degree of TMB in patients with gastric cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Correlation between ", "journal": "Computational and mathematical methods in medicine", "authors": "Hu S, Zhao X, Qian F, Jin C, Hou K", "date": "2021-10-05", "evidence": [], "reference": [ { "id": "34603481", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34603481" } ] } ], "biomarker_canonical_id": "AN4227", "collision": 1 }, { "biomarker_id": "AA5007-1", "biomarker_component": [ { "biomarker": "increased GPX1 level", "assessed_biomarker_entity": { "recommended_name": "Glutathione peroxidase 1", "synonyms": [ { "synonym": "GPx-1" }, { "synonym": "GSHPx-1" }, { "synonym": "Cellular glutathione peroxidase" } ] }, "assessed_biomarker_entity_id": "UPKB:P07203", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "LP15611-4" } ], "evidence_source": [ { "id": "31844035", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31844035", "evidence_list": [ { "evidence": "Bioinformatics analysis found that high expression of GPX1 was positively correlated with tumor stage, distant metastasis and lymphatic metastasis. ROC curve analysis found that high expression of GPX1 could effectively distinguish ccRCC from normal individuals." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31844035", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31844035", "evidence_list": [ { "evidence": "Bioinformatics analysis found that high expression of GPX1 was positively correlated with tumor stage, distant metastasis and lymphatic metastasis. ROC curve analysis found that high expression of GPX1 could effectively distinguish ccRCC from normal individuals." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "GPX1, a biomarker for the diagnosis and prognosis of kidney cancer, promotes the progression of kidney cancer.", "journal": "Aging", "authors": "Cheng Y, Xu T, Li S, Ruan H", "date": "2019-12-18", "evidence": [], "reference": [ { "id": "31844035", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31844035" } ] } ], "biomarker_canonical_id": "AA5007", "collision": 1 }, { "biomarker_id": "AA5008-1", "biomarker_component": [ { "biomarker": "increased SPAG9 level", "assessed_biomarker_entity": { "recommended_name": "C-Jun-amino-terminal kinase-interacting protein 4", "synonyms": [ { "synonym": "JIP-4" }, { "synonym": "JNK-interacting protein 4" }, { "synonym": "Cancer/testis antigen 89" }, { "synonym": "CT89" }, { "synonym": "Human lung cancer oncogene 6 protein" }, { "synonym": "HLC-6" }, { "synonym": "JNK-associated leucine-zipper protein" }, { "synonym": "JLP" }, { "synonym": "Mitogen-activated protein kinase 8-interacting protein 4" }, { "synonym": "Proliferation-inducing protein 6" }, { "synonym": "Protein highly expressed in testis" }, { "synonym": "PHET" }, { "synonym": "Sperm surface protein" }, { "synonym": "Sperm-associated antigen 9" }, { "synonym": "Sperm-specific protein" }, { "synonym": "Sunday driver 1" } ] }, "assessed_biomarker_entity_id": "UPKB:O60271", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "25033008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25033008", "evidence_list": [ { "evidence": "SPAG9 was upregulated in NMSC when compared with normal skin. In conclusion, SPAG9 is expressed in NMSC cases." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "25033008", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25033008", "evidence_list": [ { "evidence": "SPAG9 was upregulated in NMSC when compared with normal skin. In conclusion, SPAG9 is expressed in NMSC cases." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Immunohistochemical expression of sperm-associated antigen 9 in nonmelanoma skin cancer.", "journal": "The American Journal of dermatopathology", "authors": "Seleit I, Bakry OA, Samaka RM, Malak MA", "date": "2014-07-18", "evidence": [], "reference": [ { "id": "25033008", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25033008" } ] } ], "biomarker_canonical_id": "AA5008", "collision": 1 }, { "biomarker_id": "AN4228-1", "biomarker_component": [ { "biomarker": "decreased FGFR3 level", "assessed_biomarker_entity": { "recommended_name": "Fibroblast growth factor receptor 3", "synonyms": [ { "synonym": "FGFR-3" } ] }, "assessed_biomarker_entity_id": "UPKB: P22607", "assessed_entity_type": "protein", "specimen": [ { "name": "urinary bladder", "id": "UBERON:0001255", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001255", "loinc_code": "LP19706-8" } ], "evidence_source": [ { "id": "28927152", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28927152", "evidence_list": [ { "evidence": "Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P<0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "28927152", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28927152", "evidence_list": [ { "evidence": "Low FGFR3 expression level was associated with high-grade tumors and cancer progression (P=0.006 and P=0.001), whereas FGFR3 mutation status was not associated with cancer progression. Kaplan-Meier analysis revealed a similar result (log-rank, P<0.001). Multivariate analysis identified low FGFR3 expression level (odds ratio, 3.300; 95% confidence interval, 1.310-8.313; P=0.011) as an independent predictor of cancer progression." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Expression levels of ", "journal": "Oncology letters", "authors": "Kang HW, Kim YH, Jeong P, Park C, Kim WT, Ryu DH, Cha EJ, Ha YS, Kim TH, Kwon TG, Moon SK, Choi YH, Yun SJ, Kim WJ", "date": "2017-09-21", "evidence": [], "reference": [ { "id": "28927152", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/28927152" } ] } ], "biomarker_canonical_id": "AN4228", "collision": 1 }, { "biomarker_id": "AN4229-1", "biomarker_component": [ { "biomarker": "increased methylation", "assessed_biomarker_entity": { "recommended_name": "BarH-like 2 homeobox protein gene methylation", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NY43", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "27441821", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27441821", "evidence_list": [ { "evidence": "High levels of BARHL2 methylation were detected in three of seven GC cell lines; consistent with this, these cell lines expressed low levels of BARHL2. Treatment of these cell lines with 5-aza-2'-deoxycytidine restored BARHL2 expression. Levels of BARHL2 methylation in 18 normal and 14 atrophic gastritis samples were low irrespective of Helicobacter pylori infection. High levels of BARHL2 methylation were observed in gastric wash-derived DNA obtained from early GC patients before endoscopic resection (ER), but methylation was significantly lower after curative ER. Analysis using gastric juice derived exoDNA samples revealed that BARHL2 methylation yielded an area under the curve of 0.923 with 90% sensitivity and 100% specificity with respect to discriminating GC patients from non-GC controls." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "27441821", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27441821", "evidence_list": [ { "evidence": "High levels of BARHL2 methylation were detected in three of seven GC cell lines; consistent with this, these cell lines expressed low levels of BARHL2. Treatment of these cell lines with 5-aza-2'-deoxycytidine restored BARHL2 expression. Levels of BARHL2 methylation in 18 normal and 14 atrophic gastritis samples were low irrespective of Helicobacter pylori infection. High levels of BARHL2 methylation were observed in gastric wash-derived DNA obtained from early GC patients before endoscopic resection (ER), but methylation was significantly lower after curative ER. Analysis using gastric juice derived exoDNA samples revealed that BARHL2 methylation yielded an area under the curve of 0.923 with 90% sensitivity and 100% specificity with respect to discriminating GC patients from non-GC controls." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "BARHL2 Methylation Using Gastric Wash DNA or Gastric Juice Exosomal DNA is a Useful Marker For Early Detection of Gastric Cancer in an H. pylori-Independent Manner.", "journal": "Clinical and translational gastroenterology", "authors": "Yamamoto H, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Maehata T, Yasuda H, Itoh F", "date": "2016-07-22", "evidence": [], "reference": [ { "id": "27441821", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27441821" } ] } ], "biomarker_canonical_id": "AN4229", "collision": 1 }, { "biomarker_id": "AN4230-1", "biomarker_component": [ { "biomarker": "increased methylation", "assessed_biomarker_entity": { "recommended_name": "GDNF family receptor alpha-3 gene promoter methylation", "synonyms": [ { "synonym": "GDNF receptor alpha-3" }, { "synonym": "GDNFR-alpha-3" }, { "synonym": "GFR-alpha-3" } ] }, "assessed_biomarker_entity_id": "UPKB:O60609", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "26984265", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26984265", "evidence_list": [ { "evidence": "The different DNA methylation clusters of the tumors and normal tissue indicate that aberrant DNA methylation is a distinct feature of gastric cancer, although there is little difference in the overall, and low, methylation levels between the two tissue types. The GFRA3 promoter region showed marked hypermethylation in almost all tumors, and its correlation with survival and other clinicopathological parameters may have important prognostic significance." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "26984265", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26984265", "evidence_list": [ { "evidence": "The different DNA methylation clusters of the tumors and normal tissue indicate that aberrant DNA methylation is a distinct feature of gastric cancer, although there is little difference in the overall, and low, methylation levels between the two tissue types. The GFRA3 promoter region showed marked hypermethylation in almost all tumors, and its correlation with survival and other clinicopathological parameters may have important prognostic significance." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer.", "journal": "BMC cancer", "authors": "Eftang LL, Klajic J, Kristensen VN, Tost J, Esbensen QY, Blom GP, Bukholm IR, Bukholm G", "date": "2016-03-18", "evidence": [], "reference": [ { "id": "26984265", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26984265" } ] } ], "biomarker_canonical_id": "AN4230", "collision": 1 }, { "biomarker_id": "AN4231-1", "biomarker_component": [ { "biomarker": "decreased GXP3 level", "assessed_biomarker_entity": { "recommended_name": "Glutathione peroxidase 3", "synonyms": [ { "synonym": "GPx-3" }, { "synonym": "GSHPx-3" }, { "synonym": "Extracellular glutathione peroxidase" }, { "synonym": "Plasma glutathione peroxidase" }, { "synonym": "GPx-P" }, { "synonym": "GSHPx-P" } ] }, "assessed_biomarker_entity_id": "UPKB:P22352", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "" } ], "evidence_source": [ { "id": "23071548", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23071548", "evidence_list": [ { "evidence": "Downregulation or silencing of GPX3 was detected in 8 of 9 cancer cell lines, 83% (90/108) gastric cancers samples, as compared to non-tumor adjacent normal gastric samples (P<0.0001). Examination of GPX3 promoter demonstrated DNA hypermethylation (= 10% methylation level determined by Bisulfite Pyrosequencing) in 6 of 9 cancer cell lines and 60% of gastric cancer samples (P = 0.007). We also detected a significant loss of DNA copy number of GPX3 in gastric cancers (P<0.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "23071548", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23071548", "evidence_list": [ { "evidence": "Downregulation or silencing of GPX3 was detected in 8 of 9 cancer cell lines, 83% (90/108) gastric cancers samples, as compared to non-tumor adjacent normal gastric samples (P<0.0001). Examination of GPX3 promoter demonstrated DNA hypermethylation (= 10% methylation level determined by Bisulfite Pyrosequencing) in 6 of 9 cancer cell lines and 60% of gastric cancer samples (P = 0.007). We also detected a significant loss of DNA copy number of GPX3 in gastric cancers (P<0.001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas.", "journal": "PloS one", "authors": "Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W", "date": "2012-10-17", "evidence": [], "reference": [ { "id": "23071548", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/23071548" } ] } ], "biomarker_canonical_id": "AN4231", "collision": 1 }, { "biomarker_id": "AA5013-1", "biomarker_component": [ { "biomarker": "increased SNHG5 level", "assessed_biomarker_entity": { "recommended_name": "Long noncoding RNA SNHG5", "synonyms": [] }, "assessed_biomarker_entity_id": "RNAC:URS000075B42D", "assessed_entity_type": "RNA", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "32281285", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281285", "evidence_list": [ { "evidence": "SNHG5 expression was found to be remarkably increased in ccRCC samples." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "32194916", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32194916", "evidence_list": [ { "evidence": "SNHG5 expression levels were significantly increased in ccRCC tissues compared to those in non-tumor tissue. Inhibition of SNHG5 expression significantly reduced invasion ability and increased apoptosis rate of 786-O RCC cells infected with shR-NA-SNHG5." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32281285", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281285", "evidence_list": [ { "evidence": "SNHG5 expression was found to be remarkably increased in ccRCC samples." } ], "tags": [ { "tag": "condition" } ] }, { "id": "32194916", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32194916", "evidence_list": [ { "evidence": "SNHG5 expression levels were significantly increased in ccRCC tissues compared to those in non-tumor tissue. Inhibition of SNHG5 expression significantly reduced invasion ability and increased apoptosis rate of 786-O RCC cells infected with shR-NA-SNHG5." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The lncRNA SNHG5-mediated miR-205-5p downregulation contributes to the progression of clear cell renal cell carcinoma by targeting ZEB1.", "journal": "Cancer medicine", "authors": "Xiang W, Lv L, Zhou G, Wu W, Yuan J, Zhang C, Jiang G", "date": "2020-04-14", "evidence": [], "reference": [ { "id": "32281285", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32281285" } ] }, { "title": "Long non-coding RNA SNHG5 affects the invasion and apoptosis of renal cell carcinoma by regulating the miR-363-3p-Twist1 interaction.", "journal": "American journal of translational research", "authors": "Li WZ, Zou Y, Song ZY, Wei ZW, Chen G, Cai QL, Wang Z", "date": "2020-03-21", "evidence": [], "reference": [ { "id": "32194916", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32194916" } ] } ], "biomarker_canonical_id": "AA5013", "collision": 1 }, { "biomarker_id": "AN4232-1", "biomarker_component": [ { "biomarker": "BRACAnalysis CDx ovarian cancer germline BRCA1, BRCA2 mutations panel", "assessed_biomarker_entity": { "recommended_name": "BRCA1", "synonyms": [ { "synonym": "RING finger protein 53" }, { "synonym": "RING-type E3 ubiquitin transferase BRCA1" } ] }, "assessed_biomarker_entity_id": "UPKB:P38398", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21636-6" } ], "evidence_source": [ { "id": "P140020", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "P140020", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4232", "collision": 1 }, { "biomarker_id": "AN4233-1", "biomarker_component": [ { "biomarker": "BRACAnalysis CDx ovarian cancer germline BRCA1, BRCA2 mutations panel", "assessed_biomarker_entity": { "recommended_name": "BRCA2", "synonyms": [ { "synonym": "Fanconi anemia group D1 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P51587", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "21636-6" } ], "evidence_source": [ { "id": "P140020", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "P140020", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140020", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4233", "collision": 1 }, { "biomarker_id": "AN4234-1", "biomarker_component": [ { "biomarker": "Cologuard colorectal cancer KRAS, BMP3, NDRG4, HBB panel", "assessed_biomarker_entity": { "recommended_name": "KRAS", "synonyms": [ { "synonym": "K-Ras 2" }, { "synonym": "Ki-Ras" }, { "synonym": "c-K-ras" }, { "synonym": "c-Ki-ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01116", "assessed_entity_type": "protein", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "77354-9" } ], "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4234", "collision": 1 }, { "biomarker_id": "AN4235-1", "biomarker_component": [ { "biomarker": "Cologuard colorectal cancer KRAS, BMP3, NDRG4, HBB panel", "assessed_biomarker_entity": { "recommended_name": "BMP3", "synonyms": [ { "synonym": "BMP-3" }, { "synonym": "Bone morphogenetic protein 3A" }, { "synonym": "BMP-3A" }, { "synonym": "Osteogenin" } ] }, "assessed_biomarker_entity_id": "UPKB:P12645", "assessed_entity_type": "protein", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "77354-9" } ], "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4235", "collision": 1 }, { "biomarker_id": "AN4236-1", "biomarker_component": [ { "biomarker": "Cologuard colorectal cancer KRAS, BMP3, NDRG4, HBB panel", "assessed_biomarker_entity": { "recommended_name": "NDRG4", "synonyms": [ { "synonym": "Brain development-related molecule 1" }, { "synonym": "N-myc downstream-regulated gene 4 protein" }, { "synonym": "Vascular smooth muscle cell-associated protein 8" }, { "synonym": "SMAP-8" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9ULP0", "assessed_entity_type": "protein", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "77354-9" } ], "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4236", "collision": 1 }, { "biomarker_id": "AN4237-1", "biomarker_component": [ { "biomarker": "Cologuard colorectal cancer KRAS, BMP3, NDRG4, HBB panel", "assessed_biomarker_entity": { "recommended_name": "HBB", "synonyms": [ { "synonym": "Beta-globin" }, { "synonym": "Hemoglobin beta chain" } ] }, "assessed_biomarker_entity_id": "UPKB:P68871", "assessed_entity_type": "protein", "specimen": [ { "name": "feces", "id": "UBERON:0001988", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001988", "loinc_code": "77354-9" } ], "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P130017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017", "evidence_list": [ { "evidence": "Panel of identified gene and protein alterations in colorectal cancer to screen adults of either sex, 50 years or older, who are at typical average risk for CRC. The genes are KRAS (UPKB:P01116), BMP3 (UPKB:P12645), NDRG4 (UPKB:Q9ULP0), and the hemoglobin (HBB) protein." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4237", "collision": 1 }, { "biomarker_id": "AN4462-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Praxis colorectal cancer extended KRAS, NRAS mutations panel", "synonyms": [ { "synonym": "K-Ras 2" }, { "synonym": "Ki-Ras" }, { "synonym": "c-K-ras" }, { "synonym": "c-Ki-ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01116", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81420-2" } ], "evidence_source": [ { "id": "P160038", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160038", "evidence_list": [ { "evidence": "Panel of identified KRAS (UPKB:P01116) and NRAS (UPKB:P01111) gene predictive biomarkers (mutations) in colorectal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Praxis colorectal cancer extended KRAS, NRAS mutations panel", "synonyms": [ { "synonym": "Transforming protein N-Ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01111", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81420-2" } ], "evidence_source": [ { "id": "P160038", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160038", "evidence_list": [ { "evidence": "Panel of identified KRAS (UPKB:P01116) and NRAS (UPKB:P01111) gene predictive biomarkers (mutations) in colorectal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P160038", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160038", "evidence_list": [ { "evidence": "Panel of identified KRAS (UPKB:P01116) and NRAS (UPKB:P01111) gene predictive biomarkers (mutations) in colorectal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4462", "collision": 0 }, { "biomarker_id": "AN4463-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "FoundationFocus CDxBRCA ovarian cancer BRCA1, BRCA2 mutations panel", "synonyms": [ { "synonym": "RING finger protein 53" }, { "synonym": "RING-type E3 ubiquitin transferase BRCA1" } ] }, "assessed_biomarker_entity_id": "UPKB:P38398", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "94191-4" } ], "evidence_source": [ { "id": "P160018", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160018", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in ovarian cancer. The genes are BRCA1 (UPKB:P38398) and BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "FoundationFocus CDxBRCA ovarian cancer BRCA1, BRCA2 mutations panel", "synonyms": [ { "synonym": "Fanconi anemia group D1 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P51587", "assessed_entity_type": "protein", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "94191-4" } ], "evidence_source": [ { "id": "P160018", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160018", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in ovarian cancer. The genes are BRCA1 (UPKB:P38398) and BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "P160018", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160018", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in ovarian cancer. The genes are BRCA1 (UPKB:P38398) and BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4463", "collision": 0 }, { "biomarker_id": "AN4464-1", "biomarker_component": [ { "biomarker": "increased level", "assessed_biomarker_entity": { "recommended_name": "GeneSearch breast cancer breast lymph node MG, KRT19 expression panel", "synonyms": [ { "synonym": "Cytokeratin-19" }, { "synonym": "CK-19" }, { "synonym": "Keratin-19" }, { "synonym": "K19" } ] }, "assessed_biomarker_entity_id": "UPKB:P08727", "assessed_entity_type": "protein", "specimen": [ { "name": "lymph node", "id": "UBERON:0000029", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000029", "loinc_code": "" } ], "evidence_source": [ { "id": "P060017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P060017", "evidence_list": [ { "evidence": "Gene expression levels (measured by the Ct value determined when the fluorescent signal exceeds a pre-defined threshold limit. If the external controls are valid, then the Ct value for each gene marker in the patient sample is compared to marker-specific Ct cutoff values. Samples with Ct values less than or equal to one or both of the cutoff values for MG or CKi9 are considered positive. The Cutoff Ct values are as follows: MG < 31, CK19 < 30, Internal Control < 36.) for breast cancer metastasis. The genes are MG and KRT19 (UPKB:P08727)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased level", "assessed_biomarker_entity": { "recommended_name": "GeneSearch breast cancer breast lymph node MG, KRT19 expression panel", "synonyms": [ { "synonym": "Lacryglobin" }, { "synonym": "Lipophilin-C" }, { "synonym": "Mammaglobin-2" }, { "synonym": "Secretoglobin family 2A member 1" } ] }, "assessed_biomarker_entity_id": "UPKB:O75556", "assessed_entity_type": "protein", "specimen": [ { "name": "lymph node", "id": "UBERON:0000029", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000029", "loinc_code": "" } ], "evidence_source": [ { "id": "P060017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P060017", "evidence_list": [ { "evidence": "Gene expression levels (measured by the Ct value determined when the fluorescent signal exceeds a pre-defined threshold limit. If the external controls are valid, then the Ct value for each gene marker in the patient sample is compared to marker-specific Ct cutoff values. Samples with Ct values less than or equal to one or both of the cutoff values for MG or CKi9 are considered positive. The Cutoff Ct values are as follows: MG < 31, CK19 < 30, Internal Control < 36.) for breast cancer metastasis. The genes are MG and KRT19 (UPKB:P08727)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "P060017", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P060017", "evidence_list": [ { "evidence": "Gene expression levels (measured by the Ct value determined when the fluorescent signal exceeds a pre-defined threshold limit. If the external controls are valid, then the Ct value for each gene marker in the patient sample is compared to marker-specific Ct cutoff values. Samples with Ct values less than or equal to one or both of the cutoff values for MG or CKi9 are considered positive. The Cutoff Ct values are as follows: MG < 31, CK19 < 30, Internal Control < 36.) for breast cancer metastasis. The genes are MG and KRT19 (UPKB:P08727)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4464", "collision": 0 }, { "biomarker_id": "AN4465-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Anaplastic lymphoma kinase" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UM73", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Cell division protein kinase 4" }, { "synonym": "PSK-J3" } ] }, "assessed_biomarker_entity_id": "UPKB:P11802", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Discoidin domain receptor 2" }, { "synonym": "CD167 antigen-like family member B" }, { "synonym": "Discoidin domain-containing receptor tyrosine kinase 2" }, { "synonym": "Neurotrophic tyrosine kinase, receptor-related 3" }, { "synonym": "Receptor protein-tyrosine kinase TKT" }, { "synonym": "Tyrosine-protein kinase TYRO10" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16832", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "MAP kinase kinase 1" }, { "synonym": "MAPKK 1" }, { "synonym": "MKK1" }, { "synonym": "ERK activator kinase 1" }, { "synonym": "MAPK/ERK kinase 1" }, { "synonym": "MEK 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q02750", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "MAP kinase kinase 2" }, { "synonym": "MAPKK 2" }, { "synonym": "ERK activator kinase 2" }, { "synonym": "MAPK/ERK kinase 2" }, { "synonym": "MEK 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P36507", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Proto-oncogene c-ErbB-1" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P00533", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "FGFR-2" }, { "synonym": "K-sam" }, { "synonym": "KGFR" }, { "synonym": "Keratinocyte growth factor receptor" } ] }, "assessed_biomarker_entity_id": "UPKB:P21802", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "FGFR-3" } ] }, "assessed_biomarker_entity_id": "UPKB:P22607", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "H-Ras-1" }, { "synonym": "Ha-Ras" }, { "synonym": "Transforming protein p21" }, { "synonym": "c-H-ras" }, { "synonym": "p21ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01112", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "K-Ras 2" }, { "synonym": "Ki-Ras" }, { "synonym": "c-K-ras" }, { "synonym": "c-Ki-ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01116", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Transforming protein N-Ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01111", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "HGF receptor" }, { "synonym": "HGF/SF receptor" }, { "synonym": "Proto-oncogene c-Met" }, { "synonym": "Scatter factor receptor" }, { "synonym": "SF receptor" }, { "synonym": "Tyrosine-protein kinase Met" } ] }, "assessed_biomarker_entity_id": "UPKB:P08581", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "SCFR" }, { "synonym": "Piebald trait protein" }, { "synonym": "PBT" }, { "synonym": "Proto-oncogene c-Kit" }, { "synonym": "Tyrosine-protein kinase Kit" }, { "synonym": "p145 c-kit" }, { "synonym": "v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog" } ] }, "assessed_biomarker_entity_id": "UPKB:P10721", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "PI3-kinase subunit alpha" }, { "synonym": "PI3K-alpha" }, { "synonym": "PI3Kalpha" }, { "synonym": "PtdIns-3-kinase subunit alpha" }, { "synonym": "Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha" }, { "synonym": "PtdIns-3-kinase subunit p110-alpha" }, { "synonym": "p110alpha" }, { "synonym": "Phosphoinositide 3-kinase alpha" }, { "synonym": "Phosphoinositide-3-kinase catalytic alpha polypeptide" }, { "synonym": "Serine/threonine protein kinase PIK3CA" } ] }, "assessed_biomarker_entity_id": "UPKB:P42336", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "PDGF-R-alpha" }, { "synonym": "PDGFR-alpha" }, { "synonym": "Alpha platelet-derived growth factor receptor" }, { "synonym": "Alpha-type platelet-derived growth factor receptor" }, { "synonym": "CD140 antigen-like family member A" }, { "synonym": "CD140a antigen" }, { "synonym": "Platelet-derived growth factor alpha receptor" }, { "synonym": "Platelet-derived growth factor receptor 2" }, { "synonym": "PDGFR-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P16234", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Cadherin family member 12" }, { "synonym": "Proto-oncogene c-Ret" } ] }, "assessed_biomarker_entity_id": "UPKB:P07949", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Proto-oncogene c-Ros" }, { "synonym": "Proto-oncogene c-Ros-1" }, { "synonym": "Receptor tyrosine kinase c-ros oncogene 1" }, { "synonym": "c-Ros receptor tyrosine kinase" } ] }, "assessed_biomarker_entity_id": "UPKB:P08922", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Protein kinase B" }, { "synonym": "PKB" }, { "synonym": "Protein kinase B alpha" }, { "synonym": "PKB alpha" }, { "synonym": "Proto-oncogene c-Akt" }, { "synonym": "RAC-PK-alpha" } ] }, "assessed_biomarker_entity_id": "UPKB:P31749", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Proto-oncogene c-RAF" }, { "synonym": "cRaf" }, { "synonym": "Raf-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P04049", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Metastatic lymph node gene 19 protein" }, { "synonym": "MLN 19" }, { "synonym": "Proto-oncogene Neu" }, { "synonym": "Proto-oncogene c-ErbB-2" }, { "synonym": "Tyrosine kinase-type cell surface receptor HER2" }, { "synonym": "p185erbB2" } ] }, "assessed_biomarker_entity_id": "UPKB:P04626", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Proto-oncogene-like protein c-ErbB-3" }, { "synonym": "Tyrosine kinase-type cell surface receptor HER3" } ] }, "assessed_biomarker_entity_id": "UPKB:P21860", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "Proto-oncogene B-Raf" }, { "synonym": "p94" }, { "synonym": "v-Raf murine sarcoma viral oncogene homolog B1" } ] }, "assessed_biomarker_entity_id": "UPKB:P15056", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Oncomine lung cancer Dx 23 target gene mutations panel", "synonyms": [ { "synonym": "FK506-binding protein 12-rapamycin complex-associated protein 1" }, { "synonym": "FKBP12-rapamycin complex-associated protein" }, { "synonym": "Mammalian target of rapamycin" }, { "synonym": "mTOR" }, { "synonym": "Mechanistic target of rapamycin" }, { "synonym": "Rapamycin and FKBP12 target 1" }, { "synonym": "Rapamycin target protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P42345", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "" } ], "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "P160045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160045", "evidence_list": [ { "evidence": "Panel of identified gene predictive biomarkers (mutations) in lung cancer. The genes are ALK (UPKB:Q9UM73), CDK4 (UPKB:P11802), DDR2 (UPKB:Q16832), MAP2K1 (UPKB:Q02750), MAP2K2 (UPKB:P36507), EGFR (UPKB:P00533), FGFR2 (UPKB:P21802), FGFR3 (UPKB:P22607), HRAS (UPKB:P01112), KRAS (UPKB:P01116), NRAS (UPKB:P01111), MET (UPKB:P08581), KIT (UPKB:P10721), PIK3CA (UPKB:P42336), PGFRA (UPKB:P16234), RET (UPKB:P07949), ROS1 (UPKB:P08922), ATK1 (UPKB:P31749), RAF1 (UPKB:P04049), ERBB2 (UPKB:P04626), ERBB3 (UPKB:P21860), BRAF (UPKB:P15056), MTOR (UPKB:P42345)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4465", "collision": 0 }, { "biomarker_id": "AN4466-1", "biomarker_component": [ { "biomarker": "mRNA ratio", "assessed_biomarker_entity": { "recommended_name": "PROGENSA prostate cancer PCA3, PSA mRNA ratio", "synonyms": [ { "synonym": "PSA" }, { "synonym": "Gamma-seminoprotein" }, { "synonym": "Seminin" }, { "synonym": "Kallikrein-3" }, { "synonym": "P-30 antigen" }, { "synonym": "Semenogelase" } ] }, "assessed_biomarker_entity_id": "UPKB:P07288", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "P100033", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100033", "evidence_list": [ { "evidence": "PCA3 score of measured ratio of PCA3 mRNA to PSA mRNA (UPKB:P07288) level as risk biomarker for prostate cancer patients. A PCA3 Score <25 is associated with a decreased likelihood of a positive biopsy. Prostatic biopsy is required for diagnosis of cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "mRNA ratio", "assessed_biomarker_entity": { "recommended_name": "PROGENSA prostate cancer PCA3, PSA mRNA ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "RNAC:URS00008E3A1F", "assessed_entity_type": "RNA", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "P100033", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100033", "evidence_list": [ { "evidence": "PCA3 score of measured ratio of PCA3 mRNA to PSA mRNA (UPKB:P07288) level as risk biomarker for prostate cancer patients. A PCA3 Score <25 is associated with a decreased likelihood of a positive biopsy. Prostatic biopsy is required for diagnosis of cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "P100033", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100033", "evidence_list": [ { "evidence": "PCA3 score of measured ratio of PCA3 mRNA to PSA mRNA (UPKB:P07288) level as risk biomarker for prostate cancer patients. A PCA3 Score <25 is associated with a decreased likelihood of a positive biopsy. Prostatic biopsy is required for diagnosis of cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4466", "collision": 0 }, { "biomarker_id": "AN4467-1", "biomarker_component": [ { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "ARP3-beta" }, { "synonym": "Actin-like protein 3B" }, { "synonym": "Actin-related protein ARP4" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9P1U1", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NQW6", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P10415", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Arylamide acetylase 1" }, { "synonym": "Monomorphic arylamine N-acetyltransferase" }, { "synonym": "MNAT" }, { "synonym": "N-acetyltransferase type 1" }, { "synonym": "NAT-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P18440", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Apoptosis inhibitor 4" }, { "synonym": "Apoptosis inhibitor survivin" } ] }, "assessed_biomarker_entity_id": "UPKB:O15392", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "BAG-1" }, { "synonym": "Bcl-2-associated athanogene 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99933", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "BVR A" }, { "synonym": "Biliverdin-IX alpha-reductase" } ] }, "assessed_biomarker_entity_id": "UPKB:P53004", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Placental cadherin" }, { "synonym": "P-cadherin" } ] }, "assessed_biomarker_entity_id": "UPKB:P22223", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "CDC6-related protein" }, { "synonym": "Cdc18-related protein" }, { "synonym": "HsCdc18" }, { "synonym": "p62(cdc6)" }, { "synonym": "HsCDC6" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99741", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "p55CDC" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12834", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "CENP-F" }, { "synonym": "AH antigen" }, { "synonym": "Kinetochore protein CENPF" }, { "synonym": "Mitosin" } ] }, "assessed_biomarker_entity_id": "UPKB:P49454", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Cep55" }, { "synonym": "Up-regulated in colon cancer 6" } ] }, "assessed_biomarker_entity_id": "UPKB:Q53EZ4", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "CF5" }, { "synonym": "Putative MAPK-activating protein PM08" }, { "synonym": "Putative NF-kappa-B-activating protein 102" }, { "synonym": "Retinoid-inducible nuclear factor" }, { "synonym": "RINF" } ] }, "assessed_biomarker_entity_id": "UPKB:Q7LFL8", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "3-PGDH" }, { "synonym": "2-oxoglutarate reductase" }, { "synonym": "Malate dehydrogenase" } ] }, "assessed_biomarker_entity_id": "UPKB:O43175", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Double minute 2 protein" }, { "synonym": "Hdm2" }, { "synonym": "Oncoprotein Mdm2" }, { "synonym": "RING-type E3 ubiquitin transferase Mdm2" }, { "synonym": "p53-binding protein Mdm2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q00987", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Proto-oncogene c-ErbB-1" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P00533", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "ER" }, { "synonym": "ER-alpha" }, { "synonym": "Estradiol receptor" }, { "synonym": "Nuclear receptor subfamily 3 group A member 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P03372", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "hExo1" }, { "synonym": "Exonuclease I" }, { "synonym": "hExoI" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UQ84", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "FGFR-4" } ] }, "assessed_biomarker_entity_id": "UPKB:P22455", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Forkhead-related protein FKHL7" }, { "synonym": "Forkhead-related transcription factor 3" }, { "synonym": "FREAC-3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12948", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P24864", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P14635", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "B47" }, { "synonym": "Epidermal growth factor receptor GRB-7" }, { "synonym": "GRB7 adapter protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14451", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "HNF-3-alpha" }, { "synonym": "HNF-3A" }, { "synonym": "Forkhead box protein A1" }, { "synonym": "Transcription factor 3A" }, { "synonym": "TCF-3A" } ] }, "assessed_biomarker_entity_id": "UPKB:P55317", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Cytokeratin-14" }, { "synonym": "CK-14" }, { "synonym": "Keratin-14" }, { "synonym": "K14" } ] }, "assessed_biomarker_entity_id": "UPKB:P02533", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "39.1" }, { "synonym": "Cytokeratin-17" }, { "synonym": "CK-17" }, { "synonym": "Keratin-17" }, { "synonym": "K17" } ] }, "assessed_biomarker_entity_id": "UPKB:Q04695", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "58 kDa cytokeratin" }, { "synonym": "Cytokeratin-5" }, { "synonym": "CK-5" }, { "synonym": "Keratin-5" }, { "synonym": "K5" }, { "synonym": "Type-II keratin Kb5" } ] }, "assessed_biomarker_entity_id": "UPKB:P13647", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Kinesin-like protein 6" }, { "synonym": "Mitotic centromere-associated kinesin" }, { "synonym": "MCAK" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99661", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Highly expressed in cancer protein" }, { "synonym": "Kinetochore protein Hec1" }, { "synonym": "HsHec1" }, { "synonym": "Kinetochore-associated protein 2" }, { "synonym": "Retinoblastoma-associated protein HEC" } ] }, "assessed_biomarker_entity_id": "UPKB:O14777", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "hNuf2" }, { "synonym": "hNuf2R" }, { "synonym": "hsNuf2" }, { "synonym": "Cell division cycle-associated protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZD4", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "hMELK" }, { "synonym": "Protein kinase Eg3" }, { "synonym": "pEg3 kinase" }, { "synonym": "Protein kinase PK38" }, { "synonym": "hPK38" }, { "synonym": "Tyrosine-protein kinase MELK" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14680", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "MIA protein 2" }, { "synonym": "CTAGE family member 5 ER export factor" }, { "synonym": "Cutaneous T-cell lymphoma-associated antigen 5" }, { "synonym": "Meningioma-expressed antigen 6/11" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96PC5", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Exophilin-3" }, { "synonym": "Slp homolog lacking C2 domains a" }, { "synonym": "SlaC2-a" }, { "synonym": "Synaptotagmin-like protein 2a" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BV36", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Neurofibrillary tangle protein" }, { "synonym": "Paired helical filament-tau" }, { "synonym": "PHF-tau" } ] }, "assessed_biomarker_entity_id": "UPKB:P10636", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Nucleolar phosphoprotein Nopp34" }, { "synonym": "Nucleolar protein interacting with the FHA domain of pKI-67" }, { "synonym": "hNIFK" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BYG3", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "B-Myb" }, { "synonym": "Myb-like protein 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P10244", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Class E basic helix-loop-helix protein 39" }, { "synonym": "bHLHe39" }, { "synonym": "Proto-oncogene c-Myc" }, { "synonym": "Transcription factor p64" } ] }, "assessed_biomarker_entity_id": "UPKB:P01106", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9Y5N6", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Ferredoxin-plastoquinone reductase 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8H112", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "G-protein coupled receptor GPCR1" }, { "synonym": "hGPCR1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UJ42", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Antigen identified by monoclonal antibody Ki-67" }, { "synonym": "Antigen KI-67" }, { "synonym": "Antigen Ki67" } ] }, "assessed_biomarker_entity_id": "UPKB:P46013", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Metastatic lymph node gene 19 protein" }, { "synonym": "MLN 19" }, { "synonym": "Proto-oncogene Neu" }, { "synonym": "Proto-oncogene c-ErbB-2" }, { "synonym": "Tyrosine kinase-type cell surface receptor HER2" }, { "synonym": "p185erbB2" } ] }, "assessed_biomarker_entity_id": "UPKB:P04626", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Ribonucleotide reductase small chain" }, { "synonym": "Ribonucleotide reductase small subunit" } ] }, "assessed_biomarker_entity_id": "UPKB:P31350", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "FRP-1" }, { "synonym": "sFRP-1" }, { "synonym": "Secreted apoptosis-related protein 2" }, { "synonym": "SARP-2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8N474", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Esp1-associated protein" }, { "synonym": "Pituitary tumor-transforming gene 1 protein" }, { "synonym": "Tumor-transforming protein 1" }, { "synonym": "hPTTG" } ] }, "assessed_biomarker_entity_id": "UPKB:O95997", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "SL-3" }, { "synonym": "ST3" }, { "synonym": "Matrix metalloproteinase-11" }, { "synonym": "MMP-11" } ] }, "assessed_biomarker_entity_id": "UPKB:P24347", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "TS" }, { "synonym": "TSase" } ] }, "assessed_biomarker_entity_id": "UPKB:P04818", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q96B21", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "(E3-independent) E2 ubiquitin-conjugating enzyme C" }, { "synonym": "E2 ubiquitin-conjugating enzyme C" }, { "synonym": "UbcH10" }, { "synonym": "Ubiquitin carrier protein C" }, { "synonym": "Ubiquitin-protein ligase C" } ] }, "assessed_biomarker_entity_id": "UPKB:O00762", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Cell proliferation-inducing gene 50 protein" }, { "synonym": "E2 ubiquitin-conjugating enzyme T" }, { "synonym": "Ubiquitin carrier protein T" }, { "synonym": "Ubiquitin-protein ligase T" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NPD8", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Prosigna breast cancer 51 mRNA expression panel", "synonyms": [ { "synonym": "Estrogen-regulated protein LIV-1" }, { "synonym": "Solute carrier family 39 member 6" }, { "synonym": "Zrt- and Irt-like protein 6" }, { "synonym": "ZIP-6" } ] }, "assessed_biomarker_entity_id": "UPKB:Q13433", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "76546-1" } ], "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "K130010", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K130010", "evidence_list": [ { "evidence": "Gene expression signature profile (measured by calculating the amount of each RNA entered into a proprietary algorithm to produce a Prosigna score (0-100) and risk category (low 0-40/intermediate 41-60/high 41-40 for node-negative classification and 61-100 for node positive classification) for breast cancer patients. The genes are ACTR3B (UPKB:Q9P1U1), ANLN (UPKB:Q9NQW6), BCL2 (UPKB:P10415), NAT1 (UPKB:P18440), BIRC5 (UPKB:O15392), BAG1 (UPKB:Q99933), BLVRA (UPKB:P53004), CDH3 (UPKB:P22223), CDC6 (UPKB:Q99741), CDC20 (UPKB:Q12834), CENPF (UPKB:P49454), CEP55 (UPKB:Q53EZ4), CXXC5 (UPKB:Q7LFL8), PHGDH (UPKB:O43175), MDM2 (UPKB:Q00987), EGFR (UPKB:P00533), ESR1 (UPKB:P03372), EXO1 (UPKB:Q9UQ84), FGFR4 (UPKB:P22455), FOXC1 (UPKB:Q12948), CCNE1 (UPKB:P24864), CCNB1 (UPKB:P14635), GRB7 (UPKB:Q14451), FOXA1 (UPKB:P55317), KRT14 (UPKB:P02533), KRT17 (UPKB:Q04695), KRT5 (UPKB:P13647), KIF2C (UPKB:Q99661), NDC80 (UPKB:O14777), NUF2 (UPKB:Q9BZD4), MELK (UPKB:Q14680), MIA2 (UPKB:Q96PC5), MLPH (UPKB:Q9BV36), MAPT (UPKB:P10636), MIKF (UPKB:Q9BYG3), MYBL2 (UPKB:P10244), MYC (UPKB:P01106), ORC6 (UPKB:Q9Y5N6), PGRL1A (UPKB:Q8H112), GPR160 (UPKB:Q9UJ42), MKI67 (UPKB:P46013), ERBB2 (UPKB:P04626), RRM2 (UPKB:P31350), SFRP1 (UPKB:Q8N474), PTTG1 (UPKB:O95997), MMPL1 (UPKB:P24347), TYMS (UPKB:P04818), TMEM45B (UPKB:Q96B21), UBE3C (UPKB:O00762), UBE2T (UPKB:Q9NPD8), SLC39A6 (UPKB:Q13433)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4467", "collision": 0 }, { "biomarker_id": "AN4468-1", "biomarker_component": [ { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Ventana colorectal cancer BRAF, MLH1, MSH2, MSH6, PMS2 panel", "synonyms": [ { "synonym": "MutL protein homolog 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P40692", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Ventana colorectal cancer BRAF, MLH1, MSH2, MSH6, PMS2 panel", "synonyms": [ { "synonym": "hMSH2" }, { "synonym": "MutS protein homolog 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P43246", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Ventana colorectal cancer BRAF, MLH1, MSH2, MSH6, PMS2 panel", "synonyms": [ { "synonym": "hMSH6" }, { "synonym": "G/T mismatch-binding protein" }, { "synonym": "GTBP" }, { "synonym": "GTMBP" }, { "synonym": "MutS protein homolog 6" }, { "synonym": "MutS-alpha 160 kDa subunit" }, { "synonym": "p160" } ] }, "assessed_biomarker_entity_id": "UPKB:P52701", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Ventana colorectal cancer BRAF, MLH1, MSH2, MSH6, PMS2 panel", "synonyms": [ { "synonym": "DNA mismatch repair protein PMS2" }, { "synonym": "PMS1 protein homolog 2" } ] }, "assessed_biomarker_entity_id": "UPKB:P54278", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "expression level", "assessed_biomarker_entity": { "recommended_name": "Ventana colorectal cancer BRAF, MLH1, MSH2, MSH6, PMS2 panel", "synonyms": [ { "synonym": "Proto-oncogene B-Raf" }, { "synonym": "p94" }, { "synonym": "v-Raf murine sarcoma viral oncogene homolog B1" } ] }, "assessed_biomarker_entity_id": "UPKB:P15056", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "81691-8" } ], "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "DEN170026", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170026", "evidence_list": [ { "evidence": "Panel of identified protein prognostic biomarkers (differential expression) and a gene prognostic biomarker (mutation) in colorectal cancer. The proteins are MLH1 (UPKB:P40692), MSH2 (UPKB:P43246), MSH6 (UPKB:P52701), PMS2 (UPKB:P54278) and the gene is BRAF (UPKB:P15056)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4468", "collision": 0 }, { "biomarker_id": "AN4238-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "COBAS colorectal cancer KRAS somatic codon mutations panel", "synonyms": [ { "synonym": "K-Ras 2" }, { "synonym": "Ki-Ras" }, { "synonym": "c-K-ras" }, { "synonym": "c-Ki-ras" } ] }, "assessed_biomarker_entity_id": "UPKB:P01116", "assessed_entity_type": "protein", "specimen": [ { "name": "colon", "id": "UBERON:0001155", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001155", "loinc_code": "" } ], "evidence_source": [ { "id": "P140023", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140023", "evidence_list": [ { "evidence": "The Cobas KRAS Mutation Test, for use with the cobas 4800 System, is a real-time PCR test for the detection of seven somatic mutations in codons 12 and 13 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients for whom treatment with Erbitux (cetuximab) or with Vectibix (panitumumab) may be indicated based on a no mutation detected result. Specimens are processed using the cobas DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "P140023", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140023", "evidence_list": [ { "evidence": "The Cobas KRAS Mutation Test, for use with the cobas 4800 System, is a real-time PCR test for the detection of seven somatic mutations in codons 12 and 13 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients for whom treatment with Erbitux (cetuximab) or with Vectibix (panitumumab) may be indicated based on a no mutation detected result. Specimens are processed using the cobas DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4238", "collision": 1 }, { "biomarker_id": "AN4319-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Dako breast cancer TOP2A copy number FISH panel", "synonyms": [ { "synonym": "DNA topoisomerase II, alpha isozyme" } ] }, "assessed_biomarker_entity_id": "UPKB:P11388", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "63070-7" } ], "evidence_source": [ { "id": "P050045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050045", "evidence_list": [ { "evidence": "TOP2A FISH pharmDx Kit is designed to detect amplifications and deletions (copy number changes) of the TOP2A gene using fluorescence in situ hybridization (FISH) technique on formalin- fixed, paraffin-embedded human breast cancer tissue specimens. Deletions and amplifications of the TOP2A gene serve as a marker for poor prognosis in high-risk breast cancer patients. Results from the TOP2A FISH pharmDx MT Kit are intended for use as an adjunct to existing clinical and pathological information." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "P050045", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P050045", "evidence_list": [ { "evidence": "TOP2A FISH pharmDx Kit is designed to detect amplifications and deletions (copy number changes) of the TOP2A gene using fluorescence in situ hybridization (FISH) technique on formalin- fixed, paraffin-embedded human breast cancer tissue specimens. Deletions and amplifications of the TOP2A gene serve as a marker for poor prognosis in high-risk breast cancer patients. Results from the TOP2A FISH pharmDx MT Kit are intended for use as an adjunct to existing clinical and pathological information." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4319", "collision": 1 }, { "biomarker_id": "AN4259-2", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "THXID skin cancer BRAF V600E, K mutations panel", "synonyms": [ { "synonym": "Proto-oncogene B-Raf" }, { "synonym": "p94" }, { "synonym": "v-Raf murine sarcoma viral oncogene homolog B1" } ] }, "assessed_biomarker_entity_id": "UPKB:P15056", "assessed_entity_type": "protein", "specimen": [ { "name": "skin epidermis", "id": "UBERON:0001003", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001003", "loinc_code": "" } ], "evidence_source": [ { "id": "P120014", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120014", "evidence_list": [ { "evidence": "THXID BRAF kit is an in vitro diagnostic device intended for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin embedded (ffpe) human melanoma tissue. the THXID BRAF KIT is a real-time PCR test on the abi 7500 fast dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF v600e mutation for treatment with dabrafenib [tafinlar ] and as an aid in selecting melanoma patients whose tumors carry the BRAF v600e or v600k mutation for treatment with trametinib [mekinist]." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "P120014", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P120014", "evidence_list": [ { "evidence": "THXID BRAF kit is an in vitro diagnostic device intended for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin embedded (ffpe) human melanoma tissue. the THXID BRAF KIT is a real-time PCR test on the abi 7500 fast dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF v600e mutation for treatment with dabrafenib [tafinlar ] and as an aid in selecting melanoma patients whose tumors carry the BRAF v600e or v600k mutation for treatment with trametinib [mekinist]." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4259", "collision": 1 }, { "biomarker_id": "AN4320-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Invader skin cancer UGT1A1 *1, *28 alleles panel", "synonyms": [ { "synonym": "UGT1A1" }, { "synonym": "Bilirubin-specific UDPGT isozyme 1" }, { "synonym": "hUG-BR1" }, { "synonym": "UDP-glucuronosyltransferase 1-1" }, { "synonym": "UDPGT 1-1" }, { "synonym": "UGT1*1" }, { "synonym": "UGT1-01" }, { "synonym": "UGT1.1" }, { "synonym": "UDP-glucuronosyltransferase 1A isoform 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P22309", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "K051824", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K051824", "evidence_list": [ { "evidence": "The Invader UGT1A1 Molecular Assay is an in vitro diagnostic test for the detection and genotyping of the *1 (TA6) and *28 (TA7) alleles of the UDP glucuronosyltransferase 1A1 (UGT1A1) gene in genomic DNA from whole peripheral blood as an aid in the identification of patients with greater risk for decreased UDP-glucuronosyltransferase activity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:4159", "recommended_name": { "id": "DOID:4159", "name": "skin cancer", "description": "An integumentary system cancer located_in the skin that is the uncontrolled growth of abnormal skin cells.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, "synonyms": [ { "id": "DOID:4159", "name": "CA - skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "malignant neoplasm of skin", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" }, { "id": "DOID:4159", "name": "melanoma and Non-melanoma skin cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4159" } ] }, "evidence_source": [ { "id": "K051824", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K051824", "evidence_list": [ { "evidence": "The Invader UGT1A1 Molecular Assay is an in vitro diagnostic test for the detection and genotyping of the *1 (TA6) and *28 (TA7) alleles of the UDP glucuronosyltransferase 1A1 (UGT1A1) gene in genomic DNA from whole peripheral blood as an aid in the identification of patients with greater risk for decreased UDP-glucuronosyltransferase activity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4320", "collision": 1 }, { "biomarker_id": "AN4216-3", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "THERASCREEN breast cancer PIK3CA exonic mutations panel", "synonyms": [ { "synonym": "PI3-kinase subunit alpha" }, { "synonym": "PI3K-alpha" }, { "synonym": "PI3Kalpha" }, { "synonym": "PtdIns-3-kinase subunit alpha" }, { "synonym": "Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha" }, { "synonym": "PtdIns-3-kinase subunit p110-alpha" }, { "synonym": "p110alpha" }, { "synonym": "Phosphoinositide 3-kinase alpha" }, { "synonym": "Phosphoinositide-3-kinase catalytic alpha polypeptide" }, { "synonym": "Serine/threonine protein kinase PIK3CA" } ] }, "assessed_biomarker_entity_id": "UPKB:P42336", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "60034-6" }, { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "60034-6" } ], "evidence_source": [ { "id": "P190001", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190001", "evidence_list": [ { "evidence": "Therascreen PIK3CA RGQ PCR Kit is a real-time qualitative PCR test for the detection of 11 mutations in the PIK3CA gene (Exon 7: C420R; Exon 9: E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and Exon 20: H1047L, H1047R, H1047Y) using genomic DNA (gDNA) extracted from formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood ... The test is intended to aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAY (alpelisib) based on a PIK3CA Mutation Detected result." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "P190001", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190001", "evidence_list": [ { "evidence": "Therascreen PIK3CA RGQ PCR Kit is a real-time qualitative PCR test for the detection of 11 mutations in the PIK3CA gene (Exon 7: C420R; Exon 9: E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R; and Exon 20: H1047L, H1047R, H1047Y) using genomic DNA (gDNA) extracted from formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue or circulating tumor DNA (ctDNA) from plasma derived from K2EDTA anticoagulated peripheral whole blood ... The test is intended to aid clinicians in identifying breast cancer patients who may be eligible for treatment with PIQRAY (alpelisib) based on a PIK3CA Mutation Detected result." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4216", "collision": 1 }, { "biomarker_id": "AN4321-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "23andMe colorectal cancer MUTYH mutations panel", "synonyms": [ { "synonym": "MutY homolog" }, { "synonym": "hMYH" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UIF7", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "K182784", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K182784", "evidence_list": [ { "evidence": "The 23andMe PGS Genetic Health Risk Report for MUTYH Associated Polyposis is indicated for reporting of the Y179C and the G396D variants in the MUTYH gene. The report describes if a person is at increased risk of developing colorectal cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "K182784", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=K182784", "evidence_list": [ { "evidence": "The 23andMe PGS Genetic Health Risk Report for MUTYH Associated Polyposis is indicated for reporting of the Y179C and the G396D variants in the MUTYH gene. The report describes if a person is at increased risk of developing colorectal cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4321", "collision": 1 }, { "biomarker_id": "AN4243-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Vysis lung cancer ALK gene rearrangements panel", "synonyms": [ { "synonym": "Anaplastic lymphoma kinase" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UM73", "assessed_entity_type": "protein", "specimen": [ { "name": "lung", "id": "UBERON:0002048", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002048", "loinc_code": "78205-2" } ], "evidence_source": [ { "id": "P110012", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110012", "evidence_list": [ { "evidence": "The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non- small cell lung cancer (NSCLC) tissue specimens ... The test is for prescription use only." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "P110012", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110012", "evidence_list": [ { "evidence": "The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non- small cell lung cancer (NSCLC) tissue specimens ... The test is for prescription use only." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4243", "collision": 1 }, { "biomarker_id": "AN4463-2", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "23andMe breast and ovarian cancer BRCA1, BRCA2 mutations panel", "synonyms": [ { "synonym": "RING finger protein 53" }, { "synonym": "RING-type E3 ubiquitin transferase BRCA1" } ] }, "assessed_biomarker_entity_id": "UPKB:P38398", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "21640-8" } ], "evidence_source": [ { "id": "DEN170046", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170046", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in breast cancer. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "23andMe breast and ovarian cancer BRCA1, BRCA2 mutations panel", "synonyms": [ { "synonym": "Fanconi anemia group D1 protein" } ] }, "assessed_biomarker_entity_id": "UPKB:P51587", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "21640-8" } ], "evidence_source": [ { "id": "DEN170046", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170046", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in breast cancer. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "DEN170046", "database": "Ftcid", "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=DEN170046", "evidence_list": [ { "evidence": "Panel of identified gene risk biomarkers (mutations) in breast cancer. The genes are BRCA1 (UPKB:P38398), BRCA2 (UPKB:P51587)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [], "biomarker_canonical_id": "AN4463", "collision": 0 }, { "biomarker_id": "AA5014-1", "biomarker_component": [ { "biomarker": "increased sTRA level", "assessed_biomarker_entity": { "recommended_name": "Sialylated tumor-related antigen", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G78959US", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33093149", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33093149", "evidence_list": [ { "evidence": "Furthermore, a blood-plasma test for the sTRA glycan identified the PDACs that showed rapid relapse following neoadjuvant chemotherapy. This research demonstrates the use of the sTRA glycan to identify the PDAC cases that are highly resistant to chemotherapy." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:1793", "recommended_name": { "id": "DOID:1793", "name": "pancreatic cancer", "description": "An endocrine gland cancer located_in the pancreas.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, "synonyms": [ { "id": "DOID:1793", "name": "Ca head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of head of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "Ca tail of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "pancreas neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" }, { "id": "DOID:1793", "name": "malignant neoplasm of body of pancreas", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1793" } ] }, "evidence_source": [ { "id": "33093149", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33093149", "evidence_list": [ { "evidence": "Furthermore, a blood-plasma test for the sTRA glycan identified the PDACs that showed rapid relapse following neoadjuvant chemotherapy. This research demonstrates the use of the sTRA glycan to identify the PDAC cases that are highly resistant to chemotherapy." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Gao C, Wisniewski L, Liu Y, Staal B, Beddows I, Plenker D, Aldakkak M, Hall J, Barnett D, Gouda MK, Allen P, Drake R, Zureikat A, Huang Y, Evans D, Singhi A, Brand RE, Tuveson DA, Tsai S, Haab BB", "date": "2020-10-24", "evidence": [], "reference": [ { "id": "33093149", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33093149" } ] } ], "biomarker_canonical_id": "AA5014", "collision": 1 }, { "biomarker_id": "AN4322-1", "biomarker_component": [ { "biomarker": "increased trisialylated triantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Trisialylated triantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G53972TI", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "20491449", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449", "evidence_list": [ { "evidence": "From these representative chromatograms, it appears that the biantennary-monosialylated N-linked glycan is down-regulated in Stage IV breast cancer, while the fucosylated triantennary-trisialylated N-linked glycan appears to be up-regulated under such a condition. A biantennary-monosialylated N-linked glycan and a fucosylated triantennary-trisialylated structure were implicated as potential indicators of late-stage breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "20491449", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449", "evidence_list": [ { "evidence": "From these representative chromatograms, it appears that the biantennary-monosialylated N-linked glycan is down-regulated in Stage IV breast cancer, while the fucosylated triantennary-trisialylated N-linked glycan appears to be up-regulated under such a condition. A biantennary-monosialylated N-linked glycan and a fucosylated triantennary-trisialylated structure were implicated as potential indicators of late-stage breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery.", "journal": "Analytical chemistry", "authors": "Alley WR, Madera M, Mechref Y, Novotny MV", "date": "2010-05-25", "evidence": [], "reference": [ { "id": "20491449", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449" } ] } ], "biomarker_canonical_id": "AN4322", "collision": 1 }, { "biomarker_id": "AN4323-1", "biomarker_component": [ { "biomarker": "decreased monosialylated biantennary N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Monosialylated biantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G73813HX", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "20491449", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449", "evidence_list": [ { "evidence": "From these representative chromatograms, it appears that the biantennary-monosialylated N-linked glycan is down-regulated in Stage IV breast cancer, while the fucosylated triantennary-trisialylated N-linked glycan appears to be up-regulated under such a condition. A biantennary-monosialylated N-linked glycan and a fucosylated triantennary-trisialylated structure were implicated as potential indicators of late-stage breast cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "20491449", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449", "evidence_list": [ { "evidence": "From these representative chromatograms, it appears that the biantennary-monosialylated N-linked glycan is down-regulated in Stage IV breast cancer, while the fucosylated triantennary-trisialylated N-linked glycan appears to be up-regulated under such a condition. A biantennary-monosialylated N-linked glycan and a fucosylated triantennary-trisialylated structure were implicated as potential indicators of late-stage breast cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery.", "journal": "Analytical chemistry", "authors": "Alley WR, Madera M, Mechref Y, Novotny MV", "date": "2010-05-25", "evidence": [], "reference": [ { "id": "20491449", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/20491449" } ] } ], "biomarker_canonical_id": "AN4323", "collision": 1 }, { "biomarker_id": "AN4469-1", "biomarker_component": [ { "biomarker": "increased LRG-FTG level", "assessed_biomarker_entity": { "recommended_name": "Lewis fucosylated triantennary N-glycan on leucine-rich alpha-2-glycoprotein-1", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G33187NK", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29642865", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29642865", "evidence_list": [ { "evidence": "Leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan (LRG-FTG) was identified as CRC marker after evaluating 30,000 candidate glycopeptide peaks. Serum LRG-FTG was significantly elevated in CRC patients compared with healthy volunteers, and its accuracy as a CRC tumor marker was equal to that of CEA. LRG with biantennary glycan did not change between CRC patients and healthy individuals, which meant that the sugar chain alteration in LRG was key to cancer diagnosis. The elution time (33 min) and m/z (1975.37, z4) of this marker was just coincident with leucine-rich alpha-2-glycoprotein-1, whose Asn79 was modified with fucosylated triantennary N-glycan (LRG-FTG)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased LRG-FTG level", "assessed_biomarker_entity": { "recommended_name": "Lewis fucosylated triantennary N-glycan on leucine-rich alpha-2-glycoprotein-1", "synonyms": [ { "synonym": "LRG" } ] }, "assessed_biomarker_entity_id": "UPKB:P02750", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "29642865", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29642865", "evidence_list": [ { "evidence": "Leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan (LRG-FTG) was identified as CRC marker after evaluating 30,000 candidate glycopeptide peaks. Serum LRG-FTG was significantly elevated in CRC patients compared with healthy volunteers, and its accuracy as a CRC tumor marker was equal to that of CEA. LRG with biantennary glycan did not change between CRC patients and healthy individuals, which meant that the sugar chain alteration in LRG was key to cancer diagnosis. The elution time (33 min) and m/z (1975.37, z4) of this marker was just coincident with leucine-rich alpha-2-glycoprotein-1, whose Asn79 was modified with fucosylated triantennary N-glycan (LRG-FTG)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "29642865", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29642865", "evidence_list": [ { "evidence": "Leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan (LRG-FTG) was identified as CRC marker after evaluating 30,000 candidate glycopeptide peaks. Serum LRG-FTG was significantly elevated in CRC patients compared with healthy volunteers, and its accuracy as a CRC tumor marker was equal to that of CEA. LRG with biantennary glycan did not change between CRC patients and healthy individuals, which meant that the sugar chain alteration in LRG was key to cancer diagnosis. The elution time (33 min) and m/z (1975.37, z4) of this marker was just coincident with leucine-rich alpha-2-glycoprotein-1, whose Asn79 was modified with fucosylated triantennary N-glycan (LRG-FTG)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.", "journal": "BMC cancer", "authors": "Shinozaki E, Tanabe K, Akiyoshi T, Tsuchida T, Miyazaki Y, Kojima N, Igarashi M, Ueno M, Suenaga M, Mizunuma N, Yamaguchi K, Nakayama K, Iijima S, Yamaguchi T", "date": "2018-04-13", "evidence": [], "reference": [ { "id": "29642865", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29642865" } ] }, { "title": "Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.", "journal": "BMC cancer", "authors": "Shinozaki E, Tanabe K, Akiyoshi T, Tsuchida T, Miyazaki Y, Kojima N, Igarashi M, Ueno M, Suenaga M, Mizunuma N, Yamaguchi K, Nakayama K, Iijima S, Yamaguchi T", "date": "2018-04-13", "evidence": [], "reference": [ { "id": "29642865", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29642865" } ] } ], "biomarker_canonical_id": "AN4469", "collision": 0 }, { "biomarker_id": "AA5015-1", "biomarker_component": [ { "biomarker": "increased A3FG1 level", "assessed_biomarker_entity": { "recommended_name": "Lewis x fucosylated monogalactosylated triantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G36521AS", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18818422", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18818422", "evidence_list": [ { "evidence": "Following digestion with sialidase and beta-galactosidase, the alpha1,3-fucosylated trisialylated triantennary structure (A3FG3S3, GU 10.75) digested to form the alpha1,3-fucosylated monogalactosylated triantennary structure (A3FG1). We observed a significant difference in the trends of both A3FG1 and CA 15-3 in all 10 patients. Interestingly, we found that A3FG1 increased in all the second samples, clearly consistent with breast cancer progression and/or metastasis. This preliminary result suggests that compared to the commonly measured CA 15-3 and CEA, the glycan marker A3FG1, quantified from whole serum of breast cancer patients, could be more reliable for detecting disease progression and metastasis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18818422", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18818422", "evidence_list": [ { "evidence": "Following digestion with sialidase and beta-galactosidase, the alpha1,3-fucosylated trisialylated triantennary structure (A3FG3S3, GU 10.75) digested to form the alpha1,3-fucosylated monogalactosylated triantennary structure (A3FG1). We observed a significant difference in the trends of both A3FG1 and CA 15-3 in all 10 patients. Interestingly, we found that A3FG1 increased in all the second samples, clearly consistent with breast cancer progression and/or metastasis. This preliminary result suggests that compared to the commonly measured CA 15-3 and CEA, the glycan marker A3FG1, quantified from whole serum of breast cancer patients, could be more reliable for detecting disease progression and metastasis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression.", "journal": "Glycobiology", "authors": "Abd Hamid UM, Royle L, Saldova R, Radcliffe CM, Harvey DJ, Storr SJ, Pardo M, Antrobus R, Chapman CJ, Zitzmann N, Robertson JF, Dwek RA, Rudd PM", "date": "2008-09-27", "evidence": [], "reference": [ { "id": "18818422", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18818422" } ] } ], "biomarker_canonical_id": "AA5015", "collision": 1 }, { "biomarker_id": "AN4325-1", "biomarker_component": [ { "biomarker": "increased GalNAc level", "assessed_biomarker_entity": { "recommended_name": "Alpha-N-acetylgalactosamine", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G57321FI", "assessed_entity_type": "glycan", "specimen": [ { "name": "brain", "id": "UBERON:0000955", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000955", "loinc_code": "" } ], "evidence_source": [ { "id": "22435486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486", "evidence_list": [ { "evidence": "Fluorescently labeled lectins that specifically recognize \u03b1-N-acetylgalactosamine (GalNAc) and \u03b1-N-acetylglucosamine (GlcNAc) differentially bound to the cell surface based on the state of cellular differentiation. GalNAc and GlcNAc were highly expressed on the surface of undifferentiated cells and showed markedly reduced expression over a 12-day duration of differentiation. Our preliminary results on a single cerebellar GBM suggest that GalNAc and GlcNAc are novel biomarkers for identifying glioma-derived stem cells and can be used to isolate cancer stem cells from unsorted cell populations, thereby creating new cell lines for research or clinical testing." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1319", "recommended_name": { "id": "DOID:1319", "name": "brain cancer", "description": "A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, "synonyms": [ { "id": "DOID:1319", "name": "malignant brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "BT - Brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult malignant brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary malignant neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of adult brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "tumor of the Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm, adult", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" } ] }, "evidence_source": [ { "id": "22435486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486", "evidence_list": [ { "evidence": "Fluorescently labeled lectins that specifically recognize \u03b1-N-acetylgalactosamine (GalNAc) and \u03b1-N-acetylglucosamine (GlcNAc) differentially bound to the cell surface based on the state of cellular differentiation. GalNAc and GlcNAc were highly expressed on the surface of undifferentiated cells and showed markedly reduced expression over a 12-day duration of differentiation. Our preliminary results on a single cerebellar GBM suggest that GalNAc and GlcNAc are novel biomarkers for identifying glioma-derived stem cells and can be used to isolate cancer stem cells from unsorted cell populations, thereby creating new cell lines for research or clinical testing." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells.", "journal": "Stem cells and development", "authors": "Tucker-Burden C, Chappa P, Krishnamoorthy M, Gerwe BA, Scharer CD, Heimburg-Molinaro J, Harris W, Usta SN, Eilertson CD, Hadjipanayis CG, Stice SL, Brat DJ, Nash RJ", "date": "2012-03-23", "evidence": [], "reference": [ { "id": "22435486", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486" } ] } ], "biomarker_canonical_id": "AN4325", "collision": 1 }, { "biomarker_id": "AN4326-1", "biomarker_component": [ { "biomarker": "increased GlcNAc level", "assessed_biomarker_entity": { "recommended_name": "Alpha-N-acetylglucosamine", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G68544GH", "assessed_entity_type": "glycan", "specimen": [ { "name": "brain", "id": "UBERON:0000955", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000955", "loinc_code": "" } ], "evidence_source": [ { "id": "22435486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486", "evidence_list": [ { "evidence": "Fluorescently labeled lectins that specifically recognize \u03b1-N-acetylgalactosamine (GalNAc) and \u03b1-N-acetylglucosamine (GlcNAc) differentially bound to the cell surface based on the state of cellular differentiation. GalNAc and GlcNAc were highly expressed on the surface of undifferentiated cells and showed markedly reduced expression over a 12-day duration of differentiation. Our preliminary results on a single cerebellar GBM suggest that GalNAc and GlcNAc are novel biomarkers for identifying glioma-derived stem cells and can be used to isolate cancer stem cells from unsorted cell populations, thereby creating new cell lines for research or clinical testing." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1319", "recommended_name": { "id": "DOID:1319", "name": "brain cancer", "description": "A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, "synonyms": [ { "id": "DOID:1319", "name": "malignant brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "BT - Brain tumour", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult malignant brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary malignant neoplasm of brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "adult brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "malignant tumor of adult brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "tumor of the Brain", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "primary brain neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" }, { "id": "DOID:1319", "name": "brain neoplasm, adult", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1319" } ] }, "evidence_source": [ { "id": "22435486", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486", "evidence_list": [ { "evidence": "Fluorescently labeled lectins that specifically recognize \u03b1-N-acetylgalactosamine (GalNAc) and \u03b1-N-acetylglucosamine (GlcNAc) differentially bound to the cell surface based on the state of cellular differentiation. GalNAc and GlcNAc were highly expressed on the surface of undifferentiated cells and showed markedly reduced expression over a 12-day duration of differentiation. Our preliminary results on a single cerebellar GBM suggest that GalNAc and GlcNAc are novel biomarkers for identifying glioma-derived stem cells and can be used to isolate cancer stem cells from unsorted cell populations, thereby creating new cell lines for research or clinical testing." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Lectins identify glycan biomarkers on glioblastoma-derived cancer stem cells.", "journal": "Stem cells and development", "authors": "Tucker-Burden C, Chappa P, Krishnamoorthy M, Gerwe BA, Scharer CD, Heimburg-Molinaro J, Harris W, Usta SN, Eilertson CD, Hadjipanayis CG, Stice SL, Brat DJ, Nash RJ", "date": "2012-03-23", "evidence": [], "reference": [ { "id": "22435486", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22435486" } ] } ], "biomarker_canonical_id": "AN4326", "collision": 1 }, { "biomarker_id": "AN4470-1", "biomarker_component": [ { "biomarker": "increased FA2 and SLex level, Sialyl Lewis x level", "assessed_biomarker_entity": { "recommended_name": "Agalactosylated biantennary core fucosylated N-glycan and Sialyl Lewis x", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G64669AQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17884841", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17884841", "evidence_list": [ { "evidence": "We have described differences between control and advanced ovarian cancer sera: a doubling in the amount of FA2 and SLex structures in whole serum glycan profiles and a shift in the sialic acid linkage from alpha2,3 to alpha2,6 in disialylated fractions. We have demonstrated that the level of SLex alone is not specific for ovarian cancer, but a combination of FA2 and SLex significantly improves the separation of benign gynecological conditions from ovarian cancer. This suggests that a combination of these two markers would improve the diagnosis of ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased FA2 and SLex level, Sialyl Lewis x level", "assessed_biomarker_entity": { "recommended_name": "Agalactosylated biantennary core fucosylated N-glycan and Sialyl Lewis x", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G00054MO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "17884841", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17884841", "evidence_list": [ { "evidence": "We have described differences between control and advanced ovarian cancer sera: a doubling in the amount of FA2 and SLex structures in whole serum glycan profiles and a shift in the sialic acid linkage from alpha2,3 to alpha2,6 in disialylated fractions. We have demonstrated that the level of SLex alone is not specific for ovarian cancer, but a combination of FA2 and SLex significantly improves the separation of benign gynecological conditions from ovarian cancer. This suggests that a combination of these two markers would improve the diagnosis of ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "17884841", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17884841", "evidence_list": [ { "evidence": "We have described differences between control and advanced ovarian cancer sera: a doubling in the amount of FA2 and SLex structures in whole serum glycan profiles and a shift in the sialic acid linkage from alpha2,3 to alpha2,6 in disialylated fractions. We have demonstrated that the level of SLex alone is not specific for ovarian cancer, but a combination of FA2 and SLex significantly improves the separation of benign gynecological conditions from ovarian cancer. This suggests that a combination of these two markers would improve the diagnosis of ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG.", "journal": "Glycobiology", "authors": "Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM", "date": "2007-09-22", "evidence": [], "reference": [ { "id": "17884841", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17884841" } ] }, { "title": "Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG.", "journal": "Glycobiology", "authors": "Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, Banks RE, Hutson R, Harvey DJ, Antrobus R, Petrescu SM, Dwek RA, Rudd PM", "date": "2007-09-22", "evidence": [], "reference": [ { "id": "17884841", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17884841" } ] } ], "biomarker_canonical_id": "AN4470", "collision": 0 }, { "biomarker_id": "AN4471-1", "biomarker_component": [ { "biomarker": "increased S-HPX", "assessed_biomarker_entity": { "recommended_name": "Disialylated to monosialylated O-glycoforms of hemopexin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G90233EO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27688741", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741", "evidence_list": [ { "evidence": "S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cirrhotic patient of HCV etiology and can be quantified by an LC-MS/MS-MRM assay in unfractionated serum of patients. Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of liver disease that could have a role in monitoring the progression of liver pathology. The ratio of disialylated (NeuAc2Hex1HexNAc1) to monosialylated (NeuAc1Hex1HexNAc1) glycoforms of the peptide TPLPPTSAHGNVAEGETKPDPVTER of HPX carrying one O-glycan on the T1 (S-HPX) was used as a final quantitative measure for evaluation of liver disease. The results show an approximately fourfold increase in disialylated O-glycopeptide of HPX in cirrhosis and further increase in the cirrhotics with HCC with a simultaneous approximately 20 % decrease in the monosialylated O-glycopeptide of HPX." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased S-HPX", "assessed_biomarker_entity": { "recommended_name": "Disialylated to monosialylated O-glycoforms of hemopexin ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G23384FD", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27688741", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741", "evidence_list": [ { "evidence": "S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cirrhotic patient of HCV etiology and can be quantified by an LC-MS/MS-MRM assay in unfractionated serum of patients. Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of liver disease that could have a role in monitoring the progression of liver pathology. The ratio of disialylated (NeuAc2Hex1HexNAc1) to monosialylated (NeuAc1Hex1HexNAc1) glycoforms of the peptide TPLPPTSAHGNVAEGETKPDPVTER of HPX carrying one O-glycan on the T1 (S-HPX) was used as a final quantitative measure for evaluation of liver disease. The results show an approximately fourfold increase in disialylated O-glycopeptide of HPX in cirrhosis and further increase in the cirrhotics with HCC with a simultaneous approximately 20 % decrease in the monosialylated O-glycopeptide of HPX." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased S-HPX", "assessed_biomarker_entity": { "recommended_name": "Disialylated to monosialylated O-glycoforms of hemopexin ratio", "synonyms": [ { "synonym": "Beta-1B-glycoprotein" } ] }, "assessed_biomarker_entity_id": "UPKB:P02790", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27688741", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741", "evidence_list": [ { "evidence": "S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cirrhotic patient of HCV etiology and can be quantified by an LC-MS/MS-MRM assay in unfractionated serum of patients. Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of liver disease that could have a role in monitoring the progression of liver pathology. The ratio of disialylated (NeuAc2Hex1HexNAc1) to monosialylated (NeuAc1Hex1HexNAc1) glycoforms of the peptide TPLPPTSAHGNVAEGETKPDPVTER of HPX carrying one O-glycan on the T1 (S-HPX) was used as a final quantitative measure for evaluation of liver disease. The results show an approximately fourfold increase in disialylated O-glycopeptide of HPX in cirrhosis and further increase in the cirrhotics with HCC with a simultaneous approximately 20 % decrease in the monosialylated O-glycopeptide of HPX." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "27688741", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741", "evidence_list": [ { "evidence": "S-HPX, a measure of sialylated O-glycoforms of hemopexin, progressively increases in fibrotic and cirrhotic patient of HCV etiology and can be quantified by an LC-MS/MS-MRM assay in unfractionated serum of patients. Quantification of sialylated O-glycoforms of this liver secreted glycoprotein represents a novel measure of the stage of liver disease that could have a role in monitoring the progression of liver pathology. The ratio of disialylated (NeuAc2Hex1HexNAc1) to monosialylated (NeuAc1Hex1HexNAc1) glycoforms of the peptide TPLPPTSAHGNVAEGETKPDPVTER of HPX carrying one O-glycan on the T1 (S-HPX) was used as a final quantitative measure for evaluation of liver disease. The results show an approximately fourfold increase in disialylated O-glycopeptide of HPX in cirrhosis and further increase in the cirrhotics with HCC with a simultaneous approximately 20 % decrease in the monosialylated O-glycopeptide of HPX." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.", "journal": "Clinical proteomics", "authors": "Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R", "date": "2016-10-01", "evidence": [], "reference": [ { "id": "27688741", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741" } ] }, { "title": "Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.", "journal": "Clinical proteomics", "authors": "Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R", "date": "2016-10-01", "evidence": [], "reference": [ { "id": "27688741", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741" } ] }, { "title": "Increased sialylation of site specific O-glycoforms of hemopexin in liver disease.", "journal": "Clinical proteomics", "authors": "Sanda M, Benicky J, Wu J, Wang Y, Makambi K, Ahn J, Smith CI, Zhao P, Zhang L, Goldman R", "date": "2016-10-01", "evidence": [], "reference": [ { "id": "27688741", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27688741" } ] } ], "biomarker_canonical_id": "AN4471", "collision": 0 }, { "biomarker_id": "AA5016-1", "biomarker_component": [ { "biomarker": "decreased ALKBH5 level", "assessed_biomarker_entity": { "recommended_name": "Alkylation repair homologue 5", "synonyms": [ { "synonym": "Alkylated DNA repair protein alkB homolog 5" }, { "synonym": "Alpha-ketoglutarate-dependent dioxygenase alkB homolog 5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q6P6C2", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31985880", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880", "evidence_list": [ { "evidence": "ALKBH5 was significantly reduced in RCC compared to normal tissue (P < 0.001), low expression levels of ALKBH5 and FTO were correlated with a shorter overall survival (OS: ALKBH5 log-rank P = 0.007; FTO log-rank P = 0.033) and cancer-specific survival (CSS: ALKBH5 log-rank P = 0.018; FTO log-rank P = 0.029" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "34683137", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137", "evidence_list": [ { "evidence": ". Univariate analysis showed that higher FTO expression was associated with better overall and progression free survival in both ccRCC and pRCC patients. No associations were disclosed concerning ALKBH5 expressions levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31985880", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880", "evidence_list": [ { "evidence": "ALKBH5 was significantly reduced in RCC compared to normal tissue (P < 0.001), low expression levels of ALKBH5 and FTO were correlated with a shorter overall survival (OS: ALKBH5 log-rank P = 0.007; FTO log-rank P = 0.033) and cancer-specific survival (CSS: ALKBH5 log-rank P = 0.018; FTO log-rank P = 0.029" } ], "tags": [ { "tag": "condition" } ] }, { "id": "34683137", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137", "evidence_list": [ { "evidence": ". Univariate analysis showed that higher FTO expression was associated with better overall and progression free survival in both ccRCC and pRCC patients. No associations were disclosed concerning ALKBH5 expressions levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The N", "journal": "BJU international", "authors": "Strick A, von Hagen F, Gundert L, Kl\u00fcmper N, Tolkach Y, Schmidt D, Kristiansen G, Toma M, Ritter M, Ellinger J", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31985880", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880" } ] }, { "title": "Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes.", "journal": "Journal of personalized medicine", "authors": "Guimar\u00e3es-Teixeira C, Barros-Silva D, Lobo J, Soares-Fernandes D, Const\u00e2ncio V, Leite-Silva P, Silva-Santos R, Braga I, Henrique R, Miranda-Gon\u00e7alves V, Jer\u00f3nimo C", "date": "2021-10-24", "evidence": [], "reference": [ { "id": "34683137", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137" } ] } ], "biomarker_canonical_id": "AA5016", "collision": 1 }, { "biomarker_id": "AA5017-1", "biomarker_component": [ { "biomarker": "decreased FTO level", "assessed_biomarker_entity": { "recommended_name": "Alpha-ketoglutarate-dependent dioxygenase", "synonyms": [ { "synonym": "Fat mass and obesity-associated protein" }, { "synonym": "U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO" }, { "synonym": "U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO" }, { "synonym": "mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO" }, { "synonym": "m6A(m)-demethylase FTO" }, { "synonym": "mRNA N(6)-methyladenosine demethylase FTO" }, { "synonym": "tRNA N1-methyl adenine demethylase FTO" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9C0B1", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31985880", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880", "evidence_list": [ { "evidence": "ALKBH5 was significantly reduced in RCC compared to normal tissue (P < 0.001), low expression levels of ALKBH5 and FTO were correlated with a shorter overall survival (OS: ALKBH5 log-rank P = 0.007; FTO log-rank P = 0.033) and cancer-specific survival (CSS: ALKBH5 log-rank P = 0.018; FTO log-rank P = 0.029" } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "34683137", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137", "evidence_list": [ { "evidence": ". Univariate analysis showed that higher FTO expression was associated with better overall and progression free survival in both ccRCC and pRCC patients. No associations were disclosed concerning ALKBH5 expressions levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31985880", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880", "evidence_list": [ { "evidence": "ALKBH5 was significantly reduced in RCC compared to normal tissue (P < 0.001), low expression levels of ALKBH5 and FTO were correlated with a shorter overall survival (OS: ALKBH5 log-rank P = 0.007; FTO log-rank P = 0.033) and cancer-specific survival (CSS: ALKBH5 log-rank P = 0.018; FTO log-rank P = 0.029" } ], "tags": [ { "tag": "condition" } ] }, { "id": "34683137", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137", "evidence_list": [ { "evidence": ". Univariate analysis showed that higher FTO expression was associated with better overall and progression free survival in both ccRCC and pRCC patients. No associations were disclosed concerning ALKBH5 expressions levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The N", "journal": "BJU international", "authors": "Strick A, von Hagen F, Gundert L, Kl\u00fcmper N, Tolkach Y, Schmidt D, Kristiansen G, Toma M, Ritter M, Ellinger J", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31985880", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31985880" } ] }, { "title": "Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes.", "journal": "Journal of personalized medicine", "authors": "Guimar\u00e3es-Teixeira C, Barros-Silva D, Lobo J, Soares-Fernandes D, Const\u00e2ncio V, Leite-Silva P, Silva-Santos R, Braga I, Henrique R, Miranda-Gon\u00e7alves V, Jer\u00f3nimo C", "date": "2021-10-24", "evidence": [], "reference": [ { "id": "34683137", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/34683137" } ] } ], "biomarker_canonical_id": "AA5017", "collision": 1 }, { "biomarker_id": "AA5018-1", "biomarker_component": [ { "biomarker": "differentially measured MIR-576 level", "assessed_biomarker_entity": { "recommended_name": "miR-576", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003583", "assessed_entity_type": "miRNA", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "Thirteen miRNAs that were significantly differentially expressed in RCC patients were identified, 10 of them have been proved to be associated with kidney cancer in other studies, miR-576, miR-616 and miR-133a-2 are three newly discovered biomarkers of RCC in this study. We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. Our findings may have guiding significance for the early diagnosis of renal cell carcinoma." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "Thirteen miRNAs that were significantly differentially expressed in RCC patients were identified, 10 of them have been proved to be associated with kidney cancer in other studies, miR-576, miR-616 and miR-133a-2 are three newly discovered biomarkers of RCC in this study. We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. Our findings may have guiding significance for the early diagnosis of renal cell carcinoma." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Computational identification and analysis of early diagnostic biomarkers for kidney cancer.", "journal": "Journal of human genetics", "authors": "Tang T, Du X, Zhang X, Niu W, Li C, Tan J", "date": "2019-07-28", "evidence": [], "reference": [ { "id": "31350524", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524" } ] } ], "biomarker_canonical_id": "AA5018", "collision": 1 }, { "biomarker_id": "AA5019-1", "biomarker_component": [ { "biomarker": "differentially measured MIR-616 level", "assessed_biomarker_entity": { "recommended_name": "miR-616", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0003629", "assessed_entity_type": "miRNA", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "Thirteen miRNAs that were significantly differentially expressed in RCC patients were identified, 10 of them have been proved to be associated with kidney cancer in other studies, miR-576, miR-616 and miR-133a-2 are three newly discovered biomarkers of RCC in this study. We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. Our findings may have guiding significance for the early diagnosis of renal cell carcinoma." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "Thirteen miRNAs that were significantly differentially expressed in RCC patients were identified, 10 of them have been proved to be associated with kidney cancer in other studies, miR-576, miR-616 and miR-133a-2 are three newly discovered biomarkers of RCC in this study. We found that the target genes of miR-576 (CUL3 and RAC1) are involved in the regulation of multiple cancer-related biological pathways, and the target gene of miR-616 (ASB13 and FBXW2) has been reported to be associated with the development of other cancers. Our findings may have guiding significance for the early diagnosis of renal cell carcinoma." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Computational identification and analysis of early diagnostic biomarkers for kidney cancer.", "journal": "Journal of human genetics", "authors": "Tang T, Du X, Zhang X, Niu W, Li C, Tan J", "date": "2019-07-28", "evidence": [], "reference": [ { "id": "31350524", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524" } ] } ], "biomarker_canonical_id": "AA5019", "collision": 1 }, { "biomarker_id": "AA5020-1", "biomarker_component": [ { "biomarker": "increased P4HB level", "assessed_biomarker_entity": { "recommended_name": "Prolyl 4-hydroxylase, beta polypeptide", "synonyms": [ { "synonym": "PDI" }, { "synonym": "Cellular thyroid hormone-binding protein" }, { "synonym": "Prolyl 4-hydroxylase subunit beta" }, { "synonym": "p55" } ] }, "assessed_biomarker_entity_id": "UPKB:P07237", "assessed_entity_type": "protein", "specimen": [ { "name": "kidney", "id": "UBERON:0002113", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002113", "loinc_code": "" } ], "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "High expression of P4HB mRNA was related to significantly worse Overall Survival (OS) for KIRC patients (Kidney renal cell carcinoma) (p<0.0001). Univariate Cox regression analyses, showed higher stage and high P4HB mRNA expression exhibited unfavorable effects on OS (p<0.0001 and p<0.0001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "31350524", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524", "evidence_list": [ { "evidence": "High expression of P4HB mRNA was related to significantly worse Overall Survival (OS) for KIRC patients (Kidney renal cell carcinoma) (p<0.0001). Univariate Cox regression analyses, showed higher stage and high P4HB mRNA expression exhibited unfavorable effects on OS (p<0.0001 and p<0.0001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Computational identification and analysis of early diagnostic biomarkers for kidney cancer.", "journal": "Journal of human genetics", "authors": "Tang T, Du X, Zhang X, Niu W, Li C, Tan J", "date": "2019-07-28", "evidence": [], "reference": [ { "id": "31350524", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31350524" } ] } ], "biomarker_canonical_id": "AA5020", "collision": 1 }, { "biomarker_id": "AN4332-1", "biomarker_component": [ { "biomarker": "differentially measured 4-hydroxybenzoate level", "assessed_biomarker_entity": { "recommended_name": "4-Hydroxybenzoate", "synonyms": [] }, "assessed_biomarker_entity_id": "HGNC:25223", "assessed_entity_type": "gene", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "MTHU027525" } ], "evidence_source": [ { "id": "21348635", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635", "evidence_list": [ { "evidence": "Quinolinate, 4-hydroxybenzoate, and gentisate were significantly differentially expressed between the two groups at an FDR (False Discovery Rate) of 0.26, 4-hydroxybenzoate and gentisate being decreased in cancer patients urine compared to normal patients' urine." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "21348635", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635", "evidence_list": [ { "evidence": "Quinolinate, 4-hydroxybenzoate, and gentisate were significantly differentially expressed between the two groups at an FDR (False Discovery Rate) of 0.26, 4-hydroxybenzoate and gentisate being decreased in cancer patients urine compared to normal patients' urine." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.", "journal": "Omics : a journal of integrative biology", "authors": "Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH", "date": "2011-02-26", "evidence": [], "reference": [ { "id": "21348635", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635" } ] } ], "biomarker_canonical_id": "AN4332", "collision": 1 }, { "biomarker_id": "AN4333-1", "biomarker_component": [ { "biomarker": "differentially measured gentisate level", "assessed_biomarker_entity": { "recommended_name": "Gentisate", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q330M9", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "47858-6" } ], "evidence_source": [ { "id": "21348635", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635", "evidence_list": [ { "evidence": "Quinolinate, 4-hydroxybenzoate, and gentisate were significantly differentially expressed between the two groups at an FDR (False Discovery Rate) of 0.26, 4-hydroxybenzoate and gentisate being decreased in cancer patients urine compared to normal patients' urine." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "21348635", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635", "evidence_list": [ { "evidence": "Quinolinate, 4-hydroxybenzoate, and gentisate were significantly differentially expressed between the two groups at an FDR (False Discovery Rate) of 0.26, 4-hydroxybenzoate and gentisate being decreased in cancer patients urine compared to normal patients' urine." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.", "journal": "Omics : a journal of integrative biology", "authors": "Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH", "date": "2011-02-26", "evidence": [], "reference": [ { "id": "21348635", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21348635" } ] } ], "biomarker_canonical_id": "AN4333", "collision": 1 }, { "biomarker_id": "AA5023-1", "biomarker_component": [ { "biomarker": "increased IL1B level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-1 beta protein", "synonyms": [ { "synonym": "IL-1 beta" }, { "synonym": "Catabolin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01584", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "13629-1" }, { "name": "blood serum", "id": "UBERON:0001977", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001977", "loinc_code": "13629-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "13629-1" } ], "evidence_source": [ { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. IL-6 was one of the most robust prognostic markers of survival. It remained independently associated with severity and predictive of outcome. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" }, { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32511562", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562", "evidence_list": [ { "evidence": "COVID-19 is associated with high levels of IL-6, TNF-a, IL-1b, and CXCL8/IL-8. IL-6 was one of the most robust prognostic markers of survival. It remained independently associated with severity and predictive of outcome. Furthermore, elevated TNF-a, known to contribute to organ damage, was also a strong predictor of poor outcome." } ], "tags": [ { "tag": "condition" } ] }, { "id": "31986264", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264", "evidence_list": [ { "evidence": "We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFN gamma, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Initial plasma IL1B concentrations were higher in both ICU patients and non-ICU patients than in healthy adults." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "An inflammatory cytokine signature helps predict COVID-19 severity and death.", "journal": "medRxiv : the preprint server for health sciences", "authors": "Del Valle DM, Kim-Schulze S, Hsin-Hui H, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz T, Madduri D, Stock A, Marron T, Xie H, Patel MK, van Oekelen O, Rahman A, Kovatch P, Aberg J, Schadt E, Jagannath S, Mazumdar M, Charney A, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S", "date": "2020-06-09", "evidence": [], "reference": [ { "id": "32511562", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32511562" } ] }, { "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.", "journal": "Lancet (London, England)", "authors": "Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B", "date": "2020-01-28", "evidence": [], "reference": [ { "id": "31986264", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31986264" } ] } ], "biomarker_canonical_id": "AA5023", "collision": 1 }, { "biomarker_id": "AA5023-2", "biomarker_component": [ { "biomarker": "increased IL1B level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-1 beta protein", "synonyms": [ { "synonym": "IL-1 beta" }, { "synonym": "Catabolin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01584", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "13629-1" } ], "evidence_source": [ { "id": "21109482", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21109482", "evidence_list": [ { "evidence": "IL1B protein and IL8 protein as well as S100P mRNA were increased the most between all OSCC patients and controls with a fold change of 3.96, 3.09, and 3.24 respectively. Combined markers proved to be the strongest discriminator of OSCC with an AUC of 0.86 for all cancer patients (IL1B protein + SAT1 mRNA + DUSP1 mRNA), 0.85 for T1-T2 (IL1B mRNA + SAT1 mRNA + DUSP1 mRNA), and 0.88 for T3-T4 (IL1B protein + DUSP1 mRNA) (Figure 1\u00a0and\u00a0Table 3). The sensitivity/specificity for these groups were 0.89/0.78, 0.67/0.96, and 0.82/0.84 respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11934", "recommended_name": { "id": "DOID:11934", "name": "head and neck cancer", "description": "An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, "synonyms": [ { "id": "DOID:11934", "name": "head and neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head/neck neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "head and neck tumours", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" }, { "id": "DOID:11934", "name": "tumor of head and neck", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11934" } ] }, "evidence_source": [ { "id": "21109482", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21109482", "evidence_list": [ { "evidence": "IL1B protein and IL8 protein as well as S100P mRNA were increased the most between all OSCC patients and controls with a fold change of 3.96, 3.09, and 3.24 respectively. Combined markers proved to be the strongest discriminator of OSCC with an AUC of 0.86 for all cancer patients (IL1B protein + SAT1 mRNA + DUSP1 mRNA), 0.85 for T1-T2 (IL1B mRNA + SAT1 mRNA + DUSP1 mRNA), and 0.88 for T3-T4 (IL1B protein + DUSP1 mRNA) (Figure 1\u00a0and\u00a0Table 3). The sensitivity/specificity for these groups were 0.89/0.78, 0.67/0.96, and 0.82/0.84 respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Oral squamous cell carcinoma detection by salivary biomarkers in a Serbian population.", "journal": "Oral oncology", "authors": "Brinkmann O, Kastratovic DA, Dimitrijevic MV, Konstantinovic VS, Jelovac DB, Antic J, Nesic VS, Markovic SZ, Martinovic ZR, Akin D, Spielmann N, Zhou H, Wong DT", "date": "2010-11-27", "evidence": [], "reference": [ { "id": "21109482", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/21109482" } ] } ], "biomarker_canonical_id": "AA5023", "collision": 1 }, { "biomarker_id": "AN4334-1", "biomarker_component": [ { "biomarker": "decreased IL1B level", "assessed_biomarker_entity": { "recommended_name": "Interleukin-1 beta protein", "synonyms": [ { "synonym": "IL-1 beta" }, { "synonym": "Catabolin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01584", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "13629-1" } ], "evidence_source": [ { "id": "17595242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17595242", "evidence_list": [ { "evidence": "Changes in expression of IL1B, early growth response gene 3, and prostaglandin-endoperoxide synthase 2 resolved within 4 months of insulin therapy and were also observed in T2D, suggesting that they resulted from hyperglycemia. With use of a knowledge base, 81 of 282 genes could be placed within a network of interrelated genes with predicted functions including apoptosis and cell proliferation. IL1B and the MYC oncogene were the most highly connected genes in the network. IL1B was highly overexpressed in both T1D and T2D, whereas MYC was dysregulated only in T1D." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "17595242", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17595242", "evidence_list": [ { "evidence": "Changes in expression of IL1B, early growth response gene 3, and prostaglandin-endoperoxide synthase 2 resolved within 4 months of insulin therapy and were also observed in T2D, suggesting that they resulted from hyperglycemia. With use of a knowledge base, 81 of 282 genes could be placed within a network of interrelated genes with predicted functions including apoptosis and cell proliferation. IL1B and the MYC oncogene were the most highly connected genes in the network. IL1B was highly overexpressed in both T1D and T2D, whereas MYC was dysregulated only in T1D." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Gene expression in peripheral blood mononuclear cells from children with diabetes.", "journal": "The Journal of clinical endocrinology and metabolism", "authors": "Kaizer EC, Glaser CL, Chaussabel D, Banchereau J, Pascual V, White PC", "date": "2007-06-28", "evidence": [], "reference": [ { "id": "17595242", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/17595242" } ] } ], "biomarker_canonical_id": "AN4334", "collision": 1 }, { "biomarker_id": "AN4472-1", "biomarker_component": [ { "biomarker": "increased IFNG, CD274, LAG3, CXCL9 level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "IFN-gamma" }, { "synonym": "Immune interferon" } ] }, "assessed_biomarker_entity_id": "UPKB:P01579", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFN gamma-positive (IFN gamma+) signature comprising IFN gamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFN gamma+ signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFN gamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG, CD274, LAG3, CXCL9 level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "PD-L1" }, { "synonym": "PDCD1 ligand 1" }, { "synonym": "Programmed death ligand 1" }, { "synonym": "hPD-L1" }, { "synonym": "B7 homolog 1" }, { "synonym": "B7-H1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZQ7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFN gamma-positive (IFN gamma+) signature comprising IFN gamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFN gamma+ signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFN gamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG, CD274, LAG3, CXCL9 level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "LAG-3" } ] }, "assessed_biomarker_entity_id": "UPKB:P18627", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFN gamma-positive (IFN gamma+) signature comprising IFN gamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFN gamma+ signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFN gamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG, CD274, LAG3, CXCL9 level", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "Gamma-interferon-induced monokine" }, { "synonym": "Monokine induced by interferon-gamma" }, { "synonym": "HuMIG" }, { "synonym": "MIG" }, { "synonym": "Small-inducible cytokine B9" } ] }, "assessed_biomarker_entity_id": "UPKB:Q07325", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFN gamma-positive (IFN gamma+) signature comprising IFN gamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFN gamma+ signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFN gamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFN gamma-positive (IFN gamma+) signature comprising IFN gamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFN gamma+ signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFN gamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] } ], "biomarker_canonical_id": "AN4472", "collision": 0 }, { "biomarker_id": "AN4472-2", "biomarker_component": [ { "biomarker": "increased IFNG+ signature", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "IFN-gamma" }, { "synonym": "Immune interferon" } ] }, "assessed_biomarker_entity_id": "UPKB:P01579", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFNgamma-positive (IFNgamma+) signature comprising IFNgamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNgamma+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFNgamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG+ signature", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "PD-L1" }, { "synonym": "PDCD1 ligand 1" }, { "synonym": "Programmed death ligand 1" }, { "synonym": "hPD-L1" }, { "synonym": "B7 homolog 1" }, { "synonym": "B7-H1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZQ7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFNgamma-positive (IFNgamma+) signature comprising IFNgamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNgamma+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFNgamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG+ signature", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "LAG-3" } ] }, "assessed_biomarker_entity_id": "UPKB:P18627", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFNgamma-positive (IFNgamma+) signature comprising IFNgamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNgamma+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFNgamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased IFNG+ signature", "assessed_biomarker_entity": { "recommended_name": "Interferon gamma+ signature panel", "synonyms": [ { "synonym": "Gamma-interferon-induced monokine" }, { "synonym": "Monokine induced by interferon-gamma" }, { "synonym": "HuMIG" }, { "synonym": "MIG" }, { "synonym": "Small-inducible cytokine B9" } ] }, "assessed_biomarker_entity_id": "UPKB:Q07325", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "12729-0" } ], "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFNgamma-positive (IFNgamma+) signature comprising IFNgamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNgamma+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFNgamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "29716923", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923", "evidence_list": [ { "evidence": "In the NSCLC discovery set, a four-gene IFNgamma-positive (IFNgamma+) signature comprising IFNgamma, CD274, LAG3, and CXCL9 was associated with higher overall response rates, longer median progression-free survival, and overall survival compared with signature-low patients. IFNgamma+-signature NSCLC patients had improved survival regardless of IHC PD-L1 status. These associations were replicated in a urothelial cancer cohort. The IFNgamma+ signature was induced 2-fold (P = 0.003) by durvalumab after 8 weeks of therapy in patients with NSCLC, and baseline signature was associated with TMB but not survival in TCGA data." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] }, { "title": "Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K", "date": "2018-05-03", "evidence": [], "reference": [ { "id": "29716923", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29716923" } ] } ], "biomarker_canonical_id": "AN4472", "collision": 0 }, { "biomarker_id": "AN4337-1", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-2", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-3", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:4362", "recommended_name": { "id": "DOID:4362", "name": "cervical cancer", "description": "A female reproductive organ cancer that is located_in the cervix.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, "synonyms": [ { "id": "DOID:4362", "name": "tumor of the Cervix Uteri", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix uteri cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "cervix cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "neoplasm of uterine cervix", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" }, { "id": "DOID:4362", "name": "uterine cervical neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_4362" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-4", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-5", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-6", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2531", "recommended_name": { "id": "DOID:2531", "name": "hematologic cancer", "description": "An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, "synonyms": [ { "id": "DOID:2531", "name": "Hematologic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematologic malignancy", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic and lymphoid system tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "blood cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "malignant hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "Hematological tumors", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" }, { "id": "DOID:2531", "name": "hematopoietic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2531" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-7", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:263", "recommended_name": { "id": "DOID:263", "name": "kidney cancer", "description": "A urinary system cancer that is located_in the kidney.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, "synonyms": [ { "id": "DOID:263", "name": "malignant tumour of kidney", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "malignant neoplasm of kidney except pelvis", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" }, { "id": "DOID:263", "name": "renal cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_263" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-8", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-9", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-10", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-11", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-12", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:8584", "recommended_name": { "id": "DOID:8584", "name": "lymphoma", "description": "A mature B-cell neoplasm of B-cells found in the germinal center.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, "synonyms": [ { "id": "DOID:8584", "name": "Burkitt's tumor or lymphoma", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "small Non-Cleaved cell Lymphoma, Burkitt's type", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt lymphoma/leukaemia", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt's Lymphoma", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "Burkitt's tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" }, { "id": "DOID:8584", "name": "malignant lymphoma, Burkitt's type", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_8584" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4337-13", "biomarker_component": [ { "biomarker": "decreased ALB-GLO ratio", "assessed_biomarker_entity": { "recommended_name": "Albumin to Globulin ratio Measurement", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C74894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "35706-1" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "35706-1" } ], "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32479790", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790", "evidence_list": [ { "evidence": "Resistant organ damage indices (albumin and albumin-globulin ratio) were significantly associated with lower severity of COVID-19 in patients with cancer (table 3)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.", "journal": "The Lancet. Oncology", "authors": "Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y, Liu S, Cheng B, Wang J, Zhang M, Wang L, Niu S, Yao Z, Deng X, Zhou F, Wei W, Li Q, Chen X, Chen W, Yang Q, Wu S, Fan J, Shu B, Hu Z, Wang S, Yang XP, Liu W, Miao X, Wang Z", "date": "2020-06-02", "evidence": [], "reference": [ { "id": "32479790", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32479790" } ] } ], "biomarker_canonical_id": "AN4337", "collision": 1 }, { "biomarker_id": "AN4473-1", "biomarker_component": [ { "biomarker": "decreased LCRNLR ratio", "assessed_biomarker_entity": { "recommended_name": "LCR to NLR ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "CO:CL_0000542", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased LCRNLR ratio", "assessed_biomarker_entity": { "recommended_name": "LCR to NLR ratio", "synonyms": [ { "synonym": "polymorphonuclear neutrophil" }, { "synonym": "poly" }, { "synonym": "PMN" }, { "synonym": "neutrophilic leucocyte" }, { "synonym": "polynuclear neutrophilic leukocyte" }, { "synonym": "neutrophil leucocyte" }, { "synonym": "neutrocyte" }, { "synonym": "polymorphonuclear leucocyte" }, { "synonym": "polynuclear neutrophilic leucocyte" }, { "synonym": "polymorphonuclear leukocyte" }, { "synonym": "neutrophil leukocyte" }, { "synonym": "neutrophilic leukocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000775", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased LCRNLR ratio", "assessed_biomarker_entity": { "recommended_name": "LCR to NLR ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32655735", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735", "evidence_list": [ { "evidence": "A lower LCR and a high NLR could serve as predictive markers for in-hospital complications and mortality in patients with COVID-19. Compared to NLR, high LCR on presentation accurately predicts the in-hospital need for IMV and an upgrade to the ICU." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.", "journal": "Journal of clinical medicine research", "authors": "Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, Haq S, Madara J, Boigon M, Haas DC, Fischman DL", "date": "2020-07-14", "evidence": [], "reference": [ { "id": "32655735", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735" } ] }, { "title": "Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.", "journal": "Journal of clinical medicine research", "authors": "Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, Haq S, Madara J, Boigon M, Haas DC, Fischman DL", "date": "2020-07-14", "evidence": [], "reference": [ { "id": "32655735", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735" } ] }, { "title": "Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19.", "journal": "Journal of clinical medicine research", "authors": "Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, Haq S, Madara J, Boigon M, Haas DC, Fischman DL", "date": "2020-07-14", "evidence": [], "reference": [ { "id": "32655735", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32655735" } ] } ], "biomarker_canonical_id": "AN4473", "collision": 0 }, { "biomarker_id": "AN4474-1", "biomarker_component": [ { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Scurfin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZS1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "E3 ubiquitin-protein ligase TRAF2" }, { "synonym": "RING-type E3 ubiquitin transferase TRAF2" }, { "synonym": "Tumor necrosis factor type 2 receptor-associated protein 3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12933", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Medulla oblongata-derived protein" }, { "synonym": "Protein Mob" }, { "synonym": "Sphingomyelin synthase 1" }, { "synonym": "Transmembrane protein 23" } ] }, "assessed_biomarker_entity_id": "UPKB:Q86VZ5", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9HCE3", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "ANK-3" }, { "synonym": "Ankyrin-G" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12955", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Garpin" }, { "synonym": "Glycoprotein A repetitions predominant" }, { "synonym": "GARP" }, { "synonym": "Leucine-rich repeat-containing protein 32" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14392", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:9351", "recommended_name": { "id": "DOID:9351", "name": "diabetes mellitus", "description": "A glucose metabolism disease that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" }, "synonyms": [ { "id": "DOID:9351", "name": "diabetes", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9351" } ] }, "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] } ], "biomarker_canonical_id": "AN4474", "collision": 0 }, { "biomarker_id": "AN4474-2", "biomarker_component": [ { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Scurfin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZS1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "E3 ubiquitin-protein ligase TRAF2" }, { "synonym": "RING-type E3 ubiquitin transferase TRAF2" }, { "synonym": "Tumor necrosis factor type 2 receptor-associated protein 3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12933", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Medulla oblongata-derived protein" }, { "synonym": "Protein Mob" }, { "synonym": "Sphingomyelin synthase 1" }, { "synonym": "Transmembrane protein 23" } ] }, "assessed_biomarker_entity_id": "UPKB:Q86VZ5", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9HCE3", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "ANK-3" }, { "synonym": "Ankyrin-G" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12955", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "altered FOXP3, TNFRSF1B, TMEM23, ZNF532, ANK3, LRRC32 expression", "assessed_biomarker_entity": { "recommended_name": "Type 1 diabetes regulatory T cell gene panel", "synonyms": [ { "synonym": "Garpin" }, { "synonym": "Glycoprotein A repetitions predominant" }, { "synonym": "GARP" }, { "synonym": "Leucine-rich repeat-containing protein 32" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14392", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "90413-6" } ], "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "26786322", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322", "evidence_list": [ { "evidence": "By using biomarker discovery analysis, we found that expression of a combination of six genes, including TNFRSF1B (CD120b) and FOXP3, was significantly different between Tregs from subjects with new-onset T1D and control subjects, resulting in a sensitive (mean \u00b1 SD 0.86 \u00b1 0.14) and specific (0.78 \u00b1 0.18) biomarker algorithm. Thus, although the proportion of Tregs in peripheral blood is similar between children with T1D and control subjects, significant changes in gene expression can be detected early in disease process. Lower expression of FOXP3, TNFRSF1B (CD120b), TMEM23 (SGMS1), ZNF532, ANK3, and increased LRRC32 (GARP)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] }, { "title": "A Regulatory T-Cell Gene Signature Is a Specific and Sensitive Biomarker to Identify Children With New-Onset Type 1 Diabetes.", "journal": "Diabetes", "authors": "Pesenacker AM, Wang AY, Singh A, Gillies J, Kim Y, Piccirillo CA, Nguyen D, Haining WN, Tebbutt SJ, Panagiotopoulos C, Levings MK", "date": "2016-01-21", "evidence": [], "reference": [ { "id": "26786322", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/26786322" } ] } ], "biomarker_canonical_id": "AN4474", "collision": 0 }, { "biomarker_id": "AN4345-1", "biomarker_component": [ { "biomarker": "presence of", "assessed_biomarker_entity": { "recommended_name": "Ras association domain-containing protein 1 gene methylation", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NS23", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "24980613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613", "evidence_list": [ { "evidence": "RASSF1 was methylated in 45% of prostate cancer urine samples with methylation intensity significantly higher in prostate cancer than in benign prostatic hyperplasia cases (p = 0.018). In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively). On multivariate analysis RASSF1 methylation together with pathological stage was the most significant predictor of biochemical recurrence in patients with Gleason score 6 tumors when analyzed in tissue and urine (p \u22640.001)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "24980613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613", "evidence_list": [ { "evidence": "RASSF1 was methylated in 45% of prostate cancer urine samples with methylation intensity significantly higher in prostate cancer than in benign prostatic hyperplasia cases (p = 0.018). In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively). On multivariate analysis RASSF1 methylation together with pathological stage was the most significant predictor of biochemical recurrence in patients with Gleason score 6 tumors when analyzed in tissue and urine (p \u22640.001)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic value of RASSF1 promoter methylation in prostate cancer.", "journal": "The Journal of urology", "authors": "Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F", "date": "2014-07-02", "evidence": [], "reference": [ { "id": "24980613", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613" } ] } ], "biomarker_canonical_id": "AN4345", "collision": 1 }, { "biomarker_id": "AN4475-1", "biomarker_component": [ { "biomarker": "increased CA125, HE4, E-CAD, IL-6 level", "assessed_biomarker_entity": { "recommended_name": "Earlier stage ovarian cancer IL6, WFDC2, MUC16, CDH1 panel", "synonyms": [ { "synonym": "IL-6" }, { "synonym": "B-cell stimulatory factor 2" }, { "synonym": "BSF-2" }, { "synonym": "CTL differentiation factor" }, { "synonym": "CDF" }, { "synonym": "Hybridoma growth factor" }, { "synonym": "Interferon beta-2" }, { "synonym": "IFN-beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P05231", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4|10334-1|26881-3" } ], "evidence_source": [ { "id": "29572027", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027", "evidence_list": [ { "evidence": "The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased CA125, HE4, E-CAD, IL-6 level", "assessed_biomarker_entity": { "recommended_name": "Earlier stage ovarian cancer IL6, WFDC2, MUC16, CDH1 panel", "synonyms": [ { "synonym": "Epididymal secretory protein E4" }, { "synonym": "Major epididymis-specific protein E4" }, { "synonym": "Putative protease inhibitor WAP5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14508", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4|10334-1|26881-3" } ], "evidence_source": [ { "id": "29572027", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027", "evidence_list": [ { "evidence": "The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased CA125, HE4, E-CAD, IL-6 level", "assessed_biomarker_entity": { "recommended_name": "Earlier stage ovarian cancer IL6, WFDC2, MUC16, CDH1 panel", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4|10334-1|26881-3" } ], "evidence_source": [ { "id": "29572027", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027", "evidence_list": [ { "evidence": "The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased CA125, HE4, E-CAD, IL-6 level", "assessed_biomarker_entity": { "recommended_name": "Earlier stage ovarian cancer IL6, WFDC2, MUC16, CDH1 panel", "synonyms": [ { "synonym": "CAM 120/80" }, { "synonym": "Epithelial cadherin" }, { "synonym": "E-cadherin" }, { "synonym": "Uvomorulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P12830", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "55180-4|10334-1|26881-3" } ], "evidence_source": [ { "id": "29572027", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027", "evidence_list": [ { "evidence": "The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "29572027", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027", "evidence_list": [ { "evidence": "The four-marker panel, CA125, HE4, E-CAD, and IL-6, shows potential in detecting serous ovarian cancer at earlier stages. The 4-marker panel had the highest average sensitivity under the region of its ROC curve corresponding to specificity ranging from 100% down to ~95%." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.", "journal": "Gynecologic oncology", "authors": "Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD", "date": "2018-03-25", "evidence": [], "reference": [ { "id": "29572027", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027" } ] }, { "title": "A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.", "journal": "Gynecologic oncology", "authors": "Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD", "date": "2018-03-25", "evidence": [], "reference": [ { "id": "29572027", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027" } ] }, { "title": "A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.", "journal": "Gynecologic oncology", "authors": "Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD", "date": "2018-03-25", "evidence": [], "reference": [ { "id": "29572027", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027" } ] }, { "title": "A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.", "journal": "Gynecologic oncology", "authors": "Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD", "date": "2018-03-25", "evidence": [], "reference": [ { "id": "29572027", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29572027" } ] } ], "biomarker_canonical_id": "AN4475", "collision": 0 }, { "biomarker_id": "AN4476-1", "biomarker_component": [ { "biomarker": "decreased MIR-191-5P, MIR-1246 level", "assessed_biomarker_entity": { "recommended_name": "Uterine cancer circulating miR-191-5p, miR-1246 panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0006381", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31599471", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31599471", "evidence_list": [ { "evidence": "7 miRNAs were selected as candidate miRNAs with a cross- validation score greater than 0.75 and an absolute value of fold change (log2) >0.5, and expression level significantly lower in Uterine Leiomyosarcoma (ULMS). All ULMS patients were precisely identified as having a positive DI using the two-miRNA prediction model. \u2026the best combination was determined, which consisted of two miRNAs (miR-191-5p and miR-1246). Thus, the identified combination of two miRNAs is a promising biomarker for ULMS screening and distinction from ULM. The optimal model consisted of two miRNAs (miR-1246 and miR-191-5p)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased MIR-191-5P, MIR-1246 level", "assessed_biomarker_entity": { "recommended_name": "Uterine cancer circulating miR-191-5p, miR-1246 panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000440", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31599471", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31599471", "evidence_list": [ { "evidence": "7 miRNAs were selected as candidate miRNAs with a cross- validation score greater than 0.75 and an absolute value of fold change (log2) >0.5, and expression level significantly lower in Uterine Leiomyosarcoma (ULMS). All ULMS patients were precisely identified as having a positive DI using the two-miRNA prediction model. \u2026the best combination was determined, which consisted of two miRNAs (miR-191-5p and miR-1246). Thus, the identified combination of two miRNAs is a promising biomarker for ULMS screening and distinction from ULM. The optimal model consisted of two miRNAs (miR-1246 and miR-191-5p)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "31599471", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31599471", "evidence_list": [ { "evidence": "7 miRNAs were selected as candidate miRNAs with a cross- validation score greater than 0.75 and an absolute value of fold change (log2) >0.5, and expression level significantly lower in Uterine Leiomyosarcoma (ULMS). All ULMS patients were precisely identified as having a positive DI using the two-miRNA prediction model. \u2026the best combination was determined, which consisted of two miRNAs (miR-191-5p and miR-1246). Thus, the identified combination of two miRNAs is a promising biomarker for ULMS screening and distinction from ULM. The optimal model consisted of two miRNAs (miR-1246 and miR-191-5p)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.", "journal": "Cancer science", "authors": "Yokoi A, Matsuzaki J, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T, Ochiya T", "date": "2019-10-11", "evidence": [], "reference": [ { "id": "31599471", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31599471" } ] }, { "title": "Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.", "journal": "Cancer science", "authors": "Yokoi A, Matsuzaki J, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T, Ochiya T", "date": "2019-10-11", "evidence": [], "reference": [ { "id": "31599471", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31599471" } ] } ], "biomarker_canonical_id": "AN4476", "collision": 0 }, { "biomarker_id": "AN4477-1", "biomarker_component": [ { "biomarker": "decreased MIR-124-3p, MIR-146a-5p, MIR-155-5p, MIR-335-5p level", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer downregulated miRNA-124-3p, miRNA-146a-5p, miRNA-155-5p, miRNA-335-5p panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000422", "assessed_entity_type": "miRNA", "specimen": [], "evidence_source": [ { "id": "24805774", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774", "evidence_list": [ { "evidence": "...4 screened miRNAs, mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p were found to be downregulated in gastric cancer. Clinical significance and bioinformatic analysis on the target genes of these 4 miRNAs indicated that they were deeply involved in tumorigenesis, suggesting roles such as miRNA tumor suppressors in gastric cancer tumorigenesis which could be applied in gastric cancer diagnosis and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased MIR-124-3p, MIR-146a-5p, MIR-155-5p, MIR-335-5p level", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer downregulated miRNA-124-3p, miRNA-146a-5p, miRNA-155-5p, miRNA-335-5p panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000449", "assessed_entity_type": "miRNA", "specimen": [], "evidence_source": [ { "id": "24805774", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774", "evidence_list": [ { "evidence": "...4 screened miRNAs, mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p were found to be downregulated in gastric cancer. Clinical significance and bioinformatic analysis on the target genes of these 4 miRNAs indicated that they were deeply involved in tumorigenesis, suggesting roles such as miRNA tumor suppressors in gastric cancer tumorigenesis which could be applied in gastric cancer diagnosis and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased MIR-124-3p, MIR-146a-5p, MIR-155-5p, MIR-335-5p level", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer downregulated miRNA-124-3p, miRNA-146a-5p, miRNA-155-5p, miRNA-335-5p panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000646", "assessed_entity_type": "miRNA", "specimen": [], "evidence_source": [ { "id": "24805774", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774", "evidence_list": [ { "evidence": "...4 screened miRNAs, mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p were found to be downregulated in gastric cancer. Clinical significance and bioinformatic analysis on the target genes of these 4 miRNAs indicated that they were deeply involved in tumorigenesis, suggesting roles such as miRNA tumor suppressors in gastric cancer tumorigenesis which could be applied in gastric cancer diagnosis and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased MIR-124-3p, MIR-146a-5p, MIR-155-5p, MIR-335-5p level", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer downregulated miRNA-124-3p, miRNA-146a-5p, miRNA-155-5p, miRNA-335-5p panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MIMAT0000765", "assessed_entity_type": "miRNA", "specimen": [], "evidence_source": [ { "id": "24805774", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774", "evidence_list": [ { "evidence": "...4 screened miRNAs, mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p were found to be downregulated in gastric cancer. Clinical significance and bioinformatic analysis on the target genes of these 4 miRNAs indicated that they were deeply involved in tumorigenesis, suggesting roles such as miRNA tumor suppressors in gastric cancer tumorigenesis which could be applied in gastric cancer diagnosis and prognosis." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "24805774", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774", "evidence_list": [ { "evidence": "...4 screened miRNAs, mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p were found to be downregulated in gastric cancer. Clinical significance and bioinformatic analysis on the target genes of these 4 miRNAs indicated that they were deeply involved in tumorigenesis, suggesting roles such as miRNA tumor suppressors in gastric cancer tumorigenesis which could be applied in gastric cancer diagnosis and prognosis." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.", "journal": "International journal of oncology", "authors": "Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D, Zhou Y", "date": "2014-05-09", "evidence": [], "reference": [ { "id": "24805774", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774" } ] }, { "title": "The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.", "journal": "International journal of oncology", "authors": "Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D, Zhou Y", "date": "2014-05-09", "evidence": [], "reference": [ { "id": "24805774", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774" } ] }, { "title": "The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.", "journal": "International journal of oncology", "authors": "Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D, Zhou Y", "date": "2014-05-09", "evidence": [], "reference": [ { "id": "24805774", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774" } ] }, { "title": "The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis.", "journal": "International journal of oncology", "authors": "Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D, Zhou Y", "date": "2014-05-09", "evidence": [], "reference": [ { "id": "24805774", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24805774" } ] } ], "biomarker_canonical_id": "AN4477", "collision": 0 }, { "biomarker_id": "AN4478-1", "biomarker_component": [ { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "Bone sialoprotein 1" }, { "synonym": "Nephropontin" }, { "synonym": "Secreted phosphoprotein 1" }, { "synonym": "SPP-1" }, { "synonym": "Urinary stone protein" }, { "synonym": "Uropontin" } ] }, "assessed_biomarker_entity_id": "UPKB:P10451", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "Obese protein" }, { "synonym": "Obesity factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P41159", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "PRL" } ] }, "assessed_biomarker_entity_id": "UPKB:P01236", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "IGF-II" }, { "synonym": "Somatomedin-A" }, { "synonym": "T3M-11-derived growth factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P01344", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MUC16, OPN, LEP, PRL, IGF2, MIF level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer OPN, MUC16, LEP, PRL, IGF2, MIF expression panel", "synonyms": [ { "synonym": "MIF" }, { "synonym": "Glycosylation-inhibiting factor" }, { "synonym": "GIF" }, { "synonym": "L-dopachrome isomerase" }, { "synonym": "L-dopachrome tautomerase" }, { "synonym": "Phenylpyruvate tautomerase" } ] }, "assessed_biomarker_entity_id": "UPKB:P14174", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "10334-1|21365-2|15081-3|2485-1" } ], "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "18258665", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665", "evidence_list": [ { "evidence": "We describe the first blood biomarker test with a sensitivity of 95.3% and a specificity of 99.4% for the detection of ovarian cancer. Six markers provided a significant improvement over CA-125 alone for ovarian cancer detection. Validation was performed with a blinded cohort. This novel multiplex platform has the potential for efficient screening in patients who are at high risk for ovarian cancer. The combination of the six markers (leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125) provided a better differentiation than CA-125." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] }, { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] }, { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] }, { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] }, { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] }, { "title": "Diagnostic markers for early detection of ovarian cancer.", "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authors": "Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G", "date": "2008-02-09", "evidence": [], "reference": [ { "id": "18258665", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18258665" } ] } ], "biomarker_canonical_id": "AN4478", "collision": 0 }, { "biomarker_id": "AN4479-1", "biomarker_component": [ { "biomarker": "increased tryptophan metabolites level", "assessed_biomarker_entity": { "recommended_name": "High-grade urinary bladder cancer upregulated tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:123932", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased tryptophan metabolites level", "assessed_biomarker_entity": { "recommended_name": "High-grade urinary bladder cancer upregulated tryptophan metabolism panel", "synonyms": [ { "synonym": "1,3-dihydroxypropan-2-yl (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate" } ] }, "assessed_biomarker_entity_id": "CHEBI:168264", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased tryptophan metabolites level", "assessed_biomarker_entity": { "recommended_name": "High-grade urinary bladder cancer upregulated tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:14717808", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased tryptophan metabolites level", "assessed_biomarker_entity": { "recommended_name": "High-grade urinary bladder cancer upregulated tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:46937960", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] } ], "biomarker_canonical_id": "AN4479", "collision": 0 }, { "biomarker_id": "AN4480-1", "biomarker_component": [ { "biomarker": "measured 3-Hydroxy-cis-5-tetradecenoylcarnitine, 6-Ketoestriol, Beta-cortolone, Tetrahydrocorticosterone, Heptylmalonic acid level", "assessed_biomarker_entity": { "recommended_name": "Low-grade urinary bladder cancer tryptophan metabolism panel", "synonyms": [ { "synonym": "Hydroxytetradecenoyl-L-carnitine" }, { "synonym": "3-Hydroxy-5Z-tetradecenoylcarnitine" }, { "synonym": "(4S)-4-{[(5Z)-3-hydroxytetradec-5-enoyl]oxy}-4-(trimethylazaniumyl)butanoate" }, { "synonym": "3-Hydroxy-5-tetradecenoylcarnitine" }, { "synonym": "3-Hydroxytetradecenoylcarnitine" }, { "synonym": "3-Hydroxy-5(Z)-tetradecenoylcarnitine" } ] }, "assessed_biomarker_entity_id": "CHEBI:89748", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 3-Hydroxy-cis-5-tetradecenoylcarnitine, 6-Ketoestriol, Beta-cortolone, Tetrahydrocorticosterone, Heptylmalonic acid level", "assessed_biomarker_entity": { "recommended_name": "Low-grade urinary bladder cancer tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:11876959", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 3-Hydroxy-cis-5-tetradecenoylcarnitine, 6-Ketoestriol, Beta-cortolone, Tetrahydrocorticosterone, Heptylmalonic acid level", "assessed_biomarker_entity": { "recommended_name": "Low-grade urinary bladder cancer tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:245259", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 3-Hydroxy-cis-5-tetradecenoylcarnitine, 6-Ketoestriol, Beta-cortolone, Tetrahydrocorticosterone, Heptylmalonic acid level", "assessed_biomarker_entity": { "recommended_name": "Low-grade urinary bladder cancer tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:65553", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 3-Hydroxy-cis-5-tetradecenoylcarnitine, 6-Ketoestriol, Beta-cortolone, Tetrahydrocorticosterone, Heptylmalonic acid level", "assessed_biomarker_entity": { "recommended_name": "Low-grade urinary bladder cancer tryptophan metabolism panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PCCID:136574", "assessed_entity_type": "metabolite", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:11054", "recommended_name": { "id": "DOID:11054", "name": "urinary bladder cancer", "description": "An urinary system cancer that results_in malignant growth located_in the urinary bladder.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, "synonyms": [ { "id": "DOID:11054", "name": "tumor of the bladder", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" }, { "id": "DOID:11054", "name": "bladder cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_11054" } ] }, "evidence_source": [ { "id": "30450336", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336", "evidence_list": [ { "evidence": "Panels of metabolites were discovered to have potential value for high-grade NMIBC and low-grade NMIBC diagnosis as well as for NMIBC grading distinction. Our data will not only benefit the application of the urine metabolome in disease biomarker discovery but also contribute to the exploration of the initiation of NMIBC. Metabolites involved in tryptophan metabolism were upregulated in the urine of high-grade NMIBC patients when compared with low-grade NMIBC patients with the presence or absence of hematuria. The metabolite panel including dopamine 4-sulfate, MG00/1846Z,9Z,12Z,15Z/00, aspartyl-histidine, and tyrosyl-methionine was found in a discovery set, which showed the predictive ability to distinguish the NMIBC group from the control group with an area under the curve (AUC) of 0.838 in an external validation set. The AUC of the panel for low-grade NMIBC samples, which consisted of 3-hydroxy-cis-5-tetradecenoylcarnitine, 6-ketoestriol, beta-cortolone, tetrahydrocorticosterone, and heptylmalonic acid, was 0.899. The sensitivity and specificity were 0.881 and 0.786, respectively." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] }, { "title": "Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer.", "journal": "Frontiers in oncology", "authors": "Cheng X, Liu X, Liu X, Guo Z, Sun H, Zhang M, Ji Z, Sun W", "date": "2018-11-20", "evidence": [], "reference": [ { "id": "30450336", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30450336" } ] } ], "biomarker_canonical_id": "AN4480", "collision": 0 }, { "biomarker_id": "AN4481-1", "biomarker_component": [ { "biomarker": "measured TRIM21, NY-ESO-1, TP53, PAX8 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer TRIM21, NY-ESO-1, TP53, PAX8 expression panel", "synonyms": [ { "synonym": "52 kDa Ro protein" }, { "synonym": "52 kDa ribonucleoprotein autoantigen Ro/SS-A" }, { "synonym": "RING finger protein 81" }, { "synonym": "Ro(SS-A)" }, { "synonym": "Sjoegren syndrome type A antigen" }, { "synonym": "SS-A" }, { "synonym": "Tripartite motif-containing protein 21" } ] }, "assessed_biomarker_entity_id": "UPKB:P19474", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32083570", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570", "evidence_list": [ { "evidence": "TRIM21 achieved the highest sensitivity in the first validation screening of 33% with 100% specificity. Combining TRIM21 with NY-ESO-1, TP53, and PAX8 provided 67% sensitivity with 94% specificity, and 56% sensitivity at 98% specificity. These four markers resulted in 46% sensitivity with 98% specificity in the second validation cohort. Autoantibodies to TRIM21, NY-ESO-1, and TP53 may complement CA125 in screening of women at genetic risk for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured TRIM21, NY-ESO-1, TP53, PAX8 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer TRIM21, NY-ESO-1, TP53, PAX8 expression panel", "synonyms": [ { "synonym": "Autoimmunogenic cancer/testis antigen NY-ESO-1" }, { "synonym": "Cancer/testis antigen 6.1" }, { "synonym": "CT6.1" }, { "synonym": "L antigen family member 2" }, { "synonym": "LAGE-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P78358", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32083570", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570", "evidence_list": [ { "evidence": "TRIM21 achieved the highest sensitivity in the first validation screening of 33% with 100% specificity. Combining TRIM21 with NY-ESO-1, TP53, and PAX8 provided 67% sensitivity with 94% specificity, and 56% sensitivity at 98% specificity. These four markers resulted in 46% sensitivity with 98% specificity in the second validation cohort. Autoantibodies to TRIM21, NY-ESO-1, and TP53 may complement CA125 in screening of women at genetic risk for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured TRIM21, NY-ESO-1, TP53, PAX8 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer TRIM21, NY-ESO-1, TP53, PAX8 expression panel", "synonyms": [ { "synonym": "Antigen NY-CO-13" }, { "synonym": "Phosphoprotein p53" }, { "synonym": "Tumor suppressor p53" } ] }, "assessed_biomarker_entity_id": "UPKB:P04637", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32083570", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570", "evidence_list": [ { "evidence": "TRIM21 achieved the highest sensitivity in the first validation screening of 33% with 100% specificity. Combining TRIM21 with NY-ESO-1, TP53, and PAX8 provided 67% sensitivity with 94% specificity, and 56% sensitivity at 98% specificity. These four markers resulted in 46% sensitivity with 98% specificity in the second validation cohort. Autoantibodies to TRIM21, NY-ESO-1, and TP53 may complement CA125 in screening of women at genetic risk for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured TRIM21, NY-ESO-1, TP53, PAX8 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer TRIM21, NY-ESO-1, TP53, PAX8 expression panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q06710", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32083570", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570", "evidence_list": [ { "evidence": "TRIM21 achieved the highest sensitivity in the first validation screening of 33% with 100% specificity. Combining TRIM21 with NY-ESO-1, TP53, and PAX8 provided 67% sensitivity with 94% specificity, and 56% sensitivity at 98% specificity. These four markers resulted in 46% sensitivity with 98% specificity in the second validation cohort. Autoantibodies to TRIM21, NY-ESO-1, and TP53 may complement CA125 in screening of women at genetic risk for ovarian cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "32083570", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570", "evidence_list": [ { "evidence": "TRIM21 achieved the highest sensitivity in the first validation screening of 33% with 100% specificity. Combining TRIM21 with NY-ESO-1, TP53, and PAX8 provided 67% sensitivity with 94% specificity, and 56% sensitivity at 98% specificity. These four markers resulted in 46% sensitivity with 98% specificity in the second validation cohort. Autoantibodies to TRIM21, NY-ESO-1, and TP53 may complement CA125 in screening of women at genetic risk for ovarian cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32083570", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570" } ] }, { "title": "Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32083570", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570" } ] }, { "title": "Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32083570", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570" } ] }, { "title": "Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.", "journal": "Cancer biomarkers : section A of Disease markers", "authors": "Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA", "date": "2020-02-23", "evidence": [], "reference": [ { "id": "32083570", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32083570" } ] } ], "biomarker_canonical_id": "AN4481", "collision": 0 }, { "biomarker_id": "AN4482-1", "biomarker_component": [ { "biomarker": "increased MIR-1246, MIR-21 level", "assessed_biomarker_entity": { "recommended_name": "Breast cancer miR-1246, miR-21 plasma exosome panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0006381", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27608715", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27608715", "evidence_list": [ { "evidence": "This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased MIR-1246, MIR-21 level", "assessed_biomarker_entity": { "recommended_name": "Breast cancer miR-1246, miR-21 plasma exosome panel", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000077", "assessed_entity_type": "miRNA", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "27608715", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27608715", "evidence_list": [ { "evidence": "This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "27608715", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27608715", "evidence_list": [ { "evidence": "This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Plasma exosome microRNAs are indicative of breast cancer.", "journal": "Breast cancer research : BCR", "authors": "Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ", "date": "2016-09-10", "evidence": [], "reference": [ { "id": "27608715", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27608715" } ] }, { "title": "Plasma exosome microRNAs are indicative of breast cancer.", "journal": "Breast cancer research : BCR", "authors": "Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ", "date": "2016-09-10", "evidence": [], "reference": [ { "id": "27608715", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/27608715" } ] } ], "biomarker_canonical_id": "AN4482", "collision": 0 }, { "biomarker_id": "AN4483-1", "biomarker_component": [ { "biomarker": "decreased IL1B, AGPAT1, B2M, BASP2, IER3 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer AGPAT1, B2M, BASP2, IER3, IL1B RNA signature panel", "synonyms": [ { "synonym": "IL-1 beta" }, { "synonym": "Catabolin" } ] }, "assessed_biomarker_entity_id": "UPKB:P01584", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased IL1B, AGPAT1, B2M, BASP2, IER3 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer AGPAT1, B2M, BASP2, IER3, IL1B RNA signature panel", "synonyms": [ { "synonym": "1-acylglycerol-3-phosphate O-acyltransferase 1" }, { "synonym": "1-AGP acyltransferase 1" }, { "synonym": "1-AGPAT 1" }, { "synonym": "Lysophosphatidic acid acyltransferase alpha" }, { "synonym": "LPAAT-alpha" }, { "synonym": "Protein G15" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99943", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased IL1B, AGPAT1, B2M, BASP2, IER3 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer AGPAT1, B2M, BASP2, IER3, IL1B RNA signature panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P61769", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased IL1B, AGPAT1, B2M, BASP2, IER3 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer AGPAT1, B2M, BASP2, IER3, IL1B RNA signature panel", "synonyms": [ { "synonym": "Axonal membrane protein GAP-43" }, { "synonym": "Growth-associated protein 43" }, { "synonym": "Neural phosphoprotein B-50" }, { "synonym": "pp46" } ] }, "assessed_biomarker_entity_id": "UPKB:P17677", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "decreased IL1B, AGPAT1, B2M, BASP2, IER3 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer AGPAT1, B2M, BASP2, IER3, IL1B RNA signature panel", "synonyms": [ { "synonym": "Differentiation-dependent gene 2 protein" }, { "synonym": "Protein DIF-2" }, { "synonym": "Immediate early protein GLY96" }, { "synonym": "Immediate early response 3 protein" }, { "synonym": "PACAP-responsive gene 1 protein" }, { "synonym": "Protein PRG1" } ] }, "assessed_biomarker_entity_id": "UPKB:P46695", "assessed_entity_type": "protein", "specimen": [ { "name": "saliva", "id": "UBERON:0001836", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001836", "loinc_code": "" } ], "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "22095100", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100", "evidence_list": [ { "evidence": "The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.", "journal": "Journal of molecular medicine (Berlin, Germany)", "authors": "Lee YH, Kim JH, Zhou H, Kim BW, Wong DT", "date": "2011-11-19", "evidence": [], "reference": [ { "id": "22095100", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100" } ] }, { "title": "Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.", "journal": "Journal of molecular medicine (Berlin, Germany)", "authors": "Lee YH, Kim JH, Zhou H, Kim BW, Wong DT", "date": "2011-11-19", "evidence": [], "reference": [ { "id": "22095100", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100" } ] }, { "title": "Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.", "journal": "Journal of molecular medicine (Berlin, Germany)", "authors": "Lee YH, Kim JH, Zhou H, Kim BW, Wong DT", "date": "2011-11-19", "evidence": [], "reference": [ { "id": "22095100", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100" } ] }, { "title": "Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.", "journal": "Journal of molecular medicine (Berlin, Germany)", "authors": "Lee YH, Kim JH, Zhou H, Kim BW, Wong DT", "date": "2011-11-19", "evidence": [], "reference": [ { "id": "22095100", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100" } ] }, { "title": "Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.", "journal": "Journal of molecular medicine (Berlin, Germany)", "authors": "Lee YH, Kim JH, Zhou H, Kim BW, Wong DT", "date": "2011-11-19", "evidence": [], "reference": [ { "id": "22095100", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/22095100" } ] } ], "biomarker_canonical_id": "AN4483", "collision": 0 }, { "biomarker_id": "AN4484-1", "biomarker_component": [ { "biomarker": "increased HSP27, ALDH6A1, PHB level", "assessed_biomarker_entity": { "recommended_name": "Prostate cancer trio-biomarker HSP27, ALDH6A1, Prohibitin overexpression panel", "synonyms": [ { "synonym": "HspB3" }, { "synonym": "Heat shock 17 kDa protein" }, { "synonym": "HSP 17" }, { "synonym": "Protein 3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q12988", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "30396985", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985", "evidence_list": [ { "evidence": "In the present study, ALDH6A1 overexpression was significantly associated with lymphatic invasion in PCa. SP27 expression is correlated with clinical PCa progression, with the highest expression found in metastatic PCa. HSP expression independently predicts clinical outcome in prostate cancer, However, unlike previous studies showing that prohibitin expression suppresses prostate cancer, our findings show that prohibitin expression is higher in prostate cancer compared to normal cells. Also, this expression was stronger in higher-grade than in lower-grade cancers, and was stronger in metastatic prostate cancer than in localised cancers. HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients. However, all three proteins were a stronger marker than each one separately." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased HSP27, ALDH6A1, PHB level", "assessed_biomarker_entity": { "recommended_name": "Prostate cancer trio-biomarker HSP27, ALDH6A1, Prohibitin overexpression panel", "synonyms": [ { "synonym": "MMSDH" }, { "synonym": "Aldehyde dehydrogenase family 6 member A1" }, { "synonym": "Malonate-semialdehyde dehydrogenase [acylating]" } ] }, "assessed_biomarker_entity_id": "UPKB:Q02252", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "30396985", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985", "evidence_list": [ { "evidence": "In the present study, ALDH6A1 overexpression was significantly associated with lymphatic invasion in PCa. SP27 expression is correlated with clinical PCa progression, with the highest expression found in metastatic PCa. HSP expression independently predicts clinical outcome in prostate cancer, However, unlike previous studies showing that prohibitin expression suppresses prostate cancer, our findings show that prohibitin expression is higher in prostate cancer compared to normal cells. Also, this expression was stronger in higher-grade than in lower-grade cancers, and was stronger in metastatic prostate cancer than in localised cancers. HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients. However, all three proteins were a stronger marker than each one separately." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased HSP27, ALDH6A1, PHB level", "assessed_biomarker_entity": { "recommended_name": "Prostate cancer trio-biomarker HSP27, ALDH6A1, Prohibitin overexpression panel", "synonyms": [ { "synonym": "B-cell receptor-associated protein BAP37" }, { "synonym": "D-prohibitin" }, { "synonym": "Repressor of estrogen receptor activity" } ] }, "assessed_biomarker_entity_id": "UPKB:Q99623", "assessed_entity_type": "protein", "specimen": [ { "name": "prostate gland", "id": "UBERON:0002367", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002367", "loinc_code": "" } ], "evidence_source": [ { "id": "30396985", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985", "evidence_list": [ { "evidence": "In the present study, ALDH6A1 overexpression was significantly associated with lymphatic invasion in PCa. SP27 expression is correlated with clinical PCa progression, with the highest expression found in metastatic PCa. HSP expression independently predicts clinical outcome in prostate cancer, However, unlike previous studies showing that prohibitin expression suppresses prostate cancer, our findings show that prohibitin expression is higher in prostate cancer compared to normal cells. Also, this expression was stronger in higher-grade than in lower-grade cancers, and was stronger in metastatic prostate cancer than in localised cancers. HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients. However, all three proteins were a stronger marker than each one separately." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "30396985", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985", "evidence_list": [ { "evidence": "In the present study, ALDH6A1 overexpression was significantly associated with lymphatic invasion in PCa. SP27 expression is correlated with clinical PCa progression, with the highest expression found in metastatic PCa. HSP expression independently predicts clinical outcome in prostate cancer, However, unlike previous studies showing that prohibitin expression suppresses prostate cancer, our findings show that prohibitin expression is higher in prostate cancer compared to normal cells. Also, this expression was stronger in higher-grade than in lower-grade cancers, and was stronger in metastatic prostate cancer than in localised cancers. HSP 27, ALDH6A1 and prohibitin were highly specific to metastatic tumor cells. Of all proteins, phohibitin had the highest value in predicting survival. However, all three proteins were a stronger marker than each one separately. Trio-biomarker composed of HSP27, ALDH6A1 and prohibitin may predict survival of metastatic prostate cancer patients. However, all three proteins were a stronger marker than each one separately." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer.", "journal": "Anticancer research", "authors": "Cho SY, Kang S, Kim DS, Na HJ, Kim YJ, Choi YD, Cho NH", "date": "2018-11-07", "evidence": [], "reference": [ { "id": "30396985", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985" } ] }, { "title": "HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer.", "journal": "Anticancer research", "authors": "Cho SY, Kang S, Kim DS, Na HJ, Kim YJ, Choi YD, Cho NH", "date": "2018-11-07", "evidence": [], "reference": [ { "id": "30396985", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985" } ] }, { "title": "HSP27, ALDH6A1 and Prohibitin Act as a Trio-biomarker to Predict Survival in Late Metastatic Prostate Cancer.", "journal": "Anticancer research", "authors": "Cho SY, Kang S, Kim DS, Na HJ, Kim YJ, Choi YD, Cho NH", "date": "2018-11-07", "evidence": [], "reference": [ { "id": "30396985", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30396985" } ] } ], "biomarker_canonical_id": "AN4484", "collision": 0 }, { "biomarker_id": "AN4485-1", "biomarker_component": [ { "biomarker": "increased ECM1, TMPRSS4 level", "assessed_biomarker_entity": { "recommended_name": "Thyroid gland cancer upregulated ECM1, TMPRSS4 expression panel", "synonyms": [ { "synonym": "Channel-activating protease 2" }, { "synonym": "CAPH2" }, { "synonym": "Membrane-type serine protease 2" }, { "synonym": "MT-SP2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NRS4", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "16135921", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921", "evidence_list": [ { "evidence": "By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased ECM1, TMPRSS4 level", "assessed_biomarker_entity": { "recommended_name": "Thyroid gland cancer upregulated ECM1, TMPRSS4 expression panel", "synonyms": [ { "synonym": "Secretory component p85" } ] }, "assessed_biomarker_entity_id": "UPKB:Q16610", "assessed_entity_type": "protein", "specimen": [ { "name": "thyroid gland", "id": "UBERON:0002046", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0002046", "loinc_code": "" } ], "evidence_source": [ { "id": "16135921", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921", "evidence_list": [ { "evidence": "By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1781", "recommended_name": { "id": "DOID:1781", "name": "thyroid gland cancer", "description": "An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, "synonyms": [ { "id": "DOID:1781", "name": "neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "thyroid gland cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant tumour of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "Thyroid gland neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" }, { "id": "DOID:1781", "name": "malignant neoplasm of thyroid gland", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1781" } ] }, "evidence_source": [ { "id": "16135921", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921", "evidence_list": [ { "evidence": "By cDNA array analysis, ADAMTS8, ECM1, MMP8, PLAU, SELP, and TMPRSS4 were upregulated, and by quantitative PCR, ECM1, SELP, and TMPRSS4 mRNA expression was higher in malignant (n = 57) than in benign (n = 38) thyroid neoplasms. Combining both markers improved their diagnostic use (AUC 0.985; sensitivity, 91.7%; specificity, 89.8%; positive predictive value, 85.7%; negative predictive value, 82.8%). ECM1 and TMPRSS4 expression analysis improved the diagnostic accuracy of FNA biopsy in 35 of 38 indeterminate or suspicious results." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.", "journal": "Annals of surgery", "authors": "Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A", "date": "2005-09-02", "evidence": [], "reference": [ { "id": "16135921", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921" } ] }, { "title": "ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.", "journal": "Annals of surgery", "authors": "Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A", "date": "2005-09-02", "evidence": [], "reference": [ { "id": "16135921", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16135921" } ] } ], "biomarker_canonical_id": "AN4485", "collision": 0 }, { "biomarker_id": "AN4486-1", "biomarker_component": [ { "biomarker": "increased GOLM1, FC-KIN, FC-A1AT level", "assessed_biomarker_entity": { "recommended_name": "Liver cancer GOLM1, FC-KIN, FC-A1AT panel", "synonyms": [ { "synonym": "Alpha-2-thiol proteinase inhibitor" }, { "synonym": "Fitzgerald factor" }, { "synonym": "High molecular weight kininogen" }, { "synonym": "HMWK" }, { "synonym": "Williams-Fitzgerald-Flaujeac factor" } ] }, "assessed_biomarker_entity_id": "UPKB:P01042", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19454616", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616", "evidence_list": [ { "evidence": "The levels of fucosylated kininogen (Fc-Kin) and fucosylated \u03b1-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, \u03b1-fetoprotein, and GP73. These markers when used in combination with GP73 had an overall performance that was better than AFP alone. GP73 had a mean increase of 2.4-fold in patients with cirrhosis, 8.4-fold in patients with stage I or II HCC, and 8.1-fold in patients with stage III or IV HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased GOLM1, FC-KIN, FC-A1AT level", "assessed_biomarker_entity": { "recommended_name": "Liver cancer GOLM1, FC-KIN, FC-A1AT panel", "synonyms": [ { "synonym": "Alpha-1-fetoprotein" }, { "synonym": "Alpha-fetoglobulin" } ] }, "assessed_biomarker_entity_id": "UPKB:P02771", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19454616", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616", "evidence_list": [ { "evidence": "The levels of fucosylated kininogen (Fc-Kin) and fucosylated \u03b1-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, \u03b1-fetoprotein, and GP73. These markers when used in combination with GP73 had an overall performance that was better than AFP alone. GP73 had a mean increase of 2.4-fold in patients with cirrhosis, 8.4-fold in patients with stage I or II HCC, and 8.1-fold in patients with stage III or IV HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased GOLM1, FC-KIN, FC-A1AT level", "assessed_biomarker_entity": { "recommended_name": "Liver cancer GOLM1, FC-KIN, FC-A1AT panel", "synonyms": [ { "synonym": "Golgi membrane protein GP73" }, { "synonym": "Golgi phosphoprotein 2" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8NBJ4", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19454616", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616", "evidence_list": [ { "evidence": "The levels of fucosylated kininogen (Fc-Kin) and fucosylated \u03b1-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, \u03b1-fetoprotein, and GP73. These markers when used in combination with GP73 had an overall performance that was better than AFP alone. GP73 had a mean increase of 2.4-fold in patients with cirrhosis, 8.4-fold in patients with stage I or II HCC, and 8.1-fold in patients with stage III or IV HCC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "19454616", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616", "evidence_list": [ { "evidence": "The levels of fucosylated kininogen (Fc-Kin) and fucosylated \u03b1-1-antitrypsin were significantly higher in patients with HCC compared with those with cirrhosis (P < 0.0001). Greatest performance was achieved through the combination of Fc-Kin, \u03b1-fetoprotein, and GP73. These markers when used in combination with GP73 had an overall performance that was better than AFP alone. GP73 had a mean increase of 2.4-fold in patients with cirrhosis, 8.4-fold in patients with stage I or II HCC, and 8.1-fold in patients with stage III or IV HCC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS", "date": "2009-05-21", "evidence": [], "reference": [ { "id": "19454616", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616" } ] }, { "title": "Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS", "date": "2009-05-21", "evidence": [], "reference": [ { "id": "19454616", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616" } ] }, { "title": "Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma.", "journal": "Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology", "authors": "Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS", "date": "2009-05-21", "evidence": [], "reference": [ { "id": "19454616", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19454616" } ] } ], "biomarker_canonical_id": "AN4486", "collision": 0 }, { "biomarker_id": "AN4487-1", "biomarker_component": [ { "biomarker": "increased OPN, CA125 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer Osteopontin, MUC16 expression panel", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "11926891", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891", "evidence_list": [ { "evidence": "Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16764622", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16764622", "evidence_list": [ { "evidence": "Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women. The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125. The specificity was moderate. Sensitivity increased to 93.8% with the combination of CA125, compared to 84.4% with CA125 alone." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased OPN, CA125 level", "assessed_biomarker_entity": { "recommended_name": "Ovarian cancer Osteopontin, MUC16 expression panel", "synonyms": [ { "synonym": "Bone sialoprotein 1" }, { "synonym": "Nephropontin" }, { "synonym": "Secreted phosphoprotein 1" }, { "synonym": "SPP-1" }, { "synonym": "Urinary stone protein" }, { "synonym": "Uropontin" } ] }, "assessed_biomarker_entity_id": "UPKB:P10451", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "11926891", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891", "evidence_list": [ { "evidence": "Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] }, { "id": "16764622", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16764622", "evidence_list": [ { "evidence": "Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women. The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125. The specificity was moderate. Sensitivity increased to 93.8% with the combination of CA125, compared to 84.4% with CA125 alone." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "11926891", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891", "evidence_list": [ { "evidence": "Osteopontin levels in plasma were significantly higher (P<.001) in 51 patients with epithelial ovarian cancer (486.5 ng/mL) compared with those of 107 healthy controls (147.1 ng/mL), 46 patients with benign ovarian disease (254.4 ng/mL), and 47 patients with other gynecologic cancers (260.9 ng/mL)." } ], "tags": [ { "tag": "condition" } ] }, { "id": "16764622", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16764622", "evidence_list": [ { "evidence": "Preoperative plasma OPN levels were significantly higher in patients with ovarian cancer than in those with benign ovarian tumor, in other gynecologic patients or in healthy women. The sensitivity of preoperative plasma OPN in detecting ovarian cancer was 81.3% and almost reached that of CA125. The specificity was moderate. Sensitivity increased to 93.8% with the combination of CA125, compared to 84.4% with CA125 alone." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Osteopontin as a potential diagnostic biomarker for ovarian cancer.", "journal": "JAMA", "authors": "Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC", "date": "2002-04-03", "evidence": [], "reference": [ { "id": "11926891", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891" } ] }, { "title": "Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.", "journal": "The journal of obstetrics and gynaecology research", "authors": "Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T", "date": "2006-06-13", "evidence": [], "reference": [ { "id": "16764622", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16764622" } ] }, { "title": "Osteopontin as a potential diagnostic biomarker for ovarian cancer.", "journal": "JAMA", "authors": "Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC", "date": "2002-04-03", "evidence": [], "reference": [ { "id": "11926891", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/11926891" } ] }, { "title": "Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.", "journal": "The journal of obstetrics and gynaecology research", "authors": "Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, Douchi T", "date": "2006-06-13", "evidence": [], "reference": [ { "id": "16764622", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/16764622" } ] } ], "biomarker_canonical_id": "AN4487", "collision": 0 }, { "biomarker_id": "AN4488-1", "biomarker_component": [ { "biomarker": "measured CEACAM5, SART3, A1AT, RBP level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer CEACAM5, SART3, A1AT, RBP protein panel", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" } ] }, "assessed_biomarker_entity_id": "UPKB:P06731", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18065730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730", "evidence_list": [ { "evidence": "Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha1-antitrypsin, and squamous cell carcinoma antigen-were collectively found to correctly classify the majority of lung cancer. This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured CEACAM5, SART3, A1AT, RBP level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer CEACAM5, SART3, A1AT, RBP protein panel", "synonyms": [ { "synonym": "SART-3" }, { "synonym": "Tat-interacting protein of 110 kDa" }, { "synonym": "Tip110" }, { "synonym": "p110 nuclear RNA-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q15020", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18065730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730", "evidence_list": [ { "evidence": "Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha1-antitrypsin, and squamous cell carcinoma antigen-were collectively found to correctly classify the majority of lung cancer. This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured CEACAM5, SART3, A1AT, RBP level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer CEACAM5, SART3, A1AT, RBP protein panel", "synonyms": [ { "synonym": "Alpha-1 protease inhibitor" }, { "synonym": "Alpha-1-antiproteinase" }, { "synonym": "Serpin A1" } ] }, "assessed_biomarker_entity_id": "UPKB:P01009", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18065730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730", "evidence_list": [ { "evidence": "Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha1-antitrypsin, and squamous cell carcinoma antigen-were collectively found to correctly classify the majority of lung cancer. This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured CEACAM5, SART3, A1AT, RBP level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer CEACAM5, SART3, A1AT, RBP protein panel", "synonyms": [ { "synonym": "Cellular retinol-binding protein" }, { "synonym": "CRBP" }, { "synonym": "Cellular retinol-binding protein I" }, { "synonym": "CRBP-I" } ] }, "assessed_biomarker_entity_id": "UPKB:P09455", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18065730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730", "evidence_list": [ { "evidence": "Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha1-antitrypsin, and squamous cell carcinoma antigen-were collectively found to correctly classify the majority of lung cancer. This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "18065730", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730", "evidence_list": [ { "evidence": "Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha1-antitrypsin, and squamous cell carcinoma antigen-were collectively found to correctly classify the majority of lung cancer. This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Panel of serum biomarkers for the diagnosis of lung cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE", "date": "2007-12-11", "evidence": [], "reference": [ { "id": "18065730", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730" } ] }, { "title": "Panel of serum biomarkers for the diagnosis of lung cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE", "date": "2007-12-11", "evidence": [], "reference": [ { "id": "18065730", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730" } ] }, { "title": "Panel of serum biomarkers for the diagnosis of lung cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE", "date": "2007-12-11", "evidence": [], "reference": [ { "id": "18065730", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730" } ] }, { "title": "Panel of serum biomarkers for the diagnosis of lung cancer.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE", "date": "2007-12-11", "evidence": [], "reference": [ { "id": "18065730", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18065730" } ] } ], "biomarker_canonical_id": "AN4488", "collision": 0 }, { "biomarker_id": "AN4489-1", "biomarker_component": [ { "biomarker": "increased SAA1, CRP level", "assessed_biomarker_entity": { "recommended_name": "Breast cancer circulating SAA1, CRP panel", "synonyms": [ { "synonym": "SAA" } ] }, "assessed_biomarker_entity_id": "UPKB:P0DJI8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, and body mass index." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased SAA1, CRP level", "assessed_biomarker_entity": { "recommended_name": "Breast cancer circulating SAA1, CRP panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P02741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "71426-1" } ], "evidence_source": [ { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, and body mass index." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "19470939", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939", "evidence_list": [ { "evidence": "Circulating SAA and CRP may be important prognostic markers for long-term survival in breast cancer patients, independent of race, tumor stage, and body mass index." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM", "date": "2009-05-28", "evidence": [], "reference": [ { "id": "19470939", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939" } ] }, { "title": "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.", "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology", "authors": "Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM", "date": "2009-05-28", "evidence": [], "reference": [ { "id": "19470939", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19470939" } ] } ], "biomarker_canonical_id": "AN4489", "collision": 0 }, { "biomarker_id": "AN4490-1", "biomarker_component": [ { "biomarker": "hypermethylated P16, RASSF1A, RPRM, RUNX3 gene", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer circulating methylated P16, RASSF1A, RPRM, RUNX3 DNA panel", "synonyms": [ { "synonym": "Alternative reading frame" }, { "synonym": "ARF" }, { "synonym": "Cyclin-dependent kinase inhibitor 2A" }, { "synonym": "p14ARF" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8N726", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32431794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794", "evidence_list": [ { "evidence": "Methylated P16, RASSF1A, RPRM, and RUNX3 were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3%) compared to the controls (15.9, 0.0, 6.8, and 4.5%), respectively (p<0.001). Stratification of patients showed that RPRM (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and p<0.001) and RUNX3 (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and p<0.001) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of RPRM and RUNX3 in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95% CI:0.793-0.957; p<0.001), higher sensitivity of 0.82 and reduced specificity of 0.89." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "hypermethylated P16, RASSF1A, RPRM, RUNX3 gene", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer circulating methylated P16, RASSF1A, RPRM, RUNX3 DNA panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NS23", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32431794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794", "evidence_list": [ { "evidence": "Methylated P16, RASSF1A, RPRM, and RUNX3 were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3%) compared to the controls (15.9, 0.0, 6.8, and 4.5%), respectively (p<0.001). Stratification of patients showed that RPRM (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and p<0.001) and RUNX3 (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and p<0.001) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of RPRM and RUNX3 in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95% CI:0.793-0.957; p<0.001), higher sensitivity of 0.82 and reduced specificity of 0.89." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "hypermethylated P16, RASSF1A, RPRM, RUNX3 gene", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer circulating methylated P16, RASSF1A, RPRM, RUNX3 DNA panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NS64", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32431794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794", "evidence_list": [ { "evidence": "Methylated P16, RASSF1A, RPRM, and RUNX3 were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3%) compared to the controls (15.9, 0.0, 6.8, and 4.5%), respectively (p<0.001). Stratification of patients showed that RPRM (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and p<0.001) and RUNX3 (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and p<0.001) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of RPRM and RUNX3 in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95% CI:0.793-0.957; p<0.001), higher sensitivity of 0.82 and reduced specificity of 0.89." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "hypermethylated P16, RASSF1A, RPRM, RUNX3 gene", "assessed_biomarker_entity": { "recommended_name": "Gastric cancer circulating methylated P16, RASSF1A, RPRM, RUNX3 DNA panel", "synonyms": [ { "synonym": "Acute myeloid leukemia 2 protein" }, { "synonym": "Core-binding factor subunit alpha-3" }, { "synonym": "CBF-alpha-3" }, { "synonym": "Oncogene AML-2" }, { "synonym": "Polyomavirus enhancer-binding protein 2 alpha C subunit" }, { "synonym": "PEA2-alpha C" }, { "synonym": "PEBP2-alpha C" }, { "synonym": "SL3-3 enhancer factor 1 alpha C subunit" }, { "synonym": "SL3/AKV core-binding factor alpha C subunit" } ] }, "assessed_biomarker_entity_id": "UPKB:Q13761", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "32431794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794", "evidence_list": [ { "evidence": "Methylated P16, RASSF1A, RPRM, and RUNX3 were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3%) compared to the controls (15.9, 0.0, 6.8, and 4.5%), respectively (p<0.001). Stratification of patients showed that RPRM (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and p<0.001) and RUNX3 (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and p<0.001) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of RPRM and RUNX3 in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95% CI:0.793-0.957; p<0.001), higher sensitivity of 0.82 and reduced specificity of 0.89." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "32431794", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794", "evidence_list": [ { "evidence": "Methylated P16, RASSF1A, RPRM, and RUNX3 were significantly higher in the GC patients (41.7, 33.3, 66.7, and 58.3%) compared to the controls (15.9, 0.0, 6.8, and 4.5%), respectively (p<0.001). Stratification of patients showed that RPRM (AUC: 0.70, Sensitivity: 0.47, Specificity: 0.93, and p<0.001) and RUNX3 (AUC: 0.77, Sensitivity: 0.59, Specificity: 0.95, and p<0.001) had the highest performances in detection of early-stage (I+II) GC. The combined methylation of RPRM and RUNX3 in detection of early-stage GC had a higher AUC of 0.88 (SE=0.042; 95% CI:0.793-0.957; p<0.001), higher sensitivity of 0.82 and reduced specificity of 0.89." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Methylation Analysis of ", "journal": "Avicenna journal of medical biotechnology", "authors": "Saliminejad K, Soleymani Fard S, Khorram Khorshid HR, Yaghmaie M, Mahmoodzadeh H, Mousavi SA, Ghaffari SH", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32431794", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794" } ] }, { "title": "Methylation Analysis of ", "journal": "Avicenna journal of medical biotechnology", "authors": "Saliminejad K, Soleymani Fard S, Khorram Khorshid HR, Yaghmaie M, Mahmoodzadeh H, Mousavi SA, Ghaffari SH", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32431794", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794" } ] }, { "title": "Methylation Analysis of ", "journal": "Avicenna journal of medical biotechnology", "authors": "Saliminejad K, Soleymani Fard S, Khorram Khorshid HR, Yaghmaie M, Mahmoodzadeh H, Mousavi SA, Ghaffari SH", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32431794", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794" } ] }, { "title": "Methylation Analysis of ", "journal": "Avicenna journal of medical biotechnology", "authors": "Saliminejad K, Soleymani Fard S, Khorram Khorshid HR, Yaghmaie M, Mahmoodzadeh H, Mousavi SA, Ghaffari SH", "date": "2020-05-21", "evidence": [], "reference": [ { "id": "32431794", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32431794" } ] } ], "biomarker_canonical_id": "AN4490", "collision": 0 }, { "biomarker_id": "AN4491-1", "biomarker_component": [ { "biomarker": "increased CD44, EPCAM, TGM2 level", "assessed_biomarker_entity": { "recommended_name": "Uterine cancer increased plasma CD44, EPCAM, TGM2 panel", "synonyms": [ { "synonym": "Ep-CAM" }, { "synonym": "Adenocarcinoma-associated antigen" }, { "synonym": "Cell surface glycoprotein Trop-1" }, { "synonym": "Epithelial cell surface antigen" }, { "synonym": "Epithelial glycoprotein" }, { "synonym": "EGP" }, { "synonym": "Epithelial glycoprotein 314" }, { "synonym": "EGP314" }, { "synonym": "hEGP314" }, { "synonym": "KS 1/4 antigen" }, { "synonym": "KSA" }, { "synonym": "Major gastrointestinal tumor-associated protein GA733-2" }, { "synonym": "Tumor-associated calcium signal transducer 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P16422", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "LP234195-8" } ], "evidence_source": [ { "id": "31035965", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965", "evidence_list": [ { "evidence": "Significantly increased concentration in EC as compared to healthy controls were found in case of CD44 (p < 0.001), EpCAM (p = 0.033) and TGM2 (p < 0.001). EpCAM and mesothelin concentrations differed based on FIGO stages. Regression analysis revealed marker panels with high accuracy in detection of EC (Endometrial cancer). The highest AUC 0.937 was attributed to the 3-marker panel of CD44/TGM2/EpCAM (84% sensitivity, 100% specificity), FIGO IA samples were discriminated from more advanced stages of EC with the mesothelin/grade 1 model featuring AUC of 0.911 (95.24% sensitivity, 78.26% specificity). Novel plasma biomarkers presenting good accuracy in diagnosing EC were found with TGM2 reported for the first time as plasma marker. It was also revealed that endometriosis may share similarities in the pattern of markers alterations characteristic for EC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased CD44, EPCAM, TGM2 level", "assessed_biomarker_entity": { "recommended_name": "Uterine cancer increased plasma CD44, EPCAM, TGM2 panel", "synonyms": [ { "synonym": "CDw44" }, { "synonym": "Epican" }, { "synonym": "Extracellular matrix receptor III" }, { "synonym": "ECMR-III" }, { "synonym": "GP90 lymphocyte homing/adhesion receptor" }, { "synonym": "HUTCH-I" }, { "synonym": "Heparan sulfate proteoglycan" }, { "synonym": "Hermes antigen" }, { "synonym": "Hyaluronate receptor" }, { "synonym": "Phagocytic glycoprotein 1" }, { "synonym": "PGP-1" }, { "synonym": "Phagocytic glycoprotein I" }, { "synonym": "PGP-I" } ] }, "assessed_biomarker_entity_id": "UPKB:P16070", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "LP234195-8" } ], "evidence_source": [ { "id": "31035965", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965", "evidence_list": [ { "evidence": "Significantly increased concentration in EC as compared to healthy controls were found in case of CD44 (p < 0.001), EpCAM (p = 0.033) and TGM2 (p < 0.001). EpCAM and mesothelin concentrations differed based on FIGO stages. Regression analysis revealed marker panels with high accuracy in detection of EC (Endometrial cancer). The highest AUC 0.937 was attributed to the 3-marker panel of CD44/TGM2/EpCAM (84% sensitivity, 100% specificity), FIGO IA samples were discriminated from more advanced stages of EC with the mesothelin/grade 1 model featuring AUC of 0.911 (95.24% sensitivity, 78.26% specificity). Novel plasma biomarkers presenting good accuracy in diagnosing EC were found with TGM2 reported for the first time as plasma marker. It was also revealed that endometriosis may share similarities in the pattern of markers alterations characteristic for EC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased CD44, EPCAM, TGM2 level", "assessed_biomarker_entity": { "recommended_name": "Uterine cancer increased plasma CD44, EPCAM, TGM2 panel", "synonyms": [ { "synonym": "Erythrocyte transglutaminase" }, { "synonym": "Heart G alpha(h)" }, { "synonym": "hhG alpha(h)" }, { "synonym": "Isopeptidase TGM2" }, { "synonym": "Protein G alpha(h)" }, { "synonym": "G(h)" }, { "synonym": "Protein-glutamine deamidase TGM2" }, { "synonym": "Protein-glutamine dopaminyltransferase TGM2" }, { "synonym": "Protein-glutamine histaminyltransferase TGM2" }, { "synonym": "Protein-glutamine noradrenalinyltransferase TGM2" }, { "synonym": "Protein-glutamine serotonyltransferase TGM2" }, { "synonym": "Tissue transglutaminase" }, { "synonym": "tTG" }, { "synonym": "tTgase" }, { "synonym": "Transglutaminase C" }, { "synonym": "TG(C)" }, { "synonym": "TGC" }, { "synonym": "TGase C" }, { "synonym": "Transglutaminase H" }, { "synonym": "TGase H" }, { "synonym": "Transglutaminase II" }, { "synonym": "TGase II" }, { "synonym": "Transglutaminase-2" }, { "synonym": "TG2" }, { "synonym": "TGase-2" }, { "synonym": "hTG2" } ] }, "assessed_biomarker_entity_id": "UPKB:P21980", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "LP234195-8" } ], "evidence_source": [ { "id": "31035965", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965", "evidence_list": [ { "evidence": "Significantly increased concentration in EC as compared to healthy controls were found in case of CD44 (p < 0.001), EpCAM (p = 0.033) and TGM2 (p < 0.001). EpCAM and mesothelin concentrations differed based on FIGO stages. Regression analysis revealed marker panels with high accuracy in detection of EC (Endometrial cancer). The highest AUC 0.937 was attributed to the 3-marker panel of CD44/TGM2/EpCAM (84% sensitivity, 100% specificity), FIGO IA samples were discriminated from more advanced stages of EC with the mesothelin/grade 1 model featuring AUC of 0.911 (95.24% sensitivity, 78.26% specificity). Novel plasma biomarkers presenting good accuracy in diagnosing EC were found with TGM2 reported for the first time as plasma marker. It was also revealed that endometriosis may share similarities in the pattern of markers alterations characteristic for EC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:363", "recommended_name": { "id": "DOID:363", "name": "uterine cancer", "description": "A female reproductive organ cancer that is located_in the uterus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, "synonyms": [ { "id": "DOID:363", "name": "uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "Tumour of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant uterine tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "malignant neoplasm of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "CA - cancer of uterus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" }, { "id": "DOID:363", "name": "uterus neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_363" } ] }, "evidence_source": [ { "id": "31035965", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965", "evidence_list": [ { "evidence": "Significantly increased concentration in EC as compared to healthy controls were found in case of CD44 (p < 0.001), EpCAM (p = 0.033) and TGM2 (p < 0.001). EpCAM and mesothelin concentrations differed based on FIGO stages. Regression analysis revealed marker panels with high accuracy in detection of EC (Endometrial cancer). The highest AUC 0.937 was attributed to the 3-marker panel of CD44/TGM2/EpCAM (84% sensitivity, 100% specificity), FIGO IA samples were discriminated from more advanced stages of EC with the mesothelin/grade 1 model featuring AUC of 0.911 (95.24% sensitivity, 78.26% specificity). Novel plasma biomarkers presenting good accuracy in diagnosing EC were found with TGM2 reported for the first time as plasma marker. It was also revealed that endometriosis may share similarities in the pattern of markers alterations characteristic for EC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.", "journal": "BMC cancer", "authors": "Torres A, Pac-Sosi\u0144ska M, Wiktor K, Paszkowski T, Maciejewski R, Torres K", "date": "2019-05-01", "evidence": [], "reference": [ { "id": "31035965", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965" } ] }, { "title": "CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.", "journal": "BMC cancer", "authors": "Torres A, Pac-Sosi\u0144ska M, Wiktor K, Paszkowski T, Maciejewski R, Torres K", "date": "2019-05-01", "evidence": [], "reference": [ { "id": "31035965", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965" } ] }, { "title": "CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.", "journal": "BMC cancer", "authors": "Torres A, Pac-Sosi\u0144ska M, Wiktor K, Paszkowski T, Maciejewski R, Torres K", "date": "2019-05-01", "evidence": [], "reference": [ { "id": "31035965", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31035965" } ] } ], "biomarker_canonical_id": "AN4491", "collision": 0 }, { "biomarker_id": "AN4492-1", "biomarker_component": [ { "biomarker": "measured NLR, LDH, PNI level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer peripheral blood NLR, LDH, PNI panel", "synonyms": [] }, "assessed_biomarker_entity_id": "NCIt:C141271", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32350592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592", "evidence_list": [ { "evidence": "In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs. NLR < 5, LDH < 240 U/L, or PNI \u2265 45 was favorably associated with significantly better outcomes compared with higher, higher, or lower values, respectively. The multivariate analysis determined that these parameters were independently associated with both better PFS (p = 0.049, 0.046, 0.014, respectively) and longer OS (p = 0.007, 0.031, < 0.001, respectively). Patients with three favorable factors among NLR, LDH, and PNI had better PFS and OS than did those with two, one, or none. PNI and NLR were associated with the onset of irAEs. In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured NLR, LDH, PNI level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer peripheral blood NLR, LDH, PNI panel", "synonyms": [] }, "assessed_biomarker_entity_id": "PRO:PR_000050367", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32350592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592", "evidence_list": [ { "evidence": "In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs. NLR < 5, LDH < 240 U/L, or PNI \u2265 45 was favorably associated with significantly better outcomes compared with higher, higher, or lower values, respectively. The multivariate analysis determined that these parameters were independently associated with both better PFS (p = 0.049, 0.046, 0.014, respectively) and longer OS (p = 0.007, 0.031, < 0.001, respectively). Patients with three favorable factors among NLR, LDH, and PNI had better PFS and OS than did those with two, one, or none. PNI and NLR were associated with the onset of irAEs. In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured NLR, LDH, PNI level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer peripheral blood NLR, LDH, PNI panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UNK:Prognostic nutritional index (PNI)", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "14804-9" } ], "evidence_source": [ { "id": "32350592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592", "evidence_list": [ { "evidence": "In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs. NLR < 5, LDH < 240 U/L, or PNI \u2265 45 was favorably associated with significantly better outcomes compared with higher, higher, or lower values, respectively. The multivariate analysis determined that these parameters were independently associated with both better PFS (p = 0.049, 0.046, 0.014, respectively) and longer OS (p = 0.007, 0.031, < 0.001, respectively). Patients with three favorable factors among NLR, LDH, and PNI had better PFS and OS than did those with two, one, or none. PNI and NLR were associated with the onset of irAEs. In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "32350592", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592", "evidence_list": [ { "evidence": "In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs. NLR < 5, LDH < 240 U/L, or PNI \u2265 45 was favorably associated with significantly better outcomes compared with higher, higher, or lower values, respectively. The multivariate analysis determined that these parameters were independently associated with both better PFS (p = 0.049, 0.046, 0.014, respectively) and longer OS (p = 0.007, 0.031, < 0.001, respectively). Patients with three favorable factors among NLR, LDH, and PNI had better PFS and OS than did those with two, one, or none. PNI and NLR were associated with the onset of irAEs. In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.", "journal": "Cancer immunology, immunotherapy : CII", "authors": "Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y", "date": "2020-05-01", "evidence": [], "reference": [ { "id": "32350592", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592" } ] }, { "title": "Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.", "journal": "Cancer immunology, immunotherapy : CII", "authors": "Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y", "date": "2020-05-01", "evidence": [], "reference": [ { "id": "32350592", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592" } ] }, { "title": "Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.", "journal": "Cancer immunology, immunotherapy : CII", "authors": "Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y", "date": "2020-05-01", "evidence": [], "reference": [ { "id": "32350592", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32350592" } ] } ], "biomarker_canonical_id": "AN4492", "collision": 0 }, { "biomarker_id": "AN4493-1", "biomarker_component": [ { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "PCNP" }, { "synonym": "PEST-containing nuclear protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WW12", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Cysteine-rich with EGF-like domain protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96HD1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Amino acid transporter A1" }, { "synonym": "N-system amino acid transporter 2" }, { "synonym": "Solute carrier family 38 member 1" }, { "synonym": "System A amino acid transporter 1" }, { "synonym": "System N amino acid transporter 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9H2H9", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Beta-tropomyosin" }, { "synonym": "Tropomyosin-2" } ] }, "assessed_biomarker_entity_id": "UPKB:P07951", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "SMAP55" }, { "synonym": "Transducin beta-like protein 1X" }, { "synonym": "Transducin-beta-like protein 1, X-linked" } ] }, "assessed_biomarker_entity_id": "UPKB:O60907", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "17-beta-HSD 3" }, { "synonym": "Estradiol 17-beta-dehydrogenase 2" }, { "synonym": "Short chain dehydrogenase/reductase family 12C member 2" }, { "synonym": "Testicular 17-beta-hydroxysteroid dehydrogenase" }, { "synonym": "Testosterone 17-beta-dehydrogenase 3" } ] }, "assessed_biomarker_entity_id": "UPKB:P37058", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Dispanin subfamily A member 2b" }, { "synonym": "DSPA2b" }, { "synonym": "Interferon-inducible protein 1-8U" } ] }, "assessed_biomarker_entity_id": "UPKB:Q01628", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "B-lymphocyte surface antigen B1" }, { "synonym": "Bp35" }, { "synonym": "Leukocyte surface antigen Leu-16" }, { "synonym": "Membrane-spanning 4-domains subfamily A member 1" } ] }, "assessed_biomarker_entity_id": "UPKB:P11836", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q8N6V9", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Exocrine differentiation and proliferation factor" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9H3Y8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Protein phosphatase 1 myosin-binding subunit of 85 kDa" }, { "synonym": "Protein phosphatase 1 myosin-binding subunit p85" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9BZL4", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "DIPP-2" }, { "synonym": "Diadenosine 5',5'''-P1,P6-hexaphosphate hydrolase 2" }, { "synonym": "Nucleoside diphosphate-linked moiety X motif 4" }, { "synonym": "Nudix motif 4" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9NZJ9", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Laminin B1s chain" }, { "synonym": "Laminin-11 subunit beta" }, { "synonym": "Laminin-14 subunit beta" }, { "synonym": "Laminin-15 subunit beta" }, { "synonym": "Laminin-3 subunit beta" }, { "synonym": "Laminin-4 subunit beta" }, { "synonym": "Laminin-7 subunit beta" }, { "synonym": "Laminin-9 subunit beta" }, { "synonym": "S-laminin subunit beta" }, { "synonym": "S-LAM beta" } ] }, "assessed_biomarker_entity_id": "UPKB:P55268", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q8IXV7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P12111", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Dilute myosin heavy chain, non-muscle" }, { "synonym": "Myosin heavy chain 12" }, { "synonym": "Myosin-12" }, { "synonym": "Myoxin" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y4I1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Acid sphingomyelinase" }, { "synonym": "aSMase" } ] }, "assessed_biomarker_entity_id": "UPKB:P17405", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Zinc finger protein 326" }, { "synonym": "Zinc finger protein interacting with mRNPs and DBC1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q5BKZ1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Just another zinc finger protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UL40", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "PKC-interacting cousin of thioredoxin" }, { "synonym": "PICOT" }, { "synonym": "PKC-theta-interacting protein" }, { "synonym": "PKCq-interacting protein" }, { "synonym": "Thioredoxin-like protein 2" } ] }, "assessed_biomarker_entity_id": "UPKB:O76003", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Basement membrane autoantigen p105" }, { "synonym": "Lectin galactoside-binding soluble 3-binding protein" }, { "synonym": "Mac-2-binding protein" }, { "synonym": "MAC2BP" }, { "synonym": "Mac-2 BP" }, { "synonym": "Tumor-associated antigen 90K" } ] }, "assessed_biomarker_entity_id": "UPKB:Q08380", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "20 kDa myosin light chain" }, { "synonym": "LC20" }, { "synonym": "MLC-2C" }, { "synonym": "Myosin RLC" }, { "synonym": "Myosin regulatory light chain 2, smooth muscle isoform" }, { "synonym": "Myosin regulatory light chain 9" }, { "synonym": "Myosin regulatory light chain MRLC1" } ] }, "assessed_biomarker_entity_id": "UPKB:P24844", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9Y5V0", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:A4D0V7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "SAM domain-containing protein 14" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8IZD0", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "NADP-regulated thyroid-hormone-binding protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q14894", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Ng" }, { "synonym": "RC3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q92686", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "PDHE1-B" } ] }, "assessed_biomarker_entity_id": "UPKB:P11177", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9GZN7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Protein WAVE-1" }, { "synonym": "Verprolin homology domain-containing protein 1" }, { "synonym": "Wiskott-Aldrich syndrome protein family member 1" }, { "synonym": "WASP family protein member 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q92558", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "HECT domain and RCC1-like domain-containing protein 2" }, { "synonym": "HECT-type E3 ubiquitin transferase HERC2" } ] }, "assessed_biomarker_entity_id": "UPKB:O95714", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Testis-expressed protein 27" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9H8U3", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "CTCL tumor antigen se20-10" }, { "synonym": "Tumor- and microtubule-associated protein" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WWK9", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:P36404", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "SRrp53" }, { "synonym": "Arginine/serine-rich coiled-coil protein 1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q96IZ7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Endo-glucoronidase" }, { "synonym": "Heparanase-1" }, { "synonym": "Hpa1" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y251", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "MutL protein homolog 3" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9UHC1", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "Lymphopain" } ] }, "assessed_biomarker_entity_id": "UPKB:P56202", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "AMPK subunit beta-2" } ] }, "assessed_biomarker_entity_id": "UPKB:O43741", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "DTD" }, { "synonym": "DNA-unwinding element-binding protein B" }, { "synonym": "DUE-B" }, { "synonym": "Gly-tRNA(Ala) deacylase" }, { "synonym": "Histidyl-tRNA synthase-related" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8TEA8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:O75955", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [ { "synonym": "RNA exonuclease 2 homolog" }, { "synonym": "Small fragment nuclease" } ] }, "assessed_biomarker_entity_id": "UPKB:Q9Y3B8", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured 48 gene expression level", "assessed_biomarker_entity": { "recommended_name": "Lung cancer forty-eight-gene TEP liquid-biopsy panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UNK:6 proteins", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1324", "recommended_name": { "id": "DOID:1324", "name": "lung cancer", "description": "A respiratory system cancer that is located_in the lung.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1324" }, "synonyms": [] }, "evidence_source": [ { "id": "30532555", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555", "evidence_list": [ { "evidence": "48 biomarker genes accurately predicted NSCLC with leave-one-out cross-validation (LOOCV) sensitivity, specificity, accuracy, and Matthews correlation coefficients of 0.925, 0.827, 0.889, and 0.760, respectively. Network analysis of the 48 genes revealed that the WASF1 actin cytoskeleton module, PRKAB2 kinase module, RSRC1 ribosomal protein module, PDHB carbohydrate-metabolism module, and three intermodule hubs (TPM2, MYL9, and PPP1R12C) may play important roles in NSCLC tumorigenesis and progression. The 48-gene TEP liquid-biopsy biomarkers will facilitate early screening of NSCLC and prolong the survival of cancer patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] }, { "title": "Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer.", "journal": "OncoTargets and therapy", "authors": "Sheng M, Dong Z, Xie Y", "date": "2018-12-12", "evidence": [], "reference": [ { "id": "30532555", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30532555" } ] } ], "biomarker_canonical_id": "AN4493", "collision": 0 }, { "biomarker_id": "AA5026-1", "biomarker_component": [ { "biomarker": "increased PLAT aggregation", "assessed_biomarker_entity": { "recommended_name": "Platelet aggregation", "synonyms": [ { "synonym": "anucleate thrombocyte" }, { "synonym": "blood platelet" }, { "synonym": "enucleate thrombocyte" } ] }, "assessed_biomarker_entity_id": "CO:CL_0000233", "assessed_entity_type": "cell", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "11125-2" } ], "evidence_source": [ { "id": "7829253", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7829253", "evidence_list": [ { "evidence": "Platelets significantly increased the invasiveness of the 3 types of mammalian tumor cell tested (MDA-MB231, MCF-7 and ZR-51). This increased invasiveness is due, at least partially, to an increase in gelatinase secretion. This was shown in the case of MDA-MB231 where the basal level of gelatinase was greatly stimulated by platelets." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "risk" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "7829253", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7829253", "evidence_list": [ { "evidence": "Platelets significantly increased the invasiveness of the 3 types of mammalian tumor cell tested (MDA-MB231, MCF-7 and ZR-51). This increased invasiveness is due, at least partially, to an increase in gelatinase secretion. This was shown in the case of MDA-MB231 where the basal level of gelatinase was greatly stimulated by platelets." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "The effect of platelets on invasiveness and protease production of human mammary tumor cells.", "journal": "International journal of cancer", "authors": "Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S", "date": "1995-01-27", "evidence": [], "reference": [ { "id": "7829253", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/7829253" } ] } ], "biomarker_canonical_id": "AA5026", "collision": 1 }, { "biomarker_id": "AA5027-1", "biomarker_component": [ { "biomarker": "increased ANGPT2 level", "assessed_biomarker_entity": { "recommended_name": "Angiopoietin-2 protein", "synonyms": [ { "synonym": "ANG-2" } ] }, "assessed_biomarker_entity_id": "UPKB:O15123", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" }, { "name": "blood plasma", "id": "UBERON:0001969", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001969", "loinc_code": "" } ], "evidence_source": [ { "id": "32458111", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32458111", "evidence_list": [ { "evidence": "Angiopoietin-2 is a relevant predictive factor for ICU direct admission in COVID-19 patients. This result showing an endothelial activation reinforces the hypothesis of a COVID-19-associated microvascular dysfunction." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:0080600", "recommended_name": { "id": "DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, "synonyms": [ { "id": "DOID:0080600", "name": "SARS-CoV-2 infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan coronavirus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "COVID19", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "Wuhan seafood market pneumonia virus infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019-nCoV infection", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" }, { "id": "DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_0080600" } ] }, "evidence_source": [ { "id": "32458111", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32458111", "evidence_list": [ { "evidence": "Angiopoietin-2 is a relevant predictive factor for ICU direct admission in COVID-19 patients. This result showing an endothelial activation reinforces the hypothesis of a COVID-19-associated microvascular dysfunction." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.", "journal": "Angiogenesis", "authors": "Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, Khider L, Hadjadj J, Goudot G, Debuc B, Juvin P, Hauw-Berlemont C, Augy JL, Peron N, Messas E, Planquette B, Sanchez O, Charbit B, Gaussem P, Duffy D, Terrier B, Mirault T, Diehl JL", "date": "2020-05-28", "evidence": [], "reference": [ { "id": "32458111", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/32458111" } ] } ], "biomarker_canonical_id": "AA5027", "collision": 1 }, { "biomarker_id": "AA5028-1", "biomarker_component": [ { "biomarker": "increased EGFR level", "assessed_biomarker_entity": { "recommended_name": "Epidermal growth factor receptor protein", "synonyms": [ { "synonym": "Proto-oncogene c-ErbB-1" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P00533", "assessed_entity_type": "protein", "specimen": [ { "name": "breast", "id": "UBERON:0000310", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000310", "loinc_code": "13659-8" } ], "evidence_source": [ { "id": "30431376", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30431376", "evidence_list": [ { "evidence": "The high expression of EGFR can be used to predict the severity of IBC, as well as the candidate biomarkers of metastasis, and it may also be associated with poor prognosis of IBC patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30431376", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30431376", "evidence_list": [ { "evidence": "The high expression of EGFR can be used to predict the severity of IBC, as well as the candidate biomarkers of metastasis, and it may also be associated with poor prognosis of IBC patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Relationship of Epidermal Growth Factor Receptor Expression with Clinical Symptoms and Metastasis of Invasive Breast Cancer.", "journal": "Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research", "authors": "Han L, Li L, Wang N, Xiong Y, Li Y, Gu Y", "date": "2018-11-16", "evidence": [], "reference": [ { "id": "30431376", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30431376" } ] } ], "biomarker_canonical_id": "AA5028", "collision": 1 }, { "biomarker_id": "AA5028-2", "biomarker_component": [ { "biomarker": "increased EGFR level", "assessed_biomarker_entity": { "recommended_name": "Epidermal growth factor receptor protein", "synonyms": [ { "synonym": "Proto-oncogene c-ErbB-1" }, { "synonym": "Receptor tyrosine-protein kinase erbB-1" } ] }, "assessed_biomarker_entity_id": "UPKB:P00533", "assessed_entity_type": "protein", "specimen": [ { "name": "stomach", "id": "UBERON:0000945", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000945", "loinc_code": "13659-8" } ], "evidence_source": [ { "id": "18397279", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18397279", "evidence_list": [ { "evidence": "One hundred and forty cases (27.4%) showed EGFR overexpression by IHC. EGFR overexpression was associated with older age (P = 0.001), moderately or poorly differentiated histology (P = 0.001) and higher stage disease (P = 0.046)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "18397279", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18397279", "evidence_list": [ { "evidence": "One hundred and forty cases (27.4%) showed EGFR overexpression by IHC. EGFR overexpression was associated with older age (P = 0.001), moderately or poorly differentiated histology (P = 0.001) and higher stage disease (P = 0.046)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number.", "journal": "Histopathology", "authors": "Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH", "date": "2008-04-10", "evidence": [], "reference": [ { "id": "18397279", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18397279" } ] } ], "biomarker_canonical_id": "AA5028", "collision": 1 }, { "biomarker_id": "AA5029-1", "biomarker_component": [ { "biomarker": "increased monosialylated core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Monosialylated core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G35622MN", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5029", "collision": 1 }, { "biomarker_id": "AN4436-1", "biomarker_component": [ { "biomarker": "increased disialylated Lewis fucosylated triantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Disialylated Lewis fucosylated triantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G03692CL", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AN4436", "collision": 1 }, { "biomarker_id": "AA5031-1", "biomarker_component": [ { "biomarker": "increased disialylated tetraantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Disialylated tetraantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G28790AT", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5031", "collision": 1 }, { "biomarker_id": "AA5032-1", "biomarker_component": [ { "biomarker": "increased trisialylated Lewis fucosylated triantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Trisialylated Lewis fucosylated triantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G20102QS", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5032", "collision": 1 }, { "biomarker_id": "AA5033-1", "biomarker_component": [ { "biomarker": "increased trisialylated core fucosylated tetraantennary N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Trisialylated core fucosylated tetraantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G72750GQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5033", "collision": 1 }, { "biomarker_id": "AA5034-1", "biomarker_component": [ { "biomarker": "increased tetrasialylated tetraantennary N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Tetrasialylated tetraantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G66374JF", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5034", "collision": 1 }, { "biomarker_id": "AA5035-1", "biomarker_component": [ { "biomarker": "decreased disialylated triantennary N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Disialylated triantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G46440UD", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5035", "collision": 1 }, { "biomarker_id": "AA5036-1", "biomarker_component": [ { "biomarker": "decreased monosialylated hybrid N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Monosialylated hybrid N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G41793DV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "18487288", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288", "evidence_list": [ { "evidence": "Two statistical procedures implicated several sialylated and fucosylated N-glycan structures as highly probable biomarkers. Quantitative changes according to a cancer stage resulted when we categorized the glycans according to molecular size, number of oligomer branches, and abundance of sugar residues. Increases in sialylation and fucosylation of glycan structures appeared to be indicative of cancer progression. Different statistical evaluations confirmed independently that changes in the relative intensities of 8 N-glycans are characteristic of breast cancer (P < 0.001), whereas other glycan structures might contribute additionally to distinctions in the statistically recognizable patterns (different stages)." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles.", "journal": "Clinical chemistry", "authors": "Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, Schnaper L, Hickey RJ, Malkas LH, Novotny MV", "date": "2008-05-20", "evidence": [], "reference": [ { "id": "18487288", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/18487288" } ] } ], "biomarker_canonical_id": "AA5036", "collision": 1 }, { "biomarker_id": "AA5037-1", "biomarker_component": [ { "biomarker": "increased (A2G1(6)FB) level", "assessed_biomarker_entity": { "recommended_name": "Biantennary bisected core fucosylated N-glycan FB)", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G85767HW", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "33255418", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33255418", "evidence_list": [ { "evidence": "The level of serum N-glycan A2G1(6)FB, a biantennary N-glycan containing core fucose and bisecting GlcNAc residues, was significantly higher in hepatitis C virus (HCV)-infected cirrhotic patients with HCC than in those without HCC. In addition, A2G1(6)FB was detectable in HCV-infected patients with early-stage HCC. In conclusion, the N-glycan A2G1(6)FB may be a potential biomarker to detect early HCC development in HCV-infected patients." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:3571", "recommended_name": { "id": "DOID:3571", "name": "liver cancer", "description": "A hepatobiliary system cancer that is located_in the liver.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, "synonyms": [ { "id": "DOID:3571", "name": "resectable malignant neoplasm of the liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary liver cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, not specified as primary or secondary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Resectable malignant neoplasm of Liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "non-resectable primary hepatic malignant neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant tumor of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver, primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "Ca liver - primary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "primary malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "hepatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant hepato-biliary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" }, { "id": "DOID:3571", "name": "malignant neoplasm of liver", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_3571" } ] }, "evidence_source": [ { "id": "33255418", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33255418", "evidence_list": [ { "evidence": "The level of serum N-glycan A2G1(6)FB, a biantennary N-glycan containing core fucose and bisecting GlcNAc residues, was significantly higher in hepatitis C virus (HCV)-infected cirrhotic patients with HCC than in those without HCC. In addition, A2G1(6)FB was detectable in HCV-infected patients with early-stage HCC. In conclusion, the N-glycan A2G1(6)FB may be a potential biomarker to detect early HCC development in HCV-infected patients." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "A Potential Serum ", "journal": "International journal of molecular sciences", "authors": "Higashi M, Yoshimura T, Usui N, Kano Y, Deguchi A, Tanabe K, Uchimura Y, Kuriyama S, Suzuki Y, Masaki T, Ikenaka K", "date": "2020-12-02", "evidence": [], "reference": [ { "id": "33255418", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/33255418" } ] } ], "biomarker_canonical_id": "AA5037", "collision": 1 }, { "biomarker_id": "AN4494-1", "biomarker_component": [ { "biomarker": "measured CD44 STn glycoforms", "assessed_biomarker_entity": { "recommended_name": "Circulating CD44v6 variant and STn O-glycoform panel", "synonyms": [ { "synonym": "CDw44" }, { "synonym": "Epican" }, { "synonym": "Extracellular matrix receptor III" }, { "synonym": "ECMR-III" }, { "synonym": "GP90 lymphocyte homing/adhesion receptor" }, { "synonym": "HUTCH-I" }, { "synonym": "Heparan sulfate proteoglycan" }, { "synonym": "Hermes antigen" }, { "synonym": "Hyaluronate receptor" }, { "synonym": "Phagocytic glycoprotein 1" }, { "synonym": "PGP-1" }, { "synonym": "Phagocytic glycoprotein I" }, { "synonym": "PGP-I" } ] }, "assessed_biomarker_entity_id": "UPKB:P16070", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. We confirmed that gastric cancer tissue express the CD44v6 variant and carries STn O-glycans by in situ PLA. It is therefore likely that CD44v6/STn in serum originate from cancer cells and may represent a useful biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured CD44 STn glycoforms", "assessed_biomarker_entity": { "recommended_name": "Circulating CD44v6 variant and STn O-glycoform panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G36123IU", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. We confirmed that gastric cancer tissue express the CD44v6 variant and carries STn O-glycans by in situ PLA. It is therefore likely that CD44v6/STn in serum originate from cancer cells and may represent a useful biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. We confirmed that gastric cancer tissue express the CD44v6 variant and carries STn O-glycans by in situ PLA. It is therefore likely that CD44v6/STn in serum originate from cancer cells and may represent a useful biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.", "journal": "Molecular & cellular proteomics : MCP", "authors": "Campos D, Freitas D, Gomes J, Magalh\u00e3es A, Steentoft C, Gomes C, Vester-Christensen MB, Ferreira JA, Afonso LP, Santos LL, Pinto de Sousa J, Mandel U, Clausen H, Vakhrushev SY, Reis CA", "date": "2015-03-31", "evidence": [], "reference": [ { "id": "25813380", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380" } ] }, { "title": "Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.", "journal": "Molecular & cellular proteomics : MCP", "authors": "Campos D, Freitas D, Gomes J, Magalh\u00e3es A, Steentoft C, Gomes C, Vester-Christensen MB, Ferreira JA, Afonso LP, Santos LL, Pinto de Sousa J, Mandel U, Clausen H, Vakhrushev SY, Reis CA", "date": "2015-03-31", "evidence": [], "reference": [ { "id": "25813380", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380" } ] } ], "biomarker_canonical_id": "AN4494", "collision": 0 }, { "biomarker_id": "AN4495-1", "biomarker_component": [ { "biomarker": "measured GalNAc-T5 STn glycoforms", "assessed_biomarker_entity": { "recommended_name": "Circulating GalNAc-T5 and STn O-glycoform panel", "synonyms": [ { "synonym": "Polypeptide GalNAc transferase 5" }, { "synonym": "GalNAc-T5" }, { "synonym": "pp-GaNTase 5" }, { "synonym": "Protein-UDP acetylgalactosaminyltransferase 5" }, { "synonym": "UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 5" } ] }, "assessed_biomarker_entity_id": "UPKB:Q7Z7M9", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. Nevertheless, the present study provides compelling evidence that GalNAc-T5 is shed from gastric tumors with STn O-glycans and may have potential as a biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "measured GalNAc-T5 STn glycoforms", "assessed_biomarker_entity": { "recommended_name": "Circulating GalNAc-T5 and STn O-glycoform panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G36123IU", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. Nevertheless, the present study provides compelling evidence that GalNAc-T5 is shed from gastric tumors with STn O-glycans and may have potential as a biomarker." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10534", "recommended_name": { "id": "DOID:10534", "name": "stomach cancer", "description": "A gastrointestinal system cancer that is located_in the stomach.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, "synonyms": [ { "id": "DOID:10534", "name": "gastric neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" }, { "id": "DOID:10534", "name": "gastric cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10534" } ] }, "evidence_source": [ { "id": "25813380", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380", "evidence_list": [ { "evidence": "Two identified candidate O-glycoprotein biomarkers (CD44 and GalNAc-T5) circulating with the STn glycoform were further validated as being expressed in gastric cancer tissue. This study clearly shows that cancer patients have a variety of circulating O-glycoproteins with the STn glycoform, and supports the hypothesis that these glycoproteins originate from the cancer tissue. Nevertheless, the present study provides compelling evidence that GalNAc-T5 is shed from gastric tumors with STn O-glycans and may have potential as a biomarker." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.", "journal": "Molecular & cellular proteomics : MCP", "authors": "Campos D, Freitas D, Gomes J, Magalh\u00e3es A, Steentoft C, Gomes C, Vester-Christensen MB, Ferreira JA, Afonso LP, Santos LL, Pinto de Sousa J, Mandel U, Clausen H, Vakhrushev SY, Reis CA", "date": "2015-03-31", "evidence": [], "reference": [ { "id": "25813380", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380" } ] }, { "title": "Probing the O-glycoproteome of gastric cancer cell lines for biomarker discovery.", "journal": "Molecular & cellular proteomics : MCP", "authors": "Campos D, Freitas D, Gomes J, Magalh\u00e3es A, Steentoft C, Gomes C, Vester-Christensen MB, Ferreira JA, Afonso LP, Santos LL, Pinto de Sousa J, Mandel U, Clausen H, Vakhrushev SY, Reis CA", "date": "2015-03-31", "evidence": [], "reference": [ { "id": "25813380", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25813380" } ] } ], "biomarker_canonical_id": "AN4495", "collision": 0 }, { "biomarker_id": "AA5038-1", "biomarker_component": [ { "biomarker": "decreased biantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Biantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G52069SB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.", "journal": "Journal of proteome research", "authors": "Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV", "date": "2009-05-16", "evidence": [], "reference": [ { "id": "19441788", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788" } ] } ], "biomarker_canonical_id": "AA5038", "collision": 1 }, { "biomarker_id": "AA5039-1", "biomarker_component": [ { "biomarker": "decreased monogalactosylated biantennary core fucosylated N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Monogalactosylated biantennary core fucosylated N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G86265JV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.", "journal": "Journal of proteome research", "authors": "Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV", "date": "2009-05-16", "evidence": [], "reference": [ { "id": "19441788", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788" } ] } ], "biomarker_canonical_id": "AA5039", "collision": 1 }, { "biomarker_id": "AA5040-1", "biomarker_component": [ { "biomarker": "decreased monosialylated monogalactosylated biantennary N-glycan level", "assessed_biomarker_entity": { "recommended_name": "Monosialylated monogalactosylated biantennary N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G06014UR", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:5041", "recommended_name": { "id": "DOID:5041", "name": "esophageal cancer", "description": "A gastrointestinal system cancer that is located_in the esophagus.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, "synonyms": [ { "id": "DOID:5041", "name": "Ca lower third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of middle third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Distal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of abdominal esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of the middle Third of the esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of lower third of oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of distal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "Ca middle third oesophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of upper third esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant neoplasm of proximal third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "malignant tumor of Proximal Third of esophagus", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" }, { "id": "DOID:5041", "name": "esophagus cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_5041" } ] }, "evidence_source": [ { "id": "19441788", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788", "evidence_list": [ { "evidence": "The changes in the relative intensities of three of the known glycan structures predicted esophageal adenocarcinoma with 94% sensitivity and better than 60% specificity as determined by receiver operating characteristic (ROC) analysis. We have demonstrated that comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers. These markers can differentiate disease-free from HGD, disease-free from EAC, and HGD from EAC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.", "journal": "Journal of proteome research", "authors": "Mechref Y, Hussein A, Bekesova S, Pungpapong V, Zhang M, Dobrolecki LE, Hickey RJ, Hammoud ZT, Novotny MV", "date": "2009-05-16", "evidence": [], "reference": [ { "id": "19441788", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/19441788" } ] } ], "biomarker_canonical_id": "AA5040", "collision": 1 }, { "biomarker_id": "AA5041-1", "biomarker_component": [ { "biomarker": "increased F0H6N2S0 level", "assessed_biomarker_entity": { "recommended_name": "Man6 high mannose N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G80966KZ", "assessed_entity_type": "glycan", "specimen": [ { "name": "tissue", "id": "UBERON:0000479", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000479", "loinc_code": "" } ], "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Comprehensive N-Glycome Profiling of Cells and Tissues for Breast Cancer Diagnosis.", "journal": "Journal of proteome research", "authors": "Li Q, Li G, Zhou Y, Zhang X, Sun M, Jiang H, Yu G", "date": "2019-03-20", "evidence": [], "reference": [ { "id": "30889355", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355" } ] } ], "biomarker_canonical_id": "AA5041", "collision": 1 }, { "biomarker_id": "AA5042-1", "biomarker_component": [ { "biomarker": "increased F0H7N2S0 level", "assessed_biomarker_entity": { "recommended_name": "Man7 high mannose N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G36059IK", "assessed_entity_type": "glycan", "specimen": [ { "name": "tissue", "id": "UBERON:0000479", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000479", "loinc_code": "" } ], "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Comprehensive N-Glycome Profiling of Cells and Tissues for Breast Cancer Diagnosis.", "journal": "Journal of proteome research", "authors": "Li Q, Li G, Zhou Y, Zhang X, Sun M, Jiang H, Yu G", "date": "2019-03-20", "evidence": [], "reference": [ { "id": "30889355", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355" } ] } ], "biomarker_canonical_id": "AA5042", "collision": 1 }, { "biomarker_id": "AA5043-1", "biomarker_component": [ { "biomarker": "increased F0H8N2S0 level", "assessed_biomarker_entity": { "recommended_name": "Man8 high mannose N-glycan", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G66676MI", "assessed_entity_type": "glycan", "specimen": [ { "name": "tissue", "id": "UBERON:0000479", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000479", "loinc_code": "" } ], "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "30889355", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355", "evidence_list": [ { "evidence": "In comparing the N-glycan profiles of healthy individuals with those suffering from breast cancer, six N-glycans with AUC greater than 0.9 indicated excellent diagnostic accuracy (Figure 4). Of those, two bisected N-glycans (F0H4N5S0 and F1H4N5S0, Figure 4A,B) exhibited decreased relative abundances, while the other four N-glycans included three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, and F0H8N2S0, Figure 4C,D,E), and fucosylated glycan (F1H3N2S0, Figure 4F) exhibited increased relative abundances. Overall, three high-mannose N-glycans (F0H6N2S0, F0H7N2S0, F0H8N2S0) exhibited significant diagnostic accuracy in both breast cancer cells and tissues, suggesting their potential role in biomarkers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Comprehensive N-Glycome Profiling of Cells and Tissues for Breast Cancer Diagnosis.", "journal": "Journal of proteome research", "authors": "Li Q, Li G, Zhou Y, Zhang X, Sun M, Jiang H, Yu G", "date": "2019-03-20", "evidence": [], "reference": [ { "id": "30889355", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/30889355" } ] } ], "biomarker_canonical_id": "AA5043", "collision": 1 }, { "biomarker_id": "AN4496-1", "biomarker_component": [ { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G41793DV", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G46440UD", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G44246UD", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G67579EM", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G42079FQ", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G53972TI", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G12638YK", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G09503CT", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased eight N-glycans level", "assessed_biomarker_entity": { "recommended_name": "Nine sialylated and fucosylated CRPC N-glycans panel", "synonyms": [] }, "assessed_biomarker_entity_id": "UNK:Triantennary N-glycan", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "31727974", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974", "evidence_list": [ { "evidence": "N-Glycan profiling was compared between the non-CRPC (BPH, newly diagnosed PC and PC-ADT) and CRPC patients. We obtained the quantitative score for CRPC (CRPC N-glycan score) by discriminant analysis based on the combination of 9 N-glycans that were significantly associated with CRPC. The median CRPC N-glycan score was found to be significantly greater in CRPC patients than in non-CRPC patients. The overexpression of specific N-glycans may be associated with their castration-resistant status and be a potential biomarker for CRPC." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] }, { "title": "Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.", "journal": "Scientific reports", "authors": "Matsumoto T, Hatakeyama S, Yoneyama T, Tobisawa Y, Ishibashi Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ito H, Nishimura SI, Ohyama C", "date": "2019-11-16", "evidence": [], "reference": [ { "id": "31727974", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/31727974" } ] } ], "biomarker_canonical_id": "AN4496", "collision": 0 }, { "biomarker_id": "AN4497-1", "biomarker_component": [ { "biomarker": "increased monosialylated monoantennary N-glycan to digalactosylated biantennary core fucosylated N-glycan ratio", "assessed_biomarker_entity": { "recommended_name": "Monosialylated monoantennary N-glycan to digalactosylated biantennary core fucosylated N-glycan ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G36949LL", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "35064597", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35064597", "evidence_list": [ { "evidence": "Serum glycans, especially the m/z 1708/1914 ratio, were useful for the diagnosis, staging, and prognosis prediction of CRC. The glycan ratio m/z 1708/1914 showed a higher area under the receiver operating characteristic curve (0.889) than any other single glycan or conventional tumor marker, such as carcinoembryonic antigen (0.766, P = 0.040) and carbohydrate antigen 19-9 (0.615, P < 0.001). High m/z 1708/1914 was also correlated with an advanced cancer stage and short overall survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased monosialylated monoantennary N-glycan to digalactosylated biantennary core fucosylated N-glycan ratio", "assessed_biomarker_entity": { "recommended_name": "Monosialylated monoantennary N-glycan to digalactosylated biantennary core fucosylated N-glycan ratio", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G52069SB", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "35064597", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35064597", "evidence_list": [ { "evidence": "Serum glycans, especially the m/z 1708/1914 ratio, were useful for the diagnosis, staging, and prognosis prediction of CRC. The glycan ratio m/z 1708/1914 showed a higher area under the receiver operating characteristic curve (0.889) than any other single glycan or conventional tumor marker, such as carcinoembryonic antigen (0.766, P = 0.040) and carbohydrate antigen 19-9 (0.615, P < 0.001). High m/z 1708/1914 was also correlated with an advanced cancer stage and short overall survival." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:9256", "recommended_name": { "id": "DOID:9256", "name": "colorectal cancer", "description": "A large intestine cancer that is located_in the colon and/or located_in the rectum.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_9256" }, "synonyms": [] }, "evidence_source": [ { "id": "35064597", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35064597", "evidence_list": [ { "evidence": "Serum glycans, especially the m/z 1708/1914 ratio, were useful for the diagnosis, staging, and prognosis prediction of CRC. The glycan ratio m/z 1708/1914 showed a higher area under the receiver operating characteristic curve (0.889) than any other single glycan or conventional tumor marker, such as carcinoembryonic antigen (0.766, P = 0.040) and carbohydrate antigen 19-9 (0.615, P < 0.001). High m/z 1708/1914 was also correlated with an advanced cancer stage and short overall survival." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Clinical utility of a serum glycome analysis in patients with colorectal cancer.", "journal": "Journal of gastroenterology and hepatology", "authors": "Takei D, Harada K, Nouso K, Miyahara K, Dohi C, Matsushita H, Kinugasa H, Hiraoka S, Nishimura SI, Okada H", "date": "2022-01-23", "evidence": [], "reference": [ { "id": "35064597", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35064597" } ] }, { "title": "Clinical utility of a serum glycome analysis in patients with colorectal cancer.", "journal": "Journal of gastroenterology and hepatology", "authors": "Takei D, Harada K, Nouso K, Miyahara K, Dohi C, Matsushita H, Kinugasa H, Hiraoka S, Nishimura SI, Okada H", "date": "2022-01-23", "evidence": [], "reference": [ { "id": "35064597", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35064597" } ] } ], "biomarker_canonical_id": "AN4497", "collision": 0 }, { "biomarker_id": "AA5044-1", "biomarker_component": [ { "biomarker": "increased Neu5Gc level", "assessed_biomarker_entity": { "recommended_name": "Neu5Gc", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G26366JF", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "35346112", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35346112", "evidence_list": [ { "evidence": "Analysis of sera from breast cancer cases revealed significantly elevated levels of Neu5Gc biomarkers at all stages of breast cancer. We show that Neu5Gc serum biomarker levels can discriminate breast cancer patients from cancer-free individuals with 98.96% sensitivity and 100% specificity. Neu5Gc serum biomarkers are a promising new tool for early detection and disease monitoring for breast cancer that may complement current imaging- and biopsy-based approaches." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "condition": { "id": "DOID:1612", "recommended_name": { "id": "DOID:1612", "name": "breast cancer", "description": "A thoracic cancer that originates in the mammary gland.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, "synonyms": [ { "id": "DOID:1612", "name": "malignant tumor of the breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "breast tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "primary breast cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "mammary tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" }, { "id": "DOID:1612", "name": "malignant neoplasm of breast", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_1612" } ] }, "evidence_source": [ { "id": "35346112", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35346112", "evidence_list": [ { "evidence": "Analysis of sera from breast cancer cases revealed significantly elevated levels of Neu5Gc biomarkers at all stages of breast cancer. We show that Neu5Gc serum biomarker levels can discriminate breast cancer patients from cancer-free individuals with 98.96% sensitivity and 100% specificity. Neu5Gc serum biomarkers are a promising new tool for early detection and disease monitoring for breast cancer that may complement current imaging- and biopsy-based approaches." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.", "journal": "BMC cancer", "authors": "Shewell LK, Day CJ, Kutasovic JR, Abrahams JL, Wang J, Poole J, Niland C, Ferguson K, Saunus JM, Lakhani SR, von Itzstein M, Paton JC, Paton AW, Jennings MP", "date": "2022-03-30", "evidence": [], "reference": [ { "id": "35346112", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/35346112" } ] } ], "biomarker_canonical_id": "AA5044", "collision": 1 }, { "biomarker_id": "AN4498-1", "biomarker_component": [ { "biomarker": "increased Tn glycoform of CA125", "assessed_biomarker_entity": { "recommended_name": "CA125-Tn glycoform", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G57321FI", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "36564848", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/36564848", "evidence_list": [ { "evidence": "Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased Tn glycoform of CA125", "assessed_biomarker_entity": { "recommended_name": "CA125-Tn glycoform", "synonyms": [ { "synonym": "MUC-16" }, { "synonym": "Ovarian cancer-related tumor marker CA125" }, { "synonym": "CA-125" }, { "synonym": "Ovarian carcinoma antigen CA125" } ] }, "assessed_biomarker_entity_id": "UPKB:Q8WXI7", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "36564848", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/36564848", "evidence_list": [ { "evidence": "Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "predictive" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "36564848", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/36564848", "evidence_list": [ { "evidence": "Serum CA125-Tn level could be a novel biomarker for peritoneal dissemination and a promising predictor of surgical completeness in ovarian cancer. Patients with lower CA125-Tn levels were more likely to have no residual disease. CA125-Tn could help surgeons to adopt optimized treatment strategies for patients with advanced ovarian cancer as a pre-treatment evaluator." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.", "journal": "Journal of ovarian research", "authors": "Jin X, Du M, Wang Y, Wang Y, Lu Y, Xu C, Zhang X", "date": "2022-12-24", "evidence": [], "reference": [ { "id": "36564848", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/36564848" } ] }, { "title": "Evaluation of serum CA125-Tn glycoform in peritoneal dissemination and surgical completeness of high-grade serous ovarian cancer.", "journal": "Journal of ovarian research", "authors": "Jin X, Du M, Wang Y, Wang Y, Lu Y, Xu C, Zhang X", "date": "2022-12-24", "evidence": [], "reference": [ { "id": "36564848", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/36564848" } ] } ], "biomarker_canonical_id": "AN4498", "collision": 0 }, { "biomarker_id": "AN4499-1", "biomarker_component": [ { "biomarker": "increased fucosylated PSA level", "assessed_biomarker_entity": { "recommended_name": "Fucosylated PSA", "synonyms": [] }, "assessed_biomarker_entity_id": "GTC:G09737HO", "assessed_entity_type": "glycan", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25553114", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25553114", "evidence_list": [ { "evidence": "Among three fucosylated glycoproteins, the fucosylated PSA was significantly increased and correlated with the tumor Gleason score (p<0.05). The ratio of fucosylated PSA showed a marked increase in aggressive tumors in comparison to non-aggressive tumors. ROC analysis also showed an improved predictive power of fucosylated PSA in the identification of aggressive Pca. Our data suggested that the fucosylated PSA had the potential to be used as a biomarker to separate aggressive from non-aggressive prostate cancers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] }, { "biomarker": "increased fucosylated PSA level", "assessed_biomarker_entity": { "recommended_name": "Fucosylated PSA", "synonyms": [ { "synonym": "PSA" }, { "synonym": "Gamma-seminoprotein" }, { "synonym": "Seminin" }, { "synonym": "Kallikrein-3" }, { "synonym": "P-30 antigen" }, { "synonym": "Semenogelase" } ] }, "assessed_biomarker_entity_id": "UPKB:P07288", "assessed_entity_type": "protein", "specimen": [ { "name": "blood", "id": "UBERON:0000178", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "25553114", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25553114", "evidence_list": [ { "evidence": "Among three fucosylated glycoproteins, the fucosylated PSA was significantly increased and correlated with the tumor Gleason score (p<0.05). The ratio of fucosylated PSA showed a marked increase in aggressive tumors in comparison to non-aggressive tumors. ROC analysis also showed an improved predictive power of fucosylated PSA in the identification of aggressive Pca. Our data suggested that the fucosylated PSA had the potential to be used as a biomarker to separate aggressive from non-aggressive prostate cancers." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "diagnostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "25553114", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25553114", "evidence_list": [ { "evidence": "Among three fucosylated glycoproteins, the fucosylated PSA was significantly increased and correlated with the tumor Gleason score (p<0.05). The ratio of fucosylated PSA showed a marked increase in aggressive tumors in comparison to non-aggressive tumors. ROC analysis also showed an improved predictive power of fucosylated PSA in the identification of aggressive Pca. Our data suggested that the fucosylated PSA had the potential to be used as a biomarker to separate aggressive from non-aggressive prostate cancers." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.", "journal": "Theranostics", "authors": "Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW", "date": "2015-01-02", "evidence": [], "reference": [ { "id": "25553114", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25553114" } ] }, { "title": "Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.", "journal": "Theranostics", "authors": "Li QK, Chen L, Ao MH, Chiu JH, Zhang Z, Zhang H, Chan DW", "date": "2015-01-02", "evidence": [], "reference": [ { "id": "25553114", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/25553114" } ] } ], "biomarker_canonical_id": "AN4499", "collision": 0 }, { "biomarker_id": "AA5045-1", "biomarker_component": [ { "biomarker": "hypermethylated MIR-9-1 gene", "assessed_biomarker_entity": { "recommended_name": "miRNA-9-1 gene", "synonyms": [] }, "assessed_biomarker_entity_id": "MRB:MI0000466", "assessed_entity_type": "miRNA", "specimen": [ { "name": "ovary", "id": "UBERON:0000992", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0000992", "loinc_code": "" } ], "evidence_source": [ { "id": "29313235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235", "evidence_list": [ { "evidence": "...five microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) methylated in the majority of tumor specimens in comparison with paired specimens of histologically intact tissue (37-57% vs. 4-9%, p<0.01). Methylation of three genes (MIR-9-1, MIR-9-3, and MIR-130b) was significantly (p\u22640.05) associated with the parameters of ovarian cancer progress (clinical stage, differentiation degree, tumor size, and presence of metastases). These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:2394", "recommended_name": { "id": "DOID:2394", "name": "ovarian cancer", "description": "A female reproductive organ cancer that is located_in the ovary.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, "synonyms": [ { "id": "DOID:2394", "name": "primary ovarian cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "tumor of the Ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovary neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant tumour of ovary", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "malignant Ovarian tumor", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" }, { "id": "DOID:2394", "name": "ovarian neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_2394" } ] }, "evidence_source": [ { "id": "29313235", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235", "evidence_list": [ { "evidence": "...five microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) methylated in the majority of tumor specimens in comparison with paired specimens of histologically intact tissue (37-57% vs. 4-9%, p<0.01). Methylation of three genes (MIR-9-1, MIR-9-3, and MIR-130b) was significantly (p\u22640.05) associated with the parameters of ovarian cancer progress (clinical stage, differentiation degree, tumor size, and presence of metastases). These findings attest to oncosuppressive role of the studied microRNA genes (MIR-9-1, MIR-9-3, MIR-107, MIR-1258, and MIR-130b) in the pathogenesis and progress of ovarian cancer and indicated their prognostic potential." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Five Hypermethylated MicroRNA Genes as Potential Markers of Ovarian Cancer.", "journal": "Bulletin of experimental biology and medicine", "authors": "Braga EA, Loginov VI, Burdennyi AM, Filippova EA, Pronina IV, Kurevlev SV, Kazubskaya TP, Kushlinskii DN, Utkin DO, Ermilova VD, Kushlinskii NE", "date": "2018-01-10", "evidence": [], "reference": [ { "id": "29313235", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/29313235" } ] } ], "biomarker_canonical_id": "AA5045", "collision": 1 }, { "biomarker_id": "AN4384-2", "biomarker_component": [ { "biomarker": "hypermethylated RASSF1 gene", "assessed_biomarker_entity": { "recommended_name": "Ras association domain-containing protein 1 gene", "synonyms": [] }, "assessed_biomarker_entity_id": "UPKB:Q9NS23", "assessed_entity_type": "protein", "specimen": [ { "name": "urine", "id": "UBERON:0001088", "name_space": "Uberon", "url": "http://purl.obolibrary.org/obo/UBERON_0001088", "loinc_code": "" } ], "evidence_source": [ { "id": "24980613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613", "evidence_list": [ { "evidence": "Hypermethylation of RASSF1 in cancerous tissue and urine from patients with prostate cancer correlated with biochemical recurrence after radical prostatectomy. The prognostic potential of this biomarker deserves further investigation." } ], "tags": [ { "tag": "biomarker" }, { "tag": "assessed_biomarker_entity" }, { "tag": "assessed_biomarker_entity_id" }, { "tag": "assessed_entity_type" } ] } ] } ], "best_biomarker_role": [ { "role": "prognostic" } ], "condition": { "id": "DOID:10283", "recommended_name": { "id": "DOID:10283", "name": "prostate cancer", "description": "A male reproductive organ cancer that is located_in the prostate.", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, "synonyms": [ { "id": "DOID:10283", "name": "prostate neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "NGP - new growth of prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostate cancer, familial", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic neoplasm", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "malignant tumor of the prostate", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "hereditary prostate cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" }, { "id": "DOID:10283", "name": "prostatic cancer", "resource": "Disease Ontology", "url": "http://purl.obolibrary.org/obo/DOID_10283" } ] }, "evidence_source": [ { "id": "24980613", "database": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613", "evidence_list": [ { "evidence": "Hypermethylation of RASSF1 in cancerous tissue and urine from patients with prostate cancer correlated with biochemical recurrence after radical prostatectomy. The prognostic potential of this biomarker deserves further investigation." } ], "tags": [ { "tag": "condition" } ] } ], "citation": [ { "title": "Prognostic value of RASSF1 promoter methylation in prostate cancer.", "journal": "The Journal of urology", "authors": "Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F", "date": "2014-07-02", "evidence": [], "reference": [ { "id": "24980613", "type": "Pubmed", "url": "https://pubmed.ncbi.nlm.nih.gov/24980613" } ] } ], "biomarker_canonical_id": "AN4384", "collision": 1 } ]